Clustering O 0 0.0002271702396683395
of O 0 3.8332349504344165e-05
missense O 0 4.2605763155734167e-05
mutations O 0 7.521029147028457e-06
in O 0 1.5066501873661764e-05
the O 0 0.00018078589346259832
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
gene O 0 1.161123964266153e-05
in O 0 5.3751155064674094e-06
a O 0 3.369559408383793e-06
sporadic B-Disease 0 0.17704539000988007
T I-Disease 1 0.9996432065963745
- I-Disease 0 0.02508586272597313
cell I-Disease 0 0.006860901135951281
leukaemia I-Disease 1 0.9981489181518555
. O 0 3.3193605304404628e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 1 0.8355382084846497
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.4556256878204294e-07
is O 0 8.622661340496052e-08
a O 0 1.6498162835887342e-07
recessive B-Disease 0 6.5183935475943144e-06
multi I-Disease 1 0.9879053831100464
- I-Disease 1 0.9994645714759827
system I-Disease 0 0.02985302172601223
disorder I-Disease 0 0.4582526981830597
caused O 0 9.698103531263769e-05
by O 0 2.0427098945674516e-07
mutations O 0 5.450903728387857e-08
in O 0 6.021413696544187e-07
the O 0 1.9412216261116555e-06
ATM O 0 1.142282326327404e-05
gene O 0 7.619652251378284e-07
at O 0 1.0574201041890774e-05
11q22 O 0 6.19417141933809e-06
- O 0 4.57723126601195e-06
q23 O 0 6.709140052407747e-06
( O 0 2.3743714905322122e-07
ref O 0 6.240281891223276e-06
. O 0 6.061605972718098e-08
3 O 0 6.701222332594625e-07
) O 0 2.3310464314363344e-07
. O 0 4.994194569007959e-07

The O 0 0.00012530764797702432
risk O 0 5.9279671404510736e-05
of O 0 0.0001401515182806179
cancer B-Disease 1 0.8773438930511475
, O 0 3.6312035263108555e-06
especially O 0 2.187028258049395e-06
lymphoid B-Disease 0 0.0034325614105910063
neoplasias I-Disease 0 0.005981248803436756
, O 0 7.215297728180303e-07
is O 0 2.1088953872094862e-07
substantially O 0 2.1044966160843614e-06
elevated O 0 0.0006507334182970226
in O 0 1.7524205759400502e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.973091108695371e-06
and O 0 5.182434392736468e-07
has O 0 2.8630282145059027e-07
long O 0 1.5842358891404729e-07
been O 0 7.180619121527343e-08
associated O 0 5.965421934206461e-08
with O 0 1.1209108663479128e-07
chromosomal O 1 1.0
instability O 1 1.0
. O 0 2.5721483325469308e-05

By O 0 3.4764794691000134e-05
analysing O 0 0.00020006763224955648
tumour B-Disease 1 1.0
DNA O 0 1.4714097233081702e-05
from O 0 2.462494194332976e-06
patients O 0 1.8971816473367653e-07
with O 0 4.116646223906173e-08
sporadic B-Disease 0 0.00011055212962673977
T I-Disease 0 0.006204643286764622
- I-Disease 0 5.532623617909849e-05
cell I-Disease 0 0.00010662755084922537
prolymphocytic I-Disease 0 0.00020687622600235045
leukaemia I-Disease 0 0.1293259859085083
( O 0 1.5731221765236114e-06
T B-Disease 0 3.4585802495712414e-05
- I-Disease 0 1.2203134247101843e-05
PLL I-Disease 0 3.942979674320668e-05
) O 0 4.6636412065481636e-08
, O 0 1.512524150371064e-08
a O 0 6.547224273845131e-08
rare O 0 3.6511002576844476e-07
clonal B-Disease 0 1.1971649655606598e-05
malignancy I-Disease 0 1.4465989806922153e-05
with O 0 2.7237305744165496e-08
similarities O 0 1.6502158928233257e-07
to O 0 1.9531177031240077e-07
a O 0 2.5238418857043143e-06
mature B-Disease 0 4.443921625352232e-06
T I-Disease 0 5.3535110055236146e-05
- I-Disease 0 1.5891364455455914e-05
cell I-Disease 0 2.256958032376133e-05
leukaemia I-Disease 0 0.0004747843195218593
seen O 0 4.3354348235880025e-06
in O 0 1.5972780147421872e-06
A B-Disease 1 0.9906003475189209
- I-Disease 0 0.0005378682399168611
T I-Disease 1 0.6975146532058716
, O 0 6.778262218176678e-08
we O 0 1.1130638633005674e-08
demonstrate O 0 3.8504499144664805e-08
a O 0 1.330776768782016e-07
high O 0 1.0301031352355494e-06
frequency O 0 3.266299017923302e-07
of O 0 2.099152652590419e-06
ATM O 0 2.188722100981977e-05
mutations O 0 4.78053323149652e-07
in O 0 6.15111594015616e-06
T B-Disease 0 0.00020952319027855992
- I-Disease 0 3.6373978218762204e-05
PLL I-Disease 0 0.00015377660747617483
. O 0 6.74462739880255e-07

In O 0 2.8591190130100586e-05
marked O 0 2.093580405926332e-05
contrast O 0 1.1986405752395513e-06
to O 0 3.635069845131511e-07
the O 0 1.5852499473112402e-06
ATM O 0 1.743816574162338e-05
mutation O 0 3.632276559528691e-07
pattern O 0 4.604713467415422e-06
in O 0 7.641667252755724e-06
A B-Disease 1 0.9999988079071045
- I-Disease 1 0.9997360110282898
T I-Disease 1 0.999998927116394
, O 0 2.0184862137284654e-07
the O 0 1.0718658671748926e-07
most O 0 7.233704746312242e-09
frequent O 0 1.8657420497447674e-08
nucleotide O 0 1.2436375129709631e-07
changes O 0 2.36559678512549e-08
in O 0 5.124587687532767e-08
this O 0 5.5621782735215675e-08
leukaemia B-Disease 0 1.011093809211161e-05
were O 0 4.957163355356897e-07
missense O 0 2.713319190661423e-06
mutations O 0 7.154513355089875e-07
. O 0 7.383432034657744e-07

These O 0 1.1933907444472425e-05
clustered O 0 2.1241328795440495e-05
in O 0 2.814181925714365e-06
the O 0 2.1302482764440356e-06
region O 0 1.2298352203288232e-06
corresponding O 0 4.51534924650332e-06
to O 0 1.5788529026394826e-06
the O 0 1.741302003210876e-05
kinase O 0 7.0286346272041555e-06
domain O 0 3.725459464476444e-06
, O 0 1.4999586994690617e-07
which O 0 8.764079950651649e-08
is O 0 5.8300134497812905e-08
highly O 0 9.598672789934426e-08
conserved O 0 6.602201096939098e-07
in O 0 7.829830792616121e-07
ATM O 0 1.3652394045493565e-05
- O 0 7.517892868236231e-07
related O 0 2.1896107682550792e-07
proteins O 0 1.1478536521281058e-07
in O 0 3.669167369935167e-07
mouse O 0 6.090591568863601e-07
, O 0 5.2126704730426354e-08
yeast O 0 2.0640113973513508e-07
and O 0 4.0432345826957317e-07
Drosophila O 0 7.179897693276871e-06
. O 0 7.89614830409846e-07

The O 0 0.00015173772408161312
resulting O 0 8.324767259182408e-05
amino O 0 1.874629560916219e-05
- O 0 1.7999031115323305e-05
acid O 0 1.497941752859333e-06
substitutions O 0 4.41356974079099e-07
are O 0 9.372296716492201e-08
predicted O 0 5.519818842003588e-07
to O 0 5.975694250537344e-08
interfere O 0 4.856273676523415e-07
with O 0 4.959442208019027e-07
ATP O 0 0.0013544021639972925
binding O 0 1.1091907481386443e-06
or O 0 6.065724278414564e-07
substrate O 0 2.5724666556925513e-06
recognition O 0 3.37865299115947e-06
. O 0 2.3126776795834303e-06

Two O 0 1.852908098953776e-05
of O 0 1.8258215277455747e-05
seventeen O 0 3.0497254556394182e-05
mutated O 0 2.6686084311222658e-05
T B-Disease 0 0.0002583094174042344
- I-Disease 0 2.5582512535038404e-05
PLL I-Disease 0 7.600688695674762e-05
samples O 0 2.73044634013786e-07
had O 0 1.0407637773823808e-06
a O 0 6.816026711931045e-07
previously O 0 1.9045975250264746e-06
reported O 0 1.2959532796230633e-05
A B-Disease 1 0.999984860420227
- I-Disease 1 0.9998809099197388
T I-Disease 1 0.9999961853027344
allele O 0 1.6542242519790307e-05
. O 0 2.6474942842469318e-06

In O 0 4.9891823437064886e-05
contrast O 0 5.852033154951641e-06
, O 0 6.161751002764504e-07
no O 0 1.995074683236453e-07
mutations O 0 1.412455077343111e-07
were O 0 8.874154104887566e-07
detected O 0 7.207306111922662e-07
in O 0 4.4389048525772523e-07
the O 0 2.1948007997707464e-06
p53 O 0 2.965007070088177e-06
gene O 0 4.794476922143076e-07
, O 0 9.383386867511945e-08
suggesting O 0 3.2427229257336876e-07
that O 0 7.926360012788791e-08
this O 0 1.2085130265404587e-06
tumour B-Disease 1 1.0
suppressor O 1 0.988315224647522
is O 0 2.6301304956177773e-07
not O 0 2.806752164019599e-08
frequently O 0 3.716562346767205e-08
altered O 0 1.277588381753958e-07
in O 0 2.0320894122960453e-07
this O 0 7.415624168061186e-07
leukaemia B-Disease 0 0.0033532457891851664
. O 0 3.894908786605811e-06

Occasional O 0 0.00010404214117443189
missense O 0 0.0001241527497768402
mutations O 0 5.801737188448897e-06
in O 0 8.018514563445933e-06
ATM O 0 0.00010337452840758488
were O 0 4.18580975747318e-06
also O 0 2.771427034531371e-07
found O 0 4.06943911457347e-07
in O 0 3.5555096928874264e-06
tumour B-Disease 1 1.0
DNA O 0 6.094971467973664e-06
from O 0 4.997204541723477e-06
patients O 0 6.062335273782082e-07
with O 0 7.568449404971034e-07
B B-Disease 0 0.0004047171678394079
- I-Disease 0 0.0001784381311153993
cell I-Disease 0 0.010800011456012726
non I-Disease 0 0.13492321968078613
- I-Disease 0 0.029577311128377914
Hodgkins I-Disease 1 0.9999998807907104
lymphomas I-Disease 0 0.0006428487249650061
( O 0 4.923772394249681e-07
B B-Disease 0 5.05174739373615e-06
- I-Disease 0 8.872884791344404e-07
NHL I-Disease 0 1.1457531172709423e-06
) O 0 3.106637080918517e-08
and O 0 7.338336871498541e-08
a O 0 6.793961802031845e-07
B B-Disease 0 1.520988553238567e-05
- I-Disease 0 6.872120138723403e-06
NHL I-Disease 0 9.810614756133873e-06
cell O 0 6.82093741488643e-06
line O 0 8.693191375641618e-06
. O 0 6.000180974297109e-07

The O 0 2.0818495613639243e-05
evidence O 0 1.4326213886306505e-06
of O 0 2.0959839730494423e-06
a O 0 4.0152454516828584e-07
significant O 0 2.38725675671958e-07
proportion O 0 2.0024947389174486e-06
of O 0 0.0002217423461843282
loss O 0 0.138363778591156
- O 0 2.056926859950181e-05
of O 0 0.0001992955949390307
- O 0 9.623880941944662e-06
function O 0 1.4397710401681252e-06
mutations O 0 5.7207195425235113e-08
and O 0 1.1527572496561334e-07
a O 0 4.243508726631262e-07
complete O 0 1.3199691011323011e-06
absence O 0 9.477704224991612e-06
of O 0 9.159638466371689e-06
the O 0 1.129234192376316e-06
normal O 0 8.591762821197335e-07
copy O 0 5.041502504354867e-07
of O 0 1.0333018281016848e-06
ATM O 0 5.955752385489177e-06
in O 0 3.04583522847679e-07
the O 0 5.055841256762506e-07
majority O 0 1.1052578940962121e-07
of O 0 5.002530542697059e-06
mutated O 0 2.0544432118185796e-05
tumours B-Disease 1 0.9999973773956299
establishes O 0 7.558094694104511e-06
somatic O 0 5.0864041440945584e-06
inactivation O 0 1.8062029994325712e-05
of O 0 3.1434124139195774e-06
this O 0 9.487170871125272e-08
gene O 0 6.955593789825798e-08
in O 0 1.6774696121046873e-07
the O 0 5.492502737070026e-07
pathogenesis O 0 9.864541425486095e-06
of O 0 7.112123057595454e-06
sporadic B-Disease 0 0.00047726999036967754
T I-Disease 0 0.07343695312738419
- I-Disease 0 0.00029925748822279274
PLL I-Disease 0 0.000222091082832776
and O 0 2.8898483606099035e-07
suggests O 0 1.8993684136603406e-07
that O 0 5.119361290439883e-08
ATM O 0 5.092272203910397e-06
acts O 0 6.715437734783336e-07
as O 0 1.2938781992488657e-06
a O 0 1.081720802176278e-05
tumour B-Disease 1 1.0
suppressor O 1 0.9457805156707764
. O 0 3.5442972148302943e-06

As O 0 4.284648457542062e-05
constitutional O 0 3.445901893428527e-05
DNA O 0 3.987050149589777e-06
was O 0 7.348669896600768e-06
not O 0 5.930616708837988e-08
available O 0 5.775008560249262e-08
, O 0 1.0038105813237053e-07
a O 0 7.134542556741508e-07
putative O 0 5.637974027195014e-05
hereditary O 1 0.9997796416282654
predisposition O 1 0.9949625730514526
to O 0 0.00010685403685783967
T B-Disease 1 0.6247844099998474
- I-Disease 0 0.0002685017534531653
PLL I-Disease 0 0.0002061095874523744
will O 0 1.2773531921084214e-07
require O 0 2.4496900508097497e-08
further O 0 1.4996712138781731e-07
investigation O 0 8.758947842579801e-07
. O 0 2.480950627159473e-07
. O 0 7.47797798794636e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.0002820069494191557
kinase O 0 3.1450643291464075e-05
is O 0 2.5005186898852116e-07
involved O 0 3.169542139858095e-08
in O 0 5.183521523122181e-08
the O 0 7.804246848763796e-08
modulation O 0 1.7288739684317989e-07
of O 0 4.736477876576828e-07
the O 0 7.217348070298613e-07
Ca2 O 0 3.483569798845565e-06
+ O 0 5.764185516454745e-06
homeostasis O 0 1.4295451364887413e-05
in O 0 4.206835455988767e-06
skeletal O 0 0.2933274507522583
muscle O 0 3.607055259635672e-05
cells O 0 1.1420655027905013e-05
. O 0 2.36851906265656e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.000768353056628257
DM B-Disease 1 1.0
) O 0 4.909690687782131e-06
, O 0 1.925068460195689e-07
the O 0 6.246458497116691e-07
most O 0 3.765640883557353e-07
prevalent O 0 0.0001744945766404271
muscular B-Disease 1 0.999994158744812
disorder I-Disease 1 0.8775738477706909
in O 0 4.286666808184236e-06
adults O 0 1.5715581014319469e-07
, O 0 5.922545653902489e-08
is O 0 4.4878124327851765e-08
caused O 0 5.906717888137791e-07
by O 0 1.246230567630846e-07
( O 0 7.941159196889203e-08
CTG O 0 4.693098162533715e-06
) O 0 6.162608201520925e-08
n O 0 3.7545996178778296e-07
- O 0 2.7278022685095493e-07
repeat O 0 1.0349167212098109e-07
expansion O 0 4.83189126043726e-07
in O 0 4.1263387373646765e-08
a O 0 5.2317446375127474e-08
gene O 0 2.826182310400327e-08
encoding O 0 1.0330589361728926e-07
a O 0 6.166636126181402e-07
protein O 0 8.139227247738745e-07
kinase O 0 6.118271812738385e-06
( O 0 9.435034371563233e-07
DM B-Disease 1 0.9931720495223999
protein O 0 7.357575213973178e-06
kinase O 0 7.3052779043791816e-06
; O 0 2.340198790307113e-07
DMPK O 0 1.2056812920491211e-05
) O 0 4.834514300000592e-08
and O 0 2.4367304618522212e-08
involves O 0 2.4724752023530527e-08
changes O 0 3.008908677770705e-08
in O 0 3.2305030117640854e-07
cytoarchitecture O 0 4.834356786886929e-06
and O 0 3.6994370589127357e-07
ion O 0 5.199766383157112e-05
homeostasis O 0 0.00011482864647405222
. O 0 3.716651917784475e-06

To O 0 1.1606611224124208e-05
obtain O 0 4.711528617917793e-06
clues O 0 8.426351087109651e-06
to O 0 4.652571305996389e-07
the O 0 1.5860060784689267e-06
normal O 0 4.423659447638784e-06
biological O 0 5.64338415642851e-06
role O 0 4.514815373113379e-06
of O 0 3.9418555388692766e-05
DMPK O 0 0.00027171566034667194
in O 0 5.438676907942863e-06
cellular O 0 2.563052112236619e-05
ion O 0 3.3373966289218515e-05
homeostasis O 0 4.1140734538203105e-05
, O 0 4.368502573015576e-07
we O 0 5.958690962870605e-08
have O 0 3.488584709998577e-08
compared O 0 1.2865714893450786e-07
the O 0 8.266292184089252e-08
resting O 0 1.7245000663024257e-06
[ O 0 1.3124072495429573e-07
Ca2 O 0 3.4185859476565383e-07
+ O 0 6.946193025214598e-07
] O 0 5.006383503314282e-07
i O 0 2.211111080896444e-07
, O 0 4.3117815096138656e-08
the O 0 1.774835425294441e-07
amplitude O 0 1.3842882253811695e-06
and O 0 2.3743940857912094e-07
shape O 0 8.571466310058895e-07
of O 0 5.1737956709985156e-06
depolarization O 0 1.9411201719776727e-05
- O 0 6.610734089917969e-06
induced O 0 1.4322280549095012e-05
Ca2 O 0 3.879627456626622e-06
+ O 0 2.4256860342575237e-06
transients O 0 2.816528649418615e-06
, O 0 7.044285155188845e-08
and O 0 7.647520305908984e-08
the O 0 3.4995287023775745e-07
content O 0 1.654263854788951e-07
of O 0 4.226547844154993e-06
ATP O 0 7.982685201568529e-05
- O 0 2.061907480310765e-06
driven O 0 3.6170122257317416e-06
ion O 0 2.2568456188309938e-06
pumps O 0 6.603613655897789e-06
in O 0 3.3082330901379464e-06
cultured O 0 0.00022789875220041722
skeletal O 1 0.9774606227874756
muscle O 0 2.256443985970691e-05
cells O 0 3.4021068131551147e-06
of O 0 1.3388962543103844e-05
wild O 0 9.068687631952344e-07
- O 0 3.730877722318837e-07
type O 0 1.3294526013396535e-07
and O 0 1.3172825674701016e-07
DMPK O 0 8.457208423351403e-06
[ O 0 4.0439596205033013e-07
- O 0 8.033600238377403e-07
/ O 0 1.4602478586311918e-06
- O 0 2.3881248125690036e-06
] O 0 7.893046358731226e-07
knockout O 0 8.094585609796923e-06
mice O 0 6.0958604990446474e-06
. O 0 1.1044249959013541e-06

In O 0 9.83806312433444e-05
vitro O 0 0.00013459612091537565
- O 0 3.2129031751537696e-05
differentiated O 0 7.167671810748288e-06
DMPK O 0 0.00017543182184454054
[ O 0 4.550498942990089e-06
- O 0 4.284758233552566e-06
/ O 0 5.48227444596705e-06
- O 0 4.232832452544244e-06
] O 0 9.439398809263366e-07
myotubes O 0 2.3237937512021745e-06
exhibit O 0 6.36886340998899e-07
a O 0 5.422872959570668e-07
higher O 0 9.207598736793443e-07
resting O 0 2.6455206807440845e-06
[ O 0 2.0897894614790857e-07
Ca2 O 0 6.558310587934102e-07
+ O 0 1.268293431166967e-06
] O 0 8.67900723733328e-07
i O 0 3.6959070826014795e-07
than O 0 6.581192479870879e-08
do O 0 4.06728126733924e-08
wild O 0 1.8535304491251736e-07
- O 0 6.123684670455987e-07
type O 0 8.975608238870336e-07
myotubes O 0 5.5765144679753575e-06
because O 0 1.015666413195504e-07
of O 0 8.451109465568152e-07
an O 0 1.2020264250622859e-07
altered O 0 2.876781195482181e-07
open O 0 4.895515530733974e-07
probability O 0 2.588383836155117e-07
of O 0 2.1337596081139054e-06
voltage O 0 2.9218017516541295e-05
- O 0 9.48709612202947e-07
dependent O 0 9.047627145264414e-07
l O 0 4.905263608634414e-07
- O 0 6.286420983769858e-08
type O 0 3.33598144663938e-08
Ca2 O 0 1.6182144690901623e-07
+ O 0 6.083903514308986e-08
and O 0 5.095299471236103e-08
Na O 0 1.5971622815413866e-06
+ O 0 5.645621854455385e-07
channels O 0 6.801131462452759e-07
. O 0 6.741270794918819e-07

The O 0 9.475474507780746e-05
mutant O 0 7.375855057034642e-05
myotubes O 0 0.00010831322288140655
exhibit O 0 5.186886937735835e-06
smaller O 0 3.002920720973634e-07
and O 0 1.5170783740359184e-07
slower O 0 1.7678632957540685e-06
Ca2 O 0 1.6808402278911672e-06
+ O 0 5.711985409107001e-07
responses O 0 5.3372623654013296e-08
upon O 0 3.860701838220848e-07
triggering O 0 3.032710083061829e-06
by O 0 1.0503384118010217e-07
acetylcholine O 0 1.4539626818077522e-06
or O 0 8.364083470269179e-08
high O 0 2.5452454792684875e-06
external O 0 2.619007091198e-06
K O 0 1.4670155906060245e-05
+ O 0 2.75059665000299e-06
. O 0 1.3781379948341055e-06

In O 0 3.966028816648759e-05
addition O 0 1.8195406710219686e-06
, O 0 1.7938769758529816e-07
we O 0 1.687722495091748e-08
observed O 0 5.734889185760039e-08
that O 0 9.186530647298241e-09
these O 0 1.553172701562744e-08
Ca2 O 0 2.0307015802245587e-06
+ O 0 3.214345952073927e-06
transients O 0 7.942437150632031e-06
partially O 0 2.0723875877592945e-06
result O 0 1.6210519504511467e-07
from O 0 1.088334187215878e-07
an O 0 1.710054853276688e-08
influx O 0 5.876691133721579e-08
of O 0 1.9574120813103946e-07
extracellular O 0 5.04983233895473e-07
Ca2 O 0 5.062644277131767e-07
+ O 0 3.2781198910925013e-07
through O 0 9.215666096906716e-08
the O 0 2.3702537532699353e-07
l O 0 5.571313863583782e-07
- O 0 1.036584009739272e-07
type O 0 6.992559775653717e-08
Ca2 O 0 8.082560611910594e-07
+ O 0 6.729471238031692e-07
channel O 0 1.0766641480586259e-06
. O 0 6.937825105524098e-07

Neither O 0 6.091943942010403e-05
the O 0 9.922017852659337e-06
content O 0 9.106743164011277e-07
nor O 0 6.956999527574226e-07
the O 0 1.9514122584496363e-07
activity O 0 3.414337186313787e-07
of O 0 1.0538456081121694e-06
Na O 0 4.3882459976885e-06
+ O 0 7.407948032778222e-07
/ O 0 7.267201453942107e-07
K O 0 1.7011238924169447e-06
+ O 0 6.70587610329676e-07
ATPase O 0 2.4691962607903406e-06
and O 0 4.396542863105424e-07
sarcoplasmic O 0 7.86312284617452e-06
reticulum O 0 7.619167263328563e-06
Ca2 O 0 4.447304945642827e-06
+ O 0 6.4842997744563036e-06
- O 0 7.809531780367251e-06
ATPase O 0 1.1575284588616341e-05
are O 0 4.668633835080982e-08
affected O 0 1.590171052612277e-07
by O 0 4.022304835871182e-07
DMPK O 0 0.0001643822033656761
absence O 0 3.4175543987657875e-05
. O 0 2.19686990021728e-06

In O 0 3.235037002013996e-05
conclusion O 0 9.440971552976407e-06
, O 0 5.287027988742921e-07
our O 0 2.1180743203785823e-07
data O 0 3.6287417515268316e-07
suggest O 0 2.4954016453193617e-07
that O 0 4.2571161884552566e-07
DMPK O 0 4.206975063425489e-05
is O 0 6.576366899935238e-07
involved O 0 2.277078152701506e-07
in O 0 3.780361055305548e-07
modulating O 0 2.194187572968076e-06
the O 0 3.510700139486289e-07
initial O 0 3.732838536052441e-07
events O 0 1.9559361419396737e-07
of O 0 2.3949305614223704e-06
excitation O 0 2.988034611917101e-05
- O 0 8.86183261172846e-05
contraction O 0 0.00023332508862949908
coupling O 0 6.685265816486208e-06
in O 0 3.0804799280303996e-06
skeletal O 0 0.003126581199467182
muscle O 0 9.044624675880186e-06
. O 0 3.508795600737358e-07
. O 0 6.961585086173727e-07

Constitutional O 0 0.0027169331442564726
RB1 O 0 0.4080815017223358
- O 0 0.00028463598573580384
gene O 0 2.490787210263079e-06
mutations O 0 3.6776626188839145e-07
in O 0 2.871951210181578e-07
patients O 0 1.8232753973279614e-07
with O 0 1.0363883262698437e-07
isolated O 0 5.879078798898263e-06
unilateral B-Disease 0 0.00016039583715610206
retinoblastoma I-Disease 1 0.9985454082489014
. O 0 9.318879165221006e-06

In O 0 3.508546797093004e-05
most O 0 1.2829744946429855e-06
patients O 0 5.900299697714217e-07
with O 0 1.1710289271604779e-07
isolated O 0 5.052962023910368e-06
unilateral B-Disease 0 0.00011270243703620508
retinoblastoma I-Disease 1 0.9999314546585083
, O 0 2.5520123472233536e-06
tumor B-Disease 0 0.0007661817944608629
development O 0 1.0822054719028529e-06
is O 0 2.4603945547596595e-08
initiated O 0 1.0583320886325964e-07
by O 0 2.7096261234760277e-08
somatic O 0 5.614507472273544e-07
inactivation O 0 5.483111181092681e-06
of O 0 1.5777992530274787e-06
both O 0 1.3879549953799142e-07
alleles O 0 1.169950678558962e-07
of O 0 1.2144411130066146e-06
the O 0 4.3054305933765136e-06
RB1 O 0 0.00016491158748976886
gene O 0 2.2555352643394144e-06
. O 0 1.5490536497964058e-06

However O 0 3.641507282736711e-05
, O 0 9.68206563811691e-07
some O 0 2.0497694208643225e-08
of O 0 2.5575667450539186e-07
these O 0 6.983110267810844e-08
patients O 0 6.623162676078209e-07
can O 0 1.0521490168002856e-07
transmit O 0 4.194464963802602e-06
retinoblastoma B-Disease 0 0.10501185059547424
predisposition O 0 0.00024531898088753223
to O 0 8.540410476598481e-07
their O 0 7.40080224659323e-07
offspring O 0 6.330432370305061e-06
. O 0 2.444722213112982e-06

To O 0 6.144197413959773e-06
determine O 0 5.220675234340888e-07
the O 0 8.664055712870322e-07
frequency O 0 1.115739678425598e-06
and O 0 1.4619337207477656e-07
nature O 0 4.203472201425029e-07
of O 0 3.0482169677270576e-06
constitutional O 0 8.32658406579867e-05
RB1 O 0 0.0009815430967137218
- O 0 2.015345307881944e-05
gene O 0 3.381607598385017e-07
mutations O 0 1.0690155960446646e-07
in O 0 2.5260160896323214e-07
patients O 0 7.671743418313781e-08
with O 0 3.870603393352212e-08
isolated O 0 1.931042106662062e-06
unilateral B-Disease 0 3.18577658617869e-05
retinoblastoma I-Disease 0 0.0005638051079586148
, O 0 1.1083569262382298e-07
we O 0 1.7139145214173368e-08
analyzed O 0 5.173584938233944e-08
DNA O 0 9.032955006205157e-08
from O 0 6.666285230494395e-07
peripheral O 0 1.4183083294483367e-05
blood O 0 6.023646619723877e-06
and O 0 2.12940926758165e-06
from O 0 2.0739767933264375e-05
tumor B-Disease 1 0.9996716976165771
tissue O 0 0.00040988915134221315
. O 0 5.512072220881237e-06

The O 0 7.528056448791176e-05
analysis O 0 1.1480148714326788e-05
of O 0 0.00012709441944025457
tumors B-Disease 1 1.0
from O 0 3.326570731587708e-05
54 O 0 6.982542799960356e-06
( O 0 8.870264167626374e-08
71 O 0 7.732037943242176e-07
% O 0 4.9701618820563453e-08
) O 0 1.492472634367914e-08
of O 0 3.952395388751029e-07
76 O 0 6.42066652289941e-06
informative O 0 6.842762445558037e-07
patients O 0 3.6815859516536875e-07
showed O 0 3.146483550153789e-06
loss O 0 4.5491710807255e-06
of O 0 5.137554126122268e-06
constitutional O 0 2.8890051908092573e-05
heterozygosity O 0 9.241866791853681e-05
( O 0 2.0624031549232313e-06
LOH O 0 0.0006695556221529841
) O 0 3.631057552411221e-07
at O 0 4.029579031339381e-06
intragenic O 0 5.54268917767331e-05
loci O 0 1.0568917787168175e-05
. O 0 2.683437514860998e-06

Three O 0 2.2007043298799545e-05
of O 0 1.8613915017340332e-05
13 O 0 5.733683065045625e-05
uninformative O 0 0.0005129018099978566
patients O 0 3.8800380934844725e-06
had O 0 7.99549980001757e-06
constitutional O 0 4.022110442747362e-05
deletions O 0 5.2326515287859365e-05
. O 0 4.170516604062868e-06

For O 0 2.040458821284119e-05
39 O 0 4.000306216767058e-05
randomly O 0 3.566601435522898e-06
selected O 0 1.3602309081761632e-05
tumors B-Disease 1 0.9999998807907104
, O 0 5.1054053074039984e-06
SSCP O 0 0.0002777374174911529
, O 0 1.5248371028064867e-06
hetero O 0 1.0078207196784206e-05
- O 0 4.2564074647089e-06
duplex O 0 2.379404213570524e-05
analysis O 0 1.7115631578690227e-07
, O 0 5.2545857442964916e-08
sequencing O 0 4.418320145305188e-07
, O 0 8.960677888580904e-08
and O 0 9.435613179675784e-08
Southern O 0 8.510507996106753e-07
blot O 0 3.1866411518421955e-06
analysis O 0 1.5923578189358523e-07
were O 0 2.8100416216148005e-07
used O 0 5.78380543458934e-08
to O 0 5.238994305045708e-08
identify O 0 1.6795921453649498e-07
mutations O 0 2.505192469470785e-06
. O 0 3.924558768630959e-06

Mutations O 0 2.2891521439305507e-05
were O 0 7.531882147304714e-06
detected O 0 2.3055908968672156e-06
in O 0 4.442005092641921e-07
21 O 0 1.412410824741528e-06
( O 0 3.686999860974538e-08
91 O 0 8.597778560215374e-07
% O 0 8.199304346589997e-08
) O 0 5.2896300672955476e-08
of O 0 3.6372787235450232e-06
23 O 0 0.01507320161908865
tumors B-Disease 1 1.0
with O 0 0.00046743161510676146
LOH O 1 1.0
. O 0 2.7882695576408878e-05

In O 0 2.160642179660499e-05
6 O 0 9.162119567918126e-06
( O 0 2.552106934672338e-07
38 O 0 7.250241083056608e-07
% O 0 8.071324231195831e-08
) O 0 2.62272550344278e-08
of O 0 4.233922027196968e-06
16 O 0 0.00042095984099432826
tumors B-Disease 1 1.0
without O 0 0.00013496998872142285
LOH O 1 0.9999023675918579
, O 0 6.967218268982833e-07
one O 0 1.404495151291485e-07
mutation O 0 7.93873624616026e-08
was O 0 3.474826371530071e-06
detected O 0 4.677516187712172e-07
, O 0 2.2178094027935913e-08
and O 0 1.2577880070807623e-08
in O 0 9.587292737478492e-08
9 O 0 1.0163325896428432e-06
( O 0 3.0169079678898925e-08
56 O 0 4.477646484701836e-07
% O 0 1.1415753675692031e-07
) O 0 9.872249506770459e-08
of O 0 4.856203759118216e-06
the O 0 0.00087166135199368
tumors B-Disease 1 1.0
without O 0 0.0014141203137114644
LOH O 1 0.9999949932098389
, O 0 4.4751405425813573e-07
both O 0 6.209970848658486e-08
mutations O 0 1.6223944498960918e-07
were O 0 7.949598170853278e-07
found O 0 3.1190288041216263e-07
. O 0 4.744923103316978e-07

Thus O 0 2.9284045012900606e-05
, O 0 6.065949946787441e-07
a O 0 2.22309978425983e-07
total O 0 5.601697807833261e-07
of O 0 2.172688255086541e-06
45 O 0 1.639407969378226e-06
mutations O 0 2.1899637658862048e-07
were O 0 1.8281330085301306e-06
identified O 0 8.611581279183156e-07
in O 0 4.208352038403973e-06
tumors B-Disease 1 1.0
of O 0 0.0010072407312691212
36 O 0 0.00022136024199426174
patients O 0 1.0428330824652221e-05
. O 0 5.732335921493359e-06

Thirty O 0 0.0005678028101101518
- O 0 6.0855043557239696e-05
nine O 0 1.365192474622745e-05
of O 0 8.13101178209763e-06
the O 0 4.310623808123637e-06
mutations O 0 4.824432267014345e-07
- O 0 2.8792401280952618e-06
including O 0 7.260537131514866e-07
34 O 0 1.922704996104585e-06
small O 0 1.5471033520952915e-07
mutations O 0 1.3027928957853874e-07
, O 0 1.8774603915971966e-07
2 O 0 3.966142969602515e-07
large O 0 2.25252264840492e-07
structural O 0 9.243505337508395e-05
alterations O 0 0.00016595586203038692
, O 0 1.745525082696986e-06
and O 0 1.268104711016349e-06
hypermethylation O 0 0.00021297423518262804
in O 0 2.0157182007096708e-05
3 O 0 0.00013678921095561236
tumors O 1 1.0
- O 0 1.016892110783374e-05
were O 0 6.604241207242012e-07
not O 0 1.6153983040112507e-08
detected O 0 9.839634174113598e-08
in O 0 4.63224978375365e-08
the O 0 1.3388130071234627e-07
corresponding O 0 1.3020131746088737e-06
peripheral O 0 8.011825411813334e-05
blood O 0 1.2499036529334262e-05
DNA O 0 4.383026407595025e-06
. O 0 3.0386331673071254e-06

In O 0 5.614944893750362e-05
6 O 0 1.786454777175095e-05
( O 0 5.199325414650957e-07
17 O 0 1.240949814018677e-06
% O 0 9.886306884254736e-08
) O 0 3.618695032514552e-08
of O 0 6.06945036452089e-07
the O 0 2.6591164896672126e-06
36 O 0 8.348928531631827e-06
patients O 0 4.2184274207102135e-07
, O 0 9.097986719552864e-08
a O 0 2.0639720332837896e-07
mutation O 0 1.1292691937114796e-07
was O 0 6.099768143030815e-06
detected O 0 3.2295110941049643e-07
in O 0 1.963003484206638e-07
constitutional O 0 5.764943580288673e-07
DNA O 0 1.0290706597970711e-07
, O 0 7.091792753044501e-08
and O 0 6.393838702933863e-08
1 O 0 5.174754846848373e-07
of O 0 5.986349265185709e-07
these O 0 8.749182001110967e-08
mutations O 0 2.755914181307162e-07
is O 0 2.2115075637429982e-07
known O 0 2.743889808698441e-07
to O 0 3.021722250196035e-08
be O 0 9.629369657204734e-08
associated O 0 1.7744869751368242e-07
with O 0 7.683971858796212e-08
reduced O 0 7.907959115982521e-06
expressivity O 0 0.00011374952009646222
. O 0 7.554671810794389e-06

The O 0 5.4221280151978135e-05
presence O 0 8.269197678600904e-06
of O 0 1.0210511391051114e-05
a O 0 3.168162947986275e-06
constitutional O 0 1.2585106560436543e-05
mutation O 0 6.754591481694661e-07
was O 0 1.5254394384101033e-05
not O 0 6.960132736821834e-08
associated O 0 7.68011787499745e-08
with O 0 1.7250259887191532e-08
an O 0 8.212217039726966e-08
early O 0 5.426794587037875e-07
age O 0 1.3441879218589747e-06
at O 0 6.726899300701916e-06
treatment O 0 3.1884771942713996e-06
. O 0 1.8892188791141962e-06

In O 0 5.0784969062078744e-05
1 O 0 4.039708073833026e-05
patient O 0 1.1301508493488654e-05
, O 0 1.4180767493598978e-06
somatic O 0 1.554821210447699e-05
mosaicism O 0 0.00010754023969639093
was O 0 9.021313417179044e-06
demonstrated O 0 3.087733944084903e-07
by O 0 3.136310056106595e-08
molecular O 0 1.7425864484721387e-07
analysis O 0 2.572694235425388e-08
of O 0 1.7621778169996105e-07
DNA O 0 9.7083749039939e-08
and O 0 2.7355184784028097e-07
RNA O 0 2.3173802219389472e-06
from O 0 5.590124146692688e-06
peripheral O 0 0.00018914358224719763
blood O 0 3.0196368243196048e-05
. O 0 3.939486759918509e-06

In O 0 4.811296457774006e-05
2 O 0 2.91744163405383e-05
patients O 0 1.0555868357187137e-06
without O 0 2.952158979496744e-07
a O 0 6.143473569864e-07
detectable O 0 1.073243583959993e-05
mutation O 0 2.887002494844637e-07
in O 0 1.8512881752030808e-06
peripheral O 0 0.000120708325994201
blood O 0 2.1810128600918688e-05
, O 0 7.3474677719787e-07
mosaicism O 0 2.6081968826474622e-05
was O 0 6.2234094002633356e-06
suggested O 0 1.068251336278081e-07
because O 0 1.2643013747037912e-08
1 O 0 1.499832791296285e-07
of O 0 1.6284788273424056e-07
the O 0 1.2423661246430129e-06
patients O 0 4.394125880935462e-06
showed O 0 0.0003486070781946182
multifocal O 1 0.999998927116394
tumors B-Disease 1 1.0
and O 0 9.758964552020188e-06
the O 0 2.1601761091005756e-06
other O 0 2.8982681143929767e-08
later O 0 2.8045104727425496e-07
developed O 0 5.199319730309071e-07
bilateral B-Disease 0 6.802509597036988e-05
retinoblastoma I-Disease 0 0.02348143421113491
. O 0 9.371781743539032e-06

In O 0 7.549668225692585e-05
conclusion O 0 1.6684705769876018e-05
, O 0 1.0460973953740904e-06
our O 0 3.65346181752102e-07
results O 0 2.9362442433011893e-07
emphasize O 0 1.9913129278847919e-07
that O 0 8.075080870639795e-08
the O 0 7.335327723012597e-07
manifestation O 0 2.6247076675645076e-05
and O 0 6.527175742121472e-07
transmissibility O 0 4.955100666848011e-05
of O 0 1.3765666153631173e-05
retinoblastoma B-Disease 0 0.00012279760267119855
depend O 0 2.536043211875949e-06
on O 0 1.4056025975150988e-05
the O 0 1.8956095573230414e-06
nature O 0 6.094385298638372e-07
of O 0 3.1351344205177156e-06
the O 0 1.8846786815629457e-06
first O 0 1.6275670304821688e-06
mutation O 0 8.922169314473649e-08
, O 0 7.09946661459071e-08
its O 0 7.271181345913647e-08
time O 0 9.702876724304588e-08
in O 0 1.688505619767966e-07
development O 0 1.299993186876236e-06
, O 0 8.255625516540022e-08
and O 0 9.228048725162807e-08
the O 0 6.266625973694318e-07
number O 0 6.0976122995271e-07
and O 0 7.427543664562108e-07
types O 0 1.2734250276480452e-06
of O 0 0.000732549000531435
cells O 0 6.348939223244088e-06
that O 0 2.552070270667173e-07
are O 0 5.9657068618435e-08
affected O 0 1.2974933838449942e-07
. O 0 7.612724317596076e-08
. O 0 2.942209107459348e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9109900593757629
the I-Disease 0 0.00012174360017525032
fifth I-Disease 0 5.642971518682316e-05
component I-Disease 0 2.6888478714681696e-06
of I-Disease 0 7.0040782702562865e-06
complement I-Disease 0 3.8130240227474133e-06
in O 0 2.8399555958458222e-05
man O 0 0.00014553316577803344
. O 0 3.1322206268669106e-06

I O 0 0.0037930714897811413
. O 0 5.80227242608089e-05

Clinical O 0 0.02287708781659603
, O 0 5.2052979299332947e-05
immunochemical O 0 0.0009713215986266732
, O 0 1.229884333042719e-06
and O 0 3.0161953645801987e-07
family O 0 5.38448034603789e-07
studies O 0 2.736546321102651e-06
. O 0 2.1885095975449076e-06

The O 0 8.650681593280751e-06
first O 0 1.2998358442928293e-06
recognized O 0 1.4055016208658344e-06
human O 0 4.489598723012023e-06
kindred O 0 8.543239528080449e-05
with O 0 3.816767730313586e-06
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 1 0.9986839890480042
fifth I-Disease 1 0.8961596488952637
component I-Disease 0 2.536591091484297e-05
of I-Disease 0 2.4142913389368914e-05
complement I-Disease 0 5.662468083755812e-06
( O 0 2.3150123524828814e-06
C5 O 0 9.587522799847648e-05
) O 0 2.2714303327120433e-07
is O 0 7.948554525682994e-08
described O 0 3.3925871889550763e-07
. O 0 7.953086083034577e-07

The O 0 0.00027692964067682624
proband O 0 0.0009671942098066211
, O 0 5.199094630370382e-06
a O 0 3.243763785576448e-06
20 O 0 5.412573500507278e-06
- O 0 7.362895757978549e-06
year O 0 6.997835953370668e-06
- O 0 7.3351138780708425e-06
old O 0 4.4728330976795405e-06
black O 0 2.481693854861078e-07
female O 0 1.081469918062794e-06
with O 0 9.728624718263745e-06
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.9999992847442627
age O 0 0.0006757915834896266
11 O 0 6.370652045006864e-06
, O 0 1.0873361588892294e-07
lacked O 0 4.225491920806235e-06
serum O 0 8.3711369370576e-05
hemolytic O 0 0.15477629005908966
complement O 0 3.0871087801642716e-06
activity O 0 9.961134310287889e-06
, O 0 1.0435271491360254e-07
even O 0 2.5832511241219436e-08
during O 0 1.5490564919673488e-06
remission O 0 1.3454278814606369e-05
. O 0 1.3452511211653473e-06

C5 O 0 0.05829155445098877
was O 0 0.0006465449114330113
undetectable O 0 0.00046122560161165893
in O 0 3.19705463880382e-06
her O 0 1.504602096247254e-06
serum O 0 1.393401271343464e-05
by O 0 4.305174456931127e-07
both O 0 3.850039433928032e-07
immunodiffusion O 0 4.335780249675736e-05
and O 0 1.910178298203391e-06
hemolytic O 1 0.9999035596847534
assays O 0 5.057280577602796e-05
. O 0 4.375914159027161e-06

Other O 0 3.286178298367304e-06
complement O 0 3.4775184758473188e-06
components O 0 3.958331944886595e-06
were O 0 9.227342729900556e-07
normal O 0 1.1090140787928249e-06
during O 0 1.9424846868787427e-06
remission O 0 1.1057044503104407e-05
of O 0 7.668095349799842e-06
lupus O 0 0.00011943833669647574
, O 0 9.702891929919133e-07
but O 0 4.0368308873439673e-07
C1 O 0 3.0451077691395767e-05
, O 0 3.9620300640308415e-07
C4 O 0 1.7591413779882714e-05
, O 0 3.6879603726447385e-07
C2 O 0 7.092156920407433e-06
, O 0 1.389752384284293e-07
and O 0 3.12657221002155e-07
C3 O 0 0.0005343423108570278
levels O 0 5.140474604559131e-05
fell O 0 0.006090324372053146
during O 0 1.7294314602622762e-05
exacerbations O 0 0.002639382379129529
. O 0 7.280059890035773e-06

A O 0 0.001835568225942552
younger O 0 2.8278162062633783e-05
half O 0 4.990317847841652e-06
- O 0 8.916884326026775e-06
sister O 0 9.530846909910906e-06
, O 0 3.717278787007672e-07
who O 0 1.33168072125045e-07
had O 0 4.639315193344373e-06
no O 0 3.518907760735601e-05
underlying O 1 0.9999998807907104
disease O 1 0.9999992847442627
, O 0 2.7282676455797628e-06
was O 0 6.335432408377528e-05
also O 0 2.1629723789828859e-07
found O 0 8.465792689094087e-08
to O 0 7.61933307558138e-08
lack O 0 1.0992741408699658e-05
immunochemically O 0 0.002260389272123575
detectable O 0 0.09955024719238281
C5 O 0 0.03251488879323006
. O 0 6.803637006669305e-06

By O 0 0.00025707113672979176
hemolytic O 1 0.9999345541000366
assay O 0 0.0005729757249355316
, O 0 2.771688741631806e-06
she O 0 2.2861081561131869e-07
exhibited O 0 3.184578190484899e-06
1 O 0 6.334239515126683e-07
- O 0 1.9645915472210618e-07
2 O 0 1.3134076937149075e-07
% O 0 3.152798200289908e-08
of O 0 3.8547420899703866e-07
the O 0 1.2410397403073148e-06
normal O 0 7.815469871275127e-06
serum O 0 1.6353764294763096e-05
C5 O 0 2.9397646358120255e-05
level O 0 2.496468596291379e-06
and O 0 7.72358603740031e-08
normal O 0 2.234605460671446e-07
concentrations O 0 2.5343697984681057e-07
of O 0 2.590161614079989e-07
other O 0 2.7319094542122002e-08
complement O 0 7.943414175315411e-07
components O 0 6.48299510430661e-06
. O 0 2.0180850697215647e-06

C5 O 0 0.01650145649909973
levels O 0 0.00028972988366149366
of O 0 4.158812953392044e-05
other O 0 5.746385340898996e-07
family O 0 2.9274815460667014e-07
members O 0 5.445365047762607e-08
were O 0 5.198918415771914e-07
either O 0 1.1775860286888928e-07
normal O 0 1.3208632481109817e-06
or O 0 2.3161352658007672e-07
approximately O 0 3.864363407046767e-07
half O 0 6.432412646972807e-07
- O 0 1.6336410908479593e-06
normal O 0 4.2284969481443113e-07
, O 0 1.7552885367422277e-08
consistent O 0 6.190056467403338e-08
with O 0 2.663488807286285e-08
autosomal O 0 1.9334763692313572e-06
codominant O 0 6.909723197168205e-06
inheritance O 0 1.9090258263076976e-07
of O 0 3.389156120192638e-07
the O 0 6.94707409820694e-07
gene O 0 2.174174369429238e-06
determining O 0 4.705162064055912e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 9.678765309217852e-06

Normal O 0 0.008427624590694904
hemolytic O 1 0.9999393224716187
titers O 0 0.004293476231396198
were O 0 1.2225439604662824e-05
restored O 0 8.380869985558093e-06
to O 0 1.4601640430100815e-07
both O 0 2.3446196451004653e-07
homozygous O 0 9.280963240598794e-06
C5 B-Disease 1 0.9999903440475464
- I-Disease 1 0.8640976548194885
deficient I-Disease 1 0.9999991655349731
( O 0 2.6507434540690156e-06
C5D B-Disease 1 0.9999960660934448
) O 0 1.9392921046801348e-07
sera O 0 2.526724756535259e-06
by O 0 1.3215490035634048e-08
addition O 0 1.8086945274831123e-08
of O 0 6.551803153342917e-07
highly O 0 2.122797241099761e-06
purified O 0 2.3883159883553162e-05
human O 0 1.5896608601906337e-05
C5 O 0 0.0004199412069283426
. O 0 1.7990852256843937e-06

In O 0 8.4632498328574e-05
specific O 0 1.4171996554068755e-05
C5 O 0 0.0015716672642156482
titrations O 0 0.00022234891366679221
, O 0 1.9432386579865124e-06
however O 0 4.734996252864221e-07
, O 0 1.0659249483069289e-07
it O 0 2.6768120164888387e-08
was O 0 2.4973783183668274e-06
noted O 0 1.4559063288288598e-07
that O 0 2.2746467820411453e-08
when O 0 3.3184342385084165e-08
limited O 0 3.1997061000765825e-08
amounts O 0 8.817399077543087e-08
of O 0 3.443070227149292e-06
C5 O 0 3.2660627766745165e-05
were O 0 1.1386064215912484e-06
assayed O 0 2.105118710460374e-06
in O 0 1.5640939921013342e-07
the O 0 1.324064982100026e-07
presence O 0 1.343741615755789e-07
of O 0 1.500117605246487e-06
low O 0 1.3562723324866965e-05
dilutions O 0 2.790504186123144e-05
of O 0 1.9475246517686173e-05
either O 0 2.3406135369441472e-05
C5D B-Disease 1 0.9999988079071045
serum O 0 0.00015204476949293166
, O 0 1.6161892517629894e-06
curving O 0 9.63139973464422e-06
rather O 0 5.9250201189797735e-08
than O 0 3.405276771673016e-08
linear O 0 8.875016987985873e-07
dose O 0 3.116547986792284e-06
- O 0 2.4266810214612633e-06
response O 0 2.2458281989656825e-07
plots O 0 6.045568738954898e-07
were O 0 4.606148706898239e-07
consistently O 0 2.3755877975872863e-07
obtained O 0 2.0017125734739238e-07
, O 0 4.455198876485156e-08
suggesting O 0 5.514726097999301e-08
some O 0 2.034807522477422e-08
inhibitory O 0 4.16198645325494e-06
effect O 0 6.560802830790635e-06
. O 0 1.168668745776813e-06

Further O 0 2.1457590264617465e-05
studies O 0 1.1799251296906732e-05
suggested O 0 2.0145141661487287e-06
that O 0 2.815648088017042e-07
low O 0 1.591186628502328e-05
dilutions O 0 0.00010988389840349555
of O 0 0.00016689719632267952
C5D B-Disease 1 0.9999986886978149
serum O 0 3.4552638680906966e-05
contain O 0 8.58982900808769e-07
a O 0 1.5098111134648207e-06
factor O 0 7.820427185833978e-07
( O 0 6.645966266205505e-08
or O 0 5.137986391900995e-08
factors O 0 1.227232502287734e-07
) O 0 4.560381228202459e-08
interfering O 0 1.9031035947136843e-07
at O 0 1.2955574675288517e-06
some O 0 1.8443186533545486e-08
step O 0 3.5942278486800205e-07
in O 0 3.4217467259622936e-07
the O 0 2.538167564125615e-06
hemolytic O 0 0.006119126453995705
assay O 0 1.4369985365192406e-05
of O 0 5.2546234655892476e-05
C5 O 0 0.00021649037080351263
, O 0 1.8412927715871774e-07
rather O 0 2.6469891167835158e-08
than O 0 1.849130093489748e-08
a O 0 1.6674260905347182e-07
true O 0 1.1237573289690772e-06
C5 O 0 6.764917634427547e-05
inhibitor O 0 2.6589503249851987e-05
or O 0 9.087647754313366e-07
inactivator O 0 2.754367596935481e-05
. O 0 8.000891398296517e-07

Of O 0 0.00011833190364995971
clinical O 0 0.00022836860443931073
interest O 0 3.657834167825058e-05
are O 0 5.23466951563023e-07
( O 0 1.3141294630258926e-07
a O 0 1.0271899952840613e-07
) O 0 1.3789879460546217e-08
the O 0 5.1878142670602756e-08
documentation O 0 9.11624113086873e-07
of O 0 0.00046533040585927665
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 1 0.9985358715057373
vasculitis B-Disease 1 1.0
, O 0 0.00024896746617741883
and O 0 0.00013838295126333833
arthritis B-Disease 1 1.0
in O 0 1.7515516447019763e-05
an O 0 1.4116984630163643e-06
individual O 0 2.5894405553117394e-07
lacking O 0 3.630459832493216e-05
C5 O 0 0.00015544930647592992
( O 0 2.0019282942485006e-07
and O 0 7.20231838613472e-08
its O 0 2.8519480110844597e-07
biologic O 0 1.262687237613136e-05
functions O 0 1.2085279195162002e-06
) O 0 5.063049712816792e-08
, O 0 3.6334956377004346e-08
and O 0 5.73662859437718e-08
( O 0 5.516819712170218e-08
b O 0 2.4336168280569836e-07
) O 0 1.1890112894263893e-08
a O 0 5.98803922002844e-08
remarkable O 0 6.304047133198765e-07
propensity O 0 1.0168513654207345e-05
to O 0 2.925314902313403e-06
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 0.00032651107176207006
the O 0 9.075894195120782e-05
proband O 0 9.850294736679643e-05
, O 0 1.6726835383451544e-07
even O 0 3.165566653251517e-08
during O 0 2.9710881221944874e-07
periods O 0 3.783307818139292e-07
of O 0 1.5207272099360125e-06
low O 0 1.1339889169903472e-05
- O 0 1.314612404712534e-06
dose O 0 1.1885180128956563e-06
or O 0 2.868680439860327e-07
alternate O 0 6.638516651946702e-07
- O 0 4.050632014696021e-06
day O 0 3.3530732252984308e-06
corticosteroid O 0 0.00022750449716113508
therapy O 0 1.0164519153477158e-05
. O 0 9.309846973337699e-07

Other O 0 4.114772309549153e-06
observations O 0 7.304246992134722e-06
indicate O 0 1.0561351700744126e-05
that O 0 8.968053180069546e-07
the O 0 1.4821990589553025e-05
C5D B-Disease 1 0.9999942779541016
state O 0 2.571036702647689e-06
is O 0 5.608989681604726e-07
compatible O 0 2.8120092565586674e-07
with O 0 3.782116664297064e-08
normal O 0 4.140288183407392e-06
coagulation O 0 1.8748243746813387e-05
function O 0 1.7970327235161676e-06
and O 0 2.0871883066320152e-07
the O 0 2.664261842255655e-07
capacity O 0 1.1079210935349693e-06
to O 0 1.3002608056922327e-07
mount O 0 2.9345774237299338e-05
a O 0 2.1796363398607355e-06
neutrophilic O 0 0.00033265945967286825
leukocytosis O 0 0.0005272389389574528
during O 0 6.687997665721923e-05
pyogenic B-Disease 0 0.0009077118593268096
infection I-Disease 0 2.056111225101631e-05
. O 0 1.9178726518020994e-07
. O 0 4.84990096083493e-07

Susceptibility O 1 0.9922829270362854
to O 0 0.004828593693673611
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.8245917558670044
twins O 0 0.00033663283102214336
: O 0 3.731952631369495e-07
the O 0 3.661204743821145e-07
role O 0 4.0080374219542136e-07
of O 0 2.5421331883990206e-06
genes O 0 5.54577866296313e-07
, O 0 9.643390512792394e-07
HLA O 0 2.9264838303788565e-05
, O 0 1.9670831363782781e-07
and O 0 1.408683090176055e-07
the O 0 1.210946038554539e-06
environment O 0 3.433210622461047e-06
. O 0 1.5951346767906216e-06

OBJECTIVE O 0 7.157241634558886e-05
To O 0 2.0761774521815823e-06
determine O 0 4.0904112097450707e-07
the O 0 1.0664876981536509e-06
relative O 0 7.085545348672895e-06
effects O 0 1.2756450814777054e-05
of O 0 2.0797483557544183e-06
genetic O 0 4.0940875578598934e-07
and O 0 1.9005209139777435e-07
environmental O 0 5.638304401145433e-07
factors O 0 1.9408943785492738e-07
in O 0 6.458333814407524e-07
susceptibility O 0 0.00043528186506591737
to O 0 0.00022043328499421477
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 8.744059596210718e-05
AS B-Disease 1 0.9999889135360718
) O 0 4.0179725147027057e-07
. O 0 2.2783206077292562e-07

METHODS O 0 0.0006032268283888698
Twins O 0 0.00045010700705461204
with O 0 4.678659024648368e-06
AS B-Disease 1 0.9998637437820435
were O 0 5.223282641964033e-06
identified O 0 2.4553929733883706e-07
from O 0 1.3559684930442018e-07
the O 0 1.0099696368115474e-07
Royal O 0 4.0706145227886736e-05
National O 0 0.00021369308524299413
Hospital O 1 0.9997146725654602
for O 0 0.00012030282232444733
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 8.812038868200034e-05
. O 0 4.565378276311094e-06

Clinical O 0 0.0008315539453178644
and O 0 6.885345101181883e-06
radiographic O 0 9.947660873876885e-05
examinations O 0 0.00012147828238084912
were O 0 4.5007191147306e-06
performed O 0 9.618014473744552e-07
to O 0 1.0444689735322754e-07
establish O 0 1.9706255898199743e-06
diagnoses O 0 0.000917336146812886
, O 0 2.8403680971678114e-06
and O 0 5.7645761444291566e-06
disease O 1 0.9997958540916443
severity O 0 0.4576251208782196
was O 0 0.00011993158841505647
assessed O 0 6.457483436861366e-07
using O 0 3.0386683391725455e-08
a O 0 4.2360039032018904e-08
combination O 0 5.098225841493331e-08
of O 0 4.2957168489010655e-07
validated O 0 5.251026777841616e-06
scoring O 0 2.6289819743396947e-06
systems O 0 8.483972123940475e-06
. O 0 1.029142822517315e-06

HLA O 0 0.009130045771598816
typing O 0 0.00032888512942008674
for O 0 1.918110683618579e-05
HLA O 0 0.00030768144642934203
- O 0 4.492927837418392e-05
B27 O 0 4.484695818973705e-05
, O 0 9.813830956773018e-07
HLA O 0 1.1129894119221717e-05
- O 0 4.9453205974714365e-06
B60 O 0 1.139170035457937e-05
, O 0 2.287111300347533e-07
and O 0 5.237106392996793e-07
HLA O 0 5.499075268744491e-05
- O 0 2.3721046090940945e-05
DR1 O 0 0.003017372451722622
was O 0 1.2241283002367709e-05
performed O 0 1.0398667882327572e-06
by O 0 3.0991390076451353e-07
polymerase O 0 5.212350060901372e-06
chain O 0 1.418244551132375e-06
reaction O 0 2.7276666969555663e-07
with O 0 4.436044065414535e-08
sequence O 0 2.8289929332458996e-07
- O 0 7.850750876059465e-07
specific O 0 4.7896051569296105e-08
primers O 0 3.043058541152277e-06
, O 0 1.4121575020453747e-07
and O 0 1.1380046061049143e-07
zygosity O 0 6.893866611790145e-06
was O 0 2.1129851575096836e-06
assessed O 0 9.671167617852916e-07
using O 0 2.3493716128086817e-07
microsatellite O 0 1.1527034075697884e-05
markers O 0 1.2974570381629746e-05
. O 0 2.800629545163247e-06

Genetic O 0 0.00011181151057826355
and O 0 7.11795883034938e-06
environmental O 0 4.514074589678785e-06
variance O 0 2.581936769274762e-06
components O 0 6.341078915284015e-06
were O 0 2.739920319072553e-06
assessed O 0 1.9594456261984305e-06
with O 0 1.0265240746321069e-07
the O 0 1.2494083421188407e-06
program O 0 1.254543576578726e-06
Mx O 0 1.5106065802683588e-05
, O 0 5.39741691341078e-08
using O 0 3.5953036103819613e-08
data O 0 1.6350971066003694e-07
from O 0 1.2383721070818865e-07
this O 0 2.3228260204177786e-08
and O 0 3.63305225903332e-08
previous O 0 2.503324481040181e-07
studies O 0 3.0416609320127463e-07
of O 0 1.5146250689213048e-06
twins O 0 1.2275722838239744e-05
with O 0 1.036749722516106e-06
AS B-Disease 1 0.9999251365661621
. O 0 3.295913984402432e-06

RESULTS O 0 0.00023657614656258374
Six O 0 8.929981959227007e-06
of O 0 9.651565051171929e-06
8 O 0 2.6199533749604598e-05
monozygotic O 0 2.4146505893440917e-05
( O 0 1.5930139625197626e-06
MZ O 0 0.00026702237664721906
) O 0 6.323314778455824e-07
twin O 0 1.0222690434602555e-05
pairs O 0 3.8190617601685517e-07
were O 0 9.907380444929004e-06
disease O 0 7.843280036468059e-05
concordant O 0 3.0332708774949424e-05
, O 0 1.1545605360652189e-07
compared O 0 1.6269154912151862e-07
with O 0 2.0206751827345215e-08
4 O 0 8.560764399589971e-07
of O 0 2.518818973840098e-06
15 O 0 3.6216861190041527e-06
B27 O 0 7.900903256086167e-06
- O 0 2.955385980385472e-06
positive O 0 1.0542437394178705e-06
dizygotic O 0 1.3532800039683934e-05
( O 0 8.124841315293452e-07
DZ O 0 7.217377424240112e-05
) O 0 2.2680578126710316e-07
twin O 0 4.6527761696779635e-06
pairs O 0 1.1132256361179316e-07
( O 0 6.705224819825162e-08
27 O 0 9.960251645679818e-07
% O 0 5.8268561531349405e-08
) O 0 1.4791587510387672e-08
and O 0 4.152131438672768e-08
4 O 0 6.528152880491689e-07
of O 0 4.909770268568536e-06
32 O 0 3.98463562305551e-05
DZ O 0 0.00206781760789454
twin O 0 7.100409857230261e-05
pairs O 0 2.578078408532747e-07
overall O 0 1.9021106254513143e-06
( O 0 4.2869263694456095e-08
12 O 0 8.296967735077487e-08
. O 0 4.9315094230450995e-09
5 O 0 1.048297022521183e-07
% O 0 9.395206745921314e-08
) O 0 9.426996427919221e-08
. O 0 4.3508327962626936e-07

Nonsignificant O 0 0.0037149095442146063
increases O 0 3.433683014009148e-05
in O 0 3.332113692522398e-06
similarity O 0 1.4438301150221378e-06
with O 0 8.778166460388093e-08
regard O 0 5.87000897667167e-07
to O 0 1.829694298294271e-07
age O 0 1.344751854048809e-05
at O 0 0.0385618656873703
disease O 0 0.007468797266483307
onset O 1 0.8588727116584778
and O 0 6.921818567207083e-07
all O 0 8.529213602059826e-08
of O 0 3.4471836443117354e-06
the O 0 1.435471585864434e-05
disease O 0 0.0005836193449795246
severity O 0 3.182367072440684e-05
scores O 0 2.4103649138851324e-06
assessed O 0 1.5074285784066888e-06
were O 0 7.015865435278101e-07
noted O 0 6.003821226840955e-07
in O 0 8.691762900525646e-07
disease O 0 7.479642954422161e-05
- O 0 2.760952338576317e-05
concordant O 0 0.0001714859827188775
MZ O 0 0.13058869540691376
twins O 0 1.3989775652589742e-05
compared O 0 1.143342956311244e-06
with O 0 2.343464018395025e-07
concordant O 0 0.0003812519134953618
DZ O 1 0.9990003705024719
twins O 0 0.00023051330936141312
. O 0 5.59920545128989e-06

HLA O 0 0.30062335729599
- O 0 0.0018052634550258517
B27 O 0 0.0006475614500232041
and O 0 5.778749255114235e-06
B60 O 0 7.303978782147169e-05
were O 0 7.521158295276109e-06
associated O 0 1.335528509116557e-06
with O 0 1.8579548566322046e-07
the O 0 3.7288020394044e-05
disease O 1 0.5494565367698669
in O 0 2.8004746127407998e-05
probands O 0 0.0013056190218776464
, O 0 1.7621205472551082e-07
and O 0 4.38247305112327e-08
the O 0 2.3709478114142257e-07
rate O 0 3.153946408929187e-06
of O 0 1.0769515483843861e-06
disease O 0 1.717959275993053e-05
concordance O 0 2.0397117623360828e-05
was O 0 1.082489688997157e-05
significantly O 0 6.000558983032533e-07
increased O 0 2.8304145871516084e-06
among O 0 7.271805202435644e-07
DZ O 0 0.00022332966909743845
twin O 0 3.032293352589477e-05
pairs O 0 4.039958412249689e-07
in O 0 9.289040576732077e-07
which O 0 4.0055920180748217e-07
the O 0 2.615602397781913e-06
co O 0 9.561974366079085e-06
- O 0 1.01664381872979e-05
twin O 0 3.162254506605677e-05
was O 0 1.2289475307625253e-05
positive O 0 1.600289465386595e-07
for O 0 1.620898899545864e-07
both O 0 5.524316293303855e-07
B27 O 0 3.490292147034779e-05
and O 0 3.815282980212942e-06
DR1 O 0 0.24499066174030304
. O 0 4.544657258520601e-06

Additive O 0 0.00034239920205436647
genetic O 0 2.492341081961058e-05
effects O 0 4.225382144795731e-05
were O 0 2.664299927346292e-06
estimated O 0 2.197516266733146e-07
to O 0 2.622340389279998e-08
contribute O 0 5.029468042039298e-08
97 O 0 1.6747502513680956e-06
% O 0 4.3499692736759243e-08
of O 0 1.0997546695534766e-07
the O 0 1.1144663147888423e-07
population O 0 2.4822561783821584e-08
variance O 0 3.8297116589092184e-07
. O 0 5.735665240536036e-07

CONCLUSION O 0 0.0006905381451360881
Susceptibility O 0 0.0015187488170340657
to O 0 3.1466843211092055e-05
AS B-Disease 1 0.9997590184211731
is O 0 8.879521260496404e-07
largely O 0 4.779256528308906e-07
genetically O 0 5.904622923935676e-08
determined O 0 1.2125715898037015e-07
, O 0 6.107283923029172e-08
and O 0 8.934618023204166e-08
the O 0 8.723668543098029e-07
environmental O 0 3.734192205229192e-06
trigger O 0 5.951119419478346e-06
for O 0 9.149293873633724e-07
the O 0 1.978625004994683e-05
disease O 0 0.02866627462208271
is O 0 1.700116740721569e-06
probably O 0 2.7156904707226204e-06
ubiquitous O 0 5.312193934514653e-06
. O 0 8.781479436947848e-07

HLA O 1 0.5825526714324951
- O 0 0.000614697695709765
B27 O 0 0.00010858189489226788
accounts O 0 2.5990195240410685e-07
for O 0 5.0283169628073665e-08
a O 0 7.0673927154985e-08
minority O 0 1.3136677523561957e-08
of O 0 2.0481991214182926e-07
the O 0 2.2508370989271498e-07
overall O 0 2.372402832406806e-06
genetic O 0 7.438998750330938e-07
susceptibility O 0 7.762089080642909e-05
to O 0 8.375404831895139e-06
AS B-Disease 1 0.9999994039535522
. O 0 6.276013209571829e-06

Cell O 0 0.0019447320373728871
cycle O 0 0.00016077529289759696
- O 0 2.0373441657284275e-05
dependent O 0 3.7717038594564656e-06
colocalization O 0 1.7817488696891814e-05
of O 0 1.1026970241800882e-05
BARD1 O 0 0.00014918659871909767
and O 0 7.780523674227879e-07
BRCA1 O 0 6.652840056631248e-07
proteins O 0 6.920446082858689e-08
in O 0 1.4191738273439114e-07
discrete O 0 1.0778650221254793e-06
nuclear O 0 2.2378915673471056e-05
domains O 0 2.225225034635514e-05
. O 0 3.3982676086452557e-06

Germ O 0 0.15035323798656464
- O 0 0.00026695977430790663
line O 0 1.611801599210594e-05
mutations O 0 2.1569329078374722e-07
of O 0 1.8995908703800524e-06
the O 0 3.847187599603785e-06
BRCA1 O 0 1.3655388102051802e-05
gene O 0 2.169272192986682e-06
predispose O 0 5.901852091483306e-06
women O 0 1.6935986479893472e-07
to O 0 4.5716856078570345e-08
early O 0 8.713502211321611e-06
- O 1 0.5895124077796936
onset O 1 0.9999997615814209
breast B-Disease 1 1.0
and I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 5.691572937394085e-07
compromising O 0 7.338168188653071e-07
the O 0 9.780727623365237e-07
genes O 0 4.3462043208819523e-07
presumptive O 0 8.732426977076102e-06
function O 0 7.972929552124697e-07
as O 0 2.657243101111817e-07
a O 0 8.769629857852124e-07
tumor B-Disease 0 0.00044982368126511574
suppressor O 0 0.0008613797836005688
. O 0 2.8306656076892978e-06

Although O 0 1.1400611583667342e-05
the O 0 1.8045640899799764e-05
biochemical O 0 8.330762648256496e-05
properties O 0 5.467878145282157e-05
of O 0 4.801071190740913e-05
BRCA1 O 0 4.430704575497657e-05
polypeptides O 0 5.099231202621013e-06
are O 0 1.0030623087686763e-07
not O 0 5.342721820511542e-08
understood O 0 1.1409735378720143e-07
, O 0 1.8736123763574142e-08
their O 0 9.236286402369842e-09
expression O 0 1.198683605707629e-07
pattern O 0 9.106838660954963e-07
and O 0 2.9232910492282826e-07
subcellular O 0 4.219108814140782e-05
localization O 0 3.03923570754705e-05
suggest O 0 4.145516925291304e-07
a O 0 4.811690814676695e-07
role O 0 9.858736120804679e-07
in O 0 1.4014581211085897e-06
cell O 0 1.6172924006241374e-05
- O 0 1.4073542843107134e-05
cycle O 0 7.4456243055465166e-06
regulation O 0 4.059468665218446e-06
. O 0 1.5364565797426621e-06

When O 0 0.0005851014284417033
resting O 0 0.0014567001489922404
cells O 0 1.704833994153887e-05
are O 0 5.047323270446213e-07
induced O 0 1.3443838724924717e-05
to O 0 3.0327541367114463e-07
proliferate O 0 1.3463651384881814e-06
, O 0 1.1642075037343602e-07
the O 0 3.132837207431294e-07
steady O 0 8.045078175200615e-06
- O 0 3.791036817801796e-07
state O 0 9.968654524072917e-08
levels O 0 6.440423589992861e-07
of O 0 8.46060913772817e-07
BRCA1 O 0 9.569951089360984e-07
increase O 0 1.539743720968545e-06
in O 0 2.3124480321712326e-06
late O 0 1.9504481315379962e-05
G1 O 0 6.060108262317954e-06
and O 0 2.5365499922713752e-08
reach O 0 5.304492134428074e-08
a O 0 4.393126573631889e-08
maximum O 0 7.552118290732324e-07
during O 0 6.673398729617475e-06
S O 0 4.949301728629507e-05
phase O 0 1.5810641343705356e-05
. O 0 1.3095445865474176e-06

Moreover O 0 0.00018611480481922626
, O 0 4.5391734602162614e-06
in O 0 3.544067340044421e-06
S O 0 8.645173511467874e-05
phase O 0 3.584690057323314e-05
cells O 0 3.2844986890268046e-06
, O 0 5.89298849718034e-07
BRCA1 O 0 2.1442160687001888e-06
polypeptides O 0 1.7217639651789796e-06
are O 0 6.086027326546173e-08
hyperphosphorylated O 0 1.872810571512673e-06
and O 0 4.414486909354309e-08
accumulate O 0 2.0203388828576863e-07
into O 0 9.868089279052583e-08
discrete O 0 1.4657897509096074e-06
subnuclear O 0 1.7019552615238354e-05
foci O 0 2.7866482923855074e-05
termed O 0 8.455200259049889e-06
" O 0 2.5512335923849605e-06
BRCA1 O 0 2.7434396088210633e-06
nuclear O 0 1.2947401046403684e-05
dots O 0 1.4662072317150887e-05
. O 0 1.7763844653018168e-06

" O 0 0.0003434889076743275
BRCA1 O 0 0.00025603719404898584
associates O 0 8.8349828729406e-05
in O 0 1.4774268493056297e-06
vivo O 0 1.1478396118036471e-05
with O 0 1.5864250713093497e-07
a O 0 2.3192949356598547e-06
structurally O 0 3.239837315049954e-05
related O 0 2.7125638553116005e-06
protein O 0 2.0153031073277816e-05
termed O 0 0.0001116724670282565
BARD1 O 0 0.0023487380240112543
. O 0 7.209216164483223e-06

Here O 0 0.00010434618161525577
we O 0 1.441631297893764e-06
show O 0 5.821534614369739e-07
that O 0 1.4439180517911154e-07
the O 0 1.0660220368663431e-06
steady O 0 1.6187212168006226e-05
- O 0 6.766777005395852e-07
state O 0 3.7057048984934227e-07
levels O 0 5.154662176209968e-06
of O 0 2.3442456949851476e-05
BARD1 O 0 0.0005039153038524091
, O 0 3.433144399878074e-07
unlike O 0 6.450085976439368e-08
those O 0 3.027578188152802e-08
of O 0 1.0190015018451959e-06
BRCA1 O 0 2.5076449219341157e-06
, O 0 8.136180440487806e-08
remain O 0 1.143027503758276e-07
relatively O 0 1.2557168638238636e-08
constant O 0 9.2368011905819e-08
during O 0 9.362743753627001e-07
cell O 0 3.137655994578381e-06
cycle O 0 5.815885742777027e-06
progression O 0 2.0981755369575694e-05
. O 0 1.2823775250581093e-06

However O 0 0.0001373631675960496
, O 0 1.3026021406403743e-05
immunostaining O 0 0.0001512062008259818
revealed O 0 1.535360934212804e-05
that O 0 6.537354693136876e-07
BARD1 O 0 7.715596439084038e-05
resides O 0 5.111563950777054e-06
within O 0 4.824257189284253e-07
BRCA1 O 0 1.119392209147918e-06
nuclear O 0 8.37007064546924e-06
dots O 0 3.3590422390261665e-06
during O 0 1.227429493155796e-05
S O 0 2.3861897716415115e-05
phase O 0 5.870311269973172e-06
of O 0 6.8278163780632894e-06
the O 0 4.879127573076403e-06
cell O 0 1.2896359294245485e-05
cycle O 0 4.368879672256298e-06
, O 0 3.112722524178935e-08
but O 0 1.0020885454764539e-08
not O 0 7.570800875100758e-09
during O 0 3.238819488160516e-07
the O 0 6.249771331567899e-07
G1 O 0 2.0325775039964356e-05
phase O 0 1.188803889817791e-05
. O 0 2.8552783533086767e-06

Nevertheless O 0 0.000630232912953943
, O 0 3.7251269532134756e-05
BARD1 O 0 0.0004916815087199211
polypeptides O 0 1.1350838576618116e-05
are O 0 2.187321257451913e-07
found O 0 1.1639743036084838e-07
exclusively O 0 4.2720134985074765e-08
in O 0 1.6158334403826302e-07
the O 0 4.7207439024532505e-07
nuclear O 0 3.1903691706247628e-06
fractions O 0 1.8804112187353894e-06
of O 0 7.756204468023498e-06
both O 0 2.955817308247788e-06
G1 O 0 3.846307299681939e-05
- O 0 2.249988028779626e-06
and O 0 7.778283475090575e-07
S O 0 2.8428499717847444e-05
- O 0 3.2038519748311955e-06
phase O 0 8.240368515544105e-06
cells O 0 2.776763267320348e-06
. O 0 1.0052884817923768e-06

Therefore O 0 8.775452442932874e-05
, O 0 4.911385985906236e-06
progression O 0 4.1977262299042195e-05
to O 0 8.379091127608262e-07
S O 0 3.331329207867384e-05
phase O 0 9.379400580655783e-06
is O 0 2.906545262248983e-07
accompanied O 0 3.605309473186935e-07
by O 0 6.187955392533695e-08
the O 0 1.306262475964104e-07
aggregation O 0 3.8017171277715534e-07
of O 0 1.5714816754552885e-06
nuclear O 0 2.8738890250679106e-05
BARD1 O 0 8.056690421653911e-05
polypeptides O 0 2.5937038117263e-06
into O 0 7.219881581477239e-07
BRCA1 O 0 4.135761173529318e-06
nuclear O 0 2.221222166554071e-05
dots O 0 2.8767601179424673e-05
. O 0 4.084344709553989e-06

This O 0 3.101655238424428e-05
cell O 0 9.054628026206046e-05
cycle O 0 2.2728851035935804e-05
- O 0 6.46396802039817e-06
dependent O 0 1.3125290934112854e-06
colocalization O 0 1.3812505130772479e-05
of O 0 7.081215244397754e-06
BARD1 O 0 0.00015191765851341188
and O 0 1.079210392163077e-06
BRCA1 O 0 2.565597014836385e-06
indicates O 0 1.7473388425059966e-06
a O 0 2.1949419704014872e-07
role O 0 4.608205301792623e-07
for O 0 5.276601200421283e-07
BARD1 O 0 6.348882016027346e-05
in O 0 2.9850118608010234e-06
BRCA1 O 0 1.4695388927066233e-05
- O 0 4.2242540075676516e-05
mediated O 0 0.00012295154738239944
tumor B-Disease 1 0.7226166129112244
suppression O 0 0.019054997712373734
. O 0 3.173950972268358e-06

Ethnic O 0 4.782257292390568e-06
differences O 0 4.701362740888726e-06
in O 0 5.500452061824035e-06
the O 0 6.742866389686242e-06
HFE O 0 0.0002682338817976415
codon O 0 2.8708018362522125e-05
282 O 0 1.3822573237121105e-05
( O 0 1.4364410390044213e-06
Cys O 0 0.00026753151905722916
/ O 0 2.8794165700674057e-05
Tyr O 0 4.9485181079944596e-05
) O 0 3.758113962248899e-07
polymorphism O 0 3.7756121855636593e-06
. O 0 3.554343493306078e-06

Recent O 0 1.0835163266165182e-05
studies O 0 2.515998176022549e-06
have O 0 1.9780409843406233e-07
shown O 0 1.0396466905149282e-06
that O 0 8.951758900366258e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.0002192607062170282
HH B-Disease 1 1.0
) O 0 1.1571888762773597e-06
is O 0 1.5844867107261962e-07
likely O 0 9.324475058747339e-08
to O 0 5.8962722704336556e-08
be O 0 3.173989000515576e-07
caused O 0 4.3303521124471445e-06
by O 0 1.3449916025365383e-07
homozygosity O 0 4.522434210230131e-06
for O 0 2.2087485263000417e-07
a O 0 9.311053759120114e-07
Cys282Tyr O 0 6.2563653955294285e-06
mutation O 0 1.669360898404193e-07
in O 0 5.79570382797101e-07
the O 0 1.7894360553327715e-06
HFE O 0 3.4027576475637034e-05
gene O 0 5.511697054316755e-07
located O 0 3.894117526215268e-06
4 O 0 2.6355764930485748e-06
. O 0 4.1336653566759196e-07

5 O 0 0.0001579711533850059
Mb O 0 0.001058799447491765
telomeric O 0 0.0003813925723079592
to O 0 1.9084565792581998e-05
HLA O 0 0.0043927887454628944
- O 0 0.00010197416122537106
A O 0 5.455076097860001e-05
. O 0 2.2453796191257425e-06

Population O 0 6.781482170481468e-06
studies O 0 2.4395731088588946e-06
of O 0 1.1957156402786495e-06
this O 0 7.323417605675786e-08
polymorphism O 0 2.490646693331655e-07
are O 0 3.7807968311653894e-08
facilitated O 0 7.418015002258471e-07
by O 0 9.680029222636222e-08
the O 0 2.0793883948044822e-07
fact O 0 5.0093820647134635e-08
that O 0 4.220431293333604e-08
the O 0 6.572730626430712e-07
Cys282Tyr O 0 1.1731359336408786e-05
mutation O 0 3.589729828945565e-07
creates O 0 8.257205763584352e-07
a O 0 1.3941024690211634e-06
Rsal O 0 3.6002511478727683e-05
restriction O 0 5.03896353620803e-06
site O 0 6.884175945742754e-06
. O 0 9.846004331848235e-07

We O 0 2.302446409885306e-05
have O 0 8.058461844484555e-07
studied O 0 5.6916114772320725e-06
the O 0 2.5604765596654033e-06
codon O 0 1.092831098503666e-05
282 O 0 1.0350809134251904e-05
( O 0 2.0720001430163393e-06
Cys O 0 0.0006206661928445101
/ O 0 2.7637659513857216e-05
Tyr O 0 2.5526680474285968e-05
) O 0 8.430728826169798e-08
polymorphism O 0 1.162272766919159e-07
in O 0 6.257721452129772e-08
different O 0 4.076085691195885e-09
ethnic O 0 1.7760571680014436e-08
groups O 0 7.04982312527136e-08
. O 0 4.862136506744719e-07

In O 0 2.711542219913099e-05
agreement O 0 4.401893420435954e-06
with O 0 3.4814001992344856e-07
previous O 0 7.916652066342067e-06
observations O 0 6.1617074607056566e-06
the O 0 1.0403218766441569e-05
Tyr O 0 5.816061093355529e-05
allele O 0 2.443084213155089e-06
appeared O 0 3.071292439926765e-06
to O 0 1.41141825338309e-07
be O 0 1.3281878352700005e-07
rare O 0 2.9578177418443374e-07
or O 0 5.4710528729629e-07
absent O 0 1.21530308661022e-06
in O 0 3.4855392527788354e-07
Asiatic O 0 2.7888381737284362e-06
( O 0 3.876417764558937e-08
Indian O 0 1.4854981600365136e-07
, O 0 5.661970448045395e-08
Chinese O 0 1.6801273261535243e-07
) O 0 4.138382081464442e-08
populations O 0 3.738624343441188e-08
. O 0 2.4742402615629544e-07

The O 0 4.799596717930399e-05
highest O 0 2.723073703236878e-05
allele O 0 1.7813958947954234e-06
frequency O 0 2.070757545880042e-06
( O 0 7.186345385434834e-08
7 O 0 1.6090842791527393e-07
. O 0 5.070633246617717e-09
5 O 0 3.569829587490858e-08
% O 0 1.4630502143120339e-08
) O 0 1.2113853031792132e-08
was O 0 8.372325623895449e-07
found O 0 3.813845594891063e-08
in O 0 2.776482688204851e-07
Swedes O 0 4.629450813808944e-06
. O 0 9.118971320276614e-07

Saamis O 0 0.001026215497404337
( O 0 5.266072093945695e-06
2 O 0 2.4308085357915843e-06
% O 0 2.2125033183328924e-07
) O 0 5.2615860113292e-08
and O 0 1.2269387639207707e-07
Mordvinians O 0 3.869352440233342e-06
( O 0 8.791940331320802e-08
1 O 0 2.400953462711186e-07
. O 0 9.032642189765738e-09
8 O 0 1.3926246822393296e-07
% O 0 3.242799806457697e-08
) O 0 9.203858120088171e-09
had O 0 1.6744216679853707e-07
significantly O 0 1.5435192324275704e-07
lower O 0 1.1491104032756994e-06
frequencies O 0 3.097614182934194e-07
of O 0 1.5682463754274067e-06
the O 0 5.150013748789206e-06
Tyr O 0 4.720064680441283e-05
allele O 0 3.02605963042879e-06
. O 0 1.1260596011197777e-06

Comparisons O 0 2.594302532088477e-05
with O 0 5.843377834935382e-07
allele O 0 2.079706746371812e-06
frequencies O 0 1.4720247918376117e-06
based O 0 1.7384002148901345e-07
on O 0 1.0984587106577237e-06
prevalence O 0 1.332487772742752e-05
estimates O 0 1.3001989600525121e-06
of O 0 5.978190529276617e-06
HH B-Disease 1 0.9999474287033081
showed O 0 3.258900687796995e-05
some O 0 3.7396978314063745e-07
disagreements O 0 3.3789879125833977e-06
with O 0 2.43364695506898e-07
the O 0 2.386308096902212e-06
RFLP O 0 6.584427410416538e-06
data O 0 4.925495886709541e-07
, O 0 5.121402324448354e-08
particularly O 0 8.174414034556321e-08
in O 0 4.3761667711805785e-07
Finns O 0 3.1740842132421676e-06
. O 0 1.2297882676648442e-06

The O 0 0.0002198380243498832
newly O 0 9.978557500289753e-05
described O 0 2.3132701244321652e-05
HFE O 0 0.0010485942475497723
marker O 0 8.065514703048393e-05
provides O 0 1.1821875887108035e-06
a O 0 9.453182769902924e-07
new O 0 3.1323949656325567e-07
approach O 0 3.076872587826074e-07
to O 0 1.1116766529539746e-07
the O 0 6.274058819144557e-07
screening O 0 7.324505872929876e-07
of O 0 2.770574610622134e-05
HH B-Disease 1 0.999988317489624
as O 0 1.5358998552983394e-06
well O 0 5.312643125421346e-08
as O 0 3.707619811166296e-08
studies O 0 4.618442872583728e-08
of O 0 1.6730217566873762e-07
the O 0 2.0735525652071374e-07
relationship O 0 1.1963811630266719e-07
between O 0 8.533303912372503e-07
the O 0 4.996766165277222e-06
HFE O 0 0.0006204699166119099
Tyr O 0 2.372502967773471e-05
allele O 0 7.125975116650807e-07
and O 0 1.0218962387398278e-07
different O 0 1.2930600234994927e-07
disorders O 1 0.9949500560760498
including O 0 0.00020950680482201278
cancer B-Disease 1 0.9999994039535522

Autosomal B-Disease 1 0.9999982118606567
dominant I-Disease 1 0.9999953508377075
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9998713731765747
associated O 0 2.27665782404074e-06
with O 0 1.0801427663409413e-07
a O 0 8.535020583622099e-07
missense O 0 2.1825608200742863e-06
mutation O 0 3.8495034004881745e-07
encoding O 0 7.944763069644978e-07
Gly23 O 0 1.8142340195481665e-05
- O 0 3.5618493257061346e-06
- O 0 4.5728897930530366e-06
> O 0 3.442308525336557e-06
Val O 0 9.888765816867817e-06
in O 0 1.6484619891343755e-06
neurophysin O 0 0.00022282027930486947
II O 1 0.9550999999046326
. O 0 7.909482519607991e-06

Autosomal B-Disease 1 0.9999815225601196
dominant I-Disease 1 0.9998732805252075
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999936819076538
( O 0 1.550275737827178e-05
ADNDI B-Disease 0 0.4950118362903595
) O 0 5.610733637695375e-07
is O 0 2.0373849451971182e-07
an O 0 3.1369081625598483e-06
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 1.0
by O 0 0.00026202513254247606
progressive O 1 0.9999009370803833
degeneration O 1 0.9999998807907104
of O 0 0.03389095142483711
the O 0 5.15589454153087e-05
magnocellular O 0 0.00013171050522942096
neurons O 0 4.710055236500921e-06
of O 0 1.1806151633209083e-05
the O 0 2.3570863049826585e-05
hypothalamus O 0 3.0239938496379182e-05
leading O 0 1.1025697858713102e-05
to O 0 2.1872210709261708e-07
decreased O 0 2.7697396944859065e-05
ability O 0 3.913601176463999e-07
to O 0 2.5405842052350636e-07
produce O 0 5.368913207348669e-07
the O 0 1.8054490283248015e-05
hormone O 0 4.053917291457765e-05
arginine O 0 1.3035740266786888e-05
vasopressin O 0 8.027711373870261e-06
( O 0 1.128237386183173e-06
AVP O 0 5.9286114264978096e-05
) O 0 2.0676917245054938e-07
. O 0 5.598205348178453e-07

Affected O 0 7.14733760105446e-05
individuals O 0 6.028435564076062e-07
are O 0 3.591041490835778e-07
not O 0 1.260762019228423e-07
symptomatic O 0 3.303955963929184e-05
at O 0 1.5784007700858638e-05
birth O 0 3.956316504627466e-06
, O 0 5.038512540522788e-08
but O 0 1.3377442265039008e-08
usually O 0 1.1033285574058027e-07
develop O 0 8.074986226347391e-07
diabetes B-Disease 1 0.9997326731681824
insipidus I-Disease 0 0.0014551818603649735
at O 0 0.00010911749268416315
1 O 0 2.1386326807260048e-06
- O 0 1.8167005464420072e-06
6 O 0 5.861595582246082e-06
yr O 0 3.1550254789181054e-05
of O 0 2.3542324925074354e-06
age O 0 9.45807641983265e-06
. O 0 1.5919371207928634e-06

The O 0 1.3824471352563705e-05
genetic O 0 2.3498942027799785e-06
locus O 0 1.617864654690493e-05
of O 0 3.279386510257609e-05
the O 0 7.982000533957034e-05
disease O 0 0.009976893663406372
is O 0 2.783141781037557e-06
the O 0 1.2493126632762142e-05
AVP O 0 0.00025915232254192233
- O 0 1.4683425433759112e-05
neurophysin O 0 2.8655120331677608e-05
II O 0 0.0073015992529690266
( O 0 9.934893796526012e-07
NPII O 0 4.307664858060889e-05
) O 0 1.7475592528626294e-07
gene O 0 1.3239070995041402e-07
, O 0 8.623550229458488e-08
and O 0 1.3870048576336558e-07
mutations O 0 1.7570914678799454e-07
that O 0 5.363827426663192e-07
cause O 0 3.2758449378889054e-05
ADNDI B-Disease 0 0.006045043468475342
have O 0 1.096984760806663e-06
been O 0 8.349011864083877e-07
found O 0 5.226767996191484e-08
in O 0 5.161609450965443e-08
both O 0 3.8481008601820577e-08
the O 0 4.479252311284654e-07
signal O 0 7.785299203533214e-06
peptide O 0 2.2996925963525428e-06
of O 0 8.772525688982569e-06
the O 0 2.1280986402416602e-05
prepro O 0 0.000397518218960613
- O 0 0.00041867210529744625
AVP O 0 0.0010790341766551137
- O 0 2.042438973148819e-05
NPII O 0 9.279741789214313e-05
precursor O 0 6.5650833676045295e-06
and O 0 1.5455681534604082e-07
within O 0 6.454553158619092e-07
NPII O 0 7.821284089004621e-05
itself O 0 1.1439308309491025e-06
. O 0 1.9730664462258574e-06

An O 0 0.00014783593360334635
affected O 0 3.398950138944201e-05
girl O 0 3.2045922125689685e-05
who O 0 1.368068296869751e-06
presented O 0 3.430693823247566e-06
at O 0 2.355180731683504e-05
9 O 0 5.4525739869859535e-06
months O 0 1.042126427819312e-06
of O 0 1.8623202322487487e-06
age O 0 5.290248282108223e-06
and O 0 8.9837783434632e-07
her O 0 2.4834982923493953e-06
similarly O 0 1.5175040971371345e-05
affected O 0 1.2398293620208278e-05
younger O 0 1.427347888238728e-05
brother O 0 3.5502747778082266e-05
and O 0 1.6658078720865888e-06
father O 0 3.733818175533088e-06
were O 0 7.771536161271797e-07
all O 0 3.214264054918203e-08
found O 0 4.9711569971577774e-08
to O 0 2.3527141124191076e-08
have O 0 5.9310238498255785e-08
a O 0 1.543174903417821e-07
novel O 0 4.820963681595458e-07
missense O 0 2.48091782850679e-06
mutation O 0 3.7281139952938247e-07
( O 0 1.2234836788138637e-07
G1758 O 0 2.9353445825108793e-06
- O 0 1.1516709719217033e-06
- O 0 2.3034065179672325e-06
> O 0 1.4521818911816808e-06
T O 0 1.8287990997123416e-06
) O 0 3.109031965209397e-08
encoding O 0 5.224913834922518e-08
the O 0 9.142690942098852e-07
amino O 0 7.838361852918752e-07
acid O 0 4.2749763906613225e-07
substitution O 0 1.4327266626423807e-06
Gly23 O 0 8.963359505287372e-06
- O 0 3.4060676625813358e-06
- O 0 3.973354523623129e-06
> O 0 2.443897301418474e-06
Val O 0 1.8691756849875674e-05
within O 0 3.81634890800342e-06
NPII O 0 0.0002592306991573423
. O 0 4.804230684385402e-06

The O 0 5.396732012741268e-05
mutation O 0 4.441586952452781e-06
was O 0 5.606670129054692e-06
confirmed O 0 2.665222496034403e-07
by O 0 3.802318460088827e-08
restriction O 0 1.121067384701746e-06
endonuclease O 0 1.5759822417749092e-05
analysis O 0 7.544222171418369e-07
. O 0 1.0694689080992248e-06

A O 0 0.0010369118535891175
T1 O 0 0.00546644814312458
- O 0 3.9458762330468744e-05
weighted O 0 1.612099731573835e-05
magnetic O 0 7.595965598738985e-06
resonance O 0 4.561160949378973e-06
imaging O 0 3.48608082276769e-05
of O 0 6.159488839330152e-05
the O 0 0.0003840901190415025
fathers O 0 0.0014773393049836159
pituitary O 1 0.987722635269165
gland O 0 0.0005397671484388411
demonstrates O 0 5.736131242883857e-06
an O 0 1.8859983583752182e-06
attenuated O 0 0.00022365845507010818
posterior O 0 0.07536570727825165
pituitary O 1 0.9999735355377197
bright O 0 0.00017226314230356365
spot O 0 2.132220470230095e-05
. O 0 1.1012928098352859e-06

This O 0 1.4770331290492322e-05
mutation O 0 8.484465979563538e-06
may O 0 3.6370290672493866e-06
be O 0 2.0547609835830372e-07
valuable O 0 2.598700064027071e-07
for O 0 1.7955920839085593e-07
developing O 0 4.0445536342303967e-07
models O 0 1.1084241577918874e-06
of O 0 4.527128112385981e-05
dominantly B-Disease 1 0.9999397993087769
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 4.289063326723408e-06
as O 0 2.149488977920555e-07
the O 0 9.794078437153075e-08
early O 0 2.560896064096596e-07
age O 0 3.5208290682930965e-07
of O 0 1.9338083347975044e-06
onset O 1 0.7192047238349915
of O 0 0.00017288513481616974
symptoms O 1 0.7213625311851501
suggests O 0 1.0179534228882403e-06
that O 0 4.037207546048194e-08
this O 0 6.34771311069926e-08
mutation O 0 2.102248686242092e-07
may O 0 3.788774449731136e-07
be O 0 1.2557867989926308e-07
particularly O 0 1.043551023371947e-07
deleterious O 0 1.829484631343803e-06
to O 0 2.0477773432503454e-07
the O 0 3.6016433568875073e-06
magnocellular O 0 0.000178145885001868
neuron O 0 5.895286813029088e-05
. O 0 1.0892848649746156e-06
. O 0 1.8071482372761238e-06

Frequent O 0 0.00010036425373982638
inactivation O 0 0.002228035591542721
of O 0 0.0007674891385249794
PTEN O 1 0.9999489784240723
/ O 0 0.0012968964874744415
MMAC1 O 0 0.013034394942224026
in O 0 1.6559541109018028e-05
primary O 1 0.9999992847442627
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.306295184302144e-05

Sporadic B-Disease 1 0.9999997615814209
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 0.006741451099514961
the O 0 2.3063625121721998e-05
most O 0 5.675918828274007e-07
common O 0 6.524487048409355e-07
male B-Disease 0 7.793291842972394e-06
cancer I-Disease 0 4.1001458157552406e-05
in O 0 7.412905688397586e-06
the O 0 8.23342543299077e-06
Western O 0 4.730501132144127e-06
world O 0 1.4906624983268557e-06
, O 0 4.719127844055038e-08
yet O 0 1.7494125259531756e-08
many O 0 3.824581096267821e-09
of O 0 1.268772251705741e-07
the O 0 3.7303973954294634e-07
major O 0 5.669199367730471e-07
genetic O 0 1.0299071817598815e-07
events O 0 1.7294740928264218e-07
involved O 0 9.846937132351741e-08
in O 0 2.7366195354261436e-07
the O 0 8.565460234422062e-07
progression O 0 1.32426866912283e-05
of O 0 6.759901793884637e-07
this O 0 3.2016970408221823e-07
often O 0 9.540663086227141e-07
fatal O 0 0.006104298867285252
cancer B-Disease 0 0.0004429141408763826
remain O 0 1.894042725325562e-06
to O 0 1.0717207032939768e-07
be O 0 5.699111511603405e-07
elucidated O 0 5.398770372266881e-05
. O 0 1.8347823242947925e-06

Numerous O 0 0.00016137183411046863
cytogenetic O 0 0.10940983146429062
and O 0 2.502964525774587e-05
allelotype O 0 0.000433126202551648
studies O 0 4.397563316160813e-06
have O 0 3.310368299480615e-07
reported O 0 7.534889050475613e-07
frequent O 0 3.0397529826586833e-07
loss O 0 1.5285850167856552e-05
of O 0 5.06039650645107e-05
heterozygosity O 1 0.9837316274642944
on O 0 0.14227856695652008
chromosomal O 1 0.9999597072601318
arm O 1 0.9327437877655029
10q O 0 0.0007848315872251987
in O 0 2.148740713892039e-05
sporadic B-Disease 1 0.9999995231628418
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5144954886636697e-05

Deletion O 0 0.0009236037149094045
mapping O 0 8.352765144081786e-05
studies O 0 1.8066613847622648e-05
have O 0 1.3487605201589759e-06
unambiguously O 0 5.314544978318736e-06
identified O 0 6.395193281605316e-07
a O 0 7.451303645211738e-07
region O 0 8.219658411690034e-07
of O 0 1.732529744913336e-05
chromosome O 0 0.00021045298490207642
10q23 O 0 0.00013575759658124298
to O 0 4.2552855461508443e-07
be O 0 2.006523232012114e-07
the O 0 4.2731340954560437e-07
minimal O 0 1.899543690342398e-06
area O 0 1.7666010307948454e-06
of O 0 3.4947036056109937e-06
loss O 0 7.096456829458475e-05
. O 0 2.9236971386126243e-06

A O 0 0.0002251092082588002
new O 0 1.0345636837882921e-05
tumor B-Disease 0 0.00047487669507972896
suppressor O 0 0.0012427711626514792
gene O 0 2.8961987936781952e-06
, O 0 1.0700555321818683e-06
PTEN O 0 0.0002699245233088732
/ O 0 2.4530514565412886e-05
MMAC1 O 0 0.0003734947822522372
, O 0 1.65313770139619e-06
was O 0 5.4914715292397887e-05
isolated O 0 4.733651167043718e-06
recently O 0 5.590902674157405e-06
at O 0 3.828874923783587e-06
this O 0 4.975141010277184e-08
region O 0 1.9848626209295617e-07
of O 0 5.510306436917745e-06
chromosome O 0 8.327521209139377e-05
10q23 O 0 5.522777064470574e-05
and O 0 1.3141385579729103e-06
found O 0 2.2793464893311466e-07
to O 0 1.3583158597896272e-08
be O 0 2.8545320773787353e-08
inactivated O 0 2.528091158637835e-07
by O 0 1.4193410891039093e-08
mutation O 0 1.8249258104674482e-08
in O 0 2.408144723631267e-07
three O 0 8.88416343514109e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.0007913833833299577
lines O 0 9.970201972464565e-06
. O 0 1.0100347935804166e-06

We O 0 2.0631330698961392e-05
screened O 0 0.00010147228022105992
80 O 0 0.0006242863601073623
prostate B-Disease 1 0.9999845027923584
tumors I-Disease 1 1.0
by O 0 2.918156724263099e-06
microsatellite O 0 1.2077688552381005e-05
analysis O 0 3.45370807508516e-07
and O 0 3.146076892335259e-07
found O 0 3.504324581626861e-07
chromosome O 0 4.425515726325102e-06
10q23 O 0 1.266396702703787e-05
to O 0 3.4743553101179714e-07
be O 0 1.9884568303041306e-07
deleted O 0 1.4120874425316288e-07
in O 0 8.463548795134557e-08
23 O 0 1.6140436400746694e-06
cases O 0 3.510596116029774e-07
. O 0 1.9265962691861205e-06

We O 0 1.3432150808512233e-05
then O 0 8.550842380827817e-07
proceeded O 0 7.145260383367713e-07
with O 0 1.1879957462213042e-08
sequence O 0 5.1977188775254035e-08
analysis O 0 2.934753950967206e-08
of O 0 5.349411367205903e-07
the O 0 2.5588653898012126e-06
entire O 0 3.142150308121927e-05
PTEN O 0 0.0010771454544737935
/ O 0 2.7940886866417713e-05
MMAC1 O 0 7.250282214954495e-05
coding O 0 6.050418051017914e-06
region O 0 1.5545261931038112e-06
and O 0 4.977675871487008e-07
tested O 0 5.659702537741396e-07
for O 0 2.245654826538157e-07
homozygous O 0 9.05381568827579e-07
deletion O 0 2.275337919854792e-06
with O 0 1.1494924478938628e-07
new O 0 1.1074795338572585e-06
intragenic O 0 8.092169991869014e-06
markers O 0 1.1349810620231437e-06
in O 0 1.5065533887081983e-07
these O 0 1.815863548415564e-08
23 O 0 8.507520874445618e-07
cases O 0 3.503842549434921e-08
with O 0 7.749557084935077e-08
10q23 O 0 4.4761291064787656e-05
loss O 0 4.1542862163623795e-05
of O 0 5.7627246860647574e-05
heterozygosity O 0 0.003182479180395603
. O 0 1.075557156582363e-05

The O 0 4.160979005973786e-05
identification O 0 3.937661404052051e-06
of O 0 9.624863196222577e-06
the O 0 8.457434887532145e-06
second O 0 6.572394340764731e-06
mutational O 0 2.2546370018972084e-05
event O 0 2.070471282422659e-06
in O 0 5.371955467126099e-07
10 O 0 2.98240337315292e-07
( O 0 4.475400672276919e-08
43 O 0 8.706231255928287e-07
% O 0 1.4321788057714002e-06
) O 0 4.452168013813207e-06
tumors B-Disease 1 1.0
establishes O 0 0.0014311729464679956
PTEN O 1 0.9997610449790955
/ O 0 0.00022573875321540982
MMAC1 O 0 0.0002504063304513693
as O 0 5.984431936667534e-07
a O 0 3.1650418463868846e-07
main O 0 2.793192834360525e-06
inactivation O 0 1.3254184523248114e-05
target O 0 4.319914523875923e-07
of O 0 1.2234187352078152e-06
10q O 0 2.9131351766409352e-05
loss O 0 9.18602199817542e-06
in O 0 5.3481635404750705e-06
sporadic B-Disease 1 0.9999921321868896
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.4651411675004056e-06
. O 0 1.3934298976892023e-06

Risk O 0 0.00010655732330633327
reversals O 0 5.138984852237627e-05
in O 0 2.9986480853949615e-07
predictive O 0 2.3420727757184068e-06
testing O 0 1.2133551763326977e-06
for O 0 1.536447962280363e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.178136350674322e-06

The O 0 9.821857020142488e-06
first O 0 1.539689378660114e-06
predictive O 0 4.711303972726455e-06
testing O 0 2.051173623840441e-06
for O 0 1.7118718460551463e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999991655349731
( O 0 3.9154676301222935e-07
HD B-Disease 0 1.056938162946608e-05
) O 0 7.619769348821137e-08
was O 0 1.1021566024282947e-06
based O 0 5.662337798639783e-08
on O 0 3.4996051567759423e-07
analysis O 0 1.1439042424399304e-07
of O 0 2.2389046989701455e-06
linked O 0 6.808037142036483e-06
polymorphic O 0 7.30921044578281e-07
DNA O 0 2.193807802086667e-07
markers O 0 7.060756388455047e-07
to O 0 1.0891378110500227e-07
estimate O 0 3.183975536558137e-07
the O 0 1.3008448718210275e-07
likelihood O 0 3.585172692055494e-07
of O 0 2.509472778911004e-06
inheriting O 0 9.582230632076971e-06
the O 0 5.536130061045696e-07
mutation O 0 2.1038994191258098e-07
for O 0 2.24002718596239e-07
HD B-Disease 0 2.2024680220056325e-05
. O 0 1.9938963760068873e-06

Limits O 0 3.033299981325399e-05
to O 0 6.554234346367593e-07
accuracy O 0 1.6327953744621482e-06
included O 0 6.139882771094562e-07
recombination O 0 1.595583540847656e-07
between O 0 3.845576941330364e-07
the O 0 4.2916468601106317e-07
DNA O 0 1.6416063886026677e-07
markers O 0 9.485141845289036e-07
and O 0 5.178393394089653e-07
the O 0 2.8089696115785046e-06
mutation O 0 9.142307249021542e-07
, O 0 4.1323332311549166e-07
pedigree O 0 1.260287490367773e-06
structure O 0 2.826716126946849e-06
, O 0 8.559020159282227e-08
and O 0 3.228106493224914e-08
whether O 0 2.2651304831811103e-08
DNA O 0 8.782989624478432e-08
samples O 0 1.2530043136393942e-07
were O 0 6.291579097705835e-07
available O 0 4.2542630751540855e-08
from O 0 3.715585137342714e-07
family O 0 2.542671211358538e-07
members O 0 3.6918277146469336e-07
. O 0 1.2749001143674832e-06

With O 0 4.790619641426019e-06
direct O 0 1.0798582479765173e-05
tests O 0 1.7039263866536203e-06
for O 0 1.03219383618125e-06
the O 0 4.0061254367174115e-06
HD B-Disease 0 2.5651550458860584e-05
mutation O 0 5.115554699841596e-07
, O 0 1.3862035075362655e-07
we O 0 4.113788776294314e-08
have O 0 3.141261473160739e-08
assessed O 0 2.6885530246545386e-07
the O 0 1.1260848964411707e-07
accuracy O 0 3.0466136990980885e-07
of O 0 5.451412334878114e-07
results O 0 4.15090511296512e-07
obtained O 0 9.331072874374513e-07
by O 0 1.766870951769306e-07
linkage O 0 2.9196291961852694e-06
approaches O 0 9.535770004731603e-07
when O 0 2.0501884989698738e-07
requested O 0 2.6809922815118625e-07
to O 0 9.992812977088761e-08
do O 0 4.1989448362755866e-08
so O 0 1.5828156563202356e-08
by O 0 1.991401532563941e-08
the O 0 6.83957281921721e-08
test O 0 7.178482519520912e-08
individuals O 0 3.0962791441879745e-08
. O 0 5.952527999397716e-07

For O 0 2.5258179448428564e-05
six O 0 2.3011975827103015e-06
such O 0 1.7606524238544807e-07
individuals O 0 8.127199180307798e-08
, O 0 5.395244784267561e-08
there O 0 3.6130533231926165e-08
was O 0 7.055674018374702e-07
significant O 0 1.6256204560249898e-07
disparity O 0 7.300433253476513e-07
between O 0 5.757432859354594e-07
the O 0 1.0608982847770676e-06
tests O 0 1.0108076367032481e-06
. O 0 1.666351295170898e-06

Three O 0 9.72607231233269e-05
went O 0 6.918105646036565e-05
from O 0 3.212614501535427e-06
a O 0 1.8927698874904308e-06
decreased O 0 0.00010355576523579657
risk O 0 1.1039448963856557e-06
to O 0 1.4359778788275435e-07
an O 0 2.4573327550569957e-07
increased O 0 4.664634161599679e-06
risk O 0 2.77977301266219e-06
, O 0 1.1157445101162011e-07
while O 0 7.435949811451792e-08
in O 0 1.1096832253087996e-07
another O 0 1.2625837086943648e-07
three O 0 6.343888259152664e-08
the O 0 2.7660937007567554e-07
risk O 0 8.231142487602483e-07
was O 0 2.2000707758706994e-05
decreased O 0 0.0001207949171657674
. O 0 2.4929665869422024e-06

Knowledge O 0 0.0001855888549471274
of O 0 0.00011383849778212607
the O 0 1.2197072464914527e-05
potential O 0 4.793864263774594e-06
reasons O 0 7.860205073484394e-07
for O 0 3.4466535225874395e-07
these O 0 4.645486484378125e-08
changes O 0 1.003293803591987e-07
in O 0 6.974470352361095e-07
results O 0 1.3188516732043354e-06
and O 0 2.5595971919756266e-07
impact O 0 1.3785285091216792e-06
of O 0 2.7519820378074655e-06
these O 0 1.5984255696821492e-07
risk O 0 2.698331627470907e-06
reversals O 0 7.323256431845948e-05
on O 0 6.611648586840602e-06
both O 0 3.7451906109708943e-07
patients O 0 2.8075399427507364e-07
and O 0 3.784051045840897e-07
the O 0 1.6520156123078777e-06
counseling O 0 1.2972808463018737e-06
team O 0 1.8380295330189256e-07
can O 0 4.473966797036155e-08
assist O 0 2.5946118853426015e-07
in O 0 7.392717975562846e-07
the O 0 1.5443201846210286e-06
development O 0 2.389108885836322e-06
of O 0 6.348514943965711e-06
strategies O 0 8.743215857975883e-07
for O 0 7.384607556559786e-07
the O 0 3.3032490591722308e-06
prevention O 0 1.1585534593905322e-05
and O 0 3.810962994066358e-07
, O 0 5.601581420933144e-08
where O 0 5.587634177572909e-08
necessary O 0 2.1787168691389525e-07
, O 0 2.438879391775117e-07
management O 0 6.006341664033243e-07
of O 0 1.0848167448784807e-06
a O 0 2.1278176518535474e-06
risk O 0 2.4763392048043897e-06
reversal O 0 4.110301688342588e-06
in O 0 1.441461989770687e-07
any O 0 2.4080797800252185e-08
predictive O 0 7.977744189702207e-07
testing O 0 2.9884904506616294e-07
program O 0 8.165217764144472e-07
. O 0 1.1569434832381376e-07
. O 0 5.561965394917934e-07

A O 0 4.986281419405714e-05
novel O 0 2.945026608358603e-06
common O 0 7.274967970261059e-07
missense O 0 3.1235463211487513e-06
mutation O 0 6.8669049824166e-07
G301C O 0 1.0391993782832287e-05
in O 0 1.6540396927666734e-06
the O 0 2.5440031095058657e-06
N O 0 8.387923116970342e-06
- O 0 5.919602699577808e-06
acetylgalactosamine O 0 3.1129573471844196e-05
- O 0 1.0603424925648142e-05
6 O 0 1.0124263098987285e-05
- O 0 8.562727089156397e-06
sulfate O 0 2.2101967260823585e-05
sulfatase O 0 0.00012583592615555972
gene O 0 1.190167154163646e-06
in O 0 2.931472863565432e-06
mucopolysaccharidosis B-Disease 0 0.00016259975382126868
IVA I-Disease 0 0.004535480868071318
. O 0 8.235734640038572e-06

Mucopolysaccharidosis B-Disease 0 0.01176220178604126
IVA I-Disease 1 0.9975372552871704
( O 0 0.00018485802866052836
MPS B-Disease 1 0.9999946355819702
IVA I-Disease 1 1.0
) O 0 1.04591379113117e-06
is O 0 1.2029195772811363e-07
an O 0 2.862471433218161e-07
autosomal B-Disease 1 0.9992895126342773
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 1.0
by O 0 1.539350523671601e-05
a O 0 8.937132224673405e-05
genetic B-Disease 1 0.9999982118606567
defect I-Disease 1 0.9999979734420776
in O 0 5.754925950895995e-05
N O 0 3.786797242355533e-05
- O 0 6.880054115754319e-06
acetylgalactosamine O 0 2.1456649847095832e-05
- O 0 4.403497769089881e-06
6 O 0 1.0782263416331261e-05
- O 0 9.896766641759314e-06
sulfate O 0 3.102389018749818e-05
sulfatase O 0 0.0001242913567693904
( O 0 1.0999566484315437e-06
GALNS O 0 7.624644786119461e-05
) O 0 4.2664032662287354e-07
. O 0 3.0418928531616984e-07

In O 0 7.137910870369524e-05
previous O 0 2.9897904823883437e-05
studies O 0 6.78101650919416e-06
, O 0 6.351115757752268e-07
we O 0 1.4407501680580026e-07
have O 0 1.0797740657153554e-07
found O 0 1.1469279570519575e-07
two O 0 3.518414715131257e-08
common O 0 5.698177574231522e-08
mutations O 0 8.876915558175824e-08
in O 0 1.0780058801174164e-06
Caucasians O 0 4.787358420799137e-07
and O 0 1.7289215747950948e-07
Japanese O 0 3.186647063557757e-06
, O 0 4.833084403799148e-07
respectively O 0 3.9348947211692575e-06
. O 0 1.1483500657050172e-06

To O 0 2.363010025874246e-05
characterize O 0 3.224204920115881e-05
the O 0 1.3058583135716617e-05
mutational O 0 0.00012411964416969568
spectrum O 0 2.8658196242759004e-06
in O 0 2.1568773433955357e-07
various O 0 4.640916628773084e-08
ethnic O 0 3.0411325013801616e-08
groups O 0 1.1722352866172514e-08
, O 0 1.932556337180813e-08
mutations O 0 1.177730446499936e-08
in O 0 1.9928896222154435e-07
the O 0 6.516607982121059e-07
GALNS O 0 1.333840555162169e-05
gene O 0 2.739878652846528e-07
in O 0 2.6616612558427732e-06
Colombian O 0 5.901671465835534e-05
MPS B-Disease 1 0.9999164342880249
IVA I-Disease 1 1.0
patients O 0 9.626000974094495e-06
were O 0 5.311616405379027e-06
investigated O 0 2.2793581138103036e-06
, O 0 1.0465828381711617e-07
and O 0 5.13635995957884e-08
genetic O 0 9.744270812461764e-08
backgrounds O 0 3.827443606496672e-08
were O 0 1.2595553755545552e-07
extensively O 0 6.048762912769234e-08
analyzed O 0 7.381010647122821e-08
to O 0 4.370060935343645e-08
identify O 0 3.045933283374325e-08
racial O 0 2.6744905312625633e-07
origin O 0 1.1295944801759106e-07
, O 0 4.103507222907865e-08
based O 0 3.9303568399873257e-08
on O 0 5.003690830562846e-07
mitochondrial O 0 1.942203198268544e-06
DNA O 0 1.7219890935393778e-07
( O 0 5.03073458446579e-08
mtDNA O 0 1.5761465022023913e-07
) O 0 1.0435709185685482e-07
lineages O 0 1.0364767604187364e-06
. O 0 7.832795745343901e-07

Three O 0 1.9860544853145257e-05
novel O 0 1.284003064938588e-05
missense O 0 4.7761826863279566e-05
mutations O 0 4.023941528430441e-06
never O 0 4.949944013787899e-06
identified O 0 1.1625093065958936e-06
previously O 0 1.147721604866092e-06
in O 0 3.7271612995937176e-07
other O 0 3.3356187145727745e-08
populations O 0 4.297347899751003e-08
and O 0 8.785352179074835e-08
found O 0 1.3938098675225774e-07
in O 0 2.699371748349222e-07
16 O 0 1.3778476386505645e-06
out O 0 1.426794966619127e-07
of O 0 3.4912525279651163e-06
19 O 0 4.531663944362663e-05
Colombian O 0 7.94167717685923e-05
MPS B-Disease 0 0.046064503490924835
IVA I-Disease 1 0.9676001071929932
unrelated O 0 1.6780949181338656e-06
alleles O 0 1.4840325945897348e-07
account O 0 1.0827314156358625e-07
for O 0 2.6519066409491643e-07
84 O 0 1.5467609046027064e-05
. O 0 1.5421200032506022e-06

2 O 0 2.5896581064444035e-05
% O 0 1.9836129467876162e-06
of O 0 2.2972003534960095e-06
the O 0 7.877600296524179e-07
alleles O 0 2.1552858697759802e-07
in O 0 8.857922750848957e-08
this O 0 4.2157004997989134e-08
study O 0 3.0382574323084555e-07
. O 0 4.420267316618265e-07

The O 0 0.0001884519588202238
G301C O 0 0.0005659196758642793
and O 0 3.4593883810885018e-06
S162F O 0 2.970493551401887e-05
mutations O 0 4.118892888982373e-07
account O 0 3.5864073311131506e-07
for O 0 5.879325613022957e-07
68 O 0 3.247292625019327e-05
. O 0 2.301856056874385e-06

4 O 0 3.889878644258715e-05
% O 0 2.169924073314178e-06
and O 0 6.441737809836923e-07
10 O 0 3.3807996260293294e-06
. O 0 1.5134872910493868e-06

5 O 0 3.80215460609179e-05
% O 0 1.8390516061117523e-06
of O 0 3.431874802117818e-06
mutations O 0 9.360217632092827e-07
, O 0 6.618300858463044e-07
respectively O 0 2.6961195089825196e-06
, O 0 1.1176253167377581e-07
whereas O 0 2.7194303697797295e-07
the O 0 1.2858163245255128e-06
remaining O 0 2.6257296212861547e-06
F69V O 0 5.677721856045537e-05
is O 0 1.5009317166914116e-07
limited O 0 5.359634158708104e-08
to O 0 3.267198778189595e-08
a O 0 2.4072815563158656e-07
single O 0 7.188072572716919e-07
allele O 0 1.9123363017570227e-06
. O 0 1.2736119288092596e-06

The O 0 7.683649891987443e-05
skewed O 0 5.340218558558263e-05
prevalence O 0 7.351229578489438e-05
of O 0 1.5807383533683605e-05
G301C O 0 5.0182519771624357e-05
in O 0 1.703984935375047e-06
only O 0 3.9269630747185147e-07
Colombian O 0 2.8055801521986723e-06
patients O 0 1.6768298394254089e-07
and O 0 1.0174405673524234e-07
haplotype O 0 4.808461540051212e-07
analysis O 0 3.667557635367302e-08
by O 0 3.239288659528938e-08
restriction O 0 2.369851586081495e-07
fragment O 0 2.0200691608351917e-07
length O 0 1.6262005431144644e-07
polymorphisms O 0 3.3941503829737485e-07
in O 0 6.041972824277764e-07
the O 0 2.186613301091711e-06
GALNS O 0 8.030442404560745e-05
gene O 0 8.03235991497786e-07
suggest O 0 2.741996070199093e-07
that O 0 9.962097635707323e-08
G301C O 0 3.8562825466215145e-06
originated O 0 5.033277830079896e-07
from O 0 1.9727605149455485e-07
a O 0 1.9460914302271703e-07
common O 0 2.0190483951409988e-07
ancestor O 0 8.183513273252174e-06
. O 0 1.965895762623404e-06

Investigation O 0 8.398682257393375e-05
of O 0 9.36528613237897e-06
the O 0 2.146454335161252e-06
genetic O 0 6.142670940789685e-07
background O 0 4.61629440451361e-07
by O 0 2.7387685008761764e-07
means O 0 3.3456166192991077e-07
of O 0 3.774071501538856e-06
mtDNA O 0 7.710455065534916e-07
lineages O 0 6.204394935593882e-07
indicate O 0 4.4383037334227993e-07
that O 0 4.683904109015202e-08
all O 0 6.533539931297128e-08
our O 0 1.722197708886597e-07
patients O 0 1.9715717769486218e-07
are O 0 3.060427999912463e-08
probably O 0 1.454629483532699e-07
of O 0 3.2781480285848374e-07
native O 0 7.507017016905593e-07
American O 0 3.813020384768606e-06
descent O 0 0.00010477291652932763

Low O 0 0.0001305713230976835
frequency O 0 1.179078117274912e-05
of O 0 5.88773673371179e-06
BRCA1 O 0 1.3175016647437587e-05
germline O 0 5.137612333783181e-06
mutations O 0 6.391667994876116e-08
in O 0 8.495782566342314e-08
45 O 0 1.1740833087969804e-06
German O 0 0.014049424789845943
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.521081225699163e-06
. O 0 1.0941344044113066e-06

In O 0 6.2483750298270024e-06
this O 0 1.1563776070033782e-07
study O 0 8.389552164089764e-08
we O 0 1.2350703570973565e-08
investigated O 0 1.5829763810870645e-07
45 O 0 2.3135510218708077e-06
German O 1 0.8233819007873535
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.122618099065221e-07
for O 0 2.3054450082327094e-07
germline O 0 4.323048415244557e-06
mutations O 0 7.27385867094199e-08
in O 0 1.6088281995507714e-07
the O 0 9.484734277975804e-07
BRCA1 O 0 6.196747563080862e-06
gene O 0 2.5613262550905347e-06
. O 0 1.4962770364945754e-06

We O 0 3.3600830647628754e-05
identified O 0 5.323848654370522e-06
four O 0 8.393455459554389e-07
germline O 0 1.4294715583673678e-05
mutations O 0 4.38285752579759e-07
in O 0 1.3444149544739048e-06
three O 0 7.448295036738273e-06
breast B-Disease 1 0.9996533393859863
cancer I-Disease 1 0.9790002703666687
families O 0 3.4037452678603586e-07
and O 0 3.793908547322644e-07
in O 0 1.1920986253244337e-05
one O 0 0.02496686391532421
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 7.501845175283961e-06
. O 0 3.632941059095174e-08
among O 0 7.759656028838435e-09
these O 0 6.4760570239741355e-09
were O 0 2.348553920228369e-07
one O 0 7.142863012177258e-08
frameshift O 0 9.092831874113472e-07
mutation O 0 1.222902596964559e-07
, O 0 1.0091319779803598e-07
one O 0 5.1619249319401206e-08
nonsense O 0 8.987283308670158e-07
mutation O 0 7.130910972819038e-08
, O 0 6.915393413464699e-08
one O 0 4.055777225175916e-08
novel O 0 1.8562138848210452e-07
splice O 0 1.6858650724316249e-06
site O 0 7.219937288027722e-07
mutation O 0 1.0780146197930662e-07
, O 0 4.810644327335467e-08
and O 0 4.242399853637835e-08
one O 0 1.910712512653845e-07
missense O 0 6.7775254137814045e-06
mutation O 0 3.5482710245560156e-06
. O 0 5.669465281243902e-06

The O 0 9.500970918452367e-05
missense O 0 8.906427683541551e-05
mutation O 0 7.113866558938753e-06
was O 0 4.123256803723052e-05
also O 0 3.0426997454924276e-07
found O 0 9.108543252978052e-08
in O 0 3.125770433598518e-07
2 O 0 2.48495757659839e-06
. O 0 1.125990820582956e-06

8 O 0 8.583784801885486e-05
% O 0 3.255329147577868e-06
of O 0 9.191577191813849e-06
the O 0 6.9072457336005755e-06
general O 0 5.114962277730228e-06
population O 0 3.1821448942537245e-07
, O 0 1.1656073439780812e-07
suggesting O 0 9.241153264838431e-08
that O 0 1.3476990190497418e-08
it O 0 1.510359126655203e-08
is O 0 9.695495606365512e-08
not O 0 1.4882391496939817e-07
disease O 0 1.2613680155482143e-05
associated O 0 1.614428470020357e-06
. O 0 1.9554693153622793e-06

The O 0 2.4518843929399736e-05
average O 0 1.2258316019142512e-05
age O 0 6.915207450219896e-06
of O 0 3.234959876863286e-05
disease O 1 0.9960508942604065
onset O 1 0.9999346733093262
in O 0 6.571422545675887e-06
those O 0 2.475628093634441e-07
families O 0 1.9722413924228022e-07
harbouring O 0 2.9527114747907035e-05
causative O 0 7.708905286563095e-06
mutations O 0 5.759684427175671e-07
was O 0 8.18144417280564e-06
between O 0 9.754439815878868e-07
32 O 0 8.734583389014006e-06
. O 0 1.28210604088963e-06

3 O 0 9.147488890448585e-05
and O 0 4.543148861557711e-06
37 O 0 5.792305455543101e-05
. O 0 6.9995444391679484e-06

4 O 0 0.0002410573506494984
years O 0 1.3850507457391359e-05
, O 0 6.045142413313442e-07
whereas O 0 6.201460678312287e-07
the O 0 1.2014353387712617e-06
family O 0 9.937252798408736e-07
harbouring O 0 4.280669963918626e-05
the O 0 1.883318645923282e-06
missense O 0 6.316447979770601e-06
mutation O 0 3.8294012938422384e-07
had O 0 1.9954468370997347e-06
an O 0 9.579760984479435e-08
average O 0 2.4720938540667703e-07
age O 0 4.80656353829545e-07
of O 0 2.801657728923601e-06
onset O 0 0.009697480127215385
of O 0 0.00014519691467285156
51 O 0 9.465774928685278e-05
. O 0 5.861137196916388e-06

2 O 0 0.00023321500339079648
years O 0 3.969328463426791e-05
. O 0 5.976126431050943e-06

These O 0 6.3455854615313e-06
findings O 0 4.997728410671698e-06
show O 0 1.431599798706884e-06
that O 0 6.198587243488873e-07
BRCA1 O 0 7.949227438075468e-06
is O 0 8.507602728968777e-07
implicated O 0 7.940930117911194e-07
in O 0 8.105356386067797e-08
a O 0 5.645191691883156e-08
small O 0 1.2383374325963814e-08
fraction O 0 1.382230152557895e-07
of O 0 6.532271072501317e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.330547878656944e-07
suggesting O 0 5.571595238507143e-07
the O 0 1.8157203385271714e-07
involvement O 0 2.773396943211992e-07
of O 0 4.4887542571814265e-07
another O 0 2.2101751540049008e-07
susceptibility O 0 2.261167082906468e-06
gene O 0 1.2019545465591364e-06
( O 0 7.920327220745094e-07
s O 0 1.9043767679249868e-05
) O 0 1.8956311578222085e-06

Paternal O 0 0.4233262240886688
transmission O 1 0.9999210834503174
of O 1 0.999998927116394
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0001234727242263034

We O 0 1.7013031538226642e-05
report O 0 1.1891495432791999e-06
a O 0 2.7801019086837186e-07
rare O 0 3.122784733022854e-07
case O 0 6.460477379732765e-07
of O 0 2.2042311684344895e-05
paternally O 1 0.9999489784240723
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 5.360459181247279e-05
DM B-Disease 1 1.0
) O 0 1.3483000884662033e-06
. O 0 5.63258026886615e-07

The O 0 0.00018471814109943807
proband O 0 0.0003557554155122489
is O 0 1.4514010899802088e-06
a O 0 2.1452224245877005e-06
23 O 0 1.6524265447515063e-05
year O 0 1.0002411727327853e-05
old O 0 0.0001745944464346394
, O 0 1.9609595256042667e-05
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.0004422477795742452
who O 0 8.500706462655216e-05
suffers O 1 0.9999998807907104
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.00032852942240424454

He O 0 3.708602162078023e-05
presented O 0 1.9650895410450175e-05
with O 0 7.232863026729319e-06
respiratory O 1 1.0
and O 0 5.9089812566526234e-05
feeding O 0 0.00045406672870740294
difficulties O 0 0.0002389753790339455
at O 0 0.010640335269272327
birth O 0 0.00024000884150154889
. O 0 2.1949936126475222e-06

His O 0 0.00036979280412197113
two O 0 6.867964839329943e-05
sibs O 1 0.9996312856674194
suffer O 0 0.00039276713505387306
from O 0 2.6116889785043895e-05
childhood O 0 0.06265044957399368
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 4.7547786380164325e-05

Their O 0 4.190322579233907e-05
late O 0 0.00025421311147511005
father O 0 2.0010777006973512e-05
had O 0 4.142349553148961e-06
the O 0 6.004783585922269e-07
adult O 0 5.225980430623167e-07
type O 0 5.1751376304309815e-06
of O 0 0.12877719104290009
DM B-Disease 1 1.0
, O 0 4.9089885578723624e-06
with O 0 6.144088615656074e-07
onset O 1 0.9124736785888672
around O 0 1.3577373465523124e-05
30 O 0 5.164724825590383e-06
years O 0 1.598270046088146e-06
. O 0 7.689101266805665e-07

Only O 0 5.556538326345617e-06
six O 0 1.0939570529444609e-06
other O 0 1.8361472342576235e-08
cases O 0 2.7486398934684075e-08
of O 0 2.8897400170535548e-06
paternal O 1 0.9619060754776001
transmission O 1 0.9999959468841553
of O 1 0.9999998807907104
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.00016744200547691435
been O 0 8.731685738894157e-06
reported O 0 1.8040282157016918e-06
recently O 0 1.8519592686061515e-06
. O 0 1.0363384035372292e-06

We O 0 5.781362233392429e-06
review O 0 2.158359848181135e-06
the O 0 7.169888931457535e-07
sex O 0 3.4830603112823155e-07
related O 0 7.682651244067529e-07
effects O 0 4.928756879962748e-06
on O 0 7.47265539757791e-06
transmission O 0 0.0028522151987999678
of O 1 0.8690014481544495
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00028791825752705336

Decreased O 0 0.12875163555145264
fertility O 0 0.00018180982442572713
of O 0 2.487727215338964e-06
males O 0 7.75502826400043e-08
with O 0 3.733009279471844e-08
adult O 0 3.2366228879254777e-06
onset O 1 0.9999815225601196
DM B-Disease 1 1.0
and O 0 9.367556776851416e-05
contraction O 0 0.004072608891874552
of O 0 6.574017788807396e-06
the O 0 1.0332810234103817e-06
repeat O 0 2.9760735742456745e-07
upon O 0 5.251940820016898e-07
male O 0 4.902551040686376e-07
transmission O 0 1.0235226000077091e-06
contribute O 0 5.713435058396499e-08
to O 0 3.925779523683559e-08
the O 0 3.2776853231553105e-07
almost O 0 2.5025320837812615e-07
absent O 0 3.004427640007634e-07
occurrence O 0 7.650146471860353e-08
of O 0 3.229030482998496e-07
paternal O 0 1.98112684302032e-05
transmission O 0 0.00014675475540570915
of O 0 0.033505816012620926
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00011578146950341761

Also O 0 0.0001344170595984906
the O 0 2.142708035535179e-05
fathers O 0 1.2118311133235693e-05
of O 0 1.0324190952815115e-05
the O 0 1.9205450371373445e-05
reported O 0 9.533623233437538e-05
congenitally O 0 0.010263606905937195
affected O 0 2.0122599835303845e-06
children O 0 8.881536928129208e-07
showed O 0 2.6818261176231317e-06
, O 0 8.01691797391868e-08
on O 0 1.2289698361200863e-06
average O 0 1.474400619372318e-06
, O 0 1.972388048443463e-07
shorter O 0 2.7286603199172532e-06
CTG O 0 4.587462535710074e-05
repeat O 0 1.0779020840345765e-06
lengths O 0 2.0670954654633533e-06
and O 0 1.1778140418527983e-07
hence O 0 5.873754957974597e-07
less O 0 3.345201946558518e-07
severe O 0 0.0028890122193843126
clinical O 1 0.9315072298049927
symptoms O 1 0.7044990062713623
than O 0 3.467569342774368e-07
the O 0 8.275124514511845e-07
mothers O 0 2.163968986224063e-07
of O 0 2.8984402433707146e-07
children O 0 6.414800282072974e-07
with O 0 3.445776883381768e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00018408062169328332

We O 0 7.675309461774305e-06
conclude O 0 7.112231742212316e-06
that O 0 4.821897618967341e-07
paternal O 0 0.00010088972339872271
transmission O 0 0.17597763240337372
of O 1 0.9994205236434937
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.00014176522381603718
rare O 0 9.312119573223754e-07
and O 0 2.3875367105574696e-07
preferentially O 0 1.3495785822215112e-07
occurs O 0 1.1717975212377496e-07
with O 0 4.089520899697163e-08
onset O 0 0.00023556216910947114
of O 0 0.00015117997827474028
DM B-Disease 1 1.0
past O 0 9.780179425433744e-06
30 O 0 2.013939820244559e-06
years O 0 3.2047333320406324e-07
in O 0 1.5319471913244342e-07
the O 0 7.621679856129049e-07
father O 0 3.474743834885885e-06
. O 0 3.0409879059334344e-07
. O 0 1.0565506727289176e-06

The O 0 0.00015022953448351473
RB1 O 0 0.002002001041546464
gene O 0 4.259055003785761e-06
mutation O 0 3.7090848081788863e-07
in O 0 3.90542084005574e-07
a O 0 1.0006638149206992e-06
child O 0 5.2303707889223006e-06
with O 0 4.29996543971356e-06
ectopic B-Disease 1 0.9999995231628418
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.00010766592458821833

The O 0 0.00035321139148436487
RB1 O 0 0.002604755572974682
gene O 0 6.301826488197548e-06
mutation O 0 1.7555147451275843e-06
was O 0 4.554176030069357e-06
investigated O 0 4.946773515257519e-07
in O 0 3.199822629085247e-07
a O 0 1.0915892971752328e-06
child O 0 7.974435902724508e-06
with O 0 2.4569392280682223e-06
ectopic B-Disease 1 0.9999946355819702
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9999715089797974
using O 0 1.2888019682577578e-06
DNA O 0 4.281092174096557e-07
obtained O 0 1.3667902294400847e-06
from O 0 8.828588420328742e-07
both O 0 2.750067267243139e-07
the O 0 5.217731541051762e-06
pineal B-Disease 0 0.001443180488422513
and I-Disease 0 9.92224522633478e-06
retinal I-Disease 1 0.9998675584793091
tumours I-Disease 1 1.0
of O 0 0.0001437866158084944
the O 0 2.178046815970447e-05
patient O 0 2.508594661776442e-05
. O 0 2.747835878835758e-06

A O 0 0.00017553154611960053
nonsense O 0 5.135888568474911e-05
mutation O 0 1.7984144733418361e-06
in O 0 1.2230419770276058e-06
exon O 0 1.6240288687185966e-06
17 O 0 1.8906085870185052e-06
( O 0 1.362926553838406e-07
codon O 0 1.834310069170897e-06
556 O 0 1.5667289972043363e-06
) O 0 4.8489482651348226e-08
of O 0 7.905069310254476e-07
the O 0 5.349234470486408e-06
RB1 O 0 7.903268851805478e-05
gene O 0 6.985587219787703e-07
was O 0 1.0991546332661528e-05
found O 0 1.883613549580332e-07
to O 0 3.795717518073616e-08
be O 0 8.680002849814628e-08
present O 0 2.3778588342793228e-07
homozygously O 0 7.324908892769599e-06
in O 0 6.782289574402967e-07
both O 0 2.4280322463710036e-07
the O 0 3.3168385016324464e-06
retinal B-Disease 0 0.00015779426030348986
and I-Disease 0 4.1630701161921024e-06
the I-Disease 0 0.0002033369819400832
pineal I-Disease 1 0.9999361038208008
tumours I-Disease 1 1.0
. O 0 1.0558159374340903e-05

The O 0 2.4902550649130717e-05
same O 0 1.463585476813023e-06
mutation O 0 8.70340841174766e-07
was O 0 8.762257493799552e-06
present O 0 6.848879934295837e-07
heterozygously O 0 5.369013706513215e-06
in O 0 1.0426423386888928e-06
the O 0 1.4894802689013886e-06
DNA O 0 2.9449435601236473e-07
from O 0 1.3233697018222301e-06
the O 0 2.822282340275706e-06
constitutional O 0 7.855657713662367e-06
cells O 0 1.7929721707332646e-06
of O 0 1.3334589311853051e-05
the O 0 6.798616141168168e-06
patient O 0 3.7473166685231263e-06
, O 0 2.2907218522050243e-07
proving O 0 4.212059820929426e-07
it O 0 7.30121030301234e-09
to O 0 6.511579719870042e-09
be O 0 2.757508887896165e-08
of O 0 3.880761028085544e-07
germline O 0 4.082156010554172e-06
origin O 0 8.005623612916679e-07
. O 0 1.003123202281131e-06

The O 0 4.388192974147387e-05
initial O 0 9.602043064660393e-06
mutation O 0 2.964481154776877e-06
was O 0 8.165185136022046e-06
shown O 0 2.2369104613062518e-07
to O 0 4.6230702821503655e-08
have O 0 3.750465893403998e-08
occurred O 0 1.6688927644281648e-06
in O 0 2.548643465161149e-07
the O 0 1.6093786143756006e-06
paternally O 0 1.8160239051212557e-05
derived O 0 7.90450576459989e-06
RB1 O 0 0.0002264712966280058
allele O 0 5.498957307281671e-06
. O 0 1.2721552593575325e-06

The O 0 0.00015274663746822625
mutation O 0 6.25662778475089e-06
is O 0 1.4829236079094699e-06
in O 0 6.870998845442955e-07
an O 0 2.828367087204242e-07
area O 0 1.5351997717516497e-06
of O 0 6.0999254856142215e-06
the O 0 1.0948047929559834e-05
gene O 0 4.634909771539242e-07
that O 0 4.6943461029513855e-07
encodes O 0 1.009850848276983e-06
the O 0 4.325292138673831e-06
protein O 0 1.8435961237628362e-06
- O 0 1.8025302779278718e-06
binding O 0 1.2969815088581527e-06
region O 0 4.8506590246688575e-06
known O 0 1.1344626727805007e-05
as O 0 2.3248951492860215e-06
the O 0 3.3346284453728003e-06
pocket O 0 1.240035180671839e-05
region O 0 2.644355390657438e-06
and O 0 1.4078841559239663e-06
has O 0 8.312235308949312e-07
been O 0 8.113320291158743e-07
detected O 0 6.592624686163617e-07
in O 0 1.15493271835021e-07
other O 0 8.74519034965715e-09
cases O 0 3.9503408544305785e-08
of O 0 2.1898229078942677e-06
retinoblastoma B-Disease 0 0.00024066903279162943
. O 0 5.429041038951254e-07
. O 0 9.747689091454959e-07

Low O 0 0.0009438593406230211
levels O 0 2.9022930903011e-05
of O 0 1.0242813914373983e-05
beta O 0 6.201347423484549e-05
hexosaminidase O 0 3.5183169529773295e-05
A O 0 4.170242391410284e-06
in O 0 2.794562590224814e-07
healthy O 0 2.102758145383632e-07
individuals O 0 6.058668233777098e-09
with O 0 4.090004779300216e-08
apparent O 0 0.0077331154607236385
deficiency O 1 0.9999994039535522
of O 0 0.17385892570018768
this O 0 8.06274329079315e-06
enzyme O 0 1.3045240848441608e-05
. O 0 2.0640186448872555e-06

Appreciable O 0 0.001966973999515176
beta O 0 0.0006482870085164905
hexosaminidase O 0 0.0004370459937490523
A O 0 6.717559153912589e-05
( O 0 1.5295297544071218e-06
hex O 0 2.5375782570336014e-05
A O 0 4.69533188152127e-06
) O 0 9.299609615709414e-08
activity O 0 2.733924873155047e-07
has O 0 5.68712401616267e-08
been O 0 1.0173260278634189e-07
detected O 0 9.067044288713078e-07
in O 0 1.7851612028607633e-06
cultured O 0 0.0012729979353025556
skin O 0 0.4864864647388458
fibroblasts O 1 0.9596852660179138
and O 0 0.0002570865908637643
melanoma B-Disease 1 0.9999998807907104
tissue O 1 0.9955961108207703
from O 0 1.765821252774913e-05
healthy O 0 5.882943128199258e-07
individuals O 0 8.422673225538801e-09
previously O 0 3.413910860672331e-07
reported O 0 5.310723736329237e-07
as O 0 9.343967235508899e-07
having O 0 3.947169716411736e-06
deficiency B-Disease 0 0.042137082666158676
of I-Disease 0 6.726373976562172e-05
hex I-Disease 0 6.586802919628099e-05
A I-Disease 0 3.830946297966875e-06
activity O 0 1.6435768657174776e-06
indistinguishable O 0 3.125030900719139e-07
from O 0 5.203501629580387e-08
that O 0 3.556507310875645e-09
of O 0 7.965917347974028e-08
patients O 0 1.2261281767678156e-07
with O 0 1.180680101242615e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999991655349731
( O 0 6.464411853812635e-06
TSD B-Disease 0 0.0018235249444842339
) O 0 8.442369789918303e-07
. O 0 6.957138793950435e-07

Identification O 0 3.596963142626919e-05
and O 0 1.182794676424237e-05
quantitation O 0 0.0005343647790141404
of O 0 0.0002887817972805351
hex O 0 0.0003020291915163398
A O 0 1.3507195035344921e-05
, O 0 1.638186120089813e-07
amounting O 0 2.6136076485272497e-06
to O 0 2.997881836108718e-07
3 O 0 4.527672899712343e-06
. O 0 1.2471537047531456e-06

5 O 0 5.599321229965426e-05
% O 0 5.595842594630085e-06
- O 0 1.286987117055105e-05
6 O 0 1.552289177197963e-05
. O 0 2.7029109332943335e-06

9 O 0 6.422735896194354e-05
% O 0 1.2369880550977541e-06
of O 0 1.914975200634217e-06
total O 0 1.1483060916361865e-05
beta O 0 4.0234295738628134e-05
hexosaminidase O 0 2.5119314159383066e-05
activity O 0 5.670568498317152e-06
, O 0 1.0587883991775016e-07
has O 0 1.981663722006033e-08
been O 0 4.690806321150376e-08
obtained O 0 2.1700944330405036e-07
by O 0 3.7105141359461413e-07
cellulose O 0 1.0492583896848373e-05
acetate O 0 7.2228408498631325e-06
gel O 0 9.597767530067358e-06
electrophoresis O 0 9.418291483598296e-06
, O 0 1.7312213458353654e-06
DEAE O 0 4.46880585514009e-05
- O 0 2.9643342713825405e-06
cellulose O 0 3.867186933348421e-06
ion O 0 4.645943590730894e-06
- O 0 4.540268946584547e-06
exchange O 0 1.487144527345663e-05
chromatography O 0 3.224364627385512e-05
, O 0 5.795510560346884e-07
radial O 0 1.5192316823231522e-05
immunodiffusion O 0 2.526283060433343e-05
, O 0 2.9656982292181056e-07
and O 0 4.6974403744570736e-07
radioimmunoassay O 0 6.877704436192289e-05
. O 0 3.5472121453494765e-06

Previous O 0 0.00034054648131132126
family O 0 6.677211786154658e-06
studies O 0 3.013072273461148e-06
suggested O 0 1.1321661759211565e-06
that O 0 8.429201159287913e-08
these O 0 3.186246999575815e-08
individuals O 0 6.84560248487287e-08
may O 0 1.7330482933175517e-06
be O 0 4.1482417145743966e-07
compound O 0 5.496639460034203e-06
heterozygotes O 0 1.0955669722534367e-06
for O 0 1.5525912999692082e-07
the O 0 3.3371276231264346e-07
common O 0 2.631806239605794e-07
mutant O 0 3.262875907239504e-06
TSD B-Disease 0 5.384491669246927e-05
gene O 0 3.9781022564966406e-07
and O 0 1.111975720391456e-07
a O 0 1.6015657422485674e-07
rare O 0 1.4850094487428578e-07
( O 0 7.838304583174249e-08
allelic O 0 8.55922905884654e-07
) O 0 6.705901967052341e-08
mutant O 0 1.7141422858912847e-06
gene O 0 1.2653287058128626e-06
. O 0 1.3461879007081734e-06

Thus O 0 5.581025470746681e-05
, O 0 3.3063217870221706e-06
the O 0 2.0867414605163503e-06
postulated O 0 9.374321052746382e-06
rate O 0 4.786788394994801e-06
mutant O 0 1.599189317857963e-06
gene O 0 2.708242163862451e-07
appears O 0 2.635842974996194e-07
to O 0 1.7287741016502878e-08
code O 0 2.5723997154614153e-08
for O 0 2.949012056774336e-08
the O 0 1.3426783596059977e-07
expression O 0 2.1918022241607105e-07
of O 0 1.065993501470075e-06
low O 0 3.3894580155902077e-06
amounts O 0 4.6452379365291563e-07
of O 0 6.218520866241306e-06
hex O 0 7.128850847948343e-05
A O 0 2.2517509933095425e-05
. O 0 3.7745248846476898e-06

Heterozygotes O 0 0.0015150705585256219
for O 0 1.0843826203199569e-05
the O 0 6.549225417984417e-06
rare O 0 2.5262283998017665e-06
mutant O 0 1.2153112947999034e-05
may O 0 1.5685021708122804e-06
be O 0 1.59484883965888e-07
indistinguishable O 0 4.4672734134110215e-07
from O 0 1.3231345974418218e-07
heterozygotes O 0 5.690562829840928e-07
for O 0 4.841093215190995e-08
the O 0 4.3875667188331136e-07
common O 0 1.5965166539899656e-06
TSD B-Disease 0 0.00017639932048041373
mutant O 0 1.5175693079072516e-05
. O 0 2.8173319606139557e-06

However O 0 8.920601430872921e-06
, O 0 4.294488178402389e-07
direct O 0 1.2253325394340209e-06
visualization O 0 1.7843709429143928e-05
and O 0 2.026464926530025e-06
quantitation O 0 0.0004833659331779927
of O 0 0.0006729675806127489
hex O 0 0.00034617685014382005
A O 0 8.376298865186982e-06
by O 0 2.2576733726964449e-07
the O 0 2.1290649954153196e-07
methods O 0 4.132392348310532e-07
described O 0 7.385530125247897e-07
may O 0 4.7375075951094914e-07
prevent O 0 4.2744181882881094e-07
false O 0 1.411780658600037e-06
- O 0 3.473862534519867e-06
positive O 0 3.8276814962046046e-07
prenatal O 0 0.00014871392340864986
diagnosis O 0 0.0010387173388153315
of O 0 0.0005875976057723165
TSD B-Disease 0 0.041141945868730545
in O 0 9.547339686832856e-06
fetuses O 0 1.5681291188229807e-05
having O 0 8.210554369725287e-07
the O 0 1.3864828360965475e-06
incomplete O 0 1.0488031875866e-05
hex B-Disease 0 6.814429798396304e-05
A I-Disease 0 6.108669185778126e-05
deficiency I-Disease 0 0.1393134742975235
of O 0 3.9023034332785755e-05
the O 0 1.529210749140475e-05
type O 0 1.7827820556703955e-05
described O 0 1.8829540522347088e-06
in O 0 1.166594188362069e-06
the O 0 2.4017235773499124e-06
four O 0 1.4168533652991755e-06
healthy O 0 3.7047541354695568e-06
individuals O 0 1.5454354524990777e-06

The O 0 0.00018007674952968955
tumor B-Disease 0 0.06006177142262459
suppressor O 0 0.05024529993534088
gene O 0 2.083279650832992e-05
Smad4 O 0 0.0003013980749528855
/ O 0 4.119121877010912e-05
Dpc4 O 0 4.875408558291383e-05
is O 0 1.7658619810845266e-07
required O 0 8.996864409027694e-08
for O 0 3.7349610693127033e-07
gastrulation O 0 1.5010626157163642e-05
and O 0 4.6552341359529237e-07
later O 0 1.6447811503894627e-06
for O 0 4.568765348267334e-07
anterior O 0 9.2028894869145e-05
development O 0 5.334287379810121e-06
of O 0 5.242810857453151e-06
the O 0 5.786447673017392e-06
mouse O 0 3.0178889574017376e-06
embryo O 0 4.124657607462723e-06
. O 0 1.0209566880803322e-06

Mutations O 0 2.9809083571308292e-05
in O 0 1.1017846190952696e-05
the O 0 1.8506018022890203e-05
SMAD4 O 0 0.0016763628227636218
/ O 0 0.000494740204885602
DPC4 O 0 0.006662581115961075
tumor B-Disease 1 0.9720662236213684
suppressor O 0 0.08505714684724808
gene O 0 7.611909609295253e-07
, O 0 1.3730556247537606e-07
a O 0 4.70179713829566e-07
key O 0 2.760630195552949e-06
signal O 0 1.47534938150784e-05
transducer O 0 9.87809744401602e-06
in O 0 2.6420518679515226e-06
most O 0 1.046413672156632e-06
TGFbeta O 0 0.00011686328070936725
- O 0 4.782245014212094e-05
related O 0 1.0119581020262558e-05
pathways O 0 9.166637028101832e-06
, O 0 3.502405832023214e-08
are O 0 1.624822276724558e-09
involved O 0 2.5118889190878235e-09
in O 0 1.704879970532147e-08
50 O 0 1.6491554788444773e-07
% O 0 2.5604467168705014e-07
of O 0 1.7698403098620474e-05
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999963045120239
. O 0 3.3672044082777575e-05

Homozygous O 0 0.0018846715101972222
Smad4 O 0 0.00418856181204319
mutant O 0 0.00017372160800732672
mice O 0 6.125725485617295e-05
die O 0 1.3589045011030976e-05
before O 0 2.3131055968406145e-06
day O 0 2.3618920295120915e-06
7 O 0 4.9485611270938534e-06
. O 0 8.171683703039889e-07

5 O 0 3.57267381332349e-05
of O 0 2.7917551051359624e-05
embryogenesis O 0 0.0003307159640826285
. O 0 1.8713497411226854e-05

Mutant O 0 0.00015486848133150488
embryos O 0 1.0231215128442273e-05
have O 0 9.928671715897508e-07
reduced O 0 1.2175814845249988e-06
size O 0 9.297638143834774e-07
, O 0 3.559516414952668e-07
fail O 0 5.558105158343096e-07
to O 0 2.47328244995515e-07
gastrulate O 0 1.657284337852616e-05
or O 0 8.679379561726819e-07
express O 0 2.763865438737412e-07
a O 0 1.0810687172124744e-06
mesodermal O 0 1.3558868886320852e-05
marker O 0 1.3414088243735023e-05
, O 0 7.283715319772455e-08
and O 0 7.900278120587245e-08
show O 0 6.746776080035488e-07
abnormal O 0 0.00032925501000136137
visceral O 0 0.0002466050209477544
endoderm O 0 0.000495554821100086
development O 0 2.735397356445901e-05
. O 0 1.1757550737456768e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 0.0038697842974215746
the O 0 0.00039819939411245286
Smad4 O 0 0.2337067872285843
- O 0 0.004830019548535347
deficient O 0 0.0003124355571344495
embryos O 0 1.212646111525828e-06
results O 0 5.737021524510055e-07
from O 0 3.104528900621517e-07
reduced O 0 2.4475402824464254e-06
cell O 0 6.115448286436731e-06
proliferation O 0 1.052327934303321e-05
rather O 0 6.67010766619569e-08
than O 0 2.415218780527084e-08
increased O 0 8.54934228300408e-07
apoptosis O 0 2.1444662706926465e-05
. O 0 1.028967176353035e-06

Aggregation O 0 0.0002554110833443701
of O 0 5.7478624512441456e-05
mutant O 0 0.00010708476474974304
Smad4 O 0 0.0008930839248932898
ES O 0 0.0019716168753802776
cells O 0 1.1416694860599819e-06
with O 0 9.79417151825146e-08
wild O 0 5.589259330918139e-07
- O 0 1.814858023863053e-06
type O 0 4.784465090779122e-06
tetraploid O 0 4.3895994167542085e-05
morulae O 0 0.0001591364707564935
rescues O 0 1.98793422896415e-05
the O 0 1.5372363122878596e-05
gastrulation B-Disease 0 0.0005871346220374107
defect I-Disease 0 0.00015243396046571434
. O 0 4.116845047974493e-06

These O 0 6.956462129892316e-06
results O 0 1.1719852409441955e-05
indicate O 0 5.3968883548805024e-06
that O 0 1.117313559007016e-06
Smad4 O 0 3.336505324114114e-05
is O 0 2.7237209110353433e-07
initially O 0 1.536745202201928e-07
required O 0 5.284406512373607e-08
for O 0 1.2632546031454694e-07
the O 0 6.801163863201509e-07
differentiation O 0 2.1015582660766086e-06
of O 0 2.1440286218421534e-05
the O 0 3.108939927187748e-05
visceral O 0 9.980193863157183e-05
endoderm O 0 0.00010022481728810817
and O 0 1.2471524541979306e-06
that O 0 1.7032554922025156e-07
the O 0 2.0701079392893007e-06
gastrulation B-Disease 0 3.7548110412899405e-05
defect I-Disease 0 7.348333383561112e-06
in O 0 1.198988229589304e-06
the O 0 3.072165554840467e-06
epiblast O 0 7.654521323274821e-05
is O 0 5.719082309951773e-07
secondary O 0 8.365537723875605e-06
and O 0 6.027561312293983e-07
non O 0 2.1772555555799045e-05
- O 0 2.3570863049826585e-05
cell O 0 1.3959071111457888e-05
autonomous O 0 1.0329931683372706e-05
. O 0 2.3599848191224737e-06

Rescued O 0 0.0007082177908159792
embryos O 0 3.791306880884804e-05
show O 0 7.029179687378928e-05
severe O 1 0.9579993486404419
anterior O 1 0.9970075488090515
truncations O 1 0.6261586546897888
, O 0 2.0748118458868703e-06
indicating O 0 7.26711596144014e-06
a O 0 4.5589681008095795e-07
second O 0 5.737185801990563e-07
important O 0 1.5281125342880841e-07
role O 0 1.0925057267741067e-06
for O 0 1.0194477226832532e-06
Smad4 O 0 0.0002339287311770022
in O 0 1.468286518502282e-05
anterior O 0 0.3635707497596741
patterning O 0 0.006017728708684444
during O 0 0.002343328669667244
embryogenesis O 0 0.00017864206165540963
. O 0 2.9451755381160183e-06

Prevalence O 0 0.001106945564970374
of O 0 0.00012314868217799813
p16 O 0 0.0002089960325974971
and O 0 6.776491318305489e-06
CDK4 O 0 0.0012995752040296793
germline O 0 5.712452548323199e-05
mutations O 0 1.0617545740387868e-06
in O 0 5.2558166316885035e-06
48 O 0 6.032578676240519e-05
melanoma B-Disease 1 0.9985876083374023
- O 0 0.006691196002066135
prone O 0 4.0373895899392664e-05
families O 0 1.3411273869223805e-07
in O 0 4.136362861117959e-07
France O 0 7.123201157810399e-06
. O 0 4.6384170673263725e-06

The O 0 5.2233535825507715e-05
French O 0 0.0002467296726536006
Familial B-Disease 1 0.9996190071105957
Melanoma I-Disease 1 1.0
Study O 0 5.220883394940756e-05
Group O 0 3.430988272157265e-06
. O 0 8.595155236434948e-07

Germline O 0 0.0019883757922798395
mutations O 0 3.0610863177571446e-05
in O 0 1.3871936062059831e-05
the O 0 1.1968898434133735e-05
p16 O 0 2.4433018552372232e-05
and O 0 2.930556092906045e-06
CDK4 O 0 0.00033950756187550724
genes O 0 1.4281552012107568e-06
have O 0 5.389350690165884e-07
been O 0 4.705161416040937e-07
reported O 0 3.837495228253829e-07
in O 0 1.723661711139357e-07
a O 0 5.851145488122711e-07
subset O 0 5.230994247540366e-06
of O 0 9.169724944513291e-05
melanoma B-Disease 1 0.9999939203262329
pedigrees O 0 5.705995499738492e-05
, O 0 1.8051933636797912e-07
but O 0 1.0723889332098224e-08
their O 0 1.2268996485431671e-08
prevalence O 0 1.770434664649656e-06
is O 0 4.979223433565494e-08
not O 0 1.72171255030662e-08
well O 0 8.464452605494444e-08
known O 0 9.869431778497528e-07
. O 0 1.1188062671863008e-06

We O 0 1.0189694876316935e-05
searched O 0 4.2255887819919735e-06
for O 0 1.829812958931143e-07
such O 0 2.550019360114675e-07
germline O 0 9.204656635120045e-06
mutations O 0 6.096553875067912e-07
in O 0 4.300506589061115e-06
48 O 0 2.4074146494967863e-05
French O 0 0.0008516767993569374
melanoma B-Disease 1 0.9999995231628418
- O 1 0.5219054818153381
prone O 0 9.326698636868969e-05
families O 0 1.8585645022994868e-07
selected O 0 3.911265196165914e-07
according O 0 1.5675958309202542e-07
to O 0 7.126410395130733e-08
two O 0 3.0871950684741023e-07
major O 0 3.0915400657249847e-06
criteria O 0 1.4562842807208654e-06
families O 0 1.1325662541139536e-07
with O 0 7.193737872057682e-08
at O 0 1.4068335985939484e-05
least O 0 1.0137252104414074e-07
three O 0 1.1568376123705093e-07
affected O 0 1.0447260478940734e-07
members O 0 4.986313228982908e-08
( O 0 2.8489134606957123e-08
n O 0 3.3888071016008325e-07
= O 0 4.0950558855001873e-07
20 O 0 6.186108976180549e-07
) O 0 8.901720605081209e-08
or O 0 8.153298836077738e-08
families O 0 2.5189139662984417e-08
with O 0 5.034814165583157e-08
two O 0 4.684413283939648e-07
affected O 0 1.145235387411958e-06
members O 0 1.8286057468230865e-07
, O 0 1.0348693280093357e-07
one O 0 5.0925503813914474e-08
of O 0 6.84234464642941e-07
them O 0 4.586655677485396e-08
affected O 0 2.532576957037236e-07
before O 0 5.482820597535465e-07
the O 0 4.1215335500055517e-07
age O 0 4.181840722594643e-07
of O 0 6.378162424880429e-07
50 O 0 4.4456834302764037e-07
( O 0 6.06945036452089e-08
n O 0 3.7079107073623163e-07
= O 0 4.2226940877299057e-07
28 O 0 1.4952356650610454e-06
) O 0 3.093285982913585e-08
, O 0 7.374843402629949e-09
and O 0 3.9808356611104045e-09
one O 0 8.04780064811439e-09
additional O 0 4.8174022992952814e-08
minor O 0 9.065488484338857e-06
criterion O 0 0.0001761240273481235
. O 0 3.7145186979614664e-06

Sixteen O 0 0.00023934956698212773
different O 0 2.658743824213161e-06
p16 O 0 0.00011121125862700865
germline O 0 7.588658627355471e-05
mutations O 0 1.618702185623988e-06
were O 0 2.334584678465035e-06
found O 0 1.518528733868152e-07
in O 0 1.3742229043600673e-07
21 O 0 2.1754913177574053e-06
families O 0 4.891576210752646e-08
, O 0 5.371423483779836e-08
while O 0 5.595206431507904e-08
one O 0 2.266319540922268e-07
germline O 0 4.9901277634489816e-06
mutation O 0 4.872571253144997e-07
, O 0 4.4341535954117717e-07
Arg24His O 0 6.124191713752225e-06
, O 0 8.597551470757026e-08
was O 0 1.3916622947363066e-06
detected O 0 4.970906388734875e-07
in O 0 8.173429364433105e-07
the O 0 5.6553876675025094e-06
CDK4 O 0 0.000793911109212786
gene O 0 6.589949407498352e-06
. O 0 4.876620096183615e-06

The O 0 2.0987459720345214e-05
frequency O 0 1.2567297744681127e-05
of O 0 1.2470341971493326e-05
p16 O 0 1.9765579054364935e-05
gene O 0 9.765423101271153e-07
mutation O 0 2.085664334572357e-07
in O 0 4.4764468043467787e-07
our O 0 1.1540144839727873e-07
sample O 0 4.4921460329305773e-08
( O 0 4.91217342357686e-08
44 O 0 4.08958442221774e-07
% O 0 9.411707679873871e-08
) O 0 3.219282973532245e-08
is O 0 2.6919158457872072e-08
among O 0 1.4979626428157644e-08
the O 0 1.2627005219201237e-07
highest O 0 4.433237791090505e-06
rates O 0 8.970704925559403e-07
yet O 0 6.784379991131573e-08
reported O 0 5.836354830535129e-07
and O 0 2.2626655038493482e-07
the O 0 1.6992365772239282e-06
CDK4 O 0 4.0562266804045066e-05
mutation O 0 1.1462981319709797e-07
is O 0 8.865359291121422e-08
the O 0 1.6475254938086437e-07
second O 0 2.548716224737291e-07
mutation O 0 3.457543584772793e-08
detected O 0 1.8441889437781356e-07
in O 0 4.4915800856415444e-08
this O 0 2.343528215931201e-08
gene O 0 2.280622908301666e-07
worldwide O 0 8.221649636652728e-07
. O 0 1.439680431758461e-06

In O 0 0.00014826253755018115
summary O 0 0.00019789361977018416
, O 0 1.3847133004674106e-06
our O 0 4.53214738627139e-07
results O 0 3.7314222822715237e-07
show O 0 1.7917125205713091e-07
frequent O 0 4.5152876282372745e-07
involvement O 0 1.6524188595212763e-06
of O 0 4.465179699764121e-06
the O 0 5.032178250985453e-06
p16 O 0 1.984294067369774e-05
gene O 0 1.0740674269982264e-06
in O 0 1.7451056919526309e-06
familial B-Disease 0 0.00020949760801158845
melanoma I-Disease 1 0.999764621257782
and O 0 1.3459812180371955e-06
confirm O 0 6.944417805243575e-07
the O 0 1.041187601913407e-06
role O 0 1.1374527275620494e-06
of O 0 2.198072434111964e-05
the O 0 2.5618792278692126e-05
CDK4 O 0 0.005779018625617027
gene O 0 2.36086520999379e-06
as O 0 2.4929568098741584e-06
a O 0 4.022422672278481e-06
melanoma B-Disease 0 0.004466397222131491
- O 0 5.1844668632838875e-05
predisposing O 0 4.9373651563655585e-05
gene O 0 1.29012016714114e-06
. O 0 3.161783581617783e-07
. O 0 1.1004991620211513e-06

Progression O 0 0.0035251916851848364
of O 0 0.00021116694551892579
somatic O 0 0.00020182727894280106
CTG O 0 0.0003177928156219423
repeat O 0 2.095620175168733e-06
length O 0 5.305827812662756e-07
heterogeneity O 0 1.205822513838939e-06
in O 0 3.203614937774546e-07
the O 0 6.432259169741883e-07
blood O 0 3.4278484690730693e-06
cells O 0 8.745944796828553e-06
of O 0 0.2695964276790619
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 9.210369898937643e-05
. O 0 3.918914899259107e-06

The O 0 4.734527010441525e-06
genetic O 0 1.6238801663348568e-06
basis O 0 1.7411561202607118e-05
of O 0 0.0010047073010355234
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.7143747754744254e-05
DM B-Disease 1 1.0
) O 0 4.202742900361045e-07
is O 0 1.2172733931947732e-07
the O 0 2.20910038706279e-07
expansion O 0 2.3334005163633265e-06
of O 0 4.290437573217787e-06
an O 0 5.282983238430461e-06
unstable O 0 5.761900683864951e-05
CTG O 0 7.289755740202963e-05
repeat O 0 9.883400480248383e-07
in O 0 8.108694373731851e-07
the O 0 9.11799702407734e-07
34 O 0 2.779614078463055e-06
UTR O 0 1.9372106180526316e-05
of O 0 8.812035048322286e-06
the O 0 2.6478672225493938e-05
DM B-Disease 1 0.9999252557754517
protein O 0 1.284902282350231e-05
kinase O 0 8.077026905084495e-06
gene O 0 3.6178846585244173e-07
on O 0 2.329996050320915e-06
chromosome O 0 9.426046744920313e-06
19 O 0 1.0941983418888412e-05
. O 0 1.0527567155804718e-06

One O 0 3.453889803495258e-05
of O 0 2.1986385036143474e-05
the O 0 1.0510039828659501e-05
principal O 0 2.9916473067714833e-05
features O 0 1.1525872878337395e-06
of O 0 2.85139412881108e-05
the O 0 0.0001770669623510912
DM B-Disease 1 1.0
mutation O 0 7.029117568890797e-06
is O 0 1.0458899168952485e-06
an O 0 2.9804584755765973e-07
extraordinarily O 0 4.158474894211395e-06
high O 0 2.333552583877463e-05
level O 0 2.3718219381407835e-05
of O 0 6.560269684996456e-05
somatic O 0 0.0004051927535329014
mosaicism O 0 0.02041264809668064
, O 0 7.753088766548899e-07
due O 0 2.9194511625973973e-06
to O 0 3.744533216831769e-08
an O 0 9.838357328817438e-08
extremely O 0 1.53385499856995e-07
high O 0 2.552109435782768e-06
degree O 0 8.143279046635143e-06
of O 0 2.6671074010664597e-05
somatic O 0 7.242963329190388e-05
instability O 0 2.910280818468891e-05
both O 0 1.5511719198002538e-07
within O 0 7.390209333379971e-08
and O 0 4.760951100024613e-08
between O 0 2.7533104685062426e-07
different O 0 4.477347559372902e-08
tissues O 0 5.9178078117838595e-06
. O 0 1.8503033061278984e-06

This O 0 5.536972821573727e-05
instability O 0 0.0001644469448365271
appears O 0 4.551614438241813e-06
to O 0 2.1132763095010887e-07
be O 0 1.6293020621560572e-07
biased O 0 3.863707433993113e-07
towards O 0 2.558359710747027e-07
further O 0 7.183207628713717e-08
expansion O 0 4.779293476531166e-07
and O 0 3.677889992559358e-08
continuous O 0 1.001196437755425e-06
throughout O 0 1.6479245346090465e-07
the O 0 8.057331797317602e-07
life O 0 6.959806455597572e-07
of O 0 2.8753242986567784e-06
an O 0 5.902517159483978e-07
individual O 0 4.5866904940794484e-08
, O 0 7.696086612440922e-08
features O 0 4.083659632669878e-08
that O 0 2.2149093226175864e-08
could O 0 3.105310142359485e-08
be O 0 2.2275855826592306e-08
associated O 0 1.5359562510752767e-08
with O 0 1.3635957252233766e-08
the O 0 1.2769540944645996e-06
progressive O 0 1.5087292013049591e-05
nature O 0 5.132178557687439e-07
of O 0 1.2266946214367636e-05
the O 0 4.6349185140570626e-05
disease O 0 0.0032967079896479845
. O 0 3.9447277231374756e-06

Although O 0 1.0945834219455719e-05
increasing O 0 5.0252624532731716e-06
measured O 0 1.0782326171465684e-05
allele O 0 9.089398531614279e-07
size O 0 2.793939302137005e-07
between O 0 9.989494174078573e-07
patients O 0 7.121626595107955e-07
clearly O 0 1.87177334964872e-07
correlates O 0 4.400779687330214e-07
with O 0 2.6025587018807528e-08
an O 0 4.957673738203994e-08
increased O 0 1.0440880942041986e-06
severity O 0 1.4836543414276093e-05
of O 0 0.00041551710455678403
symptoms O 0 0.15758925676345825
and O 0 2.5062870463443687e-06
an O 0 9.208512778968725e-07
earlier O 0 1.1565666682145093e-06
age O 0 1.2285796628930257e-06
of O 0 2.866707973225857e-06
onset O 0 0.0003048177750315517
, O 0 1.2022613304907281e-07
this O 0 1.9006797913334594e-08
correlation O 0 4.766629899677355e-07
is O 0 1.0472777489667351e-07
not O 0 2.8351500702683552e-08
precise O 0 2.677547854545992e-07
and O 0 2.9830630410287995e-07
measured O 0 4.847061063628644e-06
allele O 0 8.971646252575738e-07
length O 0 1.3336320989765227e-06
cannot O 0 3.6206492382007127e-07
be O 0 1.5505922590364207e-07
used O 0 5.147913384462299e-08
as O 0 2.2895985551940612e-08
an O 0 7.879041419300847e-09
accurate O 0 6.502646243689014e-08
predictor O 0 4.959895250067348e-06
of O 0 1.7301565549132647e-06
age O 0 5.31194109498756e-06
of O 0 3.932893378078006e-05
onset O 1 0.999660849571228
. O 0 1.2880909707746468e-05

In O 0 1.4915249266778119e-05
order O 0 1.381335437145026e-06
to O 0 2.5525571345497156e-07
further O 0 3.9684280750407197e-07
characterize O 0 2.9733489554928383e-06
the O 0 2.4080950424831826e-06
dynamics O 0 1.014762710838113e-05
of O 0 0.00021939663565717638
DM B-Disease 1 1.0
CTG O 0 0.01669354736804962
repeat O 0 4.507660923991352e-05
somatic O 0 4.6508801460731775e-05
instability O 0 1.728984534565825e-05
, O 0 1.1461898452580499e-07
we O 0 1.4299820882968106e-08
have O 0 7.337871199553092e-09
studied O 0 1.1658785581403208e-07
repeat O 0 3.712347051987308e-08
length O 0 5.108466183401106e-08
changes O 0 1.0168445641056678e-08
over O 0 4.828137178947145e-08
time O 0 8.551938179834906e-08
in O 0 1.0281578397552948e-06
111 O 0 0.26777422428131104
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 6.211789127519296e-07
with O 0 2.3510677849003514e-08
varying O 0 2.4341159132745815e-07
clinical O 0 1.9795763364527375e-05
severity O 0 0.00010652674245648086
and O 0 4.701735178969102e-06
CTG O 0 6.626424874411896e-05
repeat O 0 8.296713076560991e-07
size O 0 1.1965512669576128e-07
over O 0 2.6083534976351075e-07
time O 0 5.3146397505088316e-08
intervals O 0 1.0344430734221532e-07
of O 0 4.607014432167489e-07
1 O 0 8.039517069846625e-07
- O 0 4.3878011979359144e-07
7 O 0 1.203667011395737e-06
years O 0 8.192299105758138e-07
. O 0 4.630076944067696e-07

We O 0 2.706545637920499e-05
have O 0 8.897229122339922e-07
found O 0 2.3605987564678799e-07
a O 0 2.0972446179712279e-07
direct O 0 7.217761890387919e-07
progression O 0 5.1127059123246e-05
of O 0 4.7016451389936265e-06
the O 0 1.1133206498925574e-06
size O 0 2.8050189371242595e-07
heterogeneity O 0 2.0663958366640145e-06
over O 0 7.281714715645649e-07
time O 0 2.349013072944217e-07
related O 0 2.3581620212098642e-07
to O 0 1.6215358300541993e-07
initial O 0 2.740458512562327e-06
CTG O 0 6.014965765643865e-05
repeat O 0 9.60142642725259e-07
size O 0 4.226465080137132e-07
and O 0 2.582852687282866e-07
the O 0 3.7321055401662306e-07
time O 0 1.0840312114623885e-07
interval O 0 5.324313860910479e-07
and O 0 9.425180280686618e-08
always O 0 5.316961448897928e-08
biased O 0 2.541003425449162e-07
towards O 0 1.5941219544401974e-07
further O 0 1.6883575426618336e-07
expansion O 0 6.318918167380616e-06
. O 0 1.3582454130300903e-06

Attempts O 0 6.893120735185221e-05
to O 0 4.379775873530889e-06
mathematically O 0 9.66688367043389e-06
model O 0 4.996451480110409e-06
the O 0 4.056666512042284e-06
dynamics O 0 8.211641215893906e-06
have O 0 3.890336017775553e-07
proved O 0 1.959057044587098e-06
only O 0 1.4371671852586587e-07
partially O 0 2.5265417207265273e-06
successful O 0 2.275237420690246e-07
suggesting O 0 1.115168046794679e-07
that O 0 4.58138948999931e-09
individual O 0 1.1786084330722701e-09
specific O 0 1.2861281817322379e-08
genetic O 0 3.701551065660169e-07
and O 0 1.5468893934666994e-06
/ O 0 7.822008046787232e-05
or O 0 2.3645739020139445e-06
environmental O 0 3.369077603565529e-06
factors O 0 3.6366509448271245e-07
also O 0 1.7709078292682534e-07
play O 0 1.9418034469254053e-07
a O 0 3.0389904281946656e-07
role O 0 5.507645823854546e-07
in O 0 1.6034515510909841e-06
somatic O 0 2.7575741114560515e-05
mosaicism O 0 0.00013760372530668974
. O 0 3.912063561983814e-07
. O 0 8.714995374248247e-07

Aspartylglucosaminuria B-Disease 1 0.9999637603759766
among O 0 1.0199202733929269e-05
Palestinian O 0 7.100213406374678e-05
Arabs O 0 2.3833923478377983e-05
. O 0 6.384902917488944e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.007252924144268036
AGU B-Disease 1 1.0
) O 0 1.7019644928950584e-06
is O 0 2.613866740830417e-07
a O 0 2.65148173639318e-07
rare O 0 1.777106376721349e-06
disorder B-Disease 1 0.9894909262657166
of I-Disease 1 0.9997153878211975
glycoprotein I-Disease 1 1.0
metabolism I-Disease 1 0.9999996423721313
caused O 0 0.08440442383289337
by O 0 5.199181032367051e-07
the O 0 1.0820664101629518e-05
deficiency B-Disease 1 0.9887354969978333
of I-Disease 0 0.00019579040235839784
the I-Disease 0 9.269676229450852e-05
lysosomal I-Disease 0 0.1848258674144745
enzyme I-Disease 0 7.841884325898718e-06
aspartylglucosaminidase I-Disease 0 4.219712354824878e-05
( O 0 6.288873350968061e-07
AGA O 0 0.00010696067329263315
) O 0 5.55494693799119e-07
. O 0 7.908507768661366e-07

AGU B-Disease 1 1.0
is O 0 0.00020942531409673393
inherited O 0 0.008763780817389488
as O 0 6.6361576500639785e-06
an O 0 2.937621047749417e-06
autosomal O 0 0.00022154583712108433
recessive O 0 0.0005373258027248085
trait O 0 8.780694770393893e-06
and O 0 1.2528959132396267e-06
occurs O 0 1.2823514339288522e-07
with O 0 2.1367025482277313e-08
a O 0 4.417852039750869e-07
high O 0 9.842307008511852e-06
frequency O 0 3.5711380519387603e-07
in O 0 2.8582240929608815e-07
Finland O 0 2.1647285564085905e-07
because O 0 4.996347513497312e-08
of O 0 1.0648342367858277e-06
a O 0 1.7220431800524238e-06
founder O 0 1.4051763173483778e-05
effect O 0 3.138164856864023e-06
. O 0 1.1256300922468654e-06

While O 0 9.645956015447155e-05
very O 0 4.476597041502828e-06
few O 0 2.1520293103094446e-06
patients O 0 4.477104994293768e-06
with O 0 4.861514298681868e-06
AGU B-Disease 1 1.0
have O 0 2.993096359205083e-06
been O 0 2.168895662180148e-06
reported O 0 1.0190015018451959e-06
from O 0 6.68747020426963e-07
non O 0 3.432644234635518e-06
- O 0 1.5611642538715387e-06
Finnish O 0 6.283073616941692e-06
origin O 0 7.904285439508385e-07
, O 0 3.735716234132269e-07
we O 0 2.9276992563609383e-07
diagnosed O 0 0.00020511912589427084
the O 0 3.32487638843304e-06
disorder O 0 9.174797014566138e-05
in O 0 3.2496282074134797e-06
8 O 0 1.2692041309492197e-05
patients O 0 1.7767305848792603e-07
originating O 0 6.134603722784959e-07
from O 0 8.394015367230168e-07
3 O 0 9.780858363228617e-07
unrelated O 0 2.0180395665647666e-07
families O 0 2.004931154431233e-08
, O 0 2.5892198607380124e-08
all O 0 2.4438284285110967e-08
Palestinian O 0 1.2077813380528823e-06
Arabs O 0 2.2349061623572197e-07
from O 0 2.773460607841116e-07
the O 0 1.454938853839849e-07
region O 0 1.9972753761976492e-07
of O 0 1.5856309119044454e-06
Jerusalem O 0 0.00018550286768004298
. O 0 4.777588856086368e-06

The O 0 0.00010068326810142025
clinical O 0 0.14847198128700256
diagnosis O 1 0.9999905824661255
of O 1 0.9999995231628418
AGU B-Disease 1 1.0
is O 0 3.76967218471691e-05
often O 0 4.272082776424213e-07
difficult O 0 1.361769079721853e-07
, O 0 3.8555210579716004e-08
in O 0 5.855578066871203e-08
particular O 0 9.131069589329854e-08
early O 0 5.691844080502051e-07
in O 0 5.788617158941634e-07
the O 0 1.409388801221212e-06
course O 0 2.7153873816132545e-06
of O 0 1.2690007679339033e-05
the O 0 8.484484715154395e-05
disease O 0 0.00853389035910368
, O 0 6.80037942402123e-07
and O 0 1.6236187150298065e-07
most O 0 8.107768678655702e-08
of O 0 2.299885636602994e-06
the O 0 9.67845153354574e-06
patients O 0 5.495638561114902e-06
are O 0 1.2020381063848617e-06
diagnosed O 0 0.003060106886550784
after O 0 2.770605306068319e-06
the O 0 3.820172764790186e-07
age O 0 4.87374222757353e-07
of O 0 9.082380074687535e-07
5 O 0 1.6531345181647339e-06
years O 0 1.6620297174085863e-06
. O 0 1.6173549965969869e-06

However O 0 2.3912192773423158e-05
, O 0 1.4017188050274854e-06
since O 0 9.538043741486035e-07
these O 0 4.8847983435962306e-08
patients O 0 2.2628209705999325e-07
excrete O 0 6.288915415098018e-07
early O 0 3.436554436575534e-07
large O 0 2.751368128883769e-07
amounts O 0 4.086079457010783e-07
of O 0 1.2646901268453803e-05
aspartylglucosamine O 0 4.232140781823546e-05
in O 0 2.9992797863087617e-06
urine O 0 1.2576903145600227e-06
, O 0 7.952952074674613e-08
biochemical O 0 6.666800231869274e-07
screening O 0 2.7929692691941455e-07
is O 0 1.0690583707173573e-07
easy O 0 3.82621720973475e-08
by O 0 5.731980579071205e-08
urine O 0 4.388432728319458e-07
chromatography O 0 1.1435980013629887e-05
. O 0 3.0964150710133254e-07
. O 0 1.0885102028623805e-06

Detection O 0 0.0001556645438540727
of O 0 4.0677350625628605e-05
heterozygous O 0 4.384113253763644e-06
carriers O 0 1.1152886827403563e-06
of O 0 7.828210982552264e-06
the O 0 5.313584551913664e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 1.0
( O 0 1.361028989776969e-05
ATM O 0 0.0002796318440232426
) O 0 1.1152062739938629e-07
gene O 0 1.4042339557818195e-07
by O 0 2.989146139498189e-07
G2 O 0 0.00012879066343884915
phase O 0 9.237677659257315e-06
chromosomal O 0 3.613255830714479e-05
radiosensitivity O 0 5.974475425318815e-05
of O 0 2.8077642127755098e-05
peripheral O 0 0.006132838316261768
blood O 0 0.00013814745761919767
lymphocytes O 0 0.00010668767208699137
. O 0 2.100686515404959e-06

In O 0 0.002830335171893239
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 1 0.6409673094749451
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.6327720686604152e-06
patients O 0 3.042638638817152e-07
, O 0 2.5343448228909438e-08
mutations O 0 1.419205819530589e-08
in O 0 1.4637150513863162e-07
a O 0 4.2623932472452e-07
single O 0 2.45099698759077e-07
gene O 0 2.1217134360540513e-07
, O 0 1.6015306414374209e-07
ATM O 0 6.1019445638521574e-06
, O 0 1.0707886133332067e-08
result O 0 2.3747467992052407e-08
in O 0 2.4279302124341484e-07
an O 0 7.554521289421245e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 8.128258741635364e-06
embraces O 0 1.021410525936517e-06
a O 0 1.7094801307848684e-07
variety O 0 4.4049993874750726e-08
of O 0 9.794673587748548e-07
clinical O 0 1.176900968857808e-05
features O 0 7.242542778840289e-07
and O 0 3.6076619380764896e-07
manifests O 0 6.930590075171494e-07
extreme O 0 6.545379164890619e-06
radiosensitivity O 0 5.717673775507137e-05
and O 0 5.090811896479863e-07
a O 0 8.998981115837523e-07
strong O 0 8.086499860837648e-07
pre O 0 8.644918125355616e-05
- O 0 3.065322380280122e-05
disposition O 0 3.059781374759041e-05
to O 0 1.7967000758289942e-06
malignancy B-Disease 0 0.0006156542804092169
. O 0 3.6371748137753457e-06

Heterozygotes O 0 0.0003831078647635877
for O 0 8.643260116514284e-06
the O 0 9.198855877912138e-06
ATM O 0 9.235222387360409e-05
gene O 0 5.999940526635328e-07
have O 0 1.3050497216227086e-07
no O 0 1.2570569651870755e-07
clinical O 0 3.518815219649696e-06
expression O 0 4.339447059464874e-06
of O 0 0.0006960429018363357
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.7766996052159811e-06
may O 0 5.314768259268021e-06
be O 0 2.0779048099939246e-06
cancer B-Disease 0 3.251974703744054e-05
prone O 0 1.6695230442564934e-06
with O 0 2.179738878282933e-08
a O 0 3.6774767409042397e-07
moderate O 0 1.1259973007327062e-06
increase O 0 2.991587280121166e-07
in O 0 2.991170902078011e-07
in O 0 7.128251695576182e-07
vitro O 0 2.849918200809043e-05
radiosensitivity O 0 0.00011743848153855652
. O 0 1.8357432054472156e-06

We O 0 1.6317604604410008e-05
performed O 0 1.5259618521668017e-05
a O 0 5.080092250864254e-06
blind O 0 2.5135344912996516e-05
chromosomal O 0 1.9200486349291168e-05
analysis O 0 9.886302905215416e-07
on O 0 2.1871805074624717e-05
G2 O 0 0.0003640308859758079
- O 0 3.4969903026649263e-06
phase O 0 6.34541629551677e-06
lymphocytes O 0 2.4913549623306608e-06
from O 0 7.30023828054982e-07
7 O 0 2.8933195608260576e-06
unrelated O 0 2.4906375983846374e-06
A B-Disease 1 0.998762845993042
- I-Disease 1 0.9930661916732788
T I-Disease 1 0.9999710321426392
patients O 0 8.640810165161383e-07
, O 0 8.733609746514048e-08
13 O 0 5.290286253512022e-07
obligate O 0 1.0613475751597434e-06
A B-Disease 1 0.9387543797492981
- I-Disease 0 0.0024230254348367453
T I-Disease 1 0.8859139680862427
heterozygotes O 0 5.681394668499706e-06
( O 0 1.2100301205464348e-07
parents O 0 2.4215289329276857e-08
of O 0 5.541866698877129e-07
the O 0 1.13829048586922e-06
patients O 0 1.7093121584821347e-07
) O 0 5.956316329047695e-08
, O 0 4.769794514913883e-08
and O 0 8.340792589933699e-08
14 O 0 1.8343956753597013e-06
normal O 0 2.3973893803486135e-06
controls O 0 9.75140892478521e-07
following O 0 1.46059323924419e-06
X O 0 8.169725333573297e-06
- O 0 1.0004509931604844e-06
irradiation O 0 2.172311042158981e-06
with O 0 8.708027365855742e-08
1 O 0 2.5382887542946264e-06
Gy O 0 1.2553176020446699e-05
in O 0 1.63107429784759e-07
order O 0 1.4202488785031164e-07
to O 0 9.136313394719764e-08
evaluate O 0 2.3574693841510452e-07
this O 0 2.742314961778902e-07
cytogenetic O 0 2.32635393331293e-05
method O 0 7.979692213666567e-07
as O 0 3.3218356065845e-07
a O 0 1.6449490658487775e-07
tool O 0 2.255887068258744e-07
for O 0 3.9896704606690037e-08
detection O 0 6.959600682421296e-07
of O 0 1.0173363079957198e-05
ATM O 0 0.00030830310424789786
carriers O 0 6.972648861847119e-06
. O 0 4.082880423084134e-06

Both O 0 0.00032662253943271935
A B-Disease 1 0.9999955892562866
- I-Disease 1 0.9999828338623047
T I-Disease 1 0.9999996423721313
homozygotes O 0 4.8395922931376845e-05
and O 0 7.806217467987153e-07
heterozygotes O 0 5.449767286336282e-06
showed O 0 1.5972749451975687e-06
significantly O 0 3.556347110134084e-07
increased O 0 9.271569751945208e-07
levels O 0 1.5650431350877625e-06
of O 0 3.415780838622595e-06
radiation O 0 0.003071639919653535
- O 0 8.658976730657741e-05
induced O 0 0.0001782371400622651
chromatid O 0 0.0002790044527500868
damage O 0 4.345549314166419e-05
relative O 0 3.0734840947843622e-06
to O 0 1.2650544078951498e-07
that O 0 6.563742260823346e-08
of O 0 1.7169858210763778e-06
normal O 0 1.5175432054093108e-05
controls O 0 2.6598178010317497e-05
. O 0 2.3478244202124188e-06

These O 0 5.089023943583015e-06
results O 0 6.247302735573612e-06
show O 0 2.6961040475725895e-06
that O 0 4.2712233039310377e-07
the O 0 4.776618879986927e-06
G2 O 0 0.0004236383247189224
- O 0 1.0232854037894867e-05
phase O 0 3.4046952350763604e-05
chromosomal O 0 7.921709038782865e-05
radiosensitivity O 0 0.00020173934171907604
assay O 0 1.6382095054723322e-05
can O 0 8.637096726715754e-08
be O 0 8.675500851040852e-08
used O 0 3.542035642567498e-08
for O 0 3.294796613317885e-08
the O 0 2.258957039202869e-07
detection O 0 9.786008376977406e-07
of O 0 4.6863904572092e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999977350234985
T I-Disease 1 0.9999988079071045
heterozygotes O 0 5.622585376841016e-05
. O 0 3.3156431982206414e-06

In O 0 2.5448001906624995e-05
combination O 0 3.844377715722658e-06
with O 0 4.0194214534494677e-07
molecular O 0 3.073204425163567e-05
genetic O 0 1.647462454457127e-06
analyses O 0 1.897642619042017e-06
, O 0 2.783885406643094e-07
this O 0 5.7393759078649964e-08
test O 0 8.057234879288444e-08
may O 0 1.8773583576603414e-07
be O 0 1.818483852389363e-08
of O 0 6.638011029735935e-08
value O 0 1.5278109799510275e-07
in O 0 9.581259519109153e-08
studies O 0 1.0892603796719413e-07
of O 0 3.417927416649036e-07
familial B-Disease 0 1.9969907043559942e-06
and I-Disease 0 8.397466331189207e-07
sporadic I-Disease 0 4.2805884731933475e-05
cancers I-Disease 0 0.0003653614257927984
aimed O 0 2.9489526696124813e-06
at O 0 1.936517719514086e-06
determination O 0 5.8658958579371756e-08
of O 0 2.7526019152901426e-07
the O 0 2.121930009479911e-07
potential O 0 2.0531841471438383e-07
involvement O 0 7.42844974865875e-07
of O 0 2.7580881578614935e-06
ATM O 0 9.559477621223778e-05
mutations O 0 6.480451588686265e-07
in O 0 3.763827635339112e-06
tumor B-Disease 1 0.9998854398727417
risk O 0 5.8163568610325456e-06
or O 0 7.574557798761816e-07
development O 0 1.700671305115975e-06
. O 0 1.8283965630416787e-07
. O 0 8.39894767068472e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
: O 0 7.421959708153736e-06
identification O 0 5.089996193419211e-07
and O 0 3.186782180364389e-07
detection O 0 8.355730642506387e-06
of O 0 0.06967802345752716
founder O 1 0.7547217607498169
- O 0 1.3895688425691333e-05
effect O 0 3.09179927171499e-06
mutations O 0 1.7434508947644645e-07
in O 0 3.587768730994867e-07
the O 0 7.422006547130877e-07
ATM O 0 1.4565839592250995e-05
gene O 0 1.098088304729572e-07
in O 0 4.090308891591121e-08
ethnic O 0 4.810534193211424e-08
populations O 0 2.127934379814178e-07
. O 0 4.6911011963857163e-07

To O 0 3.7334050375648076e-06
facilitate O 0 4.480509232962504e-06
the O 0 3.2336147341993637e-06
evaluation O 0 5.319301635609008e-06
of O 0 2.7835962100652978e-05
ATM O 0 0.0025607282295823097
heterozygotes O 0 3.110986654064618e-05
for O 0 1.0187040970777161e-06
susceptibility O 0 2.7344063710188493e-05
to O 0 9.475756996835116e-07
other O 0 6.51854747957259e-07
diseases O 0 0.20987440645694733
, O 0 1.1950629641432897e-07
such O 0 8.675202423091832e-08
as O 0 2.1333493350539356e-05
breast B-Disease 1 0.9455975890159607
cancer I-Disease 0 0.2387586236000061
, O 0 4.801500494977518e-07
we O 0 4.63419382867869e-08
have O 0 3.7006259390182095e-08
attempted O 0 3.653186411156639e-07
to O 0 9.607409623413332e-08
define O 0 1.7223437964730692e-07
the O 0 6.078776664253382e-07
most O 0 6.24709528551648e-08
common O 0 3.793213565472797e-08
mutations O 0 1.7882568315030767e-08
and O 0 1.867404719746446e-08
their O 0 1.5447231049847687e-08
frequencies O 0 6.976147233217489e-07
in O 0 3.3787816846597707e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9997321963310242
telangiectasia I-Disease 1 1.0
( O 0 4.651798735721968e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999340772628784
T I-Disease 1 0.9999988079071045
) O 0 3.521332700984203e-07
homozygotes O 0 1.5938892374833813e-06
from O 0 1.9852318189350626e-07
10 O 0 5.901211608261292e-08
ethnic O 0 1.5162155975190217e-08
populations O 0 9.214681995217688e-08
. O 0 3.211742978237453e-07

Both O 0 1.2618180335266516e-05
genomic O 0 3.1656280043534935e-05
mutations O 0 2.23603683480178e-06
and O 0 2.7552283654586063e-07
their O 0 1.2135514282363147e-07
effects O 0 1.6049432360887295e-06
on O 0 2.38364464166807e-06
cDNA O 0 2.3109755602490623e-06
were O 0 6.944649726392527e-07
characterized O 0 8.024106250559271e-07
. O 0 5.313671636031359e-07

Protein O 0 0.00021121669851709157
- O 0 3.951810867874883e-05
truncation O 0 6.175533781060949e-05
testing O 0 1.5231161114570568e-06
of O 0 2.8951908461749554e-06
the O 0 7.939203214846202e-07
entire O 0 1.7578669258000446e-06
ATM O 0 5.771424639533507e-06
cDNA O 0 1.007044488687825e-06
detected O 0 1.168581775345956e-06
92 O 0 2.770840410448727e-06
( O 0 6.136545493973244e-08
66 O 0 8.37560037325602e-07
% O 0 7.816969116447581e-08
) O 0 2.243883656660728e-08
truncating O 0 5.624555683425569e-07
mutations O 0 6.377821648584359e-08
in O 0 1.563607838761527e-07
140 O 0 5.235722824181721e-07
mutant O 0 4.1309030507363786e-07
alleles O 0 2.822369253863144e-07
screened O 0 1.0692536989154178e-06
. O 0 4.843499255002826e-07

The O 0 0.0002480590483173728
haplotyping O 0 0.0010422072373330593
of O 0 7.070518040563911e-05
patients O 0 3.837363237835234e-06
with O 0 3.551222675923782e-07
identical O 0 5.473226337926462e-06
mutations O 0 3.934072992706206e-06
indicates O 0 1.023504046315793e-05
that O 0 1.018178181766416e-07
almost O 0 1.436344945204837e-07
all O 0 1.5256670593544186e-08
of O 0 1.1402023147866203e-07
these O 0 1.013523842630093e-08
represent O 0 6.212849967823786e-08
common O 0 6.963544763038954e-08
ancestry O 0 1.2796857618013746e-07
and O 0 4.951002097186574e-08
that O 0 2.091290163264148e-08
very O 0 2.4233216322500084e-08
few O 0 4.0595075745386566e-08
spontaneously O 0 2.9052316108391096e-07
recurring O 0 3.819185621978249e-06
ATM O 0 1.2349133612588048e-05
mutations O 0 1.5651490059553907e-07
exist O 0 5.048556204201304e-07
. O 0 7.454679575857881e-07

Assays O 0 7.687703327974305e-05
requiring O 0 6.12222947893315e-06
minimal O 0 8.903874913812615e-06
amounts O 0 1.1182089565409115e-06
of O 0 2.244202050860622e-06
genomic O 0 2.0783327272511087e-06
DNA O 0 3.178683982696384e-07
were O 0 4.4345975425130746e-07
designed O 0 2.1610240708014317e-07
to O 0 1.715818065406438e-08
allow O 0 2.2178433312092238e-08
rapid O 0 8.873003025655635e-07
screening O 0 1.5127989172469825e-07
for O 0 5.467126129587996e-08
common O 0 7.620932507279576e-08
ethnic O 0 8.461143607974009e-08
mutations O 0 5.936767593084369e-07
. O 0 7.123882141968352e-07

These O 0 4.9105383368441835e-06
rapid O 0 5.977855107630603e-05
assays O 0 7.12498149368912e-06
detected O 0 4.79776099382434e-06
mutations O 0 2.7217447495786473e-07
in O 0 5.501194095813844e-07
76 O 0 2.643987500050571e-06
% O 0 1.6017735049445037e-07
of O 0 1.783473067007435e-06
Costa O 0 4.721131517726462e-06
Rican O 0 1.526341657154262e-05
patients O 0 3.134687176498119e-07
( O 0 7.769492782472298e-08
3 O 0 2.253450901434917e-07
) O 0 1.2364256285479769e-08
, O 0 1.2823192285793539e-08
50 O 0 5.4416585015815144e-08
% O 0 4.1821600405000936e-08
of O 0 7.189581197053485e-07
Norwegian O 0 1.1685711797326803e-05
patients O 0 3.369879664205655e-07
( O 0 5.307498085471707e-08
1 O 0 2.212549787827811e-07
) O 0 2.3700678752902604e-08
, O 0 1.0795799809670825e-08
25 O 0 8.759868563856799e-08
% O 0 2.936753062954267e-08
of O 0 3.527426315486082e-07
Polish O 0 7.647412530786823e-06
patients O 0 8.45573708829761e-07
( O 0 8.543118212855916e-08
4 O 0 4.0499455167264387e-07
) O 0 1.2018297468330275e-08
, O 0 7.4324439935935516e-09
and O 0 2.3297834772506576e-08
14 O 0 2.60050740052975e-07
% O 0 4.899597527696642e-08
of O 0 8.303615572913259e-07
Italian O 0 6.447843134083087e-06
patients O 0 8.327882596859126e-07
( O 0 1.1860377924222121e-07
1 O 0 8.583294288655452e-07
) O 0 4.118475871450755e-08
, O 0 3.002373460958552e-08
as O 0 3.4976991969415394e-08
well O 0 3.092365830070776e-08
as O 0 4.4573237545364464e-08
in O 0 9.320936555923254e-08
patients O 0 6.74186253490916e-08
of O 0 2.123633521478041e-06
Amish O 0 2.477941416145768e-05
/ O 0 8.4556677393266e-06
Mennonite O 0 4.36617210652912e-06
and O 0 2.6190917878921027e-07
Irish O 0 1.2024853504044586e-06
English O 0 1.3922623338658013e-06
backgrounds O 0 5.48720436199801e-07
. O 0 1.1028294011339312e-06

Additional O 0 1.7200838556163944e-05
mutations O 0 3.9501710489275865e-06
were O 0 4.353067197371274e-06
observed O 0 1.095613015422714e-06
in O 0 6.741900619999797e-07
Japanese O 0 4.203049684292637e-06
, O 0 3.7101037264619663e-07
Utah O 0 5.176594186195871e-06
Mormon O 0 1.83827830824157e-06
, O 0 5.5735309700821745e-08
and O 0 7.136693369602654e-08
African O 0 5.871676762581046e-07
American O 0 9.804205092223128e-07
patients O 0 6.817417670390569e-07
. O 0 1.2796824648830807e-06

These O 0 1.8900028635471244e-06
assays O 0 4.604361947713187e-06
should O 0 1.9981592913609347e-07
facilitate O 0 7.364493512795889e-07
screening O 0 1.7139002466137754e-06
for O 0 3.3483152037661057e-06
A B-Disease 1 0.9999768733978271
- I-Disease 1 0.9992020726203918
T I-Disease 1 0.9999352693557739
heterozygotes O 0 2.0608695194823667e-06
in O 0 1.0025841135075098e-07
the O 0 6.207981328998358e-08
populations O 0 1.961054962862363e-08
studied O 0 4.0580837890047405e-07
. O 0 1.196458896401964e-07
. O 0 8.667178690302535e-07

The O 0 0.0005366617115214467
von B-Disease 1 0.9601189494132996
Hippel I-Disease 1 0.9999902248382568
- I-Disease 1 0.9999947547912598
Lindau I-Disease 1 0.9999991655349731
tumor I-Disease 1 0.9999972581863403
suppressor O 1 0.9727714657783508
gene O 0 5.968483947071945e-07
is O 0 4.340305892469587e-08
required O 0 2.9761805464545432e-08
for O 0 5.968836802594524e-08
cell O 0 3.2821378681546776e-06
cycle O 0 1.854891593211505e-06
exit O 0 9.809499488255824e-07
upon O 0 4.742652208733489e-07
serum O 0 1.7226098862010986e-05
withdrawal O 0 2.3318929379456677e-05
. O 0 2.7754661005019443e-06

The O 0 5.0642203859752044e-05
inactivation O 0 0.0004483672964852303
of O 0 8.799551869742572e-05
the O 0 3.97047188016586e-05
von B-Disease 1 0.739668607711792
Hippel I-Disease 1 0.9999533891677856
- I-Disease 1 0.9999799728393555
Lindau I-Disease 1 0.9999951124191284
( I-Disease 0 5.910975596634671e-05
VHL I-Disease 1 0.959457516670227
) I-Disease 0 7.1056829256122e-06
tumor I-Disease 1 0.9999362230300903
suppressor O 1 0.9999774694442749
gene O 0 3.946985543734627e-06
predisposes O 0 6.381098046404077e-06
affected O 0 2.3588435738020053e-07
individuals O 0 9.785373400461594e-09
to O 0 1.998700049909985e-08
the O 0 2.677936208783649e-06
human O 1 0.999519944190979
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 5.515098564501386e-07
is O 0 3.9444760346896146e-08
associated O 0 2.6963556720716042e-08
with O 0 3.549502025634865e-08
sporadic B-Disease 1 0.9739040732383728
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 8.143961167661473e-05
RCC B-Disease 1 0.9999842643737793
) O 0 8.046006314543774e-07
and O 0 2.745863412201288e-06
brain B-Disease 1 0.9989564418792725
hemangioblastomas I-Disease 1 0.5522168874740601
. O 0 7.084740900609177e-06

VHL O 0 0.07991387695074081
- O 0 0.0005136447725817561
negative O 0 3.602537981350906e-05
786 O 0 0.0005647199577651918
- O 0 7.960443326737732e-05
0 O 0 2.4402605049544945e-05
RCC B-Disease 0 0.0019678673706948757
cells O 0 4.492660991672892e-06
are O 0 3.559526362550969e-07
tumorigenic O 0 2.4815833967295475e-05
in O 0 4.375275238999166e-06
nude O 0 7.043552614049986e-05
mice O 0 1.9034589513466926e-06
which O 0 1.3674730325874407e-07
is O 0 2.8890841718975935e-08
suppressed O 0 1.9964716102549573e-07
by O 0 2.4637380136027787e-08
the O 0 1.6134282532220823e-07
reintroduction O 0 2.71771136794996e-06
of O 0 4.784994416695554e-06
VHL B-Disease 0 0.00042394452611915767
. O 0 6.383739673765376e-06

Remarkably O 0 0.0009791188640519977
, O 0 2.7968926588073373e-06
this O 0 1.5359013616489392e-07
occurs O 0 1.6115214407363965e-07
without O 0 9.195018435548263e-08
affecting O 0 2.782826129532623e-07
the O 0 1.0571804978098953e-06
growth O 0 2.7258122372586513e-06
rate O 0 1.6246423228949425e-06
and O 0 1.6066309171947069e-07
cell O 0 4.045296918775421e-06
cycle O 0 1.262968112314411e-06
profile O 0 7.381869693290355e-08
of O 0 4.0485517160959716e-07
these O 0 4.769039918528506e-08
cells O 0 2.419828035726823e-07
in O 0 3.704701327933435e-07
culture O 0 1.0173663440582459e-06
. O 0 7.646877975275856e-07

The O 0 0.00021880294661968946
786 O 0 0.00035947159631177783
- O 0 2.837649117282126e-05
0 O 0 7.334596375585534e-06
cell O 0 7.2153989094658755e-06
line O 0 5.096523182146484e-06
, O 0 1.1152488355037349e-07
like O 0 9.279906976189523e-08
many O 0 5.5322249892242326e-08
cancer B-Disease 0 5.724305538024055e-06
cells O 0 7.037288014544174e-07
, O 0 8.102558268774374e-08
fails O 0 4.878410919673115e-08
to O 0 3.0999842692835955e-08
exit O 0 7.212780133158958e-07
the O 0 3.7804008456987503e-07
cell O 0 1.5562350199616048e-06
cycle O 0 6.113572226240649e-07
upon O 0 3.147460461150331e-07
serum O 0 6.662149644398596e-06
withdrawal O 0 8.620475455245469e-06
. O 0 2.287002871526056e-06

Here O 0 0.0001690355857135728
, O 0 3.3337414606648963e-06
it O 0 1.1766609020469332e-07
is O 0 5.0007901819526523e-08
shown O 0 5.660275448349239e-08
that O 0 2.8906770310754837e-08
reintroduction O 0 6.973286872380413e-07
of O 0 9.112355314755405e-07
the O 0 7.121212775018648e-07
wild O 0 3.155523984332831e-07
- O 0 2.588924189694808e-06
type O 0 3.337265980007942e-06
VHL B-Disease 0 7.862203347031027e-05
gene O 0 5.540059646591544e-07
restores O 0 2.3532199975306867e-06
the O 0 6.839950970061182e-07
ability O 0 1.6728718321701308e-07
of O 0 4.944989632349461e-05
VHL O 0 0.15064118802547455
- O 0 0.0008648644434288144
negative O 0 4.3564043153310195e-05
RCC B-Disease 1 0.9997454285621643
cancer I-Disease 0 7.952259693411179e-06
cells O 0 2.447014821882476e-07
to O 0 7.309991900683599e-08
exit O 0 7.050454655654903e-07
the O 0 3.1645407716496265e-07
cell O 0 1.7648244465817697e-06
cycle O 0 8.283565193778486e-07
and O 0 9.307842674388667e-08
enter O 0 9.653530241848784e-07
G0 O 0 5.24992065038532e-05
/ O 0 2.57293027061678e-06
quiescence O 0 4.510545750235906e-06
in O 0 5.940578944318986e-07
low O 0 1.6786882042651996e-05
serum O 0 2.429549022053834e-05
. O 0 1.977214196813293e-06

Both O 0 0.00017801971989683807
VHL O 0 0.07342889159917831
- O 0 0.00033084905589930713
positive O 0 1.1628460015344899e-05
and O 0 7.1487625064037275e-06
VHL O 0 0.006366281770169735
- O 0 8.848878496792167e-05
negative O 0 9.043295904120896e-06
RCC B-Disease 0 0.15839743614196777
cells O 0 1.6359672372345813e-06
exit O 0 4.107938821107382e-06
the O 0 1.097903577829129e-06
cell O 0 3.314511332064285e-06
cycle O 0 1.9477120076771826e-06
by O 0 7.09081930949651e-08
contact O 0 3.5853881286129763e-07
inhibition O 0 2.1777705114800483e-05
. O 0 2.1070750335638877e-06

The O 0 0.0001716004917398095
cyclin O 0 0.00031690215109847486
- O 0 5.6318054703297094e-05
dependent O 0 8.220495146815665e-06
kinase O 0 1.9796292690443806e-05
inhibitor O 0 1.3226102964836173e-05
, O 0 1.6389000734307047e-07
p27 O 0 7.4435297392483335e-06
, O 0 2.1657136528574483e-07
accumulates O 0 9.38925609261787e-07
upon O 0 1.04431705949537e-06
serum O 0 6.130700967332814e-06
withdrawal O 0 6.6041429818142205e-06
, O 0 2.494735440450313e-07
only O 0 3.223166089583174e-08
in O 0 1.9803985651378753e-07
the O 0 4.165502218711481e-07
presence O 0 6.354429729071853e-07
of O 0 2.86042268271558e-05
VHL B-Disease 0 0.00020915112691000104
, O 0 2.387263293712749e-07
as O 0 9.933125255656705e-08
a O 0 9.115825605476857e-08
result O 0 6.313890565934344e-08
of O 0 9.924524420057423e-07
the O 0 6.525382900690602e-07
stabilization O 0 4.24262861997704e-06
of O 0 4.092622475582175e-06
the O 0 6.282156846282305e-06
protein O 0 8.326839633809868e-06
. O 0 5.55850465389085e-06

We O 0 1.673434417170938e-05
propose O 0 5.462588433147175e-06
that O 0 6.934041607564723e-07
the O 0 1.9567939943954116e-06
loss O 0 6.066237347113201e-06
of O 0 6.576156010851264e-06
wild O 0 3.841848865704378e-06
- O 0 8.196753333322704e-05
type O 0 0.00010023380309576169
VHL B-Disease 0 0.16690976917743683
gene O 0 1.1310728496027878e-06
results O 0 5.797290327791416e-07
in O 0 3.3011440336849773e-07
a O 0 4.075047002061183e-07
specific O 0 2.822891644882475e-07
cellular O 0 0.0008253038395196199
defect O 0 7.003953942330554e-05
in O 0 6.885541552037466e-06
serum O 0 0.00016533448069822043
- O 0 7.863222708692774e-05
dependent O 0 7.5991683843312785e-06
growth O 0 6.331234999379376e-06
control O 0 1.3810694099447574e-06
, O 0 7.084952358127339e-08
which O 0 7.542453062114873e-08
may O 0 3.965318455811939e-07
initiate O 0 2.450032070555608e-06
tumor B-Disease 0 0.0006532506668008864
formation O 0 1.7769432815839536e-05
. O 0 4.042666660097893e-06

This O 0 1.2538267583295237e-05
is O 0 3.3608432659093523e-06
corrected O 0 4.297013674658956e-06
by O 0 2.1139433670214203e-07
the O 0 4.869449412581162e-07
reintroduction O 0 1.9477752175589558e-06
of O 0 2.4633302473375807e-06
wild O 0 1.61376817686687e-06
- O 0 2.4563007173128426e-05
type O 0 9.868580673355609e-05
VHL B-Disease 0 0.328993558883667
, O 0 7.62313584345975e-06
implicating O 0 0.0010985583066940308
VHL B-Disease 0 0.010193262249231339
as O 0 4.094441464985721e-06
the O 0 2.471750121912919e-06
first O 0 3.595774614950642e-06
tumor B-Disease 0 0.003907622769474983
suppressor O 0 0.00025910118711180985
involved O 0 3.4572605045468663e-07
in O 0 6.699420396216738e-07
the O 0 1.3102829825584195e-06
regulation O 0 5.58064641609235e-07
of O 0 8.0601521403878e-06
cell O 0 8.444772538496181e-05
cycle O 0 3.6952329537598416e-05
exit O 0 6.97991299603018e-06
, O 0 1.1881525097123813e-07
which O 0 4.712004297857675e-08
is O 0 3.3990342984679955e-08
consistent O 0 6.606950364584918e-08
with O 0 1.5799171748653862e-08
its O 0 1.8334112894535792e-07
gatekeeper O 0 1.3579082406067755e-05
function O 0 7.4473535960351e-07
in O 0 3.7673257224923873e-07
the O 0 6.010036941006547e-06
kidney O 0 0.09860356897115707
. O 0 5.12059216362104e-07
. O 0 8.797909458735376e-07

Piebaldism B-Disease 1 1.0
with O 0 0.0017175896791741252
deafness B-Disease 1 1.0
: O 0 6.164564183563925e-06
molecular O 0 6.955195658520097e-06
evidence O 0 4.6756744609410816e-07
for O 0 3.1614158046977536e-07
an O 0 2.5175461360049667e-06
expanded O 0 0.0010184976272284985
syndrome O 1 1.0
. O 0 1.5193070794339292e-05

In O 0 6.444552855100483e-05
a O 0 1.0286590622854419e-05
South O 0 7.901204298832454e-06
African O 0 1.8831964325727313e-06
girl O 0 1.3740423128183465e-06
of O 0 1.4774057035538135e-06
Xhosa O 0 6.113634299254045e-05
stock O 0 1.408898697263794e-05
with O 0 7.89276271007111e-08
severe O 1 0.9887288808822632
piebaldism B-Disease 1 0.9998750686645508
and O 0 0.00014546213787980378
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 5.428117219707929e-06
identified O 0 2.31416365181758e-07
a O 0 9.525810185095906e-08
novel O 0 1.398796740659236e-07
missense O 0 7.307844498427585e-07
substitution O 0 1.139618916567997e-06
at O 0 2.1919977370998822e-06
a O 0 2.3721737818505062e-07
highly O 0 2.737739634994796e-07
conserved O 0 9.010153689814615e-07
residue O 0 1.8643282828634256e-06
in O 0 4.614661293089739e-07
the O 0 8.612673809693661e-07
intracellular O 0 4.848217031394597e-06
kinase O 0 5.694640549336327e-06
domain O 0 2.8003437364532147e-06
of O 0 9.29201632970944e-06
the O 0 3.0761046218685806e-05
KIT O 0 4.3607888073893264e-05
proto O 0 0.0001850164117058739
- O 0 3.0350067390827462e-05
oncogene O 0 5.4285177611745894e-05
, O 0 5.209569167163863e-07
R796G O 0 1.3444530850392766e-05
. O 0 8.595384883847146e-07

Though O 0 0.00028533561271615326
auditory B-Disease 0 0.1995725780725479
anomalies I-Disease 0 0.05774563550949097
have O 0 3.553584292603773e-06
been O 0 1.175632860395126e-06
observed O 0 7.635145493622986e-07
in O 0 6.187767098708719e-07
mice O 0 1.0017541853812872e-06
with O 0 9.461744809868833e-08
dominant O 0 3.929236299882177e-06
white O 0 1.261125476048619e-06
spotting O 0 1.2035996405757032e-05
( O 0 1.1731924587365938e-06
W O 0 0.00013952986046206206
) O 0 2.257462341503924e-07
due O 0 5.675091415469069e-06
to O 0 7.995247415237827e-07
KIT O 0 8.928545139497146e-05
mutations O 0 1.0545280019869097e-05
, O 0 3.0278635676950216e-05
deafness B-Disease 1 1.0
is O 0 4.4349360450723907e-07
not O 0 2.186868108822182e-08
typical O 0 1.2277452299258584e-07
in O 0 2.542082029322046e-07
human O 0 1.3128058071742998e-06
piebaldism B-Disease 0 4.044248998980038e-05
. O 0 1.040722054312937e-06

Thus O 0 8.883976988727227e-06
, O 0 3.869541274070798e-07
the O 0 2.9546939117608417e-07
occurrence O 0 6.098372068663593e-06
of O 0 0.0024484151508659124
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 1 0.9857176542282104
this O 0 5.147622687218245e-06
patient O 0 4.135169547225814e-06
extends O 0 2.646757138791145e-06
considerably O 0 4.967508289155376e-07
the O 0 1.836974661273416e-07
phenotypic O 0 1.8879279650718672e-07
range O 0 6.201081532708486e-07
of O 0 2.1011114768043626e-06
piebaldism B-Disease 0 1.1551201168913394e-05
due O 0 8.997378245112486e-06
to O 0 4.603101615430205e-07
KIT O 0 4.608087238011649e-06
gene O 0 2.695605587632599e-07
mutation O 0 1.2730178866604547e-07
in O 0 4.2224201024509966e-07
humans O 0 6.416929210217859e-08
and O 0 1.557335167490237e-07
tightens O 0 4.126359556266834e-07
the O 0 9.745832585394965e-08
clinical O 0 7.459145763277775e-07
similarity O 0 6.509073955385247e-07
between O 0 2.370783477090299e-06
piebaldism B-Disease 0 3.2924504921538755e-05
and O 0 1.1468873850617456e-07
the O 0 7.98548072111771e-08
various O 0 2.5230107780771505e-08
forms O 0 8.249924690062471e-07
of O 0 0.1607743501663208
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.2249258816154907e-06
. O 0 1.4518302577926079e-06

Cycloheximide O 0 0.002631185809150338
facilitates O 0 4.120237645111047e-05
the O 0 2.1636935798596824e-06
identification O 0 4.218898084218381e-07
of O 0 8.523360520484857e-06
aberrant O 0 3.924815246136859e-05
transcripts O 0 2.6911748136626557e-05
resulting O 0 1.1478911801532377e-05
from O 0 3.2568386814091355e-06
a O 0 1.372097813145956e-06
novel O 0 1.4861941508570453e-06
splice O 0 8.655188139528036e-06
- O 0 2.198487891291734e-06
site O 0 2.6733098934528243e-07
mutation O 0 3.092602085530416e-08
in O 0 6.84928593841505e-08
COL17A1 O 0 9.395971574122086e-06
in O 0 9.678183232608717e-08
a O 0 1.9559118413781107e-07
patient O 0 1.3486435364029603e-06
with O 0 7.179056638051406e-07
generalized O 1 0.9995036125183105
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999994039535522
bullosa I-Disease 1 0.9940551519393921
. O 0 6.757440587534802e-06

Patients O 0 0.00018901268776971847
with O 0 1.0043858310382348e-05
generalized O 1 0.9998369216918945
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999997615814209
bullosa I-Disease 1 0.987984836101532
often O 0 3.1709330983176187e-07
show O 0 2.642888148329803e-07
decreased O 0 8.033654012251645e-06
expression O 0 4.563600555229641e-07
of O 0 2.643362222443102e-06
type O 0 1.4697042388434056e-05
XVII O 0 0.007228895556181669
collagen O 0 1.4987010217737406e-05
, O 0 4.312176429266401e-07
a O 0 3.053781085782248e-07
transmembrane O 0 2.3101645183487562e-06
hemidesmosomal O 0 7.042799552436918e-06
protein O 0 4.243727573793876e-07
encoded O 0 2.1411619854916353e-07
by O 0 4.6249220986283035e-07
COL17A1 O 0 7.53654821892269e-05
. O 0 1.9471103769319598e-06

This O 0 2.2441709006670862e-05
report O 0 6.8628987719421275e-06
documents O 0 2.3536083517683437e-06
a O 0 3.188799610143178e-06
novel O 0 7.1137037593871355e-06
splice O 0 3.8528491131728515e-05
- O 0 1.2308898476476315e-05
site O 0 1.215606857840612e-06
mutation O 0 9.389152211269902e-08
in O 0 3.366811824889737e-07
COL17A1 O 0 5.457178485812619e-05
in O 0 5.795554329779407e-07
a O 0 9.141314194494043e-07
patient O 0 7.681159331696108e-06
with O 0 4.755551344715059e-06
generalized O 1 0.9999949932098389
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9990360736846924
, O 0 1.1572872153919889e-06
and O 0 1.3505068352515082e-07
applies O 0 1.1443604108762884e-07
a O 0 9.159293057336981e-08
new O 0 6.332911084427906e-08
methodology O 0 2.4335588477697456e-07
to O 0 3.5298555189910985e-08
define O 0 1.9281057461739692e-07
and O 0 1.0391357108119337e-07
characterize O 0 5.672108613907767e-07
the O 0 5.708631078960025e-07
resulting O 0 7.102094059519004e-07
mRNA O 0 1.8339180769544328e-06
splice O 0 3.767160023926408e-06
variants O 0 4.3486798517733405e-07
. O 0 6.861811812086671e-07

Mutational O 0 0.008678012527525425
analysis O 0 5.4242220357991755e-05
of O 0 0.00011872579489136115
COL17A1 O 0 0.005140693858265877
identified O 0 1.561610770295374e-05
a O 0 1.2573975254781544e-05
maternally O 0 3.655563705251552e-05
inherited O 0 0.0001868277759058401
G O 0 8.17923282738775e-05
- O 0 9.382289135828614e-06
to O 0 1.6411224805779057e-06
- O 0 2.1969575755065307e-05
T O 0 3.62162827514112e-05
transversion O 0 2.0089686586288735e-05
at O 0 9.288090950576589e-06
the O 0 5.377481215873559e-07
- O 0 2.254665361078878e-07
1 O 0 3.383769069387199e-07
position O 0 3.6134846936874965e-07
of O 0 1.63031984357076e-06
exon O 0 6.33386889603571e-06
32 O 0 1.2779111784766428e-05
. O 0 1.8499573570807115e-06

This O 0 3.447979179327376e-05
acceptor O 0 1.1089306099165697e-05
splice O 0 7.28867162251845e-05
- O 0 2.1540316083701327e-05
site O 0 3.7087559121573577e-06
mutation O 0 2.795836735458579e-07
led O 0 1.2558866728795692e-06
to O 0 1.3274990351419547e-07
the O 0 1.1746477639462682e-06
formation O 0 4.535716016107472e-06
of O 0 3.15141114697326e-05
aberrant O 0 9.166498057311401e-05
transcripts O 0 3.1356339604826644e-05
present O 0 4.078412530361675e-06
at O 0 5.8922803873429075e-05
extremely O 0 1.175232682726346e-06
low O 0 1.4170860595186241e-05
levels O 0 4.20135847889469e-06
. O 0 6.171065933813225e-07

Based O 0 1.8797885786625557e-05
on O 0 1.1334980626998004e-05
our O 0 9.428054568161315e-07
recent O 0 5.282920483296039e-07
finding O 0 4.180564872058312e-07
that O 0 8.774288744461956e-07
cycloheximide O 0 0.00014622673916164786
stabilized O 0 0.00034686661092564464
mutant O 0 2.2882923076394945e-05
COL17A1 O 0 0.00010328454663977027
transcripts O 0 9.252347808796912e-06
in O 0 7.672064725738892e-07
keratinocytes O 0 2.658880703165778e-06
homozygous O 0 7.41418887173495e-07
for O 0 2.212294418768579e-07
a O 0 5.858208851350355e-07
frameshift O 0 5.804255124530755e-06
mutation O 0 4.413906253830646e-07
, O 0 2.6059566948788415e-07
the O 0 6.10969607350853e-07
effects O 0 8.389746653847396e-06
of O 0 2.832539212249685e-05
the O 0 1.4438960533880163e-05
splice O 0 9.406469871464651e-06
- O 0 3.2437856134492904e-06
site O 0 9.9999215308344e-07
mutation O 0 8.143445739960953e-08
on O 0 1.6172208461284754e-06
splicing O 0 6.156217864372593e-07
of O 0 6.419038072635885e-06
COL17A1 O 0 5.567130574490875e-05
transcripts O 0 3.85308430850273e-06
were O 0 3.713342664468655e-07
determined O 0 1.539158063224022e-07
using O 0 1.3661214381954778e-07
reverse O 0 1.9127467112411978e-06
transcriptase O 0 9.880527613859158e-06
polymerase O 0 7.303327038243879e-06
chain O 0 1.019545834424207e-06
reaction O 0 1.9022506592136779e-07
of O 0 7.754426860628882e-07
total O 0 1.43373813443759e-06
RNA O 0 1.5505847841268405e-06
from O 0 6.519945827676565e-07
keratinocytes O 0 1.0776461749628652e-06
incubated O 0 1.0999860933225136e-06
for O 0 1.4427162398078508e-07
2 O 0 1.3570517012340133e-06
. O 0 5.381297683015873e-07

5 O 0 0.00025676641962490976
h O 0 9.257962665287778e-05
in O 0 4.159280251769815e-06
the O 0 2.0987563402741216e-06
presence O 0 1.9156254893459845e-06
or O 0 1.3526830571208848e-06
absence O 0 5.569860149989836e-06
of O 0 9.712384780868888e-06
10 O 0 5.625925496133277e-06
microg O 0 3.7835743569303304e-05
cycloheximide O 0 4.881735731032677e-05
per O 0 1.812898881325964e-05
ml O 0 2.864151610992849e-05
. O 0 1.5483210518141277e-06

Using O 0 2.3458873329218477e-05
this O 0 1.9004316982318414e-06
approach O 0 4.850048298976617e-06
, O 0 4.794010806108417e-07
an O 0 8.522088705831266e-07
abnormally O 0 4.015802187495865e-05
spliced O 0 5.151585810381221e-06
transcript O 0 1.5570542018394917e-05
was O 0 1.10460623545805e-05
identified O 0 9.030802061715804e-08
that O 0 3.102574908098177e-08
contains O 0 8.166777121232371e-08
an O 0 1.0905825575946437e-07
extra O 0 1.3675551713276946e-07
264 O 0 3.875356469507096e-06
bases O 0 3.21761513077945e-06
upstream O 0 1.1337120668031275e-05
from O 0 1.224686457135249e-06
exon O 0 8.955839803093113e-07
32 O 0 7.251921942952322e-07
, O 0 3.833595485502883e-08
resulting O 0 1.2892674305930996e-07
in O 0 2.1821624329732003e-07
a O 0 1.026226982503431e-06
premature O 0 8.277561391878407e-06
termination O 0 8.48669878905639e-06
codon O 0 9.044917533174157e-06
27 O 0 1.403400437993696e-05
bp O 0 6.047228453098796e-06
downstream O 0 9.069526640814729e-06
from O 0 1.2608788892976008e-06
the O 0 1.4038619156053755e-06
cryptic O 0 6.303220743575366e-06
splice O 0 1.27929997688625e-05
site O 0 1.0630875294737052e-05
. O 0 2.1718763036915334e-06

Three O 0 3.661638402263634e-05
other O 0 1.0049587899629842e-06
splice O 0 6.9676898419857025e-06
variants O 0 7.126164973669802e-07
, O 0 2.130818046452987e-07
including O 0 1.2078879763066652e-07
one O 0 1.3693693290406372e-07
derived O 0 3.923743747691333e-07
from O 0 1.60500758283888e-06
the O 0 1.210733671541675e-06
skipping O 0 1.014300210044894e-06
of O 0 4.200092917017173e-06
exon O 0 1.9369385881873313e-06
32 O 0 1.4584273912987555e-06
, O 0 6.3132041816516e-08
were O 0 2.2591272852423572e-07
also O 0 1.7006975383537792e-07
identified O 0 8.16353633581457e-07
. O 0 1.4896309039613698e-06

These O 0 4.496561814448796e-06
results O 0 7.078710495989071e-06
indicate O 0 3.837334134004777e-06
the O 0 2.284287120346562e-06
usefulness O 0 5.624010555038694e-06
of O 0 8.652761607663706e-06
cycloheximide O 0 4.368818554212339e-05
treatment O 0 2.701988250919385e-06
in O 0 8.933005801736726e-07
evaluating O 0 1.1334310556776472e-06
the O 0 4.112779606657568e-06
abnormal O 0 5.439088272396475e-05
processing O 0 9.608088475943077e-06
of O 0 1.2753251212416217e-05
mRNA O 0 4.7485355025855824e-06
due O 0 1.3732702427660115e-05
to O 0 9.441064889870177e-07
splice O 0 2.4672331164765637e-06
- O 0 1.8393321852272493e-06
site O 0 8.878784569787967e-07
mutations O 0 8.101183368580678e-08
, O 0 1.5978021394857933e-07
because O 0 1.13896760467469e-07
( O 0 9.961090086108015e-08
i O 0 5.0956401764779e-07
) O 0 1.296569536179959e-07
aberrant O 0 1.4640936569776386e-06
splicing O 0 3.74013666259998e-07
often O 0 2.3303789120632246e-08
generates O 0 6.647272243753832e-08
a O 0 5.93849449614936e-07
premature O 0 2.9413999982352834e-06
termination O 0 4.057057594764046e-06
codon O 0 3.678350594782387e-06
, O 0 1.05125238292203e-07
( O 0 1.498099777563766e-08
ii O 0 1.178947286462062e-06
) O 0 2.487374928250574e-08
transcripts O 0 5.229530302131025e-07
with O 0 9.142502221948234e-08
premature O 0 1.1581800208659843e-05
termination O 0 7.89769364928361e-06
codons O 0 2.1268276668706676e-06
can O 0 2.394942910655118e-08
occur O 0 5.9447845757176765e-08
at O 0 4.069969691045117e-06
low O 0 9.651629625295755e-06
or O 0 9.411426162841963e-07
undetectable O 0 2.6458326829015277e-05
levels O 0 2.9939897103758994e-06
due O 0 3.7023030472482787e-06
to O 0 3.4072300536536204e-07
nonsense O 0 3.9393366932927165e-06
- O 0 1.089349211724766e-06
mediated O 0 2.9231453027023235e-06
mRNA O 0 1.1755398645618698e-06
decay O 0 2.582384695415385e-06
, O 0 3.821709881890456e-08
and O 0 7.84792391073097e-08
( O 0 5.811960335222466e-08
iii O 0 3.867250143230194e-06
) O 0 1.236269326909678e-07
the O 0 6.924815920683614e-07
levels O 0 2.1560722416325007e-06
of O 0 6.446642260016233e-07
these O 0 2.8878554658717803e-08
transcripts O 0 9.387115937897761e-07
can O 0 9.954059798644721e-09
be O 0 3.381381219469404e-08
increased O 0 4.2088512941518275e-07
by O 0 3.9680728036728397e-07
cycloheximide O 0 1.779106787580531e-05
. O 0 1.254937274097756e-06

A O 0 0.00014197354903444648
deletion O 0 3.6994399124523625e-05
mutation O 0 3.067949364776723e-06
in O 0 2.6048637664644048e-06
COL17A1 O 0 4.740761505672708e-05
in O 0 2.8442178745535784e-07
five O 0 1.5756295113078522e-07
Austrian O 0 1.2213170521135908e-05
families O 0 1.7084190062632842e-07
with O 0 9.419894126949657e-07
generalized O 1 0.9994034767150879
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9982921481132507
represents O 0 7.302164249267662e-06
propagation O 0 6.545279575220775e-06
of O 0 2.280673697896418e-06
an O 0 8.96004337391787e-07
ancestral O 0 1.986577444768045e-05
allele O 0 1.0956194273603614e-05
. O 0 1.8107504047293332e-06

Patients O 0 0.00028897100128233433
with O 0 1.695231367193628e-05
generalized O 1 0.9997203946113586
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.999902606010437
, O 0 9.380458436680783e-07
a O 0 2.1354624379910092e-07
usually O 0 3.827180705684441e-08
nonlethal O 0 1.929427753566415e-06
form O 0 3.0843199283481226e-07
of O 0 6.40532816760242e-05
junctional B-Disease 1 0.9999707937240601
epidermolysis I-Disease 1 0.9999576807022095
bullosa I-Disease 1 0.9149743914604187
, O 0 1.0079477306135232e-06
have O 0 2.4444210566798574e-07
generalized O 0 6.677046258118935e-06
blistering B-Disease 0 0.0002998609561473131
, O 0 5.9665881053661e-06
nail B-Disease 1 0.9999593496322632
dystrophy I-Disease 1 0.9999992847442627
, O 0 3.7706824969063746e-06
patchy B-Disease 1 0.9992434978485107
alopecia I-Disease 1 1.0
, O 0 5.495769528351957e-06
and O 0 1.365223761240486e-05
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.00039602120523341

Skin B-Disease 1 0.9998608827590942
fragility I-Disease 1 0.9987366795539856
in O 0 2.8776188628398813e-05
most O 0 4.815730676455132e-07
cases O 0 1.6800679247808148e-07
is O 0 6.84828052044395e-08
due O 0 6.774835696887749e-07
to O 0 1.6507849309732592e-08
mutations O 0 1.532164262130209e-08
in O 0 9.497509267930582e-08
the O 0 1.401237454956572e-07
gene O 0 4.081323723426067e-08
encoding O 0 1.9051137201131496e-07
type O 0 6.865071554784663e-06
XVII O 0 0.004243943840265274
collagen O 0 4.2728315747808665e-05
( O 0 2.008400542763411e-06
COL17A1 O 0 0.00012746290303766727
) O 0 4.1474862655377365e-07
. O 0 5.24579377270129e-07

Recently O 0 0.0003680006484501064
, O 0 1.1748448969228775e-06
we O 0 9.547747481519764e-08
reported O 0 2.1121962845427333e-07
five O 0 6.072321667716096e-08
Austrian O 0 6.361939995258581e-06
families O 0 1.8481433983197348e-07
with O 0 6.696475338685559e-07
generalized O 1 0.9998016953468323
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9913455247879028
who O 0 1.553782226437761e-06
share O 0 2.2505794561311632e-07
the O 0 4.0589932837065135e-07
same O 0 5.29851604369469e-07
COL17A1 O 0 0.0001473942247685045
mutation O 0 2.5281563011958497e-06
. O 0 3.2691084470570786e-06

Affected O 0 0.00018495852418709546
individuals O 0 1.1623762929957593e-06
in O 0 1.812291316127812e-06
three O 0 3.842233695650066e-07
families O 0 4.083776516949911e-08
are O 0 1.1674112343484921e-08
homozygous O 0 1.4519075364205491e-07
for O 0 3.2193818810810626e-07
4003delTC O 0 3.874012691085227e-06
, O 0 1.5932752717162657e-07
whereas O 0 1.214891227618864e-07
those O 0 2.610777016798238e-08
in O 0 1.7495452198090788e-07
two O 0 1.4938217418603017e-07
others O 0 1.3613379223897937e-07
are O 0 1.3171582224913436e-07
compound O 0 1.6663081623846665e-05
heterozygotes O 0 1.8919228750746697e-05
. O 0 3.618492428358877e-06

To O 0 1.4826443475612905e-05
determine O 0 3.6772419207409257e-06
if O 0 6.553290177180315e-07
the O 0 9.893245760395075e-07
occurrence O 0 1.6594021872151643e-06
of O 0 5.377997240429977e-06
4003delTC O 0 4.8225692808046006e-06
in O 0 2.9308168336683593e-07
these O 0 3.826392358519115e-08
unrelated O 0 2.622706176680367e-07
families O 0 3.1244404397057224e-08
signifies O 0 1.2893355005871854e-06
propagation O 0 1.299958512390731e-06
of O 0 1.6701934555385378e-06
an O 0 6.646530437137699e-07
ancestral O 0 5.822361799801001e-06
allele O 0 7.133950816751167e-07
or O 0 3.3503931717859814e-07
a O 0 1.1271790754108224e-06
mutational O 0 3.8632177165709436e-05
hot O 0 3.234867472201586e-05
spot O 0 4.391587026475463e-06
, O 0 1.3176884294807678e-07
haplotypes O 0 7.232306984406023e-07
were O 0 2.1331744903818617e-07
determined O 0 6.888222259249233e-08
for O 0 8.003014784208062e-08
polymorphisms O 0 2.1097905289479968e-07
both O 0 1.5784404183705192e-07
within O 0 2.6730754143500235e-07
and O 0 1.0806925274664536e-06
flanking O 0 0.0003992108104284853
COL17A1 O 0 0.0028999748174101114
. O 0 4.0702102523937356e-06

Five O 0 0.00012264335236977786
intragenic O 0 0.0003516485739964992
polymorphisms O 0 2.3942087864270434e-05
were O 0 4.2525366552581545e-06
chosen O 0 6.879247393953847e-07
based O 0 1.6773991262652999e-07
on O 0 1.2001756886093062e-06
their O 0 3.2475230682393885e-07
informativeness O 0 0.00012329532182775438
. O 0 4.501075181906344e-06

One O 0 0.00010261365241603926
of O 0 3.710141027113423e-05
these O 0 5.500564839167055e-07
, O 0 2.811210322306579e-07
not O 0 9.150020474635312e-08
previously O 0 1.325185849054833e-06
reported O 0 1.969291588466149e-06
, O 0 1.6004450742457266e-07
was O 0 1.0052434845420066e-05
2988 O 0 1.4628886674472596e-05
A O 0 1.3855092220182996e-05
or O 0 1.2747104847221635e-06
C O 0 1.4318879948405083e-05
that O 0 8.781851335015745e-08
introduces O 0 3.896782345691463e-07
a O 0 2.2698149848565663e-07
new O 0 1.123395776403413e-07
restriction O 0 4.683408292294189e-07
site O 0 2.8552082653732214e-07
for O 0 3.6147082482784754e-07
Eco0109 O 0 2.9048012947896495e-05
I O 0 3.195507451891899e-05
. O 0 3.528951083353604e-06

All O 0 1.0390290299255867e-05
the O 0 8.33975263958564e-06
4003delTC O 0 2.4202041458920576e-05
alleles O 0 2.326148205611389e-06
showed O 0 2.433225063214195e-06
the O 0 5.966514891042607e-07
same O 0 1.97812397573216e-07
haplotype O 0 2.3473498913517687e-06
for O 0 1.0765906210963294e-07
these O 0 7.100658905301316e-08
five O 0 5.634358899442304e-07
polymorphic O 0 3.229885351174744e-06
markers O 0 2.7003834475181065e-05
. O 0 2.273464133395464e-06

Fourteen O 0 0.00039131741505116224
microsatellite O 0 0.0004690632049459964
polymorphisms O 0 6.308230513241142e-05
were O 0 9.103755473915953e-06
selected O 0 6.971112611608987e-07
based O 0 2.683509308099019e-07
on O 0 1.5305072338378523e-06
their O 0 1.3881415839023248e-07
high O 0 4.6645785914734006e-05
heterozygosity O 0 2.2316387912724167e-05
and O 0 1.4898779454597388e-07
their O 0 8.774082260742944e-08
location O 0 1.8012054852079018e-06
within O 0 8.394655992560729e-07
10q23 O 0 3.9407997974194586e-05
- O 0 4.1854826122289523e-05
q25 O 0 6.687978020636365e-05
near O 0 0.0004501027287915349
COL17A1 O 0 0.0005188138457015157
. O 0 2.8145764190412592e-06

Three O 0 2.4214972654590383e-05
families O 0 1.0655056712494115e-06
shared O 0 8.507358870701864e-07
microsatellite O 0 3.139676118735224e-05
polymorphisms O 0 1.464387787564192e-05
covering O 0 9.16685676202178e-05
at O 0 0.00025183759862557054
most O 0 6.204281817190349e-07
19 O 0 4.340191935625626e-06
cM O 0 9.089068043977022e-06
, O 0 3.572295952380955e-07
whereas O 0 3.0965273367655755e-07
the O 0 1.0684291282814229e-06
others O 0 1.8494287701287249e-07
shared O 0 2.85525175058865e-07
smaller O 0 2.0479238571624592e-07
regions O 0 2.2928789178422448e-07
consistent O 0 1.0879984984057955e-06
with O 0 1.8198201701125072e-07
cross O 0 3.066615590796573e-06
- O 0 8.760317200540158e-07
over O 0 9.208269347027453e-08
events O 0 6.001314289960646e-08
during O 0 2.893110320201231e-07
passage O 0 1.802281133223005e-07
of O 0 5.3902766694591264e-08
this O 0 1.0422934515474935e-08
mutation O 0 1.8944835034062635e-08
through O 0 5.054356222444767e-08
several O 0 6.00125673599905e-08
generations O 0 2.9640921184181934e-07
. O 0 9.474997568759136e-07

These O 0 6.475790087279165e-06
results O 0 1.2279891961952671e-05
indicate O 0 5.160170530871255e-06
that O 0 2.874272126973665e-07
4003delTC O 0 6.899641903146403e-06
occurs O 0 1.6368694844004494e-07
on O 0 9.262758453587594e-07
a O 0 3.243264359298337e-07
single O 0 2.568208685715945e-07
ancestral O 0 4.274615548638394e-06
allele O 0 1.280036372008908e-06
. O 0 9.939493139654587e-08
. O 0 4.011050691588025e-07

The O 0 0.0001852988643804565
haptoglobin O 0 0.0016168515430763364
- O 0 8.998643897939473e-05
gene O 0 4.0383351915807e-06
deletion O 0 1.59082865138771e-05
responsible O 0 4.578073912853142e-06
for O 0 2.5646647827670677e-06
anhaptoglobinemia B-Disease 0 0.0005234968848526478
. O 0 6.733863756380742e-06

We O 0 2.6744481147034094e-05
have O 0 1.5801090285094688e-06
found O 0 4.5219670141705137e-07
an O 0 1.5226441973936744e-07
allelic O 0 1.3175418871469446e-06
deletion O 0 1.7510269572085235e-06
of O 0 2.457026857882738e-05
the O 0 2.3230017177411355e-05
haptoglobin O 0 0.00022045517107471824
( O 0 1.6523054000572301e-06
Hp O 0 1.5907527995295823e-05
) O 0 1.2838222573918756e-07
gene O 0 1.258537167814211e-07
from O 0 2.8213142400090874e-07
an O 0 5.817039649969047e-08
individual O 0 1.8339701313152545e-08
with O 0 4.973490490556287e-07
anhaptoglobinemia B-Disease 0 0.0009619659977033734
. O 0 1.027517737384187e-05

The O 0 0.000185877870535478
Hp O 0 0.00031268675229512155
gene O 0 3.0853016141918488e-06
cluster O 0 8.472409717796836e-06
consists O 0 6.751268983862246e-07
of O 0 4.400995294417953e-06
coding O 0 1.5328283780036145e-06
regions O 0 9.777947980182944e-07
of O 0 6.54685718473047e-05
the O 0 5.4038649977883324e-05
alpha O 0 2.5001085305120796e-05
chain O 0 1.1120686167487293e-06
and O 0 1.8316706018595141e-07
beta O 0 1.419260570401093e-06
chain O 0 4.2070095673807373e-07
of O 0 9.822174433793407e-07
the O 0 1.1860892072945717e-06
haptoglobin O 0 7.451164492522366e-06
gene O 0 4.6411111043198616e-07
( O 0 1.505414530811322e-07
Hp O 0 2.189206952607492e-06
) O 0 3.5474780446520526e-08
and O 0 7.980668925711143e-08
of O 0 2.2915442059456836e-06
the O 0 5.9057315411337186e-06
alpha O 0 1.5225428796838969e-05
chain O 0 8.835065159473743e-07
and O 0 1.2658328785164485e-07
beta O 0 2.3433751721313456e-06
chain O 0 5.107326614961494e-07
of O 0 9.13202484298381e-07
the O 0 1.3955643680674257e-06
haptoglobin O 0 1.213194445881527e-05
- O 0 1.4577265119442018e-06
related O 0 6.891769999128883e-07
gene O 0 3.063012457005243e-07
( O 0 2.198356696681003e-07
Hpr O 0 6.956761353649199e-06
) O 0 1.2166316309958347e-07
, O 0 7.795826206802303e-08
in O 0 4.432458240444248e-07
tandem O 0 1.84852397069335e-05
from O 0 1.8567659481050214e-06
the O 0 2.2172355329530546e-06
5 O 0 3.70519956049975e-06
side O 0 3.789268930631806e-06
. O 0 2.0706845589302247e-06

Southern O 0 0.0003718675870914012
blot O 0 0.0005964839365333319
and O 0 9.070590749615803e-06
PCR O 0 1.6149990187841468e-05
analyses O 0 1.2238961062394083e-06
have O 0 7.741076615275233e-07
indicated O 0 1.829821485443972e-06
that O 0 2.0961189761692367e-07
the O 0 5.986880751152057e-07
individual O 0 2.1083598866766806e-08
with O 0 1.60457446440887e-07
anhaptoglobinemia B-Disease 0 1.9794670151895843e-05
was O 0 1.2485978913900908e-05
homozygous O 0 1.8322226935651997e-07
for O 0 1.632183739275206e-07
the O 0 2.935989584784693e-07
gene O 0 1.2548075289942062e-07
deletion O 0 6.607907607758534e-07
and O 0 1.1829290258447145e-07
that O 0 9.667556355452689e-08
the O 0 6.2060456684776e-07
gene O 0 3.0669323791698844e-07
deletion O 0 2.189804035879206e-06
was O 0 4.146916398894973e-05
included O 0 1.9394487935642246e-06
at O 0 1.1172559425176587e-05
least O 0 1.6957594084487937e-07
from O 0 7.882356953814451e-07
the O 0 2.4510559342161287e-06
promoter O 0 1.568423795106355e-05
region O 0 1.7153180351670017e-06
of O 0 3.277201176388189e-05
Hp O 0 3.5456567275105044e-05
to O 0 9.475069759901089e-07
Hpr O 0 4.9851358198793605e-05
alpha O 0 1.2937798601342365e-05
but O 0 5.230158350855163e-08
not O 0 1.815454808706818e-08
to O 0 7.902056609054853e-08
Hpr O 0 6.9251932472980116e-06
beta O 0 3.819614903477486e-06
( O 0 3.411687714560685e-07
Hpdel O 0 1.030823386827251e-05
) O 0 3.2145283057616325e-07
. O 0 3.278535700701468e-07

In O 0 0.00013799975567962974
addition O 0 6.369280072249239e-06
, O 0 1.803068471417646e-06
we O 0 3.478997143702145e-07
found O 0 2.288424667540312e-07
seven O 0 2.011692714631863e-07
individuals O 0 2.6001421460364327e-08
with O 0 1.767735682278726e-07
hypohaptoglobinemia B-Disease 0 4.0396000258624554e-05
in O 0 9.305397725256626e-06
three O 0 1.8611021914693993e-06
families O 0 1.708028065650069e-07
, O 0 1.271789926704514e-07
and O 0 2.074060745371753e-07
the O 0 1.7088522099584225e-06
genotypes O 0 2.8996785204071784e-06
of O 0 2.375364420004189e-05
six O 0 5.530538601306034e-06
of O 0 2.5142655431409366e-05
the O 0 6.659570772171719e-06
seven O 0 7.444435254910786e-07
individuals O 0 2.431275447634107e-08
were O 0 4.1120247828985157e-07
found O 0 1.310514932129081e-07
to O 0 5.4059679399642846e-08
be O 0 7.284395451279124e-07
Hp2 O 0 0.00013315083924680948
/ O 0 7.394045678665861e-05
Hpdel O 0 0.0003216388577129692
. O 0 6.441255209210794e-06

The O 0 0.0001670337951509282
phenotypes O 0 6.731603207299486e-05
and O 0 3.402833954169182e-06
genotypes O 0 7.482539331249427e-06
in O 0 1.5593072930641938e-06
one O 0 1.8366031895311608e-07
of O 0 1.145667852142651e-06
these O 0 6.499173821339355e-08
three O 0 4.936928235110827e-07
families O 0 1.0299817887471363e-07
showed O 0 2.3886850613052957e-06
the O 0 3.881340944644762e-06
father O 0 5.30041415913729e-06
to O 0 3.2430227747681784e-07
be O 0 7.644661650374474e-07
hypohaptoglobinemic B-Disease 0 4.420707227836829e-06
( O 0 1.443649466636998e-07
Hp2 O 0 3.4723288990790024e-06
) O 0 1.079016485050488e-07
and O 0 3.8920506995054893e-07
Hp2 O 0 8.736259769648314e-05
/ O 0 3.143768844893202e-05
Hpdel O 0 0.00012190356210339814
, O 0 1.7000957086565904e-06
the O 0 2.8072768145648297e-06
mother O 0 4.501320290728472e-06
to O 0 3.374475170403457e-07
be O 0 8.117708603094798e-07
Hp2 O 0 1.1165614523633849e-05
- O 0 1.8590160379972076e-06
1 O 0 2.06630124921503e-06
and O 0 4.29109007882289e-07
Hp1 O 0 3.868721250910312e-05
/ O 0 9.112937732425053e-06
Hp2 O 0 2.7545565899345092e-05
, O 0 3.72925939018387e-07
one O 0 2.2795812526510417e-07
of O 0 1.2130243476349278e-06
the O 0 1.7807537915359717e-06
two O 0 1.9912823745471542e-07
children O 0 1.9789600003150554e-07
to O 0 1.2403576477026945e-07
be O 0 6.150091280687775e-07
hypohaptoglobinemic B-Disease 0 1.1852834177261684e-05
( O 0 3.196781506176194e-07
Hp2 O 0 9.669871360529214e-06
) O 0 1.9885212054759904e-07
and O 0 8.251963663497008e-07
Hp2 O 0 8.676242578076199e-05
/ O 0 5.981104550301097e-05
Hpdel O 0 0.00017950845358427614
, O 0 1.0692333489714656e-06
and O 0 3.7848667489015497e-07
the O 0 1.3040934163655038e-06
other O 0 1.0796669869250763e-07
child O 0 1.1959596122324e-06
to O 0 1.9596349432049465e-07
be O 0 1.1482854915811913e-06
Hp1 O 0 2.3258902729139663e-05
and O 0 1.270724510504806e-06
Hp1 O 0 0.0003320644027553499
/ O 0 3.450551594141871e-05
Hpdel O 0 3.10644754790701e-05
, O 0 2.622948898078903e-07
showing O 0 6.108193701948039e-07
an O 0 1.9482621382849175e-07
anomalous O 0 3.572895366232842e-05
inheritance O 0 1.5144896678975783e-05
of O 0 0.0008071628981269896
Hp O 0 0.0004916831385344267
phenotypes O 0 4.032523975183722e-06
in O 0 1.285303710574226e-06
the O 0 6.335368993859447e-07
child O 0 8.969892633103882e-07
with O 0 4.112675640044472e-07
Hp1 O 0 0.00031955193844623864
. O 0 5.819874786539003e-06

The O 0 0.00031065402436070144
Hp2 O 0 0.004365985281765461
/ O 0 0.0006689438596367836
Hpdel O 0 0.0008066846057772636
individuals O 0 2.099170615110779e-06
had O 0 1.2338867236394435e-05
an O 0 2.625784645715612e-06
extremely O 0 3.3503592931083404e-06
low O 0 2.3809070626157336e-05
level O 0 2.1403839127742685e-05
of O 0 4.984351107850671e-05
Hp O 0 2.326327194168698e-05
( O 0 1.2363859980268899e-07
mean O 0 4.847394734497357e-07
+ O 0 1.0557332785765539e-07
/ O 0 7.591510353677222e-08
- O 0 9.011427692939833e-08
SD O 0 7.428535013787041e-07
= O 0 1.5189574753549095e-07
0 O 0 2.9248962363226383e-08
. O 0 6.634704341479392e-09
049 O 0 3.3014714517776156e-07
+ O 0 9.346554463718348e-08
/ O 0 1.0296400176912357e-07
- O 0 6.747033864940022e-08
0 O 0 4.643182904828791e-08
. O 0 6.349623493662193e-09
043 O 0 4.591154549871135e-07
mg O 0 4.902200885226193e-07
/ O 0 1.7369950455758953e-07
ml O 0 2.799198455250007e-07
; O 0 1.0358167656931982e-08
n O 0 2.1273926620324346e-07
= O 0 1.5129344888009655e-07
6 O 0 2.6925920337816933e-07
) O 0 1.923884163090861e-08
, O 0 1.335279176117865e-08
compared O 0 6.684958719915812e-08
with O 0 1.2377140201635939e-08
the O 0 5.3473706884688e-07
level O 0 3.598443299779319e-06
( O 0 3.122069713867859e-08
1 O 0 7.488112174769412e-08
. O 0 8.53173087733694e-09
64 O 0 8.070185231190408e-08
+ O 0 4.527481678451295e-08
/ O 0 6.056509249674491e-08
- O 0 7.110809718824385e-08
1 O 0 9.001979606182431e-08
. O 0 1.409615180136825e-08
07 O 0 9.998910854847054e-07
mg O 0 1.5137586615310283e-06
/ O 0 2.6818773335435253e-07
ml O 0 1.9925001026876998e-07
) O 0 9.725625638168367e-09
obtained O 0 1.3977698642975156e-07
from O 0 3.578047653718386e-07
52 O 0 3.2284933695336804e-06
healthy O 0 5.49342416888976e-07
volunteers O 0 2.0120957344715862e-07
having O 0 8.617726621196198e-07
phenotype O 0 4.316259492043173e-06
Hp2 O 0 1.6691630662535317e-05
, O 0 2.4050808633546694e-07
whereas O 0 1.9375322324322042e-07
the O 0 2.6914031536762195e-07
serum O 0 5.63367802897119e-06
Hp O 0 9.33336832531495e-06
level O 0 3.088958237640327e-06
of O 0 1.3812327779305633e-06
an O 0 3.1937739208842686e-07
individual O 0 5.803286740047042e-08
with O 0 3.5969574696537165e-07
Hp1 O 0 0.00025111279683187604
/ O 0 3.4094711736543104e-05
Hpdel O 0 7.07833023625426e-05
was O 0 3.4967088140547276e-05
0 O 0 2.4520049919374287e-06
. O 0 7.236004648802918e-07

50 O 0 0.00011839940998470411
mg O 0 0.00012795570364687592
/ O 0 1.5187449207587633e-05
ml O 0 7.825299690011889e-06
, O 0 1.6967867111361556e-07
which O 0 7.387630773791898e-08
was O 0 6.612289098484325e-07
approximately O 0 9.66943645153151e-08
half O 0 1.2032523954985663e-07
the O 0 2.6465605174053053e-07
level O 0 4.002810328529449e-06
of O 0 6.208032573340461e-06
Hp O 0 1.4173833733366337e-05
in O 0 2.0993647922296077e-06
control O 0 5.560656973102596e-06
sera O 0 5.900556789129041e-05
from O 0 8.780206712799554e-07
the O 0 1.2717962363240076e-06
Hp1 O 0 5.9187050283071585e-06
phenotype O 0 3.9899910575513786e-07
( O 0 2.75380358516486e-08
1 O 0 1.0464231792184364e-07
. O 0 8.488830083308585e-09
26 O 0 1.889707732516399e-07
+ O 0 5.6513972168659166e-08
/ O 0 1.173667527609723e-07
- O 0 7.25168050053071e-08
0 O 0 2.807973054075319e-08
. O 0 2.8054660816678734e-09
33 O 0 8.586621191852828e-08
mg O 0 3.2396658866673533e-07
/ O 0 1.389626334002969e-07
ml O 0 9.958925062392154e-08
; O 0 9.256885924457947e-09
n O 0 1.606307620249936e-07
= O 0 2.145744986137288e-07
9 O 0 5.165672405382793e-07
) O 0 1.50664760667496e-08
, O 0 1.2655752890111671e-08
showing O 0 1.6927072010730626e-07
a O 0 1.8771650900362147e-07
gene O 0 3.428661727866711e-07
- O 0 1.9935580439778278e-06
dosage O 0 6.143875452835346e-06
effect O 0 6.0513530115713365e-06
. O 0 1.79848314019182e-06

The O 0 0.00010113071766681969
other O 0 1.0715934877225664e-06
allele O 0 2.7405812943470664e-06
( O 0 1.0280048172717215e-06
Hp2 O 0 2.3780979972798377e-05
) O 0 1.7257802653602994e-07
of O 0 1.021165076053876e-06
individuals O 0 8.304520093815881e-08
with O 0 5.868245693818608e-07
Hp2 O 0 0.0054744272492825985
/ O 0 0.0003365627198945731
Hpdel O 0 0.0017874600598588586
was O 0 0.0002838284126482904
found O 0 4.5463204401130497e-07
to O 0 8.647003824080457e-08
have O 0 9.85246089157954e-08
, O 0 2.98991551517247e-08
in O 0 5.5525642750353654e-08
all O 0 2.9254488609353757e-08
exons O 0 4.4147355993118254e-07
, O 0 1.4734061082322114e-08
no O 0 9.830025682333599e-09
mutation O 0 8.820960850641768e-09
, O 0 4.099390604750397e-09
by O 0 4.1601122546808256e-09
DNA O 0 7.295673043472561e-08
sequencing O 0 3.352075509610586e-06
. O 0 2.979079454235034e-06

On O 0 9.025578037835658e-05
the O 0 3.5044354262936395e-06
basis O 0 2.1961429865768878e-06
of O 0 2.7587248041527346e-06
the O 0 1.0506595344850211e-06
present O 0 2.65644757746486e-07
study O 0 2.3828597761621495e-07
, O 0 3.99172570553219e-08
the O 0 4.291302957426524e-07
mechanism O 0 2.340295395697467e-06
of O 0 8.80165407579625e-06
anhaptoglobinemia B-Disease 0 5.6635919463587925e-05
and O 0 1.5385297729153535e-06
the O 0 3.6543995065585477e-06
mechanism O 0 4.293912752473261e-06
of O 0 6.747432962583844e-06
anomalous O 0 0.00025531515711918473
inheritance O 0 2.0692608813988045e-05
of O 0 0.00012463291932363063
Hp O 0 0.00015427201287820935
phenotypes O 0 3.8283455978671554e-06
were O 0 2.753265789579018e-06
well O 0 4.472802288546518e-07
explained O 0 1.7617034018257982e-06
. O 0 1.3849313518221607e-06

However O 0 1.3362443496589549e-05
, O 0 8.200013894565927e-07
the O 0 6.065677666811098e-07
mechanism O 0 3.8527900869667064e-06
of O 0 8.835832886688877e-06
hypohaptoglobinemia B-Disease 0 0.0008383666863664985
remains O 0 0.00015399701078422368
unknown O 0 0.00011351157445460558

ATM O 0 0.0033621243201196194
mutations O 0 2.8310541893006302e-05
and O 0 3.3673397865641164e-06
phenotypes O 0 9.902762394631281e-05
in O 0 0.0001378963643219322
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.6839636373333633e-05
in O 0 1.4997061043686699e-05
the O 0 1.2222688383189961e-05
British O 0 3.8552971091121435e-06
Isles O 0 3.608051429182524e-06
: O 0 2.789790087831534e-08
expression O 0 3.262030290329676e-08
of O 0 1.9189153022125538e-07
mutant O 0 6.338385105664202e-07
ATM O 0 5.6590079111629166e-06
and O 0 6.286840914526692e-08
the O 0 1.8587877548270626e-07
risk O 0 3.208256202924531e-07
of O 0 6.618075985898031e-06
leukemia B-Disease 1 1.0
, O 0 0.0023143221624195576
lymphoma B-Disease 1 1.0
, O 0 1.218381839862559e-05
and O 0 1.92574443644844e-05
breast B-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999817609786987
. O 0 1.545323357277084e-05

We O 0 2.1369329260778613e-05
report O 0 4.380001428216929e-06
the O 0 9.100067472900264e-07
spectrum O 0 1.0811976380864508e-06
of O 0 2.240384901597281e-06
59 O 0 1.2836016139772255e-05
ATM O 0 2.861841676349286e-05
mutations O 0 6.466814284067368e-07
observed O 0 4.60882120023598e-06
in O 0 2.4927499907789752e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.999998927116394
telangiectasia I-Disease 1 1.0
( O 0 0.0002117235999321565
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 5.765026003246021e-07
patients O 0 1.0641028325153457e-07
in O 0 6.846006499472423e-07
the O 0 5.420430625235895e-06
British O 0 1.9290382624603808e-05
Isles O 0 4.195332803647034e-05
. O 0 3.139380169159267e-06

Of O 0 0.0003069319936912507
51 O 0 0.00011881583486683667
ATM O 0 0.00016554917965549976
mutations O 0 2.192035481130006e-06
identified O 0 1.7544202819408383e-06
in O 0 1.1572860785236116e-06
families O 0 8.804173035059648e-08
native O 0 1.0912796000184244e-07
to O 0 9.311145987567215e-08
the O 0 1.5760186897750827e-06
British O 0 4.633125172404107e-06
Isles O 0 8.19044635136379e-06
, O 0 3.670329533633776e-07
11 O 0 2.134585884050466e-06
were O 0 1.8851496861316264e-06
founder O 0 6.246325483516557e-06
mutations O 0 6.380693662322301e-08
, O 0 5.0410886132112864e-08
and O 0 3.589643782220264e-08
2 O 0 2.0073156292710337e-07
of O 0 1.5712643630649836e-07
these O 0 1.303564189925055e-08
11 O 0 8.313186867781042e-07
conferred O 0 4.844408977078274e-06
a O 0 6.285150107032678e-07
milder O 0 1.0001218697652803e-06
clinical O 0 8.400149908993626e-07
phenotype O 0 1.3979298785216088e-07
with O 0 7.21854398477717e-09
respect O 0 8.648257221466338e-08
to O 0 2.1640225611463393e-07
both O 0 3.372896799191949e-06
cerebellar B-Disease 1 0.9998632669448853
degeneration I-Disease 1 0.9999973773956299
and O 0 3.3317198813165305e-06
cellular O 0 3.5794095310848206e-05
features O 0 1.215168708768033e-06
. O 0 1.4431252566282637e-06

We O 0 9.434819367015734e-05
report O 0 1.7626343833399005e-05
, O 0 6.501095981548133e-07
in O 0 1.2243957598911948e-06
two O 0 9.021709956869017e-07
A B-Disease 1 0.9999290704727173
- I-Disease 1 0.9984214305877686
T I-Disease 1 0.9999992847442627
families O 0 5.325116489984794e-07
, O 0 2.6146821596739755e-07
an O 0 6.0062041029596e-07
ATM O 0 1.5499193978030235e-05
mutation O 0 3.65771512633728e-07
( O 0 2.537450995987456e-07
7271T O 0 3.6926060147379758e-06
- O 0 1.5078038586580078e-06
- O 0 3.983823262387887e-06
> O 0 2.4997011678351555e-06
G O 0 9.230906471202616e-06
) O 0 7.076524610738488e-08
that O 0 5.1174087190020145e-08
may O 0 2.3840033236410818e-07
be O 0 3.5667802933403436e-08
associated O 0 2.046761338192482e-08
with O 0 6.5209881938699255e-09
an O 0 7.284076986024957e-08
increased O 0 2.0766131001437316e-06
risk O 0 1.8665376728677074e-06
of O 0 0.00018577935406938195
breast B-Disease 1 0.9977946281433105
cancer I-Disease 0 0.0008152265218086541
in O 0 2.515714868422947e-06
both O 0 3.723750694462069e-07
homozygotes O 0 2.0813320134038804e-06
and O 0 2.253487565440082e-07
heterozygotes O 0 9.048869742400711e-07
( O 0 5.4169088770095186e-08
relative O 0 6.609282081626588e-07
risk O 0 1.2927222314829123e-07
12 O 0 1.7795454709812475e-07
. O 0 1.2013348538175705e-08
7 O 0 1.6432166205504473e-07
; O 0 2.698012302460029e-08
P O 0 8.159122444340028e-06
= O 0 5.283086466079112e-07
. O 0 1.1159296775531402e-07
0025 O 0 6.737260719091864e-06
) O 0 2.4135287546300788e-08
, O 0 1.1284225998053898e-08
although O 0 6.729064860877543e-09
there O 0 2.704978641077105e-08
is O 0 4.819231236297128e-08
a O 0 1.3963816059003875e-07
less O 0 5.361761168387602e-07
severe O 1 0.9988598823547363
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 3.708193503371149e-07
in O 0 2.2359415652317693e-08
terms O 0 1.4786115443143899e-08
of O 0 3.8160575144274844e-08
the O 0 7.260759815608253e-08
degree O 0 6.318302894214867e-06
of O 0 6.053901233826764e-05
cerebellar B-Disease 1 0.9999058246612549
degeneration I-Disease 1 0.9999986886978149
. O 0 1.888728547783103e-05

This O 0 1.9687060557771474e-05
mutation O 0 2.72763008979382e-06
( O 0 1.039589164975041e-06
7271T O 0 5.903878445678856e-06
- O 0 2.3486372811021283e-06
- O 0 3.5830405522574438e-06
> O 0 2.0543723167065764e-06
G O 0 5.0149692469858564e-06
) O 0 7.362773857266802e-08
also O 0 4.953627907866576e-08
allows O 0 1.7395803908470953e-08
expression O 0 1.9511702475938364e-07
of O 0 1.013653331938258e-06
full O 0 1.1762407439164235e-06
- O 0 5.685377004738257e-07
length O 0 3.1749635809319443e-07
ATM O 0 6.5074427766376175e-06
protein O 0 6.439539106395387e-07
at O 0 1.9187136786058545e-06
a O 0 1.4754147059647948e-07
level O 0 3.4489028166717617e-07
comparable O 0 1.8586565886380413e-07
with O 0 1.7799198559487195e-08
that O 0 2.556649292273505e-08
in O 0 4.744529462641367e-07
unaffected O 0 4.968900157109601e-06
individuals O 0 1.7932680407284352e-07
. O 0 8.534613584743056e-07

In O 0 4.7206314775394276e-05
addition O 0 3.4134232009819243e-06
, O 0 3.896641089795594e-07
we O 0 5.721286910898016e-08
have O 0 4.004735743023957e-08
studied O 0 1.0993159094141447e-06
18 O 0 2.165283149224706e-05
A B-Disease 1 0.9999926090240479
- I-Disease 1 0.9999973773956299
T I-Disease 1 1.0
patients O 0 3.884636953443987e-06
, O 0 1.754887648530712e-07
in O 0 2.9062596240692073e-07
15 O 0 1.3938484926256933e-06
families O 0 6.008793462797257e-08
, O 0 1.0345929979393986e-07
who O 0 1.9785144900197338e-07
developed O 0 3.866740826197201e-06
leukemia B-Disease 1 0.9999994039535522
, O 0 0.00016773349489085376
lymphoma B-Disease 1 1.0
, O 0 2.9395907404250465e-05
preleukemic O 0 0.250361829996109
T O 0 0.026309749111533165
- O 0 5.796842378913425e-05
cell O 0 5.775587123935111e-05
proliferation O 0 0.0007226916495710611
, O 0 1.3405816616796074e-06
or O 0 0.00010922513320110738
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.974764245460392e-06
mostly O 0 7.434262272454362e-08
in O 0 3.6787395174542326e-07
childhood O 0 1.7631893570069224e-05
. O 0 1.2996783880225848e-06

A O 0 0.00012341623369138688
wide O 0 9.665952347859275e-06
variety O 0 1.0092645652548526e-06
of O 0 1.258442262042081e-05
ATM O 0 9.095179120777175e-05
mutation O 0 2.860097083612345e-07
types O 0 1.8523446954077372e-07
, O 0 8.845935184353948e-08
including O 0 1.1632852192633436e-07
missense O 0 2.188004600611748e-06
mutations O 0 3.891352946538973e-07
and O 0 1.3048062328380183e-06
in O 0 6.728779226250481e-06
- O 0 2.1683206796296872e-05
frame O 0 3.528026718413457e-05
deletions O 0 2.126669414792559e-06
, O 0 2.3996554432414996e-07
were O 0 3.6487611509983253e-07
seen O 0 1.644610279072367e-07
in O 0 7.625730802374164e-08
these O 0 2.3643247359927955e-08
patients O 0 3.0888500646142347e-07
. O 0 1.32617697090609e-06

We O 0 3.170274794683792e-05
also O 0 1.795579919416923e-06
show O 0 4.0157661373996234e-07
that O 0 6.74253115562351e-08
25 O 0 6.641720915467886e-07
% O 0 1.4543007864631363e-07
of O 0 1.1053944035666063e-06
all O 0 1.3210205906943884e-06
A B-Disease 1 0.9999973773956299
- I-Disease 1 0.9999130964279175
T I-Disease 1 0.9999983310699463
patients O 0 6.646853876191017e-07
carried O 0 9.384941108692146e-07
in O 0 1.1911596402569558e-06
- O 0 4.413798251334811e-06
frame O 0 5.855170456925407e-06
deletions O 0 1.2380182852211874e-06
or O 0 8.110039857456286e-07
missense O 0 4.375642674858682e-06
mutations O 0 4.097884129805607e-07
, O 0 1.6170282890470844e-07
many O 0 1.1568801916439497e-08
of O 0 3.672815296340559e-07
which O 0 1.1484470974210126e-07
were O 0 3.060521862607857e-07
also O 0 2.742151927748182e-08
associated O 0 9.00826258032339e-09
with O 0 5.796680024872103e-09
expression O 0 9.79394698674696e-08
of O 0 1.4296924746304285e-06
mutant O 0 5.637020876747556e-06
ATM O 0 4.9966867663897574e-05
protein O 0 5.3661674428440165e-06
. O 0 2.097565811709501e-06

The O 0 9.642277291277424e-05
DMPK O 0 0.002704954007640481
gene O 0 1.4415034456760623e-05
of O 0 0.00017298523744102567
severely O 1 0.9999996423721313
affected O 1 0.9999951124191284
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 4.681985956267454e-05
is O 0 1.0903490874625277e-06
hypermethylated O 0 1.4621354239352513e-05
proximal O 0 1.6188309018616565e-05
to O 0 1.194200507370624e-07
the O 0 2.7554278858588077e-07
largely O 0 3.819932317128405e-07
expanded O 0 7.160335826483788e-07
CTG O 0 3.9902479329612106e-05
repeat O 0 3.4597283047332894e-06
. O 0 1.3647336345457006e-06

Using O 0 6.90346205374226e-05
methylation O 0 0.00022022111807018518
- O 0 6.126976222731173e-05
sensitive O 0 1.456068639527075e-05
restriction O 0 6.3932070588634815e-06
enzymes O 0 8.436268785771972e-07
, O 0 1.0707665154541246e-07
we O 0 3.3662203691164905e-08
characterized O 0 1.1231707475189978e-07
the O 0 2.2927478937617707e-07
methylation O 0 7.579160978821164e-07
pattern O 0 1.7483372403148678e-06
on O 0 2.8355721042316873e-06
the O 0 1.5338607681769645e-06
5 O 0 8.31850059057615e-07
side O 0 4.018248489501275e-07
of O 0 4.47738284492516e-06
the O 0 8.184963917301502e-06
CTG O 0 7.493663724744692e-05
repeat O 0 1.8497070186640485e-06
in O 0 6.776018608434242e-07
the O 0 1.534592342977703e-06
DMPK O 0 1.862812314357143e-05
gene O 0 1.5832239341762033e-07
of O 0 1.3427479643723927e-06
normal O 0 3.1424351618625224e-06
individuals O 0 3.318035624033655e-08
and O 0 1.3236622464773973e-07
of O 0 2.756599769782042e-06
patients O 0 8.342497494595591e-06
affected O 0 2.66621500486508e-05
with O 0 0.00023021415108814836
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.4036509077850496e-07
showing O 0 3.512207058520289e-07
expansions O 0 7.996482054295484e-07
of O 0 5.904836370973499e-07
the O 0 7.95098571870767e-07
repetitive O 0 3.3472297218395397e-06
sequence O 0 1.08766346329503e-06
. O 0 1.593291926837992e-06

The O 0 4.218400863464922e-05
gene O 0 2.3268271434062626e-06
segment O 0 2.5496624402876478e-06
analyzed O 0 4.326024622969271e-07
corresponds O 0 5.507146738636948e-07
to O 0 2.131834264673671e-07
the O 0 2.6531561161391437e-06
genomic O 0 8.902804438548628e-06
SacI O 0 0.00018676988838706166
- O 0 7.031163022475084e-06
HindIII O 0 1.1981082025158685e-05
fragment O 0 2.363965222684783e-06
carrying O 0 2.3698860331933247e-06
exons O 0 2.939100568255526e-06
11 O 0 2.5563774670445127e-06
- O 0 2.4422524802503176e-06
15 O 0 2.155926267732866e-06
. O 0 7.304277573894069e-07

There O 0 5.679931928170845e-05
is O 0 6.344653684209334e-06
constitutive O 0 1.9702762074302882e-05
methylation O 0 5.238392986939289e-06
in O 0 1.6500316633027978e-06
intron O 0 1.4530585758620873e-05
12 O 0 6.0130064412078355e-06
at O 0 3.7083459574205335e-06
restriction O 0 9.607023230273626e-07
sites O 0 1.909819786760636e-07
of O 0 2.3271200007002335e-06
SacII O 0 2.2024953068466857e-05
and O 0 1.357885366815026e-06
HhaI O 0 1.876929854915943e-05
, O 0 2.295090837378666e-07
localized O 0 1.1050044577132212e-06
1 O 0 8.508576456733863e-07
, O 0 5.4539405880404956e-08
159 O 0 1.9973953158114455e-07
- O 0 1.7072416369501298e-07
1 O 0 3.979168354817375e-07
, O 0 5.198878483270164e-08
232 O 0 7.098856826814881e-07
bp O 0 2.555753326305421e-06
upstream O 0 5.3205749281914905e-06
of O 0 5.111826794745866e-06
the O 0 1.6365496776415966e-05
CTG O 0 9.445144678466022e-05
repeat O 0 4.146705123275751e-06
, O 0 4.607581161053531e-07
whereas O 0 3.0180396493051376e-07
most O 0 1.0270450445659662e-07
, O 0 3.767457812386965e-08
if O 0 9.936229616869241e-09
not O 0 1.9453151978154892e-08
all O 0 2.4333955295219312e-08
, O 0 5.6099853651403464e-08
of O 0 4.5601552756124875e-07
the O 0 4.216078650642885e-07
other O 0 1.2768497370529985e-08
sites O 0 1.3977846435864194e-07
of O 0 4.614868885255419e-06
SacII O 0 5.788555426988751e-05
, O 0 1.645945303607732e-06
HhaI O 0 2.339604907319881e-05
, O 0 5.625284984489554e-07
and O 0 4.59194268387364e-07
HpaII O 0 3.466660200501792e-05
in O 0 1.2254388366272906e-06
this O 0 1.2664861515077064e-07
region O 0 5.911857670071186e-07
are O 0 2.34723955827576e-07
unmethylated O 0 2.3504635464632884e-06
, O 0 4.4313420488606425e-08
in O 0 7.105725785550021e-08
normal O 0 4.372529076590581e-07
individuals O 0 9.14657949380171e-09
and O 0 6.103930161316384e-08
most O 0 4.54020216977824e-08
of O 0 8.513819125255395e-07
the O 0 2.787851599350688e-06
patients O 0 1.2894338397018146e-06
. O 0 9.592722562956624e-07

In O 0 4.6936358558014035e-05
a O 0 9.787719136511441e-06
number O 0 3.092061888310127e-06
of O 0 5.217986472416669e-05
young O 0 9.239140126737766e-06
and O 0 1.1985184755758382e-05
severely O 1 0.9861771464347839
affected O 0 4.544516923488118e-05
patients O 0 3.573557023628382e-06
, O 0 1.199201591361998e-07
however O 0 4.381771034900339e-08
, O 0 1.2719397091132123e-08
complete O 0 7.990599470986126e-08
methylation O 0 4.995985705136263e-07
of O 0 7.374508754764975e-07
these O 0 3.1987173798597723e-08
restriction O 0 3.2602895316813374e-07
sites O 0 1.0237710057481308e-07
was O 0 9.371310625283513e-07
found O 0 6.594033408191535e-08
in O 0 1.1131959354315768e-07
the O 0 5.712126949219964e-07
mutated O 0 1.655561050029064e-06
allele O 0 2.660296104295412e-06
. O 0 1.6827713125167065e-06

In O 0 2.848173608072102e-05
most O 0 3.7066769209559425e-07
of O 0 4.461725779947301e-07
these O 0 3.6331904595954256e-08
patients O 0 2.473801430369349e-07
, O 0 3.3538899657514776e-08
the O 0 1.8672253077056666e-07
onset O 0 0.00034561712527647614
of O 0 1.3027487511863e-05
the O 0 0.0002516040694899857
disease O 1 0.9999990463256836
was O 1 0.9999978542327881
congenital O 1 1.0
. O 0 3.707318319357e-05

Preliminary O 0 0.00027729105204343796
in O 0 9.271012095268816e-05
vivo O 0 0.0017332095885649323
footprinting O 0 0.0012287432327866554
data O 0 1.4390145224751905e-05
gave O 0 1.4430675037147012e-06
evidence O 0 1.5162726185735664e-06
for O 0 8.901786259229993e-07
protein O 0 1.6338811974492273e-06
- O 0 2.9187690415710676e-06
DNA O 0 3.9086961578504997e-07
contact O 0 8.060675327214994e-07
in O 0 3.21297011396382e-06
normal O 0 1.8534101400291547e-05
genes O 0 1.0620138937156298e-06
at O 0 1.8053870007861406e-05
an O 0 3.720527388395567e-07
Sp1 O 0 3.2572982036072062e-06
consensus O 0 2.7352993470231013e-07
binding O 0 2.7144065484208113e-07
site O 0 2.1192877284192946e-06
upstream O 0 4.0525792428525165e-06
of O 0 2.1684531930077355e-06
the O 0 4.620602339855395e-06
CTG O 0 5.37320229341276e-05
repeat O 0 9.083644840757188e-07
and O 0 6.102661131990317e-08
for O 0 4.449695722996694e-08
a O 0 6.622771309139353e-08
significant O 0 4.9965574788757294e-08
reduction O 0 1.2532771052065073e-06
of O 0 2.472391315677669e-06
this O 0 8.428011710748251e-08
interaction O 0 1.206010722398787e-07
in O 0 2.7459944362817623e-07
cells O 0 1.3334650361684908e-07
with O 0 5.307811790089545e-08
a O 0 1.4926370113244047e-06
hypermethylated O 0 4.493784945225343e-05
DMPK O 0 0.0001116074199671857
gene O 0 1.8731819864115096e-06
. O 0 2.5032434791683045e-07
. O 0 5.349987759473152e-07

The O 0 0.0031403074972331524
hemochromatosis B-Disease 1 1.0
gene O 0 6.490031228167936e-05
product O 0 1.0636605111358222e-05
complexes O 0 1.0337736966903321e-05
with O 0 3.3428037227167806e-07
the O 0 5.756270184065215e-06
transferrin O 0 6.59598081256263e-05
receptor O 0 8.091907147900201e-06
and O 0 3.56800597955953e-07
lowers O 0 2.5342105800518766e-06
its O 0 1.046580777597228e-07
affinity O 0 2.260086233718539e-07
for O 0 1.0256688653953461e-07
ligand O 0 1.592286480445182e-06
binding O 0 9.985874385165516e-07
. O 0 6.258234748202085e-07

We O 0 4.6314587962115183e-05
recently O 0 1.758683538355399e-05
reported O 0 1.5104865269677248e-06
the O 0 3.7094739013809885e-07
positional O 0 2.9788041047140723e-06
cloning O 0 4.7654256718487886e-07
of O 0 4.756177247600135e-07
a O 0 4.6334866965480614e-07
candidate O 0 9.100188549382437e-07
gene O 0 3.326132173242513e-06
for O 0 5.013076224713586e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999932050704956
HFE O 1 0.9999902248382568
. O 0 1.2410881026880816e-05

The O 0 0.00021999656746629626
gene O 0 1.0049434422398917e-05
product O 0 2.726166030697641e-06
, O 0 4.314784405323735e-07
a O 0 9.358432748740597e-07
member O 0 1.393124193782569e-06
of O 0 7.092549367371248e-06
the O 0 1.1882020771736279e-05
major O 0 0.00015011441428214312
histocompatibility O 1 0.7121500968933105
complex O 0 0.19095101952552795
class O 0 2.566158218542114e-05
I O 0 2.262172711198218e-05
- O 0 2.752507043624064e-06
like O 0 2.2961943102473015e-07
family O 0 1.0676584594193628e-07
, O 0 5.8980383244033874e-08
was O 0 1.5997370610421058e-06
found O 0 7.372497634605679e-08
to O 0 4.673855258374715e-08
have O 0 1.6675261349519133e-07
a O 0 1.2489484788602567e-06
mutation O 0 3.94689607219334e-07
, O 0 1.1918129985133419e-06
Cys O 0 3.0321778467623517e-05
- O 0 6.239300091692712e-06
282 O 0 1.3906188542023301e-05
- O 0 4.472590262594167e-06
- O 0 6.217216196091613e-06
> O 0 3.6282647215557517e-06
Tyr O 0 7.75111675466178e-06
( O 0 2.161089867058763e-07
C282Y O 0 1.4416699514185893e-06
) O 0 2.183675285039044e-08
, O 0 6.8978960321430804e-09
in O 0 2.0572151981923525e-08
85 O 0 2.3462503406790347e-07
% O 0 4.1573457565391436e-08
of O 0 5.514588679034205e-07
patient O 0 8.680697646923363e-06
chromosomes O 0 1.6878495443961583e-05
. O 0 6.540225058415672e-06

This O 0 9.918082469084766e-06
mutation O 0 5.061590400146088e-06
eliminates O 0 6.588403721252689e-06
the O 0 1.599979555066966e-06
ability O 0 4.46870956238854e-07
of O 0 1.8727709175436758e-05
HFE O 0 0.0006515643908642232
to O 0 3.858791387756355e-06
associate O 0 1.4287096746556927e-05
with O 0 7.055377864162438e-07
beta2 O 0 0.00016905365919228643
- O 0 0.0001275161193916574
microglobulin O 0 0.0002262895432068035
( O 0 7.928089189590537e-07
beta2m O 0 1.481601157138357e-05
) O 0 1.0866622801586345e-07
and O 0 1.4274823456617014e-07
prevents O 0 8.286417596536921e-07
cell O 0 4.9409914936404675e-05
- O 0 1.652330502110999e-05
surface O 0 1.9852081095450558e-05
expression O 0 1.150015668827109e-05
. O 0 1.6702698530934867e-06

A O 0 0.00024522634339518845
second O 0 2.2076896129874513e-05
mutation O 0 1.3874378055334091e-06
that O 0 4.4081389205530286e-07
has O 0 5.505351055035135e-07
no O 0 2.5096326794482593e-07
effect O 0 4.3103937059640884e-06
on O 0 4.121031452086754e-05
beta2m O 0 0.00028507891693152487
association O 0 6.5776680457929615e-06
, O 0 6.937341936463781e-07
H63D O 0 2.6880716177402064e-05
, O 0 2.674146344361361e-07
was O 0 4.840843303099973e-06
found O 0 1.4623476829456195e-07
in O 0 2.6587235879560467e-07
eight O 0 2.651787553986651e-07
out O 0 9.29941421645708e-08
of O 0 1.3186429441702785e-06
nine O 0 3.2138434562511975e-06
patients O 0 4.413047918205848e-07
heterozygous O 0 2.886862375817145e-07
for O 0 4.2846170345001156e-07
the O 0 3.5167286114301533e-06
C282Y O 0 2.531192876631394e-05
mutant O 0 1.233583316206932e-05
. O 0 2.1660307538695633e-06

In O 0 9.462308662477881e-05
this O 0 2.718551286307047e-06
report O 0 2.135121349056135e-06
, O 0 1.701030072354115e-07
we O 0 3.601727982527336e-08
demonstrate O 0 2.3167140739133174e-07
in O 0 9.243389627044962e-07
cultured O 0 1.674917439231649e-05
293 O 0 2.246946132800076e-05
cells O 0 5.055478141002823e-06
overexpressing O 0 1.811022411857266e-05
wild O 0 5.61114006814023e-07
- O 0 1.4872886140437913e-06
type O 0 7.536297630394984e-07
or O 0 5.263573825686763e-07
mutant O 0 3.810613861787715e-06
HFE O 0 3.689103323267773e-05
proteins O 0 1.3925131270298152e-07
that O 0 5.592485763372679e-08
both O 0 5.3889198881051925e-08
the O 0 2.9428713332890766e-07
wild O 0 2.907925988893112e-07
- O 0 2.1945288608549163e-06
type O 0 1.8099942735716468e-06
and O 0 3.278365056758048e-06
H63D O 0 0.0245984960347414
HFE O 0 0.0010423441417515278
proteins O 0 1.923075387821882e-06
form O 0 1.0076948910864303e-06
stable O 0 7.212337095552357e-06
complexes O 0 9.968472340915469e-07
with O 0 3.870640341574472e-08
the O 0 9.695057769931736e-07
transferrin O 0 1.0489431588212028e-05
receptor O 0 3.4387060168228345e-06
( O 0 2.41413033563731e-07
TfR O 0 6.0271500842645764e-05
) O 0 1.8514846544803731e-07
. O 0 2.3885388600319857e-07

The O 0 0.00012647711264435202
C282Y O 0 0.0001564075646456331
mutation O 0 4.900447493128013e-06
nearly O 0 7.139755325624719e-06
completely O 0 2.4877792839106405e-06
prevents O 0 4.449984771781601e-07
the O 0 1.6331738379449234e-06
association O 0 7.081749799908721e-07
of O 0 9.718385172163835e-07
the O 0 1.4379281765286578e-06
mutant O 0 7.753452337055933e-06
HFE O 0 0.00013555542682297528
protein O 0 1.3161441074771574e-06
with O 0 1.7040679267665837e-07
the O 0 6.378822490660241e-06
TfR O 0 0.01892731711268425
. O 0 4.526006705418695e-06

Studies O 0 0.00011172189260832965
on O 0 4.388544402900152e-05
cell O 0 3.742542685358785e-05
- O 0 7.111241757229436e-06
associated O 0 1.6462939811390243e-06
transferrin O 0 4.443356010597199e-05
at O 0 2.1844309230800718e-05
37 O 0 3.7632964904332766e-06
degrees O 0 6.0240763559704646e-05
C O 0 3.59761506842915e-05
suggest O 0 4.846987735618313e-07
that O 0 1.210016336017361e-07
the O 0 5.628762664855458e-07
overexpressed O 0 5.613165285467403e-06
wild O 0 4.1121424487755576e-07
- O 0 1.5774681969560334e-06
type O 0 2.5396204819116974e-06
HFE O 0 8.208877989090979e-05
protein O 0 1.4364588878379436e-06
decreases O 0 9.298223062614852e-07
the O 0 5.015290867049771e-07
affinity O 0 3.3825429568423715e-07
of O 0 2.1071314222353976e-06
the O 0 1.825067101890454e-06
TfR O 0 0.0003416769322939217
for O 0 1.6684184629411902e-06
transferrin O 0 7.366688805632293e-05
. O 0 4.155263923166785e-06

The O 0 0.0007183082634583116
overexpressed O 0 0.0032087438739836216
H63D O 0 0.010119849815964699
protein O 0 7.24278434063308e-05
does O 0 9.013144222080882e-07
not O 0 2.7430630211711104e-07
have O 0 1.004118814762478e-07
this O 0 4.092361649554732e-08
effect O 0 4.0167086012843356e-07
, O 0 3.5055535363426316e-08
providing O 0 2.6994637636335028e-08
the O 0 9.266675959906934e-08
first O 0 8.709373133797271e-08
direct O 0 1.0574281361641624e-07
evidence O 0 1.4471963538653654e-07
for O 0 1.2355468470559572e-07
a O 0 4.2990325255232165e-07
functional O 0 2.4034970920183696e-06
consequence O 0 4.87659690406872e-06
of O 0 4.76581180919311e-06
the O 0 8.728912689548451e-06
H63D O 0 0.0002787018602248281
mutation O 0 2.390307827226934e-06
. O 0 1.6124205330925179e-06

Addition O 0 3.946290598833002e-05
of O 0 6.97137729730457e-05
soluble O 0 0.00011074816575273871
wild O 0 8.817582966003101e-06
- O 0 3.1325940653914586e-05
type O 0 5.653188782162033e-05
HFE O 1 0.7081027030944824
/ O 0 0.00011169482604600489
beta2m O 0 0.00010069901327369735
heterodimers O 0 1.404937847837573e-05
to O 0 9.415026056558418e-07
cultured O 0 9.186949682771228e-06
cells O 0 7.531555752393615e-07
also O 0 1.970537937268091e-07
decreased O 0 6.430740540963598e-06
the O 0 2.579795079782343e-07
apparent O 0 5.046788942308922e-07
affinity O 0 5.380014727052185e-07
of O 0 4.49116214440437e-06
the O 0 2.8689914870483335e-06
TfR O 0 0.00011809563875431195
for O 0 4.314957209317072e-07
its O 0 6.639124308094324e-07
ligand O 0 5.020898697694065e-06
under O 0 5.044233148510102e-06
steady O 0 4.9810678319772705e-05
- O 0 1.01677085240226e-06
state O 0 2.977953101890307e-07
conditions O 0 1.8346511296840617e-06
, O 0 7.249204969639322e-08
both O 0 3.569080675447367e-08
in O 0 1.880422360045486e-07
293 O 0 1.8490720776753733e-06
cells O 0 1.566881451253721e-07
and O 0 2.3555053019208572e-07
in O 0 1.7165044710054644e-06
HeLa O 0 4.199431714368984e-05
cells O 0 1.7795960047806147e-06
. O 0 7.264041528287635e-07

Furthermore O 0 8.463088306598365e-05
, O 0 2.9520788302761503e-06
at O 0 5.266744665277656e-06
4 O 0 1.4777029946344555e-06
degrees O 0 2.4975897758849896e-05
C O 0 2.1328449292923324e-05
, O 0 2.878364853131643e-07
the O 0 1.5909810144876246e-06
added O 0 2.304891950188903e-06
soluble O 0 4.316383183322614e-06
complex O 0 8.084286491794046e-06
of O 0 2.4514845790690742e-05
HFE O 0 0.005010662600398064
/ O 0 3.8252415833994746e-05
beta2m O 0 2.3334103389061056e-05
inhibited O 0 3.4794788916769903e-06
binding O 0 9.61166847446293e-07
of O 0 5.815990789415082e-06
transferrin O 0 3.119173561572097e-05
to O 0 2.3277905256691156e-06
HeLa O 0 0.00010779494914459065
cell O 0 2.3960177713888697e-05
TfR O 0 0.00040419469587504864
in O 0 1.185728478958481e-06
a O 0 1.5332478824348073e-06
concentration O 0 1.7751986888470128e-05
- O 0 8.693107702129055e-06
dependent O 0 1.8640935195435304e-06
manner O 0 1.6234188251473824e-06
. O 0 1.3279918675834779e-06

Scatchard O 0 0.0019788395147770643
plots O 0 7.668190664844587e-05
of O 0 1.01200639619492e-05
these O 0 2.251852606605098e-07
data O 0 1.122089997807052e-06
indicate O 0 9.522792083771492e-07
that O 0 1.860713894075161e-07
the O 0 1.467384208808653e-06
added O 0 1.634660520721809e-06
heterodimer O 0 5.008798780181678e-06
substantially O 0 1.0090546993524185e-06
reduced O 0 2.1384846604632912e-07
the O 0 1.2894260237317212e-07
affinity O 0 2.626656225857005e-07
of O 0 3.7286229144228855e-06
TfR O 0 0.0004528475983534008
for O 0 1.7559634670760715e-06
transferrin O 0 0.00010930056305369362
. O 0 5.486793270392809e-06

These O 0 6.19868569629034e-06
results O 0 7.812161129550077e-06
establish O 0 2.049468548648292e-06
a O 0 2.3052480173646472e-06
molecular O 0 5.56087979930453e-06
link O 0 5.294492893881397e-06
between O 0 6.964952717680717e-06
HFE O 0 0.0002462652628310025
and O 0 1.031881765811704e-06
a O 0 1.6674355265422491e-06
key O 0 4.3735731196647976e-06
protein O 0 8.372468869310978e-07
involved O 0 5.828033522448095e-07
in O 0 2.244544702989515e-06
iron O 0 0.0009451381047256291
transport O 0 3.1506358936894685e-05
, O 0 4.58356879562416e-07
the O 0 1.669249172664422e-06
TfR O 0 0.0015531722456216812
, O 0 2.4286526922878693e-07
and O 0 1.1474213579276693e-07
raise O 0 1.1243775333014128e-07
the O 0 4.1492782543173234e-07
possibility O 0 4.747910793412302e-07
that O 0 1.0497415559029832e-07
alterations O 0 1.7780183725335519e-06
in O 0 5.235069124864822e-07
this O 0 1.287698410123994e-07
regulatory O 0 9.190334822051227e-07
mechanism O 0 2.307654312971863e-06
may O 0 5.832326905874652e-07
play O 0 4.902878814050382e-08
a O 0 4.964552857700255e-08
role O 0 1.6044749884258636e-07
in O 0 3.399595982500614e-07
the O 0 1.977585725398967e-06
pathogenesis O 0 0.3833790719509125
of O 1 0.9821470379829407
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 5.060782496002503e-05
. O 0 5.1743727453867905e-06

Genomic O 0 0.00013100882642902434
organization O 0 6.844949894002639e-06
of O 0 6.257492714212276e-06
the O 0 8.127608452923596e-06
UBE3A O 0 0.0007955529144965112
/ O 0 2.7434647563495673e-05
E6 O 0 6.747104634996504e-05
- O 0 1.6857535229064524e-05
AP O 0 3.8961793507041875e-06
gene O 0 1.6220772636188485e-07
and O 0 1.1032885538497794e-07
related O 0 1.3682927146874135e-06
pseudogenes O 0 4.6728597226319835e-05
. O 0 2.227085587946931e-06

The O 0 0.0002512804639991373
UBE3A O 0 0.0017685299972072244
gene O 0 9.20491038414184e-06
encodes O 0 8.088728463917505e-06
the O 0 9.198925909004174e-06
E6 O 0 7.537367491750047e-05
- O 0 2.9697426725761034e-05
AP O 0 3.7875521229580045e-05
ubiquitin O 0 1.8526538042351604e-05
- O 0 9.247424713976216e-06
protein O 0 3.983279839303577e-06
ligase O 0 1.3864641914551612e-06
and O 0 2.3411610072798794e-07
has O 0 1.8142370095119986e-07
recently O 0 1.3716055491386214e-07
been O 0 7.811961211245944e-08
shown O 0 1.5644946671500293e-08
to O 0 1.9633867864854437e-08
be O 0 8.928621753057087e-08
mutated O 0 1.4382574136106996e-06
in O 0 0.0021521400194615126
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0022360722068697214
who O 0 3.43669285030046e-06
lack O 0 2.8755039238603786e-05
15q11 O 0 0.00036754802567884326
- O 0 6.59934594295919e-05
q13 O 0 3.21600200550165e-05
deletions O 0 5.411742677097209e-06
or O 0 1.0373598797741579e-06
chromosome O 0 1.2113157936255448e-05
15 O 0 1.0618604392220732e-05
paternal O 0 0.0011926991865038872
uniparental B-Disease 1 0.988163948059082
disomy I-Disease 0 0.005315103102475405
. O 0 8.084633009275422e-06

Previous O 0 0.0002695482689887285
UBE3A O 0 0.0017050170572474599
cDNA O 0 5.350204082787968e-05
analysis O 0 7.815544336153835e-07
has O 0 1.6277971326417173e-07
shown O 0 1.3241344731795834e-07
a O 0 3.376477479832829e-07
coding O 0 4.283362784462952e-07
region O 0 2.466249213739502e-07
of O 0 7.814425657670654e-07
approximately O 0 8.088983918241865e-07
2 O 0 3.5421885513642337e-06
. O 0 9.307254913437646e-07

6 O 0 0.00028673376073129475
kb O 0 0.00042932425276376307
and O 0 8.110419003060088e-06
a O 0 4.151972007093718e-06
3 O 0 1.8263398260387476e-06
- O 0 2.7822925403597765e-06
untranslated O 0 2.1556981664616615e-05
region O 0 1.9801975668087834e-06
( O 0 2.5266183456551516e-07
UTR O 0 1.0797120921779424e-05
) O 0 8.135419449217807e-08
of O 0 2.542761194490595e-06
< O 0 6.122124432295095e-06
50 O 0 3.798864781856537e-06
bp O 0 4.857204658037517e-06
, O 0 1.1463658466936977e-07
whereas O 0 1.3647384378145944e-07
Northern O 0 1.1938008981360326e-07
analysis O 0 2.6250377871406272e-08
has O 0 4.247597829021288e-08
indicated O 0 6.18840374499996e-08
mRNA O 0 6.257292284317373e-08
sizes O 0 2.0717372706258175e-08
of O 0 6.10787878940755e-07
5 O 0 1.2500221373556997e-06
- O 0 1.3392209439189173e-06
8 O 0 3.7201766645011958e-06
kb O 0 3.577450479497202e-05
. O 0 1.4614821566283354e-06

We O 0 1.3502184629032854e-05
have O 0 4.854676376453426e-07
analyzed O 0 5.49841445263155e-07
additional O 0 4.2501508801251475e-07
cDNA O 0 6.940200819371967e-06
clones O 0 1.1846365168821649e-06
and O 0 8.778886950722153e-08
provide O 0 3.095895095839296e-08
evidence O 0 1.1014487455440758e-07
for O 0 4.336367354085269e-08
an O 0 9.674233325540627e-08
additional O 0 1.1844169023333961e-07
0 O 0 1.758792564032774e-06
. O 0 5.311123913998017e-07

5 O 0 9.941800817614421e-05
kb O 0 0.00012974227138329297
of O 0 2.3706505089649e-05
5 O 0 6.228753136383602e-06
- O 0 3.2241857752524083e-06
UTR O 0 1.7450858649681322e-05
and O 0 4.072350918704615e-07
> O 0 1.2217537914693821e-06
2 O 0 1.0462050568094128e-06
kb O 0 8.534795597370248e-06
of O 0 4.997466476197587e-06
3 O 0 1.252395122719463e-05
- O 0 2.014296296692919e-05
UTR O 0 0.0001622868439881131
. O 0 1.3190668823881424e-06

We O 0 2.161487100238446e-05
have O 0 8.765164238866419e-07
established O 0 8.99235828910605e-07
the O 0 3.1346243645202776e-07
genomic O 0 1.1509287105582189e-06
organization O 0 6.718807412653405e-07
of O 0 2.990605253216927e-06
UBE3A O 0 7.613957131979987e-05
and O 0 5.414057113739545e-07
the O 0 4.776568403030979e-07
sequence O 0 2.660072766502708e-07
of O 0 1.093250193662243e-05
intron O 0 0.00010758484131656587
- O 0 2.158210008929018e-05
exon O 0 7.257827746798284e-06
borders O 0 1.247280920324556e-06
. O 0 1.7802969978220062e-06

We O 0 7.271149661391973e-05
have O 0 3.411630132177379e-06
also O 0 1.4063839444133919e-06
mapped O 0 1.579500462867145e-06
two O 0 4.065808241193736e-07
highly O 0 9.87633256954723e-07
homologous O 0 3.0471212539850967e-06
processed O 0 6.295027560554445e-06
pseudogenes O 0 1.564490594319068e-05
, O 0 9.842221970757237e-07
UBE3AP1 O 0 3.555045623215847e-05
and O 0 1.8691063132791896e-06
UBE3AP2 O 0 4.463456934900023e-05
, O 0 2.617541383642674e-07
to O 0 3.275809845604272e-08
chromosomes O 0 1.8261816592257674e-07
2 O 0 6.292130478868785e-07
and O 0 2.8465541390687576e-07
21 O 0 3.0115097615635023e-06
, O 0 1.3217423600053735e-07
respectively O 0 6.515731456602225e-07
, O 0 1.872490607013333e-08
and O 0 1.0468559352716511e-08
determined O 0 6.755068682195997e-08
their O 0 4.733750458285613e-08
genomic O 0 1.47979449138802e-06
organization O 0 1.541655365144834e-06
. O 0 1.3139856491761748e-06

These O 0 8.377762242162134e-06
results O 0 1.934181000251556e-06
will O 0 4.6403144438045274e-08
form O 0 9.047004922990709e-09
the O 0 2.679560218155075e-08
basis O 0 3.307628659854345e-08
for O 0 1.0892474477941505e-08
studies O 0 4.979716905495479e-08
of O 0 3.487474771191046e-07
mutation O 0 1.5943332698498125e-07
and O 0 2.1758762613899307e-07
imprinting O 0 1.008875642583007e-05
of O 0 2.2328180421027355e-05
UBE3A O 0 0.001746339607052505
. O 0 4.446876573638292e-06

Mutation O 0 0.00010938522609649226
spectrum O 0 3.2811698474688455e-05
and O 0 1.8563338244348415e-06
genotype O 0 1.0316906809748616e-05
- O 0 1.0181283869314939e-05
phenotype O 0 2.155644551748992e-06
analyses O 0 6.249944135561236e-07
in O 0 2.1597065824607853e-06
Cowden B-Disease 1 0.9998132586479187
disease I-Disease 1 0.8773998618125916
and O 0 1.6397756553487852e-05
Bannayan B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 8.036673193601018e-07
two O 0 1.5813693607924506e-06
hamartoma B-Disease 1 0.9981029033660889
syndromes I-Disease 1 0.9208989143371582
with O 0 5.075424269307405e-06
germline O 1 0.894241452217102
PTEN O 1 0.897456169128418
mutation O 0 4.759920557262376e-06
. O 0 1.0667338301573182e-06

The O 0 0.0026842004153877497
tumour B-Disease 1 1.0
suppressor O 1 0.9999791383743286
gene O 0 5.8937752328347415e-05
PTEN O 0 0.000403767655370757
, O 0 1.86645621624848e-07
which O 0 2.3988745212477625e-08
maps O 0 2.2603425975376013e-07
to O 0 2.707260762235819e-07
10q23 O 0 6.519705493701622e-05
. O 0 5.743378551414935e-06

3 O 0 1.871333734015934e-05
and O 0 3.847183620564465e-07
encodes O 0 1.0267957577525522e-06
a O 0 7.125784691197623e-07
403 O 0 2.0179850253043696e-06
amino O 0 7.467672844541084e-07
acid O 0 2.542067250033142e-07
dual O 0 3.689459390443517e-06
specificity O 0 6.162494628370041e-06
phosphatase O 0 0.00010748722706921399
( O 0 1.6565544456170755e-06
protein O 0 5.62028935746639e-06
tyrosine O 0 1.5612025890732184e-05
phosphatase O 0 2.8110622224630788e-05
; O 0 4.955849135512835e-07
PTPase O 0 5.626290203508688e-06
) O 0 9.070645035080815e-08
, O 0 3.484262478536948e-08
was O 0 3.286762932930287e-07
shown O 0 7.950585967364532e-08
recently O 0 2.3628511769402394e-07
to O 0 1.2959039175086673e-08
play O 0 5.643135736477234e-08
a O 0 1.5760848270929273e-07
broad O 0 2.0851234694418963e-07
role O 0 4.3632732626974757e-07
in O 0 6.308966931101168e-07
human O 0 4.9645141189103015e-06
malignancy B-Disease 0 0.0002854027843568474
. O 0 2.131432893293095e-06

Somatic O 0 0.024102669209241867
PTEN O 0 0.021113257855176926
deletions O 0 3.618869959609583e-05
and O 0 5.822795401400072e-07
mutations O 0 1.1887317441505729e-07
were O 0 1.2556263584428962e-07
observed O 0 4.0667462286592126e-08
in O 0 4.9252513178998925e-08
sporadic B-Disease 0 1.5196925232885405e-05
breast I-Disease 1 0.9996558427810669
, I-Disease 0 0.00031998541089706123
brain I-Disease 1 0.9999995231628418
, I-Disease 0 4.9625108658801764e-05
prostate I-Disease 1 1.0
and I-Disease 1 0.999342143535614
kidney I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
cell O 0 0.12692420184612274
lines O 0 2.752606633293908e-06
and O 0 4.992308433315884e-08
in O 0 1.3923364861057053e-07
several O 0 1.2417982020451745e-07
primary O 0 0.00033139673178084195
tumours B-Disease 1 1.0
such O 0 4.5212169652586454e-07
as O 0 9.095820860238746e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.997784435749054
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999768733978271
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 4.879260086454451e-05

In O 0 3.058955917367712e-05
addition O 0 8.748564141569659e-06
, O 0 4.0217400965048e-06
PTEN O 0 0.0005775652243755758
was O 0 9.021649020723999e-06
identified O 0 2.1622278723043564e-07
as O 0 5.021014004569224e-08
the O 0 6.075310921005439e-08
susceptibility O 0 2.8124809432483744e-06
gene O 0 3.012624745224457e-07
for O 0 3.438223075136193e-07
two O 0 7.329905201913789e-06
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9998093247413635
( O 0 5.282441861709231e-07
CD B-Disease 0 7.79848141974071e-06
; O 0 2.0349632734451006e-07
MIM O 0 5.808473360957578e-05
158350 O 0 9.20327875064686e-06
) O 0 1.629901902333586e-07
and O 0 4.066595522544958e-07
Bannayan B-Disease 0 4.402318154461682e-05
- I-Disease 0 5.346812031348236e-05
Zonana I-Disease 0 0.00042004830902442336
( I-Disease 0 1.431523401151935e-06
BZS I-Disease 0 0.0001454185985494405
) I-Disease 0 4.5128209080758097e-07
or I-Disease 0 8.085281706371461e-07
Ruvalcaba I-Disease 0 2.7335825507179834e-05
- I-Disease 0 2.623476211738307e-05
Riley I-Disease 0 6.551040860358626e-05
- I-Disease 0 0.007367799058556557
Smith I-Disease 0 0.001581283169798553
syndrome I-Disease 1 0.9999988079071045
( O 0 7.838700184947811e-06
MIM O 1 0.8562030792236328
153480 O 0 0.0002985951432492584
) O 0 1.657504185459402e-06
. O 0 1.342395876235969e-06

Constitutive O 0 0.0014382627559825778
DNA O 0 2.7970421797363088e-05
from O 0 9.337250048702117e-06
37 O 0 7.896722308942117e-06
CD B-Disease 0 4.648722097044811e-06
families O 0 1.0766235192249951e-07
and O 0 2.070140254772923e-07
seven O 0 1.0154781193705276e-06
BZS B-Disease 0 7.814820855855942e-05
families O 0 5.5029893530900154e-08
was O 0 4.300045191030222e-07
screened O 0 7.73004728671367e-07
for O 0 8.335574079865182e-07
germline O 0 7.001023914199322e-05
PTEN O 0 0.00047949145664460957
mutations O 0 2.2793515199737158e-06
. O 0 2.7106318611913593e-06

PTEN O 0 0.011373230256140232
mutations O 0 1.200605220219586e-05
were O 0 1.0522275260882452e-05
identified O 0 6.77639945934061e-07
in O 0 3.2631791668791266e-07
30 O 0 8.449110850961006e-07
of O 0 2.0571308141370537e-06
37 O 0 2.4682403818587773e-06
( O 0 1.2833913842769107e-07
81 O 0 1.7403722267772537e-06
% O 0 1.3747576588230004e-07
) O 0 4.9318412465026995e-08
CD B-Disease 0 7.283318836925901e-07
families O 0 2.3827228190498317e-08
, O 0 1.9938109829809036e-08
including O 0 3.821491034727842e-08
missense O 0 8.678411518303619e-07
and O 0 7.232223993014486e-07
nonsense O 0 2.29052147915354e-05
point O 0 7.250086582644144e-06
mutations O 0 1.718414495144316e-07
, O 0 1.2485287470553885e-07
deletions O 0 4.27460577157035e-07
, O 0 1.1415002632020332e-07
insertions O 0 3.373542085682857e-07
, O 0 6.197747381975205e-08
a O 0 1.8515127919727092e-07
deletion O 0 4.772725333168637e-06
/ O 0 6.919455699971877e-06
insertion O 0 5.79787092647166e-06
and O 0 1.880303557300067e-06
splice O 0 2.4985234631458297e-05
site O 0 1.054570202541072e-05
mutations O 0 1.5792143130965997e-06
. O 0 1.9937749584642006e-06

These O 0 6.173023848532466e-06
mutations O 0 1.5730935274405056e-06
were O 0 3.2056366308097495e-06
scattered O 0 6.17001830960362e-07
over O 0 4.903973263026273e-07
the O 0 1.0662660088200937e-06
entire O 0 1.6885585409909254e-06
length O 0 2.270842060170253e-06
of O 0 7.20029347576201e-05
PTEN O 0 0.0002859410014934838
, O 0 2.9925288913545955e-07
with O 0 6.314035516652439e-08
the O 0 6.609407705582271e-07
exception O 0 4.781873599313258e-07
of O 0 4.168083250988275e-06
the O 0 1.7754224472810165e-06
first O 0 1.6708020211808616e-06
, O 0 2.653573858424352e-07
fourth O 0 3.6394508242665324e-06
and O 0 2.9918726340838475e-07
last O 0 5.4817101045046e-06
exons O 0 9.960983334167395e-06
. O 0 2.4293995011248626e-06

A O 0 0.0003939259913749993
hot O 0 9.90515181911178e-05
spot O 0 1.9118304408038966e-05
for O 0 2.049009253823897e-06
PTEN O 0 8.481702388962731e-05
mutation O 0 4.937936068927229e-07
in O 0 8.992984703581897e-07
CD B-Disease 0 6.439578100980725e-06
was O 0 1.3171399587008636e-05
identified O 0 1.8017742320353136e-07
in O 0 3.101853565112833e-07
exon O 0 4.449072150691791e-07
5 O 0 4.0586800764685904e-07
that O 0 9.237734843736689e-08
contains O 0 3.2111151426761353e-07
the O 0 3.5119030599162215e-06
PTPase O 0 3.929440208594315e-05
core O 0 1.2150702787039336e-05
motif O 0 1.74513218098582e-06
, O 0 4.890092952791747e-08
with O 0 9.511627041547399e-09
13 O 0 3.016474181549711e-07
of O 0 8.498941497236956e-07
30 O 0 1.1353956779203145e-06
( O 0 2.753913719288903e-08
43 O 0 3.3840404967122595e-07
% O 0 5.4233183277574426e-08
) O 0 2.5204519360499944e-08
CD B-Disease 0 2.579263878033089e-07
mutations O 0 2.092862416702701e-08
identified O 0 8.41413410057612e-08
in O 0 1.3240637031231017e-07
this O 0 1.6243883749211818e-07
exon O 0 3.553448777893209e-06
. O 0 1.0946500879072119e-06

Seven O 0 0.00013727645273320377
of O 0 6.806389865232632e-05
30 O 0 1.902198710013181e-05
( O 0 4.588878255162854e-07
23 O 0 3.550860355971963e-06
% O 0 1.6296267801862996e-07
) O 0 2.8957813924535003e-08
were O 0 2.0964067459772195e-07
within O 0 1.2558970752252208e-07
the O 0 1.5687998029534356e-06
core O 0 7.2678367359912954e-06
motif O 0 2.459475808791467e-06
, O 0 8.765635328700228e-08
the O 0 2.3084945155460446e-07
majority O 0 7.336447538364155e-08
( O 0 3.7891133786160935e-08
five O 0 1.1001050381764799e-07
of O 0 1.7438279655834776e-06
seven O 0 1.3400167517829686e-06
) O 0 7.439084726001965e-08
of O 0 4.4793034703616286e-07
which O 0 2.4982543322948914e-07
were O 0 1.507120941823814e-06
missense O 0 2.5433869268454146e-06
mutations O 0 4.0124777456185257e-07
, O 0 1.9802247663847083e-07
possibly O 0 2.494421380561107e-07
pointing O 0 4.616734656792687e-07
to O 0 2.299787560389177e-08
the O 0 9.894210961647332e-08
functional O 0 3.386332423360727e-07
significance O 0 8.473965635857894e-07
of O 0 4.226846158417175e-06
this O 0 5.7488301763442e-07
region O 0 4.044432898808736e-06
. O 0 2.983870672323974e-06

Germline O 0 0.02691894769668579
PTEN O 0 0.009235459379851818
mutations O 0 1.87437362910714e-05
were O 0 8.132538823701907e-06
identified O 0 4.230707588703808e-07
in O 0 1.5349085913385352e-07
four O 0 1.5835168198918836e-07
of O 0 2.2025676571502117e-06
seven O 0 1.072053464667988e-06
( O 0 1.6461542884371738e-07
57 O 0 2.0178695194772445e-06
% O 0 3.4787848335327e-07
) O 0 1.80931948534635e-07
BZS B-Disease 0 5.109236008138396e-05
families O 0 1.1414415013177859e-07
studied O 0 7.1431468313676305e-06
. O 0 1.9703097677847836e-06

Interestingly O 0 0.00047400908078998327
, O 0 6.608622697967803e-06
none O 0 9.23303787203622e-07
of O 0 9.712687187857227e-07
these O 0 5.2772147540736114e-08
mutations O 0 1.9006949969480047e-07
was O 0 6.946153916942421e-06
observed O 0 2.449088185585424e-07
in O 0 4.163329947459715e-07
the O 0 1.5980124317138689e-06
PTPase O 0 7.90227422839962e-05
core O 0 4.461371645447798e-05
motif O 0 2.082703576888889e-05
. O 0 2.523035846024868e-06

It O 0 1.6326679542544298e-05
is O 0 1.9161445834470214e-06
also O 0 6.195189143909374e-07
worthy O 0 1.567977164995682e-06
of O 0 2.512430228307494e-06
note O 0 9.046393074640946e-07
that O 0 5.8910448075266686e-08
a O 0 4.836524567508604e-07
single O 0 6.353320713969879e-07
nonsense O 0 8.625459486211184e-06
point O 0 4.71121438749833e-06
mutation O 0 1.1763098228811941e-07
, O 0 1.2709023167190026e-07
R233X O 0 1.4054239727556705e-06
, O 0 7.62000169629573e-08
was O 0 1.0586202279228019e-06
observed O 0 2.570399146861746e-07
in O 0 4.776409241458168e-07
the O 0 1.9288206658529816e-06
germline O 0 5.965177024336299e-06
DNA O 0 4.654399674564047e-07
from O 0 1.1214555115657276e-06
two O 0 1.7006034624955646e-07
unrelated O 0 8.714554837752075e-07
CD B-Disease 0 4.618456841853913e-06
families O 0 7.440517890699994e-08
and O 0 2.620283794385614e-07
one O 0 1.2939300404468668e-06
BZS B-Disease 0 0.00048291898565366864
family O 0 2.5392619136255234e-06
. O 0 1.6924149122132803e-06

Genotype O 0 0.0028804002795368433
- O 0 0.00035792525159195065
phenotype O 0 2.6374009394203313e-05
studies O 0 1.6833201925692265e-06
were O 0 1.174625367639237e-06
not O 0 6.635035987301308e-08
performed O 0 5.080413529867656e-07
on O 0 9.754143093232415e-07
this O 0 7.108870647698495e-08
small O 0 1.3003970877889515e-07
group O 0 8.455545952301691e-08
of O 0 2.7740584300772753e-06
BZS B-Disease 0 0.0006571346311829984
families O 0 1.0130543159903027e-06
. O 0 2.6681777853809763e-06

However O 0 5.1231112593086436e-05
, O 0 4.262354650563793e-06
genotype O 0 1.483246887801215e-05
- O 0 1.5822768546058796e-05
phenotype O 0 5.648181286233012e-06
analysis O 0 1.2016931805192144e-06
inthe O 0 1.726285699987784e-05
group O 0 2.5699435468595766e-07
of O 0 3.387848437341745e-06
CD B-Disease 0 1.580657044542022e-05
families O 0 2.5420575866519357e-07
revealed O 0 2.119708142345189e-06
two O 0 2.890997734539269e-07
possible O 0 5.897081791772507e-07
associations O 0 5.340398843145522e-07
worthy O 0 2.481542651366908e-06
of O 0 5.35754588781856e-06
follow O 0 2.069396174420035e-07
- O 0 4.0215684293798404e-07
up O 0 7.857539685574011e-08
in O 0 3.636074552559876e-08
independent O 0 3.7104566530388183e-08
analyses O 0 2.781703756227216e-07
. O 0 1.1120537237729877e-06

The O 0 0.00011760925553971902
first O 0 2.051381306955591e-05
was O 0 0.00010524152457946911
an O 0 2.5235315206373343e-06
association O 0 4.419509878061945e-06
noted O 0 8.941655664784776e-07
in O 0 5.985144753140048e-07
the O 0 1.08051108327345e-06
group O 0 6.524710016719837e-08
of O 0 1.3101479225952062e-06
CD B-Disease 0 2.0480170860537328e-05
families O 0 9.078710405674428e-08
with O 0 1.7085801573557546e-06
breast B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.4350545067572966e-05

A O 0 6.467776256613433e-05
correlation O 0 2.0588993720593862e-05
was O 0 1.9846194845740683e-05
observed O 0 6.975042765589023e-07
between O 0 7.232679308799561e-07
the O 0 8.461100833301316e-07
presence O 0 1.180851199933386e-06
/ O 0 7.436548003170174e-06
absence O 0 4.136996267334325e-06
of O 0 6.363705779222073e-06
a O 0 8.342497494595591e-06
PTEN O 0 0.00017776191816665232
mutation O 0 1.0226253976952648e-07
and O 0 6.149563347435105e-08
the O 0 1.332073225057684e-07
type O 0 6.265950673878251e-07
of O 0 7.113835454219952e-05
breast O 1 0.9975875616073608
involvement O 1 0.6762077212333679
( O 0 2.6413401428726502e-05
unaffected O 0 0.0002025865251198411
versus O 0 0.00014818282215856016
benign O 0 0.0014328749384731054
versus O 0 4.438410178408958e-05
malignant O 0 0.000492771272547543
) O 0 4.996176130589447e-07
. O 0 5.470786845762632e-07

Specifically O 0 0.00012987098307348788
and O 0 9.266953384212684e-06
more O 0 7.177756060627871e-07
directly O 0 1.1503734640427865e-06
, O 0 2.048861347248021e-07
an O 0 3.4980004670615017e-07
association O 0 8.389661729779618e-07
was O 0 2.9477830594260013e-06
also O 0 4.7857515284022156e-08
observed O 0 5.806021619036983e-08
between O 0 6.21439113501765e-08
the O 0 5.1525898214777044e-08
presence O 0 3.961674011065952e-08
of O 0 2.6916958972833527e-07
a O 0 3.5020366340177134e-06
PTEN O 0 0.014693915843963623
mutation O 0 3.835669303953182e-06
and O 0 2.604642759251874e-05
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999992847442627
. O 0 1.3597328688774724e-05

Secondly O 0 0.0021549637895077467
, O 0 2.0604431483661756e-05
there O 0 4.3867148633580655e-06
appeared O 0 5.922708623984363e-06
to O 0 2.797797264975088e-07
be O 0 8.606835990576656e-07
an O 0 7.539489956798207e-07
interdependent O 0 6.113174094934948e-06
association O 0 9.488217642683594e-07
between O 0 6.293403203017078e-07
mutations O 0 5.06112371567724e-07
upstream O 0 1.803573286451865e-05
and O 0 3.6351599419504055e-07
within O 0 6.258736107156437e-07
the O 0 4.109078872716054e-06
PTPase O 0 6.624188972637057e-05
core O 0 3.4296343073947355e-05
motif O 0 8.85415374796139e-06
, O 0 6.112027790550201e-07
the O 0 1.2663691677516908e-06
core O 0 4.127419742872007e-06
motif O 0 1.7190747030326747e-06
containing O 0 4.137033613460517e-07
the O 0 2.2157361456720537e-07
majority O 0 4.2751679529828834e-08
of O 0 1.3814409385304316e-06
missense O 0 2.556038452894427e-06
mutations O 0 3.067628426833835e-07
, O 0 1.5859259860917518e-07
and O 0 5.193318841634209e-08
the O 0 2.2579813219181233e-07
involvement O 0 5.729536383114464e-07
of O 0 1.9493454601615667e-06
all O 0 2.3921816705296806e-07
major O 0 4.9665675760479644e-05
organ O 1 0.9999992847442627
systems O 0 0.1251048892736435
( O 0 4.242227987560909e-06
central O 0 0.0025473213754594326
nervous O 0 0.0006847698241472244
system O 0 0.00038232983206398785
, O 0 8.962692845670972e-06
thyroid O 1 0.9999994039535522
, O 0 2.8461916372179985e-05
breast O 1 0.9999755620956421
, O 0 0.0003966823860537261
skin O 1 0.9997991919517517
and O 1 0.9998466968536377
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 5.417254214989953e-05
. O 0 3.7318884551496012e-06

However O 0 0.0001070375947165303
, O 0 5.824466825288255e-06
these O 0 1.7351919723296305e-07
observations O 0 2.4857017706381157e-06
would O 0 7.988090260369063e-07
need O 0 4.770622581418138e-07
to O 0 2.845468429768516e-07
be O 0 3.70670846905341e-07
confirmed O 0 2.1249290682590072e-07
by O 0 4.333093173158886e-08
studying O 0 1.0493552338175505e-07
a O 0 6.438678923359475e-08
larger O 0 3.915847912594472e-08
number O 0 4.8390621287808244e-08
of O 0 9.502089710622386e-07
CD B-Disease 0 7.207745056803105e-06
families O 0 1.8310942095922655e-07
. O 0 6.917503014847171e-07

Molecular O 1 0.9981406927108765
defects O 1 0.9997612833976746
leading O 0 5.9646899899234995e-05
to O 0 3.811777276041539e-07
human O 0 1.730613803374581e-06
complement B-Disease 0 5.151477307663299e-05
component I-Disease 1 0.9999949932098389
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.4045466741663404e-05
an O 0 8.084125511231832e-07
African O 0 6.060028567844711e-07
- O 0 3.1588713227392873e-06
American O 0 5.257523980617407e-07
family O 0 2.8175662691865e-07
. O 0 3.5235800055488653e-07

Complement B-Disease 0 0.001090408070012927
component I-Disease 1 0.9945300221443176
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.7252306861337274e-05
C6D B-Disease 0 0.0011054566130042076
) O 0 1.2495561350078788e-06
was O 0 5.625203266390599e-05
diagnosed O 0 4.169654494035058e-05
in O 0 2.3746119950374123e-06
a O 0 5.470565156429075e-06
16 O 0 9.45845567912329e-06
- O 0 4.4099697333876975e-06
year O 0 6.637942988163559e-06
- O 0 2.487321353328298e-06
old O 0 5.472057182487333e-06
African O 0 5.268615836939716e-07
- O 0 8.560812716496002e-07
American O 0 1.9955427887907717e-07
male O 0 5.570065582105599e-07
with O 0 1.3945758610134362e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.685866118350532e-05

The O 0 0.000826672650873661
patients O 0 0.00013118131028022617
father O 0 0.0003018933057319373
and O 0 1.3792549907520879e-05
two O 0 9.606137609807774e-06
brothers O 0 0.00024296467017848045
also O 0 9.062410754268058e-06
had O 0 0.0001593370398040861
C6D B-Disease 0 0.03097839653491974
, O 0 4.1656812754808925e-07
but O 0 2.6026876653872932e-08
gave O 0 7.389843403871055e-08
no O 0 3.814704285787229e-08
history O 0 2.93244397653325e-07
of O 0 4.912819804303581e-06
meningitis B-Disease 1 1.0
or O 0 4.876192178926431e-06
other O 0 3.5189725622331025e-07
neisserial B-Disease 0 0.0012781686382368207
infection I-Disease 0 0.013155998662114143
. O 0 6.250306341826217e-06

By O 0 1.059525766322622e-05
using O 0 1.6688227333361283e-06
exon O 0 5.6025332924036775e-06
- O 0 1.6179149042727659e-06
specific O 0 1.3271255738800392e-07
polymerase O 0 1.2680184227065183e-05
chain O 0 4.164729944022838e-06
reaction O 0 6.216180281626293e-07
( O 0 8.315916488754738e-08
PCR O 0 3.4327612752349523e-07
) O 0 6.594649448743439e-08
/ O 0 4.619694209395675e-07
single O 0 2.9462188422257896e-07
- O 0 1.06055836113228e-06
strand O 0 1.2747007076541195e-06
conformation O 0 2.6883660098064865e-07
polymorphism O 0 7.191488293756265e-08
as O 0 6.2045486970419e-08
a O 0 2.626039119490997e-08
screening O 0 2.8703324161938326e-08
step O 0 5.960464477539063e-08
and O 0 2.2832750801171642e-08
nucleotide O 0 9.683500934443146e-08
sequencing O 0 1.069093116257136e-07
of O 0 5.994644993734255e-07
target O 0 5.247275112196803e-07
exons O 0 4.636704886706866e-07
, O 0 3.699990358541072e-08
we O 0 1.6365707011800623e-08
determined O 0 4.119678109759661e-08
that O 0 6.696929233385163e-08
the O 0 7.521837233070983e-07
proband O 0 8.891198376659304e-06
was O 0 6.252833827602444e-06
a O 0 4.873165835306281e-07
compound O 0 4.496389919950161e-06
heterozygote O 0 1.4067755955693428e-06
for O 0 1.6302998062656116e-07
two O 0 3.9704499954495986e-07
C6 O 0 0.00028794576064683497
gene O 0 2.653191586432513e-06
mutations O 0 2.0645284166675992e-06
. O 0 1.9929725567635614e-06

The O 0 0.00013914205192122608
first O 0 2.1629964976455085e-05
, O 0 1.0640555956342723e-06
1195delC O 0 6.8948334046581294e-06
located O 0 5.089014393888647e-06
in O 0 1.0098133316205349e-06
exon O 0 2.1343009848351358e-06
7 O 0 4.828251803701278e-06
, O 0 1.993423950352735e-07
is O 0 9.617127005867587e-08
a O 0 1.528453594801249e-07
novel O 0 2.4624748107271444e-07
mutation O 0 5.3688832934994934e-08
, O 0 6.976027577820787e-08
while O 0 7.560039705367672e-08
the O 0 4.392406367514923e-07
second O 0 1.5793257261975668e-06
, O 0 1.2021502016068553e-07
1936delG O 0 8.18343664832355e-07
in O 0 1.890554358396912e-06
exon O 0 2.4050057163549354e-06
12 O 0 3.543175125741982e-06
, O 0 2.595925820969569e-07
has O 0 2.3702831697391957e-07
been O 0 4.6118938712425006e-07
described O 0 3.2605353794679104e-07
before O 0 6.86500584379246e-07
to O 0 3.174530718297319e-07
cause O 0 7.939771421661135e-06
C6D B-Disease 0 0.00027396579389460385
in O 0 2.5507663394819247e-06
an O 0 1.222344735651859e-06
unrelated O 0 2.263205715280492e-06
African O 0 2.5170973003696417e-06
- O 0 3.754019871848868e-06
American O 0 5.39194161319756e-07
individual O 0 1.9210209245557053e-07
. O 0 2.832815198416938e-06

Both O 0 6.342488177324412e-06
mutations O 0 2.483289790689014e-06
result O 0 9.53950802795589e-07
in O 0 6.37156688299001e-07
premature O 0 7.1263402787735686e-06
termination O 0 2.701385483305785e-06
codons O 0 1.7143547665909864e-06
and O 0 2.637718807818601e-07
C6 O 0 0.00010352160461479798
null O 0 2.9781065677525476e-05
alleles O 0 2.7285536816634703e-06
. O 0 1.394109176544589e-06

Allele O 0 0.00037486242945306003
- O 0 4.512326995609328e-05
specific O 0 1.0514725090615684e-06
PCR O 0 1.1839085345854983e-05
indicated O 0 4.007183633802924e-06
that O 0 3.2691036722098943e-07
the O 0 2.3684151528868824e-06
probands O 0 5.4883308621356264e-05
two O 0 2.8576102977240225e-06
brothers O 0 5.143569069332443e-05
also O 0 1.767671164998319e-06
inherited O 0 4.314522084314376e-05
the O 0 1.4378183550434187e-05
1195delC O 0 9.225995199813042e-06
mutation O 0 4.649515119581338e-07
from O 0 6.493486921499425e-07
their O 0 5.386679546859341e-08
heterozygous O 0 2.8271372798371885e-07
mother O 0 8.10298956821498e-07
and O 0 1.4951743310120946e-07
the O 0 6.75267244787392e-07
1936delG O 0 2.497811465218547e-06
mutation O 0 1.7382046735292533e-07
from O 0 3.935585937142605e-07
their O 0 7.422232783937943e-08
homozygous O 0 3.4372696973150596e-06
father O 0 8.78010814631125e-06
. O 0 2.1454135890053294e-07
. O 0 6.656578079855535e-07

PAX6 O 0 0.015518714673817158
mutations O 0 0.00015210175479296595
reviewed O 0 0.00015019543934613466
. O 0 1.8135317077394575e-05

Mutations O 0 0.00016232386406045407
in O 0 5.8518224250292405e-05
PAX6 O 0 0.002021552063524723
are O 0 1.245954081241507e-06
responsible O 0 2.0932950519636506e-06
for O 0 2.0346735709608765e-06
human O 0 0.00020434570615179837
aniridia B-Disease 1 1.0
and O 0 2.0592253349605016e-05
have O 0 1.4539473340846598e-06
also O 0 2.615512642023532e-07
been O 0 1.5570991251934174e-07
found O 0 2.7414721159857436e-08
in O 0 7.532576518087808e-08
patients O 0 1.6505401845279266e-07
with O 0 5.224216579335916e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.922855391167104e-06
with O 0 0.03709348663687706
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.00016432358825113624
with O 0 2.0271279481676174e-06
autosomal B-Disease 1 0.9997836947441101
dominant I-Disease 1 0.9982119798660278
keratitis I-Disease 1 0.999998927116394
, O 0 5.021761353418697e-07
and O 0 7.548267433321598e-08
with O 0 4.738447785257449e-07
isolated B-Disease 1 0.8272649645805359
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.00011350312706781551

No O 0 8.783203520579264e-05
locus O 0 9.121018229052424e-05
other O 0 1.06430320556683e-06
than O 0 6.967171088945179e-07
chromosome O 0 1.4059176464797929e-05
11p13 O 0 4.340811574365944e-05
has O 0 2.347734834984294e-06
been O 0 3.896829639415955e-06
implicated O 0 1.0111034498549998e-05
in O 0 1.2605622941919137e-05
aniridia B-Disease 1 0.9999994039535522
, O 0 1.7625638975005131e-06
and O 0 1.9264602997282054e-06
PAX6 O 0 0.0007366226054728031
is O 0 2.7803191642306047e-06
clearly O 0 1.6654839782859199e-06
the O 0 1.852587956818752e-06
major O 0 5.265604613668984e-06
, O 0 1.2682579608735978e-07
if O 0 1.260155624294157e-08
not O 0 2.023834255737711e-08
only O 0 3.05017735513502e-08
, O 0 7.768959164877742e-08
gene O 0 3.505377321744163e-07
responsible O 0 2.215713720943313e-06
. O 0 3.1139750262809685e-06

Twenty O 0 0.0003716020146384835
- O 0 4.573344995151274e-05
eight O 0 4.037457529193489e-06
percent O 0 5.135055744176498e-06
of O 0 1.8552046867625904e-06
identified O 0 1.350237994302006e-06
PAX6 O 0 5.5293639888986945e-05
mutations O 0 6.771005587324908e-07
are O 0 5.465530534820573e-07
C O 0 2.357490848226007e-05
- O 0 7.956842637213413e-06
T O 0 7.386076049442636e-06
changes O 0 3.313444949526456e-07
at O 0 6.9749357862747274e-06
CpG O 0 5.890005013498012e-06
dinucleotides O 0 3.475605581115815e-06
, O 0 9.68782387644751e-08
20 O 0 1.4009582116614183e-07
% O 0 3.7775894412561684e-08
are O 0 1.5375741568846024e-08
splicing O 0 1.7967704479815438e-07
errors O 0 4.420858658704674e-06
, O 0 2.377006467213505e-07
and O 0 5.276067582826727e-08
more O 0 9.212675067260534e-09
than O 0 2.2933265952929105e-08
30 O 0 1.7066344071281492e-07
% O 0 3.219596322878715e-08
are O 0 8.416233043817556e-09
deletion O 0 4.410304370594531e-07
or O 0 1.8364525544711796e-07
insertion O 0 1.82974474682851e-06
events O 0 1.5450200407940429e-06
. O 0 2.0458403469092445e-06

There O 0 5.300517295836471e-05
is O 0 3.6337742130854167e-06
a O 0 3.0772500849707285e-06
noticeably O 0 3.262856262153946e-05
elevated O 0 0.00030866864835843444
level O 0 8.46463990455959e-06
of O 0 3.360093160154065e-06
mutation O 0 1.9383917049253796e-07
in O 0 8.066596706157725e-07
the O 0 6.08653294875694e-07
paired O 0 2.9208277396719495e-07
domain O 0 3.6379066159497597e-07
compared O 0 1.7951622055534244e-07
with O 0 1.184258380249048e-08
the O 0 3.4510216551097983e-07
rest O 0 2.1414744821868226e-07
of O 0 1.119843886954186e-06
the O 0 2.60865226664464e-06
gene O 0 2.475359451636905e-06
. O 0 2.163181989089935e-06

Increased O 0 7.538330100942403e-05
mutation O 0 5.927285201323684e-06
in O 0 4.141563749726629e-06
the O 0 1.7361797972625936e-06
homeodomain O 0 7.478244697267655e-06
is O 0 1.8053948735996528e-07
accounted O 0 5.042290922574466e-07
for O 0 6.395619323029678e-08
by O 0 1.5711789558281453e-07
the O 0 1.7507599068267155e-06
hypermutable O 0 2.4992266844492406e-05
CpG O 0 2.705374026845675e-05
dinucleotide O 0 1.5744830307085067e-05
in O 0 2.4660546387167415e-06
codon O 0 8.780878488323651e-06
240 O 0 4.651692961488152e-06
. O 0 7.042243055366271e-07

Very O 0 1.5887122572166845e-05
nearly O 0 2.930240270870854e-06
all O 0 1.3710680946132925e-07
mutations O 0 1.3695286327219947e-07
appear O 0 2.990799998769944e-07
to O 0 1.1527804133493191e-07
cause O 0 9.25635674775549e-07
loss O 0 1.1239589184697252e-05
of O 0 1.0221812772215344e-05
function O 0 6.40552298136754e-06
of O 0 2.4509841750841588e-05
the O 0 8.668867849337403e-06
mutant O 0 3.089229267061455e-06
allele O 0 5.018132469558623e-07
, O 0 5.4541690275300425e-08
and O 0 1.868088794765299e-08
more O 0 3.275083537701562e-09
than O 0 6.7862666597307e-09
80 O 0 1.0144930939759433e-07
% O 0 4.777087525553725e-08
of O 0 2.3889305111879366e-07
exonic O 0 3.5884027056454215e-06
substitutions O 0 3.248694042667921e-07
result O 0 2.5401141101610847e-07
in O 0 6.580312970072555e-07
nonsense O 0 9.312544534623157e-06
codons O 0 1.2261471965757664e-05
. O 0 1.7513276588942972e-06

In O 0 6.316019425867125e-05
a O 0 9.704274816613179e-06
gene O 0 1.2003152960460284e-06
with O 0 1.2006273664155742e-07
such O 0 1.9828685537959245e-07
extraordinarily O 0 6.935087185411248e-06
high O 0 7.57004681872786e-06
sequence O 0 6.443974598369095e-08
conservation O 0 9.065905715033296e-08
throughout O 0 2.5432161265825926e-08
evolution O 0 1.292902283012154e-07
, O 0 1.3996889869360984e-08
there O 0 1.925293879878609e-08
are O 0 2.237814378247549e-08
presumed O 0 2.1475559606187744e-06
undiscovered O 0 1.576195609231945e-05
missense O 0 3.1493595997744706e-06
mutations O 0 3.8128789014990616e-07
, O 0 1.250361378879461e-07
these O 0 1.9702179443470413e-08
are O 0 5.023638749435122e-08
hypothesized O 0 4.9408515678806e-07
to O 0 5.4885237688040434e-08
exist O 0 1.6228261756623397e-07
in O 0 1.1953779903706163e-06
as O 0 2.1473142624017783e-06
- O 0 3.3195599371538265e-06
yet O 0 1.8431093451454217e-07
unidentified O 0 2.0573779693222605e-06
phenotypes O 0 1.3073508853267413e-06
. O 0 1.4711348228502175e-07
. O 0 7.145921472329064e-07

Genetic O 0 3.069560625590384e-05
heterogeneity O 0 6.0598158597713336e-05
and O 0 1.990286818909226e-06
penetrance O 0 6.919081351952627e-05
analysis O 0 3.265511168137891e-07
of O 0 2.4492869670211803e-06
the O 0 3.6364431252877694e-06
BRCA1 O 0 7.642702257726341e-06
and O 0 1.1868020237670862e-06
BRCA2 O 0 7.4658955782069825e-06
genes O 0 8.553697057323006e-07
in O 0 7.871706657169852e-06
breast B-Disease 1 0.9875489473342896
cancer I-Disease 0 0.3175975978374481
families O 0 9.72655470832251e-07
. O 0 2.239592276964686e-06

The O 0 0.003758123144507408
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.024278786033391953
Consortium O 0 7.594768976559862e-05
. O 0 3.324261342640966e-06

The O 0 8.811279258225113e-06
contribution O 0 4.887192972091725e-06
of O 0 8.46458351588808e-06
BRCA1 O 0 2.0171086362097412e-05
and O 0 2.468546426825924e-06
BRCA2 O 0 0.00015103300393093377
to O 0 5.5540593166369945e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.9999861717224121
assessed O 0 8.76366175361909e-06
by O 0 1.0346364121005536e-07
linkage O 0 2.092752083626692e-06
and O 0 9.233419007159682e-08
mutation O 0 6.678229880208164e-08
analysis O 0 6.654147455265047e-08
in O 0 1.2985208286409033e-07
237 O 0 7.952843361636042e-07
families O 0 3.70462274190686e-08
, O 0 2.4641140683456797e-08
each O 0 4.054313773593776e-09
with O 0 1.720648867831187e-08
at O 0 2.302194161529769e-06
least O 0 2.6536719488490235e-08
four O 0 5.2148383389294395e-08
cases O 0 4.2673956812677716e-08
of O 0 5.0104576075682417e-05
breast B-Disease 1 0.9999982118606567
cancer I-Disease 1 0.5356177687644958
, O 0 6.034716193425993e-08
collected O 0 6.402687091622283e-08
by O 0 5.667480706961214e-08
the O 0 1.0841602488653734e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0006777268717996776
Consortium O 0 2.9172662834753282e-05
. O 0 1.8486206272427808e-06

Families O 0 5.645585588354152e-06
were O 0 3.402197762625292e-06
included O 0 3.909348720299022e-07
without O 0 1.010958285974084e-07
regard O 0 1.8289337333499134e-07
to O 0 4.944735820799906e-08
the O 0 2.996063983573549e-07
occurrence O 0 4.126349722355371e-06
of O 0 0.01499619148671627
ovarian B-Disease 1 1.0
or I-Disease 0 0.0018964560003951192
other I-Disease 0 3.4764939300657716e-06
cancers I-Disease 1 0.9991437196731567
. O 0 1.2962697837792803e-05

Overall O 0 0.00905799400061369
, O 0 9.224230598192662e-05
disease O 0 0.011846404522657394
was O 0 0.0005020743701606989
linked O 0 1.0717043551267125e-05
to O 0 2.484781873590691e-07
BRCA1 O 0 8.927044063966605e-07
in O 0 6.104443173171603e-07
an O 0 1.4705457829222723e-07
estimated O 0 1.945041248063717e-07
52 O 0 7.895463340901188e-07
% O 0 1.1266315880220645e-07
of O 0 2.108168473569094e-06
families O 0 1.8014890201811795e-07
, O 0 1.4178223750604957e-07
to O 0 1.791030825870621e-07
BRCA2 O 0 8.002845106602763e-07
in O 0 8.795519192972279e-07
32 O 0 1.4826861161054694e-06
% O 0 2.2693083678859693e-07
of O 0 1.7148289543911233e-06
families O 0 1.052630764775131e-07
, O 0 4.8831399368509665e-08
and O 0 3.35195231571106e-08
to O 0 2.671619370175904e-08
neither O 0 5.064855557179726e-08
gene O 0 3.4098395218506994e-08
in O 0 1.3930723241628584e-07
16 O 0 2.485018910647341e-07
% O 0 2.8804127083503772e-08
( O 0 1.1122234688798471e-08
95 O 0 1.3468785198256228e-07
% O 0 4.925157526258772e-08
confidence O 0 5.075600029158522e-07
interval O 0 1.937115939654177e-06
[ O 0 1.5074531347636366e-06
CI O 0 9.101095929509029e-05
] O 0 5.633230557577917e-07
6 O 0 3.2019656259762996e-07
% O 0 3.8137944358140885e-08
- O 0 7.963122072851547e-08
28 O 0 4.6350956495189166e-07
% O 0 5.3915414355287794e-08
) O 0 1.967195117913434e-08
, O 0 1.0274855632985691e-08
suggesting O 0 6.448387779300901e-08
other O 0 3.109073531959439e-08
predisposition O 0 1.1055588402086869e-05
genes O 0 2.0095426407351624e-06
. O 0 2.1769503746327246e-06

The O 0 5.362135561881587e-05
majority O 0 7.902612537691311e-07
( O 0 4.489524769724085e-07
81 O 0 3.111460728177917e-06
% O 0 2.0602355732535216e-07
) O 0 2.3142998628600253e-08
of O 0 1.2374694051686674e-06
the O 0 0.0010616411454975605
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 7.064454052851943e-07
were O 0 2.7641472115647048e-06
due O 0 1.028800215863157e-05
to O 0 4.503375805597898e-07
BRCA1 O 0 1.7667576912572258e-06
, O 0 1.8237241761198675e-07
with O 0 2.4485968808107827e-08
most O 0 4.3924060832978284e-08
others O 0 3.1884841433793554e-08
( O 0 2.5420133553666346e-08
14 O 0 2.8032323484694643e-07
% O 0 1.1048047809936179e-07
) O 0 4.222685845434171e-08
due O 0 9.465604762226576e-07
to O 0 1.747417059050349e-06
BRCA2 O 0 4.597513179760426e-05
. O 0 6.679466423520353e-06

Conversely O 0 0.0007129162549972534
, O 0 9.577616765454877e-06
the O 0 1.4458349824053585e-06
majority O 0 1.1622616824524812e-07
of O 0 2.3961870283528697e-06
families O 0 1.2426961859546282e-07
with O 0 1.3092270023662422e-07
male B-Disease 0 3.559095421223901e-05
and I-Disease 0 2.434210546198301e-05
female I-Disease 1 0.8161807656288147
breast I-Disease 1 0.999995231628418
cancer I-Disease 1 0.9997609257698059
were O 0 3.105632640654221e-05
due O 0 1.559119664307218e-05
to O 0 1.824444382236834e-07
BRCA2 O 0 4.96303869113035e-07
( O 0 6.247131523196003e-08
76 O 0 1.4836055015621241e-06
% O 0 1.9635258752259688e-07
) O 0 2.565383852015657e-07
. O 0 5.71597979615035e-07

The O 0 3.678286520880647e-05
largest O 0 7.1602657953917515e-06
proportion O 0 1.27685427742108e-06
( O 0 1.842025199039199e-07
67 O 0 1.8947853277495597e-06
% O 0 1.819003045966383e-07
) O 0 4.3425913531791593e-08
of O 0 9.47370551784843e-07
families O 0 8.789592698121851e-08
due O 0 1.2020968824799638e-05
to O 0 4.4356127659739286e-07
other O 0 1.3528102726922953e-07
genes O 0 5.091482080388232e-07
was O 0 3.2947373256320134e-05
found O 0 1.6166242744475312e-07
in O 0 1.0618664703088143e-07
families O 0 1.9535699280481822e-08
with O 0 1.938577831595012e-08
four O 0 2.1125809723798739e-07
or O 0 1.0557494078966556e-07
five O 0 6.474812153101084e-08
cases O 0 4.5284750171958876e-08
of O 0 5.830291229358409e-06
female O 0 0.0016824898775666952
breast B-Disease 1 0.9998726844787598
cancer I-Disease 0 0.2059677690267563
only O 0 1.0296473647031235e-06
. O 0 1.6772789876995375e-06

These O 0 1.8941831513075158e-05
estimates O 0 1.1447207725723274e-05
were O 0 2.544214112276677e-06
not O 0 2.3066986898356845e-07
substantially O 0 1.7612599094718462e-06
affected O 0 2.2497704321722267e-07
either O 0 3.900864342654131e-08
by O 0 5.820557902325163e-08
changing O 0 1.1287523449254877e-07
the O 0 2.8910253035974165e-07
assumed O 0 1.9252040601713816e-06
penetrance O 0 8.541488568880595e-06
model O 0 5.032395051784988e-07
for O 0 4.0654865074429836e-07
BRCA1 O 0 2.014016672546859e-06
or O 0 1.7125297802067507e-07
by O 0 3.9801015816465224e-08
including O 0 7.269974844348326e-08
or O 0 2.8225952064531157e-07
excluding O 0 2.329804829059867e-06
BRCA1 O 0 4.014593287138268e-06
mutation O 0 1.0074624015032896e-06
data O 0 1.826853804232087e-06
. O 0 6.469947493314976e-07

Among O 0 1.0384633242210839e-05
those O 0 9.314659905612643e-07
families O 0 2.113356885047324e-07
with O 0 3.7918502471256943e-07
disease O 0 0.07683170586824417
due O 0 0.003912853542715311
to O 0 1.4530380667565623e-06
BRCA1 O 0 8.986196007754188e-06
that O 0 6.075346163925133e-07
were O 0 2.2967335553403245e-06
tested O 0 1.6966087912351213e-07
by O 0 5.750113629687803e-08
one O 0 5.487613208288167e-08
of O 0 3.034414817193465e-07
the O 0 2.099323666016062e-07
standard O 0 1.192955352280478e-07
screening O 0 3.2633497681899826e-08
methods O 0 1.4950573756777885e-07
, O 0 4.5809027682253145e-08
mutations O 0 4.0775809395654505e-08
were O 0 3.69068374084236e-07
detected O 0 3.6753274912371126e-07
in O 0 1.7307759492268815e-07
the O 0 3.4640098078853043e-07
coding O 0 5.415988653112436e-07
sequence O 0 2.425662160021602e-07
or O 0 2.9006386625951563e-07
splice O 0 5.819858301947534e-07
sites O 0 9.310399917694667e-08
in O 0 5.427540372693329e-08
an O 0 4.308813572606596e-08
estimated O 0 1.743633788464649e-07
63 O 0 5.897576329516596e-07
% O 0 8.805164242176033e-08
( O 0 2.9005464696751915e-08
95 O 0 7.090737312864803e-07
% O 0 3.536177075602609e-07
CI O 0 0.00010929743439191952
51 O 0 1.2204925496916985e-06
% O 0 1.2984378372493666e-07
- O 0 1.042445433085959e-06
77 O 0 1.94403764908202e-06
% O 0 2.655581283761421e-07
) O 0 2.0442494985672965e-07
. O 0 6.968147658881207e-07

The O 0 6.499339360743761e-05
estimated O 0 6.9638967943319585e-06
sensitivity O 0 3.625027375164791e-06
was O 0 5.474291356222238e-06
identical O 0 8.479609903133678e-08
for O 0 2.7821382531101335e-08
direct O 0 1.6974308891803958e-07
sequencing O 0 4.3592058318608906e-07
and O 0 1.5570738298720244e-07
other O 0 6.657168682977499e-08
techniques O 0 4.155469923716737e-06
. O 0 3.7946715565340128e-06

The O 0 0.00016564439283683896
penetrance O 0 0.00046632500016130507
of O 0 5.6197990488726646e-05
BRCA2 O 0 2.443175981170498e-05
was O 0 1.7936728909262456e-05
estimated O 0 5.294960487844946e-07
by O 0 1.4495168443318107e-07
maximizing O 0 1.7448427342969808e-06
the O 0 2.6044660899060545e-06
LOD O 0 0.00017992244102060795
score O 0 1.6328374385921052e-06
in O 0 2.408218961136299e-06
BRCA2 O 0 9.963928278011736e-06
- O 0 7.2907105277408846e-06
mutation O 0 1.0086642987516825e-07
families O 0 1.8176065097463834e-08
, O 0 1.0482466450412176e-08
over O 0 1.676550809293076e-08
all O 0 1.556939643876376e-08
possible O 0 2.0417613200152118e-07
penetrance O 0 5.220574530540034e-05
functions O 0 4.681819063989678e-06
. O 0 2.126036861227476e-06

The O 0 8.481949407723732e-06
estimated O 0 1.8491778064344544e-06
cumulative O 0 1.1309475667076185e-05
risk O 0 2.1055082015664084e-06
of O 0 8.442397302133031e-06
breast B-Disease 0 0.1478610634803772
cancer I-Disease 0 0.02649236097931862
reached O 0 0.00011479537351988256
28 O 0 3.160208507324569e-06
% O 0 4.6120252505943427e-08
( O 0 9.190912031442622e-09
95 O 0 1.2492029100030777e-07
% O 0 6.739753644069424e-08
CI O 0 2.1696074327337556e-05
9 O 0 1.2178974202470272e-06
% O 0 6.120730233760696e-08
- O 0 9.964150393670934e-08
44 O 0 2.1537037753205368e-07
% O 0 3.807739901162677e-08
) O 0 6.04237326840007e-09
by O 0 1.535265070629066e-08
age O 0 1.341212936267766e-07
50 O 0 1.4780157187033183e-07
years O 0 5.737668473670965e-08
and O 0 2.3103746471520026e-08
84 O 0 3.9991184053178586e-07
% O 0 2.35156996097885e-08
( O 0 5.973617600574244e-09
95 O 0 1.0543306672161634e-07
% O 0 7.448768002404904e-08
CI O 0 1.868712206487544e-05
43 O 0 5.742002713304828e-07
% O 0 4.7449233875340724e-08
- O 0 1.3031321088874392e-07
95 O 0 2.728041295085859e-07
% O 0 4.0501188180996905e-08
) O 0 8.552047958687581e-09
by O 0 2.0809331147120247e-08
age O 0 3.8365732279999065e-07
70 O 0 1.0770665994641604e-06
years O 0 1.2012566230623634e-06
. O 0 1.3667146276929998e-06

The O 0 0.00023078448430169374
corresponding O 1 0.9999915361404419
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 3.101927359239198e-05
were O 0 2.281069555465365e-06
0 O 0 1.2509905218394124e-06
. O 0 2.1110363945808786e-07

4 O 0 2.119175587722566e-05
% O 0 9.719153695186833e-07
( O 0 1.2294664486489637e-07
95 O 0 9.616353509045439e-07
% O 0 2.7506442279445764e-07
CI O 0 2.9043056201771833e-05
0 O 0 2.2974734292802168e-07
% O 0 2.800912213274387e-08
- O 0 5.379564171903439e-08
1 O 0 1.0636827596499643e-07
% O 0 2.722935654730918e-08
) O 0 5.48255751908755e-09
by O 0 1.5394670427326673e-08
age O 0 9.625495067666634e-08
50 O 0 9.689690472214352e-08
years O 0 1.0647829640220152e-07
and O 0 3.576822393824841e-08
27 O 0 3.253294948990515e-07
% O 0 2.8305574772957698e-08
( O 0 6.247522499336355e-09
95 O 0 6.420602005619003e-08
% O 0 4.8594657187095436e-08
CI O 0 6.1597802414326e-06
0 O 0 1.1219075446433635e-07
% O 0 2.8874644897314283e-08
- O 0 5.181732021242169e-08
47 O 0 1.6961169535534282e-07
% O 0 2.2659557785686957e-08
) O 0 8.644344795527559e-09
by O 0 1.5471616876538974e-08
age O 0 1.989655658007905e-07
70 O 0 3.9959351738616533e-07
years O 0 1.1485516324682976e-06
. O 0 3.275088715781749e-07

The O 0 1.5896730474196374e-05
lifetime O 0 5.2000541472807527e-05
risk O 0 2.3211458028526977e-05
of O 0 8.762675133766606e-05
breast B-Disease 1 0.9999927282333374
cancer I-Disease 1 0.999263346195221
appears O 0 4.652953521144809e-06
similar O 0 9.144943646788306e-08
to O 0 1.0273761574808304e-07
the O 0 1.6076271549536614e-06
risk O 0 1.6632046708764392e-06
in O 0 2.0637294255720917e-06
BRCA1 O 0 3.6628812267736066e-06
carriers O 0 5.70138411148946e-07
, O 0 1.288429274381997e-07
but O 0 1.4022274896774434e-08
there O 0 2.5418387394893216e-08
was O 0 9.557875273458194e-07
some O 0 1.783528880139329e-08
suggestion O 0 1.9028095721296268e-07
of O 0 1.7427440752726397e-06
a O 0 2.0943334675394e-06
lower O 0 1.3590898561233189e-05
risk O 0 5.315689008966729e-07
in O 0 4.5419173488880915e-07
BRCA2 O 0 5.521461616808665e-07
carriers O 0 1.0188484367290584e-07
< O 0 1.2254587318238919e-06
50 O 0 3.278623239566514e-07
years O 0 1.6567962290992e-07
of O 0 7.270182322827168e-07
age O 0 7.650738552911207e-06
. O 0 1.3557942111219745e-06

Eye B-Disease 1 0.99993896484375
movement I-Disease 0 0.12276293337345123
abnormalities I-Disease 1 0.9995002746582031
correlate O 0 5.41736062587006e-06
with O 0 2.0128018718423846e-07
genotype O 0 1.1978421753155999e-05
in O 0 4.247308424965013e-06
autosomal O 0 0.4762277603149414
dominant O 0 0.025313057005405426
cerebellar B-Disease 1 0.9999998807907104
ataxia I-Disease 1 1.0
type I-Disease 1 0.9999996423721313
I I-Disease 1 0.9999401569366455
. O 0 1.970321318367496e-05

We O 0 5.702699490939267e-05
compared O 0 8.968644397100434e-05
horizontal O 0 0.00040280402754433453
eye O 0 0.0003885810438077897
movements O 0 0.00010006420052377507
( O 0 1.6799394870758988e-06
visually O 0 5.48512161913095e-07
guided O 0 2.1401262983999914e-06
saccades O 0 7.377170732070226e-06
, O 0 3.4119219094463915e-07
antisaccades O 0 1.6213703020184767e-06
, O 0 6.975801625230815e-08
and O 0 5.97270854996168e-08
smooth O 0 1.0398707672720775e-06
pursuit O 0 1.5559027133349446e-06
) O 0 2.5748933651925654e-08
in O 0 5.697307869922952e-08
control O 0 3.0455097999038117e-07
subjects O 0 4.6773692474744166e-07
( O 0 7.297510506987237e-08
n O 0 5.447753892440232e-07
= O 0 5.753453251600149e-07
14 O 0 7.618053814439918e-07
) O 0 4.91560392390511e-08
and O 0 2.0559912883300058e-08
patients O 0 2.7314404960065986e-08
with O 0 6.7490133481840076e-09
three O 0 6.906561367259201e-08
forms O 0 2.143908233165348e-07
of O 0 5.5148771934909746e-05
autosomal O 0 0.0007620922988280654
dominant O 0 0.0002592274686321616
cerebellar B-Disease 1 0.921509325504303
ataxias I-Disease 0 0.00048452222836203873
type I-Disease 0 3.176012251060456e-05
I I-Disease 0 3.1254090572474524e-05
spinocerebellar B-Disease 0 0.00014140192070044577
ataxias I-Disease 0 1.9070283087785356e-05
1 I-Disease 0 2.047575435426552e-06
and I-Disease 0 1.2363624080080626e-07
2 I-Disease 0 4.425754696057993e-07
( O 0 2.4877639503984028e-08
SCA1 B-Disease 0 1.6929378716667998e-06
, O 0 4.3543934680201346e-08
n O 0 2.9259325629027444e-07
= O 0 3.511229067498789e-07
11 O 0 6.11760242463788e-07
; O 0 4.162018996112238e-08
SCA2 B-Disease 0 2.712602508836426e-06
, O 0 7.382277544820681e-08
n O 0 4.0911055521064554e-07
= O 0 4.057650357935927e-07
10 O 0 1.8257306066971069e-07
) O 0 4.0793313615949955e-08
and O 0 6.54255586596264e-07
SCA3 B-Disease 1 0.9999110698699951
/ O 0 2.398189462837763e-05
Machado B-Disease 0 1.78775007952936e-05
- I-Disease 0 2.1479356291820295e-05
Joseph I-Disease 0 0.0002086408348986879
disease I-Disease 0 3.919481241609901e-05
( O 0 6.954405762371607e-07
MJD B-Disease 1 0.9801023602485657
) O 0 9.902743869361075e-08
( O 0 5.281625448105842e-08
n O 0 5.99819600211049e-07
= O 0 8.897704333321599e-07
16 O 0 8.808067946119991e-07
) O 0 2.600096138394292e-07
. O 0 7.710808063166041e-07

In O 0 0.00013010523980483413
SCA1 B-Disease 0 0.0007065560785122216
, O 0 1.5939242530293996e-06
saccade O 0 2.479470640537329e-05
amplitude O 0 1.5265659385477193e-05
was O 0 4.9795739869296085e-06
significantly O 0 2.5168543515974307e-07
increased O 0 2.0676422707310849e-07
, O 0 3.243702906274848e-08
resulting O 0 1.472999286988852e-07
in O 0 7.789284381942707e-07
hypermetria B-Disease 0 5.361542571336031e-05
. O 0 2.14234182749351e-06

The O 0 9.575206786394119e-05
smooth O 0 6.439183925976977e-05
pursuit O 0 5.471331314765848e-05
gain O 0 2.6713636543718167e-05
was O 0 0.00013772449165116996
decreased O 0 0.0005615025293081999
. O 0 3.913977252523182e-06

In O 0 0.00016404432244598866
SCA2 B-Disease 0 0.0010340757435187697
, O 0 2.989681433973601e-06
saccade O 0 4.545847332337871e-05
velocity O 0 1.827880805649329e-05
was O 0 2.411921195744071e-05
markedly O 0 4.010688644484617e-05
decreased O 0 0.00018857976829167455
. O 0 2.827427806550986e-06

The O 0 2.641030187078286e-05
percentage O 0 1.8280830772710033e-05
of O 0 1.2219704331073444e-05
errors O 0 7.329501386266202e-05
in O 0 1.9384709958103485e-05
antisaccades O 0 0.0005067245219834149
was O 0 0.00011500617256388068
greatly O 0 9.50425658174936e-07
increased O 0 1.7947890000868938e-06
and O 0 1.439179158069237e-07
was O 0 6.531932399411744e-07
significantly O 0 6.665707275033128e-08
correlated O 0 8.746079060983902e-08
with O 0 1.9650613580779464e-08
age O 0 2.329655899302452e-06
at O 0 6.806857709307224e-05
disease O 0 8.795817848294973e-05
onset O 0 0.0007197746890597045
. O 0 2.2801125396654243e-06

In O 0 2.3336417143582366e-05
addition O 0 1.5411790172947804e-06
, O 0 1.303824461729164e-07
a O 0 1.1208702233034273e-07
correlation O 0 4.849637207371416e-07
between O 0 1.097669155569747e-06
smooth O 0 9.161525667877868e-06
pursuit O 0 9.968975064111874e-06
gain O 0 2.5941390049410984e-06
and O 0 1.3708641688481293e-07
the O 0 2.6312392265026574e-07
number O 0 1.452634705856326e-07
of O 0 2.797084789563087e-06
trinucleotide O 0 5.063669595983811e-05
repeats O 0 4.6505933823937085e-06
was O 0 1.8196054952568375e-05
found O 0 1.2879897894890746e-06
. O 0 6.043078997208795e-07

In O 0 0.0030030319467186928
SCA3 B-Disease 1 1.0
, O 0 0.00019622717809397727
gaze B-Disease 0 0.011126581579446793
- I-Disease 0 0.0004837731830775738
evoked I-Disease 0 0.00010524092795094475
nystagmus I-Disease 0 0.00014923638082109392
was O 0 2.3867813069955446e-05
often O 0 6.637023375333229e-08
present O 0 1.0856865628738888e-07
as O 0 3.631577101259609e-07
was O 0 4.320385869505117e-06
saccade O 0 9.693821994005702e-06
hypometria O 0 1.3953374036645982e-05
and O 0 3.915870934179111e-07
smooth O 0 6.01156716584228e-06
pursuit O 0 1.6617965229670517e-05
gain O 0 1.689361670287326e-05
was O 0 4.469449777388945e-05
markedly O 0 2.1602505512419157e-05
decreased O 0 4.684871237259358e-05
. O 0 1.1908120995940408e-06

Three O 0 4.712009831564501e-05
major O 0 3.1748855690239e-05
criteria O 0 5.831102953379741e-06
, O 0 6.084554229346395e-07
saccade O 0 1.1493819329189137e-05
amplitude O 0 1.1042375263059512e-05
, O 0 6.491976023426105e-07
saccade O 0 6.9298835114750545e-06
velocity O 0 1.3990868865221273e-05
, O 0 4.3303998609189875e-07
and O 0 3.247328095312696e-07
presence O 0 1.4885458767821547e-06
of O 0 0.00010539268259890378
gaze B-Disease 0 0.07037059217691422
- I-Disease 0 8.679834718350321e-05
evoked I-Disease 0 1.788848385331221e-05
nystagmus I-Disease 0 8.630329830339178e-06
, O 0 7.67206529417308e-08
permitted O 0 1.5033370459605067e-07
the O 0 3.585682293305581e-07
correct O 0 4.0800713918542897e-07
assignment O 0 8.159410640473652e-07
of O 0 2.4850050976965576e-06
90 O 0 1.5413877463288372e-06
% O 0 2.1985663067880523e-07
of O 0 1.590001147633302e-06
the O 0 5.0120288506150246e-06
SCA1 B-Disease 0 2.274129838042427e-05
, O 0 1.9953543528572482e-07
90 O 0 3.3251984632443055e-07
% O 0 4.621994520448425e-08
of O 0 1.0621080264172633e-06
the O 0 3.1744900752528338e-06
SCA2 B-Disease 0 1.957718086487148e-05
, O 0 1.151328987702982e-07
and O 0 5.055107976659201e-08
93 O 0 1.2356509841993102e-06
% O 0 5.129144753368564e-08
of O 0 8.831164564071514e-07
the O 0 2.482027866790304e-06
patients O 0 9.854664995145868e-07
with O 0 2.2063159121898934e-06
SCA3 B-Disease 1 1.0
to O 0 1.4811512301093899e-06
their O 0 6.360414204209519e-07
genetically O 0 5.404709213507886e-07
confirmed O 0 2.9423931664496195e-06
patient O 0 3.993693553638877e-06
group O 0 3.543594004895567e-07
and O 0 2.41802638356603e-07
, O 0 1.50853026070763e-07
therefore O 0 1.9019296360056615e-07
, O 0 1.3725083647386782e-07
may O 0 3.4024793649223284e-07
help O 0 1.0766255797989288e-07
orient O 0 2.5970204660552554e-05
diagnoses O 0 8.31251782074105e-06
of O 0 0.00015223538503050804
SCA1 B-Disease 0 0.1608934998512268
, O 0 5.5052960306056775e-06
SCA2 B-Disease 0 0.00011946260201511905
, O 0 4.460972604647395e-07
and O 0 8.602568186688586e-07
SCA3 B-Disease 1 0.9999998807907104
at O 0 8.961693310993724e-06
early O 0 3.6523539392874227e-07
clinical O 0 8.601534773333697e-07
stages O 0 2.6538546080701053e-06
of O 0 1.3947892512078397e-05
the O 0 4.535693005891517e-05
diseases O 1 0.6861504316329956
. O 0 9.460875389777357e-07
. O 0 1.891788087959867e-06

Genetic O 0 1.375391434521589e-06
basis O 0 8.520852929905232e-07
and O 0 8.866813061558787e-08
molecular O 0 1.609433979865571e-06
mechanism O 0 1.396294555888744e-05
for O 0 5.692250852007419e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.00019964764942415059

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 1.0
causes O 0 0.00014604892930947244
more O 0 4.1234758896280255e-07
than O 0 1.3795882125577918e-07
300 O 0 2.949465738311119e-07
, O 0 4.977694700869506e-08
000 O 0 1.8758491933112964e-06
sudden O 0 2.1283210571709787e-06
deaths O 0 7.208681154224905e-07
each O 0 4.136590803227591e-08
year O 0 3.862072048832488e-07
in O 0 2.943068011518335e-07
the O 0 1.2643793070310494e-06
USA O 0 3.197996875314857e-06
alone O 0 1.4483977111012791e-06
. O 0 8.426740123468335e-07

In O 0 3.307184306322597e-05
approximately O 0 3.085578327954863e-06
5 O 0 3.4713320928858593e-06
- O 0 9.315264151155134e-07
12 O 0 3.357468472131586e-07
% O 0 5.291305171795102e-08
of O 0 9.352581997745801e-08
these O 0 7.737973817256716e-09
cases O 0 4.174922807465009e-08
, O 0 2.341647054038276e-08
there O 0 1.6032551286571106e-08
are O 0 8.17809020503546e-09
no O 0 9.482720741971207e-08
demonstrable O 0 0.003363201394677162
cardiac O 1 1.0
or O 0 3.23457716149278e-05
non O 1 0.6186994314193726
- O 1 0.9326579570770264
cardiac O 1 1.0
causes O 0 4.6530244617315475e-06
to O 0 2.507570400211989e-07
account O 0 1.532935129944235e-07
for O 0 1.1458171655931437e-07
the O 0 4.4740525595443614e-07
episode O 0 2.2828490386928024e-07
, O 0 1.343607802795077e-08
which O 0 5.307029482537473e-09
is O 0 3.6149128135321007e-09
therefore O 0 1.3177457347524069e-08
classified O 0 1.2273109462057619e-07
as O 0 8.567841177864466e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 7.901233766460791e-05
IVF B-Disease 1 1.0
) O 0 6.880146088406036e-07
. O 0 8.117282277453342e-07

A O 0 0.00010374474368290976
distinct O 0 4.55484951089602e-06
group O 0 2.4747077986830845e-06
of O 0 7.184649439295754e-05
IVF B-Disease 1 1.0
patients O 0 1.3064974154985975e-05
has O 0 1.4815835811532452e-06
been O 0 4.3397517401899677e-07
found O 0 3.824057870360775e-08
to O 0 5.159608740257227e-09
present O 0 2.1194397348267557e-08
with O 0 2.5604654396715887e-08
a O 0 8.828529303173127e-07
characteristic O 0 1.7428339560865425e-05
electrocardiographic O 0 0.0012082873145118356
pattern O 0 7.612548506585881e-05
. O 0 3.0611513466283213e-06

Because O 0 8.40037246234715e-05
of O 0 4.672244904213585e-05
the O 0 1.007205901260022e-05
small O 0 7.965306849655462e-07
size O 0 4.4384731268110045e-07
of O 0 4.199652266834164e-06
most O 0 2.695358887194743e-07
pedigrees O 0 7.454509045601299e-07
and O 0 1.0893476343198927e-07
the O 0 8.953832661973138e-07
high O 0 0.000105560953670647
incidence O 0 0.0007348319049924612
of O 0 0.0008199312724173069
sudden B-Disease 1 0.9747784733772278
death I-Disease 0 0.0032104034908115864
, O 0 1.14082880031674e-07
however O 0 1.9591707811628112e-08
, O 0 1.0041625309042956e-08
molecular O 0 2.221076016439838e-07
genetic O 0 5.8083919896034786e-08
studies O 0 7.33411752662505e-07
of O 0 1.7503625713288784e-05
IVF B-Disease 1 0.9999979734420776
have O 0 3.8154394133016467e-07
not O 0 5.727204310801426e-08
yet O 0 6.299804766740635e-08
been O 0 4.4541411625687033e-07
done O 0 3.343294849855738e-07
. O 0 1.1231038570258534e-06

Because O 0 0.00021002240828238428
IVF B-Disease 1 1.0
causes O 0 0.0117825111374259
cardiac O 1 1.0
rhythm O 1 0.9873276352882385
disturbance O 0 0.011305655352771282
, O 0 8.248335916505312e-07
we O 0 1.0219274315659277e-07
investigated O 0 3.063845213091554e-07
whether O 0 1.3991409275604383e-07
malfunction O 0 0.00010803183977259323
of O 0 3.0106768917903537e-06
ion O 0 1.0965643923555035e-05
channels O 0 2.7227390546613606e-06
could O 0 8.152612736012088e-07
cause O 0 3.5785467389359837e-06
the O 0 1.3611851272798958e-06
disorder O 0 3.0116618745523738e-06
by O 0 1.498322532711427e-08
studying O 0 3.5565292932915327e-08
mutations O 0 1.682095174260212e-08
in O 0 8.811145590925662e-08
the O 0 6.044808174010541e-07
cardiac O 0 0.00022170516604091972
sodium O 0 4.682234703068389e-06
channel O 0 6.672139079455519e-06
gene O 0 6.153157301014289e-06
SCN5A O 0 0.00023070986208040267
. O 0 3.652960231192992e-06

We O 0 3.7996931496309116e-05
have O 0 2.127703965015826e-06
now O 0 5.662380431203928e-07
identified O 0 3.022835528554424e-07
a O 0 4.224522740514658e-07
missense O 0 3.4245417737110984e-06
mutation O 0 5.387444161897292e-07
, O 0 2.2438564428739483e-07
a O 0 6.020644036652811e-07
splice O 0 4.777306912728818e-06
- O 0 6.6252114265807904e-06
donor O 0 2.0132140434725443e-06
mutation O 0 6.745219707227079e-07
, O 0 1.5512962647790118e-07
and O 0 7.616979758040543e-08
a O 0 4.961102604283951e-07
frameshift O 0 2.4475916688970756e-06
mutation O 0 7.062528339929486e-08
in O 0 3.1754845508658036e-07
the O 0 3.4356435207882896e-07
coding O 0 5.848054911439249e-07
region O 0 2.924250281921559e-07
of O 0 3.5760288028541254e-06
SCN5A O 0 0.00011479569366201758
in O 0 2.0124691673117923e-06
three O 0 4.6389218368858565e-06
IVF B-Disease 1 0.9992639422416687
families O 0 2.292911744916637e-07
. O 0 4.396111137339176e-07

We O 0 9.644186320656445e-06
show O 0 8.954336863098433e-07
that O 0 1.4334877107557986e-07
sodium O 0 2.6474944547771884e-07
channels O 0 9.71374589653351e-08
with O 0 1.959428530540208e-08
the O 0 5.603637305284792e-07
missense O 0 2.7679220693244133e-06
mutation O 0 8.005211498129938e-07
recover O 0 1.8135223172066617e-06
from O 0 1.297372591579915e-06
inactivation O 0 3.9132515667006373e-05
more O 0 4.432990508007606e-08
rapidly O 0 1.9016303554053593e-07
than O 0 2.0186721627624138e-08
normal O 0 1.8033522053428896e-07
and O 0 1.6717354611728297e-08
that O 0 1.4106183776618764e-08
the O 0 1.6214353593113628e-07
frameshift O 0 9.415583122063254e-07
mutation O 0 8.504781590090715e-08
causes O 0 1.3718945979235286e-07
the O 0 2.3679582739077887e-07
sodium O 0 1.9649327498427738e-07
channel O 0 2.81679234603871e-07
to O 0 1.1959740220390813e-07
be O 0 4.395951407332177e-07
non O 0 5.4608490245300345e-06
- O 0 7.232959433167707e-06
functional O 0 9.272699571738485e-06
. O 0 2.1847599782631733e-06

Our O 0 6.049555304343812e-05
results O 0 1.0970916264341213e-05
indicate O 0 3.0385697300516767e-06
that O 0 1.7362597759529308e-07
mutations O 0 3.2914681469264906e-07
in O 0 1.9037477159145055e-06
cardiac O 1 0.748810887336731
ion O 0 3.755423676921055e-05
- O 0 5.937752121099038e-06
channel O 0 6.945915060896368e-07
genes O 0 3.7644266370762125e-08
contribute O 0 3.1284358215089014e-08
to O 0 4.145373821984322e-08
the O 0 1.8356786313233897e-07
risk O 0 1.830402851510371e-07
of O 0 1.2689661161857657e-06
developing O 0 6.424182174669113e-06
IVF B-Disease 1 0.999930739402771
. O 0 3.1467010330743506e-07
. O 0 6.073874487810826e-07

Molecular O 0 0.0006910549127496779
heterogeneity O 0 0.0002653557457961142
in O 0 7.35738649382256e-05
mucopolysaccharidosis B-Disease 0 0.0006504388293251395
IVA I-Disease 0 0.024911891669034958
in O 0 1.0107679372595157e-05
Australia O 0 4.505506296936801e-07
and O 0 1.4522052538268326e-07
Northern O 0 3.348834525240818e-07
Ireland O 0 1.3038828683420434e-07
: O 0 2.4617934357706872e-08
nine O 0 5.6261981740135525e-08
novel O 0 1.0120213289610547e-07
mutations O 0 1.104598297274606e-07
including O 0 3.482456065739825e-07
T312S O 0 1.2733065887005068e-05
, O 0 5.7497299366104926e-08
a O 0 7.588832318106142e-08
common O 0 6.636579996666114e-08
allele O 0 3.1479254403166124e-07
that O 0 5.181821194355507e-08
confers O 0 2.6213510864181444e-06
a O 0 3.1589615900884382e-06
mild O 0 3.8823480281280354e-05
phenotype O 0 2.6243920729029924e-05
. O 0 2.0965596831956645e-06

Mucopolysaccharidosis B-Disease 0 0.05033334344625473
IVA I-Disease 1 0.998676598072052
( O 0 0.00043775333324447274
MPS B-Disease 1 0.9999969005584717
IVA I-Disease 1 1.0
) O 0 1.9814954157482134e-06
is O 0 2.0424761260073865e-07
an O 0 4.052507165397401e-07
autosomal B-Disease 1 0.9985198378562927
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9999998807907104
by O 0 8.848971447150689e-06
a O 0 6.151248089736328e-05
genetic B-Disease 1 0.9999947547912598
defect I-Disease 1 0.9999995231628418
in O 0 6.403875158866867e-05
N O 0 1.978496766241733e-05
- O 0 6.723705610056641e-06
acetylgalactosamine O 0 1.3172102626413107e-05
- O 0 4.424494363775011e-06
6 O 0 8.645205525681376e-06
- O 0 9.18545265449211e-06
sulfate O 0 2.904322354879696e-05
sulfatase O 0 0.00012211984721943736
( O 0 1.5106350019777892e-06
GALNS O 0 8.124722808133811e-05
) O 0 7.549332394773955e-07
. O 0 5.056998588770512e-07

Previous O 0 0.00010476132592884824
studies O 0 2.286708513565827e-05
of O 0 3.541361729730852e-05
patients O 0 6.045942427590489e-06
from O 0 6.894609214214142e-06
a O 0 3.973976163251791e-06
British O 0 9.227939699485432e-06
- O 0 9.433168997929897e-06
Irish O 0 8.106544555630535e-07
population O 0 3.8111913625016314e-08
showed O 0 3.285252319074061e-07
that O 0 3.467429721126791e-08
the O 0 4.496672261211643e-07
I113F O 0 8.261646144092083e-06
mutation O 0 1.7687693798507098e-07
is O 0 8.332030887459041e-08
the O 0 4.349288929006434e-08
most O 0 5.173779626943542e-09
common O 0 9.472340245508803e-09
single O 0 8.677950091851017e-08
mutation O 0 2.011834681070468e-07
among O 0 7.450955195054121e-07
MPS B-Disease 1 0.9999985694885254
IVA I-Disease 1 1.0
patients O 0 2.680133320609457e-06
and O 0 8.485579883199534e-08
produces O 0 2.422656848466431e-07
a O 0 1.2073529660483473e-06
severe O 0 0.0057754660956561565
clinical O 0 0.000788880221080035
phenotype O 0 7.51135012251325e-05
. O 0 2.7138755740452325e-06

We O 0 1.4734765500179492e-05
studied O 0 2.637592115206644e-05
mutations O 0 1.360298824693018e-06
in O 0 1.9428625819273293e-06
the O 0 3.5724974623008166e-06
GALNS O 0 4.658888065023348e-05
gene O 0 4.918858280689165e-07
from O 0 9.738508879308938e-07
23 O 0 2.673039716682979e-06
additional O 0 1.1700526556523982e-06
MPS B-Disease 1 0.7685025930404663
IVA I-Disease 1 0.9999994039535522
patients O 0 8.463985977869015e-06
( O 0 3.4580057217681315e-07
15 O 0 1.1464833278296283e-06
from O 0 7.316101005017117e-07
Australia O 0 9.360863373331085e-08
, O 0 5.299607863662459e-08
8 O 0 3.215997139704996e-07
from O 0 1.6242955780398916e-07
Northern O 0 1.4200105624695425e-07
Ireland O 0 3.486303157274051e-08
) O 0 1.8331345330580007e-08
, O 0 3.898400269264357e-09
with O 0 1.112481662346454e-09
various O 0 4.27297486282896e-08
clinical O 0 7.891942368587479e-05
phenotypes O 0 8.046808943618089e-05
( O 0 4.677173819800373e-06
severe O 1 0.6398700475692749
, O 0 5.267399956210284e-07
16 O 0 9.1689997816502e-07
cases O 0 5.157987814641274e-08
; O 0 3.580699470262516e-08
intermediate O 0 1.1654154832285712e-06
, O 0 6.015019948790723e-08
4 O 0 5.232902822172036e-07
cases O 0 7.422134018497673e-08
; O 0 1.1554846679473485e-07
mild O 0 2.163794533771579e-06
, O 0 8.83440165466709e-08
3 O 0 3.01207620623245e-07
cases O 0 5.617662779400234e-08
) O 0 1.6806977498617925e-07
. O 0 5.47565150554874e-07

We O 0 3.3197226002812386e-05
found O 0 3.060556082346011e-06
two O 0 2.6549534482001036e-07
common O 0 1.9570910581023782e-07
mutations O 0 9.84783881108342e-08
that O 0 4.965708555459969e-08
together O 0 1.8759653386268837e-08
accounted O 0 1.0218528814220917e-06
for O 0 1.390025374803372e-07
32 O 0 1.1551359193617827e-06
% O 0 1.6942077252224408e-07
of O 0 9.842381132330047e-07
the O 0 1.1470814342828817e-06
44 O 0 2.626676177897025e-06
unrelated O 0 3.0428594754994265e-07
alleles O 0 1.461827565663043e-07
in O 0 1.0741108980028002e-07
these O 0 2.009824484616729e-08
patients O 0 2.5732910557962896e-07
. O 0 4.835712843487272e-07

One O 0 3.868953717756085e-05
is O 0 2.9655952857865486e-06
the O 0 3.1239690088114003e-06
T312S O 0 4.3228825234109536e-05
mutation O 0 8.795761914370814e-07
, O 0 1.8926060363355646e-07
a O 0 7.273317237377341e-08
novel O 0 2.531355107748823e-07
mutation O 0 6.777473515739985e-08
found O 0 5.580551487582852e-08
exclusively O 0 6.938169860859489e-08
in O 0 4.815804004465463e-07
milder O 0 7.318694315472385e-06
patients O 0 2.6872944545175415e-06
. O 0 1.5081993751664413e-06

The O 0 0.00026538613019511104
other O 0 3.045836820092518e-06
is O 0 1.075810132533661e-06
the O 0 8.488605089951307e-07
previously O 0 3.024094894499285e-06
described O 0 8.86879035988386e-07
I113F O 0 1.2205077837279532e-05
that O 0 1.4455009988978418e-07
produces O 0 7.64362596328283e-07
a O 0 4.297439772926737e-06
severe O 0 0.14360161125659943
phenotype O 0 0.00018756762437988073
. O 0 5.510338269232307e-06

The O 0 0.00020024742116220295
I113F O 0 0.00030992066604085267
and O 0 6.3367078837472945e-06
T312S O 0 3.184285378665663e-05
mutations O 0 1.2190478173579322e-06
accounted O 0 3.8109044453449314e-06
for O 0 3.1388242405228084e-07
8 O 0 1.145624196396966e-06
( O 0 2.6343014880580995e-08
18 O 0 1.8076569574532186e-07
% O 0 4.573534440055482e-08
) O 0 1.2378367664211964e-08
and O 0 4.2487243945288355e-08
6 O 0 5.483955760610115e-07
( O 0 1.680181149765758e-08
14 O 0 1.0169360820100337e-07
% O 0 2.4810539400732523e-08
) O 0 5.9443165945083365e-09
of O 0 2.0961448399248184e-07
44 O 0 1.1309348337817937e-06
unrelated O 0 4.0273175727634225e-07
alleles O 0 3.314873140425334e-07
, O 0 2.414811604012357e-07
respectively O 0 2.364195097470656e-06
. O 0 9.304857826464286e-07

The O 0 8.169644570443779e-05
relatively O 0 1.3354978364077397e-05
high O 0 8.220667950809002e-05
residual O 0 0.00012787606101483107
GALNS O 0 0.001165293506346643
activity O 0 2.0003753888886422e-05
seen O 0 3.142195510008605e-06
when O 0 1.804687315143383e-07
the O 0 2.522352247069648e-07
T312S O 0 2.1527664557652315e-06
mutant O 0 1.2693800499619101e-06
cDNA O 0 2.2138929125503637e-06
is O 0 1.818284971477624e-07
overexpressed O 0 1.4918314263923094e-06
in O 0 1.638689184346731e-07
mutant O 0 5.033311936131213e-07
cells O 0 2.2110162944954936e-07
provides O 0 6.205518587876213e-08
an O 0 3.072822352123694e-08
explanation O 0 1.2375362246075383e-07
for O 0 1.5814856624274398e-07
the O 0 1.9844871985696955e-06
mild O 0 1.891313149826601e-05
phenotype O 0 1.403111127729062e-06
in O 0 3.01594781149106e-07
patients O 0 6.313252498557631e-08
with O 0 9.443963833177804e-09
this O 0 4.626898686410641e-08
mutation O 0 2.176893474370445e-07
. O 0 5.115954877510376e-07

The O 0 2.434236193948891e-05
distribution O 0 1.7171790887005045e-06
and O 0 3.7376833006419474e-07
relative O 0 1.7609526139494847e-06
frequencies O 0 1.2833318123739446e-06
of O 0 4.178008566668723e-06
the O 0 3.3806124974944396e-06
I113F O 0 1.0562490388110746e-05
and O 0 1.1765873750846367e-06
T312S O 0 1.0559005204413552e-05
mutations O 0 8.231456831708783e-07
in O 0 1.4930299130355706e-06
Australia O 0 1.7434442156627483e-07
corresponded O 0 2.3370742496808816e-07
to O 0 4.9799737666944566e-08
those O 0 4.8974481359209676e-08
observed O 0 3.159661616791709e-07
in O 0 7.041007279440237e-07
Northern O 0 7.304666951313266e-07
Ireland O 0 1.810726359963155e-07
and O 0 1.329262460103564e-07
are O 0 2.64603485788939e-08
unique O 0 3.325898845218944e-08
to O 0 5.633725308484827e-08
these O 0 4.465118053076367e-08
two O 0 1.6043082951000542e-07
populations O 0 1.1466742222410176e-07
, O 0 8.404863649502659e-08
suggesting O 0 1.37076483497367e-07
that O 0 3.263642511797116e-08
both O 0 1.230843764687961e-07
mutations O 0 1.5290876831386413e-07
were O 0 1.6723212183933356e-06
probably O 0 2.8124625828240823e-07
introduced O 0 7.238607935278196e-08
to O 0 2.1876273237353416e-08
Australia O 0 3.104327106484561e-08
by O 0 4.1121573701730085e-08
Irish O 0 3.198083504685201e-07
migrants O 0 9.836350045588915e-08
during O 0 3.707472160385805e-07
the O 0 3.658178968635184e-07
19th O 0 2.221045178885106e-06
century O 0 5.057045200373977e-06
. O 0 1.2856273770012194e-06

Haplotype O 0 0.0006914654513821006
analysis O 0 1.5317969882744364e-05
using O 0 3.2462085073348135e-06
6 O 0 1.204681393573992e-05
RFLPs O 0 1.8861312128137797e-05
provides O 0 2.5103844336626935e-07
additional O 0 1.8557308578692755e-07
data O 0 3.4282007277397497e-07
that O 0 9.396963207564113e-08
the O 0 1.348927867184102e-06
I113F O 0 1.0923997251666151e-05
mutation O 0 2.3007403626706946e-07
originated O 0 2.9504872145480476e-07
from O 0 1.1687707512919587e-07
a O 0 9.931116551342711e-08
common O 0 8.699013420709889e-08
ancestor O 0 3.681280759337824e-06
. O 0 5.996325853629969e-07

The O 0 9.325292921857908e-05
other O 0 2.233181021438213e-06
9 O 0 8.564196832594462e-06
novel O 0 1.2186711728645605e-06
mutations O 0 3.382743329893856e-07
identified O 0 2.80905567251466e-07
in O 0 2.3809904803329118e-07
these O 0 3.798744785399322e-08
23 O 0 4.608447397913551e-06
patients O 0 2.44142256633495e-07
were O 0 3.0445224297181994e-07
each O 0 7.173963201267952e-09
limited O 0 2.1520730086876938e-08
to O 0 3.2686696016526184e-08
a O 0 4.751697701976809e-07
single O 0 1.2480876421250287e-06
family O 0 1.3801939076074632e-06
. O 0 1.248896069228067e-06

These O 0 3.1801928344066255e-06
data O 0 1.206816477861139e-06
provide O 0 1.1325079185553477e-07
further O 0 8.550290431230678e-08
evidence O 0 1.2400762727793335e-07
for O 0 9.52234060491719e-08
extensive O 0 1.950913201653748e-06
allelic O 0 1.1324445040372666e-05
heterogeneity O 0 2.3256749045685865e-05
in O 0 7.771398668410257e-05
MPS B-Disease 1 0.999739944934845
IVA I-Disease 1 0.9999958276748657
in O 0 8.648207767691929e-06
British O 0 1.1786149116232991e-05
- O 0 1.1824788998637814e-05
Irish O 0 1.264807451661909e-06
patients O 0 9.03560888332322e-08
and O 0 3.6919118429068476e-08
provide O 0 2.0645540388386507e-08
evidence O 0 3.183611170243239e-07
for O 0 6.02583099862386e-07
their O 0 5.219475269768736e-07
transmission O 0 1.0980012120853644e-05
to O 0 1.6473792641136242e-07
Australia O 0 8.387727490344332e-08
by O 0 1.1399837518411005e-07
British O 0 6.945371637812059e-07
- O 0 1.1306717624393059e-06
Irish O 0 2.2021254153514747e-07
migrants O 0 9.257207267410195e-08
. O 0 1.5591803403935955e-08
. O 0 2.0381253307277802e-07

Identification O 0 3.811335045611486e-05
of O 0 4.7365228965645656e-05
constitutional O 0 0.00047308235662057996
WT1 O 0 0.005247792694717646
mutations O 0 1.561052613396896e-06
, O 0 1.683725088241772e-07
in O 0 8.64985736370727e-08
patients O 0 1.2460617426768295e-07
with O 0 8.233578085992121e-08
isolated O 0 0.0002821443777065724
diffuse B-Disease 1 0.9999995231628418
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.143382857866527e-07
and O 0 2.2263453303139613e-08
analysis O 0 1.5798569563685305e-08
of O 0 5.422759272732947e-07
genotype O 0 8.159370736393612e-06
/ O 0 8.028369848034345e-06
phenotype O 0 6.216838528416702e-07
correlations O 0 4.321826452269306e-07
by O 0 3.656821689901335e-08
use O 0 7.845540217488178e-09
of O 0 1.0893227653241411e-07
a O 0 1.6470870889406797e-07
computerized O 0 2.7363009849068476e-06
mutation O 0 4.716014530004031e-07
database O 0 1.037907054524112e-06
. O 0 6.78383571539598e-07

Constitutional O 0 0.00022509008704219013
mutations O 0 9.131936167250387e-06
of O 0 3.627888872870244e-05
the O 0 1.3929176930105314e-05
WT1 O 0 9.85314036370255e-05
gene O 0 8.01764997504506e-07
, O 0 1.4797463165905356e-07
encoding O 0 3.681709017655521e-07
a O 0 5.0617109081940725e-06
zinc O 0 0.00028060984914191067
- O 0 5.8112545957555994e-05
finger O 0 4.352230826043524e-05
transcription O 0 4.482323492993601e-05
factor O 0 2.4840810510795563e-06
involved O 0 1.041982272909081e-06
in O 0 3.147927054669708e-05
renal O 1 1.0
and O 0 0.000533288053702563
gonadal O 1 1.0
development O 0 0.00801818910986185
, O 0 2.8207816171743616e-07
are O 0 1.2689495676454499e-08
found O 0 1.0689907625760497e-08
in O 0 2.394595988164383e-08
most O 0 2.0609737916288395e-08
patients O 0 3.10072927334204e-08
with O 0 1.7870847557333036e-07
Denys B-Disease 1 0.9999973773956299
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.7737027519615367e-05
DDS B-Disease 1 1.0
) O 0 2.386996982295386e-07
, O 0 1.1185636594746029e-07
or O 0 2.925627313743462e-06
diffuse B-Disease 1 0.9794045686721802
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 3.1598974601365626e-05
DMS B-Disease 1 0.9995052814483643
) O 0 1.2820910910704697e-07
associated O 0 2.2372560692929255e-07
with O 0 3.572721993805317e-07
pseudohermaphroditism B-Disease 1 1.0
and O 0 3.8026802940294147e-05
/ O 0 0.0010537744965404272
or O 0 3.365926750120707e-05
Wilms B-Disease 1 0.9999974966049194
tumor I-Disease 1 0.9999896287918091
( O 0 5.868038897460792e-06
WT B-Disease 1 0.9998626708984375
) O 0 6.28612099262682e-07
. O 0 4.973509248884511e-07

Most O 0 8.149680979840923e-06
mutations O 0 8.04257706477074e-06
in O 0 2.8039941753377207e-05
DDS B-Disease 1 1.0
patients O 0 3.629255297710188e-05
lie O 0 2.025873982347548e-05
in O 0 3.5966218092653435e-06
exon O 0 3.0198152671800926e-06
8 O 0 2.285502887389157e-06
or O 0 2.3483097777443618e-07
exon O 0 4.008996938864584e-07
9 O 0 1.670857841418183e-06
, O 0 1.202417223566954e-07
encoding O 0 4.7668481784057803e-07
zinc O 0 3.8392492569983006e-05
finger O 0 4.2370833398308605e-05
2 O 0 1.5379460819531232e-05
or O 0 3.510637270665029e-06
zinc O 0 0.0001264539605472237
finger O 0 2.273021891596727e-05
3 O 0 2.830093308148207e-06
, O 0 1.850896609312258e-07
respectively O 0 3.964184429605666e-07
, O 0 3.587850372355206e-08
with O 0 1.853653586181281e-08
a O 0 1.2041562058584532e-06
hot O 0 1.2316367246967275e-05
spot O 0 3.979828306910349e-06
( O 0 9.227028385794256e-08
R394W O 0 1.9510248421283904e-06
) O 0 3.691714667297674e-08
in O 0 1.039476700270825e-07
exon O 0 9.447261390960193e-07
9 O 0 2.2861679553898284e-06
. O 0 3.880616930018732e-07

We O 0 1.3955064787296578e-05
analyzed O 0 4.502882802626118e-06
a O 0 1.0550664910624619e-06
series O 0 6.428003871405963e-07
of O 0 2.52659947364009e-06
24 O 0 8.063788300205488e-06
patients O 0 3.119710072496673e-07
, O 0 1.9697750985869789e-07
10 O 0 3.0044017762520525e-07
with O 0 1.6661590507283108e-07
isolated B-Disease 0 2.394697548879776e-05
DMS I-Disease 0 0.04565383121371269
( O 0 3.3187750432261964e-06
IDMS B-Disease 0 5.571347719524056e-05
) O 0 2.653621891113289e-07
, O 0 1.3164273582333408e-07
10 O 0 3.0834317499284225e-07
with O 0 2.9034421800133714e-07
DDS B-Disease 1 1.0
, O 0 6.021787157806102e-07
and O 0 1.1226310192569144e-07
4 O 0 1.1170418474648613e-06
with O 0 2.844841731075576e-07
urogenital B-Disease 1 0.9999996423721313
abnormalities I-Disease 1 0.9999997615814209
and O 0 0.0001737431448418647
/ O 1 0.841374933719635
or O 0 0.00012867873010691255
WT B-Disease 1 1.0
. O 0 5.500404768099543e-06

We O 0 6.798080721637234e-05
report O 0 1.8663702576304786e-05
WT1 O 0 0.00014672760153189301
heterozygous O 0 9.398071370014804e-07
mutations O 0 2.010729787116361e-07
in O 0 4.224974077260413e-07
16 O 0 1.9415288079471793e-06
patients O 0 6.065862123705301e-08
, O 0 4.4365936702206454e-08
4 O 0 3.341210117469018e-07
of O 0 9.433558716409607e-07
whom O 0 8.76583328590641e-07
presented O 0 4.837354936171323e-06
with O 0 1.8597785356178065e-06
IDMS B-Disease 0 0.00519930524751544
. O 0 9.705551747174468e-06

One O 0 4.089114736416377e-05
male O 0 8.084610271907877e-06
and O 0 8.866447842592606e-07
two O 0 1.09962002170505e-06
female O 0 2.3503886040998623e-05
IDMS B-Disease 1 0.9996657371520996
patients O 0 5.922629043197958e-06
with O 0 2.778177531581605e-06
WT1 O 1 0.9998800754547119
mutations O 0 6.509276136057451e-05
underwent O 1 0.9998156428337097
normal O 0 0.027535395696759224
puberty O 0 0.006871541030704975
. O 0 2.983842023240868e-06

Two O 0 3.099727109656669e-05
mutations O 0 2.06445183721371e-05
associated O 0 1.2512346984294709e-05
with O 0 2.7920527827518526e-06
IDMS B-Disease 0 0.25012728571891785
are O 0 2.299628221180683e-07
different O 0 1.2197643783906642e-08
from O 0 2.1816588002820936e-07
those O 0 3.988742136584733e-08
described O 0 4.0859549699234776e-07
in O 0 1.1518881365191191e-05
DDS B-Disease 1 1.0
patients O 0 9.464825780014507e-06
. O 0 3.023890030817711e-06

No O 0 0.0002736277529038489
WT1 O 0 0.0016782438615337014
mutations O 0 8.738107680983376e-06
were O 0 5.0021158131130505e-06
detected O 0 2.7089599825558253e-06
in O 0 4.0674214574210055e-07
the O 0 5.234838909018436e-07
six O 0 4.2519269527474535e-07
other O 0 3.094915257406683e-07
IDMS B-Disease 1 0.999722421169281
patients O 0 3.085934167756932e-06
, O 0 1.5432895850153727e-07
suggesting O 0 1.9977896670297923e-07
genetic O 0 2.2754457518203708e-07
heterogeneity O 0 3.2152686344488757e-06
of O 0 1.670287201704923e-05
this O 0 3.83969518225058e-06
disease O 0 0.002232072874903679
. O 0 3.422119334572926e-06

We O 0 3.386965181562118e-05
analyzed O 0 1.5927473214105703e-05
genotype O 0 5.932547719567083e-05
/ O 0 4.634498691302724e-05
phenotype O 0 8.274578249256592e-06
correlations O 0 1.5819388863747008e-05
, O 0 3.598844386942801e-07
on O 0 3.5729226510738954e-07
the O 0 1.0530062155567066e-07
basis O 0 1.782098024705192e-07
of O 0 7.641148158654687e-07
the O 0 1.434958335266856e-06
constitution O 0 9.318490015175485e-07
of O 0 2.9653858746314654e-06
a O 0 4.365472705103457e-06
WT1 O 0 2.837162173818797e-05
mutation O 0 1.4159131467295083e-07
database O 0 3.6828114957643265e-07
of O 0 3.7514359974011313e-06
84 O 0 5.082237476017326e-05
germ O 0 0.0004375383141450584
- O 0 3.454212492215447e-05
line O 0 6.7787668740493245e-06
mutations O 0 1.0137600270354596e-07
, O 0 3.7048348389134844e-08
to O 0 1.4784733437522846e-08
compare O 0 3.463932785052748e-08
the O 0 2.689068594463606e-07
distribution O 0 4.2535208422123105e-07
and O 0 1.8451899563842744e-07
type O 0 1.1029158031305997e-06
of O 0 1.2300332855375018e-05
mutations O 0 4.060205185396626e-07
, O 0 1.2332652943314315e-07
according O 0 4.027716826726646e-08
to O 0 2.1593383081608408e-08
the O 0 3.3806790611379256e-07
different O 0 2.1376017400598357e-07
symptoms O 0 0.0001201587074319832
. O 0 3.923682925233152e-06

This O 0 1.2467119631764945e-05
demonstrated O 0 1.266185336135095e-05
( O 0 7.531671144533902e-07
1 O 0 1.3056613852313603e-06
) O 0 1.2616905564755143e-07
the O 0 7.156689889598056e-07
association O 0 4.276399465652503e-07
between O 0 2.5080345267269877e-07
mutations O 0 6.287260134740791e-08
in O 0 6.496001674349827e-07
exons O 0 7.545934863628645e-07
8 O 0 1.2540064062704914e-06
and O 0 2.5867697672765644e-07
9 O 0 2.488842483217013e-06
and O 0 6.633840143877023e-07
DMS B-Disease 0 0.0001229993940796703
; O 0 1.0846247278095689e-07
( O 0 4.2000021238663976e-08
2 O 0 2.0095643549211673e-07
) O 0 3.955648963938074e-08
among O 0 3.132280923523467e-08
patients O 0 2.069573667995428e-07
with O 0 4.997777409698756e-07
DMS B-Disease 1 0.6741982698440552
, O 0 1.6566572469400853e-07
a O 0 1.4052884012016875e-07
higher O 0 3.2107720926433103e-07
frequency O 0 1.9589452904256177e-07
of O 0 3.376896131612739e-07
exon O 0 4.1073059264817857e-07
8 O 0 4.706678282673238e-07
mutations O 0 4.8542410979734996e-08
among O 0 3.5389156494147755e-08
46 O 0 1.390290776726033e-06
, O 0 5.417765578386025e-07
XY O 0 0.0002587713534012437
patients O 0 2.507902934212325e-07
with O 0 9.02680739045536e-08
female O 0 3.0270437036961084e-06
phenotype O 0 1.891199985948333e-06
than O 0 8.584672173128638e-08
among O 0 4.577776024916602e-08
46 O 0 1.1008613682861323e-06
, O 0 2.526555817894405e-07
XY O 0 0.00011558223923202604
patients O 0 2.2008761391134612e-07
with O 0 5.851357798292156e-08
sexual O 0 7.138885393942473e-07
ambiguity O 0 5.823339051858056e-06
or O 0 2.198303263867274e-06
male O 0 5.927314532527816e-07
phenotype O 0 4.6551855348297977e-07
; O 0 2.2312084624331874e-08
and O 0 3.6963790250865713e-08
( O 0 2.087042538789774e-08
3 O 0 1.2969502449777792e-07
) O 0 6.840092048321367e-09
statistically O 0 1.1086503270973935e-08
significant O 0 1.288195328186248e-08
evidence O 0 8.618797409098988e-08
that O 0 2.6675664344111283e-08
mutations O 0 3.748713339746246e-08
in O 0 4.962669208907755e-07
exons O 0 7.915381843304203e-07
8 O 0 1.4897160554028233e-06
and O 0 1.4804859915784618e-07
9 O 0 2.016707412622054e-06
preferentially O 0 6.182216907291149e-07
affect O 0 1.881955881799513e-06
amino O 0 8.490588925269549e-07
acids O 0 3.666998082962891e-08
with O 0 3.691712713305151e-09
different O 0 1.935772431238547e-09
functions O 0 1.0457468135882664e-07
. O 0 7.628553078120603e-08
. O 0 2.816389326198987e-07

The O 0 0.0001980712404474616
185delAG O 0 0.00029429534333758056
BRCA1 O 0 5.130904901307076e-05
mutation O 0 2.1163550627534278e-06
originated O 0 2.4674448013684014e-06
before O 0 7.860475079723983e-07
the O 0 4.6097744643702754e-07
dispersion O 0 1.9776741737587145e-06
of O 0 3.3039641493814997e-06
Jews O 0 1.376640625494474e-06
in O 0 5.344546138985606e-07
the O 0 7.448894621120417e-07
diaspora O 0 3.117651772299723e-07
and O 0 9.525319910608232e-08
is O 0 4.880067194790172e-08
not O 0 1.2228299262062592e-08
limited O 0 6.395229235067745e-08
to O 0 2.406019063982967e-07
Ashkenazim O 0 1.4741595805389807e-05
. O 0 1.7826499743023305e-06

The O 0 0.00012332468759268522
185delAG O 0 8.314587466884404e-05
mutation O 0 2.6435589006723603e-06
in O 0 2.8708091122098267e-06
BRCA1 O 0 7.800206731189974e-06
is O 0 1.9750760316128435e-07
detected O 0 4.326606131144217e-07
in O 0 6.609622715814112e-08
Ashkenazi O 0 1.9270909490387567e-07
Jews O 0 4.8446032963056496e-08
both O 0 1.1122786247597105e-08
in O 0 2.2543945021880063e-07
familial B-Disease 1 0.99637371301651
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.444650585355703e-06
in O 0 1.7079463532354566e-06
the O 0 1.68034659964178e-06
general O 0 1.8430300769978203e-06
population O 0 3.356789761710388e-07
. O 0 1.0530258123253589e-06

All O 0 9.818326361710206e-06
tested O 0 9.154049621429294e-06
Ashkenazi O 0 5.53742574993521e-06
mutation O 0 6.630227744608419e-07
carriers O 0 1.9679538354466786e-07
share O 0 7.577101968081479e-08
the O 0 1.4289601324435353e-07
same O 0 5.8568627281374575e-08
allelic O 0 2.2988856471783947e-06
pattern O 0 4.37325616076123e-06
at O 0 7.999205990927294e-06
the O 0 1.034849105963076e-06
BRCA1 O 0 9.125842552748509e-06
locus O 0 2.6458124921191484e-05
. O 0 2.5245185497624334e-06

Our O 0 4.940912185702473e-05
previous O 0 2.1056221157778054e-05
study O 0 3.0954606700106524e-06
showed O 0 2.4281903279188555e-06
that O 0 1.6204475628001092e-07
this O 0 1.8498714382531034e-07
Ashkenazi O 0 2.055807044598623e-06
mutation O 0 4.3341472633073863e-07
also O 0 8.387614229832252e-07
occurs O 0 1.7376477501329646e-07
in O 0 1.5003278974745626e-07
Iraqi O 0 1.064810817297257e-06
Jews O 0 9.32959807187217e-08
with O 0 6.295957977187072e-09
a O 0 2.5337358877663974e-08
similar O 0 2.5409661930098082e-08
allelic O 0 2.6174739105044864e-06
pattern O 0 1.529548899270594e-05
. O 0 2.4813084564812016e-06

We O 0 4.2198334995191544e-05
extended O 0 4.119286677450873e-05
our O 0 2.284659558426938e-06
analysis O 0 4.009918654901412e-07
to O 0 4.857640192312829e-07
other O 0 2.5500023070890165e-07
non O 0 6.795077297283569e-06
- O 0 4.38466531704762e-06
Ashkenazi O 0 1.3761168702330906e-06
subsets O 0 1.4938302683731308e-06
354 O 0 3.837993062916212e-06
of O 0 1.7894906250148779e-06
Moroccan O 0 1.6704958397895098e-05
origin O 0 5.165874199519749e-07
, O 0 7.725987671847179e-08
200 O 0 3.7417385101434775e-07
Yemenites O 0 1.8923113884738996e-06
and O 0 2.7011950010091823e-07
150 O 0 1.1749973509722622e-06
Iranian O 0 7.096864919731161e-06
Jews O 0 3.4734748624032363e-06
. O 0 1.362066768706427e-06

Heteroduplex O 0 0.0026557811070233583
analysis O 0 8.043551133596338e-06
complemented O 0 9.30893929762533e-06
by O 0 2.1901475122376723e-07
direct O 0 3.901050718013721e-07
DNA O 0 5.511959670911892e-07
sequencing O 0 2.7257292458671145e-06
of O 0 7.480926342395833e-06
abnormally O 0 9.086788486456499e-05
migrating O 0 4.204045751521335e-07
bands O 0 3.0340703460751683e-07
were O 0 3.24094543202591e-07
employed O 0 8.938416726778087e-07
. O 0 5.394852564677421e-07

Four O 0 8.421546226600185e-05
of O 0 5.1949882617918774e-05
Moroccan O 0 0.00011502733104862273
origin O 0 1.1734150575648528e-06
( O 0 7.132135237952753e-08
1 O 0 9.51388088310523e-08
. O 0 4.275532816677696e-09
1 O 0 7.524176481865652e-08
% O 0 3.7664374730184136e-08
) O 0 1.0713748999080508e-08
and O 0 5.117193779824447e-08
none O 0 1.455113789461393e-07
of O 0 6.074730663385708e-06
the O 0 1.591538602951914e-05
Yemenites O 0 2.59031294262968e-05
or O 0 4.642864155357529e-07
Iranians O 0 6.539013384099235e-07
was O 0 9.90055013971869e-07
a O 0 8.296397879803408e-08
carrier O 0 1.7920542916272098e-07
of O 0 4.2025021684821695e-07
the O 0 1.937393335538218e-06
185delAG O 0 1.1878904842888005e-05
mutation O 0 2.6202462777291657e-06
. O 0 2.571571258158656e-06

BRCA1 O 0 0.0003886214108206332
allelic O 0 0.0003387179458513856
patterns O 0 5.0752143579302356e-05
were O 0 8.963992513599806e-06
determined O 0 1.1037890317311394e-06
for O 0 2.436898398627818e-07
four O 0 2.693814451504295e-07
of O 0 7.511557100770005e-07
these O 0 3.906463419411921e-08
individuals O 0 5.429456351180306e-08
and O 0 1.2659523918046034e-07
for O 0 3.9976387711249117e-07
12 O 0 1.8501621070754481e-06
additional O 0 3.128564571852621e-07
non O 0 5.6253105867654085e-05
- O 0 1.3719781236432027e-05
Ashkenazi O 0 8.702728564458084e-07
185delAG O 0 7.444747325280332e-07
mutation O 0 3.716583663049278e-08
carriers O 0 6.929916906983635e-08
who O 0 1.299163727708219e-07
had O 0 9.472700185142457e-06
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.618383561843075e-05

Six O 0 0.0005763872759416699
non O 0 0.0014627304626628757
- O 0 0.0002625455381348729
Ashkenazi O 0 6.864599981781794e-06
individuals O 0 8.759969460925277e-08
shared O 0 6.168983190946165e-07
the O 0 5.055000656284392e-06
common O 0 2.6054376576212235e-06
Ashkenazi O 0 1.774951488187071e-05
haplotype O 0 3.2139756513061e-05
, O 0 9.71005647443235e-07
four O 0 5.65072866720584e-07
had O 0 4.355774763098452e-06
a O 0 1.7389985487170634e-06
closely O 0 4.07547076974879e-07
related O 0 3.55346219294006e-06
pattern O 0 3.0445213269558735e-05
, O 0 8.750431561566074e-07
and O 0 3.198422291461611e-07
the O 0 9.564021183905425e-07
rest O 0 3.545212905464723e-07
( O 0 3.199852471880149e-08
n O 0 3.265106158778508e-07
= O 0 4.411877796428598e-07
6 O 0 3.239875923100044e-07
) O 0 1.8919918076676367e-08
displayed O 0 1.1691643209132963e-07
a O 0 1.604514778819066e-07
distinct O 0 1.1461701632242693e-07
BRCA1 O 0 4.188636921753641e-06
allelic O 0 5.68075529372436e-06
pattern O 0 9.110000064538326e-06
. O 0 1.3629608019982697e-06

We O 0 1.5662792065995745e-05
conclude O 0 1.511580830992898e-05
that O 0 5.320938498698524e-07
the O 0 1.8701423414313467e-06
185delAG O 0 1.1940828699152917e-05
BRCA1 O 0 7.753208592475858e-06
mutation O 0 4.481798896449618e-07
occurs O 0 3.9656515582464635e-07
in O 0 5.607935804619046e-07
some O 0 1.980379664701104e-07
non O 0 3.078892768826336e-05
- O 0 1.6334264728357084e-05
Ashkenazi O 0 1.36803691930254e-06
populations O 0 8.32227939895347e-08
at O 0 8.749096309657034e-07
rates O 0 1.1422015688822285e-07
comparable O 0 3.217735766725127e-08
with O 0 8.980642007827555e-09
that O 0 5.6593794539594455e-08
of O 0 5.449122909340076e-06
Ashkenazim O 0 5.454951315186918e-05
. O 0 2.0527604647213593e-06

The O 0 2.626926107041072e-05
majority O 0 4.529662760432984e-07
of O 0 4.162006007391028e-06
Jewish O 0 1.0308922355761752e-05
185delAG O 0 2.0255765775800683e-05
mutation O 0 8.348127948920592e-07
carriers O 0 4.567623932416609e-07
have O 0 7.550845282366936e-08
a O 0 9.080217466816976e-08
common O 0 9.371474618546927e-08
allelic O 0 2.139036496373592e-06
pattern O 0 8.596963198215235e-06
, O 0 2.993476471147005e-07
supporting O 0 1.777006332304154e-06
the O 0 1.0430439942865632e-05
founder O 0 7.094413012964651e-05
effect O 0 3.1880513233772945e-06
notion O 0 1.3987329339215648e-06
, O 0 1.576580928031035e-07
but O 0 2.2981213376738197e-08
dating O 0 2.3057901898937416e-07
the O 0 1.9953886010171118e-07
mutations O 0 3.0190609123792456e-08
origin O 0 6.019954668090577e-08
to O 0 7.79536577510953e-08
an O 0 1.9460541977878165e-07
earlier O 0 4.861190063820686e-07
date O 0 1.1966794772888534e-06
than O 0 9.159153080418037e-08
currently O 0 4.783817075804109e-07
estimated O 0 1.949310217241873e-06
. O 0 2.1514138097700197e-06

However O 0 2.918362406489905e-05
, O 0 1.1761621863115579e-06
the O 0 3.340318244227092e-07
different O 0 2.2575264324586897e-08
allelic O 0 4.526204975263681e-06
pattern O 0 7.544153049821034e-06
at O 0 2.1956882847007364e-05
the O 0 1.6982223769446136e-06
BRCA1 O 0 2.0882723674731096e-06
locus O 0 4.533808805717854e-06
even O 0 1.5749654380670108e-07
in O 0 1.1838138647135565e-07
some O 0 1.2112074010417473e-08
Jewish O 0 3.624871283136599e-07
mutation O 0 2.0461061467358377e-07
carriers O 0 2.5990570406975166e-07
, O 0 7.43202193120851e-08
might O 0 2.8269100837974293e-08
suggest O 0 1.7098036764195967e-08
that O 0 1.1431317226140436e-08
the O 0 1.42677336611996e-07
mutation O 0 1.7130263074705e-07
arose O 0 3.1713020121060254e-07
independently O 0 1.0393021909749223e-07
. O 0 1.471270962838389e-07
. O 0 4.5799944814461924e-07

Crystal O 0 0.012492774985730648
structure O 0 0.0003079341258853674
of O 0 0.00013352844689507037
the O 0 0.00042019429383799434
hemochromatosis B-Disease 1 1.0
protein O 0 0.0007390477112494409
HFE O 0 0.03302442282438278
and O 0 1.3511036058844184e-06
characterization O 0 1.9525884908944136e-06
of O 0 1.6445991377622704e-06
its O 0 1.602257952981745e-07
interaction O 0 1.170394767768812e-07
with O 0 1.8009788504969038e-07
transferrin O 0 4.304117101128213e-05
receptor O 0 1.690802673692815e-05
. O 0 1.0955492371067521e-06

HFE O 1 0.9720517992973328
is O 0 8.537856774637476e-05
an O 0 9.298168151872233e-06
MHC O 0 6.524015770992264e-05
- O 0 3.29719805449713e-05
related O 0 5.690460511686979e-06
protein O 0 1.0123627589564421e-06
that O 0 4.005820386510095e-08
is O 0 4.876848080925811e-08
mutated O 0 4.743393944295349e-08
in O 0 3.2509379366274516e-07
the O 0 1.1672345863189548e-05
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0023709337692707777

HFE O 0 0.005508625414222479
binds O 0 3.0044990126043558e-05
to O 0 4.082269242644543e-06
transferrin O 0 6.740494427504018e-05
receptor O 0 1.1164165698573925e-05
( O 0 8.089523930721043e-07
TfR O 0 0.00013353176473174244
) O 0 9.3993115513058e-08
and O 0 4.6197556002880447e-08
reduces O 0 1.3431561285415228e-07
its O 0 1.7992809375755314e-07
affinity O 0 7.634374128429045e-07
for O 0 1.0095938023368944e-06
iron O 0 0.00027922503068111837
- O 0 6.111414222687017e-06
loaded O 0 2.0826382751693018e-06
transferrin O 0 8.4746479842579e-06
, O 0 4.543377087884437e-07
implicating O 0 3.565692895790562e-05
HFE O 0 0.0011743505019694567
in O 0 5.7916367950383574e-05
iron O 1 0.9999568462371826
metabolism O 0 0.01148597989231348
. O 0 9.864973435469437e-06

The O 0 0.00020813418086618185
2 O 0 5.567884727497585e-05
. O 0 9.790874173631892e-06

6 O 0 0.0006419304409064353
A O 0 0.0001275494578294456
crystal O 0 0.000169655482750386
structure O 0 3.4451593819539994e-05
of O 0 0.00010072831355500966
HFE O 1 0.7237587571144104
reveals O 0 6.647590453212615e-06
the O 0 1.285244934479124e-06
locations O 0 1.0360380429119687e-06
of O 0 8.727100066607818e-05
hemochromatosis B-Disease 1 1.0
mutations O 0 1.186619010695722e-05
and O 0 9.072338798432611e-06
a O 0 4.9642669182503596e-05
patch O 0 0.00012559330207295716
of O 0 0.0012993704294785857
histidines O 0 0.0026322724297642708
that O 0 1.521731178399932e-06
could O 0 5.543176939681871e-07
be O 0 2.535138321491104e-07
involved O 0 2.0207259865401284e-07
in O 0 7.857042305658979e-07
pH O 0 4.121259189560078e-05
- O 0 1.1370079846528824e-05
dependent O 0 1.4702725366078084e-06
interactions O 0 1.030077555697062e-06
. O 0 2.3495647383242613e-06

We O 0 1.2190746019768994e-05
also O 0 7.241202979457739e-07
demonstrate O 0 1.3901276361139026e-06
that O 0 1.0084602308779722e-06
soluble O 0 3.5472767194733024e-05
TfR O 0 0.05108560249209404
and O 0 6.299801498244051e-06
HFE O 0 0.00015643368533346802
bind O 0 8.877743198354437e-07
tightly O 0 1.3964670415589353e-06
at O 0 7.095484306773869e-06
the O 0 4.1854158894238935e-07
basic O 0 1.203651095238456e-06
pH O 0 8.424808584095445e-06
of O 0 2.398882497800514e-05
the O 0 9.683897587819956e-06
cell O 0 1.3051251698925626e-05
surface O 0 8.631433047412429e-06
, O 0 3.1060537253324583e-07
but O 0 4.198255965093267e-08
not O 0 7.221452591466004e-08
at O 0 3.6509716210275656e-06
the O 0 1.0638374305926845e-06
acidic O 0 2.587278004284599e-06
pH O 0 8.667570000397973e-06
of O 0 1.540980883873999e-05
intracellular O 0 7.40717223379761e-05
vesicles O 0 0.00011699306196533144
. O 0 4.357249508757377e-06

TfR O 1 0.8629194498062134
HFE O 0 0.01084113772958517
stoichiometry O 0 0.00039788143476471305
( O 0 3.244738536523073e-06
2 O 0 3.126231149508385e-06
1 O 0 1.4371618135555764e-06
) O 0 8.101074655542106e-08
differs O 0 7.849750005561873e-08
from O 0 3.3404040777895716e-07
TfR O 0 5.1902447012253106e-05
transferrin O 0 5.765538389823632e-06
stoichiometry O 0 3.892788299708627e-06
( O 0 1.3035148072049196e-07
2 O 0 4.546936054339312e-07
2 O 0 3.7449120782184764e-07
) O 0 5.75646730283097e-08
, O 0 3.608067444815788e-08
implying O 0 2.988236644796416e-07
a O 0 6.427010390552823e-08
different O 0 2.710369040315186e-09
mode O 0 1.2069551758031594e-07
of O 0 1.9736337719677977e-07
binding O 0 2.77722421060389e-07
for O 0 4.064222878241708e-07
HFE O 0 7.497495244024321e-05
and O 0 1.2195851013530046e-06
transferrin O 0 1.5831372365937568e-05
to O 0 8.187659545910719e-07
TfR O 0 0.0009967568330466747
, O 0 2.881792795506044e-07
consistent O 0 2.6639517614057695e-07
with O 0 2.3195411813503597e-08
our O 0 2.616680205846933e-07
demonstration O 0 5.907556442252826e-06
that O 0 2.4483219362991804e-07
HFE O 0 6.026414121151902e-05
, O 0 4.5768155132464017e-07
transferrin O 0 7.47977082937723e-06
, O 0 8.725984201873871e-08
and O 0 7.972423077262647e-08
TfR O 0 0.00014536645903717726
form O 0 2.2779862263178074e-07
a O 0 1.271404471481219e-06
ternary O 0 4.4761291064787656e-05
complex O 0 4.775153865921311e-05
. O 0 4.397747943585273e-06

Identification O 0 9.767205483512953e-06
of O 0 1.16806313599227e-05
three O 0 1.1906178087883745e-06
novel O 0 7.42357769922819e-07
mutations O 0 1.7802669560751383e-07
and O 0 2.3108138691441127e-07
a O 0 4.576073422413174e-07
high O 0 5.513460564543493e-06
frequency O 0 1.084012069441087e-06
of O 0 1.9506564967741724e-06
the O 0 2.0046309145982377e-06
Arg778Leu O 0 1.2320831956458278e-05
mutation O 0 2.5379929979862936e-07
in O 0 8.338420798281732e-07
Korean O 0 2.7201096600038e-05
patients O 0 5.504090836438991e-07
with O 0 4.6286817223517573e-07
Wilson B-Disease 0 0.00013731980288866907
disease I-Disease 0 0.0007137820357456803
. O 0 2.248044893349288e-06

Four O 0 7.377353176707402e-05
mutations O 0 1.0540925359237008e-05
- O 0 3.0714287277078256e-05
- O 0 2.3027361748972908e-05
R778L O 0 2.979404598590918e-05
, O 0 8.166027782863239e-07
A874V O 0 1.2887532648164779e-05
, O 0 1.4058368833502755e-06
L1083F O 0 8.93569813342765e-06
, O 0 4.607937285072694e-07
and O 0 2.8101862881158013e-07
2304delC O 0 3.3194205570907798e-06
- O 0 1.219250066242239e-06
- O 0 1.2713209116554935e-06
in O 0 1.1418502481319592e-06
the O 0 4.130097295274027e-06
copper O 0 0.00020632978703361005
- O 0 2.00739714273368e-06
transporting O 0 3.027768343599746e-06
enzyme O 0 6.301841040112777e-07
, O 0 1.5646922690848442e-07
P O 0 1.0927935363724828e-05
- O 0 8.297464546558331e-07
type O 0 2.8844535790994996e-06
ATPase O 0 3.072864274145104e-05
( O 0 5.768243340753543e-07
ATP7B O 0 1.907595833472442e-05
) O 0 5.166485195218229e-08
, O 0 2.2582412384508643e-08
were O 0 5.208903530729003e-08
identified O 0 3.312035090630161e-08
in O 0 1.9671864492920577e-07
Korean O 0 2.418296026007738e-05
Patients O 0 1.187882276099117e-06
with O 0 1.0548380942054791e-06
Wilson B-Disease 0 0.0020915581844747066
disease I-Disease 0 0.014580028131604195
. O 0 3.635406756075099e-06

Arg778Leu O 0 0.009615388698875904
, O 0 1.7812528312788345e-05
the O 0 3.953408395318547e-06
most O 0 1.8172639215663366e-07
frequently O 0 2.0009224499517586e-07
reported O 0 4.2394961496938777e-07
mutation O 0 5.86914126188276e-08
of O 0 4.135568360652542e-06
this O 0 8.673496267874725e-07
enzyme O 0 1.2339235127001302e-06
, O 0 1.9091989145181287e-07
was O 0 4.026383521704702e-06
found O 0 1.3988207570037048e-07
in O 0 1.8668887946660107e-07
six O 0 2.758004313818674e-07
of O 0 1.7902809759107186e-06
eight O 0 2.928323738160543e-06
unrelated O 0 2.4211979052779498e-06
patients O 0 6.699969503642933e-07
studied O 0 2.1276960069371853e-06
, O 0 6.30575485160989e-08
an O 0 3.695180694762712e-08
allele O 0 6.826696363759766e-08
frequency O 0 7.230734127006144e-07
of O 0 3.3130384053947637e-06
37 O 0 2.0335373847046867e-05
. O 0 2.84370184999716e-06

5 O 0 9.190445416606963e-05
% O 0 5.880530807189643e-06
, O 0 4.880560595665884e-07
which O 0 2.493279680493288e-07
is O 0 4.469033285658952e-07
considerably O 0 1.1810617479568464e-06
higher O 0 2.0585948732332326e-06
than O 0 5.7574339962229715e-08
those O 0 2.924165798390277e-08
in O 0 1.6069711250565888e-07
other O 0 4.864018876560294e-08
Asian O 0 3.253468889852229e-07
populations O 0 8.828354225443036e-08
. O 0 2.148388631439957e-07

The O 0 2.5453435227973387e-05
novel O 0 4.587838247971376e-06
single O 0 1.8501921204006067e-06
nucleotide O 0 5.692718787031481e-06
deletion O 0 1.0857071174541488e-05
, O 0 7.975188509590225e-07
2304delC O 0 5.677002263837494e-06
, O 0 2.727838364080526e-07
was O 0 1.263299282072694e-06
found O 0 9.688156410447846e-08
in O 0 2.1482122747329413e-07
one O 0 3.7863145507799345e-07
patient O 0 4.942816758557456e-06
. O 0 3.6267942959966604e-06

Since O 0 3.446007031016052e-05
a O 0 1.9331887415319216e-06
mutation O 0 3.1417772561326274e-07
at O 0 6.414802555809729e-06
cDNA O 0 3.9584979276696686e-06
nucleotide O 0 5.103234798298217e-06
2302 O 0 6.325832509901375e-05
( O 0 4.0238589349428366e-07
2302insC O 0 3.8979819692031015e-06
) O 0 3.0027891284589714e-07
had O 0 1.6773525430835434e-06
been O 0 2.214680534962099e-06
previously O 0 1.6835321048347396e-06
described O 0 5.011408461541578e-07
, O 0 4.117635654665719e-08
this O 0 2.8871230739468956e-08
region O 0 1.425802054200176e-07
of O 0 2.683238108147634e-06
the O 0 8.610582881374285e-06
ATP7B O 0 0.02601284347474575
gene O 0 1.849142449827923e-06
may O 0 1.2434577456588158e-06
be O 0 1.2164784379820048e-07
susceptible O 0 3.2781480285848374e-07
to O 0 8.560228081933019e-08
gene O 0 7.557698154414538e-06
rearrangements O 0 0.00426067179068923
causing O 1 0.987978458404541
Wilson B-Disease 0 0.017598634585738182
disease I-Disease 0 0.01664564199745655
. O 0 3.9911733438202646e-06

Disruption O 0 0.0022433290723711252
of O 0 3.167947579640895e-05
splicing O 0 5.606579179584514e-06
regulated O 0 3.7733193494204897e-06
by O 0 3.486383945983107e-07
a O 0 1.524424078525044e-06
CUG O 0 5.3292449592845514e-05
- O 0 1.5939393733788165e-06
binding O 0 9.098105806515377e-07
protein O 0 7.019913027761504e-06
in O 0 5.082334246253595e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 9.843433872447349e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00031114841112867
DM B-Disease 1 1.0
) O 0 5.495130153576611e-06
is O 0 1.1512646551636863e-06
caused O 0 8.255015018221457e-06
by O 0 4.41609159906875e-07
a O 0 1.3614979934573057e-06
CTG O 0 1.6994350517052226e-05
expansion O 0 2.843541778929648e-06
in O 0 4.261568165020435e-07
the O 0 4.651506344544032e-07
3 O 0 7.317133849937818e-07
untranslated O 0 3.436709221205092e-06
region O 0 2.4769175865912985e-07
of O 0 4.125774921703851e-06
the O 0 4.350148083176464e-05
DM B-Disease 1 1.0
gene O 0 1.5468654964934103e-05
. O 0 3.6888118302158546e-06

One O 0 2.13127914321376e-05
model O 0 1.7979644326260313e-05
of O 0 0.00011844728578580543
DM B-Disease 1 1.0
pathogenesis O 1 0.9987531900405884
suggests O 0 5.846142812515609e-06
that O 0 3.7574974953713536e-07
RNAs O 0 6.761559689039132e-06
from O 0 5.569906420532789e-07
the O 0 1.5000689757016517e-07
expanded O 0 1.2839018381782807e-07
allele O 0 5.540218595001534e-08
create O 0 2.408259014430314e-08
a O 0 4.4771937268706097e-07
gain O 0 1.446308033337118e-06
- O 0 1.107406660594279e-06
of O 0 5.0864041440945584e-06
- O 0 4.193273070995929e-06
function O 0 1.1506916735015693e-06
mutation O 0 1.0624945190329527e-07
by O 0 7.721081374256755e-08
the O 0 2.18011763308823e-07
inappropriate O 0 2.772289064978395e-07
binding O 0 1.8420865899315686e-07
of O 0 1.2204484391986625e-06
proteins O 0 1.5749819226584805e-07
to O 0 1.8936351864340395e-07
the O 0 2.884629793697968e-06
CUG O 0 0.00012305795098654926
repeats O 0 8.39338008518098e-06
. O 0 3.732486447916017e-06

Data O 0 0.0001316145935561508
presented O 0 4.23642122768797e-05
here O 0 4.528433237283025e-06
indicate O 0 2.234815383417299e-06
that O 0 1.1098526186970048e-07
the O 0 1.5220737168419873e-06
conserved O 0 3.63221124644042e-06
heterogeneous O 0 9.560496437188704e-06
nuclear O 0 7.861131598474458e-05
ribonucleoprotein O 0 0.00017366133397445083
, O 0 1.4105451100476785e-06
CUG O 0 2.7975862394669093e-05
- O 0 1.2501556057031848e-06
binding O 0 9.808395589061547e-07
protein O 0 2.6956413421430625e-06
( O 0 6.571439712388383e-07
CUG O 0 9.916624549077824e-05
- O 0 2.2539425117429346e-05
BP O 0 3.371368075022474e-05
) O 0 2.3993831632651563e-07
, O 0 1.8224427833501977e-07
may O 0 7.736264819868666e-07
mediate O 0 3.041863237740472e-06
the O 0 9.476476407144219e-06
trans O 0 9.352158485853579e-06
- O 0 3.957924491260201e-06
dominant O 0 4.69038099026875e-07
effect O 0 3.405998540984001e-07
of O 0 6.967104582145112e-07
the O 0 7.110904221008241e-07
RNA O 0 2.28584303840762e-06
. O 0 1.2767325188178802e-06

CUG O 0 0.26853007078170776
- O 0 0.0032328995876014233
BP O 0 0.0007522563100792468
was O 0 1.7236681742360815e-05
found O 0 1.8930698786334688e-07
to O 0 2.7877263164555188e-08
bind O 0 5.1135256029510856e-08
to O 0 8.070646373425916e-08
the O 0 1.8074138097290415e-06
human O 0 8.313795842695981e-05
cardiac O 1 1.0
troponin O 1 0.9999922513961792
T O 0 0.0013774989638477564
( O 0 5.885844984732103e-07
cTNT O 0 5.176811555429595e-06
) O 0 9.27647363369033e-08
pre O 0 3.873919922625646e-06
- O 0 1.165139906333934e-06
messenger O 0 5.543050178857811e-07
RNA O 0 1.6533853397504572e-07
and O 0 4.95081344809023e-08
regulate O 0 9.027598935062997e-08
its O 0 1.4830845884716837e-07
alternative O 0 4.547942467070243e-07
splicing O 0 1.5289798511730623e-06
. O 0 9.069102588910027e-07

Splicing O 0 0.00011680946772685274
of O 0 5.366213008528575e-05
cTNT O 0 0.0001643568102736026
was O 0 6.610494892811403e-05
disrupted O 0 0.00011577927216421813
in O 0 1.4147581168799661e-05
DM B-Disease 1 1.0
striated O 0 0.0020724553614854813
muscle O 0 5.7597360864747316e-05
and O 0 1.3966961205369444e-06
in O 0 1.1364010106262867e-06
normal O 0 3.3293345040874556e-06
cells O 0 3.3909796570696926e-07
expressing O 0 1.6690424331500253e-07
transcripts O 0 8.821661481306364e-07
that O 0 8.902213721739827e-08
contain O 0 5.289892897053505e-07
CUG O 0 0.00014424706751015037
repeats O 0 1.0473218935658224e-05
. O 0 3.1735937682242366e-06

Altered O 0 0.00010771695815492421
expression O 0 2.342578773095738e-05
of O 0 2.0338418835308403e-05
genes O 0 2.0100253550481284e-06
regulated O 0 6.068240054446505e-06
posttranscriptionally O 0 9.619769116397947e-06
by O 0 5.784532959296484e-07
CUG O 0 7.752812234684825e-05
- O 0 1.18398638733197e-05
BP O 0 8.749632797844242e-06
therefore O 0 1.5006084197466407e-07
may O 0 1.9529556993802544e-07
contribute O 0 1.8646733224159107e-07
to O 0 1.5203906968963565e-06
DM B-Disease 1 1.0
pathogenesis O 0 0.21889618039131165
. O 0 6.132883640930231e-07
. O 0 7.940633963698929e-07

Identification O 0 2.349550231883768e-05
of O 0 1.7992182620218955e-05
a O 0 3.870275577355642e-06
novel O 0 3.5171847230230924e-06
nonsense O 0 1.7904425476444885e-05
mutation O 0 4.1748677404029877e-07
and O 0 1.5574659073536168e-07
a O 0 2.3176356478415983e-07
missense O 0 6.709701665386092e-07
substitution O 0 1.5515788618358783e-06
in O 0 6.945239192646113e-07
the O 0 3.032640734090819e-06
vasopressin O 0 9.985084034269676e-06
- O 0 1.1813832315965556e-05
neurophysin O 0 3.015389302163385e-05
II O 0 0.0002761357754934579
gene O 0 2.6055442958750064e-07
in O 0 1.9219444880036463e-07
two O 0 4.065365644123631e-08
Spanish O 0 6.859109475954028e-07
kindreds O 0 2.4583291633462068e-06
with O 0 1.873974042609916e-07
familial B-Disease 1 0.9923779964447021
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9998902082443237
. O 0 8.840906957630068e-06

Familial B-Disease 1 0.999998927116394
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.0007849711109884083
FNDI B-Disease 1 1.0
) O 0 1.3265793086247868e-06
is O 0 1.3809467702685652e-07
an O 0 2.4446146085210785e-07
autosomal B-Disease 1 0.6748211979866028
dominant I-Disease 1 0.9999607801437378
disease I-Disease 1 1.0
caused O 1 0.9999961853027344
by O 0 5.7197459682356566e-05
deficiency O 1 1.0
in O 0 0.0006838890258222818
the O 0 0.0008885094430297613
antidiuretic O 0 0.0012792403576895595
hormone O 0 4.846778392675333e-05
arginine O 0 9.030532055476215e-06
vasopressin O 0 3.90903096558759e-06
( O 0 2.834507597526681e-07
AVP O 0 3.941418071917724e-06
) O 0 1.6944120773132454e-08
encoded O 0 3.8056199969105364e-08
by O 0 1.1321223780669243e-07
the O 0 2.4280282104882644e-06
AVP O 0 7.911788998171687e-05
- O 0 1.2892866834590677e-05
neurophysin O 0 4.564904884318821e-05
II O 0 0.10637553036212921
( O 0 5.814548785565421e-06
AVP O 0 0.0003524521889630705
- O 0 1.0262935575156007e-05
NPII O 0 3.1712334020994604e-05
) O 0 9.848195503536772e-08
gene O 0 1.5182216372977564e-07
on O 0 2.9185268886067206e-06
chromosome O 0 4.495936809689738e-05
20p13 O 0 0.00021703765378333628
. O 0 7.632439519511536e-06

In O 0 4.03551894123666e-05
this O 0 1.2313678325881483e-06
study O 0 8.254851309175137e-07
, O 0 1.927352002439875e-07
we O 0 4.888526206059396e-08
analyzed O 0 1.6847995709667885e-07
two O 0 8.684573060691037e-08
families O 0 2.385514896730001e-08
with O 0 8.392832739900769e-08
FNDI B-Disease 1 0.9999724626541138
using O 0 6.955592652957421e-07
direct O 0 2.2862921014166204e-06
automated O 0 1.9448130842647515e-05
fluorescent O 0 2.221828935944359e-06
, O 0 1.7944348940091004e-07
solid O 0 1.2141262004661257e-06
phase O 0 1.8118628304364393e-06
, O 0 7.014921976633559e-08
single O 0 8.012759877829012e-08
- O 0 2.554020568368287e-07
stranded O 0 2.977186284169875e-07
DNA O 0 2.2170143054722757e-08
sequencing O 0 3.374925938715023e-07
of O 0 2.827487151080277e-06
PCR O 0 1.5288796930690296e-05
- O 0 2.295754529768601e-05
amplified O 0 6.04475244472269e-05
AVP O 0 0.0002850832825060934
- O 0 6.731507255608449e-06
NPII O 0 2.5642500986577943e-05
DNA O 0 1.077005094884953e-06
. O 0 1.1108295439044014e-06

In O 0 0.0001346757053397596
one O 0 4.673597686633002e-06
of O 0 6.269235655054217e-06
the O 0 3.9109550016291905e-06
families O 0 2.154186375946665e-07
, O 0 7.652350575426681e-08
affected O 0 6.903650273670792e-08
individuals O 0 5.922079715503514e-09
presented O 0 3.8914788547117496e-07
a O 0 3.2162455454454175e-07
novel O 0 5.073403031019552e-07
nonsense O 0 1.1754692650356446e-06
mutation O 0 1.0810475714606582e-07
in O 0 2.0330411132363224e-07
exon O 0 1.7475426261626126e-07
3 O 0 2.8508438276730885e-07
of O 0 1.0810614412548603e-06
the O 0 1.0478796639290522e-06
gene O 0 1.0761861801711348e-07
, O 0 6.784328121511862e-08
consisting O 0 3.024570816023697e-08
in O 0 2.2829338774954522e-07
a O 0 1.0865074955290766e-06
G O 0 6.117081738921115e-06
to O 0 7.42557460853277e-07
T O 0 4.175145659246482e-05
transition O 0 6.540823960676789e-06
at O 0 1.4994344383012503e-05
nucleotide O 0 1.5853801187404315e-06
2101 O 0 1.3387341823545285e-05
, O 0 4.9963382764417474e-08
which O 0 1.904101587513196e-08
produces O 0 1.3888096894731916e-08
a O 0 6.664257767852177e-08
stop O 0 6.161150878369881e-08
signal O 0 6.055516905689728e-07
in O 0 3.3910765750988503e-07
codon O 0 2.995666363858618e-06
82 O 0 3.7265360788296675e-06
( O 0 1.758766217108132e-07
Glu O 0 1.2858828995376825e-05
) O 0 1.8749034325082903e-07
of O 0 5.492584023158997e-06
NPII O 0 0.0005903907585889101
. O 0 7.023502803349402e-06

The O 0 0.00021388223103713244
premature O 0 0.0003196683246642351
termination O 0 3.0293973395600915e-05
eliminates O 0 4.330847787059611e-06
part O 0 1.660035309214436e-06
of O 0 9.02864667295944e-06
the O 0 8.476668881485239e-06
C O 0 6.0228292568353936e-05
- O 0 1.0521142030484043e-05
terminal O 0 5.005442653782666e-05
domain O 0 9.619399179428e-07
of O 0 1.3030047739448491e-05
NPII O 0 8.945155423134565e-05
, O 0 2.6126207330889883e-07
including O 0 1.7815780495311628e-07
a O 0 7.080540740389552e-07
cysteine O 0 2.829964387274231e-07
residue O 0 2.3451930246665142e-06
in O 0 1.5783078879394452e-06
position O 0 8.63415789353894e-06
85 O 0 7.686882781854365e-06
, O 0 2.3450134278846235e-07
which O 0 1.2434276186468196e-07
could O 0 5.563228455685021e-08
be O 0 5.449905771115482e-08
involved O 0 3.0692373087504166e-08
in O 0 3.404257995498483e-07
the O 0 1.2338622354945983e-06
correct O 0 2.727000719460193e-06
folding O 0 1.6819414668134414e-05
of O 0 2.289807343913708e-05
the O 0 5.7623019529273733e-05
prohormone O 0 0.003413565456867218
. O 0 6.291642421274446e-06

In O 0 0.0001297125854762271
the O 0 3.180521889589727e-05
second O 0 1.2744935702357907e-05
family O 0 9.455120562051889e-07
, O 0 2.928846924987738e-07
a O 0 8.906712309908471e-07
G279A O 0 6.863317139504943e-06
substitution O 0 7.272079528775066e-06
at O 0 1.2731851711578202e-05
position O 0 1.0310918696632143e-06
- O 0 2.9489399366866564e-07
1 O 0 4.921542426927772e-07
of O 0 8.324548161908751e-07
the O 0 1.1460329005785752e-06
signal O 0 1.7972237401409075e-05
peptide O 0 1.7484438785686507e-06
was O 0 4.155810529482551e-06
observed O 0 1.6856884599292243e-07
in O 0 1.0752977175343403e-07
all O 0 2.6286452126100812e-08
affected O 0 1.4491808997263433e-07
individuals O 0 7.669007828781105e-08
. O 0 6.737016633451276e-07

This O 0 1.7793952792999335e-05
missense O 0 9.559294994687662e-05
mutation O 0 1.4428031136048958e-05
, O 0 2.104548684656038e-06
which O 0 2.649135922183632e-06
replaces O 0 6.35221294942312e-05
Ala O 0 0.00010848399688256904
with O 0 8.072738069131447e-07
Thr O 0 0.0005624632467515767
, O 0 1.2041033414789126e-06
is O 0 2.6209883685623936e-07
frequent O 0 5.480918048306194e-07
among O 0 2.2143406113173114e-06
FNDI B-Disease 1 1.0
patients O 0 8.341113243659493e-06
and O 0 1.6216609992625308e-06
is O 0 6.983642606428475e-07
thought O 0 1.394819122424451e-07
to O 0 2.235374374492949e-08
reduce O 0 8.611534241254049e-08
the O 0 5.000886176276254e-07
efficiency O 0 6.377214276653831e-07
of O 0 8.882570341484097e-07
cleavage O 0 5.365333436202491e-06
by O 0 5.095785695630184e-07
signal O 0 1.017289741866989e-05
peptidases O 0 1.292850083700614e-05
. O 0 1.2213537559091492e-07
. O 0 5.659330781782046e-07

Genetic O 0 4.833499770029448e-05
heterogeneity O 0 0.00033776313648559153
of O 0 0.00127348059322685
Saethre B-Disease 1 0.9999991655349731
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.3157346024381695e-06
due O 0 3.3825268474174663e-05
to O 0 8.877709092303121e-07
TWIST O 0 1.617682573851198e-05
and O 0 2.4127662072714884e-06
FGFR O 0 0.0018718374194577336
mutations O 0 6.007939191476908e-06
. O 0 4.2781148295034654e-06

Thirty O 0 0.0008958111284300685
- O 0 0.00024897651746869087
two O 0 1.3210496945248451e-06
unrelated O 0 2.0138322724960744e-06
patients O 0 1.8559909165105637e-07
with O 0 2.604847892939688e-08
features O 0 5.86717078476795e-07
of O 0 0.0102265989407897
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.8570985932674375e-07
a O 0 3.087851894179039e-07
common O 0 6.824417368989089e-07
autosomal B-Disease 0 0.00021939078578725457
dominant I-Disease 0 0.07589944452047348
condition I-Disease 1 0.9979202151298523
of O 1 0.9999457597732544
craniosynostosis B-Disease 1 1.0
and O 1 0.9997568726539612
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9999853372573853
, O 0 6.233996145965648e-07
were O 0 2.600051232093392e-07
screened O 0 1.0792345506160927e-07
for O 0 4.947801812704711e-08
mutations O 0 1.0440925990451433e-07
in O 0 9.766373523234506e-07
TWIST O 0 5.349418188416166e-06
, O 0 6.909814374012058e-07
FGFR2 O 0 4.536324559012428e-05
, O 0 5.131561806592799e-07
and O 0 1.924187017721124e-06
FGFR3 O 0 0.0005955358501523733
. O 0 7.951888619572856e-06

Nine O 0 7.039248157525435e-05
novel O 0 5.530433099920629e-06
and O 0 1.2295442957110936e-06
three O 0 1.813525841498631e-06
recurrent O 0 0.0006223253440111876
TWIST O 0 5.4193311370909214e-05
mutations O 0 8.331139724759851e-07
were O 0 8.58197608977207e-07
found O 0 3.72085331434846e-08
in O 0 8.038890797479326e-08
12 O 0 5.709883339477528e-07
families O 0 7.615221875312272e-08
. O 0 1.0063504305435345e-06

Seven O 0 0.00012301300012040883
families O 0 1.8595586652736529e-06
were O 0 2.52201084549597e-06
found O 0 2.9555732794506184e-07
to O 0 1.352343446114901e-07
have O 0 5.107374931867525e-07
the O 0 5.549299203266855e-06
FGFR3 O 0 0.00040289637399837375
P250R O 0 5.160957152838819e-05
mutation O 0 1.5170884353210567e-06
, O 0 4.5975605189596536e-07
and O 0 1.4672900761070196e-07
one O 0 1.4288484351254738e-07
individual O 0 6.132380292456219e-08
was O 0 2.5987497792812064e-05
found O 0 2.43741226313432e-07
to O 0 1.1116131304333976e-07
have O 0 2.1188520804571453e-07
an O 0 9.975841521736584e-07
FGFR2 O 0 0.00015494822582695633
VV269 O 0 4.769692895933986e-05
- O 0 1.4317951354314573e-05
270 O 0 1.244900340680033e-05
deletion O 0 1.2648082702071406e-05
. O 0 4.260785772203235e-06

To O 0 1.6397490981034935e-05
date O 0 2.0108529497520067e-05
, O 0 6.182104925755993e-07
our O 0 2.758414723302849e-07
detection O 0 1.541872961752233e-06
rate O 0 4.190250820101937e-06
for O 0 4.62019642100131e-07
TWIST O 0 2.732298298724345e-06
or O 0 6.614818062189443e-07
FGFR O 0 1.1284071661066264e-05
mutations O 0 3.15275592299713e-08
is O 0 8.659498007546063e-08
68 O 0 4.6314852397699724e-07
% O 0 9.81803722766017e-08
in O 0 4.368248482933268e-07
our O 0 5.33379943590262e-06
Saethre B-Disease 1 0.9843616485595703
- I-Disease 1 0.9999996423721313
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.0973364624078386e-05
, O 0 2.6540064368418825e-07
including O 0 2.896837543175934e-07
our O 0 5.246134264780267e-07
five O 0 4.80958931348141e-07
patients O 0 2.3203558896511822e-07
elsewhere O 0 1.3258188857889763e-07
reported O 0 2.6097370664501796e-07
with O 0 6.70922872814117e-08
TWIST O 0 6.790944098611362e-06
mutations O 0 1.4869029882902396e-06
. O 0 2.288940549988183e-06

More O 0 5.258152668830007e-06
than O 0 8.843014143167238e-07
35 O 0 2.2539054498338373e-06
different O 0 4.7550884119118564e-08
TWIST O 0 1.890139856186579e-06
mutations O 0 2.0986971094316687e-07
are O 0 5.6259725766949487e-08
now O 0 2.5108075618618386e-08
known O 0 2.648342345423771e-08
in O 0 3.8285239867263954e-08
the O 0 1.1141390388047512e-07
literature O 0 1.3995869494465296e-06
. O 0 1.2677805898420047e-06

The O 0 0.00010566287528490648
most O 0 1.0488624866411556e-06
common O 0 4.353169344994967e-07
phenotypic O 0 2.159959876735229e-06
features O 0 1.6178084933926584e-06
, O 0 2.3849787567087333e-07
present O 0 2.1323303656117787e-07
in O 0 4.326065834447945e-07
more O 0 1.8126245393546014e-08
than O 0 3.5298821643436895e-08
a O 0 2.40739609580487e-07
third O 0 9.177993547382357e-07
of O 0 2.6823067855730187e-06
our O 0 1.232279487339838e-06
patients O 0 2.3347998023837135e-07
with O 0 9.413035684247006e-08
TWIST O 0 2.1932860363449436e-06
mutations O 0 1.8098458554050012e-07
, O 0 1.1063293214874648e-07
are O 0 5.011971992985309e-08
coronal B-Disease 0 5.8995443396270275e-05
synostosis I-Disease 0 7.95839059719583e-06
, O 0 4.2688122903200565e-07
brachycephaly B-Disease 0 1.9201255781808868e-05
, O 0 2.0192017018416664e-06
low B-Disease 0 0.008718378841876984
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 0.0007480871281586587
facial B-Disease 1 0.9999995231628418
asymmetry I-Disease 1 1.0
, O 0 2.695526200113818e-05
ptosis B-Disease 1 0.9997550845146179
, O 0 4.78368929179851e-06
hypertelorism B-Disease 0 0.0005433647311292589
, O 0 1.2267075817362638e-06
broad B-Disease 0 3.507007932057604e-05
great I-Disease 1 0.9023517370223999
toes I-Disease 1 0.9998825788497925
, O 0 6.038014817022486e-07
and O 0 9.807497463043546e-07
clinodactyly B-Disease 0 0.0002585762704256922
. O 0 4.545870524452766e-06

Significant O 0 0.0003224709362257272
intra O 0 0.007573950570076704
- O 0 0.00013596033386420459
and O 0 1.317489022767404e-06
interfamilial O 0 1.9683660866576247e-05
phenotypic O 0 2.453656406942173e-06
variability O 0 1.4001761883264408e-05
is O 0 1.4135196124698268e-07
present O 0 7.003037438835236e-08
for O 0 5.8154647319952346e-08
either O 0 2.527707749777619e-07
TWIST O 0 2.8462982299970463e-06
mutations O 0 6.313107974165177e-07
or O 0 1.502866894043109e-06
FGFR O 0 8.122283907141536e-05
mutations O 0 2.898157845265814e-06
. O 0 2.697729541978333e-06

The O 0 3.4934892028104514e-05
overlap O 0 3.870330601785099e-06
in O 0 2.2720853394275764e-06
clinical O 0 7.141062724258518e-06
features O 0 1.6368084061468835e-06
and O 0 1.3462008610076737e-06
the O 0 1.98437919607386e-06
presence O 0 1.1877395991177764e-06
, O 0 2.534935390485771e-07
in O 0 3.3543511790412595e-07
the O 0 4.1246164528274676e-07
same O 0 9.152534374834431e-08
genes O 0 7.742952590206187e-08
, O 0 8.828506281588488e-08
of O 0 6.111310426604177e-07
mutations O 0 1.0559567442669504e-07
for O 0 3.205858263299888e-07
more O 0 3.3964873580316635e-08
than O 0 1.3598483405985462e-07
one O 0 5.781620870948245e-07
craniosynostotic B-Disease 0 3.318181188660674e-05
condition I-Disease 0 3.255806950619444e-05
- O 0 5.42017187399324e-06
such O 0 3.816800813183363e-07
as O 0 2.3317077193496516e-06
Saethre B-Disease 0 3.7505167711060494e-05
- I-Disease 0 2.3418930140906014e-05
Chotzen I-Disease 0 5.924350261921063e-05
, I-Disease 0 1.6695994418114424e-06
Crouzon I-Disease 0 5.289045293466188e-05
, I-Disease 0 1.6102077324831043e-06
and I-Disease 0 3.833292339550098e-06
Pfeiffer I-Disease 1 0.9833984375
syndromes I-Disease 1 0.9956436157226562
- O 0 4.5587537897517905e-05
support O 0 3.1566246434522327e-06
the O 0 5.584779501077719e-06
hypothesis O 0 1.30230625927652e-06
that O 0 1.2629257639673597e-07
TWIST O 0 1.9496931145113194e-06
and O 0 3.909050576567097e-07
FGFRs O 0 1.033125226967968e-05
are O 0 5.1541327650284074e-08
components O 0 2.5997607622230134e-07
of O 0 8.449384836239915e-07
the O 0 4.0151380176212115e-07
same O 0 2.7832800242322264e-07
molecular O 0 3.1309841688198503e-06
pathway O 0 3.560426421245211e-06
involved O 0 9.849660642657909e-08
in O 0 1.4425484096136643e-07
the O 0 2.7548759362616693e-07
modulation O 0 7.847188498999458e-06
of O 0 4.633415665011853e-05
craniofacial O 1 0.9999997615814209
and O 0 0.001177110243588686
limb O 1 0.9999997615814209
development O 0 8.169598004315048e-05
in O 0 1.6510784917045385e-06
humans O 0 1.0308032472039486e-07
. O 0 4.9374509814015255e-08
. O 0 1.663677409169395e-07

Mutation O 0 3.089780193477054e-06
analysis O 0 5.48622040241753e-07
of O 0 6.360077804856701e-06
UBE3A O 1 0.9999415874481201
in O 1 0.9984160661697388
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.8087823390960693
. O 0 9.684747965366114e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.024893902242183685
AS B-Disease 1 1.0
) O 0 1.7631102764426032e-06
is O 0 3.434080895203806e-07
caused O 0 5.538725417864043e-06
by O 0 7.077522923282231e-07
chromosome O 0 0.00018715318583417684
15q11 O 0 0.005871102213859558
- O 0 0.04282137379050255
q13 O 0 0.00029017109773121774
deletions O 0 1.3074470189167187e-05
of O 0 1.1748174074455164e-05
maternal O 0 0.00016713909280952066
origin O 0 1.4127961094345665e-06
, O 0 1.866529117933169e-07
by O 0 1.326524454725586e-07
paternal O 0 0.00010432965791551396
uniparental B-Disease 0 0.005141695961356163
disomy I-Disease 0 0.0012429098132997751
( O 0 1.0101685802510474e-05
UPD B-Disease 1 0.9983822107315063
) O 0 8.388941523662652e-07
15 O 0 1.7069385194190545e-06
, O 0 7.94684069660434e-08
by O 0 2.0510333342826925e-07
imprinting O 0 0.000492220395244658
defects O 1 0.9538711309432983
, O 0 9.748081453153645e-08
and O 0 3.8921911027500755e-08
by O 0 2.1205922351441586e-08
mutations O 0 6.264886565077177e-08
in O 0 8.6717261638114e-07
the O 0 2.5487117909506196e-06
UBE3A O 0 0.0006207236438058317
gene O 0 5.602014880423667e-06
. O 0 2.045387645921437e-06

UBE3A O 0 0.02500459924340248
encodes O 0 0.0005561647121794522
a O 0 0.000143455748911947
ubiquitin O 0 0.0002131753572029993
- O 0 2.622855936351698e-05
protein O 0 4.791542323800968e-06
ligase O 0 1.3602365243059467e-06
and O 0 4.1077132095779234e-07
shows O 0 3.4757808862195816e-06
brain O 0 0.0008517701062373817
- O 0 1.7203530660481192e-05
specific O 0 4.4486523620435037e-07
imprinting O 0 0.0002432047767797485
. O 0 4.779375558428001e-06

Here O 0 0.00010433931311126798
we O 0 2.652252987900283e-06
describe O 0 4.565395556710428e-06
UBE3A O 0 0.0003328323073219508
coding O 0 1.9183649783371948e-05
- O 0 7.653541615582071e-06
region O 0 6.787181519030128e-07
mutations O 0 1.924187671420441e-07
detected O 0 1.641105200178572e-06
by O 0 4.735353229534667e-07
SSCP O 0 2.609851253509987e-05
analysis O 0 8.885402991154479e-08
in O 0 4.144433773944911e-07
13 O 0 8.046872608247213e-06
AS B-Disease 1 0.9691594243049622
individuals O 0 3.092064915222181e-08
or O 0 2.247058006332736e-07
families O 0 9.050805260812922e-08
. O 0 5.672779366250325e-07

Two O 0 1.791745853552129e-05
identical O 0 4.053801148984348e-06
de O 0 6.225011748028919e-05
novo O 0 2.5154216928058304e-05
5 O 0 5.819286798214307e-06
- O 0 4.064745098730782e-06
bp O 0 4.695627467299346e-06
duplications O 0 2.86283375316998e-06
in O 0 8.622009204373171e-07
exon O 0 1.3357450825424166e-06
16 O 0 1.3924163795309141e-06
were O 0 7.213199637590151e-07
found O 0 4.044731269914337e-07
. O 0 6.641531058448891e-07

Among O 0 2.6863290258916095e-05
the O 0 6.844584731879877e-06
other O 0 2.00732529265224e-07
11 O 0 1.4559370811184635e-06
unique O 0 1.4570967721283523e-07
mutations O 0 1.1859405191216865e-07
, O 0 1.3751117933225032e-07
8 O 0 6.37681864645856e-07
were O 0 3.9797222939341736e-07
small O 0 5.665719271519265e-08
deletions O 0 6.490465693786973e-07
or O 0 1.362894522571878e-06
insertions O 0 1.1753305443562567e-05
predicted O 0 3.4870579838752747e-05
to O 0 1.0413543805043446e-06
cause O 0 1.5444658856722526e-05
frameshifts O 0 6.767880404368043e-05
, O 0 6.625007245020242e-07
1 O 0 1.1517379334691213e-06
was O 0 2.7625526399788214e-06
a O 0 1.9138548168484704e-07
mutation O 0 3.692552752454503e-08
to O 0 5.2822500151705754e-08
a O 0 5.827656082146859e-07
stop O 0 4.856223085880629e-07
codon O 0 1.1502198731250246e-06
, O 0 4.5946933369123144e-08
1 O 0 1.9718463306617195e-07
was O 0 1.1352506135153817e-06
a O 0 1.9023887887215096e-07
missense O 0 5.037647952121915e-07
mutation O 0 7.976834126566246e-08
, O 0 6.421177545234968e-08
and O 0 4.413148246840137e-08
1 O 0 7.466888973794994e-07
was O 0 6.214756012923317e-06
predicted O 0 2.140203605449642e-06
to O 0 1.5302022404739546e-07
cause O 0 1.5715401104898774e-06
insertion O 0 4.011787495983299e-06
of O 0 4.5289158151717857e-05
an O 0 1.1486784387670923e-05
isoleucine O 0 4.770684608956799e-05
in O 0 3.548910399331362e-06
the O 0 8.231493666244205e-06
hect O 0 3.111490877927281e-05
domain O 0 3.7258362226566533e-06
of O 0 1.5138832168304361e-05
the O 0 1.7889031369122677e-05
UBE3A O 0 7.689873018534854e-05
protein O 0 9.332995318800386e-07
, O 0 6.0917642485947e-08
which O 0 1.984258446441345e-08
functions O 0 1.2095063084416324e-07
in O 0 2.5874186349028605e-07
E2 O 0 9.626698556530755e-06
binding O 0 3.3373950714121747e-07
and O 0 3.6429963756745565e-07
ubiquitin O 0 4.8791644076118246e-06
transfer O 0 2.5710760382935405e-06
. O 0 1.5230073131533572e-06

Eight O 0 0.00011623324098763987
of O 0 2.8782473236788064e-05
the O 0 5.306487310008379e-06
cases O 0 9.737274240251281e-07
were O 0 4.875703780271579e-06
familial O 0 1.2347672054602299e-05
, O 0 5.046139222031343e-07
and O 0 9.797814470857702e-08
five O 0 1.8873700469157484e-07
were O 0 3.3027689028131135e-07
sporadic O 0 8.578305823903065e-06
. O 0 2.974052222270984e-06

In O 0 4.3959662434645e-05
two O 0 2.133004727511434e-06
familial O 0 3.218288111384027e-05
cases O 0 4.5982319534232374e-06
and O 0 8.375272386729193e-07
one O 0 5.335288051355747e-07
sporadic O 0 1.6038160538300872e-05
case O 0 7.985272532096133e-06
, O 0 6.860790904283931e-07
mosaicism O 0 2.995161230501253e-05
for O 0 1.0500234566279687e-06
UBE3A O 0 9.992365085054189e-05
mutations O 0 3.9640821114517166e-07
was O 0 9.15452983463183e-06
detected O 0 6.508651608783111e-07
in O 0 4.562921844808443e-07
the O 0 1.6599244645476574e-06
mother O 0 2.037694912360166e-06
of O 0 9.684599717729725e-06
three O 0 1.3547624803322833e-05
AS B-Disease 1 0.9999997615814209
sons O 0 3.500258389976807e-05
, O 0 2.381033539222699e-07
in O 0 8.92548598585563e-07
the O 0 2.5425429157621693e-06
maternal O 0 0.00020320519979577512
grandfather O 0 0.000492954277433455
of O 0 0.0005213532131165266
two O 0 1.5004929991846438e-05
AS B-Disease 1 0.9999996423721313
first O 0 3.9868707972345874e-05
cousins O 0 8.69310042617144e-06
, O 0 1.6148445070029993e-07
and O 0 1.4710647633364715e-07
in O 0 1.2311141972531914e-06
the O 0 4.779557912115706e-06
mother O 0 5.074939963378711e-06
of O 0 9.148866956820711e-05
an O 0 0.0001456267200410366
AS B-Disease 1 1.0
daughter O 0 0.13585807383060455
. O 0 1.7305417713942006e-05

The O 0 3.765360452234745e-05
frequencies O 0 5.8170339798380155e-06
with O 0 2.0385918730880803e-07
which O 0 1.640945725966958e-07
we O 0 8.94611034141235e-08
detected O 0 2.3210795063732803e-07
mutations O 0 4.853639268276311e-08
were O 0 3.520661095990363e-07
5 O 0 1.546359840176592e-07
( O 0 1.759478429619321e-08
14 O 0 1.0687261209341159e-07
% O 0 3.886115607087959e-08
) O 0 1.1833528823501638e-08
of O 0 3.2662023841112386e-07
35 O 0 5.606572131000576e-07
in O 0 2.520361306324048e-07
sporadic O 0 1.8439759514876641e-06
cases O 0 1.9300595965887624e-07
and O 0 1.834185923144105e-07
8 O 0 1.0796109108923702e-06
( O 0 3.514417556971239e-08
80 O 0 1.1146214973223323e-07
% O 0 1.4570683326553535e-08
) O 0 5.129503932721491e-09
of O 0 7.829235215695007e-08
10 O 0 1.4130681336155249e-07
in O 0 9.21027094591409e-08
familial O 0 1.4647765738118323e-06
cases O 0 5.496191306519904e-07
. O 0 4.1865376942951116e-07
. O 0 8.535362781003641e-07

The O 0 0.001233812072314322
hemochromatosis B-Disease 1 0.9999998807907104
845 O 0 0.007921705953776836
G O 0 0.00019551637524273247
- O 0 1.1545054803718813e-05
- O 0 5.994952516630292e-06
> O 0 1.9043251313632936e-06
A O 0 9.231232525053201e-07
and O 0 9.373083997843423e-08
187 O 0 1.1855813681904692e-06
C O 0 2.2685217118123546e-06
- O 0 4.4008342570123204e-07
- O 0 1.174676867776725e-06
> O 0 2.057900019281078e-06
G O 0 6.357676284096669e-06
mutations O 0 1.7317253764304041e-07
: O 0 4.059616287577228e-08
prevalence O 0 1.4778862578168628e-06
in O 0 1.858305722635123e-07
non O 0 4.511247425398324e-06
- O 0 3.388181312402594e-06
Caucasian O 0 9.958257578546181e-07
populations O 0 1.8470439044904197e-07
. O 0 3.039462797005399e-07

Hemochromatosis B-Disease 1 0.9999943971633911
, O 0 6.0767477407353e-05
the O 0 0.004165031481534243
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9999998807907104
, O 0 4.445329068403225e-06
leads O 0 2.0940040030836826e-06
, O 0 1.4773380030419503e-07
if O 0 1.4866036224248091e-07
untreated O 0 3.4456785215297714e-05
, O 0 1.4387316582542553e-07
to O 0 8.520121923538682e-07
progressive O 1 0.9776524305343628
iron B-Disease 1 1.0
overload I-Disease 1 0.9999935626983643
and O 0 3.58332326868549e-05
premature B-Disease 1 0.7813757061958313
death I-Disease 0 0.0016218192176893353
. O 0 3.96375662603532e-06

The O 0 0.005175252445042133
hemochromatosis B-Disease 1 1.0
gene O 0 0.0002202919131377712
, O 0 1.6901594790397212e-05
HFE O 0 0.00233813701197505
, O 0 2.660166728674085e-06
recently O 0 3.3199016797880176e-06
has O 0 5.18341778388276e-07
been O 0 9.506532023806358e-07
identified O 0 1.9128073347474128e-07
, O 0 8.50698782528525e-08
and O 0 1.0661486271601461e-07
characterization O 0 1.5368492540801526e-06
of O 0 2.8403890610206872e-05
this O 0 2.0223544652253622e-06
gene O 0 9.127558087129728e-07
has O 0 5.168210464034928e-07
shown O 0 1.8471072849024495e-07
that O 0 3.8523452872141206e-08
it O 0 7.996465711812561e-09
contains O 0 1.9333048939529363e-08
two O 0 1.9166908060697097e-08
mutations O 0 3.7608668179700544e-08
that O 0 8.032331066942788e-08
result O 0 3.0224322244976065e-07
in O 0 5.431132876765332e-07
amino O 0 2.3251693903603154e-07
acid O 0 1.4521886271268158e-07
substitutions O 0 9.845603443636719e-08
- O 0 2.956385287689045e-07
cDNA O 0 4.2660332155719516e-07
nucleotides O 0 1.227320325369874e-07
845 O 0 3.5615030355984345e-06
G O 0 2.352158844587393e-06
- O 0 4.7143601022980874e-07
- O 0 6.076493264117744e-07
> O 0 4.607216510521539e-07
A O 0 8.458205229544546e-07
( O 0 4.8419611431427256e-08
C282Y O 0 4.437127358869475e-07
) O 0 1.4543695137092527e-08
and O 0 3.870588827226129e-08
187 O 0 7.750708164167008e-07
C O 0 1.3227084991740412e-06
- O 0 4.0690358105166524e-07
- O 0 9.30256931042095e-07
> O 0 1.2664513633353636e-06
G O 0 4.054736564285122e-06
( O 0 2.956083449134894e-07
H63D O 0 1.9467799575068057e-05
) O 0 2.432020380638278e-07
. O 0 3.717761103416706e-07

Although O 0 0.0012640913482755423
hemochromatosis B-Disease 1 1.0
is O 0 6.138528533483623e-06
common O 0 3.1338410622083757e-07
in O 0 3.148159919419413e-07
Caucasians O 0 2.7518223078004667e-07
, O 0 4.105159234768507e-08
affecting O 0 7.930594136951186e-08
> O 0 1.3914218754962349e-07
= O 0 3.112117497039435e-07
1 O 0 7.669532919862831e-07
/ O 0 7.984046987985494e-07
300 O 0 2.3121077674659318e-07
individuals O 0 2.5193944708234994e-08
of O 0 3.1721717732580146e-06
northern O 0 1.8131556771550095e-06
European O 0 1.4470459746007691e-06
origin O 0 2.8984652544750134e-07
, O 0 9.208620355138919e-08
it O 0 1.2115470404694406e-08
has O 0 2.8285173314657186e-08
not O 0 1.063726973171697e-08
been O 0 5.26616439344707e-08
recognized O 0 3.1795629240605194e-08
in O 0 7.226964271467295e-08
other O 0 2.8146272867957123e-08
populations O 0 1.1132934929491967e-07
. O 0 2.789375628253765e-07

The O 0 5.129398050485179e-05
present O 0 3.948829998989822e-06
study O 0 1.2032630820613122e-06
used O 0 1.26185443605209e-06
PCR O 0 5.4874526540515944e-06
and O 0 1.081022332982684e-06
restriction O 0 8.689758942637127e-06
- O 0 2.5093675048992736e-06
enzyme O 0 2.656746573848068e-07
digestion O 0 1.45278420404793e-07
to O 0 3.856741770391636e-08
analyze O 0 5.240193345912303e-08
the O 0 2.1568854435827234e-07
frequency O 0 5.699644134438131e-07
of O 0 2.3119168872653972e-06
the O 0 3.4682018394960323e-06
845 O 0 1.932518534886185e-05
G O 0 5.189702278585173e-06
- O 0 7.208543593151262e-07
- O 0 6.538358547913958e-07
> O 0 4.346486264239502e-07
A O 0 3.260973642227327e-07
and O 0 6.59212204823234e-08
187 O 0 8.401688091908e-07
C O 0 1.167274149338482e-06
- O 0 2.1872462241390167e-07
- O 0 4.846479555453698e-07
> O 0 8.109312830129056e-07
G O 0 2.2930919385544257e-06
mutations O 0 8.085283553782574e-08
in O 0 1.2219670679769479e-06
HLA O 0 1.5608931789756753e-05
- O 0 2.322316049685469e-06
typed O 0 8.120914003484359e-07
samples O 0 1.54012269604209e-07
from O 0 7.498366585423355e-07
non O 0 3.843945250991965e-06
- O 0 1.3517120578399044e-06
Caucasian O 0 5.070027100373409e-07
populations O 0 6.619399783858171e-08
, O 0 4.18532799528748e-08
comprising O 0 7.023677994766331e-08
Australian O 0 1.6899552974791732e-06
Aboriginal O 0 1.1492614930830314e-06
, O 0 2.565831493939186e-07
Chinese O 0 7.205615588645742e-07
, O 0 8.514649607604952e-08
and O 0 2.571473203261121e-07
Pacific O 0 3.580724523999379e-06
Islanders O 0 1.746104544508853e-06
. O 0 7.935827284200059e-07

Results O 0 0.00035114469937980175
showed O 0 4.715879913419485e-05
that O 0 1.1655332627924508e-06
the O 0 3.480428176771966e-06
845 O 0 2.832247264450416e-05
G O 0 1.8972943507833406e-05
- O 0 4.541533144220011e-06
- O 0 5.438282641989645e-06
> O 0 1.7132384755313979e-06
A O 0 1.1538036233105231e-06
mutation O 0 1.0289941343444298e-07
was O 0 2.091513124469202e-06
present O 0 4.776559237029687e-08
in O 0 6.024779253266388e-08
these O 0 1.026200635578789e-08
populations O 0 1.5535460917703858e-08
( O 0 5.011902892704256e-09
allele O 0 1.0042430886869624e-08
frequency O 0 7.196496198957902e-08
0 O 0 3.460512232322799e-08
. O 0 4.122065355716131e-09
32 O 0 4.798383201887191e-08
% O 0 2.2841986080379684e-08
) O 0 9.12934261521059e-09
, O 0 1.9020072627995432e-08
and O 0 6.782542527616897e-08
, O 0 9.369651365886966e-08
furthermore O 0 3.281407146005222e-07
, O 0 5.0155104958093943e-08
it O 0 2.2448684688924914e-08
was O 0 2.022526132350322e-06
always O 0 4.945754383811618e-08
seen O 0 1.3185734815124306e-07
in O 0 3.3168966240282316e-08
conjunction O 0 1.1506012498330165e-07
with O 0 1.476884250450894e-07
HLA O 0 1.8922115486930124e-05
haplotypes O 0 3.833438768197084e-06
common O 0 2.8985203925913083e-07
in O 0 8.0608447206032e-07
Caucasians O 0 4.7410057391061855e-07
, O 0 9.914197107718792e-08
suggesting O 0 3.394357293018402e-07
that O 0 1.4690725436139473e-07
845 O 0 8.215197340177838e-06
G O 0 1.1802098924817983e-05
- O 0 5.714847247872967e-06
- O 0 1.0610991921566892e-05
> O 0 5.794980097562075e-06
A O 0 7.25861036698916e-06
may O 0 6.642974881287955e-07
have O 0 7.135999879892552e-08
been O 0 1.0562609986664029e-07
introduced O 0 5.1339505091618776e-08
into O 0 1.0453714338609643e-08
these O 0 1.7452358447300753e-09
populations O 0 5.793827639877236e-09
by O 0 1.0003183170681496e-08
Caucasian O 0 4.2641983100111247e-07
admixture O 0 3.2434020340588177e-06
. O 0 1.4484612620435655e-06

187 O 0 0.0003217161283828318
C O 0 0.00011067141895182431
- O 0 7.672922947676852e-06
- O 0 4.402598733577179e-06
> O 0 3.482685997369117e-06
G O 0 8.392747076868545e-06
was O 0 2.4329397092515137e-06
present O 0 2.425509535441961e-07
at O 0 9.056345788849285e-07
an O 0 1.7610563673997603e-08
allele O 0 1.547601513607333e-08
frequency O 0 2.4515370000699477e-07
of O 0 9.780391110325581e-07
2 O 0 3.6175886179989902e-06
. O 0 6.354278525577683e-07

68 O 0 0.00032342845224775374
% O 0 3.215023525626748e-06
in O 0 1.8864373032556614e-06
the O 0 8.596942393523932e-07
two O 0 9.51420773276368e-08
populations O 0 4.5741884946437494e-08
analyzed O 0 2.4948471377683745e-07
( O 0 1.1177191083788784e-07
Australian O 0 7.910620070106233e-07
Aboriginal O 0 3.175781273512257e-07
and O 0 2.0172736014956172e-07
Chinese O 0 1.5193789977274719e-06
) O 0 3.0790417326898023e-07
. O 0 2.9646915322700806e-07

In O 0 8.660180901642889e-05
the O 0 1.597121990926098e-05
Australian O 0 4.87799252368859e-06
Aboriginal O 0 1.3695055258722277e-06
samples O 0 2.1268388650241832e-07
, O 0 1.943567156104109e-07
187 O 0 1.2182180171294021e-06
C O 0 2.0201339339109836e-06
- O 0 6.756872039659356e-07
- O 0 2.029011511694989e-06
> O 0 3.4028955724352272e-06
G O 0 8.882858310244046e-06
was O 0 6.894727903272724e-06
found O 0 1.954119994707071e-07
to O 0 3.794848524307781e-08
be O 0 1.6643122080495232e-07
associated O 0 4.1540494066794054e-07
with O 0 3.800724073244055e-07
HLA O 0 0.0005128478514961898
haplotypes O 0 1.3425491488305852e-05
common O 0 6.923310706952179e-07
in O 0 1.6598390857325285e-06
Caucasians O 0 1.1599080380619853e-06
, O 0 5.116100965096848e-08
suggesting O 0 7.987003414200444e-08
that O 0 7.692062098385577e-09
it O 0 5.295179406061834e-09
was O 0 2.7127941848448245e-07
introduced O 0 1.1033722380204836e-08
by O 0 6.095969951047664e-09
recent O 0 4.97214358574638e-08
admixture O 0 2.00519116333453e-06
. O 0 1.5953081629049848e-06

In O 0 8.22185174911283e-05
the O 0 1.781561877578497e-05
Chinese O 0 4.756975613418035e-06
samples O 0 4.0565205949860683e-07
analyzed O 0 6.546924851136282e-07
, O 0 1.6409521208515798e-07
187 O 0 1.796539208953618e-06
C O 0 2.276774921483593e-06
- O 0 4.744986483729008e-07
- O 0 1.6821984445414273e-06
> O 0 1.9033954004044062e-06
G O 0 6.6111124397139065e-06
was O 0 4.16936336478102e-06
present O 0 4.433388198776811e-07
in O 0 1.3703141803489416e-06
association O 0 4.835560503124725e-07
with O 0 2.615187710830469e-08
a O 0 4.018317554255191e-07
wide O 0 8.891995548765408e-07
variety O 0 1.8051795791507175e-07
of O 0 2.4567925720475614e-05
HLA O 0 0.00019138000789098442
haplotypes O 0 3.4424137993482873e-06
, O 0 1.2179782515886473e-07
showing O 0 4.0605692674944294e-07
this O 0 3.105185797380727e-08
mutation O 0 1.7949476571743617e-08
to O 0 3.240030110873704e-08
be O 0 9.541958689851526e-08
widespread O 0 6.049410217201512e-07
and O 0 6.060092232473835e-07
likely O 0 1.3863134427083423e-06
to O 0 3.3102864449574554e-07
predate O 0 8.506688573106658e-06
the O 0 2.673613380466122e-06
more O 0 4.8405574659682316e-08
genetically O 0 1.1240430097814169e-07
restricted O 0 6.803758765272505e-07
845 O 0 8.013354090508074e-06
G O 0 2.9479037948476616e-06
- O 0 5.005819616599183e-07
- O 0 4.431004470006883e-07
> O 0 2.475564429005317e-07
A O 0 2.4782619334473566e-07
mutation O 0 2.056452927945429e-07
. O 0 4.919843945572211e-07

Genotype O 0 0.0007152788457460701
- O 0 9.261618833988905e-05
phenotype O 0 1.1245162568229716e-05
correlations O 0 8.060282198130153e-06
in O 0 3.472438038443215e-06
attenuated B-Disease 0 0.2868999242782593
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 3.86374413210433e-05

Germ O 1 0.583895742893219
- O 0 0.0005362457013688982
line O 0 3.024668876605574e-05
mutations O 0 6.482918024630635e-07
of O 0 5.5074592637538444e-06
the O 0 2.049855720542837e-05
tumor B-Disease 1 0.9981766939163208
suppressor O 1 0.9634723663330078
APC O 0 2.8300715712248348e-05
are O 0 7.374649868552297e-08
implicated O 0 2.0145084818068426e-06
in O 0 2.2605913727602456e-06
attenuated B-Disease 1 0.9766655564308167
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.00028747119358740747
AAPC B-Disease 1 1.0
) O 0 4.9930893197824844e-08
, O 0 2.1410258010945427e-09
a O 0 6.8631180738520925e-09
variant O 0 1.7965889753668307e-07
of O 0 6.741804827470332e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0004038521437905729
FAP B-Disease 0 0.002644158899784088
) O 0 1.2152265753684333e-06
. O 0 1.0936493026747485e-06

AAPC B-Disease 1 0.9999985694885254
is O 0 9.792350283532869e-06
recognized O 0 1.1797267234214814e-06
by O 0 1.7205773872319696e-07
the O 0 1.271299936433934e-07
occurrence O 0 3.7368636185419746e-07
of O 0 3.3200981306436006e-06
< O 0 4.040004569105804e-05
100 O 0 8.146075742843095e-06
colonic B-Disease 0 0.01056788582354784
adenomas I-Disease 0 0.00014731638657394797
and O 0 8.341651636101233e-08
a O 0 1.7050400913376507e-07
later O 0 8.910807309803204e-07
onset O 1 0.9981676340103149
of O 1 0.9998605251312256
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.8033605303789955e-07
age O 0 3.9816964658712095e-07
> O 0 2.422763145659701e-07
40 O 0 2.1261411120576668e-07
years O 0 1.6640534283851594e-07
) O 0 1.1522000420427503e-07
. O 0 3.5964907851848693e-07

The O 0 3.485047272988595e-05
aim O 0 5.8815517149923835e-06
of O 0 4.0366180655837525e-06
this O 0 1.7420065034912113e-07
study O 0 1.9712823018380732e-07
was O 0 1.2574325864989078e-06
to O 0 8.27856823093498e-08
assess O 0 1.2372983064778964e-06
genotype O 0 1.0410146387584973e-05
- O 0 3.928926889784634e-05
phenotype O 0 7.492157237720676e-06
correlations O 0 2.5712557544466108e-05
in O 0 4.489436832955107e-05
AAPC B-Disease 1 0.9999991655349731
families O 0 1.0944246469080099e-06
. O 0 1.462547402297787e-06

By O 0 4.270680801710114e-05
protein O 0 1.5914263713057153e-05
- O 0 5.761866759712575e-06
truncation O 0 2.8133716114098206e-05
test O 0 1.4002143871039152e-06
( O 0 4.146884862166189e-07
PTT O 0 7.896172064647544e-06
) O 0 9.792341160164142e-08
assay O 0 1.0175428997172276e-06
, O 0 6.397766583177145e-08
the O 0 2.3147948979840294e-07
entire O 0 1.5196036429188098e-06
coding O 0 1.2728858109767316e-06
region O 0 1.7007798760459991e-06
of O 0 2.5617984647396952e-05
the O 0 1.9759510905714706e-05
APC B-Disease 0 1.3733382729697041e-05
gene O 0 2.6536017116995936e-07
was O 0 1.9273754787718644e-06
screened O 0 3.0665520966977056e-07
in O 0 1.2012127115212934e-07
affected O 0 1.6057609286690422e-07
individuals O 0 3.255802383250739e-08
from O 0 4.517774414125597e-06
11 O 0 8.789346611592919e-05
AAPC B-Disease 1 0.999997615814209
kindreds O 0 3.207725967513397e-05
, O 0 1.790202617257819e-07
and O 0 2.3433406326489603e-08
their O 0 1.8361472342576235e-08
phenotypic O 0 4.3772101321337686e-07
differences O 0 4.7358633992189425e-07
were O 0 1.2167748536739964e-05
examined O 0 9.69894517766079e-06
. O 0 3.0654050533485133e-06

Five O 0 0.00019262988644186407
novel O 0 9.654375753598288e-05
germ O 0 0.0019658643286675215
- O 0 0.0001893175212899223
line O 0 4.907220500172116e-05
APC B-Disease 0 6.461330485763028e-06
mutations O 0 1.0471998734828958e-07
were O 0 4.0804332002153387e-07
identified O 0 9.488854146866288e-08
in O 0 3.8647908695566e-07
seven O 0 1.333453951701813e-06
kindreds O 0 3.0227914976421744e-05
. O 0 3.281411636635312e-06

Mutations O 0 4.3112318962812424e-05
were O 0 1.6536341718165204e-05
located O 0 6.382126684911782e-06
in O 0 3.83591441277531e-07
three O 0 6.374355621119321e-08
different O 0 8.05194666497755e-09
regions O 0 1.9698559583503084e-07
of O 0 9.711181519378442e-06
the O 0 1.1072514098486863e-05
APC B-Disease 0 3.5472187391860643e-06
gene O 0 1.315680577818057e-07
( O 0 2.8235691118538853e-08
1 O 0 2.274269945701235e-07
) O 0 1.5696237198881136e-08
at O 0 3.6374763112689834e-07
the O 0 1.3175892377148557e-07
5 O 0 1.8062955575715023e-07
end O 0 2.8915545158270106e-07
spanning O 0 3.825656165190594e-07
exons O 0 4.647959030990023e-07
4 O 0 3.8186138340279285e-07
and O 0 1.258401596260228e-07
5 O 0 1.8249664890390704e-07
, O 0 3.554650973569551e-08
( O 0 5.9981419830990035e-09
2 O 0 3.404640480653143e-08
) O 0 2.7308035832618316e-09
within O 0 1.3676459964528931e-08
exon O 0 5.0472078072516524e-08
9 O 0 2.7143701686327404e-07
, O 0 1.4914281365463466e-08
and O 0 1.303966978838389e-08
( O 0 1.497037160902437e-08
3 O 0 8.336625256788466e-08
) O 0 2.6706667100029335e-08
at O 0 4.2578918169056124e-07
the O 0 2.485682557562541e-07
3 O 0 9.611898121875129e-07
distal O 0 2.0639458853111137e-06
end O 0 1.9796045762632275e-06
of O 0 9.308568564847519e-07
the O 0 1.4853950460747e-06
gene O 0 1.1677340125970659e-06
. O 0 9.464322943131265e-07

Variability O 0 0.00021506320626940578
in O 0 8.0331174103776e-06
the O 0 3.145913524349453e-06
number O 0 3.495846613077447e-06
of O 1 0.8764198422431946
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 0.9996427297592163
most O 0 3.1512084319729183e-07
apparent O 0 1.0366705964770517e-06
in O 0 1.357969239279555e-07
individuals O 0 3.780419977061911e-09
with O 0 1.2414756334067079e-08
mutations O 0 6.379549688517727e-08
in O 0 8.368916724066366e-07
region O 0 1.7186305285576964e-06
1 O 0 1.4902935618010815e-05
, O 0 1.2601011576407473e-06
and O 0 5.371692623157287e-06
upper O 1 0.9999994039535522
- O 1 0.9999992847442627
gastrointestinal O 1 1.0
manifestations O 1 0.9999998807907104
were O 0 0.0006124145002104342
more O 0 6.336318136845875e-08
severe O 0 9.954095003195107e-05
in O 0 1.3562093954533339e-06
them O 0 8.083848967999074e-08
. O 0 7.15042745014216e-07

In O 0 2.5892753910738975e-05
individuals O 0 2.463444843670004e-07
with O 0 1.5187907820291002e-07
mutations O 0 2.305423123516448e-07
in O 0 9.289518629884697e-07
either O 0 2.316133276281107e-07
region O 0 6.832127610323369e-07
2 O 0 1.5038247056509135e-06
or O 0 2.3237750212956598e-07
region O 0 3.495439386824728e-07
3 O 0 7.394861540888087e-07
, O 0 6.84213006252321e-08
the O 0 1.8085344777318824e-07
average O 0 6.587873144781042e-07
number O 0 3.9230403103829303e-07
of O 0 9.591015441401396e-06
adenomas B-Disease 0 0.0004126481944695115
tended O 0 3.3862138479889836e-06
to O 0 4.0082898067339556e-07
be O 0 1.1788191613959498e-06
lower O 0 4.166938651906094e-06
than O 0 3.9788339734059264e-08
those O 0 1.688198913996075e-08
in O 0 6.15673343418166e-08
individuals O 0 8.760767222781851e-09
with O 0 1.576223951360589e-08
mutations O 0 6.025273791010477e-08
in O 0 2.625599222483288e-07
region O 0 2.5661816493993683e-07
1 O 0 7.223297870950773e-07
, O 0 2.073773330835138e-08
although O 0 1.9016010099903724e-08
age O 0 3.4262430403941835e-07
at O 0 1.8046939658233896e-06
diagnosis O 0 1.3697131180379074e-06
was O 0 2.7963033062405884e-06
similar O 0 1.709444177322439e-07
. O 0 1.527599692963122e-06

In O 0 0.00019451022672001272
all O 0 5.312824941938743e-05
AAPC B-Disease 1 0.9999983310699463
kindreds O 0 0.00031368283089250326
, O 0 7.132529162845458e-07
a O 0 6.885476295792614e-07
predominance O 0 2.2119296772871166e-05
of O 0 0.00031525385566055775
right O 1 0.9931061863899231
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9991033673286438
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999994039535522
sparing O 0 2.3714623239357024e-05
was O 0 1.3333012248040177e-05
observed O 0 1.3609956113214139e-06
. O 0 3.575792959509272e-07

No O 0 0.005561798810958862
desmoid B-Disease 1 0.9999444484710693
tumors I-Disease 1 1.0
were O 0 2.825726733135525e-05
found O 0 3.2127138638315955e-07
in O 0 2.8957879294466693e-07
these O 0 1.375654790081171e-07
kindreds O 0 3.447078779572621e-05
. O 0 3.550413566699717e-06

Our O 0 9.062376921065152e-05
data O 0 2.4691802536835894e-05
suggest O 0 2.550747012719512e-06
that O 0 6.776051009182993e-07
, O 0 1.0452985179654206e-06
in O 0 7.748027201159857e-06
AAPC B-Disease 1 0.999998927116394
families O 0 3.509280759317335e-07
, O 0 6.669750973742339e-08
the O 0 7.624566933372989e-08
location O 0 3.1751395113133185e-07
of O 0 1.866569732555945e-06
the O 0 1.2095774764020462e-05
APC B-Disease 0 6.418144039344043e-05
mutation O 0 1.0109271215696936e-06
may O 0 1.6036365195759572e-06
partially O 0 1.9649023670353927e-06
predict O 0 8.320390065819083e-08
specific O 0 3.119730251910369e-08
phenotypic O 0 2.9507841645681765e-06
expression O 0 1.0330868462915532e-05
. O 0 3.011785565831815e-06

This O 0 1.5462859664694406e-05
should O 0 1.8046097238766379e-06
help O 0 2.605755469176074e-07
in O 0 6.341788889585587e-07
the O 0 8.307940788654378e-07
design O 0 3.6252590689400677e-06
of O 0 3.163259862049017e-06
tailored O 0 2.154288267774973e-06
clinical O 0 0.0010838753078132868
- O 0 0.00042382997344247997
management O 0 1.328978942183312e-05
protocols O 0 3.2977691262203734e-06
in O 0 2.021581906319625e-07
this O 0 4.604510195349576e-08
subset O 0 4.020160986328847e-07
of O 0 1.379299192194594e-06
FAP B-Disease 0 1.4101205124461558e-05
patients O 0 3.0890416269357956e-07
. O 0 7.587196648728423e-08
. O 0 2.696587841910514e-07

Wilms B-Disease 1 0.996060311794281
' I-Disease 0 0.001836095005273819
tumor I-Disease 0 0.0020538840908557177
1 O 0 3.200853825546801e-05
and O 0 3.7529102883127052e-06
Dax O 0 0.0023812344297766685
- O 0 3.32298077410087e-06
1 O 0 1.512286985416722e-06
modulate O 0 2.1105581708980026e-06
the O 0 1.1919391909032129e-06
orphan O 0 6.527755886054365e-06
nuclear O 0 1.0933002158708405e-05
receptor O 0 5.256718850432662e-06
SF O 0 8.38275154819712e-05
- O 0 5.708674279958359e-07
1 O 0 1.467882100314455e-07
in O 0 2.284573241695398e-08
sex O 0 3.243888713200249e-08
- O 0 9.993937766239469e-08
specific O 0 1.0266079542020634e-08
gene O 0 2.6544216780166607e-07
expression O 0 1.8427084569339058e-06
. O 0 1.4032087847226649e-06

Products O 0 5.335387686500326e-05
of O 0 4.860650733462535e-05
steroidogenic O 0 0.00026504829293116927
factor O 0 1.2141725164838135e-05
1 O 0 3.5954590202891268e-06
( O 0 2.0125389710301533e-07
SF O 0 1.8111120880348608e-05
- O 0 5.799712425869075e-07
1 O 0 3.461589130893117e-07
) O 0 2.862754477916951e-08
and O 0 1.486973673081593e-07
Wilms B-Disease 0 0.00038253358798101544
tumor I-Disease 0 0.0016610822640359402
1 O 0 5.956445420451928e-06
( O 0 2.5042893980753433e-07
WT1 O 0 5.448010597319808e-06
) O 0 2.309321622817606e-08
genes O 0 9.110312504390095e-09
are O 0 3.548457749857903e-09
essential O 0 2.62411141704888e-08
for O 0 7.250933720115427e-08
mammalian O 0 3.074486812693067e-06
gonadogenesis O 0 4.441981218405999e-06
prior O 0 5.474784643411112e-07
to O 0 6.517123551930126e-08
sexual O 0 5.410417998064077e-07
differentiation O 0 8.599209650128614e-06
. O 0 2.508003717593965e-06

In O 0 5.215031706029549e-05
males O 0 2.5178967462125e-06
, O 0 2.096187927236315e-06
SF O 0 0.0002091806527459994
- O 0 2.9449308840412414e-06
1 O 0 1.0345650025556097e-06
participates O 0 5.109294320959634e-08
in O 0 5.565160066112185e-08
sexual O 0 4.383609919500486e-08
development O 0 2.7196716700927936e-07
by O 0 3.8657415046827737e-08
regulating O 0 5.57595399186539e-07
expression O 0 5.306045522956992e-07
of O 0 2.9097004698996898e-06
the O 0 7.650884981558193e-06
polypeptide O 0 3.707413998199627e-05
hormone O 0 8.210286978282966e-06
Mullerian O 0 6.338574166875333e-05
inhibiting O 0 6.4565629145363346e-06
substance O 0 4.338176950113848e-06
( O 0 7.834618145352579e-07
MIS O 0 0.00020032473548781127
) O 0 5.494283641382935e-07
. O 0 9.00347060905915e-07

Here O 0 9.800777479540557e-05
, O 0 1.8618318335938966e-06
we O 0 2.4161431610991713e-07
show O 0 9.411111818735662e-07
that O 0 1.6280141608149279e-06
WT1 O 0 0.00021537818247452378
- O 0 8.67756680236198e-05
KTS O 0 0.0009965384379029274
isoforms O 0 5.982724815112306e-06
associate O 0 8.79332310432801e-06
and O 0 4.5591895059260423e-07
synergize O 0 6.7722144194704015e-06
with O 0 8.551135692869138e-07
SF O 0 0.001463912078179419
- O 0 6.146271971374517e-06
1 O 0 5.551218578148109e-07
to O 0 6.191154255930087e-08
promote O 0 1.625023514861823e-06
MIS O 0 0.005076991859823465
expression O 0 8.841042472340632e-06
. O 0 1.8823902792064473e-06

In O 0 3.6214762076269835e-05
contrast O 0 1.154472465714207e-05
, O 0 4.05118044000119e-06
WT1 O 0 0.00032618126715533435
missense O 0 1.5026653272798285e-05
mutations O 0 1.2796507462553564e-06
, O 0 1.7802635454700066e-07
associated O 0 8.954543773143087e-08
with O 0 6.248180284273985e-08
male B-Disease 0 2.6992816856363788e-05
pseudohermaphroditism I-Disease 1 1.0
in O 0 0.3829456865787506
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.4416121985050268e-06
fail O 0 3.1016938351058343e-07
to O 0 7.814345792667154e-08
synergize O 0 9.921582204697188e-06
with O 0 1.8051191545964684e-06
SF O 1 0.9995850920677185
- O 0 0.00016381593013647944
1 O 0 1.5797468222444877e-05
. O 0 1.000868110168085e-06

Additionally O 0 0.00012263856478966773
, O 0 5.045907073508715e-06
the O 0 5.1611991693789605e-06
X O 0 0.00013443874195218086
- O 0 3.680244117276743e-05
linked O 0 3.589363404898904e-05
, O 0 4.2245065401402826e-07
candidate O 0 7.059281870169798e-07
dosage O 0 1.75712975760689e-05
- O 0 1.1250182978983503e-05
sensitive O 0 8.042270565056242e-06
sex O 0 8.256874934886582e-07
- O 0 2.96703228741535e-06
reversal O 0 1.1589777386689093e-05
gene O 0 2.53080486345425e-07
, O 0 2.414788582427718e-07
Dax O 0 6.866799230920151e-05
- O 0 6.698244305880507e-07
1 O 0 3.3810565014391614e-07
, O 0 2.457608516692744e-08
antagonizes O 0 3.068260525651567e-07
synergy O 0 5.691844080502051e-07
between O 0 2.012131517403759e-06
SF O 0 0.00014339954941533506
- O 0 2.8499680411187e-06
1 O 0 1.4045905345483334e-06
and O 0 3.784707871545834e-07
WT1 O 0 3.101320908172056e-05
, O 0 1.436012126987407e-07
most O 0 2.5335715747587528e-08
likely O 0 3.208775822827192e-08
through O 0 2.58755612492223e-08
a O 0 4.3723453302391135e-08
direct O 0 8.728680001013345e-08
interaction O 0 4.0965403513837373e-07
with O 0 5.083942369310535e-07
SF O 0 0.0071187857538461685
- O 0 1.940588845172897e-05
1 O 0 3.6051965253136586e-06
. O 0 4.3655791159835644e-07

We O 0 3.1887222576187924e-05
propose O 0 8.51845288707409e-06
that O 0 2.3302870886254823e-06
WT1 O 0 0.00015962323232088238
and O 0 4.9914219744096044e-06
Dax O 0 0.012427624315023422
- O 0 6.673494226561161e-06
1 O 0 9.62563944995054e-07
functionally O 0 3.2120277637659456e-07
oppose O 0 3.8435967297800744e-08
each O 0 7.574613825056531e-09
other O 0 1.1486635642654619e-08
in O 0 1.7221550763224514e-07
testis O 0 1.1197178537258878e-05
development O 0 2.454105924698524e-06
by O 0 4.699187741152855e-07
modulating O 0 1.3955530448583886e-05
SF O 0 0.0003194891905877739
- O 0 3.0976193556853104e-06
1 O 0 1.1886800166394096e-06
- O 0 5.862137868462014e-07
mediated O 0 2.3012041765468894e-06
transactivation O 0 1.4210932931746356e-05
. O 0 1.5936628017243493e-07
. O 0 3.0575142773159314e-07

A O 0 0.0002181621821364388
mouse O 0 2.2877249648445286e-05
model O 0 7.61199908083654e-06
for O 0 1.4927273696230259e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999998807907104
- O 1 0.9986598491668701
centre O 0 0.1589903086423874
mutations O 0 1.9481690287648235e-06
. O 0 1.0109879440278746e-06

Imprinting O 0 0.0019323270535096526
in O 0 7.057059701764956e-05
the O 0 3.057311914744787e-05
15q11 O 0 0.0001291894295718521
- O 0 3.5109966120216995e-05
q13 O 0 5.259511453914456e-05
region O 0 2.332594931431231e-06
involves O 0 1.737440356919251e-06
an O 0 1.4830806094323634e-06
imprinting O 0 1.4335631931317039e-05
centre O 0 0.00018583393830340356
( O 0 4.3521274051272485e-07
IC O 0 8.584574970882386e-06
) O 0 4.694206978683724e-08
, O 0 1.8317258820843563e-08
mapping O 0 2.8878974944746005e-07
in O 0 2.685895594822796e-07
part O 0 3.487088804376981e-07
to O 0 2.3746183330786153e-07
the O 0 2.1401649519248167e-06
promoter O 0 9.082276847038884e-06
and O 0 2.419516533791466e-07
first O 0 1.7255166540053324e-06
exon O 0 2.6565944608591963e-06
of O 0 1.2147434972575866e-05
SNRPN O 0 0.0007920069037936628
. O 0 4.9310697249893565e-06

Deletion O 0 0.0003204048553016037
of O 0 3.8306443457258865e-05
this O 0 4.145554157730658e-06
IC O 0 0.00030742926173843443
abolishes O 0 5.5242839152924716e-05
local O 0 1.3617758440886973e-06
paternally O 0 4.888642251899e-06
derived O 0 1.627204113674452e-07
gene O 0 7.220997844115118e-08
expression O 0 8.795848316367483e-08
and O 0 1.962278517453342e-08
results O 0 1.2753642408824817e-07
in O 0 2.4100870632537408e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9685297012329102
PWS B-Disease 1 1.0
) O 0 3.7379829791461816e-06
. O 0 1.940806896527647e-06

We O 0 1.8374723367742263e-05
have O 0 6.061190447326226e-07
created O 0 5.159906777407741e-07
two O 0 1.841354162479547e-07
deletion O 0 1.6090812096081208e-06
mutations O 0 3.603446430133772e-07
in O 0 2.190927943956922e-06
mice O 0 3.2712823667679913e-06
to O 0 8.261033599410439e-07
understand O 0 1.8604260958454688e-06
PWS B-Disease 1 1.0
and O 0 1.4484585335594602e-06
the O 0 1.0996536730090156e-06
mechanism O 0 1.3024763347857515e-06
of O 0 3.879986707033822e-06
this O 0 1.1548141856110306e-06
IC O 0 0.00019331322982907295
. O 0 2.2695646748616127e-06

Mice O 0 0.002806209959089756
harbouring O 0 0.00331235327757895
an O 0 1.7183852833113633e-05
intragenic O 0 0.00016681477427482605
deletion O 0 5.440904351416975e-05
in O 0 2.1382989871199243e-05
Snrpn O 0 0.002942969324067235
are O 0 1.6555105730731157e-06
phenotypically O 0 4.2305186070734635e-05
normal O 0 1.0466288586030714e-05
, O 0 1.7013951492117485e-07
suggesting O 0 1.5899814798103762e-07
that O 0 2.6742297265514026e-08
mutations O 0 9.489288288477837e-08
of O 0 1.5626658296241658e-06
SNRPN O 0 3.4550888813100755e-05
are O 0 3.018174155045017e-08
not O 0 7.298161186497509e-09
sufficient O 0 2.057920340803321e-07
to O 0 1.0227322491118684e-06
induce O 0 0.0002218828012701124
PWS B-Disease 1 1.0
. O 0 2.2120224457466975e-05

Mice O 0 0.00010640054824762046
with O 0 6.885745165163826e-07
a O 0 1.1422205261624185e-06
larger O 0 2.0416892709818057e-07
deletion O 0 2.007753209909424e-06
involving O 0 7.001314088483923e-07
both O 0 1.4749856518392335e-06
Snrpn O 0 0.00010421114711789414
and O 0 2.0733759811264463e-06
the O 0 1.6723353837733157e-05
putative O 0 0.0006582566420547664
PWS O 1 1.0
- O 0 0.0002021157561102882
IC O 0 0.00010371773532824591
lack O 0 1.4488383612842881e-06
expression O 0 6.496509854514443e-07
of O 0 3.215649030607892e-06
the O 0 1.853088178904727e-06
imprinted O 0 4.369379439594923e-06
genes O 0 1.072525947165559e-06
Zfp127 O 0 2.364479769312311e-05
( O 0 5.238654807726562e-07
mouse O 0 1.2388875347824069e-06
homologue O 0 6.533916348416824e-06
of O 0 9.20236561796628e-06
ZNF127 O 0 0.00010017685417551547
) O 0 8.320864708366571e-07
, O 0 7.284729122147837e-07
Ndn O 0 1.3911680071032606e-05
and O 0 8.681043368596875e-07
Ipw O 0 5.469807729241438e-05
, O 0 1.822599102752065e-07
and O 0 5.866321117764528e-08
manifest O 0 5.848283421983069e-07
several O 0 1.2460785114853934e-07
phenotypes O 0 3.433947313169483e-06
common O 0 1.6409580894105602e-06
to O 0 1.6006059013307095e-05
PWS B-Disease 1 1.0
infants O 1 0.8601515889167786
. O 0 5.4757847465225495e-06

These O 0 8.574723324272782e-06
data O 0 4.409015218698187e-06
demonstrate O 0 1.8409607491776114e-06
that O 0 5.807715410810488e-07
both O 0 3.803138781677262e-07
the O 0 2.225616526629892e-06
position O 0 3.5415127968008164e-06
of O 0 9.995393156714272e-06
the O 0 1.2147666893724818e-05
IC O 0 4.0645165427122265e-05
and O 0 2.611529623663955e-07
its O 0 2.173018742723798e-07
role O 0 4.491118090754753e-07
in O 0 4.7571387540301657e-07
the O 0 3.531041272708535e-07
coordinate O 0 3.216804032035725e-07
expression O 0 1.3089814956401824e-06
of O 0 1.0182953701587394e-05
genes O 0 6.532891916322114e-07
is O 0 5.590698606283695e-07
conserved O 0 4.214611237784993e-07
between O 0 1.4128769407761865e-06
mouse O 0 1.2149056374255451e-06
and O 0 2.2383657949376357e-07
human O 0 6.107983381298254e-07
, O 0 7.652277389524897e-08
and O 0 8.874071966147312e-08
indicate O 0 9.00604732123611e-07
that O 0 2.0012353729725874e-07
the O 0 1.3281793371788808e-06
mouse O 0 1.227810116688488e-06
is O 0 1.2063384247085196e-07
a O 0 1.5636122441264888e-07
suitable O 0 2.4160209477486205e-07
model O 0 4.975758542968833e-07
system O 0 4.171620560100564e-07
in O 0 1.0135957495549519e-07
which O 0 4.716896029322015e-08
to O 0 4.118342289416432e-08
investigate O 0 9.735595796200869e-08
the O 0 8.861620131028758e-07
molecular O 0 4.587356670526788e-06
mechanisms O 0 3.972149897890631e-06
of O 0 1.657208485994488e-05
imprinting O 0 1.1465804163890425e-05
in O 0 6.314276106422767e-07
this O 0 5.424653082286568e-08
region O 0 5.8865072816161046e-08
of O 0 4.399055058001977e-07
the O 0 3.0617070478911046e-07
genome O 0 3.410669648928888e-07
. O 0 8.9865402230771e-08
. O 0 5.049076321483881e-07

Mutations O 0 3.711347744683735e-05
of O 0 3.8845329981995746e-05
the O 0 6.457769814005587e-06
ATM O 0 6.0440721426857635e-05
gene O 0 7.215765549517528e-07
detected O 0 2.2792451090936083e-06
in O 0 4.317284492572071e-06
Japanese O 1 0.899693489074707
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.8756210207939148
: O 0 1.5521634111337335e-07
possible O 0 5.1942301126928214e-08
preponderance O 0 8.069681825872976e-06
of O 0 1.0826961442944594e-05
the O 0 3.151817509206012e-06
two O 0 9.164392622551532e-07
founder O 0 2.7116224373457953e-05
mutations O 0 1.0489644637345918e-06
4612del165 O 0 2.110129025822971e-05
and O 0 1.7629974990995834e-06
7883del5 O 0 6.061248859623447e-05
. O 0 5.1795273066090886e-06

The O 0 0.00042247946839779615
ATM O 0 0.0017465256387367845
( O 0 2.643847619765438e-05
A O 1 0.999698281288147
- O 1 0.9863726496696472
T O 1 0.9999802112579346
, O 0 4.024937254598626e-07
mutated O 0 1.738199699730103e-07
) O 0 3.709168794330253e-08
gene O 0 5.989981133325273e-08
on O 0 5.899556754229707e-07
human O 0 1.778493242454715e-06
chromosome O 0 6.039370418875478e-05
11q22 O 0 0.00010418192687211558
. O 0 4.539879228104837e-06

3 O 0 0.00019393261754885316
has O 0 7.5163825385970995e-06
recently O 0 3.621164523792686e-06
been O 0 7.488854407711187e-07
identified O 0 1.3712146085254062e-07
as O 0 6.222657589205483e-08
the O 0 6.640973992944055e-08
gene O 0 4.7784361356661975e-08
responsible O 0 5.760245613828374e-08
for O 0 7.091157527838732e-08
the O 0 2.288910081915674e-06
human O 0 0.004100126214325428
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9851657748222351
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 5.990134923195001e-06
. O 0 1.5822895420569694e-06

In O 0 3.7293000787030905e-05
order O 0 2.2749084109818796e-06
to O 0 4.759280614052841e-07
define O 0 5.226787607170991e-07
the O 0 1.041397126755328e-06
types O 0 5.904667546019482e-07
of O 0 0.0002911934570875019
disease O 1 0.9998375177383423
- O 0 0.0019528805278241634
causing O 0 3.211485091014765e-05
ATM O 0 2.9344208087422885e-05
mutations O 0 1.336750159453004e-07
in O 0 9.722843969939277e-07
Japanese O 0 5.9024652728112414e-05
A B-Disease 1 0.9999970197677612
- I-Disease 1 0.999971866607666
T I-Disease 1 0.9999992847442627
patients O 0 1.1360260714354808e-06
as O 0 4.397217878704396e-07
well O 0 1.2378561109471775e-07
as O 0 1.6398460900290956e-07
to O 0 3.863485886768103e-08
look O 0 7.292389625490614e-08
for O 0 8.041727994623216e-08
possible O 0 3.4604008192218316e-07
mutational O 0 3.596616807044484e-05
hotspots O 0 1.2191222594992723e-05
, O 0 2.502689540051506e-07
reverse O 0 1.1834949873446021e-06
- O 0 1.2151339205956901e-06
transcribed O 0 1.1892515203726362e-06
RNA O 0 6.390815201484656e-07
derived O 0 1.4735992692749278e-07
from O 0 3.2773414204712026e-07
ten O 0 4.595421216890827e-07
patients O 0 8.598453860031441e-08
belonging O 0 3.6332883723844134e-07
to O 0 7.274927327216574e-08
eight O 0 4.045965624754899e-07
unrelated O 0 1.045478029482183e-06
Japanese O 0 7.014522998360917e-05
A B-Disease 1 0.9999986886978149
- I-Disease 1 0.9987955093383789
T I-Disease 1 0.9999039173126221
families O 0 1.1659040666245346e-07
was O 0 1.1465947409305954e-06
analyzed O 0 1.2043440733577881e-07
for O 0 2.686386579853206e-08
mutations O 0 3.2318954623633545e-08
by O 0 1.968891893966429e-08
the O 0 7.560471715351014e-08
restriction O 0 4.3220575207669754e-07
endonuclease O 0 1.8160110357712256e-06
fingerprinting O 0 5.040877795181586e-07
method O 0 7.264076771207328e-07
. O 0 5.839439154442516e-07

As O 0 8.50593569339253e-05
has O 0 3.92430774809327e-06
been O 0 1.9041979157918831e-06
reported O 0 9.101698310587381e-07
by O 0 1.4272985993102338e-07
others O 0 7.935889811960806e-08
, O 0 3.904213841110504e-08
mutations O 0 5.872780661775323e-08
that O 0 1.243013798557513e-07
lead O 0 8.102448418867425e-07
to O 0 4.553584176392178e-07
exon O 0 9.817567843128927e-06
skipping O 0 1.6097770640044473e-05
or O 0 3.8136895454954356e-06
premature O 0 2.0100629626540467e-05
protein O 0 2.8502995519374963e-06
truncation O 0 1.562917350383941e-05
were O 0 1.851690740295453e-06
also O 0 1.257741644167254e-07
predominant O 0 2.0443273740511358e-07
in O 0 1.1330058669045684e-07
our O 0 3.091806206612091e-07
mutants O 0 4.114191597182071e-06
. O 0 1.1758077107515419e-06

Six O 0 3.922959149349481e-05
different O 0 2.908932685841137e-07
mutations O 0 1.7024188991854317e-06
were O 0 2.4698415472812485e-06
identified O 0 2.6915060402643576e-07
on O 0 1.1984828915956314e-06
12 O 0 1.0984293794535915e-06
of O 0 1.6525797263966524e-06
the O 0 2.102073494825163e-06
16 O 0 6.634810233663302e-06
alleles O 0 2.2296953829936683e-06
examined O 0 1.4323523828352336e-05
. O 0 4.055888894072268e-06

Four O 0 5.673040504916571e-05
were O 0 8.6571189967799e-06
deletions O 0 8.155169780366123e-06
involving O 0 5.138685992278624e-06
a O 0 5.555049483518815e-06
loss O 0 3.710392411448993e-05
of O 0 3.308982195449062e-05
a O 0 5.175764727027854e-06
single O 0 1.5719928114776849e-06
exon O 0 1.213895757246064e-06
exon O 0 1.244346321982448e-06
7 O 0 2.1363066480262205e-06
, O 0 1.6270814739982598e-07
exon O 0 5.167667609384807e-07
16 O 0 8.128080821734329e-07
, O 0 6.209970848658486e-08
exon O 0 3.212441299638158e-07
33 O 0 2.2591796096094185e-06
or O 0 5.701029976989958e-07
exon O 0 2.8907074920425657e-06
35 O 0 6.884891263325699e-06
. O 0 1.4732087265656446e-06

The O 0 0.00020449129806365818
others O 0 4.14245187130291e-06
were O 0 2.954472847704892e-06
minute O 0 1.5771569223943516e-06
deletions O 0 2.0567501906043617e-06
, O 0 3.64745659453547e-07
4649delA O 0 3.298775482107885e-06
in O 0 7.569409490315593e-07
exon O 0 2.8764543458237313e-06
33 O 0 5.514475560630672e-06
and O 0 5.733411967412394e-07
7883del5 O 0 1.4884584743413143e-05
in O 0 2.7738149128708756e-06
exon O 0 1.2156299817434046e-05
55 O 0 1.7675514754955657e-05
. O 0 2.6014897684945026e-06

The O 0 0.00019153575703967363
mutations O 0 3.745627327589318e-05
4612del165 O 0 0.00022324644669424742
and O 0 5.834346211486263e-06
7883del5 O 0 5.6582794059067965e-05
were O 0 1.0638441381161101e-05
found O 0 5.04308957260946e-07
in O 0 3.815061120349128e-07
more O 0 1.4570738393615557e-08
than O 0 4.615510462713246e-08
two O 0 7.267340862426863e-08
unrelated O 0 2.6794330665325106e-07
families O 0 2.4783108898418504e-08
; O 0 7.736423945914339e-09
44 O 0 1.8618624153532437e-07
% O 0 7.62807275123123e-08
( O 0 2.1840252273364058e-08
7 O 0 5.938647404946096e-07
of O 0 1.5237990282912506e-06
16 O 0 2.2785823148296913e-06
) O 0 5.134538128004351e-08
of O 0 2.981413445013459e-07
the O 0 4.98177939789457e-07
mutant O 0 4.864483003075293e-07
alleles O 0 1.927285779856902e-07
had O 0 1.05166702724091e-06
one O 0 5.094094746027622e-08
of O 0 3.7691617649215914e-07
the O 0 3.8360497001121985e-07
two O 0 1.502295106092788e-07
mutations O 0 6.600148481084034e-07
. O 0 1.5429261566168861e-06

The O 0 0.00019648403394967318
4612del165 O 0 0.00018640873895492405
mutations O 0 3.5444593322608853e-06
in O 0 3.7539696222665953e-06
three O 0 4.062816003624903e-07
different O 0 1.9168918896639298e-08
families O 0 4.3289215767572387e-08
were O 0 4.92013441544259e-07
all O 0 8.386256666881309e-08
ascribed O 0 2.259625716760638e-06
to O 0 2.696099272725405e-07
the O 0 1.7837145378507557e-06
same O 0 1.4638759466834017e-06
T O 0 8.311971214425284e-06
- O 0 1.5312883760998375e-06
- O 0 1.7043196294252994e-06
> O 0 7.822396810297505e-07
A O 0 1.2034364544888376e-06
substitution O 0 6.415852453756088e-07
at O 0 1.8642285795067437e-06
the O 0 1.795410469185299e-07
splice O 0 4.6174830004019896e-07
donor O 0 4.472491070828255e-07
site O 0 1.2072655408701394e-06
in O 0 1.480148625887523e-06
intron O 0 7.344404730247334e-05
33 O 0 3.51848138961941e-05
. O 0 4.347143203631276e-06

Microsatellite O 0 0.0010858145542442799
genotyping O 0 0.00025632540928199887
around O 0 1.7297101294388995e-05
the O 0 5.362381671147887e-06
ATM O 0 5.7882243709173054e-05
locus O 0 1.5465131582459435e-05
also O 0 9.076855462808453e-07
indicated O 0 1.1103242059107288e-06
that O 0 9.384711319171402e-08
a O 0 3.6806062553296215e-07
common O 0 2.2184084969012474e-07
haplotype O 0 6.437895990529796e-06
was O 0 5.524987045646412e-06
shared O 0 1.5740974390610063e-07
by O 0 8.516452254525575e-08
the O 0 2.774410177153186e-07
mutant O 0 5.325618985807523e-07
alleles O 0 1.3893189532154793e-07
in O 0 1.5985993684353161e-07
both O 0 1.400350413405249e-07
mutations O 0 4.774200306201237e-07
. O 0 1.0045113185697119e-06

This O 0 2.3223061361932196e-05
suggests O 0 4.336344318289775e-06
that O 0 1.916070004881476e-07
these O 0 7.920768041458359e-08
two O 0 1.0171994517804706e-06
founder O 0 3.764469875022769e-05
mutations O 0 6.415828579520166e-07
may O 0 7.926327043605852e-07
be O 0 5.3469623395585586e-08
predominant O 0 1.5886234905337915e-07
among O 0 1.0777818637563996e-08
Japanese O 0 4.316809452120651e-07
ATM O 0 1.2723671716230456e-05
mutant O 0 3.1984238830773393e-06
alleles O 0 1.031511828841758e-06
. O 0 9.906859759212239e-07

W474C O 0 0.004859201610088348
amino O 0 0.0001654877996770665
acid O 0 9.38391804083949e-06
substitution O 0 6.058663984731538e-06
affects O 0 4.5753404265269637e-07
early O 0 7.946429718685977e-07
processing O 0 7.94597497133509e-07
of O 0 1.1993038242508192e-06
the O 0 1.9276731109130196e-06
alpha O 0 2.064055934170028e-06
- O 0 1.5229143457418104e-07
subunit O 0 2.7219448384130374e-07
of O 0 1.9730475742107956e-06
beta O 0 1.3745700016443152e-05
- O 0 4.663633262680378e-06
hexosaminidase O 0 7.900224773038644e-06
A O 0 1.984294158319244e-06
and O 0 7.455049910731759e-08
is O 0 5.5997222858650275e-08
associated O 0 9.490428709568732e-08
with O 0 2.5349959287268575e-07
subacute O 1 0.991675615310669
G B-Disease 0 0.009614817798137665
( I-Disease 0 2.067943341899081e-06
M2 I-Disease 0 0.0009136885637417436
) I-Disease 0 1.329541646555299e-06
gangliosidosis I-Disease 0 4.185981742921285e-05
. O 0 1.5962790484991274e-06

Mutations O 0 4.606141374097206e-05
in O 0 1.5047059605421964e-05
the O 0 1.2101553693355527e-05
HEXA O 0 0.000225344774662517
gene O 0 7.466291549462767e-07
, O 0 1.2343737409992173e-07
encoding O 0 9.345378515490665e-08
the O 0 8.241950695264677e-07
alpha O 0 1.3762218031843076e-06
- O 0 1.6786474077434832e-07
subunit O 0 1.758415777430855e-07
of O 0 1.988700660149334e-06
beta O 0 5.15677675139159e-06
- O 0 2.5536774046486244e-06
hexosaminidase O 0 7.004292001511203e-06
A O 0 6.4106743593583815e-06
( O 0 1.7843736088707374e-07
Hex O 0 3.0562973734049592e-06
A O 0 1.0235557965643238e-06
) O 0 1.5267207942315508e-08
, O 0 6.1411333796002054e-09
that O 0 1.0032570330054114e-08
abolish O 0 4.4296186274550564e-07
Hex O 0 5.448083811643301e-06
A O 0 1.029551185638411e-06
enzyme O 0 6.049156127119204e-07
activity O 0 4.2614606172719505e-06
cause O 0 0.0001162139669759199
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9575173258781433
( O 0 1.062710907717701e-06
TSD B-Disease 0 0.00011459216329967603
) O 0 1.4562854744326614e-07
, O 0 5.830814231444492e-08
the O 0 5.95573624195822e-07
fatal O 0 0.00021905447647441179
infantile B-Disease 0 0.03869262710213661
form I-Disease 0 1.598167955307872e-06
of I-Disease 0 0.043882884085178375
G I-Disease 0 0.00018411746714264154
( I-Disease 0 6.284958544711117e-07
M2 I-Disease 0 7.129380537662655e-05
) I-Disease 0 1.3299116119469545e-07
gangliosidosis I-Disease 0 2.0653319552366156e-06
, I-Disease 0 3.53540734465696e-08
Type I-Disease 0 3.2075098488348885e-07
1 I-Disease 0 2.2281776637100847e-06
. O 0 6.313601375040889e-07

Less O 0 0.0002338301856070757
severe O 1 0.9988515377044678
, O 0 2.089941881422419e-05
subacute O 1 0.9969509840011597
( O 0 6.34965363133233e-06
juvenile O 1 0.8688960075378418
- O 0 0.0002892794436775148
onset O 1 0.999996542930603
) O 0 7.436839041474741e-06
and O 0 3.7355395761551335e-05
chronic O 1 1.0
( O 0 1.013457131193718e-05
adult O 0 5.6107914133463055e-05
- O 0 0.08496277779340744
onset O 1 0.9998655319213867
) O 0 1.713505071165855e-07
variants O 0 1.0428905028447844e-07
are O 0 2.3506910196147146e-08
characterized O 0 3.236386092453358e-08
by O 0 9.136797984865552e-09
a O 0 9.419016322453899e-08
broad O 0 3.2956484119495144e-07
spectrum O 0 3.232345875403553e-07
of O 0 1.0362119837736827e-06
clinical O 0 9.379497896588873e-06
manifestations O 0 2.55765589827206e-05
and O 0 3.5732432479562704e-07
are O 0 1.8511485677663586e-08
associated O 0 1.787615744319737e-08
with O 0 1.071759214710255e-08
residual O 0 3.820489382633241e-06
levels O 0 1.310288098466117e-05
of O 0 1.5114567759155761e-05
Hex O 0 5.480286563397385e-05
A O 0 3.613023409343441e-06
enzyme O 0 7.292723012142233e-07
activity O 0 3.099451532762032e-06
. O 0 6.857036396468175e-07

We O 0 4.2825649870792404e-05
identified O 0 9.809885341383051e-06
a O 0 6.089492671890184e-06
1422 O 0 0.0003423296438995749
G O 0 3.2085124985314906e-05
- O 0 8.350752068508882e-06
- O 0 7.016593372100033e-06
> O 0 3.4565391615615226e-06
C O 0 7.097778961906442e-06
( O 0 2.0409301271229197e-07
amino O 0 4.7404091674252413e-07
acid O 0 2.585600782367692e-07
W474C O 0 2.0155230231466703e-06
) O 0 6.534262553259396e-08
substitution O 0 2.956433036160888e-07
in O 0 1.2189880749247095e-07
the O 0 2.3539625715329748e-07
first O 0 3.2686045869922964e-07
position O 0 7.157318009376468e-07
of O 0 2.5556607852195157e-06
exon O 0 1.6597914509475231e-06
13 O 0 3.203870164725231e-06
of O 0 8.743376383790746e-06
HEXA O 0 0.00038356485310941935
of O 0 2.2046682715881616e-05
a O 0 1.04747969089658e-05
non O 0 2.8815977202611975e-05
- O 0 1.7394268070347607e-05
Jewish O 0 4.7061671466508415e-06
proband O 0 2.4561084501328878e-05
who O 0 2.884080174681003e-07
manifested O 0 1.5362395515694516e-06
a O 0 9.70922314991185e-07
subacute O 0 5.1607799832709134e-05
variant O 0 3.6651840673584957e-06
of O 0 0.00016410094394814223
G B-Disease 0 0.0002469984465278685
( I-Disease 0 1.7786491071092314e-06
M2 I-Disease 0 0.00043630835716612637
) I-Disease 0 1.5948091913742246e-06
gangliosidosis I-Disease 0 4.6952383854659274e-05
. O 0 2.171946789530921e-06

On O 0 0.00035398354521021247
the O 0 4.618959064828232e-05
second O 0 4.028943658340722e-05
maternally O 0 8.719223842490464e-05
inherited O 0 0.00015489902580156922
allele O 0 3.6718804494739743e-06
, O 0 1.178836512849557e-07
we O 0 2.3823321981808476e-08
identified O 0 8.76897985335745e-08
the O 0 4.745746764456271e-07
common O 0 5.9470348787726834e-06
infantile O 1 0.9999983310699463
disease O 1 0.9997469782829285
- O 0 0.00010444373765494674
causing O 0 8.925480506150052e-05
4 O 0 1.9007155060535297e-05
- O 0 8.823656571621541e-06
bp O 0 6.746121016476536e-06
insertion O 0 1.7643162664171541e-06
, O 0 4.61097926063303e-07
+ O 0 7.004846906966122e-07
TATC O 0 1.3234000107331667e-05
1278 O 0 1.9697239622473717e-05
, O 0 1.377216847231466e-07
in O 0 3.4187425512755e-07
exon O 0 2.319772647751961e-06
11 O 0 5.992774276819546e-06
. O 0 1.1532822554727318e-06

Pulse O 0 0.002352277049794793
- O 0 7.437253225361928e-05
chase O 0 6.6798356783692725e-06
analysis O 0 5.049928404332604e-07
using O 0 5.356349106477865e-07
proband O 0 5.995964602334425e-05
fibroblasts O 0 2.1772950276499614e-05
revealed O 0 9.919614058162551e-06
that O 0 4.623299503236922e-07
the O 0 1.7240577108168509e-06
W474C O 0 6.625799414905487e-06
- O 0 7.12778273737058e-07
containing O 0 3.861276525185531e-07
alpha O 0 2.919584858318558e-06
- O 0 3.4875409937740187e-07
subunit O 0 4.3886171852136613e-07
precursor O 0 2.2090423499321332e-06
was O 0 4.344283752288902e-06
normally O 0 1.4345174292884622e-07
synthesized O 0 5.177366233510838e-07
, O 0 5.201864183845828e-08
but O 0 1.01623962578401e-08
not O 0 1.600197130358083e-08
phosphorylated O 0 2.817095889895427e-07
or O 0 1.6053964202455973e-07
secreted O 0 5.49965193386015e-07
, O 0 6.492978599226262e-08
and O 0 5.1678551216127744e-08
the O 0 7.01460010077426e-07
mature O 0 8.27965550342924e-07
lysosomal O 0 3.321451004012488e-05
alpha O 0 5.89016281082877e-06
- O 0 3.717158563176781e-07
subunit O 0 2.710009141537739e-07
was O 0 9.122903179559216e-07
not O 0 5.657328472352674e-08
detected O 0 1.9923625131923473e-06
. O 0 9.862196748144925e-07

When O 0 7.130604353733361e-05
the O 0 1.6073134247562848e-05
W474C O 0 2.4120385205606e-05
- O 0 2.9546363293775357e-06
containing O 0 9.975947250495665e-07
alpha O 0 3.665177018774557e-06
- O 0 3.679911344534048e-07
subunit O 0 5.343058546714019e-07
was O 0 6.063056389393751e-06
transiently O 0 2.3271334157470847e-06
co O 0 1.3086182661936618e-06
- O 0 3.098713534654962e-07
expressed O 0 2.2804576360613282e-07
with O 0 4.89559930372252e-08
the O 0 1.0123878837475786e-06
beta O 0 1.2962074151801062e-06
- O 0 2.6653165718926175e-07
subunit O 0 1.9269384665676625e-07
to O 0 6.038734312596716e-08
produce O 0 2.062232624666649e-07
Hex O 0 1.6010624676709995e-05
A O 0 5.872819656360662e-06
( O 0 1.565429670336016e-07
alphabeta O 0 3.960567482863553e-06
) O 0 1.0931356797527769e-07
in O 0 1.1925678791158134e-06
COS O 0 5.1026039727730677e-05
- O 0 3.4742004118015757e-06
7 O 0 2.7885669169336325e-06
cells O 0 1.688372037733643e-07
, O 0 4.518750884585643e-08
the O 0 1.6817111259115336e-07
mature O 0 1.3335274218206905e-07
alpha O 0 8.070197736742557e-07
- O 0 1.0630296998215272e-07
subunit O 0 1.383306056368383e-07
was O 0 9.00195971098583e-07
present O 0 8.465486445174975e-08
, O 0 3.197302334001506e-08
but O 0 1.0409345385653523e-08
its O 0 6.538002850220437e-08
level O 0 3.2930829547694884e-06
was O 0 1.331121166003868e-05
much O 0 6.410794526345853e-07
lower O 0 3.976971129304729e-06
than O 0 7.96878936171197e-08
that O 0 5.1625054453552366e-08
from O 0 3.2944294048320444e-07
normal O 0 1.7471505771027296e-06
alpha O 0 3.1977710932551417e-06
- O 0 4.406192886108329e-07
subunit O 0 5.073988518233818e-07
transfections O 0 3.2059058412414743e-06
, O 0 7.859998163439741e-08
although O 0 6.53820180218645e-08
higher O 0 4.1482181245555694e-07
than O 0 2.6139160169691422e-08
in O 0 2.5723170438141096e-07
those O 0 5.996474072844649e-08
cells O 0 2.569061336998857e-07
transfected O 0 1.0362929288021405e-06
with O 0 5.211457576592693e-08
an O 0 3.1363526886707405e-07
alpha O 0 3.210176828361e-06
- O 0 5.401998919296602e-07
subunit O 0 4.900092562820646e-07
associated O 0 2.9867609896427894e-07
with O 0 4.2010037759609986e-07
infantile O 1 0.9554424285888672
TSD B-Disease 0 0.03113817609846592
. O 0 5.765538389823632e-06

Furthermore O 0 8.45242539071478e-05
, O 0 2.13155090023065e-06
the O 0 2.3063012122293003e-06
precursor O 0 6.718743861711118e-06
level O 0 1.2241901458764914e-05
of O 0 1.5307587091228925e-05
the O 0 1.544524639029987e-05
W474C O 0 3.6004021239932626e-05
alpha O 0 1.953929677256383e-05
- O 0 1.614805796634755e-06
subunit O 0 1.0565747743385145e-06
was O 0 2.7007672542822547e-06
found O 0 9.830029057411593e-08
to O 0 3.326875841480614e-08
accumulate O 0 1.6295366833674052e-07
in O 0 1.4164506012548372e-07
comparison O 0 1.7059313961453881e-07
to O 0 7.175717087193334e-08
the O 0 1.5080698858582764e-06
normal O 0 5.99488976149587e-06
alpha O 0 6.519985163322417e-06
- O 0 5.881052516087948e-07
subunit O 0 7.082417710080335e-07
precursor O 0 2.732053189902217e-06
levels O 0 3.1708318601886276e-06
. O 0 5.753327627644467e-07

We O 0 4.34425710409414e-05
conclude O 0 3.08028502331581e-05
that O 0 9.289695981351542e-07
the O 0 4.88286059407983e-06
1422 O 0 0.0002544682356528938
G O 0 3.69834597222507e-05
- O 0 7.048759925964987e-06
- O 0 4.3443747017590795e-06
> O 0 1.5939029935907456e-06
C O 0 4.716986950370483e-06
mutation O 0 4.759661820230576e-08
is O 0 5.291547466867996e-08
the O 0 1.708471160100089e-07
cause O 0 6.089662178965227e-07
of O 0 7.050978638289962e-06
Hex B-Disease 0 0.0007125545525923371
A I-Disease 0 0.004559393506497145
enzyme I-Disease 1 0.9999945163726807
deficiency I-Disease 1 1.0
in O 0 3.1994977689464577e-06
the O 0 6.618795396207133e-06
proband O 0 0.00010386313078925014
. O 0 2.3865129605837865e-06

The O 0 9.242712258128449e-05
resulting O 0 5.1114580855937675e-05
W474C O 0 8.78175487741828e-05
substitution O 0 2.4176621082006022e-05
clearly O 0 3.2312070743500954e-06
interferes O 0 1.2555345847431454e-06
with O 0 2.0575964754243614e-07
alpha O 0 3.675699417726719e-06
- O 0 2.3603152499163116e-07
subunit O 0 3.276588529388391e-07
processing O 0 6.452706884374493e-07
, O 0 5.568844585468469e-08
but O 0 1.2949352701241423e-08
because O 0 1.611032018900005e-08
the O 0 1.2446389519027434e-07
base O 0 6.075791816329001e-07
substitution O 0 1.2339635304670082e-06
falls O 0 2.210116508649662e-05
at O 0 3.419581389607629e-06
the O 0 4.180485007054813e-07
first O 0 8.291033850582608e-07
position O 0 1.7431295873393537e-06
of O 0 7.413563707814319e-06
exon O 0 3.5962889342044946e-06
13 O 0 4.044482921017334e-06
, O 0 2.686577147414937e-07
aberrant O 0 4.6482782636303455e-06
splicing O 0 1.0936452099485905e-06
may O 0 5.906638875785575e-07
also O 0 8.4768444708061e-08
contribute O 0 7.887209818591145e-08
to O 0 5.803486260447244e-07
Hex B-Disease 0 0.00012437364785000682
A I-Disease 0 8.03805814939551e-05
deficiency I-Disease 0 0.018054725602269173
in O 0 1.1791439646913204e-06
this O 0 3.179181362611416e-07
proband O 0 1.8796865333570167e-05
. O 0 2.0283970059153944e-07
. O 0 3.141097124625958e-07

Two O 0 2.878820168916718e-06
frequent O 0 3.54984808836889e-06
missense O 0 4.9736587243387476e-05
mutations O 0 2.2329884814098477e-05
in O 0 0.0021208287216722965
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 7.302182348212227e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.001966614741832018
an O 1 0.811476469039917
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999995231628418
by O 0 1.3785580449621193e-05
early O 1 0.9994356036186218
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999982118606567
goiter B-Disease 1 1.0
. O 0 9.531278919894248e-05

A O 0 4.539994552033022e-05
century O 0 3.4960301036335295e-06
after O 0 4.6195532377169e-07
its O 0 5.647270384656622e-08
recognition O 0 4.1369546011083003e-07
as O 0 1.2816464050047216e-06
a O 0 1.646942473598756e-05
syndrome O 1 0.9999872446060181
by O 0 2.9110437935742084e-06
Vaughan O 0 0.0001866116508608684
Pendred O 0 0.0014822022058069706
, O 0 9.944582188836648e-07
the O 0 6.689251677016728e-06
disease O 0 0.0007354883709922433
gene O 0 2.6751361019705655e-06
( O 0 1.2539238696263055e-06
PDS O 0 5.267412052489817e-05
) O 0 9.823600777281172e-08
was O 0 1.365009552500851e-06
mapped O 0 2.839970534296299e-07
to O 0 4.25915885671202e-07
chromosome O 0 8.741093188291416e-05
7q22 O 0 0.0008727354579605162
- O 0 0.001184946740977466
q31 O 0 0.0005952697247266769
. O 0 8.679580787429586e-06

1 O 0 0.00015373966016341
and O 0 3.497590796541772e-06
, O 0 7.196715046120516e-07
recently O 0 1.3037403050475405e-06
, O 0 4.086932392510789e-08
found O 0 2.0127783884049677e-08
to O 0 2.0386028865004846e-08
encode O 0 1.6449882878077915e-07
a O 0 9.445873843105801e-07
putative O 0 4.036943209939636e-05
sulfate O 0 4.928540511173196e-05
transporter O 0 0.00025768240448087454
. O 0 3.4051713555527385e-06

We O 0 8.035171049414203e-06
performed O 0 3.215692004232551e-06
mutation O 0 4.316319461850071e-07
analysis O 0 5.110815095576982e-07
of O 0 4.9410068641009275e-06
the O 0 1.6627080185571685e-05
PDS B-Disease 0 0.00015504164912272245
gene O 0 5.325547931533947e-07
in O 0 8.95511391263426e-07
patients O 0 8.100184913928388e-07
from O 0 2.265892362629529e-06
14 O 0 8.755025191931054e-06
Pendred B-Disease 0 2.529265111661516e-05
families O 0 8.431034359546175e-08
originating O 0 4.4580124836102186e-07
from O 0 2.3505930357714533e-07
seven O 0 7.46867101497628e-08
countries O 0 7.116328859524401e-09
and O 0 4.501820782820687e-08
identified O 0 1.4073832232952554e-07
all O 0 7.522598366449529e-08
mutations O 0 1.1145465350637096e-06
. O 0 2.4721391582716024e-06

The O 0 2.5607432689866982e-05
mutations O 0 2.0031709482282167e-06
include O 0 1.2142777450208087e-06
three O 0 6.982616582718038e-07
single O 0 7.277826625795569e-07
base O 0 4.714684109785594e-06
deletions O 0 6.729953838657821e-06
, O 0 7.750923032290302e-07
one O 0 2.0081006368855014e-07
splice O 0 1.476826810176135e-06
site O 0 3.61088382305752e-07
mutation O 0 2.5407819848055624e-08
and O 0 3.969691775296269e-08
10 O 0 2.471007292115246e-07
missense O 0 2.3417444481310667e-06
mutations O 0 1.7147667676908895e-06
. O 0 2.280815124322544e-06

One O 0 2.6212230295641348e-05
missense O 0 5.9882731875404716e-05
mutation O 0 6.073577878851211e-06
( O 0 1.9459073428151896e-06
L236P O 0 1.8145801732316613e-05
) O 0 4.34856360698177e-07
was O 0 8.963206710177474e-06
found O 0 1.6408425551617256e-07
in O 0 3.142939988265425e-07
a O 0 3.102788355135999e-07
homozygous O 0 2.8198832069392665e-07
state O 0 2.7944133762503043e-07
in O 0 7.975751259436947e-07
two O 0 3.3714835012688127e-07
consanguineous O 0 2.6199208150501363e-05
families O 0 1.5918128326575243e-07
and O 0 1.1414044820412528e-07
in O 0 3.6781150924980466e-07
a O 0 3.1308718462241814e-07
heterozygous O 0 1.1462040561127651e-07
state O 0 7.522669420723105e-08
in O 0 1.6240926470345585e-07
five O 0 6.914760319887137e-08
additional O 0 1.1841751756946906e-07
non O 0 1.5729701772215776e-05
- O 0 2.3072620024322532e-05
consanguineous O 0 3.9384256524499506e-05
families O 0 3.879458461142349e-07
. O 0 6.888142820571375e-07

Another O 0 8.002296090126038e-05
missense O 0 9.04603220988065e-05
mutation O 0 4.626987447409192e-06
( O 0 1.8346721617490402e-06
T416P O 0 1.763604632287752e-05
) O 0 3.771114052142366e-07
was O 0 6.049777766747866e-06
found O 0 1.2960045125964825e-07
in O 0 1.6061483165685786e-07
a O 0 4.2831419477806776e-07
homozygous O 0 2.1390843585322727e-07
state O 0 4.4946872890250233e-07
in O 0 8.824059136713913e-07
one O 0 4.6083061988611007e-07
family O 0 1.1361383656094404e-07
and O 0 7.145165881183857e-08
in O 0 2.539767649523128e-07
a O 0 3.1020368851386593e-07
heterozygous O 0 7.925452649715226e-08
state O 0 1.553300705836591e-07
in O 0 4.247452523031825e-07
four O 0 5.009860046811809e-07
families O 0 2.7973356964139384e-07
. O 0 9.66183847594948e-07

Pendred B-Disease 0 0.3256314992904663
patients O 0 0.0002046233566943556
in O 0 2.970218520204071e-05
three O 0 1.058870111592114e-05
non O 0 0.00011491221812320873
- O 0 3.6126562918070704e-05
consanguineous O 0 7.925358659122139e-05
families O 0 1.2783208092059795e-07
were O 0 2.0988753135497973e-07
shown O 0 8.56674517990541e-08
to O 0 9.652853094621605e-08
be O 0 3.369702881172998e-07
compound O 0 9.277538993046619e-06
heterozygotes O 0 1.5486903066630475e-06
for O 0 4.1211484358427697e-07
L236P O 0 2.00299054995412e-05
and O 0 1.5358617702077026e-06
T416P O 0 5.270396650303155e-05
. O 0 5.268483164400095e-06

In O 0 5.313007204676978e-05
total O 0 4.111453381483443e-05
, O 0 1.5753981870147982e-06
one O 0 6.347216299218417e-07
or O 0 3.444658887019614e-07
both O 0 1.21000141461991e-07
of O 0 3.0966327813075623e-06
these O 0 1.0102470326955881e-07
mutations O 0 1.5485055371300405e-07
were O 0 7.929155003694177e-07
found O 0 6.6849842994543e-08
in O 0 7.631201270896781e-08
nine O 0 2.228861148978467e-07
of O 0 5.745924909206224e-07
the O 0 1.5993251736290404e-06
14 O 0 2.62115122495743e-06
families O 0 9.22352683119243e-08
analyzed O 0 1.6067028809629846e-06
. O 0 1.9043903876081458e-06

The O 0 1.95620068552671e-05
identification O 0 9.890377441479359e-07
of O 0 3.6404644561116584e-06
two O 0 9.81507582764607e-07
frequent O 0 3.7980387332936516e-06
PDS B-Disease 0 0.00015809110482223332
mutations O 0 3.9318940991961426e-08
will O 0 7.88143150742826e-09
facilitate O 0 4.294856736919428e-08
the O 0 2.109714074549629e-07
molecular O 0 3.094386920565739e-05
diagnosis O 1 0.5194271802902222
of O 1 0.9999830722808838
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0001292838278459385

Insertional O 0 0.002142731100320816
mutation O 0 1.0074229066958651e-05
by O 0 1.5922985312499804e-06
transposable O 0 1.1310758964100387e-05
element O 0 3.7245004023134243e-06
, O 0 4.3086245682388835e-07
L1 O 0 9.058539944817312e-06
, O 0 1.353955241256699e-07
in O 0 3.2226807888946496e-07
the O 0 5.480235813593026e-06
DMD B-Disease 1 0.9999998807907104
gene O 0 1.0718816838561906e-06
results O 0 1.577017087583954e-06
in O 0 2.967683258248144e-06
X B-Disease 1 0.9998185038566589
- I-Disease 1 0.9999865293502808
linked I-Disease 1 0.9999939203262329
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
. O 0 6.22429943177849e-05

X B-Disease 1 0.9995463490486145
- I-Disease 1 0.9999604225158691
linked I-Disease 1 0.999904990196228
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
( O 0 7.448480755556375e-05
XLDCM B-Disease 1 0.6101550459861755
) O 0 2.194623931472961e-07
is O 0 6.028584209616383e-08
a O 0 1.6132283064962394e-07
clinical O 0 1.5210958736133762e-05
phenotype O 0 1.750312549120281e-05
of O 0 0.0014725758228451014
dystrophinopathy B-Disease 0 0.08290429413318634
which O 0 5.767197990280692e-07
is O 0 1.4044013596503646e-07
characterized O 0 1.038436323597125e-07
by O 0 3.3989305592285746e-08
preferential O 0 4.960955266142264e-06
myocardial B-Disease 1 0.9999995231628418
involvement I-Disease 0 2.732602979449439e-06
without O 0 4.8064343616260885e-08
any O 0 2.4985871149851846e-08
overt O 0 1.3241675560493604e-06
clinical O 0 2.2360782168107107e-05
signs O 0 5.4417232604464516e-05
of O 0 0.00216394173912704
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 9.069923544302583e-05

To O 0 4.834882929571904e-06
date O 0 7.366927547991509e-06
, O 0 1.8616653107983439e-07
several O 0 6.37287271842979e-08
mutations O 0 1.5437576905696915e-07
in O 0 1.3507816447599907e-06
the O 0 0.00016413287085015327
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.00028414817643351853
, O 0 1.2033838174829725e-05
DMD O 1 1.0
, O 0 2.8977933652640786e-07
have O 0 6.428592058682625e-08
been O 0 2.0889048357730644e-07
identified O 0 1.2209473254642944e-07
in O 0 3.3450871228524193e-07
patients O 0 4.876941375187016e-07
with O 0 5.731017722609977e-07
XLDCM B-Disease 0 0.46857061982154846
, O 0 3.992053621004743e-07
but O 0 2.242322061363211e-08
a O 0 5.131404989811017e-08
pathogenic O 0 4.1151700713726314e-08
correlation O 0 2.7187070372747257e-07
of O 0 7.137863917705545e-07
these O 0 1.2244595382071566e-07
cardiospecific O 0 9.079626579477917e-06
mutations O 0 7.742279422018328e-07
in O 0 9.425866664969362e-06
DMD O 1 1.0
with O 0 1.5592270301567623e-06
the O 0 3.1078314350452274e-05
XLDCM B-Disease 0 0.012541613541543484
phenotype O 0 9.542115549265873e-06
has O 0 1.18478794775001e-06
remained O 0 5.925488039792981e-06
to O 0 7.237461829845415e-08
be O 0 4.2556428070383845e-07
elucidated O 0 4.232003630022518e-05
. O 0 3.073232164751971e-06

We O 0 8.231500396504998e-05
report O 0 6.9869593062321655e-06
here O 0 7.551910243819293e-07
the O 0 2.923793260833918e-07
identification O 0 1.5031378097773995e-07
of O 0 1.082193193724379e-06
a O 0 8.226339218708745e-07
unique O 0 4.3981364683531865e-07
de O 0 6.163967191241682e-05
novo O 0 4.0989725675899535e-05
L1 O 0 3.402108632144518e-05
insertion O 0 2.9333605198189616e-06
in O 0 1.769003347362741e-06
the O 0 2.772183279375895e-06
muscle O 0 1.239601374436461e-06
exon O 0 1.4986762835178524e-06
1 O 0 1.849417685662047e-06
in O 0 3.2191405807679985e-06
DMD O 1 0.9999996423721313
in O 0 5.08880566485459e-06
three O 0 5.001104455004679e-06
XLDCM B-Disease 0 0.0015470593934878707
patients O 0 8.196222438527911e-07
from O 0 7.141690616663254e-07
two O 0 1.5775404449414054e-07
unrelated O 0 9.130927764999797e-07
Japanese O 0 2.5753117824933724e-06
families O 0 2.788216306726099e-07
. O 0 6.251839863580244e-07

The O 0 0.00022281943529378623
insertion O 0 7.324395119212568e-05
was O 0 5.4077103413874283e-05
a O 0 4.04883621740737e-06
5 O 0 1.7587691445442033e-06
- O 0 1.0474050213815644e-06
truncated O 0 2.598635774120339e-06
form O 0 7.394044132524868e-08
of O 0 1.5762817611175706e-06
human O 0 1.4205307934389566e-06
L1 O 0 1.1156610526086297e-05
inversely O 0 5.440440418169601e-06
integrated O 0 2.047999259957578e-06
in O 0 3.633364826782781e-07
the O 0 6.762313091712713e-07
5 O 0 6.261213343350391e-07
- O 0 5.333400849849568e-07
untranslated O 0 3.4251231681992067e-06
region O 0 6.207294518389972e-07
in O 0 1.44865464335453e-06
the O 0 3.1591960123478202e-06
muscle O 0 1.0036820867753704e-06
exon O 0 7.782787179166917e-07
1 O 0 1.0500635880816844e-06
, O 0 2.719224845293411e-08
which O 0 2.716778091382821e-08
affected O 0 5.5113087427116625e-08
the O 0 1.1171947988941611e-07
transcription O 0 1.052804009304964e-06
or O 0 1.5850822876473103e-07
the O 0 3.8215975450839323e-07
stability O 0 1.1497384093672736e-06
of O 0 4.273266767995665e-06
the O 0 8.888112461136188e-06
muscle O 0 1.9075714590144344e-06
form O 0 3.9372679339066963e-07
of O 0 1.8229193301522173e-05
dystrophin O 0 8.266075383289717e-06
transcripts O 0 6.63239325149334e-06
but O 0 9.726593219738788e-08
not O 0 3.180793939350224e-08
that O 0 3.6068840358893794e-08
of O 0 1.3380910104388022e-06
the O 0 1.922254523378797e-05
brain O 0 0.008654088713228703
or O 0 1.376556156174047e-05
Purkinje O 0 0.0008460480021312833
cell O 0 3.190650386386551e-05
form O 0 1.3085259524814319e-06
, O 0 4.5854574182158103e-07
probably O 0 5.828006237607042e-07
due O 0 1.0916018027273822e-06
to O 0 5.5157780565195935e-08
its O 0 4.9372342658671187e-08
unique O 0 3.931309322524612e-08
site O 0 4.310967653964326e-07
of O 0 7.791499001541524e-07
integration O 0 4.522843937593279e-06
. O 0 2.251327487101662e-06

We O 0 3.778828613576479e-05
speculate O 0 4.59125158158713e-06
that O 0 1.4903937994859007e-07
this O 0 4.3391139570303494e-08
insertion O 0 3.1134771916185855e-07
of O 0 8.304463108288473e-07
an O 0 4.913667908112984e-07
L1 O 0 1.2792341294698417e-05
sequence O 0 9.568966561346315e-07
in O 0 7.5235398071527015e-06
DMD O 1 1.0
is O 0 2.2524698124470888e-06
responsible O 0 1.2002820994894137e-06
for O 0 2.575960138528899e-07
some O 0 3.665109815642609e-08
of O 0 1.1878674968102132e-06
the O 0 2.3189643627574696e-07
population O 0 3.98360278097698e-08
of O 0 4.421287371769722e-07
Japanese O 0 2.4418820885330206e-06
patients O 0 4.4525316411636595e-07
with O 0 2.397651712726656e-07
XLDCM B-Disease 0 0.00024715246399864554
. O 0 5.855298468304682e-07
. O 0 1.351095988866291e-06

Severe O 1 0.9998773336410522
early O 1 0.5385259389877319
- O 1 0.9999998807907104
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.9036312699317932
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.5548783540725708
red O 1 0.99198979139328
hair O 1 0.999721109867096
pigmentation O 1 0.9999942779541016
caused O 1 0.9999936819076538
by O 0 1.3133644642948639e-05
POMC O 0 0.0018172223353758454
mutations O 0 2.854846172795078e-07
in O 0 4.954001724399859e-07
humans O 0 2.7213167186346254e-07
. O 0 3.4613645993886166e-07

Sequential O 0 0.0002776214387267828
cleavage O 0 0.00029300551977939904
of O 0 0.00018486597400624305
the O 0 2.706586747081019e-05
precursor O 0 2.870714342861902e-05
protein O 0 3.5988896343042143e-06
pre O 0 6.400566053343937e-05
- O 0 2.5667970476206392e-05
pro O 0 4.843891292694025e-05
- O 0 7.146608368202578e-06
opiomelanocortin O 0 1.567737308505457e-05
( O 0 3.276735185409052e-07
POMC O 0 1.3945299542683642e-05
) O 0 5.247204626357416e-08
generates O 0 1.6803917901597742e-07
the O 0 1.1975255347351776e-06
melanocortin O 0 2.2886590159032494e-05
peptides O 0 2.008099954764475e-06
adrenocorticotrophin O 0 1.0105038199981209e-05
( O 0 3.927124225810985e-07
ACTH O 0 8.728796274226625e-06
) O 0 1.3082035366096534e-07
, O 0 8.995971967351579e-08
melanocyte O 0 8.819533832138404e-06
- O 0 1.0983918400597759e-05
stimulating O 0 9.533127922622953e-06
hormones O 0 2.6622019504429772e-06
( O 0 1.498763282370419e-07
MSH O 0 4.131909463467309e-06
) O 0 3.608790422049424e-08
alpha O 0 4.706211029770202e-07
, O 0 2.0021644786538673e-08
beta O 0 1.849282256216611e-07
and O 0 3.418513472297491e-08
gamma O 0 6.871896971460956e-07
as O 0 1.8401534873646597e-07
well O 0 5.9536240826219e-08
as O 0 1.1898875129645603e-07
the O 0 2.096642788274039e-07
opioid O 0 3.513631554596941e-06
- O 0 8.595401368438615e-07
receptor O 0 2.0635188775486313e-06
ligand O 0 6.414117251551943e-06
beta O 0 1.815568612073548e-05
- O 0 8.970354429038707e-06
endorphin O 0 6.02126783633139e-05
. O 0 5.616579983325209e-07

While O 0 2.4568065782659687e-05
a O 0 1.7105413689932902e-06
few O 0 1.5283632137652603e-07
cases O 0 1.7260748563785455e-07
of O 0 3.487536741886288e-05
isolated O 0 0.4741051197052002
ACTH B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999977350234985
have O 0 2.5947824724426027e-06
been O 0 2.4577877866249764e-06
reported O 0 2.244227744085947e-06
( O 0 4.5146416027819214e-07
OMIM O 0 3.89798115065787e-05
201400 O 0 1.3737862900597975e-05
) O 0 3.2532824434383656e-07
, O 0 1.5176325973698113e-07
an O 0 2.5265678686992032e-06
inherited O 1 0.9999710321426392
POMC O 1 1.0
defect O 1 0.9974184036254883
has O 0 5.406629952631192e-06
not O 0 2.5646207291174505e-07
been O 0 1.1677240081553464e-06
described O 0 3.37033299047107e-07
so O 0 6.943134422954245e-08
far O 0 3.0149269036883197e-07
. O 0 5.55987583084061e-07

Recent O 0 3.554747308953665e-05
studies O 0 8.540951057511847e-06
in O 0 1.560921532473003e-06
animal O 0 3.821907341716724e-07
models O 0 2.1875445099794888e-07
elucidated O 0 4.94087998959003e-06
a O 0 9.894660024656332e-07
central O 0 2.789295649563428e-06
role O 0 1.2446168966562254e-06
of O 0 1.9247789168730378e-05
alpha O 0 3.9788410504115745e-05
- O 0 1.4459947124123573e-05
MSH O 0 2.841109744622372e-05
in O 0 6.634269880123611e-07
the O 0 1.2838386282965075e-06
regulation O 0 8.397226451961615e-07
of O 0 2.957833430627943e-06
food O 0 1.8117694935426698e-06
intake O 0 2.2555095711140893e-06
by O 0 1.4194756658980623e-07
activation O 0 1.682825882198813e-06
of O 0 6.847640634077834e-06
the O 0 1.5075011106091551e-05
brain O 0 5.4372940212488174e-05
melanocortin O 0 4.165950304013677e-05
- O 0 1.4275016155806952e-06
4 O 0 1.2545124263851903e-06
- O 0 3.778339134896669e-07
receptor O 0 6.862243253635825e-07
( O 0 1.3880013227662857e-07
MC4 O 0 1.2751148460665718e-05
- O 0 1.8825087408913532e-06
R O 0 1.8702813804338803e-06
; O 0 4.8755548931467274e-08
refs O 0 7.946611617626331e-07
3 O 0 2.3104348656488582e-07
- O 0 2.515054973173392e-07
5 O 0 2.796884928102372e-07
) O 0 1.6293292048885633e-08
and O 0 2.4343473015164818e-08
the O 0 3.2762446267042833e-07
linkage O 0 3.6824640119448304e-06
of O 0 2.0325000150478445e-05
human O 0 7.8536533692386e-05
obesity B-Disease 1 0.9999996423721313
to O 0 2.8911244953633286e-07
chromosome O 0 1.5126430525924661e-06
2 O 0 1.3696740097657312e-06
in O 0 6.093106890148192e-07
close O 0 1.4866732271912042e-06
proximity O 0 1.5210723631753353e-06
to O 0 2.8319055900283274e-07
the O 0 2.1853561520401854e-06
POMC O 0 2.8548525733640417e-05
locus O 0 3.304808615212096e-06
, O 0 1.4143961379886605e-07
led O 0 3.201290894594422e-07
to O 0 3.2120333059992845e-08
the O 0 3.2529101190448273e-07
proposal O 0 3.538477528763906e-07
of O 0 1.9807321223197505e-06
an O 0 1.7736489326125593e-06
association O 0 2.4960020255093696e-06
of O 0 5.149257503944682e-06
POMC O 0 0.001259610173292458
with O 0 8.564104518882232e-07
human O 0 0.00027871940983459353
obesity B-Disease 1 1.0
. O 0 3.5596151519712294e-06

The O 0 4.907051697955467e-05
dual O 0 3.0745472031412646e-05
role O 0 1.4582310541300103e-05
of O 0 8.43054658616893e-05
alpha O 0 0.0002769599959719926
- O 0 4.847472155233845e-05
MSH O 0 0.0001039723283611238
in O 0 6.896562467773037e-07
regulating O 0 1.0007525816035923e-05
food O 0 3.696968633448705e-06
intake O 0 1.9987011910416186e-05
and O 0 1.1217165365451365e-06
influencing O 0 4.0634156903252006e-05
hair O 0 0.00024412013590335846
pigmentation O 0 0.00032713799737393856
predicts O 0 9.831650459091179e-06
that O 0 9.356114816228e-08
the O 0 5.192408139009785e-07
phenotype O 0 1.2049190445395652e-06
associated O 0 3.368482168752962e-07
with O 0 7.651007649656094e-08
a O 0 2.564537680882495e-06
defect O 0 1.5313486073864624e-05
in O 0 5.531240276468452e-06
POMC O 0 0.00045919205876998603
function O 0 2.7313419650454307e-06
would O 0 4.047277855079301e-07
include O 0 2.453502020216547e-06
obesity B-Disease 1 1.0
, O 0 2.937106842182402e-07
alteration O 0 2.1521427697734907e-05
in O 0 1.9201073882868513e-05
pigmentation O 0 0.4994802176952362
and O 0 0.033354517072439194
ACTH B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999973773956299
. O 0 3.726525619640597e-06

The O 0 8.319655898958445e-05
observation O 0 0.0005608879728242755
of O 0 5.9883870562771335e-05
these O 0 2.055789536825614e-06
symptoms O 0 0.003422049805521965
in O 0 2.356870572839398e-05
two O 0 4.406547304824926e-06
probands O 0 0.00021908707276452333
prompted O 0 3.5383934573474107e-06
us O 0 1.543876919640752e-07
to O 0 1.666015414514277e-08
search O 0 4.1940783290783656e-08
for O 0 3.573331142092684e-08
mutations O 0 1.4407473258870596e-07
within O 0 2.343262934800805e-07
their O 0 8.594040536991088e-07
POMC O 0 0.00020042236428707838
genes O 0 1.2499136801125132e-06
. O 0 2.2229353362490656e-06

Patient O 0 0.002021006541326642
1 O 0 0.00017511012265458703
was O 0 7.702202856307849e-05
found O 0 7.839782369956083e-07
to O 0 1.5877463965807692e-07
be O 0 3.449007976996654e-07
a O 0 9.633785111873294e-07
compound O 0 6.854538696643431e-06
heterozygote O 0 1.2662750350500573e-06
for O 0 1.0392803773129344e-07
two O 0 6.760070192513012e-08
mutations O 0 6.958141085533498e-08
in O 0 7.788868856550835e-07
exon O 0 6.593473926841398e-07
3 O 0 8.228536785281904e-07
( O 0 1.1966699275944848e-07
G7013T O 0 3.1704419143352425e-06
, O 0 3.1286452895074035e-07
C7133delta O 0 3.8104903978819493e-06
) O 0 3.354043442982402e-08
which O 0 1.837723928588275e-08
interfere O 0 4.54914790282146e-08
with O 0 1.2194898424411349e-08
appropriate O 0 1.3398259568475623e-07
synthesis O 0 3.3374694794474635e-06
of O 0 1.885550227598287e-05
ACTH O 0 0.00017314215074293315
and O 0 6.350561761792051e-06
alpha O 0 0.00012356304796412587
- O 0 5.353531378204934e-05
MSH O 0 0.0002512270293664187
. O 0 1.0666850585039356e-06

Patient O 0 0.0005666225915774703
2 O 0 3.451416705502197e-05
was O 0 1.6694319128873758e-05
homozygous O 0 8.844531862450822e-07
for O 0 1.7355395698359644e-07
a O 0 2.122607867249826e-07
mutation O 0 6.742286728922409e-08
in O 0 4.4878893845634593e-07
exon O 0 1.4763719491384109e-06
2 O 0 1.247442696694634e-06
( O 0 1.4112069379734749e-07
C3804A O 0 3.641999683168251e-06
) O 0 1.3495824191522843e-07
which O 0 3.7691870602429844e-07
abolishes O 0 5.694428182323463e-05
POMC O 0 0.00024682446382939816
translation O 0 2.8700409529847093e-05
. O 0 2.9147272471163888e-06

These O 0 5.884031452296767e-06
findings O 0 2.333814336452633e-06
represent O 0 2.387919266766403e-07
the O 0 3.537094244165928e-07
first O 0 2.256614379803068e-07
examples O 0 1.5534784836290783e-07
of O 0 1.884605012492102e-06
a O 0 4.168759551248513e-05
genetic B-Disease 1 0.9999997615814209
defect I-Disease 1 1.0
within O 0 4.253940460330341e-06
the O 0 1.8233835362480022e-05
POMC O 0 0.000451108644483611
gene O 0 1.5051101343033224e-07
and O 0 2.536017973397975e-08
define O 0 8.078177415882237e-08
a O 0 3.331156221975107e-07
new O 0 2.9900577374064596e-06
monogenic B-Disease 1 0.9999997615814209
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9624850749969482
resulting O 0 1.6295535942845163e-06
in O 0 9.321964853370446e-07
early O 0 5.131247598910704e-05
- O 1 0.9958562254905701
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0008357040351256728
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.000211841324926354
red O 0 0.0015243543311953545
hair O 0 0.006666021887212992
pigmentation O 0 0.013940823264420033
. O 0 2.132132294718758e-06
. O 0 1.3745443538937252e-06

A O 0 6.521521572722122e-05
European O 0 8.700904800207354e-06
multicenter O 0 0.0002442113764118403
study O 0 7.716841537330765e-06
of O 0 0.0024734053295105696
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.689594788942486e-06
classification O 0 2.648211648192955e-06
of O 0 1.052096104103839e-05
105 O 0 2.184541335736867e-05
mutations O 0 2.629523407904344e-07
and O 0 2.779672456654225e-07
a O 0 9.378803156323556e-07
general O 0 1.6883684565982549e-06
system O 0 4.6552696630897117e-07
for O 0 8.198303902418047e-08
genotype O 0 4.353198050921492e-07
- O 0 5.804781153528893e-07
based O 0 5.643458322879269e-08
prediction O 0 2.4232861051132204e-06
of O 0 3.4494726151024224e-06
metabolic O 0 0.022169003263115883
phenotype O 0 2.3434320610249415e-05
. O 0 2.4294922695844434e-06

Phenylketonuria B-Disease 0 0.05611976608633995
( O 0 7.456155435647815e-05
PKU B-Disease 0 0.0019678205717355013
) O 0 2.2236031327338424e-06
and O 0 2.8840877348557115e-06
mild B-Disease 1 0.999874472618103
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.26547834277153015
MHP B-Disease 1 1.0
) O 0 1.785779204510618e-06
are O 0 2.281819462268686e-07
allelic B-Disease 0 0.0019244125578552485
disorders I-Disease 1 0.9999986886978149
caused O 0 0.001164245535619557
by O 0 1.6921957524118625e-07
mutations O 0 5.250588586136473e-08
in O 0 9.403507306160463e-08
the O 0 1.6618299980564188e-07
gene O 0 2.149954383412478e-07
encoding O 0 1.3162382401787909e-06
phenylalanine O 0 3.757189551834017e-05
hydroxylase O 0 3.8614565710304305e-05
( O 0 3.267092097303248e-06
PAH O 0 0.021035445854067802
) O 0 1.5362249996542232e-06
. O 0 1.3600626971310703e-06

Previous O 0 6.990656402194872e-05
studies O 0 8.853984581946861e-06
have O 0 3.8860866879986133e-07
suggested O 0 1.3893281902710441e-07
that O 0 2.184791725312607e-08
the O 0 8.858699374059142e-08
highly O 0 4.149401036102063e-07
variable O 0 2.1910445866524242e-05
metabolic O 1 0.9761534929275513
phenotypes O 0 0.0002146880724467337
of O 1 0.9986690282821655
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.00022762990556657314
with O 0 2.5922798158717342e-05
PAH O 1 1.0
genotypes O 0 0.001334208995103836
. O 0 1.148099090642063e-05

We O 0 2.9790551707264967e-05
identified O 0 9.234586286765989e-06
both O 0 1.1743723007384688e-06
causative O 0 2.7061531000072137e-05
mutations O 0 1.4142169675324112e-06
in O 0 3.964187271776609e-06
686 O 0 0.0002508670440874994
patients O 0 1.4016466138855321e-06
from O 0 1.423199364580796e-06
seven O 0 5.497302595358633e-07
European O 0 1.3064360473435954e-06
centers O 0 5.290056378726149e-06
. O 0 1.3742926512350095e-06

On O 0 6.591308920178562e-05
the O 0 1.1545389497769065e-06
basis O 0 1.24862697248318e-06
of O 0 1.9518845419952413e-06
the O 0 5.493392905009387e-07
phenotypic O 0 7.254045044646773e-07
characteristics O 0 9.307041750616918e-07
of O 0 1.5110791537154e-05
297 O 0 3.48866124113556e-05
functionally O 0 1.3110394320392516e-05
hemizygous O 0 2.475593464623671e-05
patients O 0 5.760014119005064e-07
, O 0 8.437662302185345e-08
105 O 0 2.1546763946389547e-06
of O 0 1.203203510158346e-06
the O 0 1.3835663139616372e-06
mutations O 0 2.160282264185298e-07
were O 0 5.86249484513246e-07
assigned O 0 1.2578784946981614e-07
to O 0 2.8904564075560302e-08
one O 0 2.9019743053027014e-08
of O 0 2.127447373823088e-07
four O 0 1.332158490185975e-07
arbitrary O 0 2.1326527530618478e-06
phenotype O 0 5.144751412444748e-06
categories O 0 2.6624991278367816e-06
. O 0 1.044438704411732e-06

We O 0 2.957962169602979e-05
proposed O 0 5.847569809702691e-06
and O 0 2.7597118901212525e-07
tested O 0 4.5285094074642984e-07
a O 0 1.452568199056259e-07
simple O 0 2.2304766034153545e-08
model O 0 2.6041227840778447e-08
for O 0 8.937614204285182e-09
correlation O 0 1.7905526306094544e-07
between O 0 1.3915891372562328e-07
genotype O 0 4.675567311096529e-07
and O 0 1.1468131333458587e-07
phenotypic O 0 1.6015336541386205e-06
outcome O 0 5.964773663436063e-06
. O 0 2.0002728433610173e-06

The O 0 3.66740750905592e-05
observed O 0 1.0910627679550089e-05
phenotype O 0 1.0271414794260636e-05
matched O 0 4.3899831325688865e-06
the O 0 4.048917162435828e-06
predicted O 0 4.675675427279202e-06
phenotype O 0 5.227864789958403e-07
in O 0 4.2206568195979344e-07
79 O 0 5.26572057424346e-06
% O 0 3.0754586077819113e-07
of O 0 5.151212462806143e-06
the O 0 6.4159530666074716e-06
cases O 0 9.246519425687438e-07
, O 0 1.7041459443589702e-07
and O 0 1.0871059430428431e-07
in O 0 2.1849173492682894e-07
only O 0 5.215425247229177e-08
5 O 0 2.9322652039809327e-07
of O 0 6.416648261620139e-07
184 O 0 3.780512088269461e-06
patients O 0 3.6103878642279597e-07
was O 0 7.252548584801843e-06
the O 0 8.103329491859768e-07
observed O 0 8.102201149995381e-07
phenotype O 0 6.05924867613794e-07
more O 0 2.1671199945672015e-08
than O 0 2.5105297396521564e-08
one O 0 2.7302945682095014e-08
category O 0 3.240308785734669e-07
away O 0 1.0097788560869958e-07
from O 0 1.114940459956415e-07
that O 0 5.5365109830063375e-08
expected O 0 2.162412556572235e-06
. O 0 1.1390658301024814e-06

Among O 0 3.528164961608127e-05
the O 0 1.0230337466055062e-05
seven O 0 1.9624958440545015e-06
contributing O 0 4.670772796089295e-06
centers O 0 1.5308298770833062e-06
, O 0 5.546393211375289e-08
the O 0 7.091468745556995e-08
proportion O 0 3.5772731621364073e-07
of O 0 1.1732298844435718e-05
patients O 0 3.3743765470717335e-06
for O 0 2.057515303022228e-06
whom O 0 1.715524149403791e-06
the O 0 2.0146294446021784e-06
observed O 0 1.5940655657686875e-06
phenotype O 0 7.724962074462383e-07
did O 0 1.1330880056448223e-07
not O 0 3.187486896649716e-08
match O 0 2.516964912047115e-07
the O 0 7.571726996502548e-07
predicted O 0 1.179069840873126e-06
phenotype O 0 1.8071190766022482e-07
was O 0 1.977072770387167e-06
4 O 0 1.6470038133320486e-07
% O 0 2.6895039084706696e-08
- O 0 7.797105183726671e-08
23 O 0 4.827105613003368e-07
% O 0 1.280991028806966e-07
( O 0 1.1689914458656858e-07
P O 0 2.3992739443201572e-05
< O 0 2.9748409815510968e-06
. O 0 1.867688297352288e-07
0001 O 0 1.4205906154529657e-05
) O 0 6.262533247536339e-08
, O 0 1.1964413459963907e-08
suggesting O 0 3.129331105355959e-08
that O 0 3.851233998375392e-09
differences O 0 7.624912257142569e-09
in O 0 5.059381180672062e-08
methods O 0 6.495084647895055e-08
used O 0 8.276957430553011e-08
for O 0 1.2333123322605388e-07
mutation O 0 1.3923764754508738e-06
detection O 0 1.3113806744513568e-05
or O 0 6.142234724393347e-06
phenotype O 0 2.259266511828173e-05
classification O 0 4.730320597445825e-06
may O 0 2.516110555461637e-07
account O 0 1.2413525318777374e-08
for O 0 1.0217788393163119e-08
a O 0 1.8723406824960875e-08
considerable O 0 4.465254122010265e-08
proportion O 0 5.70463100757479e-07
of O 0 1.1049307431676425e-05
genotype O 0 1.7342623323202133e-05
- O 0 5.7654178817756474e-05
phenotype O 0 8.266564691439271e-06
inconsistencies O 0 9.765389222593512e-06
. O 0 1.6112306866489234e-06

Our O 0 4.631777119357139e-05
data O 0 1.0448985449329484e-05
indicate O 0 1.1415494554967154e-05
that O 0 2.4783782919257646e-06
the O 0 3.671281592687592e-05
PAH O 1 0.9999861717224121
- O 0 4.88790356030222e-05
mutation O 0 7.117810696399829e-07
genotype O 0 4.6639172524010064e-07
is O 0 6.624262738341713e-08
the O 0 1.7173579180962406e-07
main O 0 4.5321398829401005e-06
determinant O 0 1.0525958714424632e-05
of O 0 8.487395461997949e-06
metabolic O 1 0.9776590466499329
phenotype O 0 2.4180412765417714e-06
in O 0 1.4995568164977158e-07
most O 0 5.598194974254511e-08
patients O 0 5.682601909029472e-07
with O 0 1.4394757272384595e-05
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 8.351729775313288e-05

In O 0 5.8841607824433595e-05
the O 0 4.718750460597221e-06
present O 0 1.1634122074610787e-06
study O 0 5.915647420806636e-07
, O 0 8.948875773739928e-08
the O 0 2.6908077188636526e-07
classification O 0 5.610953053292178e-07
of O 0 2.5194070985889994e-05
105 O 0 0.003781715175136924
PAH O 1 0.9999754428863525
mutations O 0 6.649023362115258e-06
may O 0 6.979034424148267e-06
allow O 0 1.7521952599963697e-07
the O 0 1.5068306993271108e-06
prediction O 0 8.182279088941868e-06
of O 0 1.5884022559475852e-06
the O 0 2.034937551798066e-06
biochemical O 0 7.282906608452322e-06
phenotype O 0 1.990605824175873e-06
in O 0 1.5514931419602362e-06
> O 0 1.153337279902189e-06
10 O 0 4.810131031263154e-07
, O 0 8.606805579347565e-08
000 O 0 1.1055610684707062e-06
genotypes O 0 7.319192150134768e-07
, O 0 2.568987724771432e-07
which O 0 8.278156826690974e-08
may O 0 1.0030488795109704e-07
be O 0 3.035297169162732e-08
useful O 0 2.0606043094062443e-08
for O 0 5.576135819751471e-08
the O 0 7.813293336766947e-07
management O 0 2.6479235657461686e-06
of O 0 1.4317978639155626e-05
hyperphenylalaninemia B-Disease 1 0.9999998807907104
in O 0 2.5523784643155523e-05
newborns O 0 9.42864062380977e-05
. O 0 2.3479587980546057e-06

Somatic O 0 0.003147528739646077
instability O 0 0.0013733558589592576
of O 0 0.00013790687080472708
the O 0 4.648915637517348e-05
CTG O 0 0.0003879233554471284
repeat O 0 7.4866788963845465e-06
in O 0 1.5141571338972426e-06
mice O 0 1.5955668004608015e-06
transgenic O 0 4.493038431974128e-06
for O 0 2.4954545096989023e-06
the O 0 0.01646100915968418
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.1188853022758849e-05
is O 0 4.339134989095328e-07
age O 0 4.549091556782514e-07
dependent O 0 1.5000746600435377e-07
but O 0 8.946619445282522e-09
not O 0 4.506861994713063e-09
correlated O 0 6.813609587652536e-08
to O 0 8.624812863899933e-09
the O 0 1.4130020531410992e-07
relative O 0 2.5335195914522046e-06
intertissue O 0 1.2818877621612046e-05
transcription O 0 2.284507172589656e-05
levels O 0 8.7449943748652e-06
and O 0 1.7318933487331378e-06
proliferative O 0 0.006367868278175592
capacities O 0 0.0002504359290469438
. O 0 7.024560545687564e-06

A O 0 0.000683038670103997
( O 0 1.0743926395662129e-05
CTG O 0 0.0002223160699941218
) O 0 1.121954028349137e-06
nexpansion O 0 1.3390188541961834e-05
in O 0 1.5042434142742422e-06
the O 0 1.979104581550928e-06
3 O 0 2.1839809960511047e-06
- O 0 1.6131389202200808e-06
untranslated O 0 1.1620456461969297e-05
region O 0 6.202099029906094e-07
( O 0 1.5666303454509034e-07
UTR O 0 1.2735275049635675e-05
) O 0 7.258169887336408e-08
of O 0 2.1322541670087958e-06
the O 0 1.9469824110274203e-05
DM O 1 0.9999912977218628
protein O 0 8.929931027523708e-06
kinase O 0 6.816567292844411e-06
gene O 0 3.4233687529194867e-07
( O 0 1.2677621441525844e-07
DMPK O 0 5.080906248622341e-06
) O 0 2.0243362541805254e-08
is O 0 1.502128377239842e-08
responsible O 0 1.466020194129669e-07
for O 0 1.5599141534039518e-06
causing O 1 0.9956352114677429
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.622585634526331e-05
DM B-Disease 1 1.0
) O 0 2.2174385776452255e-06
. O 0 1.1508287798278616e-06

Major O 0 0.007516753394156694
instability O 0 0.003908399026840925
, O 0 2.94471738016e-06
with O 0 2.1021585894231976e-07
very O 0 1.2028553442178236e-07
large O 0 2.427962613182899e-07
expansions O 0 1.6698812714821543e-06
between O 0 5.872791462024907e-07
generations O 0 1.4673544512788794e-07
and O 0 8.340505530668452e-08
high O 0 6.143347945908317e-06
levels O 0 5.999460199745954e-07
of O 0 2.855953653124743e-06
somatic O 0 1.770333074091468e-05
mosaicism O 0 0.00010678211401682347
, O 0 9.037729142846729e-08
is O 0 1.4730352049241446e-08
observed O 0 6.112504991051537e-08
in O 0 1.2108475289096532e-07
patients O 0 4.1012154383679444e-07
. O 0 6.881313652229437e-07

There O 0 4.271193756721914e-05
is O 0 1.8244824104840518e-06
a O 0 6.260592613216431e-07
good O 0 1.9898017455943773e-07
correlation O 0 8.424908060078451e-07
between O 0 1.1101442396466155e-06
repeat O 0 2.082713763229549e-06
size O 0 1.2856911553171813e-06
( O 0 3.627516775850381e-07
at O 0 2.389418796155951e-06
least O 0 6.725885270952858e-08
in O 0 2.966501426726609e-07
leucocytes O 0 7.142928552639205e-06
) O 0 7.606047347508138e-08
, O 0 2.1777024628022446e-08
clinical O 0 6.787485062886844e-07
severity O 0 4.4832190724264365e-06
and O 0 5.413809276433312e-07
age O 0 5.7540141824574675e-06
of O 0 2.14768970181467e-05
onset O 1 0.9996720552444458
. O 0 1.8848455511033535e-05

The O 0 0.0001334983971901238
trinucleotide O 0 0.002094063675031066
repeat O 0 5.573951420956291e-05
instability O 0 0.00010239060793537647
mechanisms O 0 1.1903025551873725e-05
involved O 0 2.2004930997354677e-06
in O 0 1.9736235117306933e-05
DM B-Disease 1 1.0
and O 0 1.3719223943553516e-06
other O 0 1.8982494509600656e-07
human O 0 0.00015105878992471844
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 7.372820505224809e-07
unknown O 0 3.2294481115968665e-06
. O 0 3.8446751204901375e-07

We O 0 1.1271037692495156e-05
studied O 0 5.145575414644554e-05
somatic O 0 4.055626777699217e-05
instability O 0 3.7593330489471555e-05
by O 0 1.4073231113798101e-06
measuring O 0 8.553682710044086e-05
the O 0 1.615109977137763e-05
CTG O 0 0.0001524009567219764
repeat O 0 1.913593223434873e-06
length O 0 2.1577629922830965e-06
at O 0 4.933746367896674e-06
several O 0 5.139103720352978e-08
ages O 0 1.4065165032661753e-07
in O 0 1.195224825778496e-07
various O 0 1.2160005269379326e-07
tissues O 0 1.923504669321119e-06
of O 0 1.0126957022293936e-05
transgenic O 0 7.443267350026872e-06
mice O 0 1.3691960702999495e-06
carrying O 0 1.7182634337586933e-06
a O 0 1.3905984133089078e-06
( O 0 2.5927394631253264e-07
CTG O 0 1.4358070075104479e-05
) O 0 1.1851490455683233e-07
55expansion O 0 2.6594284463499207e-06
surrounded O 0 1.442109919480572e-06
by O 0 1.8908507115611428e-07
45 O 0 9.6220787781931e-07
kb O 0 9.208379196934402e-06
of O 0 6.459728410845855e-06
the O 0 1.0399152415629942e-05
human O 0 2.6909283405984752e-05
DM B-Disease 1 1.0
region O 0 4.605503818311263e-06
, O 0 1.7997390955315495e-07
using O 0 5.142025472082423e-08
small O 0 1.4830237660135026e-07
- O 0 2.969311026390642e-06
pool O 0 2.5237866339011816e-06
PCR O 0 3.432860239627189e-06
. O 0 8.738631436244759e-07

These O 0 2.8691378247458488e-05
mice O 0 2.428499465167988e-05
have O 0 6.501505254163931e-07
been O 0 2.5625524813222e-07
shown O 0 9.119669641677319e-08
to O 0 2.0477610718216965e-08
reproduce O 0 2.9618361097050183e-08
the O 0 4.2259571841896104e-07
intergenerational O 0 2.69095653493423e-06
and O 0 6.529939469146484e-07
somatic O 0 9.294009942095727e-06
instability O 0 2.596297417767346e-05
of O 0 2.3518276066170074e-05
the O 0 1.0853292224055622e-05
55 O 0 1.2699812941718847e-05
CTG O 0 4.701596844824962e-05
repeat O 0 6.949148314561171e-07
suggesting O 0 2.74631389629576e-07
that O 0 1.9275645968264143e-08
surrounding O 0 2.5474258791291504e-07
sequences O 0 7.37698542252474e-08
and O 0 1.6993033113976708e-07
the O 0 6.013913207425503e-07
chromatin O 0 4.197805992589565e-06
environment O 0 1.7662864593148697e-07
are O 0 1.3635983009407937e-08
involved O 0 2.1862424759433452e-08
in O 0 1.8937036827537668e-07
instability O 0 1.1629169421212282e-05
mechanisms O 0 1.9589075236581266e-05
. O 0 4.036583504785085e-06

As O 0 2.960657366202213e-05
observed O 0 5.634322860714747e-06
in O 0 1.2340599369053962e-06
some O 0 1.8179399319251388e-07
of O 0 5.362315278034657e-06
the O 0 1.4471479516942054e-05
tissues O 0 3.462048698565923e-05
of O 1 0.899282693862915
DM B-Disease 1 1.0
patients O 0 7.212939817691222e-05
, O 0 2.3309175389840675e-07
there O 0 5.8827250626336536e-08
is O 0 4.360660454949539e-08
a O 0 9.490990038329983e-08
tendency O 0 7.860537465376183e-08
for O 0 4.3621660950066143e-08
repeat O 0 1.8949592117678549e-07
length O 0 1.018995703816472e-06
and O 0 8.869246812537313e-07
somatic O 0 1.3078025403956417e-05
mosaicism O 0 1.3208053132984787e-05
to O 0 1.2696133921963337e-07
increase O 0 3.19853512564805e-07
with O 0 8.42804368517136e-08
the O 0 5.348595095711062e-07
age O 0 1.0318178738089046e-06
of O 0 3.10301834360871e-06
the O 0 5.311839686328312e-06
mouse O 0 5.377489287639037e-06
. O 0 2.0180464161967393e-06

Furthermore O 0 9.766185394255444e-05
, O 0 1.9778856312768767e-06
we O 0 1.1845524738873792e-07
observed O 0 1.1050555315250676e-07
no O 0 2.054231451609212e-08
correlation O 0 2.0927113553170784e-07
between O 0 1.9796904382474168e-07
the O 0 7.380573379123234e-07
somatic O 0 1.6914209481910802e-06
mutation O 0 3.685977389977779e-07
rate O 0 8.187064850062598e-06
and O 0 5.693222533409426e-07
tissue O 0 4.7312230890383944e-05
proliferation O 0 0.0008021952235139906
capacity O 0 9.497039718553424e-05
. O 0 1.9727765447896672e-06

The O 0 7.693930092500523e-05
somatic O 0 8.159739809343591e-05
mutation O 0 4.591365268424852e-06
rates O 0 4.431428351381328e-06
in O 0 5.622764547297265e-07
different O 0 2.8883787805966676e-08
tissues O 0 1.7155961131720687e-06
were O 0 2.7075031994172605e-06
also O 0 1.955408208687004e-07
not O 0 4.671769815445259e-08
correlated O 0 5.690324087481713e-07
to O 0 1.6428968763193552e-07
the O 0 1.668326262915798e-06
relative O 0 1.3742986993747763e-05
inter O 0 5.525605956790969e-05
- O 0 6.398074219760019e-06
tissue O 0 1.6835128917591646e-06
difference O 0 6.027785843798483e-07
in O 0 6.314962206488417e-07
transcriptional O 0 4.997318683308549e-06
levels O 0 1.8703617570281494e-06
of O 0 2.2422852907766355e-06
the O 0 1.0393046068202239e-06
three O 0 4.262116988229536e-07
genes O 0 4.792748882209708e-07
( O 0 4.726424265300011e-07
DMAHP O 0 3.0028690161998384e-05
, O 0 4.612658983660367e-07
DMPK O 0 1.3773556020169053e-05
and O 0 4.105974085177877e-07
59 O 0 3.2396767437603557e-06
) O 0 1.5125911545510462e-07
surrounding O 0 7.327762432396412e-07
the O 0 6.003775752105867e-07
repeat O 0 9.7150586952921e-07
. O 0 2.47439118084003e-07
. O 0 5.77157265979622e-07

A O 0 3.903751348843798e-05
novel O 0 6.091531304264208e-06
missense O 0 1.4556826499756426e-05
mutation O 0 1.5697427215854987e-06
in O 0 1.3830517673341092e-06
patients O 0 1.0135943284694804e-06
from O 0 8.781823339631956e-07
a O 0 2.1200396531639853e-06
retinoblastoma B-Disease 0 0.0005200235755182803
pedigree O 0 9.014828719955403e-06
showing O 0 3.7006511774961837e-06
only O 0 2.2439014912833954e-07
mild O 0 3.851798282994423e-06
expression O 0 7.219558142423921e-07
of O 0 5.445361694000894e-06
the O 0 1.2252320630068425e-05
tumor B-Disease 1 0.7213227152824402
phenotype O 0 1.9530707504600286e-05
. O 0 1.517290911579039e-06

We O 0 1.0772766472655348e-05
have O 0 8.983487305158633e-07
used O 0 4.814995691049262e-07
single O 0 4.0604066953164875e-07
strand O 0 1.3106215419611544e-06
conformation O 0 5.902725206397008e-07
polymorphism O 0 1.6953600834312965e-07
analysis O 0 3.625174826993316e-08
to O 0 1.7790101836112626e-08
study O 0 5.2682938900261433e-08
the O 0 2.738616728947818e-07
27 O 0 2.4132309590640943e-06
exons O 0 1.9486149085423676e-06
of O 0 6.926230071258033e-06
the O 0 2.004045200010296e-05
RB1 O 0 0.00012142430932726711
gene O 0 4.6296617028929177e-07
in O 0 2.7146600700689305e-07
individuals O 0 3.279948757040074e-08
from O 0 2.2277964717432042e-07
a O 0 2.741452078680595e-07
family O 0 1.4712246354520175e-07
showing O 0 2.28286262426991e-06
mild O 0 1.6093074009404518e-05
expression O 0 2.582692559371935e-06
of O 0 6.111746188253164e-06
the O 0 5.064497145212954e-06
retinoblastoma B-Disease 0 0.00020208298519719392
phenotype O 0 1.8411506971460767e-05
. O 0 1.2841593388657202e-06

In O 0 2.890330506488681e-05
this O 0 1.3369710814004065e-06
family O 0 8.028162596929178e-07
affected O 0 4.65829856466371e-07
individuals O 0 7.892055009506294e-08
developed O 0 3.53095720129204e-06
unilateral B-Disease 1 0.9523286819458008
tumors I-Disease 1 1.0
and O 0 1.429029998689657e-05
, O 0 1.1098123309238872e-07
as O 0 5.3925596432691236e-08
a O 0 5.8031318417306466e-08
result O 0 4.836220313109152e-08
of O 0 5.676383807440288e-07
linkage O 0 5.977888122288277e-06
analysis O 0 1.9415571728131908e-07
, O 0 1.3263323239698366e-07
unaffected O 0 9.364315474158502e-07
mutation O 0 7.378969257842982e-08
carriers O 0 1.6939540614657744e-07
were O 0 5.230697297520237e-07
also O 0 1.1645295217022067e-07
identified O 0 1.5288253507605987e-07
within O 0 1.27990304576997e-07
the O 0 1.937428351084236e-06
pedigree O 0 1.8693255697144195e-05
. O 0 4.570997589325998e-06

A O 0 0.0001688712800387293
single O 0 9.88612555374857e-06
band O 0 7.801404535712209e-06
shift O 0 2.9367138267843984e-06
using O 0 9.417396427124913e-07
SSCP O 0 9.71784902503714e-05
was O 0 2.2178208382683806e-05
identified O 0 7.411240972032829e-07
in O 0 6.707647912662651e-07
exon O 0 9.563109415466897e-07
21 O 0 1.3676612979907077e-06
which O 0 4.4586329295270843e-08
resulted O 0 4.1072900103245047e-07
in O 0 1.6835242888646462e-07
a O 0 6.213323899828538e-07
missense O 0 2.0923371266690083e-06
mutation O 0 4.2049316562042804e-07
converting O 0 1.618209694242978e-06
a O 0 1.7839256543084048e-06
cys O 0 1.0480632226972375e-05
- O 0 2.489409780537244e-06
- O 0 1.9747210444620578e-06
> O 0 1.1063099236707785e-06
arg O 0 1.1801002983702347e-06
at O 0 2.0763498014275683e-06
nucleotide O 0 2.86329878917968e-07
position O 0 1.563651153446699e-06
28 O 0 4.757846454594983e-06
in O 0 8.020311383916123e-07
the O 0 2.971735966639244e-06
exon O 0 8.183684258256108e-06
. O 0 2.2107640234025894e-06

The O 0 5.824858817504719e-05
mutation O 0 5.1436477406241465e-06
destroyed O 0 0.0001195815930259414
an O 0 3.513216142891906e-06
NdeI O 0 6.58169956295751e-05
restriction O 0 1.9915813027182594e-05
enzyme O 0 3.965601536037866e-06
site O 0 5.306968432705617e-06
. O 0 8.904877404347644e-07

Analysis O 0 3.218103665858507e-05
of O 0 3.689310688059777e-05
all O 0 1.0435535386932315e-06
family O 0 3.7667183505618596e-07
members O 0 4.628310890097964e-08
demonstrated O 0 4.033906293443579e-07
that O 0 5.198472052825309e-08
the O 0 5.090811896479863e-07
missense O 0 4.565996277960949e-06
mutation O 0 1.8199033320343005e-06
co O 0 2.10704038181575e-05
- O 0 1.0557072528172284e-05
segregated O 0 2.7110429527965607e-06
with O 0 1.794790733811169e-07
patients O 0 2.7257733563601505e-06
with O 0 3.7808833440067247e-05
tumors B-Disease 1 1.0
or O 1 0.9997928738594055
who O 0 1.4023114999872632e-05
, O 0 1.838010206256513e-07
as O 0 1.224071866090526e-07
a O 0 1.7740232749474671e-07
result O 0 1.1801999733052071e-07
of O 0 2.5662893676781096e-06
linkage O 0 1.0257221219944768e-05
analysis O 0 2.4912191065595835e-07
had O 0 3.130118557237438e-06
been O 0 1.1655711205094121e-06
predicted O 0 3.043912784050917e-07
to O 0 1.1741596139813737e-08
carry O 0 8.927617045628722e-08
the O 0 1.0638942740115453e-06
predisposing O 0 3.2657451811246574e-05
mutation O 0 4.859321961703245e-06
. O 0 4.53129314337275e-06

These O 0 7.262792678375263e-06
observations O 0 2.6214655008516274e-05
point O 0 1.5765323041705415e-05
to O 0 3.520805478274269e-07
another O 0 2.4145768406924617e-07
region O 0 4.0890620311984094e-07
of O 0 5.725571554648923e-06
the O 0 2.1231848222669214e-05
RB1 O 0 0.00013720541028305888
gene O 0 6.272533141782333e-07
where O 0 3.7904584360148874e-07
mutations O 0 5.592922747155171e-08
only O 0 4.802210185061995e-08
modify O 0 9.08352646433741e-08
the O 0 5.163441301192506e-07
function O 0 7.590423365400056e-07
of O 0 2.17901288124267e-06
the O 0 1.7211466456501512e-06
gene O 0 4.2289971702302864e-07
and O 0 1.2325445197802765e-07
raise O 0 1.5150050103329704e-07
important O 0 1.4605652154386917e-07
questions O 0 9.954747071105885e-08
for O 0 7.41675663107344e-08
genetic O 0 4.844760042033158e-07
counseling O 0 4.6768158767918067e-07
in O 0 1.3463031223182043e-07
families O 0 1.2940661875404658e-08
with O 0 3.765824985180188e-09
these O 0 1.3741305870951237e-08
distinctive O 0 5.433723231362819e-07
phenotypes O 0 4.198370788799366e-06
. O 0 4.228004968354071e-07
. O 0 6.629639983657398e-07

Maternal B-Disease 1 0.7822649478912354
disomy I-Disease 1 0.9801115393638611
and O 0 0.003156920662149787
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.9999774694442749
with O 0 4.685530711867614e-06
gamete O 0 0.05831432715058327
complementation O 0 0.0853734239935875
in O 0 2.384606432315195e-06
a O 0 3.8550578551621584e-07
case O 0 2.1215919332462363e-07
of O 0 9.451145501770952e-07
familial O 0 2.013494395214366e-06
translocation O 0 1.656102540437132e-05
( O 0 2.580454747658223e-07
3 O 0 4.2302917790948413e-07
; O 0 1.4926690994343517e-08
15 O 0 1.0890235557781125e-07
) O 0 3.650807300914494e-08
( O 0 2.6583627743548277e-08
p25 O 0 1.7918046069098637e-06
; O 0 2.931335707501148e-08
q11 O 0 9.469478072787751e-07
. O 0 2.9830626857574316e-08
2 O 0 3.186897856721771e-07
) O 0 6.944657826579714e-08
. O 0 2.28012922320886e-07

Maternal B-Disease 1 0.9948609471321106
uniparental I-Disease 1 0.9996826648712158
disomy I-Disease 1 0.9894876480102539
( I-Disease 0 0.0002060254628304392
UPD I-Disease 1 0.9999829530715942
) I-Disease 0 1.682870788499713e-06
for I-Disease 0 6.920075747984811e-07
chromosome I-Disease 0 1.1054281458200421e-05
15 I-Disease 0 1.0836589353857562e-05
is O 0 5.18066542554152e-07
responsible O 0 4.93848688165599e-07
for O 0 1.4155189376197086e-07
an O 0 1.4688819760522165e-07
estimated O 0 1.3966359801997896e-07
30 O 0 9.563586189642592e-08
% O 0 1.534975169192876e-08
of O 0 6.31550491902999e-08
cases O 0 9.349300000849325e-08
of O 0 0.00016263325233012438
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.011339235119521618
PWS B-Disease 1 1.0
) O 0 3.146171593471081e-06
. O 0 8.665857080814021e-07

We O 0 5.1202394388383254e-05
report O 0 5.767462880612584e-06
on O 0 2.3066156700224383e-06
an O 0 1.5056083668696374e-07
unusual O 0 4.188071045518882e-07
case O 0 1.7631085711400374e-06
of O 0 2.6782863642438315e-05
maternal B-Disease 1 0.9993021488189697
disomy I-Disease 1 0.9647243022918701
15 I-Disease 0 0.0004819146706722677
in O 0 0.00023901478562038392
PWS B-Disease 1 1.0
that O 0 3.296624527138192e-06
is O 0 4.2665334376579267e-07
most O 0 3.7500793581557446e-08
consistent O 0 1.467527965814952e-07
with O 0 2.9290779579582704e-08
adjacent O 0 1.37992810778087e-06
- O 0 3.6603321973416314e-07
1 O 0 4.848309913541016e-07
segregation O 0 4.0871512396734033e-07
of O 0 9.291096603192273e-07
a O 0 1.059733449437772e-06
paternal O 0 1.2526555110525806e-05
t O 0 1.96519090422953e-06
( O 0 7.061181150902485e-08
3 O 0 2.161844321335593e-07
; O 0 1.7760571680014436e-08
15 O 0 1.9666198625145626e-07
) O 0 2.3063856602334454e-08
( O 0 3.319789243505511e-08
p25 O 0 1.3855468523615855e-06
; O 0 2.2459346382674994e-08
q11 O 0 4.094294467904547e-07
. O 0 9.592172389716325e-09
2 O 0 4.9678302360689486e-08
) O 0 3.817766547342671e-09
with O 0 5.053774732033389e-09
simultaneous O 0 7.913381523394492e-07
maternal O 0 0.00025979106430895627
meiotic O 0 0.0002860347740352154
nondisjunction O 0 8.121671271510422e-05
for O 0 7.17915327186347e-07
chromosome O 0 7.944573553686496e-06
15 O 0 5.88081138630514e-06
. O 0 9.608910431779805e-07

The O 0 0.00016335358668584377
patient O 0 7.407595694530755e-05
( O 0 2.8757633572240593e-06
J O 0 8.135825191857293e-05
. O 0 5.231225941315643e-07
B O 0 2.7663174932968104e-06
. O 0 4.099947403801707e-08
) O 0 3.427602024430598e-08
, O 0 2.7629369014903205e-08
a O 0 5.065455184194434e-07
17 O 0 3.98457905248506e-06
- O 0 3.142657078569755e-06
year O 0 1.0569180631136987e-05
- O 0 1.4504003047477454e-05
old O 0 4.9643709644442424e-05
white O 0 1.4176279137245729e-06
male O 0 4.838591394218383e-06
with O 0 6.103911800892092e-06
PWS B-Disease 1 1.0
, O 0 6.153462436486734e-06
was O 0 4.12098816013895e-05
found O 0 3.696672195019346e-07
to O 0 5.605150477094867e-08
have O 0 1.3886169369925483e-07
47 O 0 1.2464402061596047e-06
chromosomes O 0 4.187228057617176e-07
with O 0 2.9046856298009516e-07
a O 0 7.003704467933858e-06
supernumerary O 0 0.00122073816601187
, O 0 2.03957688427181e-06
paternal O 0 3.245682455599308e-05
der O 0 0.00015877695113886148
( O 0 2.2957036094339855e-07
15 O 0 3.487750745989615e-07
) O 0 2.232809137581171e-08
consisting O 0 1.1631498608721813e-07
of O 0 3.640360546341981e-06
the O 0 1.4908850062056445e-05
short O 0 1.5032229384814855e-05
arm O 0 2.3594207959831692e-05
and O 0 1.1873941048179404e-06
the O 0 9.674557077232748e-06
proximal O 0 0.001088003278709948
long O 0 9.486159797233995e-06
arm O 0 3.1561098694510292e-06
of O 0 1.6198185903704143e-06
chromosome O 0 2.778053385554813e-06
15 O 0 1.5897934417807846e-06
, O 0 9.781999210645154e-08
and O 0 3.38039541247781e-07
distal O 0 0.0001524973486084491
chromosome O 0 0.0007999833906069398
arm O 0 0.0019762609153985977
3p O 0 0.005739719141274691
. O 0 8.340540261997376e-06

The O 0 0.00047330878442153335
t O 0 6.253486208152026e-05
( O 0 1.1882357284775935e-06
3 O 0 1.7879622191685485e-06
; O 0 5.6159915828857265e-08
15 O 0 3.8684379433107097e-07
) O 0 4.9786912370564096e-08
was O 0 9.796942777029471e-07
present O 0 9.378287302297394e-08
in O 0 2.4813530785650073e-07
the O 0 5.566369623011269e-07
balanced O 0 1.351718168507432e-07
state O 0 1.2047819097915635e-07
in O 0 3.7073519365549146e-07
the O 0 1.1293655006738845e-06
patients O 0 8.241133855335647e-07
father O 0 2.807874125210219e-06
and O 0 4.3118637904626667e-07
a O 0 2.923596866821754e-06
sister O 0 2.8922298952238634e-05
. O 0 2.465944135110476e-06

Fluorescent O 0 8.589663775637746e-05
in O 0 2.0432332803466124e-06
situ O 0 1.3332199159776792e-05
hybridization O 0 2.878677776152472e-07
analysis O 0 2.498373419257405e-07
demonstrated O 0 1.6272132370431791e-06
that O 0 2.209572329547882e-07
the O 0 8.754122973186895e-06
PWS B-Disease 1 0.9999998807907104
critical O 0 2.2593310859519988e-05
region O 0 2.6556317607173696e-06
resided O 0 1.0528257007536013e-05
on O 0 5.29005183125264e-06
the O 0 1.1498644880703068e-06
derivative O 0 4.725807229988277e-06
chromosome O 0 1.2497824855017825e-06
3 O 0 7.960416041896679e-07
and O 0 1.1379383835219414e-07
that O 0 6.450627410004017e-08
there O 0 9.288937974361033e-08
was O 0 2.486024186509894e-06
no O 0 1.3177135826936137e-07
deletion O 0 6.847769782325486e-07
of O 0 8.343945410160813e-06
the O 0 5.6085336836986244e-05
PWS B-Disease 1 1.0
region O 0 4.00100498154643e-06
on O 0 8.483219062327407e-06
the O 0 1.0637126024448662e-06
normal O 0 2.3170355234469753e-06
pair O 0 3.924297402591037e-07
of O 0 2.4594526166765718e-06
15s O 0 1.3801813111058436e-05
present O 0 1.4456005601459765e-06
in O 0 6.735776423738571e-06
J O 0 0.0006621083593927324
. O 0 2.8960164399904897e-06

B O 0 0.003837699070572853
. O 0 3.586629100027494e-05

Methylation O 0 0.0001039529888657853
analysis O 0 5.2240347940823995e-06
at O 0 1.3754275641986169e-05
exon O 0 3.3591190913284663e-06
alpha O 0 5.866830179002136e-06
of O 0 2.3531997612735722e-06
the O 0 1.5958862604747992e-06
small O 0 5.924929382672417e-07
nuclear O 0 1.973220605577808e-05
ribonucleoprotein O 0 4.625332439900376e-05
- O 0 1.7478305380791426e-06
associated O 0 7.572788263132679e-07
polypeptide O 0 8.026548130146693e-06
N O 0 7.307277428481029e-06
( O 0 2.126885476627649e-07
SNRPN O 0 8.838142093736678e-06
) O 0 1.0085431512152354e-07
gene O 0 1.4045299678855372e-07
showed O 0 4.959291004524857e-07
a O 0 2.3225121026371198e-07
pattern O 0 8.598074145993451e-07
characteristic O 0 3.13089884684814e-07
of O 0 1.7007248516165419e-06
only O 0 7.2995980815449e-08
the O 0 2.739345745794708e-07
maternal O 0 8.050648830248974e-06
chromosome O 0 3.0335895644384436e-06
15 O 0 3.6464027743932093e-06
in O 0 2.5223091597581515e-06
J O 0 0.000328060588799417
. O 0 3.5663226753968047e-06

B O 0 0.0047709885984659195
. O 0 5.017399962525815e-05

Maternal B-Disease 0 0.03343756124377251
disomy I-Disease 0 0.008076819591224194
was O 0 0.00021637068130075932
confirmed O 0 3.234934865758987e-06
by O 0 3.3375349062225723e-07
polymerase O 0 1.1595637261052616e-05
chain O 0 1.7471004412072944e-06
reaction O 0 1.1081730377782151e-07
analysis O 0 4.1771372139010055e-08
of O 0 6.512923391710501e-07
microsatellite O 0 4.166755843471037e-06
repeats O 0 2.3728439373371657e-06
at O 0 8.673440788697917e-06
the O 0 9.652895869294298e-07
gamma O 0 5.02280954606249e-06
- O 0 3.8113405480544316e-06
aminobutyric O 0 1.015577890939312e-05
acid O 0 7.295407726815029e-07
receptor O 0 1.10944893094711e-06
beta3 O 0 5.520342256204458e-06
subunit O 0 8.658768706482078e-07
( O 0 2.131346406031298e-07
GABRB3 O 0 1.275421254831599e-05
) O 0 1.7445269406834996e-07
locus O 0 4.2400397433084436e-06
. O 0 1.19280207400152e-06

A O 0 0.0006235311739146709
niece O 0 0.0005336274625733495
( O 0 3.0547005280823214e-06
B O 0 1.640790833334904e-05
. O 0 1.642154501269033e-07
B O 0 1.2357605783108738e-06
. O 0 1.4311553719892345e-08
) O 0 4.75169503744155e-09
with O 0 6.24703400120552e-09
45 O 0 3.446509140303533e-07
chromosomes O 0 2.121302742352782e-07
and O 0 2.134236751771823e-07
the O 0 9.155438647212577e-07
derivative O 0 2.4304470116476296e-06
3 O 0 7.574644769192673e-07
but O 0 4.017527643895846e-08
without O 0 8.05969406769691e-08
the O 0 6.815083679612144e-07
der O 0 1.0230619409412611e-05
( O 0 7.175388816449413e-08
15 O 0 1.427811895382547e-07
) O 0 3.750294297333312e-08
demonstrated O 0 3.268794728228386e-07
a O 0 4.36428848615833e-07
phenotype O 0 1.2283910564292455e-06
consistent O 0 7.849897087908175e-07
with O 0 2.421773714900155e-08
that O 0 4.682314269643939e-08
reported O 0 3.5744565707318543e-07
for O 0 1.6808709801807709e-07
haploinsufficiency O 0 5.259255885903258e-06
of O 0 1.825389699661173e-05
distal O 0 0.0010121978120878339
3 O 0 7.099102367646992e-05
p O 0 0.00024905960890464485
. O 0 3.885774276568554e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999998807907104
associated O 0 0.00017969546024687588
with O 0 5.636817149934359e-06
unbalanced O 0 0.0012232244480401278
segregation O 0 4.6409117203438655e-05
of O 0 3.320532414363697e-05
non O 0 0.00013708104961551726
- O 0 6.90555534674786e-05
Robertsonian O 0 0.00013471656711772084
translocations O 0 3.3061591238947585e-05
has O 0 3.1917140859150095e-06
been O 0 4.4742068894265685e-06
reported O 0 2.821294856403256e-06
previously O 0 1.2016943173875916e-06
but O 0 8.065506307275427e-08
has O 0 9.933029332387378e-08
not O 0 2.9429042314177423e-08
, O 0 2.7971751137556566e-08
to O 0 2.4435861334382025e-08
our O 0 1.3888751482227235e-07
knowledge O 0 5.022728828407708e-07
, O 0 9.061186290182377e-08
been O 0 5.7728502866893905e-08
observed O 0 4.725883329115277e-08
in O 0 4.8693379994801944e-08
a O 0 1.215900908846379e-07
case O 0 5.396458391260239e-07
of O 0 2.5375033146701753e-05
PWS B-Disease 1 1.0
. O 0 1.4480246136372443e-05

Furthermore O 0 0.0004169002058915794
, O 0 7.007245585555211e-06
our O 0 1.1775931625379599e-06
findings O 0 4.4723887526743056e-07
are O 0 3.520106162113734e-08
best O 0 3.530245962224399e-08
interpreted O 0 1.5017694465768727e-07
as O 0 5.719235929291244e-08
true O 0 2.0420768009898893e-07
gamete O 0 1.0509558705962263e-05
complementation O 0 4.2863561247941107e-05
resulting O 0 2.361220822422183e-06
in O 0 6.54802670396748e-06
maternal B-Disease 1 0.9779747724533081
UPD I-Disease 1 1.0
15 I-Disease 0 0.0003261405508965254
and O 0 0.00011168204218847677
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.935211718082428
- I-Disease 1 0.99968421459198
Jampel I-Disease 1 0.9999973773956299
syndrome I-Disease 1 1.0
type I-Disease 0 0.0015193108702078462
2 I-Disease 0 0.0002455908979754895
and O 0 2.2149904907564633e-05
Stuve B-Disease 1 0.9999960660934448
- I-Disease 1 0.9999997615814209
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 2.8763369641637837e-07
a O 0 2.1634139102388872e-07
case O 0 1.0043621045952023e-07
for O 0 7.499632914687027e-08
" O 0 9.746889872985776e-07
lumping O 0 1.7111990473495098e-06
" O 0 3.4252539080625866e-06
. O 0 1.437397600057011e-06

Recent O 0 1.0545712029852439e-05
studies O 0 2.8515012218122138e-06
demonstrated O 0 4.4319949665805325e-06
the O 0 1.8126905843018903e-06
existence O 0 1.2484329090511892e-06
of O 0 3.3845481084426865e-06
a O 0 1.3860068293070071e-06
genetically O 0 1.8231763476705964e-07
distinct O 0 6.10212609331029e-08
, O 0 4.328896707761487e-08
usually O 0 1.7572983068703252e-08
lethal O 0 6.592474477429278e-08
form O 0 4.3147018402578396e-08
of O 0 1.4515007933368906e-06
the O 0 6.021383796905866e-06
Schwartz B-Disease 0 0.00016974675236269832
- I-Disease 0 0.3458440601825714
Jampel I-Disease 1 0.9994935989379883
syndrome I-Disease 1 0.9999998807907104
( O 0 4.329191597207682e-06
SJS B-Disease 1 0.9384374618530273
) O 0 7.488868618565903e-07
of O 0 3.874743197229691e-05
myotonia B-Disease 1 0.9999991655349731
and O 1 0.8079363703727722
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 6.753806701453868e-06
which O 0 6.564367254213721e-07
we O 0 1.4909240064753249e-07
called O 0 1.4044913996258401e-06
SJS B-Disease 0 0.0002966605534311384
type I-Disease 0 3.3455255561420927e-06
2 I-Disease 0 7.575290055683581e-06
. O 0 1.6657634205330396e-06

This O 0 0.00017697228759061545
disorder O 1 0.9204384088516235
is O 0 5.588850399362855e-06
reminiscent O 0 8.19683828012785e-06
of O 0 4.371913746581413e-06
another O 0 1.2479579254431883e-06
rare O 0 2.443796802253928e-06
condition O 0 0.0005254746647551656
, O 0 1.0125115750270197e-06
the O 0 1.0100972758664284e-05
Stuve B-Disease 1 0.9937851428985596
- I-Disease 1 0.9999988079071045
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.1550469177309424e-05
SWS B-Disease 1 0.9965463280677795
) O 0 3.3706027124935645e-07
, O 0 8.435458198619017e-08
which O 0 8.966644315933081e-08
comprises O 0 1.3178736253394163e-06
campomelia B-Disease 0 0.0006458332645706832
at O 1 0.6267387866973877
birth O 0 0.36682549118995667
with O 0 6.997418677201495e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 7.128470315365121e-05
contractures B-Disease 1 0.9717591404914856
, O 0 2.205574247682307e-07
and O 0 7.250255862345512e-08
early B-Disease 0 2.3314119061979e-06
death I-Disease 0 3.188867776771076e-05
. O 0 1.1000752238032874e-06

To O 0 8.790463652985636e-06
test O 0 2.990773509736755e-06
for O 0 9.119545438807108e-07
possible O 0 1.9192846139048925e-06
nosologic O 0 0.00014182334416545928
identity O 0 7.428095614159247e-07
between O 0 6.168045274534961e-06
these O 0 1.2805406868210412e-06
disorders O 1 0.5910844206809998
, O 0 2.053321139783293e-07
we O 0 2.6119574059180195e-08
reviewed O 0 1.2923720760227297e-07
the O 0 2.2429836121773405e-07
literature O 0 3.023787087386154e-07
and O 0 1.0671882222368367e-07
obtained O 0 5.77135210733104e-07
a O 0 8.665741120239545e-07
follow O 0 2.6651920848053123e-07
- O 0 1.0539300774325966e-06
up O 0 6.849768396932632e-07
of O 0 1.3548830111176358e-06
the O 0 6.183371965562401e-07
only O 0 1.2952965278145712e-07
two O 0 1.9914743631943566e-07
surviving O 0 6.437680895032827e-06
patients O 0 7.78512571741885e-07
, O 0 2.945238577467535e-07
one O 0 1.3485235683674546e-07
with O 0 1.2376047209272656e-07
SJS B-Disease 0 0.00013379710435401648
type I-Disease 0 4.586866452882532e-06
2 I-Disease 0 9.87751263892278e-06
at O 0 2.4461158318445086e-05
age O 0 6.828818186477292e-07
10 O 0 1.7894993220579636e-07
years O 0 1.6791213397482352e-07
and O 0 5.469942365721181e-08
another O 0 9.165392356180746e-08
with O 0 9.154105384823197e-08
SWS B-Disease 0 7.776951679261401e-05
at O 0 3.3356811854901025e-06
age O 0 7.537433361903823e-07
7 O 0 2.4766156911937287e-06
years O 0 1.764455987540714e-06
. O 0 7.326462423407065e-07

Patients O 0 0.00013728627527598292
reported O 0 1.4837674825685099e-05
as O 0 1.6308812291754293e-06
having O 0 3.4341830996709177e-06
either O 0 1.8931503291241825e-05
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 0.00013407912047114223
SWS B-Disease 1 0.8217481970787048
presented O 0 6.99083216204599e-07
a O 0 3.0756842761547887e-07
combination O 0 2.984719174037309e-07
of O 0 2.837644387909677e-06
a O 0 1.60056006279774e-05
severe O 1 0.9991118311882019
, O 0 6.32416276857839e-06
prenatal O 1 0.9999998807907104
- O 1 1.0
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 4.205535788059933e-06
with O 0 3.8775747270847205e-06
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999996423721313
respiratory O 1 1.0
and O 1 0.9375171065330505
feeding O 1 0.9504572153091431
difficulties O 0 0.07725635170936584
, O 0 1.1472170626802836e-06
tendency O 0 1.596356810296129e-06
to O 0 7.326657964767946e-07
hyperthermia B-Disease 0 0.04407428577542305
, O 0 9.063916905915903e-08
and O 0 5.0795801342928826e-08
frequent O 0 3.607503629154962e-07
death O 0 4.1247349145123735e-05
in O 0 1.8332730178372003e-06
infancy O 0 1.4991598618507851e-05
) O 0 2.88768458034383e-08
with O 0 1.1821369660935943e-08
a O 0 4.2950492229465453e-07
distinct O 0 8.863116249813174e-07
campomelic B-Disease 1 0.989467442035675
- I-Disease 1 0.9999980926513672
metaphyseal I-Disease 1 0.9999997615814209
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.00011447355063864961

The O 0 1.7418835341231897e-05
similarity O 0 9.519082595943473e-06
of O 0 1.8966720745083876e-05
the O 0 1.114542374125449e-05
clinical O 0 0.00010920866770902649
and O 0 2.2227443423616933e-06
radiographic O 0 0.0017172119114547968
findings O 0 2.7449643312138505e-05
is O 0 1.360872261102486e-06
so O 0 8.582446042737502e-08
extensive O 0 2.5244846710847924e-06
that O 0 1.7486905790065066e-06
these O 0 1.142431869993743e-06
disorders O 1 0.9997987151145935
appear O 0 1.5097939467523247e-06
to O 0 8.006771423652026e-08
be O 0 1.1391708198971173e-07
a O 0 2.0011304968647892e-07
single O 0 3.107793133949599e-07
entity O 0 1.928463916556211e-06
. O 0 3.1578560992784332e-06

The O 0 0.00045681922347284853
follow O 0 2.4328204744961113e-05
- O 0 2.3581023924634792e-05
up O 0 1.721951207400707e-06
observation O 0 9.272027455153875e-06
of O 0 1.3095821032038657e-06
an O 0 1.2516260028405668e-07
identical O 0 5.4684715422581576e-08
and O 0 5.500449873352409e-08
unique O 0 5.426163696142794e-08
pattern O 0 0.00015948341751936823
of O 1 0.9999058246612549
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 0.9999961853027344
in O 0 0.00012452791270334274
the O 0 2.1894695237278938e-05
two O 0 4.6950844989623874e-07
patients O 0 3.2038380481935747e-07
( O 0 9.186043570252878e-08
one O 0 8.356907699180738e-08
with O 0 1.1843400926636605e-07
SJS B-Disease 0 0.00014129449846222997
type I-Disease 0 4.098598310520174e-06
2 I-Disease 0 3.0772823720326414e-06
, O 0 1.3069454496417166e-07
one O 0 7.870363560869009e-08
with O 0 1.4532332670569303e-07
SWS B-Disease 0 0.0001524902181699872
) O 0 3.541998978562333e-07
surviving O 0 4.73897216579644e-06
beyond O 0 1.888235055957921e-05
infancy O 0 2.395789124420844e-05
adds O 0 1.17552588108083e-07
to O 0 3.94677108772612e-08
the O 0 8.154745501087746e-08
evidence O 0 7.063767526460651e-08
in O 0 1.5334073566464212e-07
favor O 0 2.520596922295226e-07
of O 0 1.2110165243939264e-06
identity O 0 6.450891305576079e-07
. O 0 2.4802602638374083e-06

The O 0 0.00011696507135638967
hypothesis O 0 2.8345766622805968e-05
that O 0 3.882703367708018e-06
SWS B-Disease 0 0.0013491250574588776
and O 0 1.4561519492417574e-05
SJS B-Disease 1 0.6735975742340088
type I-Disease 0 4.211864870740101e-05
2 I-Disease 0 1.6109839634737e-05
are O 0 1.5839776779102976e-07
the O 0 5.050173967902083e-07
same O 0 7.489483095923788e-07
disorder O 0 1.4756576092622709e-05
should O 0 3.0466537737083854e-08
be O 0 1.1574011082871039e-08
testable O 0 5.092579158372246e-08
by O 0 6.846252453840407e-09
molecular O 0 1.0905637992664197e-07
methods O 0 1.1540618771732625e-07
. O 0 9.464452688234815e-08
. O 0 5.12893961968075e-07

A O 0 6.566502270288765e-05
mouse O 0 1.0229575309494976e-05
model O 0 1.607455374141864e-06
of O 0 4.854037342738593e-06
severe O 1 0.999998927116394
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.625557005405426
defects O 1 0.9999927282333374
in O 0 3.405770257813856e-05
hemostasis O 1 0.9996777772903442
and O 0 3.72250251530204e-05
thrombosis B-Disease 1 0.9999995231628418
. O 0 1.3269791452330537e-05

von B-Disease 0 0.007016205694526434
Willebrand I-Disease 1 0.9969589710235596
factor I-Disease 0 0.00031178302015177906
( I-Disease 0 3.632558582467027e-05
vWf I-Disease 0 0.04604080319404602
) I-Disease 0 0.0016382391331717372
deficiency I-Disease 1 1.0
causes O 1 0.9999761581420898
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 1 0.9903019070625305
humans O 0 8.46431703394046e-06
. O 0 9.602131285646465e-07

We O 0 6.327384198812069e-06
generated O 0 2.624823309815838e-06
a O 0 2.8320587261987384e-06
mouse O 0 9.705520369607257e-07
model O 0 2.8520130967990553e-07
for O 0 6.545438679950166e-08
this O 0 4.0062484885083904e-08
disease O 0 2.6676153197513486e-07
by O 0 1.7482252090417205e-08
using O 0 6.243688943641246e-08
gene O 0 3.4433023188285006e-07
targeting O 0 2.7041046450904105e-06
. O 0 1.0798281664392562e-06

vWf B-Disease 0 0.06240197643637657
- I-Disease 1 0.9927977919578552
deficient I-Disease 1 0.9946976900100708
mice O 0 6.640316132688895e-05
appeared O 0 3.966475196648389e-05
normal O 0 2.3586422685184516e-05
at O 0 1.2554564818856306e-05
birth O 0 1.7387465049978346e-06
; O 0 1.7404564900402875e-08
they O 0 9.50265111043791e-09
were O 0 9.115582599861227e-08
viable O 0 1.7987593992074835e-07
and O 0 1.6099592414775543e-07
fertile O 0 1.1068248568335548e-05
. O 0 2.4359369490412064e-06

Neither O 0 0.0008168602944351733
vWf O 0 0.0036681045312434435
nor O 0 0.00028653486515395343
vWf O 0 0.0015632243594154716
propolypeptide O 0 0.0016065187519416213
( O 0 9.067010068974923e-06
von B-Disease 0 0.0004873592988587916
Willebrand I-Disease 0 0.006837255787104368
antigen O 0 6.74435796099715e-05
II O 1 0.9614933133125305
) O 0 3.5635241601994494e-07
were O 0 2.8363731985336926e-07
detectable O 0 9.603450052964035e-07
in O 0 8.033554195208126e-07
plasma O 0 1.0960437975882087e-05
, O 0 2.568664285718114e-07
platelets O 0 1.4613176517741522e-06
, O 0 2.686664117845794e-07
or O 0 1.6483504339248611e-07
endothelial O 0 2.4064329409156926e-06
cells O 0 1.1199598759503715e-07
of O 0 4.978701326763257e-07
the O 0 9.245964065485168e-07
homozygous O 0 1.827895971473481e-06
mutant O 0 7.11061784386402e-06
mice O 0 8.2086116890423e-06
. O 0 9.448288551539008e-07

The O 0 7.109455327736214e-05
mutant O 0 9.176346065942198e-05
mice O 0 6.138415483292192e-05
exhibited O 0 0.0013866322115063667
defects O 1 0.7692198157310486
in O 0 5.294265974953305e-06
hemostasis O 0 0.00031951963319443166
with O 0 2.96414867761996e-07
a O 0 4.530324986262713e-06
highly O 0 2.07802549994085e-05
prolonged O 1 0.9999971389770508
bleeding O 1 0.9999997615814209
time O 0 4.762331627716776e-06
and O 0 7.609731937918696e-07
spontaneous O 0 1.6646054064040072e-05
bleeding O 0 0.00011710635590134189
events O 0 1.891508958351551e-07
in O 0 5.116071832844682e-08
approximately O 0 2.3956465255992043e-08
10 O 0 5.991604012933749e-08
% O 0 6.023986998116015e-08
of O 0 7.942914521663624e-07
neonates O 0 3.4230997698614374e-05
. O 0 2.2631368210568326e-06

As O 0 4.158019510214217e-05
in O 0 6.024204139976064e-06
the O 0 6.277635293372441e-06
human O 0 9.74134400166804e-06
disease O 0 0.00014718245074618608
, O 0 3.308932434720191e-07
the O 0 1.1386238156774198e-06
factor O 0 1.528762709313014e-06
VIII O 0 0.0003444405156187713
level O 0 9.981270704884082e-05
in O 0 1.1755869309126865e-06
these O 0 1.4195487096912984e-07
mice O 0 9.133750040746236e-07
was O 0 4.862813057116e-06
reduced O 0 6.946444841560151e-07
strongly O 0 1.4276253068601363e-07
as O 0 7.255928125005084e-08
a O 0 5.771848421431969e-08
result O 0 5.389886226225826e-08
of O 0 2.3226650114338554e-07
the O 0 2.6033634981104115e-07
lack O 0 6.083590733396704e-07
of O 0 6.891230555083894e-07
protection O 0 8.650515042063489e-07
provided O 0 3.5373608398003853e-07
by O 0 7.367816010628303e-07
vWf O 0 4.2539904825389385e-05
. O 0 3.000678816533764e-06

Defective O 1 0.9999042749404907
thrombosis B-Disease 1 0.9999880790710449
in O 0 0.00010902366921072826
mutant O 0 5.86282076255884e-05
mice O 0 1.3379734809859656e-05
was O 0 1.2044080904161092e-05
also O 0 1.1879713213147625e-07
evident O 0 2.0167024672446132e-07
in O 0 6.654642703551872e-08
an O 0 3.7299773936183556e-08
in O 0 9.355829888590961e-08
vivo O 0 2.6156226340390276e-06
model O 0 9.17122974897211e-07
of O 0 7.730075594736263e-05
vascular B-Disease 1 1.0
injury I-Disease 1 0.9999973773956299
. O 0 2.2177171558723785e-05

In O 0 2.470635990903247e-05
this O 0 6.851199145785358e-07
model O 0 1.2604870107679744e-06
, O 0 1.6115890844048408e-07
the O 0 7.488283131351636e-07
exteriorized O 0 3.088611993007362e-05
mesentery O 0 5.774216333520599e-05
was O 0 9.510561358183622e-05
superfused O 0 1.83754600584507e-05
with O 0 7.072246717143571e-07
ferric O 0 0.0001422266650479287
chloride O 0 2.4040971766225994e-05
and O 0 1.9454398625384783e-06
the O 0 8.433875336777419e-06
accumulation O 0 0.00012107028305763379
of O 0 0.00011689214443322271
fluorescently O 0 0.00016693411453161389
labeled O 0 4.880188498646021e-06
platelets O 0 4.640984116122127e-06
was O 0 3.208368070772849e-06
observed O 0 4.456193494206673e-07
by O 0 1.3981485835756757e-07
intravital O 0 9.846738976193592e-06
microscopy O 0 6.918070084793726e-06
. O 0 1.8749335595202865e-06

We O 0 1.8813649148796685e-05
conclude O 0 1.6609837985015474e-05
that O 0 1.9566897435652209e-07
these O 0 9.851952853523471e-08
mice O 0 2.012258164540981e-06
very O 0 5.7828788868619085e-08
closely O 0 2.1886837942020065e-07
mimic O 0 3.584225123631768e-05
severe O 1 0.9992384910583496
human O 1 0.9497466683387756
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.00012655141472350806
will O 0 7.80962068347435e-07
be O 0 1.292342517444922e-07
very O 0 5.869206010089556e-09
useful O 0 3.44700801235831e-08
for O 0 4.151466370672097e-08
investigating O 0 1.8256713474329445e-07
the O 0 3.8422192005782563e-07
role O 0 7.439204523507215e-07
of O 0 4.470799012779025e-06
vWf O 0 9.037382369569968e-06
in O 0 1.9924727894249372e-06
normal O 0 1.71168903762009e-05
physiology O 0 4.1306786442874e-05
and O 0 5.121178219269495e-07
in O 0 9.140354677583673e-07
disease O 0 7.936560905363876e-06
models O 0 3.812929776358942e-07
. O 0 8.972786247340991e-08
. O 0 4.5749305854769773e-07

Oral O 0 0.0031782006844878197
contraceptives O 0 0.003855237504467368
and O 0 1.3652712596012861e-06
the O 0 2.636725639604265e-06
risk O 0 1.2812731256417464e-05
of O 1 0.7746860384941101
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.47413796489127e-05

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Clinical O 1 0.9782041311264038
Study O 0 1.101753059629118e-05
Group O 0 2.1539719909924315e-06
. O 0 1.692230853223009e-06

BACKGROUND O 0 0.0004204441502224654
Women O 0 5.485987912834389e-06
with O 0 2.0329422056875046e-07
mutations O 0 2.8439086463549756e-07
in O 0 1.0126427696377505e-06
either O 0 3.095653653417685e-07
the O 0 1.1963771839873516e-06
BRCA1 O 0 1.4013525060363463e-06
or O 0 3.6877881370855903e-07
the O 0 4.861079219153908e-07
BRCA2 O 0 1.468644086344284e-06
gene O 0 1.2065962096130534e-07
have O 0 1.4634799150314848e-08
a O 0 3.193840569792883e-08
high O 0 8.554153509976459e-07
lifetime O 0 3.3026979053829564e-06
risk O 0 1.882819015008863e-05
of O 1 0.9995771050453186
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.086017750320025e-05

Oral O 0 0.01950652524828911
contraceptives O 1 0.9147754311561584
protect O 0 0.0004118461220059544
against O 1 0.99997878074646
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 0.0012698759092018008
general O 0 9.250542643712834e-05
, O 0 7.157741492846981e-07
but O 0 4.872366332620004e-08
it O 0 1.944684591137502e-08
is O 0 3.075343713021539e-08
not O 0 3.5323608926773886e-08
known O 0 3.034064661733282e-07
whether O 0 5.875245534525675e-08
they O 0 5.7105811634983183e-08
also O 0 1.0323557120273108e-07
protect O 0 6.528556895091242e-08
against O 0 9.643262046665768e-07
hereditary B-Disease 1 0.9993526339530945
forms I-Disease 0 0.002345637185499072
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.815279291709885e-05

METHODS O 0 5.286030864226632e-05
We O 0 2.474571147104143e-06
enrolled O 0 1.2534106645034626e-05
207 O 0 9.62301783147268e-06
women O 0 5.523251616068592e-07
with O 0 3.20732465297624e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.1082583771203645e-05
161 O 0 2.0761000996571966e-05
of O 0 5.168571442482062e-05
their O 0 3.585409558581887e-06
sisters O 0 4.5837412471883e-05
as O 0 8.472817967231094e-07
controls O 0 6.020392220307258e-07
in O 0 3.0997242106423073e-07
a O 0 7.925534077912744e-07
case O 0 8.696903819327417e-07
- O 0 1.7589100025361404e-06
control O 0 8.766033943174989e-07
study O 0 9.419642310604104e-07
. O 0 1.3705925994145218e-06

All O 0 1.258088286704151e-05
the O 0 5.779603725386551e-06
patients O 0 5.877060971215542e-07
carried O 0 4.445827528343216e-07
a O 0 6.174350914989191e-07
pathogenic O 0 4.517424088135158e-07
mutation O 0 1.3810613097575697e-07
in O 0 4.248756795277586e-07
either O 0 1.212895455182661e-07
BRCA1 O 0 4.0139667589755845e-07
( O 0 7.218656605800788e-08
179 O 0 5.657204269482463e-07
women O 0 1.0702642327942158e-07
) O 0 5.47110055038047e-08
or O 0 1.442666786033442e-07
BRCA2 O 0 6.435830641748908e-07
( O 0 1.0186541743451016e-07
28 O 0 2.8286524411669234e-06
women O 0 1.3965134826321446e-07
) O 0 1.4450242247221468e-07
. O 0 2.0731768302084674e-07

The O 0 0.00042754074092954397
control O 0 7.100707443896681e-05
women O 0 2.339766524528386e-06
were O 0 1.6165686247404665e-06
enrolled O 0 1.1982680234723375e-06
regardless O 0 1.800606099777724e-07
of O 0 1.1592013606787077e-06
whether O 0 1.2923389647312433e-07
or O 0 1.299365663953722e-07
not O 0 2.4687432542691568e-08
they O 0 9.787108901093688e-09
had O 0 1.9398525807901024e-07
either O 0 2.4944498022705375e-07
mutation O 0 8.554643500247039e-07
. O 0 1.3391633046921925e-06

Lifetime O 0 0.00046945418580435216
histories O 0 7.624011777807027e-05
of O 0 6.563422357430682e-05
oral O 0 0.00017448725702706724
- O 0 6.534731801366434e-05
contraceptive O 0 4.251662903698161e-05
use O 0 3.4354107469880546e-07
were O 0 1.1886143056472065e-06
obtained O 0 6.454915819631424e-07
by O 0 6.864207193757466e-07
interview O 0 1.5769328456372023e-06
or O 0 3.4950994631799404e-07
by O 0 8.562236786247013e-08
written O 0 1.335146038172752e-07
questionnaire O 0 2.1653934823007148e-07
and O 0 1.4511766721625463e-07
were O 0 1.2430866718204925e-06
compared O 0 1.1512448736539227e-06
between O 0 9.135457617048814e-07
patients O 0 1.3875290960640996e-06
and O 0 6.03571777446632e-07
control O 0 1.0409650712972507e-05
women O 0 6.534100975841284e-07
, O 0 2.1163640440136078e-07
after O 0 5.9797531548611e-07
adjustment O 0 1.5141860103540239e-06
for O 0 1.0530223448768083e-07
year O 0 2.2847395086955657e-07
of O 0 6.114464099482575e-07
birth O 0 4.644069576897891e-06
and O 0 1.2257194157427875e-06
parity O 0 3.2351879781344905e-05
. O 0 2.4585474420746323e-06

RESULTS O 0 0.00028846802888438106
The O 0 1.1100278243247885e-05
adjusted O 0 2.8981883588130586e-05
odds O 0 1.5277573766070418e-05
ratio O 0 0.0001098124630516395
for O 0 0.0007087934063747525
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 5.160303771845065e-06
with O 0 9.832297820366875e-08
any O 0 7.438403315518372e-08
past O 0 2.7998925133942976e-07
use O 0 1.7986145905979356e-08
of O 0 3.688076617436309e-07
oral O 0 7.2830807766877115e-06
contraceptives O 0 1.8027752958005294e-05
was O 0 2.9190750865382142e-05
0 O 0 1.5541912716798834e-06
. O 0 7.474997687495488e-07

5 O 0 5.0188551540486515e-05
( O 0 2.1504004052985692e-06
95 O 0 1.1246878784731962e-05
percent O 0 3.87221371056512e-06
confidence O 0 3.951218786824029e-06
interval O 0 2.2444289697887143e-06
, O 0 7.676690927382879e-08
0 O 0 4.588178015296762e-08
. O 0 3.382760072057067e-09
3 O 0 1.8553196312609543e-08
to O 0 1.1497287566442083e-08
0 O 0 3.8375752353658754e-08
. O 0 7.4420198892255485e-09
8 O 0 3.075989525314071e-07
) O 0 6.511321259949909e-08
. O 0 1.3870590009901207e-07

The O 0 0.00013948543346486986
risk O 0 1.2985870853299275e-05
decreased O 0 2.6689955120673403e-05
with O 0 4.5785007785070775e-08
increasing O 0 3.720165580034518e-07
duration O 0 3.733992571142153e-06
of O 0 2.0788183974218555e-06
use O 0 2.018384037683063e-07
( O 0 2.0742824347053102e-07
P O 0 7.045406164252199e-06
for O 0 9.594059946493871e-08
trend O 0 4.603518561907549e-07
, O 0 2.3105377167098595e-08
< O 0 1.0527793392611784e-07
0 O 0 3.335008003091389e-08
. O 0 6.906585081623007e-09
001 O 0 5.822434445690305e-07
) O 0 9.174412340939853e-09
; O 0 3.884557564504121e-09
use O 0 1.0486045809443567e-08
for O 0 7.96236250266702e-08
six O 0 7.666520218663209e-07
or O 0 5.094153152640502e-07
more O 0 5.027300531423862e-08
years O 0 7.039087108751119e-07
was O 0 2.175099325540941e-06
associated O 0 2.468112114684118e-08
with O 0 5.308892436772794e-09
a O 0 7.871999940789465e-08
60 O 0 1.592310781006745e-07
percent O 0 2.3052581354932045e-07
reduction O 0 4.89949457005423e-07
in O 0 9.052114364749286e-07
risk O 0 3.2912212191149592e-06
. O 0 9.965174285753164e-07

Oral O 0 0.004381088539958
- O 0 0.0007553976611234248
contraceptive O 0 0.0002402018290013075
use O 0 2.693860551516991e-06
protected O 0 0.00019664879073388875
against O 1 0.9153911471366882
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 9.872001101030037e-07
for O 0 1.9557197106223612e-07
carriers O 0 8.643903726124336e-08
of O 0 1.229258259627386e-06
the O 0 8.705559366717353e-07
BRCA1 O 0 1.1739422234313679e-06
mutation O 0 1.8183820316153287e-07
( O 0 3.6724294716350414e-08
odds O 0 2.225942523637059e-07
ratio O 0 1.9578060062031e-07
, O 0 1.6217610365742985e-08
0 O 0 2.2779158115326936e-08
. O 0 2.117410247137741e-09
5 O 0 3.9335141366336757e-08
; O 0 1.1188534543293827e-08
95 O 0 3.982805480973184e-07
percent O 0 7.768023806420388e-07
confidence O 0 1.0403142596260295e-06
interval O 0 7.65242248235154e-07
, O 0 8.715072397080803e-08
0 O 0 3.2031746144411954e-08
. O 0 3.6510003909029365e-09
3 O 0 3.571873108398904e-08
to O 0 1.1181067627319408e-08
0 O 0 4.6751569726666276e-08
. O 0 7.760395881462046e-09
9 O 0 2.4486911343046813e-07
) O 0 7.68864527600499e-09
and O 0 4.778497597612841e-09
for O 0 1.8093777143235457e-08
carriers O 0 4.765493599734327e-08
of O 0 1.0886160453082994e-06
the O 0 2.5383176307514077e-06
BRCA2 O 0 1.406845399287704e-06
mutation O 0 1.780538667617293e-07
( O 0 4.698937061675679e-08
odds O 0 1.9647826832169812e-07
ratio O 0 2.4774232088020653e-07
, O 0 2.1723218779357012e-08
0 O 0 1.451794773288384e-08
. O 0 1.907513924592763e-09
4 O 0 2.8450417133285555e-08
; O 0 6.382285810957455e-09
95 O 0 3.1988889759304584e-07
percent O 0 7.900359264567669e-07
confidence O 0 1.4727914958712063e-06
interval O 0 1.3831242995365756e-06
, O 0 8.689411856721563e-08
0 O 0 4.3375500524689414e-08
. O 0 2.7327888840744663e-09
2 O 0 2.3735919896239466e-08
to O 0 8.324673395065929e-09
1 O 0 1.3120281039391557e-07
. O 0 1.0797242211424418e-08
1 O 0 2.7856808060278127e-07
) O 0 1.1003526623198923e-07
. O 0 1.8229033571515174e-07

CONCLUSIONS O 0 0.0005619247676804662
Oral O 0 0.0004680214624386281
- O 0 0.00013841065810993314
contraceptive O 0 5.801254519610666e-05
use O 0 3.098344052432367e-07
may O 0 5.538897198675841e-07
reduce O 0 1.8987745420417923e-07
the O 0 1.7313236639893148e-06
risk O 0 3.767989983316511e-05
of O 1 0.9999971389770508
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.166450212826021e-05
women O 0 1.0817716145083978e-07
with O 0 1.304061481022245e-08
pathogenic O 0 1.4281619087341824e-07
mutations O 0 5.556431048603372e-08
in O 0 1.2214597688853246e-07
the O 0 4.241308033670066e-07
BRCA1 O 0 5.642883479595184e-06
or O 0 4.418523531057872e-06
BRCA2 O 0 6.127186497906223e-05
gene O 0 5.233110277913511e-05

A O 0 0.00038315789424814284
Japanese O 0 0.00011602284939726815
family O 0 7.204418579931371e-06
with O 0 2.0630561721191043e-06
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.3383820487433695e-06
a O 0 2.006985596381128e-06
codon O 0 4.182569227850763e-06
291 O 0 1.542814288768568e-06
deletion O 0 1.0853485719053424e-06
: O 0 2.8599819401620152e-08
a O 0 7.809264701563734e-08
clinical O 0 1.4521376670018071e-06
, O 0 3.9621056657779263e-07
biochemical O 0 1.9128279745928012e-05
, O 0 5.266124389891047e-07
pathological O 0 0.00027431888156570494
, O 0 2.636939200328925e-07
and O 0 1.7532148888221855e-07
genetic O 0 1.7166681800517836e-06
report O 0 4.53536131317378e-06
. O 0 2.3205957404570654e-06

We O 0 3.90302921005059e-05
report O 0 6.807082627346972e-06
a O 0 1.9720919226529077e-06
Japanese O 0 6.942286290723132e-06
family O 0 2.0487452729867073e-06
with O 0 5.164069534657756e-06
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.00035074693732894957
ALD B-Disease 1 1.0
) O 0 6.817638791289937e-07
with O 0 1.302508394473989e-07
a O 0 1.812922278077167e-06
three O 0 6.726602919115976e-07
base O 0 3.492201358312741e-06
pair O 0 8.407170071222936e-07
deletion O 0 3.2203690807364183e-06
( O 0 2.4003927023841243e-07
delGAG O 0 2.2450883534474997e-06
291 O 0 1.0608517868604395e-06
) O 0 5.1721048777153555e-08
in O 0 2.674643724276393e-07
the O 0 8.57513259688858e-06
ALD B-Disease 1 0.9999998807907104
gene O 0 1.5541763787041418e-05
. O 0 6.219706847332418e-06

A O 0 8.613862155470997e-05
variety O 0 1.2147538654971868e-06
of O 0 4.190558684058487e-06
phenotypes O 0 3.824309715128038e-06
were O 0 5.552965944843891e-07
observed O 0 1.2774484048350132e-07
within O 0 4.732044089905685e-08
this O 0 9.278597445927517e-08
family O 0 5.830491431879636e-07
. O 0 1.151818082689715e-06

While O 0 0.00011240418098168448
the O 0 4.5033339119981974e-05
proband O 0 0.0003724189300555736
( O 0 3.053651880691177e-06
patient O 0 4.987491593055893e-06
1 O 0 5.672764928021934e-06
) O 0 2.774942231553723e-07
was O 0 3.918473794328747e-06
classified O 0 1.0458884247555034e-07
as O 0 7.489212805467105e-08
having O 0 6.683785613859072e-08
a O 0 1.2912092017813848e-07
rare O 0 1.2927185366606864e-07
intermediate O 0 3.3797230116761057e-06
type O 0 7.184714831964811e-07
of O 0 2.3338241589954123e-05
adult O 0 4.4193446228746325e-05
cerebral O 1 0.999816358089447
and O 0 3.422309600864537e-05
cerebello O 1 0.9580764770507812
- O 1 0.9065673351287842
brain O 0 0.34139111638069153
stem O 0 1.179696755571058e-05
forms O 0 5.198754706725595e-07
, O 0 2.06798929980323e-07
his O 0 2.539683464419795e-06
younger O 0 2.3667444111197256e-06
brother O 0 6.3204306570696644e-06
( O 0 1.3333288961803191e-07
patient O 0 5.642096425617638e-07
2 O 0 1.080680135601142e-06
) O 0 1.2641837088267494e-07
and O 0 6.928389666427393e-07
nephew O 0 8.806519326753914e-05
( O 0 3.0691853680764325e-07
patient O 0 1.0196256425842876e-06
3 O 0 1.1222687135159504e-06
) O 0 5.933445379469049e-08
had O 0 8.689028163644252e-07
a O 0 2.222388275185949e-06
childhood O 0 0.008853177540004253
ALD B-Disease 1 1.0
type O 0 0.00017340038903057575
. O 0 6.245735676202457e-06

Another O 0 0.00022648338926956058
nephew O 0 0.001145760528743267
( O 0 3.0801509183220332e-06
patient O 0 4.978548076906009e-06
4 O 0 5.375422915676609e-06
) O 0 1.09554235905307e-07
of O 0 2.1488283437065547e-06
patient O 0 9.873820999928284e-06
1 O 0 2.9540409741457552e-05
was O 0 5.209594019106589e-05
classified O 0 4.2807982936210465e-07
as O 0 3.062542361931264e-07
having O 0 3.290476513484464e-07
an O 0 2.567447268120304e-07
adolescent O 0 4.760914634971414e-06
form O 0 1.0105878800459323e-06
. O 0 3.7529925975832157e-06

The O 0 0.0001373205886920914
tau O 0 0.00020922653493471444
level O 0 4.1696621337905526e-05
in O 0 5.951607818133198e-06
the O 0 1.2578650967043359e-05
cerebrospinal O 0 0.00027100445004180074
fluid O 0 0.0002196302084485069
( O 0 6.297987511061365e-06
CSF O 0 0.00019580067601054907
) O 0 2.6252862994624593e-07
in O 0 4.5104502532922197e-07
patient O 0 1.4797280982747907e-06
1 O 0 7.2509583333157934e-06
was O 0 6.023668174748309e-05
as O 0 1.0087660484714434e-06
high O 0 6.277138709265273e-06
as O 0 2.42300295383302e-08
that O 0 6.330227453332782e-09
of O 0 2.3988684461073717e-07
patients O 0 9.086296017812856e-07
with O 0 1.4982989569034544e-06
Alzheimers B-Disease 1 1.0
disease I-Disease 0 0.10468607395887375
( O 0 4.7469464448113285e-07
AD B-Disease 0 6.031234079273418e-06
) O 0 2.2661097887066717e-07
. O 0 3.877476046909578e-07

His O 0 0.0005217877333052456
brain O 0 0.008156673051416874
magnetic O 0 0.0002833817561622709
resonance O 0 8.311901183333248e-05
image O 0 1.570347012602724e-05
( O 0 6.216737915565318e-07
MRI O 0 4.035357051179744e-05
) O 0 1.933349693672426e-07
showed O 0 3.5567441045714077e-06
abnormalities B-Disease 0 9.949369268724695e-05
in I-Disease 0 1.2402564379954129e-06
the I-Disease 0 4.384293333714595e-06
bilateral I-Disease 0 0.3575754761695862
cerebellar I-Disease 1 0.9999998807907104
hemispheres I-Disease 1 0.8793917894363403
and O 0 7.117737550288439e-05
brain O 1 0.6540353894233704
stem O 0 2.0890531231998466e-05
, O 0 1.2069783394963451e-07
but O 0 1.4701973860553608e-08
not O 0 1.4562069772239283e-08
in O 0 2.115235986366315e-07
the O 0 3.356205070303986e-06
cerebral O 0 0.0011399112408980727
white O 0 1.2567996918733115e-06
matter O 0 1.7307115740550216e-07
, O 0 4.8544723796339895e-08
where O 0 6.403785590691768e-08
marked O 0 5.949486308054475e-07
reductions O 0 1.3959078160041827e-06
of O 0 5.061503543402068e-06
the O 0 1.787622386473231e-05
cerebral O 0 0.0779576376080513
blood O 0 2.6716950742411427e-05
flow O 0 6.930135714355856e-05
and O 0 3.9747756090946496e-06
oxygen O 0 3.0148716177791357e-05
metabolism O 0 2.231009057140909e-05
were O 0 6.708741580041533e-07
clearly O 0 7.431001591839959e-08
demonstrated O 0 1.8222151254576602e-07
by O 0 5.1145303103794504e-08
positron O 0 1.0029968962044222e-06
emission O 0 8.095937573671108e-07
tomography O 0 2.461526719343965e-06
( O 0 2.3726306608296e-07
PET O 0 1.941119762705057e-06
) O 0 2.0438595527139114e-07
. O 0 2.8017836939397966e-07

In O 0 3.571948400349356e-05
patients O 0 4.312778401072137e-06
2 O 0 2.895721081586089e-06
and O 0 2.5503669576210086e-07
3 O 0 9.137539791481686e-07
, O 0 4.428967415037732e-08
the O 0 1.1595503224270942e-07
autopsy O 0 4.153559984843014e-06
findings O 0 7.553213663413771e-07
showed O 0 4.9399983254261315e-05
massive O 1 0.9704281687736511
demyelination B-Disease 1 1.0
of I-Disease 1 0.9999994039535522
the I-Disease 1 0.9999464750289917
cerebral I-Disease 1 0.9999997615814209
white I-Disease 0 1.2368839634291362e-05
matter I-Disease 0 4.4581489078154846e-07
with O 0 1.2650376390865858e-07
sparing O 0 8.842187639857002e-07
of O 0 1.254207018064335e-05
the O 0 5.633996624965221e-05
U O 1 0.9996274709701538
- O 0 0.00011102774442406371
fibers O 0 1.0763021236925852e-05
, O 0 1.1875226846314035e-07
compatible O 0 1.3676047672106506e-07
with O 0 1.286201722905389e-08
the O 0 2.3073233990089648e-07
findings O 0 3.975064544192719e-07
of O 0 2.321756983292289e-05
childhood O 1 0.9998044371604919
ALD B-Disease 1 1.0
. O 0 2.2095684471423738e-05

Oleic O 0 0.0061447834596037865
and O 0 0.00011089273175457492
erucic O 0 0.0025707068853080273
acids O 0 2.5640887542976998e-05
( O 0 2.677453494470683e-06
Lorenzos O 0 7.577017095172778e-05
Oil O 0 3.871423177770339e-05
) O 0 1.1855821213657691e-07
were O 0 1.9644062376755755e-07
administered O 0 1.6435316751994833e-07
to O 0 4.616831361659024e-08
patients O 0 1.0297402042169779e-07
1 O 0 6.532293923555699e-07
and O 0 1.5893114380105544e-07
4 O 0 1.1641269566098345e-06
, O 0 1.470738730802168e-08
but O 0 2.7709838867906456e-09
sufficient O 0 2.5487617349995162e-08
effectiveness O 0 4.775702677761728e-07
was O 0 3.1747622415423393e-06
not O 0 3.871652154430194e-08
obtained O 0 8.557907449358026e-07
. O 0 1.0284539939675597e-06

The O 0 0.00017745097284205258
findings O 0 1.1751659258152358e-05
in O 0 3.052347665288835e-06
this O 0 5.280527943796187e-07
family O 0 3.5745827631217253e-07
suggest O 0 2.7523392986950057e-07
that O 0 1.0949741380272826e-07
delGAG291 O 0 2.1505338736460544e-06
is O 0 1.8600626106035634e-07
part O 0 1.4713369012042676e-07
of O 0 2.4066853256954346e-06
the O 0 5.156392489880091e-06
cause O 0 1.3446531738736667e-05
of O 0 0.00022695701045449823
Japanese O 0 0.1082419604063034
ALD B-Disease 1 1.0
with O 0 5.134504021953035e-07
phenotypic O 0 7.887427273089997e-06
variations O 0 1.78330246853875e-05
. O 0 6.506456429633545e-06

Moreover O 0 0.00017899229715112597
, O 0 3.946751803596271e-06
although O 0 3.0462939548669965e-07
the O 0 6.600979531867779e-07
scale O 0 5.838336619490292e-06
of O 0 9.393444997840561e-06
the O 0 2.9944694688310847e-06
study O 0 1.9663761463561968e-07
is O 0 6.671430696769676e-08
limited O 0 7.327846418547779e-08
, O 0 6.067887881044953e-08
there O 0 6.360802018434697e-08
is O 0 8.766772197077444e-08
a O 0 2.2675172317576653e-07
possibility O 0 4.175321350885497e-07
that O 0 6.298650987446308e-07
PET O 0 6.388179372152081e-06
can O 0 2.2442267777478264e-07
detect O 0 2.5626115984778153e-06
an O 0 6.268033757805824e-06
insidious B-Disease 0 0.00028992415172979236
lesion I-Disease 1 0.5840784311294556
which O 0 7.96502604316629e-07
is O 0 2.8180230060570466e-07
undetectable O 0 2.1866862880415283e-06
by O 0 8.178874111308687e-08
computed O 0 9.441658903597272e-07
tomogram O 0 7.295502655324526e-06
( O 0 2.593748433810106e-07
CT O 0 1.5853507647989318e-05
) O 0 1.6230366384206718e-07
or O 0 2.6819691356649855e-07
MRI O 0 1.3735125321545638e-05
analysis O 0 2.118809732110094e-07
, O 0 3.681076421457874e-08
and O 0 2.617533212401213e-08
that O 0 3.533546788503372e-08
the O 0 1.6944063929713593e-07
higher O 0 9.754952543516993e-07
level O 0 7.552543479505403e-07
of O 0 5.590170530922478e-07
tau O 0 2.843484935510787e-06
reflects O 0 3.743961940472218e-08
the O 0 3.5094807060431776e-08
process O 0 5.777344469493073e-08
of O 0 1.785607310011983e-06
neuronal B-Disease 0 0.0008396263001486659
degeneration I-Disease 1 0.9995927214622498
in O 0 0.00010744071187218651
ALD B-Disease 1 1.0
. O 0 1.3825459973304532e-05

Lorenzos O 0 0.017424825578927994
Oil O 0 0.0009584483923390508
should O 0 2.667997023308999e-06
be O 0 3.2026312624111597e-07
given O 0 1.251048473704941e-07
in O 0 2.5632098754613253e-07
the O 0 3.2492673085471324e-07
early O 0 4.965443736182351e-07
stage O 0 1.767101480254496e-06
. O 0 1.5951985687934211e-07
. O 0 3.393477072677342e-07

Nonsense O 0 0.0007706540054641664
mutation O 0 7.431422545778332e-06
in O 0 2.2832589365862077e-06
exon O 0 3.2471868962602457e-06
4 O 0 1.672751864134625e-06
of O 0 1.7775945480025257e-06
human O 0 7.94388427038939e-07
complement O 0 3.226948138035368e-06
C9 O 0 0.0003427589253988117
gene O 0 5.347248475118249e-07
is O 0 1.1538219979456699e-07
the O 0 2.0237617093243898e-07
major O 0 1.5078226169862319e-06
cause O 0 8.99941937859694e-07
of O 0 4.562026788335061e-06
Japanese O 0 4.6459415898425505e-05
complement B-Disease 0 0.0002624727494549006
C9 I-Disease 1 0.9999899864196777
deficiency I-Disease 1 0.999990701675415
. O 0 6.208163085830165e-06

Deficiency B-Disease 1 0.999980092048645
of I-Disease 0 0.0006302950787357986
the I-Disease 0 5.041106487624347e-05
ninth I-Disease 0 8.238772716140375e-05
component I-Disease 0 3.953464783990057e-06
of I-Disease 0 6.821776878496166e-06
human I-Disease 0 3.3266462651226902e-06
complement I-Disease 0 6.194466550368816e-06
( O 0 1.320319142905646e-06
C9 O 0 0.00016132292512338609
) O 0 2.012233863979418e-07
is O 0 7.373819954636929e-08
the O 0 1.6700327876151277e-07
most O 0 8.27364274869069e-08
common O 0 2.353765466978075e-06
complement B-Disease 1 0.9999997615814209
deficiency I-Disease 1 1.0
in O 0 5.2278879593359306e-05
Japan O 0 3.914062745025149e-06
but O 0 6.022217746703973e-08
is O 0 5.2168282138609356e-08
rare O 0 1.573460473025534e-08
in O 0 4.272591880294385e-08
other O 0 1.685779338345128e-08
countries O 0 7.191556505858898e-08
. O 0 8.25567099127511e-07

We O 0 3.1157514968072064e-06
studied O 0 3.1389668038173113e-06
the O 0 3.4708648399828235e-07
molecular O 0 5.800663416266616e-07
basis O 0 1.5292758916984894e-06
of O 0 6.207889964571223e-05
C9 B-Disease 1 0.9999804496765137
deficiency I-Disease 1 0.9999769926071167
in O 0 1.4621633454225957e-05
four O 0 3.3191547572641866e-06
Japanese O 0 7.80481132096611e-05
C9 B-Disease 1 0.9999487400054932
- I-Disease 1 0.9993777275085449
deficient I-Disease 1 0.998336136341095
patients O 0 3.0427509045694023e-06
who O 0 7.861854101065546e-07
had O 0 6.627398397540674e-05
suffered O 1 0.9999992847442627
from O 1 0.9846574664115906
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.2502804565883707e-05

Direct O 0 2.141102413588669e-05
sequencing O 0 1.510840047558304e-05
of O 0 2.696595765883103e-05
amplified O 0 4.832126433029771e-05
C9 O 0 0.00013926667452324182
cDNA O 0 7.929071216494776e-06
and O 0 3.0094085445853125e-07
DNA O 0 3.743676870726631e-07
revealed O 0 2.1536309304792667e-06
a O 0 1.442086613678839e-06
nonsense O 0 6.281809419306228e-06
substitution O 0 1.9935200725740287e-06
( O 0 1.9051591948482383e-07
CGA O 0 1.683053710621607e-06
- O 0 4.4852626501779014e-07
- O 0 5.305453782966651e-07
> O 0 4.956865495842067e-07
TGA O 0 1.0097131735165021e-06
) O 0 2.830503476047852e-08
at O 0 5.22123798418761e-07
codon O 0 5.027866336604347e-07
95 O 0 1.5285672816389706e-07
in O 0 8.1885985991903e-08
exon O 0 2.8685491315627587e-07
4 O 0 4.817080707653076e-07
in O 0 1.857294193996495e-07
the O 0 7.602521918670391e-07
four O 0 3.6142848784948e-06
C9 B-Disease 0 0.002170529216527939
- I-Disease 0 0.0002983518352266401
deficient I-Disease 0 8.66310583660379e-05
individuals O 0 3.1623082463738683e-07
. O 0 1.5321999171646894e-06

An O 0 7.332710811169818e-05
allele O 0 1.5984278434189036e-05
- O 0 4.856736723013455e-06
specific O 0 3.6260053093428724e-07
polymerase O 0 3.511405157041736e-05
chain O 0 1.1396916306694038e-05
reaction O 0 1.0428024097564048e-06
system O 0 2.0746456357301213e-06
designed O 0 8.475193453705288e-07
to O 0 1.3733556158967986e-07
detect O 0 2.9898302500441787e-07
exclusively O 0 2.0787162213764532e-07
only O 0 1.056178362546234e-07
one O 0 9.564352154711742e-08
of O 0 9.058392720362463e-07
the O 0 9.842615327215753e-07
normal O 0 1.9640049231384182e-06
and O 0 1.5171535494573618e-07
mutant O 0 6.274023007790674e-07
alleles O 0 1.6310494288518385e-07
indicated O 0 5.471120516631345e-07
that O 0 6.676599184629595e-08
all O 0 6.600853907912096e-08
the O 0 2.4521659724996425e-07
four O 0 1.5144300391511933e-07
patients O 0 5.21468912495493e-08
were O 0 3.1152086421570857e-07
homozygous O 0 9.489976093846053e-08
for O 0 1.9103372039808164e-07
the O 0 6.318408054539759e-07
mutation O 0 9.721678395635536e-08
in O 0 4.878522759099724e-07
exon O 0 1.1519510962898494e-06
4 O 0 1.9680073819472454e-06
and O 0 1.2498297508045653e-07
that O 0 9.504286424544262e-08
the O 0 4.6184783286662423e-07
parents O 0 7.130271484356854e-08
of O 0 1.1605553709159722e-06
patient O 0 1.698776372904831e-06
2 O 0 2.756468347797636e-06
were O 0 1.7072673017537454e-06
heterozygous O 0 6.546256940964668e-07
. O 0 6.263608725021186e-07

The O 0 2.4118222427205183e-05
common O 0 1.8310958012079936e-06
mutation O 0 6.244284236345266e-07
at O 0 1.190108378068544e-05
codon O 0 2.9245309178804746e-06
95 O 0 1.294895355385961e-06
in O 0 2.6600753244565567e-07
exon O 0 9.318490015175485e-07
4 O 0 2.0987060906918487e-06
might O 0 1.4363996569954907e-07
be O 0 7.509481037004662e-08
responsible O 0 1.212696503216648e-07
for O 0 4.93225513764628e-08
most O 0 1.9117058513984375e-07
Japanese O 0 4.8650330427335575e-05
C9 B-Disease 1 0.9996581077575684
deficiency I-Disease 1 0.9986853003501892
. O 0 3.738706482181442e-07
. O 0 7.800331331964117e-07

BRCA1 O 0 0.0001929837599163875
required O 0 6.580980880244169e-06
for O 0 3.2732389172451803e-06
transcription O 0 0.00016409091767854989
- O 0 5.8481571613810956e-05
coupled O 0 5.749057527282275e-05
repair O 0 1.4556271707988344e-05
of O 0 8.438613804173656e-06
oxidative O 0 3.083011324633844e-05
DNA O 0 4.841831469093449e-06
damage O 0 0.0008137503173202276
. O 0 6.169445441628341e-06

The O 0 0.0005756425089202821
breast B-Disease 1 0.9999663829803467
and I-Disease 1 0.9997274279594421
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.01561618223786354
gene O 0 4.851362064073328e-06
BRCA1 O 0 5.356095243769232e-06
encodes O 0 2.2334900222631404e-06
a O 0 4.657419594877865e-06
zinc O 0 0.00016100448556244373
finger O 0 1.581157630425878e-05
protein O 0 8.730117997401976e-07
of O 0 1.6786710830274387e-06
unknown O 0 3.919759365089703e-06
function O 0 5.029784006183036e-06
. O 0 1.620594275664189e-06

Association O 0 0.0001676353276707232
of O 0 1.8009572158916853e-05
the O 0 5.648343176289927e-06
BRCA1 O 0 2.9587729386548745e-06
protein O 0 9.57847987592686e-07
with O 0 8.04682187549588e-08
the O 0 1.0872610118894954e-06
DNA O 0 1.1316911923131556e-06
repair O 0 4.57571804872714e-05
protein O 0 2.9399272534647025e-05
Rad51 O 0 6.888461939524859e-05
and O 0 1.3476239928422729e-06
changes O 0 1.9906217119114444e-07
in O 0 3.868773603699083e-07
the O 0 3.049669032861857e-07
phosphorylation O 0 4.5038524376650457e-07
and O 0 1.799534885549292e-07
cellular O 0 5.4367733355320524e-06
localization O 0 9.61207570071565e-06
of O 0 4.150305358052719e-06
the O 0 2.5357721824548207e-06
protein O 0 2.120990075127338e-06
after O 0 2.381383865213138e-06
exposure O 0 2.6872380658460315e-06
to O 0 4.5236234313961177e-07
DNA O 0 3.11525832330517e-06
- O 0 3.234302857890725e-05
damaging O 0 2.323032822459936e-05
agents O 0 1.3936186178398202e-06
are O 0 3.260095837731569e-08
consistent O 0 1.060700469679432e-07
with O 0 7.950824887359431e-09
a O 0 7.344819863419616e-08
role O 0 9.997597771871369e-08
for O 0 1.6154729109985055e-07
BRCA1 O 0 1.3085807495372137e-06
in O 0 9.625730399420718e-07
DNA O 0 2.593397084638127e-06
repair O 0 0.0001068080891855061
. O 0 7.75679563957965e-06

Here O 0 9.461172157898545e-05
, O 0 6.263715590648644e-07
it O 0 5.6365202283359395e-08
is O 0 3.349913413330796e-08
shown O 0 7.94131054249192e-08
that O 0 2.0427371794085047e-07
mouse O 0 3.6984602047596127e-06
embryonic O 0 1.7336786186206155e-05
stem O 0 2.151022454199847e-05
cells O 0 4.400059424369829e-06
deficient B-Disease 0 2.8516307793324813e-05
in I-Disease 0 9.06680213574873e-07
BRCA1 I-Disease 0 2.596582135083736e-06
are O 0 1.8588444561373763e-07
defective O 0 2.119332066286006e-06
in O 0 2.2012351053035673e-07
the O 0 3.3926033893294516e-07
ability O 0 3.3792019848988275e-08
to O 0 7.664372247973006e-08
carry O 0 2.0195817285184603e-07
out O 0 4.7044878215274366e-07
transcription O 0 1.276910916203633e-05
- O 0 7.551243015768705e-06
coupled O 0 2.3162659999798052e-05
repair O 0 1.7056909200618975e-05
of O 0 4.715907198260538e-05
oxidative O 0 0.00011105537851108238
DNA O 0 6.969943115109345e-06
damage O 0 0.0005293621798045933
, O 0 7.314050094464619e-07
and O 0 2.257638982428034e-07
are O 0 9.953683388630452e-08
hypersensitive O 0 5.238602625468047e-06
to O 0 2.305080073483623e-07
ionizing O 0 7.008371176198125e-05
radiation O 0 0.00010725205356720835
and O 0 8.921384164750634e-07
hydrogen O 0 2.37278982240241e-06
peroxide O 0 2.0069104721187614e-05
. O 0 2.5509318675176473e-06

These O 0 8.775420610618312e-06
results O 0 1.0482191100891214e-05
suggest O 0 1.723456080071628e-06
that O 0 5.012058181819157e-07
BRCA1 O 0 1.640132040847675e-06
participates O 0 1.2392940789140994e-06
, O 0 3.0836142173029657e-07
directly O 0 1.9003704210263095e-07
or O 0 2.199845852146609e-07
indirectly O 0 4.657454724110721e-07
, O 0 9.508638498800792e-08
in O 0 5.39695236057014e-07
transcription O 0 4.6868372010067105e-05
- O 0 4.549069490167312e-05
coupled O 0 8.372750016860664e-05
repair O 0 1.383053768222453e-05
of O 0 1.0504879355721641e-05
oxidative O 0 4.95319181936793e-05
DNA O 0 3.1557817692373646e-06
damage O 0 5.195627818466164e-05
. O 0 4.1412098994442204e-07
. O 0 5.959651048215164e-07

Truncation O 0 0.00343311601318419
mutations O 0 2.199242589995265e-05
in O 0 7.666310921194963e-06
the O 0 3.4592565043567447e-06
transactivation O 0 5.8829937188420445e-05
region O 0 1.8697464838624e-06
of O 0 2.1357758669182658e-05
PAX6 O 0 0.001491706003434956
result O 0 1.9100943973171525e-06
in O 0 3.5222130918555195e-06
dominant O 0 5.4542801990464795e-06
- O 0 2.648504505486926e-06
negative O 0 3.7553911624854663e-07
mutants O 0 1.2931651554026757e-06
. O 0 3.6834049410572334e-07

PAX6 O 0 0.022901978343725204
is O 0 4.50216575700324e-05
a O 0 9.35762727749534e-06
transcription O 0 2.8052432753611356e-05
factor O 0 1.882650508377992e-06
with O 0 1.0121120652684112e-07
two O 0 2.8396644324857334e-07
DNA O 0 3.3860288795040105e-07
- O 0 1.0030074690803303e-06
binding O 0 9.355683801004488e-07
domains O 0 2.3223892640089616e-06
( O 0 1.5375134410078317e-07
paired O 0 1.914175982165034e-07
box O 0 2.8877839213237166e-06
and O 0 4.2397064703436627e-07
homeobox O 0 2.767372961898218e-06
) O 0 8.763812786583003e-08
and O 0 2.3683851679834333e-07
a O 0 2.4571502308390336e-06
proline O 0 6.193414719746215e-06
- O 0 2.8903355087095406e-06
serine O 0 2.48027913585247e-06
- O 0 1.2411557008817908e-06
threonine O 0 9.583587825545692e-07
( O 0 7.910848864867148e-08
PST O 0 7.0848013820068445e-06
) O 0 1.1120838649958387e-07
- O 0 1.035457216858049e-06
rich O 0 3.34423532422079e-07
transactivation O 0 4.284206806914881e-05
domain O 0 1.0155527888855431e-05
. O 0 2.09893255487259e-06

PAX6 O 1 0.994750440120697
regulates O 0 0.014428908005356789
eye O 0 0.34830671548843384
development O 0 6.834735540905967e-05
in O 0 5.458755822473904e-06
animals O 0 2.1928414639660332e-07
ranging O 0 3.7201482427917654e-06
from O 0 1.179120431515912e-06
jellyfish O 0 2.0162082137176185e-07
to O 0 4.19014440922183e-08
Drosophila O 0 1.1471635161797167e-06
to O 0 9.310364390557879e-08
humans O 0 1.6523482315733418e-07
. O 0 4.0999404404828965e-07

Heterozygous O 0 4.034510857309215e-05
mutations O 0 2.9819759674865054e-06
in O 0 1.0006714319388266e-06
the O 0 1.0509912726774928e-06
human O 0 1.976561861738446e-06
PAX6 O 0 8.969431655714288e-05
gene O 0 4.5188201625023794e-07
result O 0 2.4253753849734494e-07
in O 0 1.0399981675845993e-07
various O 0 5.787557100234153e-08
phenotypes O 0 2.2562110189028317e-06
, O 0 2.3185397424185794e-07
including O 0 1.4967365586926462e-06
aniridia B-Disease 1 1.0
, O 0 2.8702543204417452e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 1.066810227712267e-06
autosomal B-Disease 0 0.00010499433847144246
dominant I-Disease 0 6.11863870290108e-05
keratitis I-Disease 1 0.998210072517395
, O 0 7.658628078388574e-07
and O 0 1.9887424969056156e-06
familial B-Disease 1 0.9999977350234985
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.0014177244156599045

It O 0 1.4596223081753124e-05
is O 0 2.6889658784057247e-06
believed O 0 1.1191744988536811e-06
that O 0 8.787765892748212e-08
the O 0 6.365936542351847e-07
mutated O 0 5.071071313977882e-07
allele O 0 8.403723086303216e-07
of O 0 8.688881280249916e-06
PAX6 O 0 0.0001955782645381987
produces O 0 4.4810980170950643e-07
an O 0 4.5547915306087816e-07
inactive O 0 3.4698030049185036e-06
protein O 0 1.8249279492010828e-06
and O 0 1.4410430821953923e-06
aniridia B-Disease 1 0.9999997615814209
is O 0 1.1276522400294198e-06
caused O 0 5.0465669119148515e-06
due O 0 6.634088549617445e-06
to O 0 2.8167843879600696e-07
genetic O 0 3.850953817163827e-06
haploinsufficiency O 0 0.0004032402648590505
. O 0 5.613138455373701e-06

However O 0 4.43132157670334e-05
, O 0 1.6509619626958738e-06
several O 0 3.50503967183613e-07
truncation O 0 2.3091088223736733e-05
mutations O 0 1.477973569308233e-06
have O 0 1.0794234412969672e-06
been O 0 7.081559942889726e-07
found O 0 5.198839048148329e-08
to O 0 1.3219976224831953e-08
occur O 0 4.5315768915088483e-08
in O 0 3.2264264859804825e-07
the O 0 3.5962684705737047e-06
C O 0 7.072352309478447e-05
- O 0 2.0009669242426753e-05
terminal O 0 6.208742706803605e-05
half O 0 1.9357075586867722e-07
of O 0 2.1172393189772265e-06
PAX6 O 0 6.714370829286054e-05
in O 0 1.315824079028971e-06
patients O 0 3.509053101424797e-07
with O 0 3.045242635835166e-07
Aniridia B-Disease 1 0.9999982118606567
resulting O 0 9.751587640494108e-06
in O 0 2.5341767013742356e-06
mutant O 0 2.5851766167761525e-06
proteins O 0 3.222094164812006e-07
that O 0 9.670230127767354e-08
retain O 0 1.756561971433257e-07
the O 0 6.225215543054219e-07
DNA O 0 3.248418067869352e-07
- O 0 1.4063530215935316e-06
binding O 0 1.3036781183473067e-06
domains O 0 2.538937451390666e-06
but O 0 1.218647440737186e-07
have O 0 1.2098085733214248e-07
lost O 0 7.658584308956051e-07
most O 0 1.231067514595452e-08
of O 0 1.6192132079595467e-07
the O 0 8.311973829222552e-07
transactivation O 0 3.5410947020864114e-05
domain O 0 9.777587365533691e-06
. O 0 1.1919744338229066e-06

It O 0 1.5127805454540066e-05
is O 0 1.9183203221473377e-06
not O 0 1.2375515723306307e-07
clear O 0 3.617018649038073e-07
whether O 0 1.1206564920485107e-07
such O 0 2.916752634973818e-07
mutants O 0 4.564228675008053e-06
really O 0 9.026460361383215e-07
behave O 0 3.2451083598061814e-07
as O 0 2.91334998792081e-07
loss O 0 8.917132277019846e-07
- O 0 6.180159175528388e-07
of O 0 2.0471068182814633e-06
- O 0 2.5434792405576445e-06
function O 0 8.126995680868276e-07
mutants O 0 5.998876986268442e-07
as O 0 2.167430608324139e-07
predicted O 0 1.8975991906700074e-06
by O 0 2.2410314670651132e-07
haploinsufficiency O 0 4.478554183151573e-05
. O 0 3.2086832106870133e-06

Contrary O 0 0.00012582537601701915
to O 0 2.945610958704492e-06
this O 0 9.029163834384235e-07
theory O 0 5.712787242373452e-06
, O 0 3.1690950663687545e-07
our O 0 2.7662491675073397e-07
data O 0 9.445513455830223e-07
showed O 0 3.5597543046606006e-06
that O 0 2.589462440028001e-07
these O 0 9.050719285141895e-08
mutants O 0 1.3095821032038657e-06
are O 0 1.1169262847943173e-07
dominant O 0 3.1930915156408446e-07
- O 0 3.5615536830846395e-07
negative O 0 1.223268952799117e-07
in O 0 2.1608549616303208e-07
transient O 0 5.471576969284797e-06
transfection O 0 1.0375734746048693e-05
assays O 0 1.2891067626696895e-06
when O 0 3.599791966735211e-07
they O 0 2.625408157541642e-08
are O 0 3.266737635954087e-08
coexpressed O 0 1.35672553369659e-06
with O 0 6.290594711799713e-08
wild O 0 6.840733703938895e-07
- O 0 1.4273559827415738e-05
type O 0 3.0203394999261945e-05
PAX6 O 0 0.00683581130579114
. O 0 5.3362005019153e-06

We O 0 3.2098283554660156e-05
found O 0 2.676878921192838e-06
that O 0 5.184164706406591e-07
the O 0 3.219048494429444e-06
dominant O 0 1.4506893421639688e-05
- O 0 9.398597285326105e-06
negative O 0 1.93639925782918e-06
effects O 0 3.4688990126596764e-05
result O 0 2.5696936063468456e-06
from O 0 5.910600293645984e-07
the O 0 1.0666408201132072e-07
enhanced O 0 1.0249863180433749e-07
DNA O 0 5.7986621726513476e-08
binding O 0 8.220475677944705e-08
ability O 0 4.5147537264256243e-08
of O 0 1.025558844958141e-06
these O 0 1.5474071801691025e-07
mutants O 0 4.891262960882159e-06
. O 0 6.023142873345932e-07

Kinetic O 0 0.0006503639160655439
studies O 0 4.455873931874521e-05
of O 0 3.681792441057041e-05
binding O 0 7.96465428720694e-06
and O 0 3.6897336030961014e-06
dissociation O 0 1.741368578223046e-05
revealed O 0 2.163945282518398e-06
that O 0 7.425744996680805e-08
various O 0 1.8135554569198575e-07
truncation O 0 1.4683102563139983e-05
mutants O 0 1.3676274193130666e-06
have O 0 2.2484042005999072e-07
3 O 0 3.9394313944285386e-07
- O 0 2.3865234766162757e-07
5 O 0 7.175490850386268e-07
- O 0 5.31179239260382e-07
fold O 0 3.9254092598639545e-07
higher O 0 1.0308303899364546e-06
affinity O 0 3.204818881386018e-07
to O 0 1.1642030273151249e-07
various O 0 7.110687505473834e-08
DNA O 0 4.335995242854551e-07
- O 0 3.7990932355569385e-07
binding O 0 1.0308465192565563e-07
sites O 0 1.7494467385859025e-07
when O 0 6.224225046480569e-08
compared O 0 8.298202658352238e-08
with O 0 1.46456624605662e-08
the O 0 3.151067176077049e-07
wild O 0 4.0694081349101907e-07
- O 0 3.1068143471202347e-06
type O 0 3.3621254260651767e-06
PAX6 O 0 0.0007926358375698328
. O 0 2.7476944524096325e-06

These O 0 9.90847638604464e-06
results O 0 5.0118328545067925e-06
provide O 0 6.993319630055339e-07
a O 0 1.4885259815855534e-06
new O 0 4.780870312970364e-07
insight O 0 2.943152139778249e-07
into O 0 5.5198089654595606e-08
the O 0 5.7156370303346193e-08
role O 0 1.8208565677468869e-07
of O 0 1.072781628863595e-06
mutant O 0 8.52020730235381e-06
PAX6 O 0 0.0003509347152430564
in O 0 1.1731762242561672e-05
causing O 0 0.00016850711836013943
aniridia B-Disease 1 0.9999922513961792
. O 0 1.252026322617894e-06
. O 0 1.2763599670506665e-06

Reversal O 0 0.013317188248038292
of O 0 0.0047329021617770195
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.006755133159458637
excellent O 0 0.0018221037462353706
neuropsychologic O 0 0.004379449877887964
outcome O 0 1.9702572899404913e-05
in O 0 9.502248758508358e-06
very B-Disease 0 9.67190544542973e-07
- I-Disease 0 8.81223695614608e-06
long I-Disease 0 8.6634290710208e-06
- I-Disease 0 1.5255558537319303e-05
chain I-Disease 0 1.0895614650507923e-05
acyl I-Disease 0 2.87253442365909e-06
- I-Disease 0 5.7855540944729e-06
coenzyme I-Disease 0 3.1315516935137566e-06
A I-Disease 0 6.808824400650337e-05
dehydrogenase I-Disease 0 0.00026505967252887785
deficiency I-Disease 1 0.9925525188446045
. O 0 3.888476840074873e-06

Very B-Disease 0 0.00012479037104640156
- I-Disease 0 6.504671182483435e-05
long I-Disease 0 2.2787193302065134e-05
- I-Disease 0 1.1932975212403107e-05
chain I-Disease 0 4.214814907754771e-06
acyl I-Disease 0 1.3027657814745908e-06
- I-Disease 0 1.2772452464560047e-06
coenzyme I-Disease 0 5.557999429584015e-07
A I-Disease 0 2.0775737539224792e-06
dehydrogenase I-Disease 0 1.5658403071938665e-06
( I-Disease 0 6.097845357544429e-07
VLCAD I-Disease 0 0.0006891341763548553
) I-Disease 0 2.920815632023732e-06
deficiency I-Disease 0 0.4789741039276123
is O 0 3.6064062669538544e-07
a O 0 2.1363291580200894e-06
disorder O 0 0.015739021822810173
of O 1 0.6440573930740356
fatty O 0 0.00012564912321977317
acid O 0 3.536062649800442e-06
beta O 0 3.5736115933104884e-06
oxidation O 0 3.8588541428907774e-07
that O 0 1.0261737060091036e-07
reportedly O 0 9.568892664901796e-07
has O 0 1.085881251583487e-07
high O 0 2.1221189854259137e-06
rates O 0 3.622521091983799e-07
of O 0 3.3307495073131577e-07
morbidity O 0 7.263263978529721e-05
and O 0 1.0458588803885505e-06
mortality O 0 0.00010367432696511969
. O 0 3.2739037578721764e-06

We O 0 1.877239628811367e-05
describe O 0 2.921545501521905e-06
the O 0 2.85082978734863e-06
outcome O 0 1.8376700836597593e-06
of O 0 5.68200175621314e-06
a O 0 2.923524561992963e-06
5 O 0 4.966625965607818e-06
- O 0 4.011848432128318e-06
year O 0 4.866853942075977e-06
- O 0 1.0957364793284796e-05
old O 0 5.291638808557764e-05
girl O 0 1.5483090464840643e-05
with O 0 2.115529241564218e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 4.7235138481482863e-05
was O 0 5.752127981395461e-05
first O 0 1.1025539379261318e-06
seen O 0 8.700869784661336e-07
at O 0 8.871640488905541e-07
5 O 0 6.041925360023015e-08
months O 0 2.863726500379471e-08
of O 0 4.3587562004177016e-08
age O 0 6.569265451616957e-07
with O 0 4.257002501617535e-07
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999855756759644
hepatomegaly B-Disease 1 1.0
, O 0 0.31662672758102417
encephalopathy B-Disease 1 0.9999929666519165
, O 0 9.413257657797658e-07
and O 0 1.8138198356609792e-06
hypotonia B-Disease 0 0.001994929974898696
. O 0 4.9675782065605745e-06

Biochemical O 0 0.0028779758140444756
studies O 0 0.0007332837558351457
indicated O 1 0.999850869178772
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 1 0.999767005443573
by O 0 8.449208053207258e-07
a O 0 1.529179712633777e-06
stable O 0 9.166314157482702e-06
yet O 0 4.3883201783501136e-07
inactive O 0 7.448877568094758e-06
enzyme O 0 1.6242736364802113e-06
. O 0 6.050801175661036e-07

Molecular O 0 0.0003285551501903683
genetic O 0 1.25156766443979e-05
analysis O 0 4.625240762834437e-06
of O 0 1.1669608284137212e-05
her O 0 1.0659331564966124e-05
VLCAD O 1 0.8254578113555908
gene O 0 1.0371826647315174e-05
revealed O 0 1.2231456821609754e-05
a O 0 3.775929144467227e-06
T1372C O 0 1.4804712918703444e-05
( O 0 5.174720172362868e-07
F458L O 0 5.230091119301505e-06
) O 0 1.5148965815114934e-07
missense O 0 1.1602941185628879e-06
mutation O 0 2.966501426726609e-07
and O 0 4.5580156893265666e-07
a O 0 5.284112376102712e-06
1668 O 0 0.002036448335275054
ACAG O 0 0.0005948863108642399
1669 O 0 0.0002992612135130912
splice O 0 2.0637509805965237e-05
site O 0 4.212065960018663e-06
mutation O 0 2.7019987101084553e-06
. O 0 1.9103895283478778e-06

After O 0 0.00011549366899998859
initial O 0 2.703217978705652e-05
treatment O 0 1.697763400443364e-05
with O 0 9.874327133729821e-07
intravenous O 0 0.00011828836431959644
glucose O 0 0.0004893189761787653
and O 0 1.1239502782700583e-05
carnitine O 0 0.00039196148281916976
, O 0 3.563442589893384e-07
the O 0 8.614891839897609e-07
patient O 0 1.2589515563377063e-06
has O 0 4.4169212287670234e-07
thrived O 0 1.9640142454591114e-06
on O 0 2.5241620278393384e-06
a O 0 1.9046175339099136e-06
low O 0 1.2954615158378147e-05
- O 0 2.4510604816896375e-06
fat O 0 2.2742444798495853e-06
diet O 0 2.86528972992528e-07
supplemented O 0 1.0074645473423516e-07
with O 0 3.8687655745661687e-08
medium O 0 1.6249041436822154e-06
- O 0 4.32329625255079e-06
chain O 0 4.4235157474759035e-06
triglyceride O 0 1.786952452675905e-05
oil O 0 1.2667324881476816e-05
and O 0 3.4560605399747146e-07
carnitine O 0 1.0193834896199405e-05
and O 0 1.4399245173990494e-07
avoidance O 0 8.239032467827201e-06
of O 0 2.5485353035037406e-05
fasting O 0 0.0001936104235937819
. O 0 2.9945438200229546e-06

Her O 0 0.005415288731455803
ventricular O 1 0.9999992847442627
hypertrophy O 1 0.9943047165870667
resolved O 0 3.296704380773008e-05
significantly O 0 2.5209385512425797e-06
over O 0 1.1637295074251597e-06
1 O 0 1.6149474504345562e-06
year O 0 6.553484581672819e-07
, O 0 8.569261922275473e-08
and O 0 1.4249090440898726e-07
cognitively O 0 3.9290111999434885e-06
, O 0 7.329733620053958e-08
she O 0 6.260777496436276e-08
is O 0 2.751582428572874e-08
in O 0 3.7919690498711134e-08
the O 0 1.5727245283869706e-07
superior O 0 1.2809987310902216e-06
range O 0 8.817716548037424e-07
for O 0 7.260080110427225e-07
age O 0 1.5728952348581515e-05
. O 0 2.562533381933463e-06

Clinical O 0 0.0005581508157774806
recognition O 0 0.0006615729071199894
of O 1 0.9999984502792358
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 8.401590457651764e-05
important O 0 1.3253968518256443e-06
because O 0 8.687207042612499e-08
it O 0 9.722620930574521e-09
is O 0 1.376501934657881e-08
one O 0 8.822610197967151e-09
of O 0 1.9918427085485746e-07
the O 0 7.481730222025362e-07
few O 0 3.9421598785338574e-07
directly O 0 5.7828287935990375e-06
treatable O 0 0.4455612301826477
causes O 0 9.090271487366408e-05
of O 1 0.9991773962974548
cardiomyopathy B-Disease 1 1.0
in O 0 0.00041035551112145185
children O 0 5.076179149909876e-06
. O 0 1.3727584757816658e-07
. O 0 6.123848379502306e-07

Cloning O 0 7.674357038922608e-05
of O 0 1.1976446330663748e-05
a O 0 2.442895493004471e-06
novel O 0 1.7511255236968282e-06
member O 0 1.8080344261761638e-06
of O 0 4.67673635284882e-06
the O 0 5.6855515140341595e-06
low O 0 4.7387995437020436e-05
- O 0 7.007726708252449e-06
density O 0 1.2260185940249357e-05
lipoprotein O 0 0.0009810775518417358
receptor O 0 6.225414836080745e-05
family O 0 6.328566996671725e-06
. O 0 1.3661594948644051e-06

A O 0 8.906325820134953e-05
gene O 0 5.183747362025315e-06
encoding O 0 2.7881360438186675e-06
a O 0 1.9161225282005034e-06
novel O 0 2.3932911972224247e-06
transmembrane O 0 5.582111953117419e-06
protein O 0 1.164888772109407e-06
was O 0 1.1187923973920988e-06
identified O 0 1.1014063439063193e-08
by O 0 2.1298045549400513e-09
DNA O 0 5.6153992566976285e-09
sequence O 0 2.2879222072447192e-08
analysis O 0 2.874353732806867e-08
within O 0 5.991581275566205e-08
the O 0 1.0016012765845517e-06
insulin B-Disease 0 0.0005639894516207278
- I-Disease 1 0.9487483501434326
dependent I-Disease 1 0.7041558027267456
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 9.460677006245533e-07
IDDM B-Disease 0 5.318122202879749e-05
) O 0 1.1795877696840762e-07
locus O 0 1.9639917354652425e-06
IDDM4 O 0 1.712198536552023e-05
on O 0 3.0870262435200857e-06
chromosome O 0 3.0351633540703915e-05
11q13 O 0 0.00010400959581602365
. O 0 4.368112968222704e-06

Based O 0 7.559739606222138e-05
on O 0 2.825233605108224e-05
its O 0 3.490839389996836e-06
chromosomal O 0 0.0001297222333960235
position O 0 2.01736456801882e-05
, O 0 2.266762635372288e-07
this O 0 3.98272135271327e-08
gene O 0 1.41232987971307e-07
is O 0 4.002834330663063e-08
a O 0 3.543387094850914e-08
candidate O 0 3.298732664802628e-08
for O 0 1.368762880815666e-08
conferring O 0 2.490675342414761e-06
susceptibility O 0 0.0001433836732758209
to O 0 1.3504914932127576e-05
diabetes B-Disease 1 0.9999971389770508
. O 0 1.5153074855334125e-05

The O 0 0.00014710752293467522
gene O 0 1.178737420559628e-05
, O 0 1.4179388472257415e-06
termed O 0 1.1061769328080118e-05
low O 0 1.7781434507924132e-05
- O 0 1.4759269788555684e-06
density O 0 1.8745045053947251e-06
lipoprotein O 0 1.794154741219245e-05
receptor O 0 1.1677562952172593e-06
related O 0 5.099782356410287e-07
protein O 0 3.5695171618499444e-07
5 O 0 7.652072326891357e-07
( O 0 5.247744994107961e-08
LRP5 O 0 3.463997245489736e-06
) O 0 2.6001719888313346e-08
, O 0 2.536269505526434e-08
encodes O 0 7.00521525232034e-08
a O 0 3.0824500640846964e-07
protein O 0 6.157016514407587e-07
of O 0 7.874274160712957e-06
1615 O 0 0.00019760982831940055
amino O 0 3.7305578644009074e-06
acids O 0 1.920138146260797e-07
that O 0 1.782036207487181e-08
contains O 0 3.8961275095061865e-08
conserved O 0 4.2927030108330655e-07
modules O 0 4.4643007868216955e-07
which O 0 4.542341969226982e-08
are O 0 1.63875721881368e-08
characteristic O 0 5.3459732640703805e-08
of O 0 8.374473736694199e-07
the O 0 1.0068064284496359e-06
low O 0 7.2423467827320565e-06
- O 0 8.589255457991385e-07
density O 0 1.8066174334308016e-06
lipoprotein O 0 6.047243005014025e-05
( O 0 9.655040003053728e-07
LDL O 0 0.00018719832587521523
) O 0 4.2514483311606455e-07
receptor O 0 2.4299974938912783e-06
family O 0 4.4999495685260626e-07
. O 0 5.515346401807619e-07

These O 0 8.054028512560762e-06
modules O 0 3.430321521591395e-05
include O 0 2.978068323500338e-06
a O 0 1.7258903426409233e-06
putative O 0 1.0616032341204118e-05
signal O 0 1.1821451153082307e-05
peptide O 0 1.5084136748555466e-06
for O 0 2.546823338889226e-07
protein O 0 9.334739843325224e-07
export O 0 3.1497202144237235e-06
, O 0 1.4793033642490627e-07
four O 0 2.670794856385328e-07
epidermal O 0 5.435073489934439e-06
growth O 0 3.5213599858252564e-06
factor O 0 3.972029389842646e-07
( O 0 1.212213192047784e-07
EGF O 0 2.2658709895040374e-06
) O 0 4.092064997962552e-08
repeats O 0 6.784728867614831e-08
with O 0 3.1914897391516206e-08
associated O 0 5.950632271378709e-07
spacer O 0 4.336857273301575e-06
domains O 0 2.2965102743910393e-06
, O 0 1.7733550805587583e-07
three O 0 2.55076855637526e-07
LDL O 0 5.618110662908293e-05
- O 0 4.262647053110413e-06
receptor O 0 3.421114342927467e-06
( O 0 1.4680404092359822e-07
LDLR O 0 8.36241088109091e-06
) O 0 5.805977565387366e-08
repeats O 0 1.4925998925718886e-07
, O 0 3.615314270177805e-08
a O 0 2.1342754052966484e-07
single O 0 2.4521423824808153e-07
transmembrane O 0 1.8158309558202745e-06
spanning O 0 1.060105932992883e-05
domain O 0 4.028803232358769e-06
, O 0 2.695055627555121e-07
and O 0 1.8589774697375105e-07
a O 0 8.745342938709655e-07
cytoplasmic O 0 9.077807590074372e-06
domain O 0 6.356039648380829e-06
. O 0 3.1577264962834306e-06

The O 0 6.266865239012986e-05
encoded O 0 1.0872053280763794e-05
protein O 0 7.72662133385893e-06
has O 0 4.799129555976833e-07
a O 0 2.945387223007856e-07
unique O 0 2.1120956716913497e-07
organization O 0 7.708588327659527e-07
of O 0 6.174177997309016e-06
EGF O 0 0.0001678552507655695
and O 0 3.5830748856824357e-06
LDLR O 0 0.0003088546800427139
repeats O 0 4.4705943764711265e-06
; O 0 2.694397664981807e-07
therefore O 0 5.09348808463983e-07
, O 0 2.543849859648617e-07
LRP5 O 0 2.261844747408759e-05
likely O 0 4.4496579221231514e-07
represents O 0 1.1455854576070124e-07
a O 0 1.1394859456004269e-07
new O 0 1.5826171306798642e-07
category O 0 8.174770300684031e-07
of O 0 2.961485961350263e-06
the O 0 1.3444889191305265e-05
LDLR O 0 0.0010472758440300822
family O 0 2.7315661554894177e-06
. O 0 1.695434207249491e-06

Both O 0 6.273322651395574e-05
human O 0 4.410713881952688e-05
and O 0 1.3444967407849617e-05
mouse O 0 4.911527503281832e-05
LRP5 O 0 0.0012747717555612326
cDNAs O 0 4.955393524141982e-05
have O 0 1.5304810858651763e-06
been O 0 2.457881464579259e-06
isolated O 0 8.225414376283879e-07
and O 0 1.5568065236948314e-07
the O 0 9.739419510879088e-07
encoded O 0 2.787163566608797e-07
mature O 0 1.32443503275681e-07
proteins O 0 2.674198995578081e-08
are O 0 8.102261972453562e-09
95 O 0 8.814910046339719e-08
% O 0 1.0571735487019396e-08
identical O 0 1.019983653094414e-08
, O 0 1.1003900013406565e-08
indicating O 0 1.4601515374579321e-07
a O 0 8.181214639080281e-08
high O 0 1.6001687299649348e-06
degree O 0 2.7080402560386574e-06
of O 0 1.7765742086339742e-06
evolutionary O 0 2.9873783660150366e-06
conservation O 0 2.394891112089681e-07
. O 0 6.263715590648644e-08
. O 0 4.239734607835999e-07

The O 0 0.0002063423889921978
APC B-Disease 0 0.0001727559429127723
variants O 0 8.206928214349318e-06
I1307K O 0 0.00010216220834990963
and O 0 2.214063897554297e-06
E1317Q O 0 0.0001134146295953542
are O 0 8.471218393424351e-07
associated O 0 3.786006345762871e-05
with O 1 0.9993877410888672
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.00010553237370913848
but O 0 3.809439874657983e-08
not O 0 1.077194156096084e-08
always O 0 1.0304255226856185e-08
with O 0 3.861376995928367e-09
a O 0 1.140324030757256e-07
family O 0 1.3189959702231135e-07
history O 0 2.4827970719343284e-06
. O 0 1.6589369806752075e-06

Classical O 0 0.013142727315425873
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0008144904859364033
FAP B-Disease 0 0.06390802562236786
) O 0 5.344821261132893e-07
is O 0 1.439354804233517e-07
a O 0 9.566539347360958e-07
high O 1 0.99986732006073
- O 1 0.9999934434890747
penetrance O 1 1.0
autosomal B-Disease 1 0.9999996423721313
dominant I-Disease 1 0.9999978542327881
disease I-Disease 1 0.9999964237213135
that O 0 4.4865331005894404e-07
predisposes O 0 3.386285243323073e-06
to O 0 9.77923804157399e-08
hundreds O 0 2.0862829330781096e-07
or O 0 9.908600873131945e-08
thousands O 0 2.578137525688362e-07
of O 0 0.0003031730593647808
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.6196784377098083
carcinoma I-Disease 1 1.0
and O 0 2.6092718599102227e-06
that O 0 1.2487015510487254e-07
results O 0 2.2526108978127013e-07
from O 0 1.518181136361818e-07
truncating O 0 6.38062033431197e-07
mutations O 0 2.748813088260249e-08
in O 0 2.0363067676498758e-07
the O 0 1.1690779047057731e-06
APC B-Disease 0 1.2538673217932228e-05
gene O 0 2.0329182461864548e-06
. O 0 1.1371751043043332e-06

A O 0 5.588662679656409e-05
variant O 0 1.739643994369544e-05
of O 0 2.1590520191239193e-05
FAP B-Disease 0 0.0001902168005472049
is O 0 7.642571290489286e-06
attenuated B-Disease 0 0.004546077456325293
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999998807907104
, O 0 8.003761649888474e-06
which O 0 8.403146125601779e-07
results O 0 2.7040969143854454e-06
from O 0 5.542339295061538e-06
germ O 0 0.0003414636303205043
- O 0 8.864698429533746e-06
line O 0 1.9852407149301143e-06
mutations O 0 3.401524750756835e-08
in O 0 1.6327318519415712e-07
the O 0 2.3629276313386072e-07
5 O 0 1.5501767336445482e-07
and O 0 2.8938048401982996e-08
3 O 0 2.0607208739420457e-07
regions O 0 5.76679717312345e-08
of O 0 2.0940019567206036e-06
the O 0 9.075765774468891e-06
APC B-Disease 0 2.3922779291751795e-05
gene O 0 3.2171888051379938e-06
. O 0 2.459067900417722e-06

Attenuated B-Disease 1 0.9999849796295166
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 0.0016940903151407838
have O 0 1.3019237030675868e-06
" O 0 1.6610250668236404e-06
multiple O 0 7.492106760764727e-06
" O 1 0.9579285383224487
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 3.4648587643459905e-07
typically O 0 1.942549232580859e-08
fewer O 0 8.058675504685198e-09
than O 0 1.7383763761813498e-08
100 O 0 1.5758338633986568e-07
) O 0 1.1918540820943235e-08
without O 0 1.9224756897529005e-08
the O 0 1.7758885917373846e-07
florid O 0 4.5593560571433045e-06
phenotype O 0 5.074840032648353e-07
of O 0 8.236560802288295e-07
classical O 0 1.1340451237629168e-05
FAP B-Disease 0 3.690788435051218e-05
. O 0 1.2729295804092544e-06

Another O 0 4.650099799619056e-05
group O 0 2.857888148355414e-06
of O 0 2.885372623495641e-06
patients O 0 1.38786788284051e-06
with O 0 3.522225995311601e-07
multiple O 0 2.614230652397964e-05
adenomas B-Disease 1 0.9999932050704956
has O 0 7.336961061810143e-06
no O 0 3.727033686118375e-07
mutations O 0 1.9674584450513066e-07
in O 0 2.0141933418926783e-06
the O 0 5.0718285820039455e-06
APC B-Disease 0 8.01334681455046e-06
gene O 0 3.5329816228113486e-07
, O 0 1.035228578416536e-07
and O 0 5.987696738429804e-08
their O 0 7.027456661035103e-08
phenotype O 0 1.9756253095692955e-06
probably O 0 1.0071627229990554e-06
results O 0 2.0091887620310445e-07
from O 0 1.4434981210342812e-07
variation O 0 1.9639341530819365e-07
at O 0 2.3957072698976845e-06
a O 0 2.5279632609453984e-07
locus O 0 1.7534299558974453e-06
, O 0 1.8135139612240891e-07
or O 0 1.7601387014565262e-07
loci O 0 4.3280218164909456e-07
, O 0 5.2032930852874415e-08
elsewhere O 0 4.278561505088874e-08
in O 0 1.0565773322923633e-07
the O 0 6.409363777493127e-07
genome O 0 1.5221926332742441e-06
. O 0 1.1602278391364962e-06

Recently O 0 0.0004493512096814811
, O 0 5.529246664082166e-06
however O 0 5.006612582292291e-07
, O 0 1.0945544914875427e-07
a O 0 2.9718844984927273e-07
missense O 0 3.384354386071209e-06
variant O 0 4.905155947199091e-06
of O 0 0.00035704264882951975
APC B-Disease 0 8.80967709235847e-05
( O 0 7.8411886761387e-07
I1307K O 0 1.6402371329604648e-05
) O 0 1.4647233115283598e-07
was O 0 2.0228906123520574e-06
described O 0 5.447411410841596e-08
that O 0 5.129768165801352e-09
confers O 0 2.324969869960114e-07
an O 0 3.2709646546891236e-08
increased O 0 2.909034719777992e-06
risk O 0 1.887986763904337e-05
of O 1 0.9999243021011353
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.3923810911364853e-05
including O 0 1.6328467609127983e-06
multiple O 0 9.341612894786522e-06
adenomas B-Disease 0 0.35224398970603943
, O 0 5.278438379718864e-07
in O 0 2.1888436094741337e-06
Ashkenazim O 0 4.144777267356403e-05
. O 0 2.0695513285318157e-06

We O 0 1.5079568584042136e-05
have O 0 4.283289172235527e-07
studied O 0 1.590456122357864e-06
a O 0 2.5739024067661376e-07
set O 0 8.416927244070393e-08
of O 0 3.257682124058192e-07
164 O 0 8.202609024010599e-06
patients O 0 3.4237507406942314e-07
with O 0 2.93725264555178e-07
multiple O 1 0.9974241256713867
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.25211864709854126
/ I-Disease 1 0.6500661969184875
or I-Disease 0 3.179576015099883e-05
carcinoma I-Disease 1 1.0
and O 0 3.4187594337709015e-06
analyzed O 0 3.894058409059653e-06
codons O 0 6.453897185565438e-06
1263 O 0 2.4872073481674306e-05
- O 0 4.0887989598559216e-06
1377 O 0 2.3652106392546557e-05
( O 0 2.1925863791238953e-07
exon O 0 8.873315664459369e-07
15G O 0 2.4985499749163864e-06
) O 0 4.5494690681380234e-08
of O 0 4.204330252832733e-07
the O 0 1.3695851066586329e-06
APC B-Disease 0 6.0846455198770855e-06
gene O 0 2.760130257684068e-07
for O 0 4.5060133402330393e-07
germ O 0 0.00039151328383013606
- O 0 2.736853093665559e-05
line O 0 1.4777997421333566e-05
variants O 0 1.4154934433463495e-06
. O 0 1.0854251968339668e-06

Three O 0 9.60769466473721e-05
patients O 0 8.119721314869821e-06
with O 0 4.453253552583192e-07
the O 0 4.669828285841504e-06
I1307K O 0 1.968578180822078e-05
allele O 0 6.896477202644746e-07
were O 0 5.96313611822552e-07
detected O 0 6.819784630351933e-07
, O 0 1.5784021201170617e-08
each O 0 7.293722070755848e-09
of O 0 1.1833776625280734e-06
Ashkenazi O 0 3.001548975589685e-05
descent O 0 0.00015283521497622132
. O 0 3.6083267787034856e-06

Four O 0 0.00023796153254806995
patients O 0 2.7542755560716614e-05
had O 0 4.8503850848646834e-05
a O 0 2.0026431229780428e-05
germ O 0 0.002152365166693926
- O 0 5.102516297483817e-05
line O 0 3.678286520880647e-05
E1317Q O 0 1.6470572518301196e-05
missense O 0 3.1609531561116455e-06
variant O 0 2.8839144761150237e-06
of O 0 2.9636288672918454e-05
APC O 0 1.586563666933216e-05
that O 0 4.392825303511927e-07
was O 0 7.100872608134523e-06
not O 0 6.29091871928722e-08
present O 0 2.1843403885668522e-07
in O 0 1.232136128237471e-06
controls O 0 3.3496596643090015e-06
; O 0 2.71208534741163e-07
one O 0 2.1767937141703442e-07
of O 0 1.243278802576242e-06
these O 0 7.17834538477291e-08
individuals O 0 4.5597374764838605e-08
had O 0 2.175943563997862e-06
an O 0 2.3401474891215912e-07
unusually O 0 4.416710623900144e-07
large O 0 1.115419081543223e-07
number O 0 2.412905644177954e-07
of O 0 1.1442503819125704e-05
metaplastic B-Disease 0 0.0003260270750615746
polyps I-Disease 0 4.261307913111523e-05
of I-Disease 0 1.585536665515974e-05
the I-Disease 0 2.6386916943010874e-05
colorectum I-Disease 0 0.00019828097720164806
. O 0 8.59725787449861e-06

There O 0 4.69178739876952e-05
is O 0 1.2673333458224079e-06
increasing O 0 8.090156029538775e-07
evidence O 0 5.944800705037778e-07
that O 0 1.0030450425801973e-07
there O 0 1.5614337200986483e-07
exist O 0 4.874365231444244e-07
germ O 0 0.00011157879634993151
- O 0 5.900563792238245e-06
line O 0 2.2399938188755186e-06
variants O 0 1.1911397734820639e-07
of O 0 2.0007116745546227e-06
the O 0 4.310212716518436e-06
APC B-Disease 0 1.1592077498789877e-05
gene O 0 2.012957480701516e-07
that O 0 2.1088103707711525e-08
predispose O 0 5.539171752388938e-07
to O 0 2.4416852539843603e-08
the O 0 1.6005198233415285e-07
development O 0 9.679148433860973e-07
of O 0 1.7018937796819955e-05
multiple O 1 0.9999936819076538
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999997615814209
carcinoma I-Disease 1 1.0
, O 0 6.375545126502402e-06
but O 0 9.547765955630894e-08
without O 0 9.880707807496947e-08
the O 0 5.755741767643485e-07
florid O 0 6.235481123439968e-06
phenotype O 0 5.462737249217753e-07
of O 0 1.253950244972657e-06
classical O 0 9.218553714163136e-06
FAP B-Disease 0 5.409647201304324e-06
, O 0 4.2466098193472135e-08
and O 0 1.210115208039042e-08
possibly O 0 1.7817541220210842e-08
with O 0 3.851873042748366e-09
importance O 0 3.998869033239316e-06
for O 1 0.9805025458335876
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 9.215984027832747e-05
in O 0 7.639749242116523e-07
the O 0 4.004308777894039e-07
general O 0 3.2705909802643873e-07
population O 0 5.056496377164876e-08
. O 0 8.045870458772697e-08
. O 0 5.660642159455165e-07

Genomic O 0 6.125316576799378e-05
structure O 0 1.2158931895100977e-05
of O 0 2.2212527710507857e-06
the O 0 6.157172720122617e-06
human O 0 0.38881826400756836
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.015214940533041954
CLD B-Disease 1 0.9998106360435486
) O 0 1.5622068758602836e-06
gene O 0 1.7045698541551246e-06
. O 0 1.5914271216388443e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.10181235522031784
CLD B-Disease 1 0.9999790191650391
) O 0 1.3496252222466865e-06
is O 0 2.0680110424109444e-07
caused O 0 6.429499990190379e-07
by O 0 2.4480739213572633e-08
mutations O 0 1.6484881015799147e-08
in O 0 9.201579587170272e-08
a O 0 9.89802373396742e-08
gene O 0 2.8747484392965816e-08
which O 0 3.106625356963377e-08
encodes O 0 2.1311451803285308e-07
an O 0 6.796618663429399e-07
intestinal O 1 0.5636734962463379
anion O 0 9.540555038256571e-05
transporter O 0 0.00046163471415638924
. O 0 3.192463282175595e-06

We O 0 3.490944436634891e-05
report O 0 3.045694711545366e-06
here O 0 2.1149334372694284e-07
the O 0 9.676779910705591e-08
complete O 0 4.0986739691106777e-07
genomic O 0 1.3961341664980864e-06
organization O 0 1.762303440955293e-06
of O 0 8.031754077819642e-06
the O 0 2.0227738787070848e-05
human O 0 2.6502721084398217e-05
CLD B-Disease 0 0.00035616548848338425
gene O 0 1.253581899618439e-06
which O 0 4.6378102069866145e-07
spans O 0 1.2794457688869443e-06
approximately O 0 3.9540731222587056e-07
39kb O 0 3.6376118259795476e-06
, O 0 8.991014510684181e-08
and O 0 5.7285920007643654e-08
comprises O 0 2.412990625089151e-07
21 O 0 3.8020723422960145e-06
exons O 0 8.941401574702468e-06
. O 0 2.2217866444407264e-06

All O 0 2.38720476772869e-05
exon O 0 5.7623954489827156e-05
/ O 0 2.0882804165012203e-05
intron O 0 3.300271418993361e-05
boundaries O 0 1.0140844324268983e-06
conform O 0 5.486063514581474e-07
to O 0 2.3453219455404906e-07
the O 0 2.123447302437853e-06
GT O 0 3.6125562473898754e-05
/ O 0 2.0787154426216148e-05
AG O 0 0.00010798012954182923
rule O 0 8.114186130114831e-06
. O 0 3.6419162370293634e-06

An O 0 3.413434387766756e-05
analysis O 0 4.142752459301846e-06
of O 0 1.4363316040544305e-05
the O 0 9.384552868141327e-06
putative O 0 4.606185757438652e-05
promoter O 0 3.0130837330943905e-05
region O 0 1.2315792901063105e-06
sequence O 0 4.800351121048152e-07
shows O 0 1.0665894478734117e-06
a O 0 3.835508323390968e-06
putative O 0 9.007623884826899e-05
TATA O 0 0.0002735844173002988
box O 0 1.2106598660466261e-05
and O 0 3.3567002333256823e-07
predicts O 0 1.3566790357799619e-06
multiple O 0 1.663490252212796e-07
transcription O 0 6.199016752361786e-06
factor O 0 4.6985786639197613e-07
binding O 0 4.3315233710927714e-07
sites O 0 7.917533366708085e-07
. O 0 6.940313141967636e-07

The O 0 0.00011008283763658255
genomic O 0 6.682572711724788e-05
structure O 0 3.979030952905305e-05
was O 0 2.9134851502021775e-05
determined O 0 7.958579431033286e-07
using O 0 8.073186563706258e-08
DNA O 0 1.9500151893225848e-07
from O 0 6.988039444877359e-07
several O 0 7.70866250832114e-08
sources O 0 3.0588120125685236e-07
including O 0 3.6082124665881565e-07
multiple O 0 9.354666872241069e-07
large O 0 1.0771328561531845e-05
- O 0 0.00010640430264174938
insert O 0 3.2945783914328786e-06
libaries O 0 9.535347089695279e-06
and O 0 1.1741690997268961e-07
genomic O 0 7.596593150083208e-07
DNA O 0 3.363297764735762e-07
from O 0 1.4926768017176073e-06
Finnish O 0 0.00035357658634893596
CLD B-Disease 1 0.8950731754302979
patients O 0 4.54516430181684e-06
and O 0 2.0616598703782074e-06
controls O 0 3.2957366784103215e-05
. O 0 3.79235643777065e-06

Exon O 0 0.0011346666142344475
- O 0 6.757149094482884e-05
specific O 0 9.938921721186489e-07
primers O 0 1.5561619875370525e-05
developed O 0 4.847135528507351e-07
in O 0 1.0311769216286848e-07
this O 0 1.9564485143064303e-08
study O 0 2.4366793027752465e-08
will O 0 1.324536835767276e-08
facilitate O 0 8.570536635943427e-08
mutation O 0 5.131170155436848e-08
screening O 0 9.942640843974004e-08
studies O 0 1.2776663993463444e-07
of O 0 4.237725761413458e-07
patients O 0 1.8668940526822553e-07
with O 0 6.231850591120747e-08
the O 0 1.8327453290112317e-05
disease O 0 0.0058178408071398735
. O 0 3.50540790350351e-06

Genomic O 0 7.805704808561131e-05
sequencing O 0 2.89380823232932e-05
of O 0 5.5648906709393486e-05
a O 0 3.0844468710711226e-05
BAC O 0 0.0009904361795634031
clone O 0 9.677244088379666e-05
H O 1 0.9998983144760132
_ O 0 1.1651443401206052e-06
RG364P16 O 0 7.1915274020284414e-06
revealed O 0 1.962407850442105e-06
the O 0 7.452412091879523e-07
presence O 0 7.834102007109323e-07
of O 0 6.868673608551035e-06
another O 0 1.7064583062165184e-06
, O 0 1.3357279726733395e-07
highly O 0 1.86574965255204e-07
homologous O 0 1.8236127630189003e-07
gene O 0 2.3244244573561446e-07
3 O 0 1.496532490818936e-06
of O 0 5.3821167966816574e-06
the O 0 1.9369059373275377e-05
CLD B-Disease 0 0.0005771646392531693
gene O 0 7.171789775384241e-07
, O 0 3.574708173914587e-08
with O 0 3.667248060779116e-09
a O 0 4.6470017167621336e-08
similar O 0 1.2569413065932622e-08
genomic O 0 5.480165441440477e-07
structure O 0 3.925850251107477e-06
, O 0 1.015155106642851e-07
recently O 0 2.2846435854262381e-07
identified O 0 9.631720843117364e-08
as O 0 2.681994999420567e-07
the O 0 1.3841779946233146e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 2.1528880097321235e-05
( O 0 2.239037257822929e-06
PDS B-Disease 0 7.095604087226093e-05
) O 0 2.0431268410447956e-07
. O 0 7.786672284737506e-08
. O 0 4.950067591380503e-07

The O 0 0.000315493147354573
APCI1307K O 0 0.03832578659057617
allele O 0 0.00014711174299009144
and O 0 2.3347147362073883e-05
cancer B-Disease 0 0.28697633743286133
risk O 0 5.2589048209483735e-06
in O 0 1.1786021332227392e-06
a O 0 1.2827957789340871e-06
community O 0 2.213613470303244e-07
- O 0 3.2354975587622903e-07
based O 0 2.0780019482913303e-08
study O 0 3.4000002813172614e-08
of O 0 5.182088784749794e-07
Ashkenazi O 0 3.1874526484898524e-06
Jews O 0 2.802651806632639e-06
. O 0 1.5496268588321982e-06

Mutations O 0 9.959905582945794e-05
in O 0 1.7880161976790987e-05
APC O 0 8.503942081006244e-05
are O 0 9.141089662989543e-08
classically O 0 5.456600774778053e-06
associated O 0 2.794048441501218e-07
with O 0 2.9493082820408745e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.017730742692947388
FAP B-Disease 0 0.040938850492239
) O 0 9.19047735692402e-08
, O 0 1.078073896820797e-08
a O 0 1.443482915419736e-07
highly O 0 8.214320405386388e-05
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9979419112205505
by O 0 3.8091951864771545e-05
multiple O 0 0.04609305411577225
intestinal O 1 1.0
polyps B-Disease 1 0.9999788999557495
and O 0 2.63788251686492e-06
, O 0 7.163464488257887e-08
without O 0 4.6396507968893275e-08
surgical O 0 3.2369403925258666e-05
intervention O 0 5.66182598049636e-06
, O 0 4.8285240694667664e-08
the O 0 1.0686690643524344e-07
development O 0 2.9341269964788808e-06
of O 0 0.0316508449614048
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.230421498301439e-05
CRC B-Disease 0 0.0018425181042402983
) O 0 3.911765418251889e-07
. O 0 6.173726774250099e-07

APC B-Disease 0 0.0030774492770433426
is O 0 1.993694604607299e-05
a O 0 2.8088408726034686e-05
tumour O 1 1.0
- O 0 0.0005339339841157198
suppressor O 0 0.0019014738500118256
gene O 0 2.0621264695819264e-07
, O 0 2.585947811439837e-08
and O 0 2.5778811973964366e-08
somatic O 0 2.8189201657369267e-06
loss O 0 9.09124210011214e-05
occurs O 0 4.107919266971294e-06
in O 0 5.501503619598225e-05
tumours B-Disease 1 1.0
. O 0 1.2980090104974806e-05

The O 0 0.0006179293268360198
germline O 0 0.001478303223848343
T O 0 0.0003184522211086005
- O 0 9.896464689518325e-06
to O 0 5.123717983224196e-07
- O 0 2.9046268537058495e-06
A O 0 3.5466505323711317e-06
transversion O 0 1.7575737729202956e-05
responsible O 0 3.1757917895447463e-06
for O 0 1.4088645912124775e-06
the O 0 1.2575882465171162e-05
APC O 0 4.016513776150532e-05
I1307K O 0 2.9182845537434332e-05
allele O 0 1.3840835890732706e-06
converts O 0 6.292328862400609e-07
the O 0 4.826295594284602e-07
wild O 0 1.3699884959805786e-07
- O 0 1.1691475521047323e-07
type O 0 8.284206387543236e-08
sequence O 0 8.934073036925838e-08
to O 0 2.1742251021805714e-07
a O 0 2.8662541353696724e-06
homopolymer O 0 0.00016265572048723698
tract O 1 0.7029329538345337
( O 0 2.2601300315727713e-06
A8 O 0 0.0005108049372211099
) O 0 9.700433878379044e-08
that O 0 6.349480941025831e-08
is O 0 2.475174767369026e-07
genetically O 0 3.4298849982405955e-07
unstable O 0 1.4087279851082712e-05
and O 0 2.501069502613973e-07
prone O 0 1.2824777968489798e-06
to O 0 1.2850951236487163e-07
somatic O 0 3.776080347961397e-06
mutation O 0 5.838057859364199e-07
. O 0 5.539531002796139e-07

The O 0 0.0002173978282371536
I1307K O 0 0.00033901171991601586
allele O 0 2.179657167289406e-05
was O 0 1.9137272829539143e-05
found O 0 4.6774047746112046e-07
in O 0 4.710629752935347e-07
6 O 0 7.153563274187036e-06
. O 0 2.0485324512264924e-06

1 O 0 9.16809804039076e-05
% O 0 4.3907243707508314e-06
of O 0 1.0959183782688342e-05
unselected O 0 0.0004994924529455602
Ashkenazi O 0 1.6352874808944762e-05
Jews O 0 5.631025032926118e-06
and O 0 1.4165805168886436e-06
higher O 0 1.6669884644215927e-05
proportions O 0 1.2157052879047114e-05
of O 0 2.4727292839088477e-05
Ashkenazim O 0 3.061442475882359e-05
with O 0 2.835962220615329e-07
family O 0 6.206406624187366e-07
or O 0 4.0459116235069814e-07
personal O 0 1.6779732732175034e-06
histories O 0 1.564328272252169e-06
of O 0 0.00039530114736407995
CRC B-Disease 0 0.0020100160036236048
( O 0 3.224758984288201e-07
ref O 0 6.248828412935836e-06
. O 0 3.8186129813766456e-08
2 O 0 3.5638842632579326e-07
) O 0 8.402475515367769e-08
. O 0 2.6380484996479936e-07

To O 0 1.0667822607501876e-05
evaluate O 0 6.686234883090947e-06
the O 0 4.913316388410749e-06
role O 0 6.853703325759852e-06
of O 0 2.8430664315237664e-05
I1307K O 0 0.00015837217506486923
in O 0 2.993999260070268e-05
cancer B-Disease 0 0.00047960595111362636
, O 0 8.200053116524941e-07
we O 0 2.462500674482726e-07
genotyped O 0 1.5223047739709727e-05
5 O 0 3.1306319669965887e-06
, O 0 6.588677479157923e-07
081 O 0 1.7571515854797326e-05
Ashkenazi O 0 1.7019384586092201e-06
volunteers O 0 1.4211931897989416e-07
in O 0 1.8920971456282132e-07
a O 0 2.990537382174807e-07
community O 0 8.643639404226633e-08
survey O 0 2.8492675596680783e-07
. O 0 4.976337208972836e-07

Risk O 0 0.0005615746486000717
of O 0 0.00013957257033325732
developing O 0 0.05365101620554924
colorectal B-Disease 1 1.0
, I-Disease 0 0.0015040201833471656
breast I-Disease 1 0.8547742366790771
and I-Disease 0 4.203931530355476e-05
other I-Disease 0 1.9994261037936667e-06
cancers I-Disease 1 0.9974431991577148
were O 0 0.00021141475008334965
compared O 0 1.390791203448316e-05
between O 0 3.396531383259571e-06
genotyped O 0 9.726220741868019e-05
I1307K O 0 1.2946549759362824e-05
carriers O 0 8.203955985663924e-07
and O 0 4.0382482779932616e-07
non O 0 2.205661530751968e-06
- O 0 5.298653036334144e-07
carriers O 0 7.219703235250563e-08
and O 0 2.0360616304060386e-08
their O 0 1.0690152763004335e-08
first O 0 2.8736144486174453e-07
- O 0 6.695638603559928e-07
degree O 0 8.020288987609092e-06
relatives O 0 1.934915189849562e-06
. O 0 1.3614408089779317e-06

Sperm O 0 4.4872158468933776e-05
DNA O 0 6.240085895115044e-06
analysis O 0 1.2032470522171934e-06
in O 0 1.921018792927498e-06
a O 0 2.253899583593011e-05
Friedreich B-Disease 1 0.9987377524375916
ataxia I-Disease 1 0.9999998807907104
premutation O 1 0.9999635219573975
carrier O 0 8.91657400643453e-05
suggests O 0 1.8816149349731859e-06
both O 0 1.3820415745158243e-07
meiotic O 0 5.989517831039848e-06
and O 0 2.2492814366614766e-07
mitotic O 0 1.519158786322805e-06
expansion O 0 2.2439494387072045e-06
in O 0 4.944141664964263e-07
the O 0 1.4570039184036432e-06
FRDA B-Disease 0 0.00010208372259512544
gene O 0 3.377460870979121e-06
. O 0 2.7135831714986125e-06

Friedreich B-Disease 1 0.9999984502792358
ataxia I-Disease 1 1.0
is O 0 0.0007796190329827368
usually O 0 1.0949906027235556e-05
caused O 0 0.00010514544555917382
by O 0 1.4950516913359024e-07
an O 0 1.3782442920273752e-07
expansion O 0 2.1277608084346866e-06
of O 0 2.2602421267947648e-06
a O 0 3.222845180061995e-06
GAA O 0 1.9652281480375677e-05
trinucleotide O 0 1.1645416634564754e-05
repeat O 0 9.254159181182331e-07
in O 0 4.6911284812267695e-07
intron O 0 5.369935479393462e-06
1 O 0 1.7942790009328746e-06
of O 0 3.4676165796554415e-06
the O 0 8.361438631254714e-06
FRDA B-Disease 0 0.0003414844104554504
gene O 0 6.5560552684473805e-06
. O 0 4.461003754840931e-06

Occasionally O 0 8.993667142931372e-05
, O 0 4.975519914296456e-06
a O 0 2.948680048575625e-06
fully O 0 2.195516799474717e-06
expanded O 0 2.9913242087786784e-06
allele O 0 1.6963221014520968e-06
has O 0 6.692127385576896e-07
been O 0 6.491047201961919e-07
found O 0 7.952952074674613e-08
to O 0 5.426878146863601e-08
arise O 0 3.563938832940039e-07
from O 0 6.940975367797364e-07
a O 0 1.2018296047244803e-06
premutation O 0 9.306294487032574e-06
of O 0 4.833582352148369e-06
100 O 0 2.916729499702342e-06
or O 0 2.352041690301121e-07
less O 0 2.302294319633802e-07
triplet O 0 2.7923359084525146e-05
repeats O 0 4.560243269224884e-06
. O 0 1.1042480991818593e-06

We O 0 2.8669575840467587e-05
have O 0 1.2243104947629035e-06
examined O 0 1.4726047083968297e-06
the O 0 4.175241770099092e-07
sperm O 0 4.5104332002665615e-07
DNA O 0 1.4796052028032136e-07
of O 0 2.6770014756039018e-06
a O 0 8.937257007346489e-06
premutation O 0 0.00020647344354074448
carrier O 0 2.646302164066583e-05
. O 0 4.93850984639721e-06

This O 0 2.047647831204813e-05
mans O 0 6.845733150839806e-05
leucocyte O 0 7.323039608309045e-05
DNA O 0 1.6764506653998978e-06
showed O 0 5.136858362675412e-06
one O 0 3.4646043900465884e-07
normal O 0 1.5945537370498641e-06
allele O 0 3.3754730566215585e-07
and O 0 1.0544975737047935e-07
one O 0 3.6919683310543405e-08
allele O 0 2.8217709058253604e-08
of O 0 1.4697030792376609e-07
approximately O 0 1.4140481141566852e-07
100 O 0 5.31436114670214e-07
repeats O 0 1.0021860816777917e-06
. O 0 7.064649594212824e-07

His O 0 0.00021028491028118879
sperm O 0 4.966316919308156e-05
showed O 0 1.4526899576594587e-05
an O 0 6.316865324151877e-07
expanded O 0 1.9206011074857088e-06
allele O 0 1.2302058394197957e-06
in O 0 1.7830070646596141e-06
a O 0 5.166099072084762e-06
tight O 0 1.3049547305854503e-05
range O 0 2.744695848377887e-06
centering O 0 6.6077718656742945e-06
on O 0 1.0885257779591484e-06
a O 0 1.7905423987940594e-07
size O 0 1.433057121857928e-07
of O 0 2.239489731437061e-06
approximately O 0 3.4465656426618807e-06
320 O 0 1.4624953109887429e-05
trinucleotide O 0 9.36905707931146e-05
repeats O 0 1.5019647435110528e-05
. O 0 2.841549303411739e-06

His O 0 0.0009534145356155932
affected O 0 0.0001828403619583696
son O 0 0.0004730112850666046
has O 0 1.3984287079438218e-06
repeat O 0 3.458302728631679e-07
sizes O 0 1.725247074091385e-07
of O 0 4.337428435974289e-06
1040 O 0 1.4415748410101514e-05
and O 0 8.80013317328121e-07
540 O 0 1.7324289729003794e-05
. O 0 9.539917300571688e-07

These O 0 4.852333859162172e-06
data O 0 5.928563041379675e-06
suggest O 0 9.318329716734297e-07
that O 0 2.8175497845950304e-07
expansion O 0 3.8498737922054715e-06
occurs O 0 2.444183451189019e-07
in O 0 3.806920005899883e-07
two O 0 5.768183442000918e-08
stages O 0 5.060399530520954e-07
, O 0 6.283687525865389e-08
the O 0 6.427904963857145e-08
first O 0 1.3916009322656464e-07
during O 0 3.319878203456028e-07
meiosis O 0 3.614611614466412e-07
followed O 0 6.414347808458842e-07
by O 0 5.6000217796281504e-08
a O 0 2.8605910529222456e-07
second O 0 1.7190830021718284e-06
mitotic O 0 1.0663296961865854e-05
expansion O 0 2.3097254597814754e-05
. O 0 3.9332926462520845e-06

We O 0 4.76718669233378e-05
also O 0 5.953344953013584e-06
show O 0 1.0200943734162138e-06
that O 0 1.1199598759503715e-07
in O 0 2.552861531057715e-07
all O 0 7.917913080746075e-08
informative O 0 4.952182734996313e-07
carrier O 0 1.913252162921708e-06
father O 0 3.0643175250588683e-06
to O 0 2.4830833922351303e-07
affected O 0 8.943993066168332e-07
child O 0 1.1635853525149287e-06
transmissions O 0 2.8933195608260576e-06
, O 0 6.023837784141506e-08
with O 0 1.9955916030767185e-08
the O 0 4.497572660966398e-07
notable O 0 5.196558845455002e-07
exception O 0 7.154233117034892e-07
of O 0 5.37431060365634e-06
the O 0 5.452917321235873e-06
premutation O 0 2.4052256776485592e-05
carrier O 0 2.096607659041183e-06
, O 0 1.2381016745166562e-07
the O 0 1.0242046499797652e-07
expansion O 0 7.345491894739098e-07
size O 0 1.4850887453121686e-07
decreases O 0 3.321472604511655e-06
. O 0 2.3641719337774703e-07
. O 0 7.286730010491738e-07

The O 0 7.283683225978166e-05
R496H O 0 0.00019967010302934796
mutation O 0 2.691372401386616e-06
of O 0 5.116133252158761e-06
arylsulfatase O 0 0.00013112228771205992
A O 0 1.103380782296881e-05
does O 0 1.7343928959689947e-07
not O 0 4.561416631077009e-07
cause O 0 0.00030698408954776824
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 1.4742242456122767e-05

Deficiency B-Disease 1 0.9999947547912598
of I-Disease 0 0.0006627144175581634
arylsulfatase I-Disease 0 0.010380316525697708
A I-Disease 0 0.00019242042617406696
( O 0 2.085321284539532e-06
ARSA O 0 0.00016232184134423733
) O 0 1.9756939195758605e-07
enzyme O 0 1.1513458275658195e-06
activity O 0 1.0408647540316451e-05
causes O 0 5.334451634553261e-05
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 1.0
( O 0 1.1967814316449221e-05
MLD B-Disease 1 0.9999997615814209
) O 0 1.0998412562912563e-06
. O 0 8.597820055911143e-07

A O 0 4.490092032938264e-05
number O 0 2.676465555850882e-06
of O 0 1.4500766155833844e-05
ARSA O 0 0.001678138505667448
gene O 0 5.744792360928841e-06
mutations O 0 3.2139230370376026e-06
responsible O 0 9.943919394572731e-06
for O 0 5.093180334370118e-06
MLD B-Disease 1 1.0
have O 0 1.8221870732304524e-06
been O 0 2.064827867798158e-06
identified O 0 7.532339054705517e-07
. O 0 6.406571628758684e-07

Recently O 0 0.00021858295076526701
, O 0 3.829777142527746e-06
the O 0 3.070627599299769e-06
R496H O 0 1.8603108401293866e-05
mutation O 0 1.2280888768145815e-06
of O 0 2.6326666556997225e-05
ARSA O 0 0.0006513988482765853
was O 0 1.6809215594548732e-05
proposed O 0 8.201101309168735e-07
to O 0 6.16717059642724e-08
be O 0 1.2693713813405338e-07
a O 0 4.2513752873674093e-07
cause O 0 3.054135504498845e-06
of O 0 0.00016150559531524777
MLD B-Disease 1 1.0
( O 0 2.2565336621482857e-06
Draghia O 0 3.592116627260111e-05
et O 0 3.1554707675240934e-05
al O 0 5.179428626433946e-06
. O 0 2.1998452837124205e-08
, O 0 3.12814947278639e-08
1997 O 0 2.5272714765378623e-07
) O 0 8.534779283309035e-08
. O 0 2.541507342357363e-07

We O 0 4.398595410748385e-05
have O 0 2.086634140141541e-06
investigated O 0 4.652647476177663e-06
the O 0 3.5391024084674427e-06
R496H O 0 1.5885956599959172e-05
mutation O 0 4.859679165747366e-07
and O 0 2.773486755813792e-07
found O 0 1.7939728991223092e-07
this O 0 2.6852443824054717e-08
mutation O 0 6.460108181727264e-08
at O 0 3.108153805442271e-06
a O 0 2.3539715243714454e-07
relatively O 0 1.2211138766815566e-07
high O 0 1.37535994326754e-06
frequency O 0 4.1927185634449415e-07
in O 0 3.011797389262938e-07
an O 0 1.5556000221295108e-07
African O 0 1.1855074433242407e-07
American O 0 9.605503947796024e-08
population O 0 1.962121309873055e-08
( O 0 1.0889088741805608e-08
f O 0 2.6831972377294733e-07
= O 0 5.368913846837131e-08
0 O 0 2.2168366697883357e-08
. O 0 7.686167258214027e-09
09 O 0 4.196134852918476e-07
, O 0 1.2936812510133677e-08
n O 0 1.9522666150351142e-07
= O 0 2.972023480651842e-07
61 O 0 6.744396046087786e-07
subjects O 0 5.658725967805367e-07
) O 0 5.022259870202106e-07
. O 0 8.992607263280661e-07

The O 0 0.0014994299272075295
ARSA O 0 0.017106542363762856
enzyme O 0 9.617556497687474e-05
activity O 0 2.7563961339183152e-05
in O 0 1.57695990310458e-06
subjects O 0 1.6846498738232185e-06
with O 0 2.0343230744401808e-07
and O 0 6.164842716316343e-07
without O 0 5.610872904071584e-07
the O 0 2.97351903100207e-06
R496H O 0 1.0729457244451623e-05
mutation O 0 6.332475663839432e-07
was O 0 5.519352271221578e-06
determined O 0 2.1758742718702706e-07
and O 0 5.0401464335436685e-08
found O 0 4.457884728026329e-08
to O 0 3.4948584470839705e-08
be O 0 2.9452354510794976e-07
normal O 0 5.524002062884392e-06
. O 0 1.2657135357585503e-06

It O 0 3.7252746096783085e-06
is O 0 6.669903314104886e-07
therefore O 0 4.564593041322951e-07
concluded O 0 1.1256430525463657e-06
that O 0 8.103207704834858e-08
the O 0 1.0203667670793948e-06
R496H O 0 5.250596132100327e-06
mutation O 0 4.283763246348826e-07
of O 0 2.1339192244340666e-05
ARSA O 0 0.0006337474915198982
does O 0 2.8801031248804065e-07
not O 0 3.2769102631391434e-07
negatively O 0 6.028263328516914e-07
influence O 0 1.1606438192757196e-06
the O 0 1.6227269270530087e-06
activity O 0 2.643614152475493e-06
of O 0 3.7773195344925625e-06
ARSA O 0 9.91478082141839e-05
and O 0 3.121087672752765e-07
is O 0 9.900100650384047e-08
not O 0 4.120573748878087e-08
a O 0 4.916007014799106e-07
cause O 0 5.246902219369076e-06
of O 0 0.0009285847190767527
MLD B-Disease 1 1.0

Down O 0 0.0018713020253926516
- O 0 5.855065683135763e-05
regulation O 0 4.784893917531008e-06
of O 0 7.620475571457064e-06
transmembrane O 0 8.483966666972265e-05
carbonic O 0 0.0002970989444293082
anhydrases O 0 0.0019098115153610706
in O 0 0.008533052168786526
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999102354049683
lines O 0 2.810968362609856e-05
by O 0 7.913230319900322e-07
wild O 0 3.684473313114722e-07
- O 0 1.8427348322802573e-06
type O 0 2.7810510800918564e-06
von B-Disease 0 0.2517238259315491
Hippel I-Disease 1 0.9993809461593628
- I-Disease 0 0.23507659137248993
Lindau I-Disease 0 0.044570233672857285
transgenes O 0 0.00018944447219837457
. O 0 3.032797167179524e-06

To O 0 8.474995411233976e-06
discover O 0 2.7272189981886186e-06
genes O 0 1.3202510444898508e-06
involved O 0 1.571615030115936e-06
in O 0 4.449226253200322e-06
von B-Disease 0 0.05258433148264885
Hippel I-Disease 1 0.9995325803756714
- I-Disease 1 0.9978123903274536
Lindau I-Disease 1 0.999871015548706
( O 0 1.7360756828566082e-05
VHL B-Disease 0 0.0006304639391601086
) O 0 7.729022968305799e-07
- O 0 2.7632643195829587e-06
mediated O 0 2.024997229455039e-05
carcinogenesis O 0 0.0007840904290787876
, O 0 2.956433036160888e-07
we O 0 1.0717779019842055e-07
used O 0 1.0367415598011576e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999923706054688
lines O 0 0.0004249619960319251
stably O 0 0.0002506839227862656
transfected O 0 1.1458600056357682e-05
with O 0 9.016310542619976e-08
wild O 0 5.81060191962024e-07
- O 0 3.3465305477875518e-06
type O 0 8.548529876861721e-06
VHL O 0 0.0006829260964877903
- O 0 1.331121166003868e-05
expressing O 0 2.6444561171956593e-06
transgenes O 0 4.78357651445549e-05
. O 0 1.6470634136567242e-06

Large O 0 3.7099500332260504e-05
- O 0 6.33135005045915e-06
scale O 0 9.519481864117552e-06
RNA O 0 3.984830073022749e-06
differential O 0 6.5657600316626485e-06
display O 0 3.1370755095849745e-06
technology O 0 2.9524674118874827e-06
applied O 0 6.565281296389003e-07
to O 0 1.1423104950836205e-07
these O 0 9.53775511902677e-08
cell O 0 2.679131512195454e-06
lines O 0 5.87722922773537e-07
identified O 0 4.4354855788242276e-08
several O 0 1.941338112487756e-08
differentially O 0 7.806463031556632e-07
expressed O 0 8.107072346774657e-08
genes O 0 3.843831208882875e-08
, O 0 1.8903866916275547e-08
including O 0 1.4501978284897632e-08
an O 0 1.2737852728150756e-07
alpha O 0 3.4593754207890015e-06
carbonic O 0 7.827867193554994e-06
anhydrase O 0 2.588119969004765e-05
gene O 0 1.0655869573383825e-06
, O 0 4.5343091414906667e-07
termed O 0 1.0584431038296316e-05
CA12 O 0 0.00031997382757253945
. O 0 5.347102614905452e-06

The O 0 0.0001092428428819403
deduced O 0 3.169924093526788e-05
protein O 0 3.187759602951701e-06
sequence O 0 1.4778720469621476e-06
was O 0 7.931174877739977e-06
classified O 0 4.738777477086842e-07
as O 0 3.733401285899163e-07
a O 0 8.9674716718946e-07
one O 0 9.243389627044962e-07
- O 0 1.5123391676752362e-05
pass O 0 8.48773470352171e-06
transmembrane O 0 0.00017971156921703368
CA O 0 2.4684268282726407e-05
possessing O 0 6.973991276026936e-06
an O 0 2.7558742203837028e-06
apparently O 0 4.405673280416522e-06
intact O 0 1.3690575997316046e-06
catalytic O 0 1.4043963574295049e-06
domain O 0 6.103267082835373e-07
in O 0 7.804200663485972e-07
the O 0 3.989833658124553e-06
extracellular O 0 5.7264158385805786e-05
CA O 0 4.029704359709285e-05
module O 0 9.380393021274358e-05
. O 0 5.163853074918734e-06

Reintroduced O 0 0.0004251270729582757
wild O 0 5.739252083003521e-05
- O 0 0.00013607731671072543
type O 0 5.720640911022201e-05
VHL B-Disease 0 0.001325387042015791
strongly O 0 4.282948339096038e-06
inhibited O 0 3.275390326962224e-06
the O 0 6.89966100253514e-07
overexpression O 0 3.8122350360936252e-06
of O 0 1.6302327594530652e-06
the O 0 1.2537541351775872e-06
CA12 O 0 1.582551522005815e-05
gene O 0 9.354990737620028e-08
in O 0 7.5296753720977e-08
the O 0 8.369268016394926e-07
parental O 0 0.00015489652287214994
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999984502792358
lines O 0 0.0008759661577641964
. O 0 7.577631095045945e-06

Similar O 0 1.7194852262036875e-05
results O 0 1.0887742064369377e-05
were O 0 1.985498101930716e-06
obtained O 0 1.193914044961275e-06
with O 0 2.776186249775492e-07
CA9 O 0 0.00012196204625070095
, O 0 2.65802384546987e-07
encoding O 0 4.310930421524972e-07
another O 0 1.3264046856420464e-06
transmembrane O 0 2.657287404872477e-05
CA O 0 2.073458972517983e-06
with O 0 4.734635083991634e-08
an O 0 3.62776233941986e-07
intact O 0 2.5015228857228067e-06
catalytic O 0 7.937318514450453e-06
domain O 0 5.895388767385157e-06
. O 0 8.407635050389217e-07

Although O 0 1.2837925169151276e-05
both O 0 2.6633015295374207e-06
domains O 0 1.243239330506185e-05
of O 0 3.6075711250305176e-05
the O 0 2.9046657800790854e-05
VHL B-Disease 0 0.00018524234474170953
protein O 0 1.6293561202473938e-06
contribute O 0 3.501284595586185e-07
to O 0 4.800168653673609e-07
regulation O 0 3.1901258807920385e-06
of O 0 2.5747451218194328e-05
CA12 O 0 0.0012946041533723474
expression O 0 2.21542995859636e-05
, O 0 1.222447281179484e-06
the O 0 1.5913922197796637e-06
elongin O 0 1.1362883014953695e-05
binding O 0 1.4070653833186952e-06
domain O 0 2.4788839709799504e-06
alone O 0 5.581423465628177e-07
could O 0 1.1473885308532772e-07
effectively O 0 8.803751256891701e-07
regulate O 0 4.661943421524484e-06
CA9 O 0 0.0004511706065386534
expression O 0 1.0801158168760594e-05
. O 0 2.6225161491311155e-06

We O 0 4.1872350266203284e-05
mapped O 0 5.599801806965843e-05
CA12 O 0 0.0010532489977777004
and O 0 9.512267752143089e-06
CA9 O 0 0.0008396725752390921
loci O 0 4.510417056735605e-06
to O 0 2.538346564051608e-07
chromosome O 0 8.034497113840189e-06
bands O 0 6.087686415412463e-06
15q22 O 0 1.979750049940776e-05
and O 0 2.4840287551342044e-06
17q21 O 0 7.633892528247088e-05
. O 0 3.39184452968766e-06

2 O 0 0.0004589109739754349
respectively O 0 0.000120681754196994
, O 0 3.4198551475128625e-06
regions O 0 2.5137267130048713e-06
prone O 0 1.1419326256145723e-05
to O 0 2.4964370481939113e-07
amplification O 0 3.8113698792585637e-06
in O 0 2.954964486434619e-07
some O 0 1.3496750739250274e-07
human O 0 1.2873283594672102e-05
cancers B-Disease 0 0.22899504005908966
. O 0 5.5884984249132685e-06

Additional O 0 1.974715451069642e-05
experiments O 0 4.056052057421766e-05
are O 0 7.305154667847091e-07
needed O 0 7.369685022240446e-07
to O 0 2.1152541762603505e-07
define O 0 6.359837243508082e-07
the O 0 2.2381916551239556e-06
role O 0 7.557136086688843e-06
of O 0 0.00010222856508335099
CA O 0 2.1286810806486756e-05
IX O 0 0.00046271318569779396
and O 0 9.46744330576621e-06
CA O 0 7.85904467193177e-06
XII O 0 0.00019466812955215573
enzymes O 0 1.0728941788329394e-06
in O 0 5.262464810584788e-07
the O 0 1.346038970950758e-06
regulation O 0 1.1363187013557763e-06
of O 0 2.3118616354622645e-06
pH O 0 1.3003419553569984e-05
in O 0 2.1122457383171422e-06
the O 0 2.7009216410078807e-06
extracellular O 0 1.1065272701671347e-05
microenvironment O 0 1.931593578774482e-05
and O 0 1.2783610259248235e-07
its O 0 6.719653100617506e-08
potential O 0 1.6291605220430938e-07
impact O 0 2.330927145521855e-06
on O 0 2.4232065698015504e-05
cancer B-Disease 0 0.07869844138622284
cell O 0 0.00014695611025672406
growth O 0 4.440958218765445e-05
. O 0 1.2302058394197957e-06

A O 0 6.062601460143924e-05
gene O 0 3.3575561246834695e-06
encoding O 0 2.72231045528315e-06
a O 0 1.9029960185434902e-06
transmembrane O 0 1.776350472937338e-05
protein O 0 2.0605275494745e-06
is O 0 5.1532381917240855e-08
mutated O 0 6.762417115169228e-08
in O 0 5.8430604354953175e-08
patients O 0 4.7242073719644395e-07
with O 0 1.8371023315921775e-06
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999951124191284
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9631627202033997
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.155224026661017e-06
. O 0 8.183990871657443e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.001212187111377716
WFS B-Disease 1 0.9998334646224976
; O 0 6.968660272832494e-06
OMIM O 0 0.008709440939128399
222300 O 0 4.960878868587315e-05
) O 0 9.499012065816714e-08
is O 0 1.1902915986183871e-07
an O 0 7.241893626996898e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 0.2790316641330719
by O 0 1.2771009096468333e-05
young O 0 1.5556161088170484e-05
- O 0 0.006116272881627083
onset O 1 0.9999924898147583
non O 1 0.9892473816871643
- O 1 0.8878005146980286
immune O 0 0.014047456905245781
insulin B-Disease 1 0.9989713430404663
- I-Disease 1 0.9992179870605469
dependent I-Disease 1 0.8991833329200745
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.0009176399325951934
progressive O 1 0.9999973773956299
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999985694885254
. O 0 1.586332291481085e-05

Linkage O 0 0.0013249707408249378
to O 0 1.4090975128056016e-05
markers O 0 4.9915717681869864e-05
on O 0 3.977505548391491e-05
chromosome O 0 0.00018310066661797464
4p O 0 0.008752674795687199
was O 0 2.4280225261463784e-05
confirmed O 0 8.020846848921792e-07
in O 0 5.597863150796911e-07
five O 0 7.506437214033213e-07
families O 0 3.8506635746671236e-07
. O 0 1.52918255480472e-06

On O 0 4.149839878664352e-05
the O 0 1.7764657513907878e-06
basis O 0 2.114380095008528e-06
of O 0 1.3737600966123864e-05
meiotic O 0 0.0025588131975382566
recombinants O 1 0.9360283017158508
and O 0 7.643084245501086e-05
disease O 1 0.9901521801948547
- O 0 7.29346284060739e-05
associated O 0 3.5265018141217297e-06
haplotypes O 0 1.3117572052578907e-05
, O 0 4.5361383627096075e-07
the O 0 3.998582997155609e-06
WFS B-Disease 0 9.106843208428472e-05
gene O 0 6.45487261863309e-07
was O 0 4.263468326826114e-06
localized O 0 1.1474895700303023e-06
to O 0 3.027693935564457e-07
a O 0 4.5727897486358415e-06
BAC O 0 0.00022037888993509114
/ O 0 1.32155491883168e-05
P1 O 0 0.00012622313806787133
contig O 0 1.579368836246431e-05
of O 0 3.084262971242424e-06
less O 0 2.0385567722769338e-07
than O 0 7.680455382796936e-08
250 O 0 7.257740435306914e-07
kb O 0 2.6884608814725652e-05
. O 0 1.7360423498757882e-06

Mutations O 0 2.2809543224866502e-05
in O 0 5.293816684570629e-06
a O 0 1.4666845800093142e-06
novel O 0 2.2404897208616603e-06
gene O 0 8.523210226485389e-07
( O 0 3.077409473917214e-07
WFS1 O 0 9.049059372046031e-06
) O 0 7.731176054903699e-08
encoding O 0 2.6165329813920835e-07
a O 0 9.885116014629602e-07
putative O 0 7.2026459747576155e-06
transmembrane O 0 4.719677690445678e-06
protein O 0 2.4238545393018285e-06
were O 0 1.91025469575834e-06
found O 0 1.2453774900222925e-07
in O 0 1.5005139175627846e-07
all O 0 4.209754322914705e-08
affected O 0 1.4332471209854702e-07
individuals O 0 3.364435841035629e-08
in O 0 1.939761432367959e-06
six O 0 2.50839348154841e-05
WFS B-Disease 0 0.0012819189578294754
families O 0 1.4093012623561663e-07
, O 0 3.583726382316854e-08
and O 0 1.2107477687095525e-08
these O 0 2.572418056345782e-09
mutations O 0 1.7369975680026073e-08
were O 0 8.473627843841314e-08
associated O 0 2.051968017724448e-08
with O 0 2.3874038745930193e-08
the O 0 4.319747404224472e-06
disease O 0 0.0016317479312419891
phenotype O 0 1.5679646821809e-05
. O 0 1.970362291103811e-06

WFS1 O 0 0.013555045239627361
appears O 0 2.5081686544581316e-05
to O 0 9.237583071808331e-07
function O 0 2.1488508537004236e-06
in O 0 5.130774525241577e-07
survival O 0 2.228572839158005e-06
of O 0 9.0955199993914e-06
islet O 0 9.794395737117156e-05
beta O 0 3.147392635582946e-05
- O 0 5.803281055705156e-06
cells O 0 2.8514719474515005e-07
and O 0 1.2548028394121502e-07
neurons O 0 8.764780545789108e-07
. O 0 1.0007594397620778e-07
. O 0 3.3243392749682243e-07

Stable O 0 0.0005506735178641975
interaction O 0 8.541024726582691e-06
between O 0 5.67881625102018e-06
the O 0 3.7548541058640694e-06
products O 0 3.616694357333472e-07
of O 0 1.3510715461961809e-06
the O 0 2.486953690095106e-06
BRCA1 O 0 3.8142425182741135e-06
and O 0 2.062289013338159e-06
BRCA2 O 0 1.1100574738520663e-05
tumor B-Disease 0 0.00045143559691496193
suppressor O 0 4.786661156686023e-05
genes O 0 1.0475514500285499e-07
in O 0 2.2402237220831012e-07
mitotic O 0 2.288181121912203e-06
and O 0 2.49681335162677e-07
meiotic O 0 3.044756522285752e-05
cells O 0 6.237830348254647e-06
. O 0 2.083405206576572e-06

BRCA1 O 0 0.0011772161815315485
and O 0 1.8673654267331585e-05
BRCA2 O 0 3.543800994521007e-05
account O 0 3.935451218239905e-07
for O 0 1.399264988322102e-07
most O 0 1.4188159980221826e-08
cases O 0 2.6646578277222943e-08
of O 0 4.425235715643794e-07
familial O 0 0.00010399850725661963
, O 0 1.5179176671153982e-06
early O 0 2.760457391559612e-05
onset O 1 0.9999982118606567
breast B-Disease 1 0.9981269240379333
and I-Disease 0 0.0012333643389865756
/ I-Disease 1 0.9999997615814209
or I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.0139549431187334e-06
encode O 0 3.007787370279402e-07
products O 0 1.906042399468788e-07
that O 0 2.0002561385012996e-08
each O 0 1.2071183164152899e-08
interact O 0 1.7855541045719292e-08
with O 0 9.043281323783958e-08
hRAD51 O 0 1.5234664715535473e-05
. O 0 2.0909567410853924e-06

Results O 0 0.00010319929424440488
presented O 0 2.3880769731476903e-05
here O 0 1.301283305110701e-06
show O 0 3.6438024153540027e-07
that O 0 7.666945833761929e-08
BRCA1 O 0 8.023608870644239e-07
and O 0 3.7517148143706436e-07
BRCA2 O 0 5.980335231470235e-07
coexist O 0 9.750871754476975e-08
in O 0 2.6340663339396997e-07
a O 0 4.3882573663722724e-07
biochemical O 0 8.457458534394391e-06
complex O 0 1.2752801012538839e-05
and O 0 7.767134775349405e-07
colocalize O 0 4.1812731069512665e-05
in O 0 7.245593678817386e-06
subnuclear O 0 0.0001577543735038489
foci O 0 0.00013902387581765652
in O 0 3.32641775457887e-06
somatic O 0 3.1568774829793256e-06
cells O 0 5.819680382046499e-07
and O 0 1.2200790422411956e-07
on O 0 4.77601247439452e-07
the O 0 2.0459209792988986e-07
axial O 0 1.0915684924839297e-06
elements O 0 3.038390730125684e-07
of O 0 3.0421763312915573e-06
developing O 0 4.708043434220599e-06
synaptonemal O 0 0.00010363242472521961
complexes O 0 2.8922797355335206e-05
. O 0 1.8617341766002937e-06

Like O 0 7.70106416894123e-05
BRCA1 O 0 6.29302958259359e-05
and O 0 8.882808288035449e-06
RAD51 O 0 0.0005103177390992641
, O 0 2.8714605377899716e-06
BRCA2 O 0 5.149424396222457e-06
relocates O 0 3.6357948829390807e-06
to O 0 3.271845230301551e-07
PCNA O 0 6.312725872703595e-06
+ O 0 3.3722554348969425e-07
replication O 0 5.9195642165832396e-08
sites O 0 6.429805665675303e-08
following O 0 7.97029429122631e-08
exposure O 0 5.965400191598746e-07
of O 0 3.7750289720861474e-06
S O 0 5.1421124226180837e-05
phase O 0 6.2289491324918345e-06
cells O 0 3.46558579167322e-07
to O 0 2.5476566634097253e-07
hydroxyurea O 0 2.0548586689983495e-05
or O 0 1.8905471961261355e-06
UV O 0 0.00015328296285588294
irradiation O 0 2.6470392185728997e-05
. O 0 1.5238484820656595e-06

Thus O 0 8.07782998890616e-05
, O 0 4.9967848099186085e-06
BRCA1 O 0 8.075902769633103e-06
and O 0 1.1422617944845115e-06
BRCA2 O 0 1.3507906260201707e-06
participate O 0 3.013130367435224e-07
, O 0 1.179265041173494e-07
together O 0 3.035598084011326e-08
, O 0 4.0957189639811986e-08
in O 0 1.839265735270601e-07
a O 0 1.1656288734229747e-06
pathway O 0 4.029609954159241e-06
( O 0 2.0254917387774185e-07
s O 0 2.2786691715737106e-06
) O 0 6.149446107883705e-08
associated O 0 1.971584993043507e-07
with O 0 5.19730214421088e-08
the O 0 2.4604050850030035e-06
activation O 0 6.673787083855132e-06
of O 0 5.7694218412507325e-05
double O 0 1.0068025403597858e-05
- O 0 6.420874342438765e-06
strand O 0 3.1228373700287193e-06
break O 0 7.953283329698024e-07
repair O 0 2.3400320969813038e-06
and O 0 3.0277979590209725e-07
/ O 0 1.3530417390938965e-06
or O 0 1.2353595479908108e-07
homologous O 0 2.988467713294085e-07
recombination O 0 6.638479135290254e-07
. O 0 7.126192258510855e-07

Dysfunction O 1 0.9999794960021973
of O 0 0.000910803850274533
this O 0 1.1981093848589808e-05
pathway O 0 0.00012653078010771424
may O 0 5.497847723745508e-07
be O 0 4.373646689259658e-08
a O 0 9.540138989905245e-08
general O 0 2.3338557753049827e-07
phenomenon O 0 1.8274046453825576e-07
in O 0 5.98077960489718e-08
the O 0 5.552595894187107e-08
majority O 0 5.149462189990572e-09
of O 0 1.3675057175532856e-07
cases O 0 1.3613897920095042e-07
of O 0 6.933453551027924e-05
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9999969005584717
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.2754570661854814e-06
. O 0 8.48742331527319e-07

A O 0 0.00012666828115470707
novel O 0 1.7594367818674073e-05
Arg362Ser O 0 6.990630208747461e-05
mutation O 0 1.073762177838944e-06
in O 0 1.3483464726959937e-06
the O 0 2.4006290004763287e-06
sterol O 0 9.922907338477671e-06
27 O 0 2.0880534066236578e-05
- O 0 9.018604032462463e-06
hydroxylase O 0 1.992006946238689e-05
gene O 0 1.0093126547872089e-06
( O 0 5.068634436611319e-07
CYP27 O 0 3.1424438930116594e-05
) O 0 2.4811541265989945e-07
: O 0 4.4158426248941396e-08
its O 0 5.865146235350949e-08
effects O 0 1.2475485391405527e-06
on O 0 2.6693890049500624e-06
pre O 0 8.51373351906659e-06
- O 0 8.055426974351576e-07
mRNA O 0 2.6848249490285525e-07
splicing O 0 1.482798950291908e-07
and O 0 1.4550457194673072e-07
enzyme O 0 5.334748607310758e-07
activity O 0 2.5818528683885233e-06
. O 0 5.560893896472408e-07

A O 0 0.00021587550872936845
novel O 0 4.105874177184887e-05
C O 0 7.940556679386646e-05
to O 0 6.932586984476075e-07
A O 0 1.9016645183000946e-06
mutation O 0 4.837363931642358e-08
in O 0 3.015453273746971e-07
the O 0 9.027803002936707e-07
sterol O 0 4.193553195364075e-06
27 O 0 9.509791198070161e-06
- O 0 6.351246611302486e-06
hydroxylase O 0 8.738408723729663e-06
gene O 0 4.81111271710688e-07
( O 0 2.5853370289041777e-07
CYP27 O 0 1.0200369615631644e-05
) O 0 4.7970836192234856e-08
was O 0 6.261959697440034e-07
identified O 0 4.0257045696989735e-08
by O 0 2.9769525511369466e-08
sequencing O 0 9.723011089590727e-07
amplified O 0 1.0948726412607357e-05
CYP27 O 0 0.00010440361074870452
gene O 0 6.949042017367901e-07
products O 0 3.1400068678522075e-07
from O 0 2.947441259948391e-07
a O 0 2.41532291056501e-07
patient O 0 1.049030515787308e-06
with O 0 2.2943563635635655e-06
cerebrotendinous B-Disease 1 0.9999991655349731
xanthomatosis I-Disease 1 0.9999926090240479
( O 0 9.728959412313998e-06
CTX B-Disease 0 0.0010434057330712676
) O 0 1.2111516980439774e-06
. O 0 1.5299717688321834e-06

The O 0 4.8194840928772464e-05
mutation O 0 7.831750735931564e-06
changed O 0 6.690980626444798e-06
the O 0 3.959449259127723e-06
adrenodoxin O 0 3.9954491512617096e-05
cofactor O 0 1.104651437344728e-05
binding O 0 1.5452557136086398e-06
residue O 0 1.1748375982278958e-05
362Arg O 0 8.107556823233608e-06
to O 0 1.219143086927943e-06
362Ser O 0 2.4388482415815815e-05
( O 0 3.449985797487898e-06
CGT O 0 0.00022122118389233947
362Arg O 0 1.3926838619227055e-05
to O 0 1.6551474573134328e-06
AGT O 0 7.941723015392199e-05
362Ser O 0 9.958001101040281e-06
) O 0 2.8926081085955957e-07
, O 0 4.722027213688307e-08
and O 0 6.96176556402861e-08
was O 0 1.0681014828151092e-05
responsible O 0 3.3689104839140782e-06
for O 0 5.637354661303107e-06
deficiency O 1 0.9999402761459351
in O 0 6.465680053224787e-05
the O 0 4.843230635742657e-05
sterol O 0 5.209340451983735e-05
27 O 0 0.00010446137457620353
- O 0 1.770449489413295e-05
hydroxylase O 0 1.5855548554100096e-05
activity O 0 1.152169716078788e-06
, O 0 3.552299077114185e-08
as O 0 2.1571977981693635e-08
confirmed O 0 3.277096993770101e-08
by O 0 1.0816040507677371e-08
expression O 0 1.7190291146107484e-07
of O 0 4.4842019519819587e-07
mutant O 0 8.599878356108093e-07
cDNA O 0 1.960030658665346e-06
into O 0 1.3006169865548145e-06
COS O 0 3.571267006918788e-05
- O 0 1.7731246089169872e-06
1 O 0 1.0790035958052613e-06
cells O 0 8.71467136676074e-07
. O 0 9.650990477894084e-07

Quantitative O 0 9.698732174001634e-05
analysis O 0 4.0953236748464406e-06
showed O 0 4.494238055485766e-06
that O 0 1.6967980798199278e-07
the O 0 5.448657702800119e-07
expression O 0 8.439785119662702e-07
of O 0 3.6047874800715363e-06
CYP27 O 0 2.809810575854499e-05
gene O 0 1.5481748505408177e-07
mRNA O 0 4.1115777094091754e-07
in O 0 1.457113398828369e-07
the O 0 3.2256636472993705e-07
patient O 0 4.14253719327462e-07
represented O 0 1.0865209105759277e-06
52 O 0 1.2819574294553604e-05
. O 0 1.8849716525437543e-06

5 O 0 2.1170546460780315e-05
% O 0 1.6067994010882103e-06
of O 0 2.9895616080466425e-06
the O 0 3.9111714613682125e-06
normal O 0 2.5876881409203634e-05
level O 0 9.427579789189622e-05
. O 0 4.603391971613746e-06

As O 0 2.400216726528015e-05
the O 0 2.471967036399292e-06
mutation O 0 8.222967267101922e-07
occurred O 0 1.3700077943212818e-05
at O 0 4.544371222436894e-06
the O 0 7.111222544153861e-07
penultimate O 0 3.7577910916297697e-06
nucleotide O 0 7.656977913939045e-07
of O 0 6.123291768744821e-06
exon O 0 1.2845035826103413e-06
6 O 0 3.860882316075731e-06
( O 0 1.198108776634399e-07
- O 0 5.984077802168031e-07
2 O 0 1.2981422514712904e-06
position O 0 1.607461513231101e-06
of O 0 6.11403720540693e-06
exon O 0 1.5228752090479247e-06
6 O 0 2.141918912457186e-06
- O 0 1.3925318853580393e-06
intron O 0 7.874529728724156e-06
6 O 0 3.3466042168583954e-06
splice O 0 2.760109055088833e-06
site O 0 2.832701738952892e-06
) O 0 1.0546403927946812e-07
of O 0 1.0205993703493732e-06
the O 0 1.926045115396846e-06
gene O 0 5.099548729958769e-07
, O 0 1.7873233559839719e-07
we O 0 6.76169449320696e-08
hypothesized O 0 3.1028653779685555e-07
that O 0 2.4432690537423696e-08
the O 0 2.6132389052690996e-07
mutation O 0 2.606660132187244e-07
may O 0 5.050299023423577e-07
partially O 0 2.2327851638692664e-06
affect O 0 2.4706656631678925e-07
the O 0 7.16794716026925e-07
normal O 0 1.148886781265901e-06
splicing O 0 2.0223899355187314e-07
efficiency O 0 3.236954455587693e-07
in O 0 1.9267308459802734e-07
exon O 0 7.318808457057457e-07
6 O 0 1.8053189023703453e-06
and O 0 1.465706986891746e-07
cause O 0 7.62078514071618e-07
alternative O 0 3.395134342554229e-07
splicing O 0 3.2098964197757596e-07
elsewhere O 0 1.4043854434930836e-07
, O 0 7.680319491498722e-09
which O 0 6.317923517684676e-09
resulted O 0 5.532024616172748e-08
in O 0 6.870285318427705e-08
decreased O 0 5.578269792749779e-06
transcript O 0 1.1524554111019825e-06
in O 0 2.523208593174786e-07
the O 0 8.730126523914805e-07
patient O 0 5.783909728052095e-06
. O 0 2.786323420878034e-06

Transfection O 0 0.004431126639246941
of O 0 0.0005790777504444122
constructed O 0 0.0011943853460252285
minigenes O 0 0.00030250466079451144
, O 0 8.298438274323416e-07
with O 0 8.55652260156603e-08
or O 0 2.9477703833435953e-07
without O 0 9.663979483320873e-08
the O 0 1.102295300370315e-06
mutation O 0 1.5714681467215996e-07
, O 0 9.36304118681619e-08
into O 0 3.4661113090805884e-07
COS O 0 1.9340119251864962e-05
- O 0 1.1326660569466185e-06
1 O 0 7.965701911416545e-07
cells O 0 1.0976193465239703e-07
confirmed O 0 1.0151376983458249e-07
that O 0 4.717580281976552e-08
the O 0 6.577176350219816e-07
mutant O 0 1.7762658899300732e-06
minigene O 0 1.4474654562945943e-05
was O 0 8.901650289772078e-06
responsible O 0 2.481516219177138e-07
for O 0 7.759452103073272e-08
a O 0 8.4797235899714e-08
mRNA O 0 1.2556479589420633e-07
species O 0 4.397945119194446e-09
alternatively O 0 1.5558225641143508e-07
spliced O 0 3.5011376553484297e-07
at O 0 3.097126182183274e-06
an O 0 2.9043340532552975e-07
activated O 0 3.0503108519042144e-06
cryptic O 0 1.8868170172936516e-06
5 O 0 1.3767955806542886e-06
splice O 0 2.580344016678282e-06
site O 0 4.883028395852307e-06
88 O 0 1.396162679156987e-05
bp O 0 7.000846380833536e-06
upstream O 0 1.0739613571786322e-05
from O 0 1.5970708773238584e-06
the O 0 6.681445938738761e-07
3 O 0 5.265471827442525e-07
end O 0 7.157741492846981e-07
of O 0 1.2298374940655776e-06
exon O 0 1.67487178259762e-06
6 O 0 4.4958073885936756e-06
. O 0 7.17705802344426e-07

Our O 0 0.00012600439367815852
data O 0 1.3154741282050963e-05
suggest O 0 2.55062536780315e-06
that O 0 3.064470774916117e-07
the O 0 1.5101970802788856e-06
C O 0 7.888412255852018e-06
to O 0 1.0607531208961518e-07
A O 0 1.731343559185916e-06
mutation O 0 1.9985843380254664e-07
at O 0 4.983236522093648e-06
the O 0 6.336190949696174e-07
penultimate O 0 2.6392513063910883e-06
nucleotide O 0 2.250744728371501e-07
of O 0 1.1150493719469523e-06
exon O 0 5.138045366948063e-07
6 O 0 8.95920607035805e-07
of O 0 1.065213041329116e-06
the O 0 1.1067203331549536e-06
CYP27 O 0 1.493107538408367e-05
gene O 0 1.5386413565465773e-07
not O 0 6.491332271707506e-08
only O 0 1.1429991531031192e-07
causes O 0 1.2821230939152883e-06
the O 0 8.948310096457135e-06
deficiency B-Disease 0 0.0019298142287880182
in I-Disease 0 3.3863755106722238e-06
the I-Disease 0 2.943616891570855e-06
sterol I-Disease 0 1.907623118313495e-05
27 I-Disease 0 3.2328563975170255e-05
- I-Disease 0 1.221679303853307e-05
hydroxylase I-Disease 0 1.98749821720412e-05
activity I-Disease 0 8.761773642618209e-06
, O 0 2.12087570616859e-07
but O 0 4.350716054091208e-08
also O 0 2.5803021230785816e-07
partially O 0 2.063288320641732e-06
leads O 0 2.299305918995742e-07
to O 0 5.0154245201383674e-08
alternative O 0 8.895678860199041e-08
pre O 0 1.2388734376145294e-06
- O 0 3.0360300229403947e-07
mRNA O 0 1.5836468492125277e-07
splicing O 0 7.125567691446122e-08
of O 0 4.1024748043128056e-07
the O 0 1.1554079719644506e-06
gene O 0 1.0870473943214165e-06
. O 0 1.2808277460862882e-06

To O 0 1.9302491637063213e-05
our O 0 7.0303849497577175e-06
knowledge O 0 6.9233110480126925e-06
, O 0 8.636781672066718e-07
this O 0 2.1520817483633436e-07
is O 0 1.911104305918343e-07
the O 0 3.0372461878869217e-07
first O 0 7.468441367564083e-07
report O 0 8.276940093310259e-07
regarding O 0 1.785937683962402e-06
effects O 0 3.13715027004946e-05
on O 0 2.6221256121061742e-05
pre O 0 2.2680311303702183e-05
- O 0 1.7427971670258557e-06
mRNA O 0 7.584822583339701e-07
splicing O 0 1.8038716120827303e-07
of O 0 1.1654487934720237e-06
a O 0 7.492726581403986e-07
mutation O 0 2.423165028631047e-07
at O 0 5.703005172108533e-06
the O 0 9.67794903772301e-07
- O 0 5.483866516442504e-07
2 O 0 4.153938562012627e-07
position O 0 2.7268865210317017e-07
of O 0 9.688245654615457e-07
a O 0 1.1390789040888194e-06
5 O 0 1.952737420651829e-06
splice O 0 5.038877588958712e-06
site O 0 7.273897153936559e-06
. O 0 1.1175266081409063e-06

ATM O 0 0.005486049689352512
germline O 0 0.0005309468833729625
mutations O 0 9.99998883344233e-06
in O 0 1.1170332982146647e-05
classical O 1 0.9997631907463074
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.6573655009269714
in O 0 2.092410795739852e-05
the O 0 9.435067113372497e-06
Dutch O 0 1.979674561880529e-05
population O 0 1.7584022771188756e-07
. O 0 3.46323361100076e-07

Germline O 0 0.0028006536886096
mutations O 0 1.815968607843388e-05
in O 0 2.9057184747216525e-06
the O 0 1.3339830502445693e-06
ATM O 0 4.0813349187374115e-05
gene O 0 1.3879311211439926e-07
are O 0 1.2812654937022216e-08
responsible O 0 4.550823007321014e-08
for O 0 1.1872441518789856e-07
the O 0 0.059682201594114304
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9973438382148743
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.5915593343816e-06
. O 0 1.0355244057791424e-06

In O 0 7.089394784998149e-05
our O 0 8.524855729774572e-06
study O 0 1.7778215806174558e-06
, O 0 2.1594561872007034e-07
we O 0 3.95173493927814e-08
have O 0 2.3257962666889398e-08
determined O 0 8.256664330019703e-08
the O 0 2.853697367299901e-07
ATM O 0 3.923529675375903e-06
mutation O 0 8.676328633328012e-08
spectrum O 0 3.0028434139239835e-07
in O 0 3.259646064179833e-07
19 O 0 4.01351690015872e-06
classical O 0 3.577221650630236e-05
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
patients O 0 2.072980350931175e-06
, O 0 1.3646889840401855e-07
including O 0 9.787056143295558e-08
some O 0 3.010309512774256e-08
immigrant O 0 3.68290614005673e-07
populations O 0 5.388776003201201e-08
, O 0 5.2044249798655073e-08
as O 0 5.8282008552623665e-08
well O 0 5.951944004323195e-08
as O 0 8.488768798997626e-08
12 O 0 2.2930647958219197e-07
of O 0 1.7787769479582494e-07
Dutch O 0 1.0209507763647707e-06
ethnic O 0 1.266079152628663e-07
origin O 0 6.599758535230649e-07
. O 0 1.125311314353894e-06

Both O 0 1.7973043213714845e-05
the O 0 7.120606824173592e-06
protein O 0 2.483739763192716e-06
truncation O 0 1.9184930351912044e-05
test O 0 1.7906754692376126e-06
( O 0 4.351131508428807e-07
PTT O 0 1.2727650755550712e-05
) O 0 8.739875312357981e-08
and O 0 9.246372911775325e-08
the O 0 3.2900246083045204e-07
restriction O 0 8.203017500818532e-07
endonuclease O 0 5.517700174095808e-06
fingerprinting O 0 1.951705826286343e-06
( O 0 2.7767001142819936e-07
REF O 0 9.320700883108657e-06
) O 0 2.9623278052781643e-08
method O 0 9.809501477775484e-08
were O 0 1.8451601135893725e-07
used O 0 7.237917287739037e-08
and O 0 3.767120304587479e-08
compared O 0 3.4469758247723803e-07
for O 0 4.828477884188942e-08
their O 0 3.2746729772270555e-08
detection O 0 4.5409385052153084e-07
efficiency O 0 7.220226621029724e-07
, O 0 4.448897783504435e-08
identifying O 0 4.29678195246197e-08
76 O 0 1.1873205494339345e-06
% O 0 7.912432664625157e-08
and O 0 4.9686928349501613e-08
60 O 0 2.1070337652417948e-07
% O 0 6.614868652832229e-08
of O 0 8.853958775034698e-07
the O 0 1.6078309954536962e-06
mutations O 0 3.777369954605092e-07
, O 0 3.470391334303713e-07
respectively O 0 3.298325964351534e-06
. O 0 8.549627636966761e-07

Most O 0 1.4086071132624056e-05
patients O 0 2.088965629809536e-06
were O 0 1.3705638366445783e-06
found O 0 1.2662893311699008e-07
to O 0 3.9801015816465224e-08
be O 0 5.20195442277327e-07
compound O 0 4.489509592531249e-05
heterozygote O 0 2.5974441086873412e-05
. O 0 2.7724477149604354e-06

Seventeen O 0 0.0006046053604222834
mutations O 0 2.4089122234727256e-05
were O 0 9.703071555122733e-06
distinct O 0 3.113212869720883e-07
, O 0 2.1659511162397393e-07
of O 0 1.1128290680062491e-06
which O 0 2.3412435723457747e-07
10 O 0 4.901326633444114e-07
were O 0 3.4958560490849777e-07
not O 0 1.1257487386728826e-07
reported O 0 1.8872308373829583e-06
previously O 0 9.558089914207812e-06
. O 0 2.2132680896902457e-06

Mutations O 0 0.00011947547318413854
are O 0 2.318649194421596e-06
small O 0 9.90670855571807e-07
deletions O 0 4.328956492827274e-06
or O 0 1.2077514384145616e-06
point O 0 2.408866748737637e-06
mutations O 0 1.2988070352548675e-07
frequently O 0 1.72167062828521e-07
affecting O 0 1.234430783370044e-06
splice O 0 9.969631719286554e-06
sites O 0 2.567371438999544e-06
. O 0 1.0731644124462036e-06

Moreover O 0 0.00011949574400205165
, O 0 3.820242000074359e-06
a O 0 3.2147597721632337e-06
16 O 0 1.3334615687199403e-05
. O 0 2.434594762235065e-06

7 O 0 0.0003407964250072837
- O 0 7.712933438597247e-05
kb O 0 0.00010647282033460215
genomic O 0 1.1162037480971776e-05
deletion O 0 8.158499440469313e-06
of O 0 2.050489274552092e-05
the O 0 9.271674571209587e-06
3 O 0 3.6792484934267122e-06
end O 0 3.201090748916613e-06
of O 0 4.107041604584083e-06
the O 0 5.787965619674651e-06
gene O 0 5.656961548083927e-07
, O 0 1.463071725993359e-07
most O 0 6.183212519772496e-08
likely O 0 2.2093720986049448e-07
a O 0 1.4050404217869072e-07
result O 0 1.2641476132557727e-07
of O 0 9.316312912233116e-07
recombination O 0 1.3013237776249298e-07
between O 0 5.759882242273306e-07
two O 0 4.839274083678902e-07
LINE O 0 4.7226849346770905e-06
elements O 0 2.7410260372562334e-07
, O 0 1.153325754899015e-07
was O 0 3.0893529583408963e-06
identified O 0 8.620866651654069e-07
. O 0 5.672141583090706e-07

The O 0 0.00019330327631905675
most O 0 1.4527346365866833e-06
frequently O 0 5.161403464626346e-07
found O 0 3.891211690643104e-07
mutation O 0 8.506209070446857e-08
, O 0 6.166511923311191e-08
identified O 0 6.150255416059736e-08
in O 0 2.4839053480718576e-07
three O 0 8.447000254818704e-07
unrelated O 0 5.018696356273722e-06
Turkish O 0 0.0003444193280301988
A B-Disease 1 1.0
- I-Disease 1 0.9999946355819702
T I-Disease 1 0.9999996423721313
individuals O 0 2.2878509753354592e-07
, O 0 2.338275919555599e-07
was O 0 4.272211299394257e-06
previously O 0 3.7718589851465367e-07
described O 0 9.239744258593419e-08
to O 0 3.047804852940317e-08
be O 0 1.2180281316886976e-07
a O 0 2.488557129254332e-07
Turkish O 0 6.643686447205255e-06
A B-Disease 1 0.9999758005142212
- I-Disease 1 0.9998922348022461
T I-Disease 1 0.9999984502792358
founder O 0 0.00017424319230485708
mutation O 0 1.1487289839351433e-06
. O 0 8.945255558501231e-07

The O 0 4.7458186600124463e-05
presence O 0 5.42654834134737e-06
of O 0 1.935807267727796e-05
a O 0 1.4927856682334095e-05
founder O 0 0.0001005221129162237
mutation O 0 2.672800007985643e-07
among O 0 4.501305994608629e-08
relatively O 0 3.5148598698242495e-08
small O 0 6.317694811741603e-09
ethnic O 0 3.296234174499091e-09
population O 0 1.53422874404896e-08
groups O 0 3.3056595238889486e-09
in O 0 8.895779757267519e-08
Western O 0 8.073962476373708e-07
Europe O 0 3.2396846449955774e-07
could O 0 6.038066402425102e-08
indicate O 0 1.7915911598720413e-07
a O 0 1.228372923378629e-07
high O 0 7.509322585974587e-07
carrier O 0 5.185439988508733e-08
frequency O 0 1.1400402399885934e-07
in O 0 3.379150470550485e-08
such O 0 3.798361092322011e-08
communities O 0 1.0064120914421437e-07
. O 0 5.015299961996789e-07

In O 0 0.00011351914145052433
patients O 0 7.492085842386587e-06
of O 0 9.9299504654482e-06
Dutch O 0 8.870770216162782e-06
ethnic O 0 3.4257791980962793e-07
origin O 0 3.27426732837921e-07
, O 0 9.769674136350659e-08
however O 0 4.552437715688029e-08
, O 0 3.229024159168148e-08
no O 0 4.6831715394546336e-08
significant O 0 6.913895163052075e-07
founder O 0 1.9992081433883868e-05
effect O 0 2.830703124345746e-06
could O 0 5.008832886232994e-07
be O 0 3.5111688134747965e-07
identified O 0 5.957707571724313e-07
. O 0 7.910348358564079e-07

The O 0 1.0599300367175601e-05
observed O 0 3.5245686831331113e-06
genetic O 0 5.98608721702476e-07
heterogeneity O 0 6.010185643390287e-06
including O 0 1.001687337520707e-06
the O 0 4.694879407907138e-06
relative O 0 5.95928831899073e-05
high O 0 0.0009575493168085814
percentage O 0 1.563108162372373e-05
of O 0 3.2004205422708765e-05
splice O 0 6.186580139910802e-05
- O 0 2.1778992959298193e-05
site O 0 1.6464587133668829e-06
mutations O 0 1.1339452754555168e-07
had O 0 9.647732213124982e-07
no O 0 1.989454574413685e-07
reflection O 0 2.22008793571149e-06
on O 0 4.5183214751887135e-06
the O 0 2.9153668492654106e-06
phenotype O 0 1.4486059626506176e-05
. O 0 2.229533720310428e-06

All O 0 1.0833189662662335e-05
patients O 0 3.6424094105313998e-06
manifested O 0 5.959956979495473e-06
classical O 0 9.563070489093661e-05
A B-Disease 1 0.9999819993972778
- I-Disease 0 0.104781374335289
T I-Disease 0 0.3236241340637207
and O 0 8.30488389169659e-08
increased O 0 1.7362924609187758e-06
cellular O 0 5.768276878370671e-06
radioresistant O 0 1.285032067244174e-05
DNA O 0 1.0456435575179057e-06
synthesis O 0 1.4136144272924867e-05
. O 0 1.593354340911901e-06

Determination O 0 4.161007018410601e-05
of O 0 2.010691969189793e-05
the O 0 3.7895363220741274e-06
genomic O 0 5.1342035476409364e-06
structure O 0 7.917798939161003e-06
of O 0 4.501830972003518e-06
the O 0 2.462320253471262e-06
COL4A4 O 0 0.00010898085020016879
gene O 0 1.43045184586299e-07
and O 0 3.091870226512583e-08
of O 0 2.716903111377178e-07
novel O 0 2.2877186438563513e-06
mutations O 0 4.9915430281544104e-05
causing O 0 0.009663697332143784
autosomal B-Disease 1 0.9999996423721313
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 5.246166983852163e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.494290624279529e-05
a O 0 2.8818834834964946e-05
progressive O 1 0.9974641799926758
hematuric B-Disease 1 0.9999992847442627
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.9987596273422241
by O 0 0.00031225569546222687
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.964423656463623
abnormalities I-Disease 1 0.9999990463256836
and O 0 5.891376076760935e-06
associated O 0 1.2892420500065782e-06
with O 0 1.2048323583258025e-07
mutations O 0 2.592175576410227e-07
in O 0 3.5041111914324574e-06
either O 0 6.098403559917642e-07
the O 0 7.3218079705839045e-06
COL4A3 O 0 0.00014213583199307323
or O 0 1.7079838698919048e-06
the O 0 2.5024655769811943e-06
COL4A4 O 0 1.6411977412644774e-05
gene O 0 1.8807165247380908e-07
, O 0 3.019412275762079e-08
which O 0 3.1710293058040406e-08
encode O 0 5.133167135795702e-08
the O 0 7.595086231049208e-07
alpha3 O 0 1.4884712982166093e-05
and O 0 6.572730626430712e-07
alpha4 O 0 5.180632069823332e-05
type O 0 4.4627548049902543e-05
IV O 1 0.9999992847442627
collagen O 1 0.7081591486930847
chains O 0 0.00012423141743056476
, O 0 6.773498739676143e-07
respectively O 0 3.5204534469812643e-06
. O 0 7.205684369182563e-07

To O 0 1.460204384784447e-05
date O 0 1.635544867895078e-05
, O 0 2.716597293783707e-07
mutation O 0 1.7051864631412172e-07
screening O 0 4.4689139144793444e-07
in O 0 1.477391606385936e-06
the O 0 2.424945932943956e-06
two O 0 5.100594648865808e-07
genes O 0 5.960395697002241e-07
has O 0 1.4220773891793215e-06
been O 0 1.3649092807099805e-06
hampered O 0 4.6266213757917285e-06
by O 0 5.121509971672822e-08
the O 0 7.214142527800504e-08
lack O 0 1.2807394966785068e-07
of O 0 6.265962610996212e-07
genomic O 0 2.7247911020822357e-06
structure O 0 6.023381956765661e-06
information O 0 1.044391751747753e-06
. O 0 1.6930380297708325e-06

We O 0 4.480237475945614e-05
report O 0 5.40528480996727e-06
here O 0 8.558421882298717e-07
the O 0 5.145489012647886e-07
complete O 0 1.2936956181874848e-06
characterization O 0 3.2036257380241295e-06
of O 0 1.3603840670839418e-05
the O 0 9.379390576214064e-06
48 O 0 1.1628791980911046e-05
exons O 0 4.303940386307659e-06
of O 0 2.1987643776810728e-05
the O 0 4.5298791519599035e-05
COL4A4 O 0 0.0006090134847909212
gene O 0 1.8821748426489648e-06
, O 0 1.152282536054372e-07
a O 0 2.0741063622153888e-07
comprehensive O 0 1.8100665784004377e-06
gene O 0 6.402247549885942e-07
screen O 0 2.299916332049179e-06
, O 0 1.1404142696846975e-07
and O 0 1.3770009132940686e-08
the O 0 6.477380765090857e-08
subsequent O 0 4.7035996431077365e-08
detection O 0 8.363652881371308e-08
of O 0 2.1991598941895063e-07
10 O 0 1.7124676787716453e-07
novel O 0 9.19196736504091e-08
mutations O 0 3.0740299195031184e-08
in O 0 5.229150801255855e-08
eight O 0 5.597842118731933e-07
patients O 0 4.271127181709744e-06
diagnosed O 0 0.04236755520105362
with O 0 2.4000978555704933e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 5.1104296289850026e-05

Furthermore O 0 7.345889753196388e-05
, O 0 3.3906574117281707e-06
we O 0 4.1676958062453195e-07
identified O 0 5.375625278247753e-07
a O 0 7.736529710200557e-07
glycine O 0 1.7082021486203303e-06
to O 0 3.5640337614495365e-07
alanine O 0 2.9853649721189868e-06
substitution O 0 1.7346554841424222e-06
in O 0 1.950135583683732e-06
the O 0 5.017930561734829e-06
collagenous O 0 4.1087645513471216e-05
domain O 0 3.4852512271754676e-06
that O 0 3.384695332897536e-07
is O 0 2.539988201988308e-07
apparently O 0 6.56700990475656e-07
silent O 0 1.3254841633170145e-06
in O 0 1.4582616358893574e-07
the O 0 3.7319560419746267e-07
heterozygous O 0 7.570514526378247e-08
carriers O 0 9.301950854023744e-08
, O 0 3.6265443981164935e-08
in O 0 1.7851614586561482e-07
11 O 0 2.1796113287564367e-06
. O 0 8.780424423093791e-07

5 O 0 4.209953112876974e-05
% O 0 2.451092996125226e-06
of O 0 5.068623067927547e-06
all O 0 8.231189667640137e-07
control O 0 2.8473680231400067e-06
individuals O 0 7.95063144209962e-08
, O 0 6.984282663324848e-08
and O 0 2.904033813422302e-08
in O 0 2.6299699129594956e-07
one O 0 5.595067520403063e-08
control O 0 7.348911879034858e-08
individual O 0 8.842119036955864e-09
homozygous O 0 6.829978360656241e-08
for O 0 5.5729888259747895e-08
this O 0 7.270973156892069e-08
glycine O 0 1.2527334547485225e-06
substitution O 0 2.3812542622181354e-06
. O 0 3.362313520938187e-07

There O 0 5.9627160226227716e-05
has O 0 3.957048647862393e-06
been O 0 2.0223505998728797e-06
no O 0 6.280644129219581e-07
previous O 0 1.5585342225676868e-06
finding O 0 2.373581367010047e-07
of O 0 3.829915840469766e-06
a O 0 2.6329462343710475e-06
glycine O 0 4.7440453272429295e-06
substitution O 0 9.588725333742332e-07
that O 0 5.330425878469214e-08
is O 0 4.492419947155213e-08
not O 0 7.066891516416263e-09
associated O 0 3.119528102502045e-08
with O 0 1.1301090729887164e-08
any O 0 1.0180325915598587e-07
obvious O 0 7.420335919050558e-07
phenotype O 0 1.068760298039706e-06
in O 0 2.2216711670353106e-07
homozygous O 0 5.443349664346897e-07
individuals O 0 8.384784422332814e-08
. O 0 6.870907327538589e-07

Founder O 0 0.002462316071614623
BRCA1 O 0 4.6789951738901436e-05
and O 0 1.165126491287083e-06
BRCA2 O 0 2.6440632154844934e-06
mutations O 0 1.0948384243647524e-07
in O 0 1.215124143527646e-07
French O 0 1.0439673133078031e-05
Canadian O 0 0.05215149372816086
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.844649199891137e-06
. O 0 1.5002235613792436e-06

We O 0 2.634577867866028e-05
have O 0 9.1628373866115e-07
identified O 0 1.6093959231966437e-07
four O 0 7.594117334974726e-08
mutations O 0 5.263081703787975e-08
in O 0 1.246922352038382e-07
each O 0 2.035370449959828e-08
of O 0 7.864562576287426e-06
the O 0 0.0008678941521793604
breast B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999995231628418
- O 1 0.8046337962150574
susceptibility O 0 0.0002012473123613745
genes O 0 1.3259557363198837e-06
, O 0 3.375724020315829e-07
BRCA1 O 0 8.80329821484338e-07
and O 0 1.160874774086551e-07
BRCA2 O 0 3.2626408597025147e-07
, O 0 6.001460661764213e-09
in O 0 1.3638792317749449e-08
French O 0 8.262121014013246e-07
Canadian O 0 3.11963158310391e-05
breast B-Disease 1 0.9995276927947998
cancer I-Disease 1 0.9882931113243103
and O 0 0.0004999632947146893
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.945615602191538e-07
from O 0 2.09740369427891e-06
Quebec O 0 1.0319977263861801e-05
. O 0 2.6952402549795806e-06

To O 0 4.345035267760977e-05
identify O 0 2.3531469196313992e-05
founder O 0 0.0010757712880149484
effects O 0 0.00014454062329605222
, O 0 9.947531225407147e-07
we O 0 6.231387317257031e-08
examined O 0 2.1924064697032009e-07
independently O 0 5.759366672464239e-08
ascertained O 0 1.4538918549078517e-06
French O 0 1.1636957424343564e-05
Canadian O 0 2.61185341514647e-05
cancer B-Disease 0 2.2206333596841432e-05
families O 0 2.912276642064171e-08
for O 0 1.6823552329015e-08
the O 0 5.743361697341243e-08
distribution O 0 6.794091689243942e-08
of O 0 2.3066546361860674e-07
these O 0 2.7339112307345204e-08
eight O 0 8.764345125200634e-07
mutations O 0 6.992372618697118e-07
. O 0 2.7420167043601396e-06

Mutations O 0 3.583910802262835e-05
were O 0 6.935867077118019e-06
found O 0 2.2648718811524304e-07
in O 0 1.1271452393657455e-07
41 O 0 8.633570018901082e-07
of O 0 1.844739244916127e-06
97 O 0 4.037212420371361e-05
families O 0 6.673180337202211e-07
. O 0 2.1744706373283407e-06

Six O 0 6.560644396813586e-05
of O 0 1.292914203077089e-05
eight O 0 1.6413181356256246e-06
mutations O 0 2.0020122803998674e-07
were O 0 9.247656862498843e-07
observed O 0 6.161457122288994e-07
at O 0 2.017369070017594e-06
least O 0 1.0661689486823889e-07
twice O 0 1.4853694665362127e-06
. O 0 6.175328621793597e-07

The O 0 0.00033917531254701316
BRCA1 O 0 0.00024135496641974896
C4446T O 0 0.00031435582786798477
mutation O 0 7.009283763181884e-06
was O 0 6.898283027112484e-05
the O 0 1.9273643374617677e-06
most O 0 7.653547839936437e-08
common O 0 7.535134471936544e-08
mutation O 0 6.320855305830264e-08
found O 0 8.564768450014526e-08
, O 0 1.4211452459278462e-08
followed O 0 6.86793981685696e-08
by O 0 4.785121632266964e-08
the O 0 7.446195695592905e-07
BRCA2 O 0 7.307465693884296e-06
8765delAG O 0 1.941977461683564e-05
mutation O 0 2.6912798603007104e-06
. O 0 2.1620064671878936e-06

Together O 0 2.399035838607233e-05
, O 0 1.4242762063076952e-06
these O 0 7.203815499678967e-08
mutations O 0 1.6506707822827593e-07
were O 0 1.0743430038928636e-06
found O 0 8.590798472596362e-08
in O 0 2.2497383156405704e-07
28 O 0 1.9621609226305736e-06
of O 0 1.9285430425952654e-06
41 O 0 4.069534952577669e-06
families O 0 4.449687196483865e-08
identified O 0 7.475982499727252e-08
to O 0 4.484757454292776e-08
have O 0 1.1338338623545496e-07
a O 0 7.427621540045948e-07
mutation O 0 1.3141385579729103e-06
. O 0 2.020544116021483e-06

The O 0 0.00010859991743927822
odds O 0 2.3561377020087093e-05
of O 0 4.758509021485224e-06
detection O 0 3.4425056583131664e-06
of O 0 5.932522071816493e-06
any O 0 4.975008778274059e-07
of O 0 1.3213343663665e-05
the O 0 4.309107225708431e-06
four O 0 7.745048833385226e-07
BRCA1 O 0 9.04559101400082e-07
mutations O 0 4.1058959254769434e-07
was O 0 2.3811000573914498e-05
18 O 0 4.428158717928454e-06
. O 0 6.683594051537511e-07

7x O 0 0.052762240171432495
greater O 0 4.3889966036658734e-05
if O 0 2.3648130991205107e-06
one O 0 4.6866517777743866e-07
or O 0 9.10856030600371e-08
more O 0 3.797323344656434e-09
cases O 0 2.1302308539361547e-07
of O 1 0.9976323843002319
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.0001725369947962463
also O 0 2.651385671015305e-07
present O 0 1.1363648155793271e-07
in O 0 3.338706733302388e-07
the O 0 1.3701599073101534e-06
family O 0 9.13791382117779e-07
. O 0 1.537919501970464e-06

The O 0 0.00011917711526621133
odds O 0 2.8331820431048982e-05
of O 0 7.411308160953922e-06
detection O 0 3.2855637073225807e-06
of O 0 5.533572220883798e-06
any O 0 5.565456717704365e-07
of O 0 1.878181501524523e-05
the O 0 9.733784281706903e-06
four O 0 2.313904133188771e-06
BRCA2 O 0 2.984858156196424e-06
mutations O 0 5.768496293967473e-07
was O 0 1.706978218862787e-05
5 O 0 3.812809381997795e-06
. O 0 1.5985839354470954e-06

3x O 0 0.00348339113406837
greater O 0 4.328377326601185e-05
if O 0 1.7261008906643838e-06
there O 0 5.777906153525691e-07
were O 0 1.0409225978946779e-06
at O 0 3.4832333994927467e-07
least O 0 4.60114568667791e-09
five O 0 1.5307328737890202e-08
cases O 0 2.260111564567069e-08
of O 0 8.723362952878233e-06
breast B-Disease 1 0.9998691082000732
cancer I-Disease 1 0.9991864562034607
in O 0 2.4713241145946085e-05
the O 0 2.3946151486597955e-05
family O 0 3.7603688269882696e-06
. O 0 2.1344310425774893e-06

Interestingly O 0 0.00023346461239270866
, O 0 2.774410177153186e-06
the O 0 6.617745498260774e-07
presence O 0 2.862438464035222e-07
of O 0 4.628422175301239e-06
a O 0 1.645654992898926e-05
breast B-Disease 0 0.4278521239757538
cancer I-Disease 0 0.1922541707754135
case O 0 9.578831850376446e-06
< O 0 2.074077565339394e-05
36 O 0 3.3204403280251427e-06
years O 0 6.748963983227441e-07
of O 0 2.5926278794941027e-06
age O 0 2.5880997327476507e-06
was O 0 4.484613327804254e-06
strongly O 0 1.0909507608403146e-07
predictive O 0 2.8007391961182293e-07
of O 0 6.143385462564765e-07
the O 0 2.8728609891004453e-07
presence O 0 8.732244083375917e-08
of O 0 5.210990252635384e-07
any O 0 4.061877945105152e-08
of O 0 8.955173598224064e-07
the O 0 4.828754072150332e-07
eight O 0 2.7529665658221347e-07
mutations O 0 2.087735850864192e-07
screened O 0 4.244692718202714e-06
. O 0 1.980361957976129e-06

Carriers O 0 4.196861482341774e-05
of O 0 2.6868132408708334e-05
the O 0 4.39711038779933e-06
same O 0 6.570142545569979e-07
mutation O 0 2.8133050022915995e-07
, O 0 1.0728086863309727e-07
from O 0 6.184049539115222e-08
different O 0 2.136762544679982e-09
families O 0 1.2534196791591512e-08
, O 0 1.6029128246941582e-08
shared O 0 2.6079799653189184e-08
similar O 0 3.685664040631309e-08
haplotypes O 0 1.7432759022995015e-06
, O 0 1.668135496402101e-07
indicating O 0 1.7031790093824384e-06
that O 0 7.86488669746177e-08
the O 0 7.823881560398149e-07
mutant O 0 2.0671802758442936e-06
alleles O 0 4.4048147174180485e-07
were O 0 1.302635382671724e-06
likely O 0 8.657021055569203e-08
to O 0 1.6292949212015628e-08
be O 0 1.9196908951357727e-08
identical O 0 3.115764002359356e-08
by O 0 7.190678985580234e-08
descent O 0 2.0294760361139197e-06
for O 0 6.467209345828451e-08
a O 0 2.425759362267854e-07
mutation O 0 1.7505450955468405e-07
in O 0 6.145002657831355e-07
the O 0 3.143751200695988e-06
founder O 0 2.0408093405421823e-05
population O 0 1.9729561984149768e-07
. O 0 1.0854521406145068e-06

The O 0 5.957951088930713e-06
identification O 0 7.54000723190984e-07
of O 0 3.0628802960563917e-06
common O 0 2.907303951360518e-06
BRCA1 O 0 3.6313635064288974e-05
and O 0 2.4619798750791233e-06
BRCA2 O 0 6.870992820040556e-06
mutations O 0 9.292375580116641e-08
will O 0 1.624671241984288e-08
facilitate O 0 6.01838223701634e-08
carrier O 0 7.661741108222486e-08
detection O 0 7.256370793129463e-08
in O 0 5.724561447095766e-08
French O 0 6.736220257153036e-06
Canadian O 0 0.00010254577500745654
breast B-Disease 1 0.999872088432312
cancer I-Disease 1 0.9944770932197571
and O 0 0.0004925909452140331
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.665655418037204e-06
. O 0 1.2244751133039244e-06

Are O 0 4.154785710852593e-05
Dp71 O 0 0.0008290762780234218
and O 0 1.290048112423392e-05
Dp140 O 0 0.001747522852383554
brain O 0 0.0033632770646363497
dystrophin O 0 6.907887291163206e-05
isoforms O 0 1.1249561566728516e-06
related O 0 4.899896453025576e-07
to O 0 2.5563599592715036e-07
cognitive B-Disease 0 0.0034453049302101135
impairment I-Disease 1 0.9999997615814209
in O 0 0.4727523922920227
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 3.2177355024032295e-05

Molecular O 0 0.0007435214356519282
study O 0 1.3347796993912198e-05
and O 0 1.0695780474634375e-06
neuropsychological O 0 9.797992788662668e-06
analysis O 0 2.7554435177989944e-07
were O 0 4.0007813595366315e-07
performed O 0 1.5884234016994014e-07
concurrently O 0 3.620511108692881e-07
on O 0 1.0984502978317323e-06
49 O 0 5.003857040719595e-06
patients O 0 9.770267297426471e-07
with O 0 6.839768957433989e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
( O 0 1.9009530660696328e-05
DMD B-Disease 1 0.9999997615814209
) O 0 8.060677458843202e-08
in O 0 2.0198584138597653e-08
order O 0 1.6157065019228867e-08
to O 0 7.831382653478158e-09
find O 0 8.480220081708012e-09
a O 0 3.041649065949059e-08
molecular O 0 1.4629210909333779e-07
explanation O 0 5.68130218425722e-08
for O 0 7.102433130512509e-08
the O 0 1.1409880471546785e-06
cognitive B-Disease 0 5.0592680054251105e-05
impairment I-Disease 0 0.007286241743713617
observed O 0 1.5584064385620877e-06
in O 0 1.6447245343442773e-06
most O 0 2.7781138669524807e-06
DMD B-Disease 1 1.0
patients O 0 1.2626233910850715e-05
. O 0 2.3972704639163567e-06

Complete O 0 6.1693528550677e-05
analysis O 0 5.070441147836391e-06
of O 0 1.504350257164333e-05
the O 0 6.449196916946676e-06
dystrophin O 0 1.2525384590844624e-05
gene O 0 1.4153583833831362e-06
was O 0 1.2752473594446201e-05
performed O 0 5.762805699305318e-07
to O 0 9.720881877228749e-08
define O 0 2.704943256048864e-07
the O 0 2.8398155791364843e-06
localization O 0 1.8349612219026312e-05
of O 0 4.460799573280383e-06
deletions O 0 3.0694095585204195e-06
and O 0 5.238914582150755e-07
duplications O 0 1.4176521290210076e-06
in O 0 2.966705210383225e-07
relation O 0 1.8702047555052559e-06
to O 0 1.7952274333765672e-07
the O 0 8.619452955827001e-07
different O 0 6.286510938480205e-07
DMD B-Disease 1 1.0
promoters O 0 0.00029182989965192974
. O 0 8.609253200120293e-06

Qualitative O 0 0.00011848410940729082
analysis O 0 2.6843108571483754e-05
of O 0 2.27406471822178e-05
the O 0 1.4696117432322353e-05
Dp71 O 0 8.681283361511305e-05
transcript O 0 1.421596243744716e-05
and O 0 5.330120984581299e-07
testing O 0 2.604409132800356e-07
for O 0 1.8998467510300543e-07
the O 0 8.507277584612893e-07
specific O 0 9.243480292298045e-08
first O 0 4.663317668018863e-06
exon O 0 1.985376911761705e-06
of O 0 6.951534942345461e-06
Dp140 O 0 2.0570681954268366e-05
were O 0 2.6202062599622877e-06
also O 0 3.823212466613768e-07
carried O 0 8.680314635967079e-07
out O 0 8.800527666608104e-07
. O 0 1.2059857681379071e-06

Neuropsychological O 0 0.0009802515851333737
analysis O 0 9.718221917864867e-06
assessed O 0 3.308698069304228e-05
verbal O 0 4.4560434616869316e-05
and O 0 7.322233614104334e-06
visuospatial O 0 0.0016177016077563167
intelligence O 0 7.342721801251173e-06
, O 0 5.10662971464626e-07
verbal O 0 1.5372450434369966e-05
memory O 1 0.8164920210838318
, O 0 4.913438829134975e-07
and O 0 3.332865503580251e-07
reading O 0 3.174879384459928e-05
skills O 0 1.8345412172493525e-05
. O 0 4.2951573959726375e-06

Comparison O 0 9.186948591377586e-05
of O 0 2.4721493900869973e-05
molecular O 0 6.930519157322124e-05
and O 0 5.658101144945249e-06
psychometric O 0 0.00019639451056718826
findings O 0 4.369854195829248e-06
demonstrated O 0 1.027008329401724e-05
that O 0 5.247134708952217e-07
deletions O 0 3.083113369939383e-06
and O 0 6.712978688483417e-07
duplications O 0 5.369771315599792e-06
that O 0 1.1415460221542162e-07
were O 0 7.535637109867821e-07
localized O 0 1.1675213045236887e-06
in O 0 2.36603113989986e-06
the O 0 7.4622867032303475e-06
distal O 0 4.217057357891463e-05
part O 0 3.3154658467537956e-06
of O 0 4.243958028382622e-05
the O 0 1.3867729649064131e-05
gene O 0 1.4919423847459257e-06
seemed O 0 7.557861181339831e-07
to O 0 2.46051179431106e-08
be O 0 2.561334966344475e-08
preferentially O 0 6.703024979515249e-08
associated O 0 7.925044798184899e-08
with O 0 1.4316938745650987e-07
cognitive B-Disease 0 0.0007102011586539447
impairment I-Disease 1 0.9995483756065369
. O 0 3.957531589549035e-06

Two O 0 9.399482951266691e-05
altered O 0 5.9005964430980384e-05
Dp71 O 0 0.00020508548186626285
transcripts O 0 3.678132270579226e-05
and O 0 1.2140242233726894e-06
two O 0 5.25837606346613e-07
deleted O 0 1.88526826150337e-06
Dp140 O 0 4.953806637786329e-06
DNA O 0 1.0661770488695765e-07
sequences O 0 4.6257866870291764e-08
were O 0 1.051531057782995e-07
found O 0 1.915104874683493e-08
in O 0 1.8937139856234353e-08
four O 0 6.495344706536343e-08
patients O 0 5.482617098095943e-07
with O 0 3.331713514853618e-06
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 5.6273122027050704e-05

These O 0 1.2790694199793506e-05
findings O 0 5.899460575164994e-06
suggest O 0 1.4072935528020025e-06
that O 0 7.04216276403713e-08
some O 0 2.3783730540571923e-08
sequences O 0 7.885569885957011e-08
located O 0 1.5669562571929418e-06
in O 0 6.108368211243942e-07
the O 0 1.2812602108169813e-06
distal O 0 2.2720982997270767e-06
part O 0 5.883537710360542e-07
of O 0 1.1602804988797288e-05
the O 0 4.573884325509425e-06
gene O 0 1.6285066806176474e-07
and O 0 1.4061288311495446e-07
, O 0 3.7266776331534857e-08
in O 0 5.513285117331179e-08
particular O 0 6.573590383140981e-08
, O 0 4.329507774514241e-08
some O 0 3.520428748515769e-08
DMD B-Disease 1 0.9983806610107422
isoforms O 0 6.171966902002168e-07
expressed O 0 4.340724331086676e-07
in O 0 1.0703698762881686e-06
the O 0 3.986981482739793e-06
brain O 0 8.0769372289069e-05
may O 0 3.1596675853506895e-07
be O 0 2.7208175268356172e-08
related O 0 4.006783527188418e-08
to O 0 3.864709086087714e-08
the O 0 1.5892400142547558e-06
cognitive B-Disease 0 0.003594777313992381
impairment I-Disease 1 0.9999896287918091
associated O 0 2.5547748009557836e-05
with O 0 1.4842924429103732e-05
DMD B-Disease 1 1.0
. O 0 3.092259476034087e-06
. O 0 1.929976178871584e-06

I1307K O 0 0.008070467971265316
APC O 0 0.0016238248208537698
and O 0 1.3723982192459516e-05
hMLH1 O 0 3.6436747905099764e-05
mutations O 0 3.6117764921073103e-06
in O 0 2.009617219300708e-06
a O 0 3.3576043279026635e-06
non O 0 4.930862269247882e-05
- O 0 9.578822755429428e-06
Jewish O 0 1.1043892982343095e-06
family O 0 1.1701514779360878e-07
with O 0 6.396376051043262e-08
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.922598938923329e-05

We O 0 6.959873644518666e-06
describe O 0 1.4488730357697932e-06
a O 0 8.078945938905235e-07
French O 0 9.991409569920506e-06
Canadian O 0 4.1896793845808133e-05
hereditary B-Disease 1 0.9999997615814209
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.0005209945375099778
HNPCC B-Disease 1 0.9998561143875122
) O 0 4.120095411508373e-07
kindred O 0 2.7880616926267976e-06
which O 0 4.67920706626046e-08
carries O 0 1.0214674972530702e-07
a O 0 3.785812197065752e-08
novel O 0 1.1783509989982122e-07
truncating O 0 1.2748247399940738e-06
mutation O 0 2.0320894122960453e-07
in O 0 6.446678639804304e-07
hMLH1 O 0 1.3455638509185519e-05
. O 0 1.5798167396496865e-06

Interestingly O 0 0.0002554344537202269
, O 0 1.3753043276665267e-05
the O 0 9.45632655202644e-06
I1307K O 0 0.00012556948058772832
APC O 0 2.369888716202695e-05
polymorphism O 0 2.328694108655327e-06
, O 0 1.6375862799122842e-07
associated O 0 4.24261017428762e-08
with O 0 5.677496695000173e-09
an O 0 6.296188814758352e-08
increased O 0 8.014348168217111e-06
risk O 0 0.000638090365100652
of O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.376999186206376e-06
is O 0 9.778286624850807e-08
also O 0 1.8964936288057288e-08
present O 0 2.0115848542445747e-08
in O 0 1.3049252345354034e-07
this O 0 1.417472219600313e-07
family O 0 6.505015903712774e-07
. O 0 1.3773194496025098e-06

The O 0 0.00013380093150772154
I1307K O 0 0.0001664586889091879
polymorphism O 0 9.098713235289324e-06
has O 0 2.4917017071857117e-06
previously O 0 8.184435387192934e-07
only O 0 5.6364338973935446e-08
been O 0 3.645745323410665e-07
identified O 0 7.819280511967008e-08
in O 0 1.2961923800958175e-07
individuals O 0 3.853484642490912e-08
of O 0 3.4638385386642767e-06
self O 0 2.6950456231134012e-05
- O 0 0.00012028389028273523
reported O 0 3.5833209039992653e-06
Ashkenazi O 0 1.2097237913621939e-06
Jewish O 0 1.4340854477268294e-06
origins O 0 1.6099190816021292e-06
. O 0 9.398214615430334e-07

In O 0 5.8858950069407e-05
addition O 0 5.145575869391905e-06
, O 0 6.079582703932829e-07
in O 0 3.690173571158084e-07
this O 0 2.3992984665710537e-07
family O 0 2.465162936005072e-07
, O 0 1.4724696484336164e-07
there O 0 1.490138004101027e-07
appears O 0 2.5412722948203736e-07
to O 0 7.416388569936316e-08
be O 0 2.420128168978408e-07
no O 0 2.2967503809923073e-07
relationship O 0 3.167584168295434e-07
between O 0 1.4677173112431774e-06
the O 0 2.7982105166302063e-06
I1307K O 0 1.8971450117533095e-06
polymorphism O 0 1.7739877478106791e-07
and O 0 1.0341747724851302e-07
the O 0 3.2174756370295654e-07
presence O 0 4.312933299388533e-07
or O 0 6.653436912529287e-07
absence O 0 2.4448738713545026e-06
of O 0 2.807298415063997e-06
cancer B-Disease 0 2.4616541850264184e-05
. O 0 1.694658493534007e-07
. O 0 5.824122126796283e-07

Identification O 0 6.529842266900232e-06
of O 0 4.049218205182115e-06
a O 0 1.3863796084478963e-06
novel O 0 8.34018578643736e-07
mutation O 0 3.1134118216868956e-07
of O 0 6.329375992208952e-06
the O 0 1.3951724213256966e-05
CPO O 0 0.0003189383423887193
gene O 0 3.522289659940725e-07
in O 0 3.501104401948396e-07
a O 0 1.121470518228307e-06
Japanese O 0 2.0789097106899135e-05
hereditary B-Disease 1 0.9999408721923828
coproporphyria I-Disease 1 0.9290102124214172
family O 0 1.0647078852343839e-05
. O 0 3.3905248528753873e-06

Hereditary B-Disease 1 0.9999997615814209
coproporphyria I-Disease 1 0.9999959468841553
( O 0 0.0006212299922481179
HCP B-Disease 1 0.9999979734420776
) O 0 4.22298626290285e-06
is O 0 3.845643163913337e-07
an O 0 8.74584316079563e-07
autosomal B-Disease 1 0.9999290704727173
dominant I-Disease 1 0.9999974966049194
disease I-Disease 1 1.0
characterized O 0 0.0007394158164970577
by O 0 2.5214289962605108e-06
a O 0 2.459136703691911e-05
deficiency B-Disease 1 0.9999967813491821
of I-Disease 1 0.9984791874885559
coproporphyrinogen I-Disease 1 0.9892702102661133
oxidase I-Disease 0 9.316821524407715e-05
( O 0 7.077401278365869e-07
CPO O 0 7.856560114305466e-05
) O 0 7.164161530681668e-08
caused O 0 2.2633324192611326e-07
by O 0 2.1147313233882414e-08
a O 0 5.380785239594843e-08
mutation O 0 6.58229666328225e-08
in O 0 4.5024435735285806e-07
the O 0 3.516507831591298e-06
CPO O 0 0.00025631856988184154
gene O 0 2.259395387227414e-06
. O 0 2.3306338334805332e-06

Only O 0 1.6505653547937982e-05
11 O 0 1.2317177606746554e-05
mutations O 0 5.41705276191351e-07
of O 0 3.525866304698866e-06
the O 0 1.8859246893043746e-06
gene O 0 3.360127038831706e-07
have O 0 1.403612799322218e-07
been O 0 3.618895618728857e-07
reported O 0 5.017644184590608e-07
in O 0 1.7819209006120218e-06
HCP B-Disease 1 0.9998403787612915
patients O 0 7.488406936317915e-06
. O 0 2.789838390526711e-06

We O 0 3.336371810291894e-05
report O 0 1.9258284282841487e-06
another O 0 2.5493312705293647e-07
mutation O 0 1.348712714843714e-07
in O 0 3.0304613574116956e-07
a O 0 7.532633503615216e-07
Japanese O 0 6.308056072157342e-06
family O 0 2.0408515410963446e-06
. O 0 1.6014663515306893e-06

Polymerase O 0 0.01200579572468996
chain O 0 0.0003959913447033614
reaction O 0 1.839393917180132e-05
- O 0 9.682752533990424e-06
single O 0 3.7920131035207305e-07
strand O 0 8.88185866187996e-07
conformational O 0 1.7630266313517495e-07
polymorphism O 0 4.842543077643313e-08
and O 0 2.3726730802309248e-08
direct O 0 6.467332269721737e-08
sequence O 0 1.1669663990687695e-07
analyses O 0 1.7747474601037538e-07
demonstrated O 0 1.4804196553086513e-06
a O 0 1.9387239262869116e-06
C O 0 6.429753284464823e-06
to O 0 2.6806549158209236e-07
T O 0 1.3294262544150115e-06
substitution O 0 1.678354522027803e-07
in O 0 9.280154245061567e-08
exon O 0 1.5162322597461753e-07
1 O 0 2.0872381867320655e-07
of O 0 7.108571367098193e-07
the O 0 1.4790340401305002e-06
CPO O 0 2.095915624522604e-05
gene O 0 2.07405690844098e-07
at O 0 2.1961827769700903e-06
nucleotide O 0 5.901447366341017e-07
position O 0 2.09485688174027e-06
85 O 0 1.7807572021411033e-06
, O 0 6.49380851314163e-08
which O 0 7.416431202500462e-08
lies O 0 4.590822015870799e-07
in O 0 1.9908020476577803e-07
the O 0 7.29908265384438e-07
putative O 0 4.651236395147862e-06
presequence O 0 3.7676343254133826e-06
for O 0 9.026548042356808e-08
targeting O 0 1.1033449709429988e-06
to O 0 6.316811891338148e-07
mitochondria O 0 1.920418617373798e-05
. O 0 3.246864935135818e-06

This O 0 5.335823971108766e-06
mutation O 0 1.4244662907003658e-06
changes O 0 7.692768804190564e-07
the O 0 1.7850113636086462e-06
codon O 0 3.41232316714013e-06
for O 0 2.2725267001533211e-07
glutamine O 0 2.8307420052442467e-07
to O 0 6.469701219202761e-08
a O 0 3.3910151842064806e-07
termination O 0 5.736918865295593e-06
codon O 0 1.1394231478334405e-05
at O 0 1.807826447475236e-05
amino O 0 2.4171006316464627e-06
acid O 0 1.078028503798123e-06
position O 0 4.457393515622243e-06
29 O 0 3.719834057847038e-05
. O 0 1.4026013559487183e-06

MaeI O 0 0.007126717362552881
restriction O 0 0.00021850940538570285
analysis O 0 7.82415099820355e-06
showed O 0 9.229012903233524e-06
two O 0 5.378670948630315e-07
other O 0 6.622354931096197e-08
carriers O 0 1.6313698836256663e-07
in O 0 3.934715664399846e-07
the O 0 1.9142248675052542e-06
family O 0 1.8658827229955932e-06
. O 0 2.1997295789333293e-06

The O 0 0.00026627545594237745
C O 0 0.0027264924719929695
- O 0 0.00048152622184716165
T O 0 6.865103205200285e-05
mutation O 0 1.7330735602172354e-07
is O 0 1.0315998366650092e-07
located O 0 3.6985693441238254e-07
within O 0 2.7409388536625556e-08
a O 0 1.1103162478320883e-07
recently O 0 1.9236608750361484e-07
proposed O 0 2.1269727312756004e-07
putative O 0 1.185889004773344e-06
alternative O 0 2.939452201644599e-07
translation O 0 1.1461989970484865e-06
initiation O 0 1.2201319350424455e-06
codon O 0 3.067990292038303e-06
( O 0 7.757913067507616e-08
TIC O 0 9.142725616584357e-07
- O 0 1.7685164266367792e-07
1 O 0 1.987874753694996e-07
) O 0 1.566101026639899e-08
, O 0 1.5887803073155737e-08
supporting O 0 1.1567085778096953e-07
that O 0 2.548434281379741e-07
TIC O 0 9.44988914852729e-06
- O 0 1.2528195156846778e-06
1 O 0 8.927512453738018e-07
is O 0 1.546640078231576e-07
the O 0 5.968011578261212e-07
real O 0 5.366162440623157e-06
TIC O 0 2.411610694252886e-05
rather O 0 3.4178393093498016e-07
than O 0 2.6416734044687473e-07
TIC O 0 6.862990176159656e-06
- O 0 1.0819030649145134e-06
2 O 0 4.3972596586172585e-07
. O 0 3.820937521936685e-08
. O 0 4.038101906189695e-07

Human B-Disease 0 8.689353308000136e-06
complement I-Disease 0 5.094542575534433e-05
factor I-Disease 0 0.009279675781726837
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 3.453171666478738e-05
with O 0 0.00027071908698417246
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.3731097877025604

This O 0 5.781605068477802e-06
study O 0 1.9001254258910194e-06
reports O 0 8.816656986709859e-07
on O 0 2.1752507564087864e-06
six O 0 6.077015086702886e-07
cases O 0 5.989616056467639e-07
of O 0 0.0006196200847625732
deficiency B-Disease 1 0.9999991655349731
in I-Disease 0 2.5560833819326945e-05
the I-Disease 0 5.628619419439929e-06
human I-Disease 0 6.232236842151906e-07
complement I-Disease 0 5.893753041164018e-07
regulatory I-Disease 0 1.9423455341893714e-06
protein I-Disease 0 3.919602932000998e-06
Factor I-Disease 0 1.69740233104676e-05
H I-Disease 1 0.9758774042129517
( O 0 5.30225690908992e-07
FH O 0 7.4202189352945425e-06
) O 0 1.2370460211741374e-08
in O 0 6.415066700071748e-09
the O 0 1.1722285364612617e-08
context O 0 1.8199134643737125e-08
of O 0 2.8871514246020524e-07
an O 0 1.1825161891465541e-05
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.025038550840691e-05

Five O 0 4.02412042603828e-05
of O 0 6.714760274917353e-06
the O 0 7.424109185194538e-07
cases O 0 5.0324040046234586e-08
were O 0 5.8359432841825765e-08
observed O 0 5.5998825132519414e-08
in O 0 2.9079027186185158e-08
children O 0 4.598323144477945e-08
presenting O 0 1.461844334471607e-07
with O 0 2.5015160645125434e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9865099787712097
HUS B-Disease 1 1.0
) O 0 1.2925985174661037e-05
. O 0 3.987597665400244e-06

Two O 0 2.6499990781303495e-05
of O 0 1.3191737707529683e-05
the O 0 3.5090104120172327e-06
children O 0 9.328581427325844e-07
exhibited O 0 5.3157640650169924e-05
a O 0 1.3735243555856869e-05
homozygous O 0 7.314942922675982e-05
deficiency O 1 0.9999946355819702
characterized O 0 1.3223391761130188e-05
by O 0 1.3668671954292222e-06
the O 0 2.352843011976802e-06
absence O 0 1.2464231076592114e-05
of O 0 1.5768888260936365e-05
the O 0 2.4310543267347384e-06
150 O 0 6.222574597813946e-07
- O 0 3.382781699201587e-07
kD O 0 7.350915325332608e-07
form O 0 8.755759495215898e-08
of O 0 6.635398221987998e-06
Factor O 0 1.7856849808595143e-05
H O 1 0.9985846281051636
and O 0 6.280009188230906e-07
the O 0 6.095914386605727e-07
presence O 0 2.3513754854320723e-07
, O 0 1.0173745579322713e-07
upon O 0 3.4776505231093324e-07
immunoblotting O 0 3.4104750739061274e-06
, O 0 8.853361777028113e-08
of O 0 6.806789656366163e-07
the O 0 1.5433147382282186e-06
42 O 0 2.741242724368931e-06
- O 0 1.2219064728924423e-06
kD O 0 1.1235955753363669e-05
Factor O 0 5.925018740526866e-06
H O 0 0.0014954878715798259
- O 0 1.9672229427669663e-06
like O 0 1.0646530057556447e-07
protein O 0 2.1029305230513273e-07
1 O 0 1.3380883956415346e-06
( O 0 1.5181421986198984e-07
FHL O 0 4.023980181955267e-06
- O 0 4.3897765067413275e-07
1 O 0 4.012156580301962e-07
) O 0 1.0820538243194733e-08
and O 0 2.5798980729518917e-08
other O 0 4.928578434260089e-08
FH O 0 7.761013876006473e-06
- O 0 1.7546510662214132e-06
related O 0 1.0263307785862708e-06
protein O 0 1.2791601875505876e-06
( O 0 3.1349830464932893e-07
FHR O 0 2.5889741664286703e-05
) O 0 1.7494551229901845e-07
bands O 0 1.4544035593644367e-06
. O 0 7.755232900308329e-07

Southern O 0 0.0001171870026155375
blot O 0 0.00015367752348538488
and O 0 4.220107712171739e-06
PCR O 0 4.982637619832531e-06
analysis O 0 2.8969481036256184e-07
of O 0 1.6758096990088234e-06
DNA O 0 6.214532959347707e-07
of O 0 5.512261850526556e-06
one O 0 1.0706006605687435e-06
patient O 0 3.3848127714009024e-06
with O 0 9.69718371379713e-07
homozygous O 0 0.00030772577156312764
deficiency O 1 0.999995231628418
ruled O 0 2.6979383619618602e-05
out O 0 5.225860491009371e-07
the O 0 3.2494003221472667e-07
presence O 0 2.687266373868624e-07
of O 0 6.782839250263351e-07
a O 0 2.3443112695531454e-07
large O 0 1.7999467161189386e-07
deletion O 0 9.800578482099809e-07
of O 0 4.169602107140236e-06
the O 0 2.5835227006609784e-06
FH O 0 3.9631635445402935e-05
gene O 0 2.5567524630787375e-07
as O 0 1.57324649308066e-07
the O 0 5.338830533219152e-07
underlying O 0 4.718228228739463e-05
defect O 0 2.1791167455376126e-05
for O 0 2.2416436422645347e-06
the O 0 0.00019302204600535333
deficiency O 1 0.9999994039535522
. O 0 2.527926699258387e-05

The O 0 6.950692477403209e-05
other O 0 4.906358412881673e-07
four O 0 2.9576540327980183e-07
children O 0 1.004197400789053e-07
presented O 0 7.387636742350878e-07
with O 0 4.524516441506421e-07
heterozygous O 0 2.62654029938858e-05
deficiency O 1 0.9993809461593628
and O 0 1.3508047231880482e-06
exhibited O 0 0.0001316722045885399
a O 0 4.518144578469219e-06
normal O 0 1.2285912816878408e-05
immunoblotting O 0 1.3960855540062767e-05
pattern O 0 1.617583279767132e-06
of O 0 1.70244493347127e-06
proteins O 0 2.3522906644757313e-07
of O 0 3.3970563890761696e-06
the O 0 1.2460808648029342e-05
FH O 0 0.00030144635820761323
family O 0 2.371647269683308e-06
. O 0 2.1981984446028946e-06

Factor B-Disease 1 0.9997661709785461
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
is O 0 1.5593534499203088e-06
the O 0 5.99149018398748e-07
only O 0 5.245893817118485e-07
complement B-Disease 1 0.9999980926513672
deficiency I-Disease 1 1.0
associated O 0 3.831397043541074e-05
with O 0 7.761413144180551e-06
HUS B-Disease 1 1.0
. O 0 1.3612976545118727e-05

These O 0 2.32317324844189e-06
observations O 0 7.984648618730716e-06
suggest O 0 1.2635415487238788e-06
a O 0 6.709100262014545e-07
role O 0 8.555247177355341e-07
for O 0 7.057888069539331e-07
FH O 0 7.142323738662526e-05
and O 0 1.3030628451815573e-06
/ O 0 1.4855740118946414e-05
or O 0 1.5119609315661364e-06
FH O 0 8.00302077550441e-05
receptors O 0 1.0094801154991728e-06
in O 0 3.036183500171319e-07
the O 0 1.6009304317776696e-06
pathogenesis O 0 0.00017778834444470704
of O 0 6.929355731699616e-05
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 1.2546666994239786e-06
. O 0 9.529406383990136e-07

Further O 0 2.8622960144275567e-06
evidence O 0 4.5788149805048306e-07
for O 0 1.4607685727696662e-07
a O 0 3.1152532642408914e-07
major O 0 1.7205229596584104e-06
ancient O 0 1.789466114132665e-05
mutation O 0 0.000600247411057353
underlying O 1 0.9999984502792358
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.0530667168495711e-05
linkage O 0 1.90955452126218e-05
disequilibrium O 0 2.5257144443457946e-05
studies O 0 4.4680064092972316e-07
in O 0 1.8300293902484555e-07
the O 0 1.6563112126277701e-07
Japanese O 0 4.995680455976981e-07
population O 0 8.674011553466698e-08
. O 0 4.269936368928029e-07

The O 0 0.00956878624856472
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.849004133371636e-05
DM B-Disease 1 1.0
) O 0 9.519051218376262e-07
mutation O 0 2.422007696623041e-07
is O 0 3.185858474807901e-07
an O 0 6.281614446379535e-07
unstable O 0 1.1949167856073473e-05
( O 0 3.2922307013905083e-07
CTG O 0 1.564995000080671e-05
) O 0 1.0213214096665979e-07
n O 0 5.73707666262635e-07
repeat O 0 4.7395005253747513e-07
, O 0 6.759451309790165e-08
present O 0 1.9399951156628958e-07
at O 0 1.7439626844861777e-06
a O 0 1.320335059062927e-07
copy O 0 1.3861995284969453e-07
number O 0 1.1921238751710916e-07
of O 0 1.8233812397738802e-06
5 O 0 1.648028046474792e-06
- O 0 1.0226600579699152e-06
37 O 0 2.1854896203876706e-06
repeats O 0 5.441719963528158e-07
on O 0 2.4014968857954955e-06
normal O 0 1.6365415831387509e-06
chromosomes O 0 6.162585464153381e-07
but O 0 6.638124716573657e-08
amplified O 0 3.30215783606036e-07
to O 0 5.792438528828825e-08
50 O 0 2.7896152232642635e-07
- O 0 2.3403396198773407e-07
3000 O 0 2.5295935301983263e-07
copies O 0 1.4874515841256652e-07
on O 0 5.666287052008556e-06
DM B-Disease 1 0.9997264742851257
chromosomes O 0 8.055349098867737e-06
. O 0 1.912803327286383e-06

Previous O 0 0.00021676796313840896
findings O 0 1.1766584975703154e-05
in O 0 3.2262219065160025e-06
Caucasian O 0 5.042482371209189e-06
populations O 0 4.673721889503213e-07
of O 0 6.0486013353511225e-06
a O 0 0.00012041505397064611
DM B-Disease 1 1.0
founder O 1 0.9932825565338135
chromosome O 0 2.040001709247008e-05
raise O 0 1.5475682175747352e-06
a O 0 5.850208140145696e-07
question O 0 5.587581242139095e-08
about O 0 2.034896873226444e-08
the O 0 7.762234588426509e-08
molecular O 0 1.8762665376925725e-07
events O 0 3.681308058389732e-08
involved O 0 3.034405793300721e-08
in O 0 5.547186532339765e-08
the O 0 2.5027040351233154e-07
expansion O 0 1.9900819552276516e-06
mutation O 0 4.609906056884938e-07
. O 0 1.4708642765981494e-06

To O 0 2.1323934561223723e-05
investigate O 0 5.85430507271667e-06
whether O 0 1.4340977259053034e-06
a O 0 6.018904514348833e-06
founder O 0 2.3802895157132298e-05
chromosome O 0 5.502954536495963e-06
for O 0 1.6034623513405677e-06
the O 0 2.7822827178169973e-05
DM B-Disease 1 1.0
mutation O 0 6.931000484655669e-07
exists O 0 2.1319685572507296e-07
in O 0 4.1778628201427637e-07
the O 0 4.128890509491612e-07
Japanese O 0 1.004183786790236e-06
population O 0 8.89042013341168e-08
, O 0 2.835701806702673e-08
we O 0 1.8933311807245445e-08
genotyped O 0 6.643304573117348e-07
families O 0 2.191076653446089e-08
using O 0 4.2109107312171545e-08
polymorphic O 0 4.191047651147528e-07
markers O 0 2.7266235065326327e-06
near O 0 4.2848201701417565e-05
the O 0 2.1552170892391587e-06
( O 0 2.068669857635541e-07
CTG O 0 9.313486771134194e-06
) O 0 9.722067773054732e-08
n O 0 9.279681876250834e-07
repeat O 0 5.567474090639735e-07
region O 0 3.053787054341228e-07
and O 0 3.457907098436408e-07
constructed O 0 2.88026512862416e-05
haplotypes O 0 2.1431291315821e-05
. O 0 2.277170324305189e-06

Six O 0 2.9858927518944256e-05
different O 0 3.995070017026592e-07
haplotypes O 0 1.8253791495226324e-05
were O 0 6.8028512032469735e-06
found O 0 1.2307738188610529e-06
and O 0 2.3727195639366983e-06
DM B-Disease 1 0.9999998807907104
alleles O 0 3.4629238143679686e-06
were O 0 3.6769754387933062e-06
always O 0 4.753891573727742e-07
haplotype O 0 6.201795713423053e-06
A O 0 5.854645678482484e-06
. O 0 1.4003185242472682e-06

To O 0 1.572481050970964e-05
find O 0 1.1922937801500666e-06
an O 0 6.43536395728006e-07
origin O 0 2.3895913159321935e-07
of O 0 5.334608431439847e-06
the O 0 4.683315182774095e-06
( O 0 4.070720081017498e-07
CTG O 0 1.3363361176743638e-05
) O 0 1.85323173695906e-07
n O 0 1.1097398555648397e-06
repeat O 0 4.952522658641101e-07
mutation O 0 8.564033038283014e-08
and O 0 7.687093983577142e-08
to O 0 7.946447055928729e-08
investigate O 0 1.1607928485091179e-07
the O 0 1.0620867669786094e-06
mechanism O 0 2.6328984858992044e-06
of O 0 8.120402526401449e-06
the O 0 1.3719485423280275e-06
expansion O 0 2.995917839143658e-06
mutation O 0 1.1832010216039635e-07
in O 0 3.098479908203444e-07
the O 0 3.138255522117106e-07
Japanese O 0 1.0006160664488561e-06
population O 0 4.082366800162163e-08
we O 0 8.783806570988872e-09
have O 0 9.14705111654257e-09
studied O 0 3.764334053357743e-07
90 O 0 1.4867271147522843e-06
Japanese O 0 4.909391009277897e-06
DM B-Disease 1 0.9998579025268555
families O 0 2.308106985537961e-07
comprising O 0 2.7464921004138887e-07
190 O 0 1.4034255855222e-06
affected O 0 3.4146597727158223e-07
and O 0 2.682160982203641e-07
130 O 0 2.0645049971790286e-06
unaffected O 0 5.161637545825215e-06
members O 0 2.701998766951874e-07
. O 0 9.172375712296343e-07

The O 0 0.0002212836261605844
results O 0 2.536617648729589e-05
suggest O 0 2.2500826162286103e-06
that O 0 2.0365806108202378e-07
a O 0 1.2034238352498505e-06
few O 0 1.911257498932173e-07
common O 0 3.286461947027419e-07
ancestral O 0 9.198557563649956e-06
mutations O 0 4.4056972114958626e-07
in O 0 1.6398598745581694e-06
both O 0 4.794293886334344e-07
Caucasian O 0 2.1325936359062325e-06
and O 0 5.045465627517842e-07
Japanese O 0 1.875920816019061e-06
populations O 0 4.0082358765403114e-08
have O 0 3.190564612509661e-08
originated O 0 6.81314133998967e-08
by O 0 1.938396643197393e-08
expansion O 0 3.087993150074908e-07
of O 0 3.662126744075067e-07
an O 0 1.8823278935542476e-07
ancestral O 0 8.629092462797416e-07
n O 0 1.315826580139401e-06
= O 0 9.972512771128095e-07
5 O 0 3.682123121961922e-07
repeat O 0 1.8301865623016056e-07
to O 0 1.8896518838573684e-07
n O 0 2.0229331312293652e-06
= O 0 2.3111915652407333e-06
19 O 0 3.305445261503337e-06
- O 0 1.6385342860303354e-06
37 O 0 1.1799585308835958e-06
copies O 0 5.891786258871434e-07
. O 0 7.69720145399333e-07

These O 0 1.4598286952605122e-06
data O 0 2.3309582957153907e-06
support O 0 9.60229613156116e-07
multistep O 0 9.450087418372277e-06
models O 0 1.4143234920993564e-06
of O 0 8.605066796008032e-06
triplet O 0 0.00019721491844393313
repeat O 0 1.4843900316918734e-05
expansion O 0 1.0564745934971143e-05
that O 0 1.1858884363391553e-07
have O 0 5.2059736077580965e-08
been O 0 5.12620097481431e-08
proposed O 0 5.8651348666671765e-08
for O 0 6.223820747663922e-08
both O 0 1.0041875384558807e-06
DM B-Disease 1 1.0
and O 0 1.6055453670560382e-05
Friedreichs B-Disease 0 0.005074540618807077
ataxia I-Disease 1 0.9968389272689819
. O 0 3.5154882880306104e-06
. O 0 2.347549070691457e-06

The O 0 1.3907753782405052e-05
molecular O 0 1.940637048392091e-05
basis O 0 2.0537127056741156e-05
of O 0 0.004256874322891235
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.199749623192474e-05
the O 0 7.321039902308257e-06
western O 0 2.071047902063583e-06
Cape O 0 3.8838070395286195e-06
, O 0 4.793626473542645e-08
South O 0 2.4457784775222535e-07
Africa O 0 1.778844875843788e-07
. O 0 1.8217893682503927e-07

Deficiency B-Disease 1 0.999984622001648
of I-Disease 0 0.0007001554477028549
the I-Disease 0 4.274689490557648e-05
sixth I-Disease 0 6.546988151967525e-05
component I-Disease 0 3.573485628294293e-06
of I-Disease 0 4.121676738577662e-06
human I-Disease 0 9.448883702134481e-07
complement I-Disease 0 2.2705301034875447e-06
( O 0 8.177905215234205e-07
C6 O 0 7.474123412976041e-05
) O 0 1.3514345198473166e-07
has O 0 1.3143562682671472e-07
been O 0 2.1973191621782462e-07
reported O 0 9.385713894971559e-08
in O 0 9.139363754684382e-08
a O 0 1.5586144286316994e-07
number O 0 2.244562864461841e-07
of O 0 4.6579348236264195e-06
families O 0 3.2523644222237635e-07
from O 0 1.7525338762425235e-06
the O 0 2.116940549967694e-06
western O 0 1.405059492753935e-06
Cape O 0 4.5430624595610425e-06
, O 0 1.3245625041236053e-07
South O 0 3.7567701838270295e-07
Africa O 0 3.9103775861804024e-07
. O 0 5.660911597260565e-07

Meningococcal B-Disease 1 0.9999985694885254
disease I-Disease 1 0.9990742206573486
is O 0 4.7867742978269234e-06
endemic O 0 9.326384997621062e-07
in O 0 3.2100189173434046e-07
the O 0 9.281832262786338e-07
Cape O 0 1.7881549183584866e-06
and O 0 5.6825914640512565e-08
almost O 0 9.156690339295892e-08
all O 0 8.7137053128572e-09
pedigrees O 0 2.095693076853422e-07
of O 0 1.5563240367555409e-06
total O 0 0.013713694177567959
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.969650151702808e-06
C6Q0 O 0 6.304989074124023e-05
) O 0 2.2289370349426463e-08
have O 0 6.869588453639608e-09
been O 0 4.008556686585507e-08
ascertained O 0 3.4432105167070404e-07
because O 0 3.0721071908601516e-08
of O 0 1.7895897599373711e-06
recurrent O 1 0.9998372793197632
disease O 1 0.9997581839561462
. O 0 6.419833425752586e-06

We O 0 1.1872857612615917e-05
have O 0 7.333453027058567e-07
sequenced O 0 1.38635846269608e-06
the O 0 7.864404096835642e-07
expressed O 0 5.412028372120403e-07
exons O 0 2.3409650111716473e-06
of O 0 9.127078556048218e-06
the O 0 1.804130442906171e-05
C6 O 0 0.00029606634052470326
gene O 0 6.387524535966804e-07
from O 0 5.262650120130274e-07
selected O 0 2.0360523933504737e-07
cases O 0 2.5875364073613127e-08
and O 0 8.263486250825736e-08
have O 0 5.716847084613619e-08
found O 0 2.221188140083541e-07
three O 0 7.401126822514925e-07
molecular O 0 0.00018224300583824515
defects O 1 0.7789283394813538
leading O 0 0.0001142894325312227
to O 0 5.707226478079974e-07
total O 0 0.21045581996440887
deficiency O 1 0.9999998807907104
879delG O 0 0.0004983576945960522
, O 0 1.7965664937946713e-06
which O 0 3.4923672842523956e-07
is O 0 1.8601141960061796e-07
the O 0 3.4170801654909155e-07
common O 0 9.407172569808608e-07
defect O 0 3.83956694349763e-06
in O 0 2.12086274586909e-06
the O 0 6.642533207923407e-06
Cape O 0 4.8596507440379355e-06
and O 0 5.628075427921431e-07
hitherto O 0 1.3840037354384549e-05
unreported O 0 6.460123131546425e-06
, O 0 2.5221189048352244e-07
and O 0 3.1902973773867416e-07
1195delC O 0 3.6535248000291176e-06
and O 0 1.1496146044009947e-06
1936delG O 0 8.210106898332015e-06
, O 0 5.35440278781607e-07
which O 0 2.0240473475041654e-07
have O 0 1.5815911069694266e-07
been O 0 6.093101774240495e-07
previously O 0 9.910716016747756e-07
reported O 0 1.1670782669170876e-06
in O 0 9.225635722032166e-07
African O 0 1.9264659840700915e-06
- O 0 8.437825272267219e-06
Americans O 0 3.287060792445118e-07
. O 0 6.304017006186768e-07

We O 0 2.7687254259944893e-05
also O 0 2.5925908175850054e-06
show O 0 1.4985561165303807e-06
that O 0 2.808402257414855e-07
the O 0 1.6682212162777432e-06
879delG O 0 9.827769645198714e-06
and O 0 2.8100760118832113e-06
1195delC O 0 0.00046314249630086124
defects O 0 0.46005192399024963
are O 0 1.8850296612527018e-07
associated O 0 2.0376840836888732e-07
with O 0 9.482991458753531e-08
characteristic O 0 0.00020969787146896124
C6 O 1 0.9999697208404541
/ O 0 0.0008210434461943805
C7 O 0 0.0004020643827971071
region O 0 1.1837365718747606e-06
DNA O 0 8.940386919675802e-07
marker O 0 1.0180759090872016e-05
haplotypes O 0 1.035393097481574e-06
, O 0 3.959944194775744e-08
although O 0 1.410080407993064e-08
small O 0 1.598778531786138e-08
variations O 0 1.5659760776998155e-07
were O 0 7.551146268269804e-07
observed O 0 1.6572165577599662e-06
. O 0 8.15505416085216e-07

The O 0 0.0005724483053199947
1936delG O 0 0.0010110808070749044
defect O 0 0.0006210985593497753
was O 0 9.895078983390704e-05
observed O 0 4.190538675175048e-06
only O 0 3.188457355918217e-07
once O 0 6.051660079720023e-07
in O 0 5.403194336395245e-07
the O 0 1.2592422535817605e-06
Cape O 0 2.052531499430188e-06
, O 0 6.275746500250534e-08
but O 0 6.717626011010225e-09
its O 0 2.945638932771999e-08
associated O 0 2.4570539380874834e-07
haplotype O 0 2.1915172965236707e-06
could O 0 3.8185700645954057e-07
be O 0 5.403616682997381e-07
deduced O 0 8.585401701566298e-06
. O 0 1.0496189588593552e-06

The O 0 0.00019518517365213484
data O 0 2.8478178137447685e-05
from O 0 7.787645699863788e-06
the O 0 3.6613550946640316e-06
haplotypes O 0 7.2060743150359485e-06
indicate O 0 1.3823173503624275e-06
that O 0 8.337484302956e-08
these O 0 5.561891924799056e-08
three O 0 1.0920327895291848e-06
molecular O 0 0.000315345503622666
defects O 0 0.2433740198612213
account O 0 8.079686040218803e-07
for O 0 4.0663612708158325e-06
the O 0 0.00044929806608706713
defects O 1 0.9763960242271423
in O 0 5.388844783738023e-06
all O 0 6.571182780135132e-07
the O 0 4.063876531290589e-06
38 O 0 1.6144260371220298e-05
unrelated O 0 3.1776248761161696e-06
C6Q0 O 0 7.589280721731484e-05
individuals O 0 6.88868198039927e-08
we O 0 1.2110899660910945e-07
have O 0 9.971945047482222e-08
studied O 0 1.077286469808314e-06
from O 0 6.330833457468543e-07
the O 0 1.2525375723271281e-06
Cape O 0 6.4420719354529865e-06
. O 0 9.75753891907516e-07

We O 0 2.8890603061881848e-05
have O 0 1.243696146957518e-06
also O 0 2.888919539145718e-07
observed O 0 3.552553948793502e-07
the O 0 1.1650309943433967e-06
879delG O 0 1.104900184145663e-05
defect O 0 5.018083356844727e-06
in O 0 1.2872407069153269e-06
two O 0 1.5531036297034007e-06
Dutch O 0 0.051807060837745667
C6 B-Disease 1 1.0
- I-Disease 1 0.9999984502792358
deficient I-Disease 1 1.0
kindreds O 0 0.00021566316718235612
, O 0 5.430501346381789e-07
but O 0 8.786274463545851e-08
the O 0 7.82302379320754e-07
879delG O 0 1.0882488822971936e-05
defect O 0 1.726326809148304e-05
in O 0 4.15715430790442e-06
the O 0 1.1243265362281818e-05
Cape O 0 2.7833708372781985e-05
probably O 0 1.8391690446151188e-06
did O 0 1.8421867764573108e-07
not O 0 9.67085753700303e-08
come O 0 5.571734362774805e-08
from O 0 1.90310530001625e-07
The O 0 2.1668373051397793e-07
Netherlands O 0 5.550307946577959e-07
. O 0 1.7685754016838473e-07
. O 0 8.242061539931456e-07

Complement B-Disease 1 0.9992850422859192
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 6.1891519180790056e-06
seven O 0 1.8419126490698545e-06
further O 0 3.3478427212685347e-06
molecular O 0 0.3268812596797943
defects O 1 0.877208948135376
and O 0 5.372273221837531e-07
their O 0 1.674665952577925e-07
associated O 0 3.2864475087990286e-06
marker O 0 3.984468276030384e-05
haplotypes O 0 1.4828706298430916e-05
. O 0 1.997756498894887e-06

Seven O 0 1.0084581845148932e-05
further O 0 9.44902694755001e-07
molecular O 0 1.328445432591252e-05
bases O 0 1.6708369003026746e-05
of O 1 0.6961011290550232
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.4056801066763e-06
described O 0 4.829140834772261e-06
. O 0 9.582153097653645e-07

All O 0 5.117133696330711e-06
these O 0 2.7679223535415076e-07
new O 0 1.2366919008854893e-06
molecular O 0 4.366477514849976e-05
defects O 0 0.00013061189383734018
involve O 0 2.5099418508034432e-06
single O 0 4.995813014829764e-06
- O 0 6.746673989255214e-06
nucleotide O 0 1.7928967963598552e-06
events O 0 8.56901408496924e-07
, O 0 1.699520453257719e-07
deletions O 0 3.717931349456194e-07
and O 0 2.8367520599204e-07
substitutions O 0 5.490188073054014e-07
, O 0 1.2439566887678666e-07
some O 0 1.7447806754944395e-08
of O 0 1.2625008594113751e-06
which O 0 3.0306088660836394e-07
alter O 0 7.711352623118728e-07
splice O 0 1.8839563153960626e-06
sites O 0 2.402667007572745e-07
, O 0 4.5174928686719795e-08
and O 0 3.6603033493065595e-08
others O 0 1.0611012157824007e-07
codons O 0 3.45097964782326e-06
. O 0 9.673528893472394e-07

They O 0 8.947747119236737e-06
are O 0 3.945183664200158e-07
distributed O 0 1.8791352829339303e-07
along O 0 6.68022948957514e-07
the O 0 1.2799558817278012e-06
C7 O 0 9.27365617826581e-05
gene O 0 6.858566621303908e-07
, O 0 6.5798616333268e-08
but O 0 4.155980004583171e-09
predominantly O 0 1.2804347804262761e-08
towards O 0 7.702005433429804e-08
the O 0 1.5243412576637638e-07
3 O 0 9.034349091052718e-07
end O 0 2.458758217471768e-06
. O 0 4.4680660948870354e-07

All O 0 7.154450486268615e-06
were O 0 2.163119916076539e-06
found O 0 1.6120964119181735e-07
in O 0 2.8552082653732214e-07
compound O 0 6.33875743005774e-06
heterozygous O 0 6.099054417063599e-07
individuals O 0 9.902083064616818e-08
. O 0 8.74779516379931e-07

The O 0 0.00029262335738167167
C6 O 0 0.11538706719875336
/ O 0 0.0010984704131260514
C7 O 0 0.004696899093687534
marker O 0 0.00013826422218699008
haplotypes O 0 4.021999120595865e-05
associated O 0 2.2840799829282332e-06
with O 0 9.867474091151962e-07
most O 0 1.936904118338134e-05
C7 B-Disease 1 0.9999998807907104
defects I-Disease 1 0.9999536275863647
are O 0 4.0861456795937556e-07
tabulated O 0 8.967617759481072e-06
. O 0 1.0019913787573387e-07
. O 0 1.7477759683970362e-07

A O 0 0.00030212884303182364
genome O 0 1.8531345631345175e-05
- O 0 5.540616257349029e-06
wide O 0 6.497488698187226e-07
search O 0 1.6387814127938327e-07
for O 0 1.295007479029664e-07
chromosomal O 0 0.0011804411187767982
loci O 0 0.00017258274601772428
linked O 0 0.0003970880061388016
to O 0 1.0679870001695235e-06
mental O 1 0.9995477795600891
health O 0 0.0003958179149776697
wellness O 0 0.002892192453145981
in O 0 9.972741281671915e-07
relatives O 0 5.656702342093922e-07
at O 0 4.5786414375470486e-06
high O 0 7.509372517233714e-05
risk O 0 3.103761173406383e-06
for O 0 1.0361811291659251e-05
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 0.9999983310699463
among O 0 1.7377418544128886e-06
the O 0 1.8042931060335832e-06
Old O 0 3.6873277622362366e-06
Order O 0 4.910393727186602e-07
Amish O 0 4.418329808686394e-06
. O 0 6.053876973055594e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9980879426002502
BPAD B-Disease 1 1.0
; O 1 0.9987877011299133
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 3.1985641726350877e-06
is O 0 1.8520850630920904e-07
characterized O 0 7.487827247132373e-08
by O 0 1.6170908168078313e-08
episodes O 0 3.41575713491693e-07
of O 0 3.9956245018402115e-05
mania B-Disease 1 0.9040781855583191
and O 0 1.4936743355065119e-05
/ O 0 0.00031865507480688393
or O 0 1.5767208196848514e-06
hypomania B-Disease 0 0.00013165699783712626
interspersed O 0 3.54900180354889e-07
with O 0 1.4683730675812967e-08
periods O 0 4.466610789677361e-06
of O 0 4.137838550377637e-05
depression B-Disease 1 0.9999366998672485
. O 0 6.785545338061638e-06

Compelling O 0 3.09879906126298e-05
evidence O 0 2.5370493403897854e-06
supports O 0 3.605082383728586e-07
a O 0 9.64865591868147e-08
significant O 0 6.113985762112861e-08
genetic O 0 2.5470737341493077e-07
component O 0 4.537199856713414e-06
in O 0 4.2461647353775334e-07
the O 0 5.504563773683913e-07
susceptibility O 0 6.759386906196596e-06
to O 0 7.655852982679789e-07
develop O 0 2.0617562768165953e-05
BPAD B-Disease 1 1.0
. O 0 1.4670631571789272e-05

To O 0 2.4410705009358935e-05
date O 0 3.949392703361809e-05
, O 0 9.430553973288625e-07
however O 0 2.260142224486117e-07
, O 0 9.249777122022351e-08
linkage O 0 2.0401646452228306e-06
studies O 0 3.290614358775201e-07
have O 0 7.336097951338161e-08
attempted O 0 3.8643855759801227e-07
only O 0 2.4994498915020813e-08
to O 0 3.939776505035297e-08
identify O 0 1.1727433957275935e-07
chromosomal O 0 8.6048552475404e-05
loci O 0 1.2814477486244868e-05
that O 0 4.6087723148957593e-07
cause O 0 4.449239440873498e-06
or O 0 3.957834167067631e-07
increase O 0 6.499397500192572e-07
the O 0 1.767431854204915e-06
risk O 0 1.357587620987033e-06
of O 0 6.837278306193184e-06
developing O 0 5.6515713367844e-05
BPAD B-Disease 1 1.0
. O 0 1.3785160263068974e-05

To O 0 1.395797971781576e-05
determine O 0 2.835861323546851e-06
whether O 0 8.811730936031381e-07
there O 0 1.2713815067399992e-06
could O 0 9.283143072025268e-07
be O 0 5.798451638838742e-07
protective O 0 1.9811250240309164e-06
alleles O 0 4.0205179629992926e-07
that O 0 1.0320899690441365e-07
prevent O 0 4.920387937090709e-07
or O 0 3.524110923081025e-07
reduce O 0 3.8029139659556677e-07
the O 0 3.920742983609671e-06
risk O 0 3.3730252653185744e-06
of O 0 4.856013038079254e-05
developing O 0 8.125125896185637e-05
BPAD B-Disease 1 1.0
, O 0 2.6817494358510885e-07
similar O 0 2.809735555331372e-08
to O 0 1.4266965386866559e-08
what O 0 4.969676226096453e-09
is O 0 6.7022551952788945e-09
observed O 0 3.9295397158412015e-08
in O 0 4.825329469326789e-08
other O 0 2.3919579916764633e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 8.420024641964119e-07
we O 0 1.1385897380478127e-07
used O 0 1.8434396906741313e-06
mental O 1 0.9958491325378418
health O 0 0.013477161526679993
wellness O 1 0.9349899291992188
( O 0 1.1273585869275848e-06
absence O 0 6.7054938881483395e-06
of O 0 1.3387008948484436e-05
any O 0 7.25950303603895e-06
psychiatric B-Disease 1 0.9999998807907104
disorder I-Disease 1 0.999813973903656
) O 0 7.796211320965085e-07
as O 0 4.02572794655498e-07
the O 0 4.603272714120976e-07
phenotype O 0 6.509272338917071e-07
in O 0 5.172046257939655e-07
our O 0 8.701301226210489e-07
genome O 0 1.3222570487414487e-06
- O 0 3.5860080060956534e-06
wide O 0 2.9539883144025225e-06
linkage O 0 1.3826896974933334e-05
scan O 0 4.450894266483374e-06
of O 0 7.961108167364728e-06
several O 0 1.09085044641688e-06
large O 0 6.62943330098642e-06
multigeneration O 0 0.0003432692028582096
Old O 0 3.802085484494455e-05
Order O 0 5.484661755872366e-07
Amish O 0 5.96897871218971e-06
pedigrees O 0 1.2875697166236932e-06
exhibiting O 0 1.0754645245469874e-06
an O 0 1.9077518231824797e-07
extremely O 0 4.816235446014616e-07
high O 0 1.781436185410712e-05
incidence O 0 0.00019399863958824426
of O 0 0.0024204268120229244
BPAD B-Disease 1 1.0
. O 0 1.8211885617347434e-05

We O 0 8.567625627620146e-05
have O 0 3.6715582609758712e-06
found O 0 7.880921657488216e-07
strong O 0 2.51850650556662e-07
evidence O 0 1.6963547011528135e-07
for O 0 2.1926322801846254e-07
a O 0 6.789518351979495e-07
locus O 0 5.2582881835405715e-06
on O 0 1.117686497309478e-05
chromosome O 0 4.444593650987372e-05
4p O 0 0.001160040614195168
at O 0 4.1426079405937344e-05
D4S2949 O 0 1.145125861512497e-05
( O 0 1.8767909182315634e-07
maximum O 0 5.338603386917384e-06
GENEHUNTER O 0 4.4345004425849766e-05
- O 0 2.0021643649670295e-06
PLUS O 0 9.797812481338042e-07
nonparametric O 0 3.085613570874557e-06
linkage O 0 9.572617045705556e-07
score O 0 3.7731899737991625e-07
= O 0 3.387514482255938e-07
4 O 0 1.8806555601713626e-07
. O 0 1.2932914295049613e-08
05 O 0 3.3313510812149616e-06
, O 0 1.0932566851806769e-07
P O 0 3.3428973438276444e-06
= O 0 1.9858130428929144e-07
5 O 0 1.0455912047291349e-07
. O 0 1.0159411978349908e-08
22 O 0 1.6454951889954827e-07
x O 0 5.703836336579116e-07
10 O 0 3.435224016357097e-07
( O 0 3.001045101314048e-08
- O 0 1.2086265144262143e-07
4 O 0 3.528213596837304e-07
) O 0 1.5504555861411973e-08
; O 0 1.817145545146559e-08
SIBPAL O 0 2.663250825207797e-06
Pempirical O 0 1.8213044086223817e-06
value O 0 6.513408266073384e-07
< O 0 8.154121360348654e-07
3 O 0 2.7503713795340445e-07
x O 0 6.013092956891342e-07
10 O 0 2.193782648873821e-07
( O 0 2.813387212086127e-08
- O 0 1.3728565306792007e-07
5 O 0 2.113707608941695e-07
) O 0 2.2331157367716514e-08
) O 0 1.6597070384705148e-08
and O 0 3.783934943157874e-08
suggestive O 0 3.2064451715996256e-07
evidence O 0 9.851878246536216e-08
for O 0 8.836862264161027e-08
a O 0 4.705089224898984e-07
locus O 0 1.9621083993115462e-06
on O 0 6.456199571402976e-06
chromosome O 0 3.0443468858720735e-05
4q O 0 0.0011799560161307454
at O 0 1.938225068442989e-05
D4S397 O 0 6.933235454198439e-06
( O 0 1.8666752055196412e-07
maximum O 0 3.382999238965567e-06
GENEHUNTER O 0 4.5397086068987846e-05
- O 0 2.893636747103301e-06
PLUS O 0 7.983985597093124e-07
nonparametric O 0 1.846701934482553e-06
linkage O 0 1.0253104392177192e-06
score O 0 2.988470555465028e-07
= O 0 1.5004536635387922e-07
3 O 0 1.1546387668204261e-07
. O 0 1.4689108596144251e-08
29 O 0 4.796397661266383e-07
, O 0 5.91921391901451e-08
P O 0 2.3374716420221375e-06
= O 0 1.2239306101946568e-07
2 O 0 8.67245617541812e-08
. O 0 5.2583328802313645e-09
57 O 0 1.3228849127244757e-07
x O 0 2.2073777472542133e-07
10 O 0 1.5428864230671024e-07
( O 0 2.9259732414743667e-08
- O 0 1.341642814622901e-07
3 O 0 1.1411324152277302e-07
) O 0 1.128478555045831e-08
; O 0 1.9743071177913407e-08
SIBPAL O 0 3.297250259493012e-06
Pempirical O 0 1.3041531019553076e-06
value O 0 3.6294613892096095e-07
< O 0 7.152651164687995e-07
1 O 0 4.317550406085502e-07
x O 0 8.966094924289791e-07
10 O 0 2.71013334440795e-07
( O 0 5.307548534005946e-08
- O 0 2.1133649852345116e-07
3 O 0 3.130280958885123e-07
) O 0 1.4526754910093587e-08
) O 0 7.361141474149235e-09
that O 0 2.7543851643940798e-09
are O 0 1.3226912898289811e-08
linked O 0 4.1341149881191086e-07
to O 0 1.455566263075525e-07
mental O 1 0.8388553261756897
health O 0 0.001526182284578681
wellness O 1 0.5116809606552124
. O 0 4.664104835683247e-06

These O 0 5.180895641387906e-06
findings O 0 4.015922058897559e-06
are O 0 2.977345445742685e-07
consistent O 0 4.3251000647615e-07
with O 0 2.5394545133394786e-08
the O 0 6.718883582834678e-07
hypothesis O 0 2.4845923007887905e-07
that O 0 1.0994921417761816e-08
certain O 0 2.533387899461559e-08
alleles O 0 3.340681189456518e-07
could O 0 2.9160071335354587e-07
prevent O 0 3.4313507057959214e-07
or O 0 1.8505649279632053e-07
modify O 0 7.779635780025274e-08
the O 0 2.439512059027038e-07
clinical O 0 1.1539067600097042e-05
manifestations O 0 0.000337238801876083
of O 0 0.07898420095443726
BPAD B-Disease 1 1.0
and O 0 1.606131377229758e-06
perhaps O 0 1.7265143981148867e-07
other O 0 6.387841011701312e-08
related O 0 4.05441242037341e-05
affective B-Disease 1 0.9999567270278931
disorders I-Disease 1 0.9999991655349731
. O 0 1.0467906577105168e-05

Segregation O 0 0.005855298601090908
distortion O 1 0.9949288368225098
in O 0 0.005105327814817429
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 4.9608595872996375e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.004666072782129049
DM B-Disease 1 1.0
) O 0 1.6125102774822153e-05
is O 0 8.857970215103705e-07
an O 0 1.3082413943266147e-06
autosomal B-Disease 0 0.014543079771101475
dominant I-Disease 1 0.9939740300178528
disease I-Disease 1 0.9999982118606567
which O 0 4.748472292703809e-06
, O 0 1.6491996746026416e-07
in O 0 6.409993602574104e-07
the O 0 1.9916044493584195e-06
typical O 0 1.0146668500965461e-06
pedigree O 0 6.88220666233974e-07
, O 0 1.4803752002023884e-08
shows O 0 1.5959907173623833e-08
a O 0 7.87791805123561e-08
three O 0 7.083654907091841e-08
generation O 0 1.0179116998187965e-06
anticipation O 0 4.219733455101959e-06
cascade O 0 0.0001755733828758821
. O 0 5.573664566327352e-06

This O 0 1.908149897644762e-06
results O 0 3.602220431275782e-06
in O 0 1.0376268619438633e-05
infertility B-Disease 1 0.9999986886978149
and O 1 0.9999668598175049
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.0270104869268835e-05
CDM B-Disease 0 0.25685402750968933
) O 0 3.910071200152743e-08
with O 0 1.2422525230704196e-08
the O 0 1.0046474017144646e-06
disappearance O 0 4.5763026719214395e-05
of O 0 0.0008193888934329152
DM B-Disease 1 1.0
in O 0 1.5260520740412176e-05
that O 0 1.2652707255256246e-06
pedigree O 0 1.3381010830926243e-05
. O 0 2.20549327423214e-06

The O 0 2.4534585463698022e-05
concept O 0 4.1679081732581835e-06
of O 0 8.386010449612513e-06
segregation O 0 2.2970618374529295e-05
distortion O 0 6.179469346534461e-05
, O 0 1.1351105655421634e-07
where O 0 6.129491936235354e-08
there O 0 2.3216834676986764e-08
is O 0 2.0102078224226716e-08
preferential O 0 2.077341036965663e-07
transmission O 0 1.4733464013261255e-06
of O 0 1.5568466551485471e-06
the O 0 9.910374956234591e-07
larger O 0 2.3474702004477876e-07
allele O 0 4.970967779627244e-07
at O 0 7.398300112981815e-06
the O 0 5.022709046897944e-06
DM B-Disease 1 0.9993336796760559
locus O 0 1.1816154255939182e-05
, O 0 3.058794391108677e-07
has O 0 1.267793692250052e-07
been O 0 2.669521563802846e-07
put O 0 9.24815353187114e-08
forward O 0 3.618757489221025e-07
to O 0 9.370116060836153e-08
explain O 0 5.282270194584271e-07
partially O 0 5.3961271078151185e-06
the O 0 1.3460852414937108e-06
maintenance O 0 3.8147027225932106e-05
of O 0 0.00012821158452425152
DM B-Disease 1 1.0
in O 0 1.15245284177945e-05
the O 0 1.9867745777446544e-06
population O 0 2.0785735443951125e-07
. O 0 4.271728357707616e-07

In O 0 5.126102041685954e-05
a O 0 1.4008812286192551e-05
survey O 0 8.316918865602929e-06
of O 0 3.387507968000136e-05
DM B-Disease 1 1.0
in O 0 4.419370088726282e-05
Northern O 0 6.901760571054183e-06
Ireland O 0 4.59812156350381e-07
, O 0 1.601538315298967e-07
59 O 0 1.441701556359476e-06
pedigrees O 0 1.178139086732699e-06
were O 0 1.2448424513422651e-06
ascertained O 0 7.505480425606947e-06
. O 0 1.1905781320820097e-06

Sibships O 0 0.005559272598475218
where O 0 3.891949381795712e-05
the O 0 6.8051940615987405e-06
status O 0 3.729867785295937e-06
of O 0 1.4269233361119404e-05
all O 0 2.1017808649048675e-06
the O 0 6.390891030605417e-06
members O 0 4.103805224531243e-07
had O 0 2.832706968547427e-06
been O 0 1.365279103993089e-06
identified O 0 2.648191639309516e-07
were O 0 3.298047772659629e-07
examined O 0 2.587021583622118e-07
to O 0 6.068802349545876e-08
determine O 0 3.039057219211827e-07
the O 0 4.462659035198158e-06
transmission O 0 4.2832754843402654e-05
of O 0 9.884270548354834e-05
the O 0 0.0007682691211812198
DM B-Disease 1 1.0
expansion O 0 0.004847691394388676
from O 0 4.82221503261826e-06
affected O 0 5.829946303492761e-07
parents O 0 4.024053978923803e-08
to O 0 3.6677672454743515e-08
their O 0 9.467034800536567e-08
offspring O 0 8.177631798389484e-07
. O 0 6.58929934616026e-07

Where O 0 4.993342736270279e-05
the O 0 8.689245987625327e-06
transmitting O 0 0.00013452234270516783
parent O 0 6.793535249016713e-06
was O 0 2.771874460449908e-05
male O 0 1.1198994798178319e-06
, O 0 2.277293162933347e-07
58 O 0 6.281785772443982e-06
. O 0 1.0076083754029241e-06

3 O 0 8.360352512681857e-05
% O 0 5.820852038596058e-06
of O 0 1.0997397112078033e-05
the O 0 8.321552741108462e-06
offspring O 0 1.788044073691708e-06
were O 0 4.887733666691929e-06
affected O 0 5.374666329771571e-07
, O 0 7.088384990083796e-08
and O 0 3.7653890672117996e-08
in O 0 2.535489045385475e-07
the O 0 5.520240051737346e-07
case O 0 2.9708360216318397e-07
of O 0 7.595651254632685e-07
a O 0 1.3442802355712047e-06
female O 0 2.8269453196116956e-06
transmitting O 0 0.000116926254122518
parent O 0 3.5942455269832863e-06
, O 0 5.860807164026482e-07
68 O 0 1.133070054493146e-05
. O 0 1.4781680874875747e-06

7 O 0 0.00013460985792335123
% O 0 9.652237167756539e-06
were O 0 8.515804438502528e-06
affected O 0 6.9448556132556405e-06
. O 0 3.8142277389852097e-06

Studies O 0 8.87532951310277e-05
on O 0 5.359298666007817e-05
meiotic O 0 0.00017933086201082915
drive O 0 2.1968717192066833e-05
in O 0 6.444357495638542e-06
DM B-Disease 1 0.9999921321868896
have O 0 1.5017049292964657e-07
shown O 0 1.92789613606692e-07
increased O 0 1.2213403124405886e-06
transmission O 0 2.416646339042927e-06
of O 0 1.1912356967513915e-06
the O 0 2.684663797936082e-07
larger O 0 5.226648269740508e-08
allele O 0 1.7457551848565345e-07
at O 0 2.3528946258011274e-06
the O 0 1.2155535387137206e-06
DM B-Disease 1 0.8707315921783447
locus O 0 4.227362296660431e-06
in O 0 1.2143761978222756e-06
non O 0 4.583313057082705e-05
- O 0 0.00012847162724938244
DM O 1 0.9999986886978149
heterozygotes O 0 2.8641461540246382e-05
for O 0 2.9667719445569674e-06
CTGn O 0 0.0002311837306478992
. O 0 5.779013918072451e-06

This O 0 2.4088024019874865e-06
study O 0 1.1101707286798046e-06
provides O 0 2.2296073609595624e-07
further O 0 1.2073419952685072e-07
evidence O 0 3.733508151526621e-07
that O 0 5.321172125150042e-07
the O 0 2.6130592232220806e-05
DM B-Disease 1 1.0
expansion O 0 0.00015173295105341822
tends O 0 1.5175775160969351e-06
to O 0 1.6797028479231813e-07
be O 0 4.193374252281501e-07
transmitted O 0 1.7219018673131359e-06
preferentially O 0 1.6360000927306828e-06
. O 0 7.08434356511134e-07

Diagnosis O 1 0.9999001026153564
of O 1 0.9925083518028259
hemochromatosis B-Disease 1 1.0
. O 0 0.0004502067749854177

If O 0 0.0010387399233877659
untreated O 1 0.9999948740005493
, O 0 9.41206599236466e-05
hemochromatosis B-Disease 1 1.0
can O 0 1.8133967387257144e-05
cause O 1 0.7390488386154175
serious O 1 0.9988921284675598
illness O 1 0.9999998807907104
and O 0 7.985836418811232e-06
early B-Disease 0 7.571759488200769e-05
death I-Disease 0 0.0003033826651517302
, O 0 1.0347390855258709e-07
but O 0 4.0981806392892395e-08
the O 0 4.894376388620003e-07
disease O 0 3.2713444397813873e-06
is O 0 1.0221614132888135e-07
still O 0 7.906368182375445e-08
substantially O 0 8.198474006348988e-07
under O 0 1.6155934645212255e-05
- O 0 0.0018790693720802665
diagnosed O 0 0.0058635929599404335
. O 0 3.2342436497856397e-06

The O 0 6.753928755642846e-05
cornerstone O 0 0.0002509502519387752
of O 0 3.1771917292644503e-06
screening O 0 6.169253765619942e-07
and O 0 1.4319341801183327e-07
case O 0 2.470677316068759e-07
detection O 0 5.452317282106378e-07
is O 0 1.0783354298382619e-07
the O 0 2.1134596295269148e-07
measurement O 0 3.79518564841419e-06
of O 0 6.150822628114838e-06
serum O 0 5.0287286285310984e-05
transferrin O 0 4.8668520321371034e-05
saturation O 0 1.717035411274992e-05
and O 0 3.399505317247531e-07
the O 0 1.2696730209427187e-06
serum O 0 1.5718364011263475e-05
ferritin O 0 0.0001061283765011467
level O 0 5.8416138926986605e-05
. O 0 2.3185828013083665e-06

Once O 0 0.00017280304746236652
the O 0 1.9205102944397368e-05
diagnosis O 0 0.0006060569430701435
is O 0 2.8789736461476423e-06
suspected O 0 8.992694347398356e-06
, O 0 2.1913008652063581e-07
physicians O 0 2.441583433210326e-07
must O 0 1.0456829357963215e-07
use O 0 2.4292575062645483e-07
serum O 0 0.00015157749294303358
ferritin O 0 0.00990565586835146
levels O 0 0.0004037687904201448
and O 0 9.81813900580164e-06
hepatic O 1 0.9999990463256836
iron O 1 0.999987006187439
stores O 0 1.0832528460014146e-05
on O 0 5.6345874327234924e-05
liver O 1 0.9481690526008606
biopsy O 0 7.263818406499922e-05
specimens O 0 4.398203543587442e-07
to O 0 1.25559523667107e-07
assess O 0 5.302580348143238e-07
patients O 0 3.7018440934843966e-07
for O 0 1.8664152889869e-07
the O 0 6.419292049031355e-07
presence O 0 1.7104582639149157e-06
of O 0 0.00012546905782073736
iron B-Disease 1 0.9998593330383301
overload I-Disease 0 0.01227241288870573
. O 0 8.293980499729514e-06

Liver O 1 0.9999998807907104
biopsy O 1 0.9999301433563232
is O 0 2.522031900298316e-05
also O 0 5.352901553123957e-07
used O 0 2.3956152972459677e-07
to O 0 6.421630871500383e-08
establish O 0 2.933724942977278e-07
the O 0 1.8125920178135857e-06
presence O 0 3.2782154448796064e-06
or O 0 1.1198076208529528e-05
absence O 0 0.00025108191766776145
of O 0 0.0013811441604048014
cirrhosis B-Disease 1 1.0
, O 0 5.452353661894449e-07
which O 0 1.3998310066654085e-07
can O 0 4.4308265501058486e-08
affect O 0 8.773661761551921e-07
prognosis O 0 0.0004452540597412735
and O 0 1.6020499060687143e-06
management O 0 1.3125705663696863e-05
. O 0 1.5583736967528239e-06

A O 0 0.0002110019268002361
DNA O 0 1.0064703928946983e-05
- O 0 6.257952463784022e-06
based O 0 3.359383811130101e-07
test O 0 1.399836264681653e-07
for O 0 3.235750796193315e-07
the O 0 3.5917787499784026e-06
HFE O 0 0.00025077929603867233
gene O 0 5.373472049541306e-07
is O 0 1.1694084633973034e-07
commercially O 0 1.1196074467534345e-07
available O 0 5.824900384254761e-08
, O 0 2.24461143005783e-08
but O 0 5.437215122583439e-09
its O 0 1.53425805393681e-08
place O 0 6.30514165322893e-08
in O 0 1.3791029118692677e-07
the O 0 1.0005015838032705e-06
diagnosis O 0 0.00021875498350709677
of O 0 0.2388579398393631
hemochromatosis B-Disease 1 1.0
is O 0 2.1126055798958987e-05
still O 0 6.86888938616903e-07
being O 0 4.0766639131106785e-07
evaluated O 0 7.410251896544651e-07
. O 0 8.885400006874988e-07

Currently O 0 0.00012456034892238677
, O 0 3.4641886941244593e-06
the O 0 1.1664340036077192e-06
most O 0 8.031534548536001e-08
useful O 0 1.1551122724995366e-07
role O 0 6.650023465226695e-07
for O 0 1.4821840466083813e-07
this O 0 5.292980986837392e-08
test O 0 5.505540556782762e-08
is O 0 4.7862076968385736e-08
in O 0 5.974212768933285e-08
the O 0 3.5823737221107876e-07
detection O 0 2.2942424493521685e-06
of O 0 0.015482206828892231
hemochromatosis B-Disease 1 1.0
in O 0 0.41941365599632263
the O 0 0.0003745389694813639
family O 0 9.393626783094078e-07
members O 0 6.936780749811078e-08
of O 0 7.159536608014605e-07
patients O 0 3.0567065323339193e-07
with O 0 8.874833667960047e-08
a O 0 2.6029763375845505e-06
proven O 0 1.1036942851205822e-05
case O 0 1.0253065738652367e-06
of O 0 4.956906650477322e-06
the O 0 2.736605347308796e-05
disease O 0 0.0012185657396912575
. O 0 3.6405619994184235e-06

It O 0 1.0943128927465295e-06
is O 0 3.827137788903201e-07
crucial O 0 1.848514784796862e-06
to O 0 1.6935774738158216e-06
diagnose O 1 0.9996432065963745
hemochromatosis B-Disease 1 1.0
before O 1 0.9999992847442627
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.0002253619604744017
because O 0 7.0514493017981295e-06
phlebotomy O 1 0.9999018907546997
therapy O 0 0.0004896930186077952
can O 0 3.128686785203172e-07
avert O 0 4.8110392526723444e-05
serious O 1 0.9978379607200623
chronic O 1 1.0
disease O 1 0.9999988079071045
and O 0 2.6460556910024025e-06
can O 0 9.99283145119989e-08
even O 0 3.9510339888693125e-08
lead O 0 1.2571672414196655e-07
to O 0 2.7400188784554302e-08
normal O 0 1.7817933439800981e-06
life O 0 7.145491736082477e-07
expectancy O 0 7.90399280958809e-06
. O 0 1.171539381061848e-07
. O 0 3.728633259925118e-07

Prevalence O 0 0.0021364742424339056
of O 0 0.00021840234694536775
the O 0 5.291002889862284e-05
I1307K O 0 0.0003989513497799635
APC B-Disease 0 6.144506915006787e-05
gene O 0 3.2432828334094665e-07
variant O 0 2.583754508123093e-07
in O 0 8.903418802219676e-08
Israeli O 0 3.583364787118626e-07
Jews O 0 7.58425926505879e-08
of O 0 6.405691266309077e-08
differing O 0 1.1395572485639605e-08
ethnic O 0 1.2455884323969713e-08
origin O 0 1.0054393584368881e-07
and O 0 8.38918410295264e-08
risk O 0 1.4861317367831361e-06
for O 0 3.825792373390868e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.7140055206255056e-05

BACKGROUND O 0 0.0004101492231711745
& O 0 0.00012046030315104872
AIMS O 0 1.7434940673410892e-05
Israeli O 0 1.5452318621100858e-05
Jews O 0 4.211347004456911e-06
of O 0 8.234446795540862e-06
European O 0 2.4365642730117543e-06
birth O 0 1.4847072634438518e-05
, O 0 4.277729033219657e-07
i O 0 3.393917324956419e-07
. O 0 5.935743274676497e-08
e O 0 3.5744429283113277e-07
. O 0 3.214116972571901e-08
, O 0 4.746135928712647e-08
Ashkenazim O 0 5.439717369881691e-07
, O 0 1.6847732098312918e-08
have O 0 8.346215274457336e-09
the O 0 2.8053452183485206e-07
highest O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9999537467956543
of O 0 2.0124394723097794e-05
any O 0 1.3068407156424655e-07
Israeli O 0 4.0261602407554165e-06
ethnic O 0 4.181793258339894e-07
group O 0 1.077216666089953e-06
. O 0 6.805101975260186e-07

The O 0 0.00035737716825678945
I1307K O 0 0.0010998985962942243
APC B-Disease 0 0.00024406846205238253
gene O 0 3.0768715078011155e-06
variant O 0 4.247588094585808e-06
was O 0 1.0274726264469791e-05
found O 0 1.1607552607983962e-07
in O 0 2.4930326958383375e-07
6 O 0 5.256648819340626e-06
. O 0 1.36514631776663e-06

1 O 0 6.252460298128426e-05
% O 0 1.4764295883651357e-06
of O 0 2.168949549741228e-06
American O 0 1.3196871577747515e-06
Jews O 0 2.3799302084626106e-07
, O 0 2.9360920805743262e-08
28 O 0 2.6978841560776345e-07
% O 0 4.993870206249085e-08
of O 0 2.6370221917204617e-07
their O 0 2.7493117613630602e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.0003592864377424121
, O 0 1.8571471116501925e-07
but O 0 1.3097498197112145e-08
not O 0 1.809101490835019e-08
in O 0 7.306130811457479e-08
non O 0 1.4242992847357527e-06
- O 0 1.472337885388697e-06
Jews O 0 7.216983135549526e-07
. O 0 4.227900376463367e-07

We O 0 3.944093259633519e-05
assessed O 0 4.4294494728092104e-05
the O 0 5.51937364434707e-06
I1307K O 0 3.134605140076019e-05
prevalence O 0 5.521942512132227e-06
in O 0 1.0894390101157114e-07
Israeli O 0 1.7029616117270052e-07
Jews O 0 7.810248092710026e-08
of O 0 3.8810341607131704e-08
differing O 0 8.661938721843399e-09
ethnic O 0 6.9663319557378145e-09
origin O 0 3.036594264926862e-08
and O 0 5.847185491347773e-08
risk O 0 1.7948368622455746e-06
for O 0 4.377058940008283e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.7250347809749655e-05

METHODS O 0 0.00010708966146921739
DNA O 0 9.458544809604064e-06
samples O 0 3.6045710203325143e-06
from O 0 3.609844497987069e-06
500 O 0 2.4223434138548328e-06
unrelated O 0 6.954817308724159e-07
Jews O 0 8.229713444052322e-07
of O 0 4.200885996397119e-06
European O 0 3.625812269092421e-06
or O 0 1.3063313417660538e-06
non O 0 7.301293862838065e-06
- O 0 2.0593488443410024e-06
European O 0 4.421987398472993e-07
origin O 0 9.021540137155171e-08
, O 0 3.0423798591527884e-08
with O 0 1.5356164340118994e-08
or O 0 2.2112038777777343e-07
without O 0 1.5630547522960114e-07
a O 0 8.441298859906965e-07
personal O 0 3.7019854062236845e-06
and O 0 4.929969236400211e-06
/ O 0 8.222713222494349e-05
or O 0 1.675617909313587e-06
family O 0 1.7625626469452982e-07
history O 0 1.6516029290869483e-06
of O 0 3.6275669117458165e-05
neoplasia B-Disease 0 0.0007120101945474744
, O 0 7.841981073397619e-07
were O 0 6.210829610608926e-07
examined O 0 5.29450574049406e-07
for O 0 3.7676596775781945e-07
the O 0 1.2298175988689763e-06
I1307K O 0 5.336597496352624e-06
variant O 0 6.570662662852556e-07
by O 0 1.5289273846974538e-07
the O 0 2.3853584707467235e-07
allele O 0 1.4434787942718685e-07
- O 0 3.086356343828811e-07
specific O 0 4.361018213216994e-08
oligonucleotide O 0 6.860575012979098e-06
( O 0 1.2880179838248296e-06
ASO O 0 0.00016400394088122994
) O 0 1.9503833925682557e-07
method O 0 1.7966418681680807e-06
. O 0 1.8159660157834878e-06

RESULTS O 0 7.052430737530813e-05
In O 0 1.9519666238920763e-06
persons O 0 5.624405048365588e-07
at O 0 2.533374527047272e-06
average O 0 1.8381801965006161e-06
risk O 0 1.8028310933004832e-06
for O 0 0.0001454479934182018
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 5.388855242927093e-06
I1307K O 0 1.5395515220006928e-05
was O 0 7.278761586348992e-06
found O 0 5.2172755005130966e-08
in O 0 1.1926732668143813e-07
5 O 0 1.3160273510948173e-06
. O 0 7.223097782116383e-07

0 O 0 1.5952282410580665e-05
% O 0 1.148428964370396e-06
of O 0 2.161754764529178e-06
120 O 0 2.3481288735638373e-06
European O 0 9.441695283385343e-07
and O 0 5.011389134779165e-07
1 O 0 6.336702426779084e-06
. O 0 1.730178041725594e-06

6 O 0 0.0001401561894454062
% O 0 4.340651685197372e-06
of O 0 8.966762834461406e-06
188 O 0 6.662950454483507e-06
non O 0 5.726270956074586e-06
- O 0 1.4374003285411163e-06
European O 0 1.9347515944900806e-07
Jews O 0 1.7954036479750357e-07
( O 0 2.996800674281985e-08
P O 0 1.6866175656105042e-06
= O 0 8.191317135697318e-08
0 O 0 4.92051910327973e-08
. O 0 9.41906641571677e-09
08 O 0 1.1764584542106604e-06
) O 0 4.164710887266665e-08
. O 0 7.740531060562716e-08

It O 0 2.4384705739066703e-06
occurred O 0 1.145582427852787e-05
in O 0 2.322094587725587e-06
15 O 0 6.543094968947116e-06
. O 0 2.253346565339598e-06

4 O 0 4.461128992261365e-05
% O 0 1.7457481362725957e-06
of O 0 2.739081537583843e-06
52 O 0 4.7524044930469245e-06
Ashkenazi O 0 1.357458131678868e-06
Israelis O 0 9.095433597394731e-07
with O 0 2.4002048348847893e-07
familial O 0 8.208399958675727e-05
cancer B-Disease 0 0.0899214968085289
( O 0 1.4528690144288703e-06
P O 0 3.8909027352929115e-05
= O 0 7.138626187952468e-07
0 O 0 2.4915303242778464e-07
. O 0 5.617480169917144e-08
02 O 0 3.2352925245504593e-06
) O 0 4.106576767526349e-08
and O 0 6.598764201726226e-08
was O 0 2.1964090137771564e-06
not O 0 4.221075045052203e-08
detected O 0 4.937563744533691e-07
in O 0 3.91137717770107e-07
51 O 0 2.6601767331158044e-06
non O 0 3.874513822665904e-06
- O 0 5.092545620755118e-07
European O 0 3.156631223077966e-08
Jews O 0 4.7313314155417174e-08
at O 0 3.3682442790450295e-07
increased O 0 1.1098309187218547e-06
cancer B-Disease 0 2.002791916311253e-05
risk O 0 1.4690098169012344e-06
. O 0 1.1038858929168782e-06

Colorectal B-Disease 1 0.9999496936798096
neoplasia I-Disease 1 0.9998835325241089
occurred O 1 0.9766585230827332
personally O 0 0.00012109360977774486
or O 0 5.171447355678538e-06
in O 0 1.853402636697865e-06
the O 0 2.132280542355147e-06
families O 0 8.408455443031926e-08
of O 0 4.244968295097351e-06
13 O 0 6.365381068462739e-06
of O 0 3.438597923377529e-05
20 O 0 1.8490987713448703e-05
Ashkenazi O 0 9.086468708119355e-06
I1307K O 0 1.5620187696185894e-05
carriers O 0 2.485815286945581e-07
, O 0 2.174915607611183e-07
8 O 0 1.09004758996889e-06
of O 0 1.122381149798457e-06
whom O 0 4.542159786069533e-07
also O 0 4.346420041656529e-07
had O 0 8.991715958472923e-07
a O 0 5.960543489891279e-07
personal O 0 1.3630830153488205e-06
or O 0 9.012388204610033e-07
family O 0 1.5268683739577682e-07
history O 0 1.6392000361520331e-06
of O 0 3.352247949806042e-05
noncolonic O 0 0.03492417559027672
neoplasia B-Disease 1 0.6845864653587341
. O 0 1.1267405170656275e-05

CONCLUSIONS O 0 0.0007180619286373258
The O 0 0.0001179086320917122
I1307K O 0 0.000732659362256527
APC O 0 0.00015697965864092112
variant O 0 4.347325557318982e-06
may O 0 4.928540988657915e-07
represent O 0 6.564155086152823e-08
a O 0 3.4716856589511735e-07
susceptibility O 0 7.600095614179736e-06
gene O 0 5.294018137647072e-06
for O 0 3.7595480534946546e-05
colorectal B-Disease 1 1.0
, I-Disease 0 4.189483661320992e-05
or I-Disease 0 4.505696324486053e-06
other I-Disease 0 5.331890520210436e-07
, I-Disease 0 1.0813563449119101e-06
cancers I-Disease 0 7.9572775575798e-05
in O 0 3.949108759115916e-06
Ashkenazi O 0 3.187546781191486e-06
Jews O 0 4.23075590560984e-07
, O 0 3.9425426479056114e-08
and O 0 3.466722020561974e-08
partially O 0 1.4416094700209214e-06
explains O 0 7.414776348468877e-08
the O 0 1.322723335306364e-07
higher O 0 8.963001164374873e-06
incidence O 0 0.2830740213394165
of O 1 0.9999788999557495
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.75134295609314e-05
European O 0 3.2464563446410466e-06
Israelis O 0 2.692697080419748e-06
. O 0 1.1827017942778184e-06

Systematic O 0 3.254093462601304e-05
analysis O 0 3.141884008073248e-06
of O 0 1.2107302609365433e-05
coproporphyrinogen O 0 0.008836418390274048
oxidase O 0 0.07834886014461517
gene O 0 0.00021689408458769321
defects O 0 0.4129279851913452
in O 0 1.3935301467427053e-05
hereditary B-Disease 1 0.9999984502792358
coproporphyria I-Disease 1 0.9245301485061646
and O 0 2.194876060457318e-06
mutation O 0 3.080882379435934e-06
update O 0 3.928763817384606e-06
. O 0 1.3722259382120683e-06

Hereditary B-Disease 1 0.9999984502792358
coproporphyria I-Disease 1 0.998357355594635
( O 0 2.3818995032343082e-05
HC B-Disease 1 0.9999622106552124
) O 0 1.1029915185645223e-06
is O 0 3.541651096838905e-07
an O 0 3.7322588468668982e-06
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.9721999764442444
autosomal O 1 1.0
dominant O 1 0.9980068802833557
inheritance O 0 0.27542468905448914
caused O 1 0.9308174848556519
by O 0 5.191674858906481e-07
deficient B-Disease 0 1.2689741197391413e-05
activity I-Disease 0 9.81414018497162e-07
of I-Disease 0 2.639367039591889e-06
coproporphyrinogen I-Disease 0 3.094965359196067e-05
III I-Disease 0 0.0006162637146189809
oxidase I-Disease 0 1.4656508938060142e-05
( O 0 4.961627837474225e-07
CPO O 0 4.6740453399252146e-05
) O 0 2.439558670630504e-07
. O 0 3.2969973062790814e-07

Clinical O 0 0.006763236131519079
manifestations O 1 0.5645269155502319
of O 0 0.007257698103785515
the O 0 0.025690235197544098
disease O 1 0.9977428913116455
are O 0 9.573441417387585e-08
characterized O 0 2.953279647499585e-07
by O 0 1.8509902588448313e-07
acute O 1 0.9999926090240479
attacks O 0 0.00015534456179011613
of O 1 0.999997615814209
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 1.079788307833951e-05
precipitated O 0 0.000154769848450087
by O 0 2.3081112487943756e-07
drugs O 0 4.239375073211704e-07
, O 0 1.174412105342526e-07
fasting O 0 2.9337661544559523e-06
, O 0 5.524695438907656e-07
cyclical O 0 0.00016520952340215445
hormonal O 0 6.901400774950162e-05
changes O 0 8.515215768056805e-07
, O 0 9.89444401966466e-07
or O 0 1.0648611350916326e-05
infectious B-Disease 1 0.999455988407135
diseases I-Disease 1 0.9992960691452026
. O 0 7.897889190644491e-06

Skin O 1 0.999996542930603
photosensitivity O 1 0.9999963045120239
may O 0 0.0019421257311478257
also O 0 2.9229806841613026e-06
be O 0 3.737119982361037e-07
present O 0 1.5513185189774958e-06
. O 0 1.5213727238005958e-06

The O 0 0.00010065946844406426
seven O 0 1.7091106201405637e-05
exons O 0 2.1918764105066657e-05
, O 0 1.411881498825096e-06
the O 0 3.028028459084453e-06
exon O 0 9.379158655065112e-06
/ O 0 7.457121228071628e-06
intron O 0 1.3399462659435812e-05
boundaries O 0 6.748462624273088e-07
and O 0 3.135189388103754e-07
part O 0 6.971730499572004e-07
of O 0 4.943745352647966e-06
3 O 0 1.261363536286808e-06
noncoding O 0 6.752176773261453e-07
sequence O 0 4.973974796484981e-07
of O 0 6.97294171914109e-06
the O 0 1.201994928123895e-05
CPO O 0 0.00013367595965974033
gene O 0 4.4507444840746757e-07
were O 0 7.661827794436249e-07
systematically O 0 3.98833236658902e-07
analyzed O 0 2.3611525534761313e-07
by O 0 1.3036466839366767e-07
an O 0 2.4558332256674476e-07
exon O 0 1.0149126410397002e-06
- O 0 9.253726034330612e-07
by O 0 8.055926059569174e-07
- O 0 4.036256086692447e-06
exon O 0 8.07382366474485e-06
denaturing O 0 9.57814627327025e-05
gradient O 0 0.00015715502377133816
gel O 0 4.1852708818623796e-05
electrophoresis O 0 2.3758628231007606e-05
( O 0 1.6129034747791593e-06
DGGE O 0 4.69830229121726e-05
) O 0 1.0009485151840636e-07
strategy O 0 3.681019933310381e-08
followed O 0 2.1002923844548604e-08
by O 0 2.358918171907476e-09
direct O 0 2.940026000430862e-08
sequencing O 0 1.3296198630996514e-07
in O 0 2.5576304096830427e-07
seven O 0 4.0516493982067914e-07
unrelated O 0 1.2596433407452423e-06
heterozygous O 0 1.530662075310829e-06
HC B-Disease 0 0.0029891557060182095
patients O 0 3.074797632507398e-06
from O 0 2.359496647841297e-06
France O 0 1.164144691756519e-06
, O 0 9.826916880228964e-08
Holland O 0 2.4792217345748213e-07
, O 0 2.056944659045712e-08
and O 0 3.0135783646301206e-08
Czech O 0 1.1781559123846819e-06
Republic O 0 5.890651209483622e-06
. O 0 4.385735792311607e-06

Seven O 0 6.0090380429755896e-05
novel O 0 5.634602530335542e-06
mutations O 0 8.875762205207138e-07
and O 0 2.730008930029726e-07
two O 0 6.890088144473339e-08
new O 0 1.1301591484880191e-07
polymorphisms O 0 7.782030593261879e-07
were O 0 2.0768566173501313e-06
detected O 0 2.0716817743959837e-05
. O 0 2.4645335088280262e-06

Among O 0 8.225090823543724e-06
these O 0 2.7390163381824095e-07
mutations O 0 3.403901018828037e-07
two O 0 2.5120633040387474e-07
are O 0 7.864226603260249e-08
missense O 0 1.8845925069399527e-06
( O 0 4.72895862912992e-07
G197W O 0 5.98279348196229e-06
, O 0 8.96446181286592e-07
W427R O 0 8.406260349147487e-06
) O 0 2.1397495686414914e-07
, O 0 9.076321560996803e-08
two O 0 1.3103061746733147e-07
are O 0 2.445153484131879e-07
nonsense O 0 1.3165245036361739e-05
( O 0 8.559360367144109e-07
Q306X O 0 1.6682255591149442e-05
, O 0 1.1119836926809512e-06
Q385X O 0 1.0302376722393092e-05
) O 0 2.652483317433507e-07
, O 0 7.100997123643538e-08
two O 0 2.5773994494215913e-08
are O 0 1.7909670191329496e-08
small O 0 6.15842452589277e-08
deletions O 0 6.411790991478483e-07
( O 0 2.2188930870470358e-07
662de14bp O 0 4.743294084619265e-06
; O 0 2.3548403760287329e-07
1168del3bp O 0 8.530782906746026e-06
removing O 0 2.9066552542644786e-06
a O 0 4.777443336934084e-06
glycine O 0 4.525277290667873e-06
at O 0 9.995088475989178e-06
position O 0 1.059523128787987e-06
390 O 0 1.3748575611316483e-06
) O 0 3.172499418724328e-08
, O 0 2.0526178090563008e-08
and O 0 1.9817470331418008e-08
one O 0 5.649629741810713e-08
is O 0 6.741541369592596e-08
a O 0 1.4428125894028199e-07
splicing O 0 3.21240776202103e-07
mutation O 0 2.670209084953967e-07
( O 0 3.023314150141232e-07
IVS1 O 0 1.6429641618742608e-05
- O 0 2.16958665077982e-06
15c O 0 6.628978098888183e-06
- O 0 8.973913736554096e-07
- O 0 1.2671762306126766e-06
> O 0 1.0699820904847002e-06
g O 0 1.3541609860112658e-06
) O 0 4.070820480706061e-08
which O 0 2.27259562279869e-08
creates O 0 7.681861546871005e-08
a O 0 1.6316765538704203e-07
new O 0 1.2215389233460883e-07
acceptor O 0 3.601515743412165e-07
splice O 0 2.174033170376788e-06
site O 0 2.1086148080939893e-06
. O 0 4.341531791851594e-07

The O 0 3.745234789676033e-05
pathological O 0 9.067830251296982e-05
significance O 0 9.381967174704187e-06
of O 0 2.8906364605063573e-05
the O 0 6.250884325709194e-06
point O 0 1.0373210898251273e-05
mutations O 0 4.975492515768565e-07
G197W O 0 1.3296646102389786e-05
, O 0 6.64003664496704e-07
W427R O 0 1.0379930245107971e-05
, O 0 6.358206405820965e-07
and O 0 4.4873502247355646e-07
the O 0 3.7652205264748773e-06
in O 0 5.618585419142619e-06
- O 0 2.981286343128886e-05
frame O 0 0.00010116465273313224
deletion O 0 3.3343581890221685e-05
390delGly O 0 3.452516466495581e-05
were O 0 4.468681254365947e-06
assessed O 0 2.0899319679301698e-06
by O 0 1.0886331125448123e-07
their O 0 6.946220310055651e-08
respective O 0 6.729118240400567e-07
expression O 0 9.51779838942457e-07
in O 0 3.325182831304119e-07
a O 0 4.231893910855433e-07
prokaryotic O 0 2.3793741377176048e-07
system O 0 5.00092426136689e-07
using O 0 8.502559012413258e-08
site O 0 8.262964570349141e-07
- O 0 4.545128149402444e-07
directed O 0 4.081464339833474e-07
mutagenesis O 0 5.5710711421852466e-06
. O 0 1.5111854736460373e-06

These O 0 5.4522934078704566e-06
mutations O 0 4.224259555485332e-06
resulted O 0 1.2354893442534376e-05
in O 0 2.2743183762941044e-06
the O 0 2.6164182145294035e-06
absence O 0 6.315194696071558e-06
or O 0 1.9706770615357527e-07
a O 0 1.6326663399013341e-07
dramatic O 0 1.3392425444180844e-06
decrease O 0 1.0473018846823834e-05
of O 0 0.00010862695489777252
CPO O 0 0.24945776164531708
activity O 0 2.7849477191921324e-05
. O 0 2.305837369931396e-06

The O 0 0.00013474457955453545
two O 0 3.9226988519658335e-06
polymorphisms O 0 4.346836249169428e-06
were O 0 2.792942495943862e-06
localized O 0 2.283161165905767e-06
in O 0 1.2593767451107851e-06
noncoding O 0 2.903582753788214e-06
part O 0 5.974167720523837e-07
of O 0 3.0167066142894328e-06
the O 0 8.065150609581906e-07
gene O 0 3.884529675701742e-08
1 O 0 2.2313389536066097e-07
) O 0 1.5592277691212075e-08
a O 0 2.045641878112292e-07
C O 0 3.817116976279067e-06
/ O 0 1.0273207635691506e-06
G O 0 1.1465051557024708e-06
polymorphism O 0 1.9864610578679276e-07
in O 0 4.848245112043514e-07
the O 0 1.4878036154186702e-06
promotor O 0 2.787232915579807e-05
region O 0 1.6117840004881145e-06
, O 0 4.511073825597123e-07
142 O 0 2.7758048872783547e-06
bp O 0 3.3174080726894317e-06
upstream O 0 6.030670647305669e-06
from O 0 6.988092309256899e-07
the O 0 4.253111001162324e-07
transcriptional O 0 1.8888459862864693e-06
initiation O 0 1.0986065035467618e-06
site O 0 1.0889233408306609e-06
( O 0 8.276168017573582e-08
- O 0 5.115847443448729e-07
142C O 0 5.909021638217382e-06
/ O 0 3.6011485917697428e-06
G O 0 5.205872184887994e-06
) O 0 9.096997644064686e-08
, O 0 5.018314297444704e-08
and O 0 5.84611505871635e-08
2 O 0 5.421517812465027e-07
) O 0 4.57493918304408e-08
a O 0 8.264004804914293e-07
6 O 0 4.495172561291838e-06
bp O 0 5.035807589592878e-06
deletion O 0 1.2041574564136681e-06
polymorphism O 0 2.3383628899864561e-07
in O 0 2.4391329134232365e-07
the O 0 4.4021189182785747e-07
3 O 0 3.764707230402564e-07
noncoding O 0 6.368644562826375e-07
part O 0 4.7182098228404357e-07
of O 0 4.6829759412503336e-06
the O 0 4.442328190634726e-06
CPO O 0 4.890692071057856e-05
gene O 0 4.184873034773773e-07
, O 0 4.0334947470910265e-07
574 O 0 6.050406682334142e-06
bp O 0 5.565038918575738e-06
downstream O 0 6.484342975454638e-06
of O 0 3.3878034173540073e-06
the O 0 1.2546991001727292e-06
last O 0 1.2555741477626725e-06
base O 0 1.0400325436421554e-06
of O 0 9.427874942957715e-07
the O 0 1.3876997400075197e-06
normal O 0 3.8782477531640325e-06
termination O 0 7.127108347049216e-06
codon O 0 3.892120275850175e-06
( O 0 1.4515323698560678e-07
+ O 0 7.34818229375378e-07
574 O 0 6.171964287204901e-06
delATTCTT O 0 7.529210506618256e-06
) O 0 4.411347731547721e-07
. O 0 5.654576966662717e-07

Five O 0 0.00033262866782024503
intragenic O 0 0.0032166466116905212
dimorphisms O 0 0.001613105647265911
are O 0 2.2298761450656457e-06
now O 0 3.559322578894353e-07
well O 0 1.3684658028978447e-07
characterized O 0 3.110408499651385e-07
and O 0 6.574417454885406e-08
the O 0 3.912545025741565e-07
high O 0 8.04747105576098e-06
degree O 0 5.7304391702928115e-06
of O 0 4.1956332097470295e-06
allelic O 0 5.433326805359684e-06
heterogeneity O 0 9.505293746769894e-06
in O 0 9.956936992239207e-06
HC B-Disease 1 0.9305094480514526
is O 0 1.6252777186309686e-06
demonstrated O 0 1.0728266488513327e-06
with O 0 4.155474897515887e-08
seven O 0 8.88570781398812e-08
new O 0 1.3745657057029348e-08
different O 0 1.1749341499722732e-09
mutations O 0 5.903527888762028e-09
making O 0 2.7642599320643058e-08
a O 0 1.0347351064865506e-07
total O 0 1.0735359410318779e-06
of O 0 8.56811038829619e-06
nineteen O 0 0.00022810505470260978
CPO O 1 0.9897969365119934
gene B-Disease 0 0.00026826176326721907
defects I-Disease 0 0.041080161929130554
reported O 0 6.632355052715866e-06
so O 0 1.1015727352514659e-07
far O 0 1.2283670969281957e-07
. O 0 4.36140936699303e-08
. O 0 3.437298516928422e-07

Coincidence O 0 0.0002631592797115445
of O 0 2.4645434677950107e-05
two O 0 1.5324527566917823e-06
novel O 0 3.2896932680159807e-06
arylsulfatase O 0 4.7230183554347605e-05
A O 0 1.8338884046897874e-06
alleles O 0 1.8350939967604063e-07
and O 0 7.687504677278412e-08
mutation O 0 2.359788453532019e-07
459 O 0 1.0978986210830044e-05
+ O 0 6.116089934948832e-06
1G O 0 0.00012525793863460422
> O 0 2.135597924279864e-06
A O 0 6.65727043269726e-07
within O 0 7.878038132957954e-08
a O 0 3.558477601472987e-07
family O 0 1.2638631119443744e-07
with O 0 2.1955722218081064e-07
metachromatic B-Disease 1 0.9999945163726807
leukodystrophy I-Disease 1 0.9999428987503052
: O 0 2.969540702224549e-08
molecular O 0 5.6803376224934254e-08
basis O 0 4.1533354533385136e-08
of O 0 3.6177294759909273e-07
phenotypic O 0 5.886523922526976e-06
heterogeneity O 0 4.1133829654427245e-05
. O 0 4.792310392076615e-06

In O 0 0.00016769221110735089
a O 0 3.0410883482545614e-05
family O 0 1.2610809108082321e-06
with O 0 4.5035559992356866e-07
three O 0 1.8531287651057937e-06
siblings O 0 1.3776335663351347e-06
, O 0 6.765655768958823e-08
one O 0 2.6678412368141835e-08
developed O 0 1.5333064595779433e-07
classical O 0 5.5221451475517824e-05
late O 0 0.36536648869514465
infantile O 1 0.999996542930603
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999978542327881
( O 0 4.7568664740538225e-06
MLD B-Disease 1 0.999993085861206
) O 0 5.382796643971233e-07
, O 0 1.1027289303910948e-07
fatal O 0 3.2199973247770686e-06
at O 0 5.7594056670495775e-06
age O 0 5.894967216590885e-07
5 O 0 6.042491236257774e-07
years O 0 2.703096981804265e-07
, O 0 3.7880798942069305e-08
with O 0 6.179203637657338e-08
deficient O 0 5.6420725741190836e-05
arylsulfatase O 0 5.275676085148007e-05
A O 0 3.90269051422365e-05
( O 0 4.672473892242124e-07
ARSA O 0 1.58834573085187e-05
) O 0 4.699958822129702e-08
activity O 0 4.774527724293876e-07
and O 0 6.060265178575719e-08
increased O 0 3.094055955443764e-06
galactosylsulfatide O 0 4.113995237275958e-05
( O 0 2.463222244841745e-06
GS O 1 0.99897301197052
) O 0 5.742227244809328e-07
excretion O 0 5.610590960714035e-06
. O 0 3.572186813016742e-07

The O 0 0.00020632623636629432
two O 0 8.453950613329653e-06
other O 0 9.449766480429389e-07
siblings O 0 4.216411070956383e-06
, O 0 7.998526712071907e-07
apparently O 0 1.3771264093520585e-06
healthy O 0 7.484241564270633e-07
at O 0 2.61511854660057e-06
12 O 0 1.9398599704345543e-07
( O 0 1.9012889040936898e-08
1 O 0 1.7800496721065429e-07
/ O 0 2.2215249373402912e-07
2 O 0 3.1704402658760955e-07
) O 0 2.1264042970869923e-08
and O 0 4.471595360655556e-08
15 O 0 4.841176064473984e-07
years O 0 6.43814530576492e-07
, O 0 1.8662763068277854e-07
respectively O 0 1.2946361493959557e-06
, O 0 4.756448745979469e-08
and O 0 9.882159446306105e-08
their O 0 3.621077553361829e-07
father O 0 1.695467290119268e-05
, O 0 5.314862505656492e-07
apparently O 0 1.5017894838820212e-06
healthy O 0 2.9530261258514656e-07
as O 0 1.2098224999590457e-07
well O 0 6.312529876595363e-08
, O 0 5.060240226839596e-08
presented O 0 6.817456892349583e-07
ARSA O 0 0.0001212676361319609
and O 0 2.5715614810906118e-06
GS O 1 0.9999345541000366
values O 0 1.7111682382164872e-07
within O 0 4.213602267100214e-08
the O 0 1.1728261029020359e-07
range O 0 6.749942258466035e-07
of O 0 1.1846754205180332e-05
MLD B-Disease 1 1.0
patients O 0 2.1756221030955203e-05
. O 0 4.542793703876669e-06

Mutation O 0 9.342682460555807e-06
screening O 0 2.4074588509392925e-06
and O 0 3.17682349759707e-07
sequence O 0 5.4679492222931e-07
analysis O 0 2.1102111702475668e-07
disclosed O 0 2.753263288468588e-06
the O 0 1.1503020687086973e-06
involvement O 0 4.733217792818323e-06
of O 0 1.0257788744638674e-05
three O 0 9.091878041544987e-07
different O 0 1.2091672374481277e-07
ARSA O 0 8.819108188617975e-05
mutations O 0 1.4214887755770178e-07
being O 0 1.0751890755500426e-07
the O 0 2.7071568098335774e-08
molecular O 0 5.0619004099417e-08
basis O 0 1.3182602742745075e-07
of O 0 2.2325339159579016e-06
intrafamilial O 0 5.6673310609767213e-05
phenotypic O 0 1.5175518456089776e-05
heterogeneity O 0 0.0001248539483640343
. O 0 1.4610454854846466e-05

The O 0 0.0002884293207898736
late O 0 0.010406536981463432
infantile O 1 0.9999895095825195
patient O 0 0.0018906955374404788
inherited O 0 0.4869460463523865
from O 0 9.24389241845347e-05
his O 0 4.165338759776205e-05
mother O 0 1.643716313992627e-05
the O 0 1.8976751334776054e-06
frequent O 0 5.069674102742283e-07
0 O 0 5.740968163081561e-07
- O 0 2.420721330054221e-07
type O 0 1.5957904508923093e-07
mutation O 0 2.159886633990027e-07
459 O 0 7.541440936620347e-06
+ O 0 2.096299795084633e-06
1G O 0 5.160396176506765e-05
> O 0 2.025243929892895e-06
A O 0 1.9141280063195154e-06
, O 0 1.0994778421036244e-07
and O 0 1.6620519716070703e-07
from O 0 5.57584769467212e-07
his O 0 1.4897103710609372e-06
father O 0 6.289704288064968e-06
a O 0 8.167273790604668e-07
novel O 0 3.5420632116256456e-07
, O 0 8.85478002032869e-08
single O 0 2.8953573405487987e-07
basepair O 0 8.720451660337858e-06
microdeletion O 0 1.0978053978760727e-05
of O 0 9.06227342056809e-06
guanine O 0 3.0319408779178048e-06
at O 0 3.4857928312703734e-06
nucleotide O 0 2.9329390827115276e-07
7 O 0 5.960571911600709e-07
in O 0 1.3453340841351746e-07
exon O 0 3.261064023263316e-07
1 O 0 6.407616410797345e-07
( O 0 1.0998638089176893e-07
7delG O 0 1.0190034345214372e-06
) O 0 2.2070177863042773e-07
. O 0 4.100249384464405e-07

The O 0 9.491608216194436e-05
two O 0 1.0176119758398272e-05
clinically O 0 0.001310899038799107
unaffected O 0 8.287389937322587e-05
siblings O 0 1.6876473409865866e-06
carried O 0 5.19983075264463e-07
the O 0 3.110396562533424e-07
maternal O 0 9.302673788624816e-06
mutation O 0 8.312996442327858e-07
459 O 0 1.476250145060476e-05
+ O 0 2.862121164071141e-06
1G O 0 8.870946476235986e-05
> O 0 3.624909822974587e-06
A O 0 3.4907661756733432e-06
and O 0 2.0474530515457445e-07
, O 0 9.59764818730946e-08
on O 0 7.713882155258034e-07
their O 0 1.6710764327854122e-07
paternal O 0 2.0507552108028904e-05
allele O 0 7.697972250753082e-07
, O 0 5.770703737084659e-08
a O 0 5.713479112046116e-08
novel O 0 8.019915753720852e-08
cytosine O 0 1.1723507498118124e-07
to O 0 3.665354597615078e-08
thymidine O 0 1.309880531152885e-06
transition O 0 3.658018840724253e-06
at O 0 8.324426744366065e-06
nucleotide O 0 2.2521285245602485e-06
2435 O 0 1.6071326172095723e-05
in O 0 4.7299778316300944e-07
exon O 0 9.011811812342785e-07
8 O 0 7.264097234838118e-07
, O 0 3.0135609563330945e-08
resulting O 0 6.710725841685417e-08
in O 0 6.85571635017368e-08
substitution O 0 6.243760140023369e-07
of O 0 2.69034080702113e-06
alanine O 0 6.069408755138284e-06
464 O 0 1.323902415606426e-05
by O 0 1.8849483467420214e-06
valine O 0 2.9220052965683863e-05
( O 0 5.765779746980115e-07
A464V O 0 1.5421952411998063e-05
) O 0 8.955540806709905e-07
. O 0 1.1179818102391437e-06

The O 0 0.00013000480248592794
fathers O 0 4.5022003178019077e-05
genotype O 0 8.526636520400643e-06
thus O 0 3.30421312355611e-06
was O 0 2.0263456462998874e-05
7delG O 0 4.38014067185577e-05
/ O 0 6.009175558574498e-05
A464V O 0 0.00012383045395836234
. O 0 4.150732820562553e-06

Mutation O 0 0.0003299481759313494
A464V O 0 0.000692341651301831
was O 0 6.22490479145199e-05
not O 0 2.966758927414048e-07
found O 0 1.2149514816428564e-07
in O 0 2.151919460402496e-07
18 O 0 7.132990504032932e-06
unrelated O 0 2.131403198291082e-05
MLD B-Disease 1 1.0
patients O 0 3.630874516602489e-06
and O 0 1.5789582903380506e-06
50 O 0 6.322908575384645e-06
controls O 0 1.36746239149943e-05
. O 0 3.567438170648529e-06

A464V O 0 0.003377040848135948
, O 0 1.8608023310662247e-05
although O 0 3.299647005405859e-06
clearly O 0 7.281621947186068e-06
modifying O 0 1.2646250070247333e-05
ARSA O 0 0.0010844927746802568
and O 0 4.400563193485141e-05
GS O 1 1.0
levels O 0 0.0002461708791088313
, O 0 5.415657824414666e-07
apparently O 0 4.2631248220459383e-07
bears O 0 2.354528305659187e-07
little O 0 1.886629696912223e-08
significance O 0 4.6317460089539964e-08
for O 0 6.68474129383867e-08
clinical O 0 4.247656761435792e-06
manifestation O 0 0.00025532685685902834
of O 1 0.8036465644836426
MLD B-Disease 1 1.0
, O 0 5.902882548980415e-06
mimicking O 0 1.2573016647365876e-05
the O 0 4.302504294173559e-06
frequent O 0 1.227033953909995e-05
ARSA O 0 0.005228154826909304
pseudodeficiency O 0 0.0014352691359817982
allele O 0 5.3603875130647793e-05
. O 0 5.93694267081446e-06

Our O 0 1.9433407942415215e-05
results O 0 2.504428039173945e-06
demonstrate O 0 7.355901630035078e-07
that O 0 4.9412097524736964e-08
in O 0 1.211993492233887e-07
certain O 0 1.762882106959296e-07
genetic O 0 3.5719522202271037e-06
conditions O 0 0.012004704214632511
MLD B-Disease 1 1.0
- O 0 0.014798924326896667
like O 0 8.922098459152039e-06
ARSA O 0 0.0007912773871794343
and O 0 6.548238616232993e-06
GS O 1 0.9999996423721313
values O 0 5.01733325108944e-07
need O 0 4.706184242309064e-08
not O 0 1.9251617189297576e-08
be O 0 2.5104485601445958e-08
paralleled O 0 3.489217590413318e-07
by O 0 4.729616875920328e-08
clinical O 0 1.4288377315097023e-05
disease O 0 8.61403259477811e-06
, O 0 2.0751263818397092e-08
a O 0 2.292989975671844e-08
finding O 0 1.5266042652228862e-08
with O 0 1.5120511065447317e-08
serious O 0 1.6167102785402676e-06
diagnostic O 0 3.6875662772217765e-05
and O 0 2.6944153432850726e-06
prognostic O 0 0.018947655335068703
implications O 0 3.972581907873973e-05
. O 0 6.27795270702336e-06

Moreover O 0 0.00029999506659805775
, O 0 6.794046839786461e-06
further O 0 5.966634034848539e-06
ARSA O 0 0.00043596996692940593
alleles O 0 3.68897372027277e-06
functionally O 0 6.635904355789535e-06
similar O 0 5.362558681554219e-07
to O 0 4.2225732954648265e-07
A464V O 0 7.717850166955031e-06
might O 0 3.144930929011025e-07
exist O 0 1.373011144778502e-07
which O 0 1.1004786415469425e-07
, O 0 1.1647866671182783e-08
together O 0 2.5662920677405054e-09
with O 0 8.670268947241766e-09
0 O 0 7.082485922182968e-07
- O 0 1.2046202755300328e-06
type O 0 1.0455528354214039e-06
mutations O 0 3.135820350053109e-07
, O 0 1.1457341031473334e-07
may O 0 7.789559504089993e-07
cause O 0 5.201479780225782e-06
pathological O 1 0.8488292098045349
ARSA O 0 0.012926202267408371
and O 0 2.180389128625393e-05
GS O 1 1.0
levels O 0 7.216630365292076e-06
, O 0 1.949772965303964e-08
but O 0 1.6502993416267486e-09
not O 0 2.54576737468426e-09
clinical O 0 4.655145460219501e-07
outbreak O 0 2.9051172987237806e-06
of O 0 3.781161467486527e-06
the O 0 2.0241495803929865e-05
disease O 0 0.0003571535926312208
. O 0 5.126875635141914e-07
. O 0 1.4053542827241472e-06

Human O 1 0.7514486908912659
MLH1 O 1 0.9999996423721313
deficiency O 1 1.0
predisposes O 0 0.001645660144276917
to O 0 1.8163393178838305e-05
hematological B-Disease 1 0.9987149238586426
malignancy I-Disease 1 0.9995701909065247
and O 0 1.2000694368907716e-05
neurofibromatosis B-Disease 1 0.9972060322761536
type I-Disease 0 0.0001534195471322164
1 I-Disease 0 0.0001223593862960115
. O 0 2.7997321012662724e-06

Heterozygous O 0 0.0010219777468591928
germ O 0 0.012829895131289959
- O 0 0.00013175950152799487
line O 0 4.424190592544619e-06
mutations O 0 7.237088794909141e-08
in O 0 6.971545474243612e-08
the O 0 9.654252153268317e-08
DNA O 0 4.3301108121340803e-07
mismatch O 0 6.399369158316404e-05
repair O 0 4.81489987578243e-05
genes O 0 1.0176594287258922e-06
lead O 0 6.280503839661833e-06
to O 0 7.527738944190787e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.828408782486804e-05

The O 0 0.000486155302496627
disease O 0 0.009747696109116077
susceptibility O 0 0.00013779844448436052
of O 0 0.00013208492600824684
individuals O 0 1.1251706837356323e-06
who O 0 3.087517825406394e-06
constitutionally O 0 4.060610808664933e-05
lack O 0 9.716942258819472e-06
both O 0 5.323273057911138e-07
wild O 0 4.7430680183424556e-07
- O 0 1.2435490361895063e-06
type O 0 5.568301730818348e-07
alleles O 0 2.841035211531562e-07
is O 0 1.4447857665800257e-07
unknown O 0 1.0521164313104236e-06
. O 0 4.024975623906357e-07

We O 0 9.579626748745795e-06
have O 0 4.543477132301632e-07
identified O 0 1.498952144629584e-07
three O 0 8.377303117867996e-08
offspring O 0 1.246352923089944e-07
in O 0 4.712076702162449e-07
a O 0 2.8465634386520833e-05
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.08484666794538498
who O 0 7.126714081095997e-06
developed O 0 6.796813977416605e-06
hematological B-Disease 0 0.07803267985582352
malignancy I-Disease 1 0.9894407391548157
at O 0 0.00030627433443441987
a O 0 1.3732536672250717e-06
very O 0 6.122212425907492e-08
early O 0 4.602377146056824e-07
age O 0 6.203767384249659e-07
, O 0 1.1288631895922663e-07
and O 0 8.517150718034827e-08
at O 0 1.7225390820385655e-06
least O 0 3.28888170031405e-08
two O 0 2.5244260015711006e-08
of O 0 3.88435239528917e-07
them O 0 2.352485140022509e-08
displayed O 0 3.8543557820958085e-06
signs O 0 2.3748300009174272e-05
of O 0 1.2791268090950325e-05
neurofibromatosis B-Disease 0 0.0012088132789358497
type I-Disease 0 3.4155604225816205e-05
1 I-Disease 0 4.673412331612781e-05
( O 0 1.1786493132603937e-06
NF1 B-Disease 0 0.00011549014743650332
) O 0 9.791235697775846e-07
. O 0 9.546014325678698e-07

DNA O 0 1.0915852726611774e-05
sequence O 0 6.89823991706362e-06
analysis O 0 2.046778945441474e-06
and O 0 4.956340831085981e-07
allele O 0 6.017693863213935e-07
- O 0 8.088227900771017e-07
specific O 0 4.077324433637841e-08
amplification O 0 1.997516392293619e-06
in O 0 4.231344803429238e-07
two O 0 2.479238219166291e-07
siblings O 0 1.3727704981647548e-06
revealed O 0 2.744423454714706e-06
a O 0 2.063205783997546e-06
homozygous O 0 4.219339189148741e-06
MLH1 O 0 7.800280582159758e-05
mutation O 0 9.269058978134126e-07
( O 0 2.0005771261821792e-07
C676T O 0 3.1640804536436917e-06
- O 0 2.2149783944769297e-06
- O 0 3.4165955185017083e-06
> O 0 2.7669982500810875e-06
Arg226Stop O 0 1.0338338142901193e-05
) O 0 4.0242886711894243e-07
. O 0 3.734651272679912e-07

Thus O 0 5.09374585817568e-05
, O 0 2.2756548787583597e-06
a O 0 1.5916850770736346e-06
homozygous O 0 9.239140126737766e-06
germ O 0 0.003385851625353098
- O 0 0.00014053573249839246
line O 0 2.7422325729276054e-05
MLH1 O 0 0.00015458122652489692
mutation O 0 2.675385815109621e-07
and O 0 2.6151633392146323e-07
consequent O 1 0.9026322960853577
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 1.9467985111987218e-05
in O 0 1.1289251915513887e-06
a O 0 4.117111984669464e-06
mutator O 0 0.003889435902237892
phenotype O 0 3.5336556720722e-06
characterized O 0 2.877091560549161e-07
by O 0 1.9798434891526995e-07
leukemia B-Disease 1 0.9414073824882507
and O 0 9.08069978322601e-06
/ O 1 0.9997192025184631
or O 0 0.11691876500844955
lymphoma B-Disease 1 1.0
associated O 0 0.0002873993944376707
with O 0 1.5292175703507382e-06
neurofibromatosis B-Disease 1 0.9992852807044983
type I-Disease 0 0.00011601444566622376
1 I-Disease 0 2.594332181615755e-05
. O 0 1.0227113023120182e-07
. O 0 4.6204564796425984e-07

Missense O 0 0.0006312061450444162
mutations O 0 2.09229692700319e-05
in O 0 8.26571249490371e-06
the O 0 1.8552507299318677e-06
most O 0 1.0374147763059227e-07
ancient O 0 6.583150593542086e-07
residues O 0 9.414944770469447e-07
of O 0 3.2330010526493425e-06
the O 0 1.0582594768493436e-05
PAX6 O 0 0.0010268668411299586
paired O 0 1.9302410692034755e-06
domain O 0 1.4949476963010966e-06
underlie O 0 3.7995530419721035e-06
a O 0 2.0532253586225124e-07
spectrum O 0 9.923379593601567e-07
of O 0 8.390435141336638e-06
human O 1 0.999691367149353
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.0001051747240126133

Mutations O 0 9.028801287058741e-06
of O 0 4.4658354454441e-06
the O 0 1.976944531634217e-06
human O 0 6.416063570213737e-06
PAX6 O 0 0.034641727805137634
gene O 0 7.356018613791093e-05
underlie O 1 0.9982988238334656
aniridia B-Disease 1 1.0
( O 0 0.3751029074192047
congenital B-Disease 1 1.0
absence I-Disease 1 0.9999216794967651
of I-Disease 1 0.9978109002113342
the I-Disease 0 0.0007089525461196899
iris I-Disease 0 0.00031171433511190116
) O 0 9.247590071481682e-08
, O 0 3.0734376821328624e-08
a O 0 1.4218588262338017e-07
rare O 0 2.1959608602628578e-06
dominant O 0 0.22228506207466125
malformation B-Disease 1 1.0
of I-Disease 1 0.9999388456344604
the I-Disease 1 0.9882977604866028
eye I-Disease 1 0.9998904466629028
. O 0 1.575576425238978e-05

The O 0 6.423238664865494e-05
spectrum O 0 4.017958417534828e-05
of O 0 5.392241291701794e-05
PAX6 O 0 0.005371648818254471
mutations O 0 2.1039522835053504e-05
in O 0 0.00010308658238500357
aniridia B-Disease 1 1.0
patients O 0 1.9382361642783508e-05
is O 0 1.3067899544694228e-06
highly O 0 3.384246838322724e-07
biased O 0 4.237838879816991e-07
, O 0 1.8518866440331294e-08
with O 0 5.413476777960113e-09
92 O 0 8.097728709799412e-07
% O 0 8.118492189623794e-08
of O 0 5.496999051501916e-07
all O 0 1.0006297657128016e-07
reported O 0 1.245862677023979e-06
mutations O 0 2.2433752633332915e-07
leading O 0 6.558300356118707e-06
to O 0 2.3320936293202976e-07
premature O 0 6.2127114688337315e-06
truncation O 0 3.713562364282552e-06
of O 0 9.283442523155827e-06
the O 0 5.455643076857086e-06
protein O 0 1.3513175645130104e-06
( O 0 2.7578991534937813e-07
nonsense O 0 3.2790060231491225e-06
, O 0 1.1087797702202806e-07
splicing O 0 9.680601920081244e-08
, O 0 6.881367653477355e-08
insertions O 0 1.623521086457913e-07
and O 0 1.3451622749016678e-07
deletions O 0 2.763612485523481e-07
) O 0 8.795261408067745e-08
and O 0 1.3002023990793532e-07
just O 0 2.9049323302388075e-07
2 O 0 4.562303956845426e-07
% O 0 1.440997436930047e-07
leading O 0 5.217852958594449e-07
to O 0 4.290656363536982e-08
substitution O 0 7.175606810960744e-07
of O 0 3.228228479201789e-06
one O 0 8.052485327425529e-07
amino O 0 6.562289627254358e-07
acid O 0 9.458623395630639e-08
by O 0 4.368111206076719e-08
another O 0 1.2179619091057248e-07
( O 0 3.077279941976485e-08
missense O 0 5.621852778858738e-07
) O 0 1.529284645584994e-07
. O 0 3.6794554603147844e-07

The O 0 2.766608668025583e-05
extraordinary O 0 1.4379582353285514e-05
conservation O 0 3.330109393573366e-06
of O 0 3.6616834222513717e-06
the O 0 3.7591926229652017e-06
PAX6 O 0 9.831431816564873e-05
protein O 0 5.642022642859956e-06
at O 0 1.777529723767657e-05
the O 0 2.291006694576936e-06
amino O 0 3.891073447448434e-06
acid O 0 1.4895257436364773e-06
level O 0 1.1179071407241281e-05
amongst O 0 8.941477176449553e-07
vertebrates O 0 3.445967649895465e-06
predicts O 0 1.0448151215314283e-06
that O 0 4.53347865914111e-08
pathological O 0 1.5778936358401552e-05
missense O 0 3.4510521800257266e-06
mutations O 0 4.920523792861786e-07
should O 0 2.1373266179125494e-07
in O 0 4.003655647011328e-07
fact O 0 2.017954869870664e-07
be O 0 1.988944262620862e-07
common O 0 7.743366126078399e-08
even O 0 6.70572291028293e-08
though O 0 3.4921928460107665e-08
they O 0 3.8111551248221076e-08
are O 0 1.487967526969669e-08
hardly O 0 2.1393148585957533e-07
ever O 0 2.5399978653695143e-07
seen O 0 1.0939174899249338e-06
in O 0 3.1294498512579594e-06
aniridia B-Disease 1 0.9999939203262329
patients O 0 1.3877189303457271e-05
. O 0 6.353809112624731e-06

This O 0 1.941859045473393e-05
indicates O 0 1.1436306522227824e-05
that O 0 2.6365341909695417e-07
there O 0 2.6452508450347523e-07
is O 0 1.4171952500419138e-07
a O 0 5.472289217323123e-07
heavy O 0 3.122512862319127e-05
ascertainment O 0 0.0068076737225055695
bias O 0 9.380848496221006e-06
in O 0 5.547693717744551e-07
the O 0 2.8929119366694067e-07
selection O 0 8.943483464918245e-08
of O 0 4.845041985390708e-07
patients O 0 1.5216832593978324e-07
for O 0 2.762105282272387e-07
PAX6 O 0 0.00011245081986999139
mutation O 0 3.013595915035694e-07
analysis O 0 6.854291001445745e-08
and O 0 3.103592760567153e-08
that O 0 3.216521093918345e-08
the O 0 5.910560503252782e-07
missing O 0 4.501942385104485e-06
PAX6 O 0 0.00027249008417129517
missense O 0 1.7780213966034353e-05
mutations O 0 2.306494934600778e-06
frequently O 0 9.839706081038457e-07
may O 0 1.7421956499674707e-06
underlie O 0 7.4075419433938805e-06
phenotypes O 0 2.985470246130717e-06
distinct O 0 2.3798325798907172e-07
from O 0 2.500785967640695e-06
textbook O 0 0.0001742149324854836
aniridia B-Disease 1 0.9999737739562988
. O 0 1.3276272511575371e-05

Here O 0 4.621769767254591e-05
we O 0 6.297954087131075e-07
present O 0 3.8921024270166527e-07
four O 0 4.1029758790500637e-07
novel O 0 1.3498157613867079e-06
PAX6 O 0 8.919014362618327e-05
missense O 0 7.914205525594298e-06
mutations O 0 6.331376312118664e-07
, O 0 1.419106183675467e-07
two O 0 5.994758822680524e-08
in O 0 3.3526498555147555e-07
association O 0 7.515183142459136e-07
with O 0 3.2814256201163516e-08
atypical O 0 0.0015864205779507756
phenotypes O 0 0.002402360551059246
ectopia B-Disease 1 0.7487712502479553
pupillae I-Disease 0 0.0029997120145708323
( O 0 7.897911018517334e-07
displaced B-Disease 0 1.0713115443650167e-06
pupils I-Disease 0 5.004691956855822e-06
) O 0 5.764795218965446e-07
and O 0 1.0379178092989605e-05
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9998515844345093
( O 0 5.317495833878638e-06
searching B-Disease 0 3.7254951621434884e-06
gaze I-Disease 0 0.00012444861931726336
) O 0 2.0155276558853075e-07
, O 0 6.043539002575926e-08
and O 0 8.706781784439954e-08
two O 0 1.5581626655603031e-07
in O 0 1.5221578451019013e-06
association O 0 1.5806864439582569e-06
with O 0 3.979091900419007e-08
more O 0 8.560277109381786e-08
recognizable O 0 1.2149937901995145e-05
aniridia B-Disease 1 0.9999998807907104
phenotypes O 0 6.15667158854194e-05
. O 0 2.9706650366279064e-06

Strikingly O 0 0.0005469019524753094
, O 0 4.5506767492042854e-06
all O 0 2.8459325562835147e-07
four O 0 2.587828475952847e-07
mutations O 0 6.639454142032264e-08
are O 0 3.8415738146113654e-08
located O 0 5.192739536141744e-07
within O 0 9.598069539151766e-08
the O 0 1.6517351468792185e-06
PAX6 O 0 4.843304486712441e-05
paired O 0 6.995828130129667e-07
domain O 0 2.604620249258005e-06
and O 0 5.389669013311504e-07
affect O 0 2.349347596464213e-06
amino O 0 2.751218517005327e-06
acids O 0 3.100280139278766e-07
which O 0 9.849285476093428e-08
are O 0 2.234828677671885e-08
highly O 0 5.860617591224582e-08
conserved O 0 1.1821013146118275e-07
in O 0 1.0472857780996492e-07
all O 0 3.5302729628483576e-08
known O 0 2.408103512152593e-07
paired O 0 2.1113122272709006e-07
domain O 0 4.2256868937329273e-07
proteins O 0 3.2103741887112847e-07
. O 0 7.593014856865921e-07

Our O 0 0.00014538614777848125
results O 0 3.062306859646924e-05
support O 0 6.39933159618522e-06
the O 0 3.3072174119297415e-06
hypothesis O 0 8.861180731400964e-07
that O 0 1.0139824269117526e-07
the O 0 3.1730053251521895e-07
under O 0 7.258266805365565e-07
- O 0 1.8983543270678638e-07
representation O 0 1.19212046456596e-07
of O 0 2.055303184533841e-06
missense O 0 1.1336936950101517e-05
mutations O 0 2.0817963104491355e-06
is O 0 1.5099004713192699e-06
caused O 0 5.218388196226442e-06
by O 0 2.2488244155738357e-07
ascertainment O 0 0.00010599265078781173
bias O 0 2.61334866991092e-06
and O 0 1.7387169748417364e-07
suggest O 0 5.792482582478442e-08
that O 0 8.46109138308293e-09
a O 0 5.1063519634908516e-08
substantial O 0 6.55854819342494e-07
burden O 0 4.012943009001901e-06
of O 0 0.00016583356773480773
PAX6 B-Disease 1 0.9999954700469971
- I-Disease 1 0.9823121428489685
related I-Disease 0 0.0026699467562139034
disease I-Disease 0 0.09288156777620316
remains O 0 4.497556801652536e-06
to O 0 4.581654522439749e-08
be O 0 1.1289859713770056e-07
uncovered O 0 2.630190692798351e-06
. O 0 9.981440030060185e-08
. O 0 5.866465926374076e-07

The O 0 6.365626904880628e-05
chromosomal O 0 7.115810149116442e-05
order O 0 2.853476416930789e-06
of O 0 9.122214578383137e-06
genes O 0 1.0998696780006867e-06
controlling O 0 1.1703334166668355e-05
the O 0 2.0839155695284717e-05
major O 0 5.820083970320411e-05
histocompatibility O 0 0.0011550571070984006
complex O 0 4.583736517815851e-05
, O 0 3.817164611064072e-07
properdin O 0 3.838648353848839e-06
factor O 0 1.4364684375323122e-06
B O 0 5.893309207749553e-06
, O 0 1.0484809820354712e-07
and O 0 3.00637935879422e-07
deficiency B-Disease 0 0.004896164406090975
of I-Disease 0 4.046586764161475e-05
the I-Disease 0 9.921923265210353e-06
second I-Disease 0 7.411450042127399e-06
component I-Disease 0 2.7978530852124095e-06
of I-Disease 0 2.3632258034922415e-06
complement I-Disease 0 8.593551683588885e-06
. O 0 7.391939107037615e-06

The O 0 9.305447747465223e-05
relationship O 0 7.78846242610598e-06
of O 0 1.9109080312773585e-05
the O 0 4.153353984293062e-06
genes O 0 5.41559074918041e-07
coding O 0 1.9371234429854667e-06
for O 0 8.489253673360508e-07
HLA O 0 8.031217475945596e-06
to O 0 9.047819560237258e-08
those O 0 9.009502832668659e-08
coding O 0 5.198189683142118e-07
for O 0 3.303146911548538e-07
properdin O 0 1.4803399608354084e-05
Factor O 0 6.729003871441819e-06
B O 0 1.0021411981142592e-05
allotypes O 0 4.274729690223467e-06
and O 0 2.2066284088850807e-07
for O 0 7.704971380917414e-07
deficiency B-Disease 0 0.0004379127931315452
of I-Disease 0 6.063896944397129e-05
the I-Disease 0 1.27652974697412e-05
second I-Disease 0 6.918928193044849e-06
component I-Disease 0 2.920047109000734e-06
of I-Disease 0 4.266441919753561e-06
complement I-Disease 0 1.9907995465473505e-06
( O 0 7.032256803540804e-07
C2 O 0 7.738227395748254e-06
) O 0 2.71829154740999e-08
was O 0 1.5234518002671393e-07
studied O 0 6.484439296627897e-08
in O 0 3.5428936229209285e-08
families O 0 3.842114182361911e-09
of O 0 2.3038867880131875e-07
patients O 0 2.281332854181528e-06
with O 0 1.6306110410369e-05
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.00010049383126897737

Patients O 0 0.00011996831744909286
were O 0 1.1520276530063711e-05
selected O 0 7.589807751173794e-07
because O 0 4.840188339017004e-08
they O 0 5.101248312655571e-09
were O 0 4.810589260273446e-08
heterozygous O 0 7.630910658917855e-08
or O 0 9.737545525467795e-08
homozygous O 0 1.6984556623356184e-06
for O 0 1.3609212146548089e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.5955843991832808e-05

12 O 0 8.175083348760381e-05
families O 0 5.812109975522617e-07
with O 0 1.026968661221872e-07
15 O 0 1.6121898624987807e-06
matings O 0 8.905148206395097e-06
informative O 0 5.5620675993850455e-06
for O 0 3.071004175581038e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.1013286894012708e-05
found O 0 5.66991843697906e-07
. O 0 4.118614356229955e-07

Of O 0 0.0006526736542582512
57 O 0 0.00022313299996312708
informative O 0 2.5262708732043393e-05
meioses O 0 0.00014955148799344897
, O 0 7.312571028705861e-07
two O 0 1.6035188821206248e-07
crossovers O 0 4.4653822328655224e-07
were O 0 4.636722508166713e-07
noted O 0 5.048594289291941e-07
between O 0 2.514796051400481e-06
the O 0 0.00034279204555787146
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.2841031775678857e-06
and O 0 6.037975026629283e-07
the O 0 5.507674359250814e-06
HLA O 0 4.6287656005006284e-05
- O 0 1.6282954675261863e-05
B O 0 1.065955530066276e-05
gene O 0 1.1133168698052032e-07
, O 0 1.6850977502258502e-08
with O 0 5.231472588462793e-09
a O 0 9.013662349843798e-08
recombinant O 0 1.7838971189121366e-07
fraction O 0 2.818178757024725e-07
of O 0 3.1507086077908752e-06
0 O 0 4.261350568413036e-06
. O 0 1.4438534208238707e-06

035 O 0 0.05328098312020302
. O 0 0.00029348445241339505

A O 0 0.00034700389369390905
lod O 0 0.0012053926475346088
score O 0 1.5386223822133616e-05
of O 0 1.38731002152781e-05
13 O 0 5.264264473225921e-06
was O 0 3.6399751479621045e-06
calculated O 0 8.984789019450545e-07
for O 0 6.208543368302344e-07
linkage O 0 8.97601930773817e-05
between O 0 0.0015406351303681731
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.267305196961388e-05
HLA O 0 7.030151755316183e-05
- O 0 5.0879662012448534e-06
B O 0 1.7428553746867692e-06
at O 0 2.0098593722650548e-07
a O 0 5.276950432175909e-09
maximum O 0 4.1000884465347553e-08
likelihood O 0 4.79580251067091e-08
value O 0 9.787785160142448e-08
of O 0 1.862052414480786e-07
the O 0 1.0702927966121933e-07
recombinant O 0 1.4055522967737488e-07
fraction O 0 9.218724983384163e-08
of O 0 7.657985747755447e-07
0 O 0 1.7115319224103587e-06
. O 0 6.312644131867273e-07

04 O 0 0.021975429728627205
. O 0 0.00012398666876833886

18 O 0 0.00014129665214568377
families O 0 1.2523224768301588e-06
with O 0 2.712178570618562e-07
21 O 0 3.418159394641407e-06
informative O 0 6.445252438425086e-07
matings O 0 3.1509041491517564e-06
for O 0 5.735446393373422e-07
both O 0 4.2830970414797775e-07
properdin O 0 2.4545210180804133e-05
Factor O 0 7.88846500654472e-06
B O 0 1.9506453099893406e-05
allotype O 0 1.005415015242761e-05
and O 0 9.878311857391964e-07
HLA O 0 5.4489573813043535e-05
- O 0 1.474118744226871e-05
B O 0 8.907390110834967e-06
were O 0 7.30562874196039e-07
found O 0 3.1205311756821175e-07
. O 0 4.656681653614214e-07

Of O 0 0.0007638150709681213
72 O 0 0.0005078086396679282
informative O 0 8.095913653960451e-05
meioses O 0 0.00039539270801469684
, O 0 3.363985570103978e-06
three O 0 1.2747469781970722e-06
recombinants O 0 2.8071541237295605e-05
were O 0 2.2890017135068774e-06
found O 0 2.3591809394929442e-07
, O 0 1.5685253984543124e-08
giving O 0 6.592949297612449e-09
a O 0 4.7762860333477875e-08
recombinant O 0 1.3772667273315164e-07
fraction O 0 1.5203821135401085e-07
of O 0 1.8088657043335843e-06
0 O 0 1.8505855905459612e-06
. O 0 8.814614034236001e-07

042 O 0 0.014366884715855122
. O 0 0.00019457493908703327

A O 0 0.0005246153450571001
lod O 0 0.0009745153365656734
score O 0 1.4816944712947588e-05
of O 0 1.8522172467783093e-05
16 O 0 5.925951427343534e-06
between O 0 5.977044565952383e-06
HLA O 0 6.841765571152791e-05
- O 0 1.5512887330260128e-05
B O 0 5.476128990267171e-06
and O 0 1.6471736330458953e-07
Factor O 0 8.478427844238468e-07
B O 0 1.890154180728132e-06
allotypes O 0 1.7419464484191849e-06
was O 0 1.0074085139422095e-06
calculated O 0 2.88737709297493e-07
at O 0 2.750919634308957e-07
a O 0 2.2716161396374446e-08
maximum O 0 1.0690298779536533e-07
likelihood O 0 1.5749203896575636e-07
value O 0 3.2554117979088915e-07
of O 0 4.7165633532131324e-07
the O 0 3.018923280251329e-07
recombinant O 0 2.486988819327962e-07
fraction O 0 2.348180032640812e-07
of O 0 1.202620751428185e-06
0 O 0 1.7731550769894966e-06
. O 0 4.840405267714232e-07

04 O 0 0.025660226121544838
. O 0 0.00015014674863778055

A O 0 8.642667671665549e-05
crossover O 0 2.1341675164876506e-05
was O 0 1.3282554391480517e-05
shown O 0 3.075408585573314e-07
to O 0 1.0164163910530988e-07
have O 0 9.502437592345814e-08
occurred O 0 1.079607727660914e-06
between O 0 1.2924743941766792e-07
genes O 0 7.360555542845759e-08
for O 0 1.5535495379026543e-07
Factor O 0 6.990798624428862e-07
B O 0 2.0599461549863918e-06
and O 0 3.9058531342561764e-07
HLA O 0 5.512251391337486e-06
- O 0 2.523550847399747e-06
D O 0 3.6297112728789216e-06
, O 0 4.550128807068177e-08
in O 0 7.943098268015092e-08
which O 0 2.3488496481149923e-07
HLA O 0 1.7832277080742642e-05
- O 0 1.4152250514598563e-05
D O 0 2.460189898556564e-05
segregared O 0 7.495137197111035e-06
with O 0 3.147949598769628e-07
HLA O 0 0.00012024155876133591
- O 0 9.387408681504894e-06
A O 0 6.524550826725317e-06
and O 0 4.928916723656585e-07
B O 0 1.8255324903293513e-05
. O 0 5.592330580839189e-07

These O 0 3.857533101836452e-06
studies O 0 3.7912932384642772e-06
suggest O 0 7.532705694757169e-07
that O 0 7.133359503086467e-08
the O 0 1.5970084632499493e-07
genes O 0 6.134930430334862e-08
for O 0 2.2872116289818223e-07
Factor O 0 8.80998504726449e-06
B O 0 0.00013499146734829992
and O 0 3.6787499993806705e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 3.604140772495157e-07
located O 0 9.880639026960125e-07
outside O 0 4.0852575011740555e-07
those O 0 2.241445606898651e-08
for O 0 2.68779700718369e-07
HLA O 0 1.3714299711864442e-05
, O 0 1.0075126510855625e-07
that O 0 3.8573595873003796e-08
the O 0 1.9949376905969984e-07
order O 0 2.2814060685050208e-07
of O 0 3.4412612421874655e-06
genese O 0 3.178339102305472e-05
is O 0 1.8891505533247255e-06
HLA O 0 8.666618668939918e-06
- O 0 3.0551957479474368e-06
A O 0 4.7955013542377856e-06
, O 0 1.4060269393212366e-07
- O 0 2.3751822197937145e-07
B O 0 1.8865524680222734e-06
, O 0 1.5193646163425e-07
- O 0 1.268449409508321e-06
D O 0 2.8338095034996513e-06
, O 0 6.170982658204593e-08
Factor O 0 1.415477299815393e-06
B O 0 4.2431325709912926e-05
allotype O 0 0.00026824514498002827
, O 0 0.00011253770207986236
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 2.155045280005652e-07
that O 0 2.522250497349887e-08
the O 0 1.2833424989366904e-07
genes O 0 2.0160484837106196e-07
coding O 0 5.651295396091882e-06
for O 0 5.009101005271077e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 6.92617732056533e-06
Factor O 0 5.441322628030321e-06
B O 0 3.368518491697614e-06
allotypes O 0 1.3391940001383773e-06
are O 0 1.7949339792266983e-08
approximately O 0 5.7155062904712395e-08
3 O 0 8.813094609649852e-08
- O 0 9.606859663335854e-08
- O 0 2.333383974928438e-07
5 O 0 4.7205682562889706e-07
centimorgans O 0 1.7599771808818332e-06
from O 0 5.627398991236987e-07
the O 0 1.1221937938898918e-06
HLA O 0 3.854319402307738e-06
- O 0 1.242920689037419e-06
A O 0 3.0444864478340605e-06
and O 0 5.473255555443757e-07
HLA O 0 2.1625983208650723e-05
- O 0 1.4358398402691819e-05
B O 0 1.5978988813003525e-05
loci O 0 6.066892979106342e-07
, O 0 3.797890002488202e-08
and O 0 1.3325034409206182e-08
that O 0 1.0261654637133688e-08
the O 0 1.413007453265891e-07
apparent O 0 1.519610918876424e-06
lack O 0 2.1066691715532215e-06
of O 0 5.731166311306879e-06
recombinants O 0 5.1688493840629235e-06
between O 0 7.378469035757007e-07
the O 0 1.4561759371645167e-06
Factor O 0 4.514686224865727e-06
B O 0 1.7669633962213993e-05
gene O 0 3.4127394883398665e-06
and O 0 3.8373531424440444e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 6.707745797029929e-06
suggests O 0 4.917001206194982e-07
that O 0 4.041121570708128e-08
these O 0 1.4824831140458627e-08
two O 0 5.46508260867995e-08
genes O 0 1.9180224342107977e-07
lie O 0 2.3227057681651786e-06
in O 0 6.792736826355394e-07
close O 0 1.208853063872084e-06
proximity O 0 1.4551847016264219e-06
to O 0 2.959745017960813e-07
one O 0 4.491486151891877e-07
another O 0 8.142403089550498e-07
. O 0 1.1541129651959636e-06

Distribution O 0 9.08516813069582e-05
of O 0 4.8694611905375496e-05
emerin O 0 0.00041482847882434726
and O 0 6.918202416272834e-06
lamins O 0 0.00019920611521229148
in O 0 3.920776634913636e-06
the O 0 7.269264187925728e-06
heart O 0 0.0003896861744578928
and O 0 5.611354367829335e-07
implications O 0 4.9747036428016145e-06
for O 0 2.9384225399553543e-06
Emery B-Disease 1 0.7409321665763855
- I-Disease 1 0.9999953508377075
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 3.5171360650565475e-05

Emerin O 0 0.00669723330065608
is O 0 3.9768758142599836e-05
a O 0 8.146013897203375e-06
nuclear O 0 3.809547706623562e-05
membrane O 0 1.705048453004565e-05
protein O 0 3.1338402095570927e-06
which O 0 4.703366585090407e-07
is O 0 5.275745706967427e-07
missing O 0 1.781390778887726e-06
or O 0 1.002815224637743e-06
defective O 0 6.148668035166338e-05
in O 0 1.9912813513656147e-05
Emery B-Disease 1 0.9965574741363525
- I-Disease 1 0.9999974966049194
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.7265787391806953e-05
EDMD B-Disease 1 1.0
) O 0 1.5568481330774375e-06
. O 0 1.1356080449331785e-06

It O 0 2.2322774384520017e-05
is O 0 3.59262116944592e-06
one O 0 4.898681709164521e-07
member O 0 9.339129860563844e-07
of O 0 3.2975331123452634e-06
a O 0 8.292462553072255e-06
family O 0 3.0657965908176266e-06
of O 0 0.0010320034343749285
lamina O 1 0.9960622191429138
- O 0 0.00048478366807103157
associated O 0 4.855671704717679e-06
proteins O 0 4.871772034675814e-07
which O 0 2.8733293788718584e-07
includes O 0 3.2781042591523146e-07
LAP1 O 0 3.780183760682121e-05
, O 0 6.655302513536299e-07
LAP2 O 0 2.1014777303207666e-05
and O 0 1.1874190022354014e-06
lamin O 0 2.6423427698318847e-05
B O 0 1.1410606930439826e-05
receptor O 0 2.6692212031775853e-06
( O 0 4.357684133537987e-07
LBR O 0 2.675958239706233e-05
) O 0 2.4029188239182986e-07
. O 0 5.341977953321475e-07

A O 0 0.0003811961505562067
panel O 0 5.3976993513060734e-05
of O 0 1.8673013983061537e-05
16 O 0 9.326578947366215e-06
monoclonal O 0 4.833997536479728e-06
antibodies O 0 1.9213780433346983e-06
( O 0 1.110569996853883e-06
mAbs O 0 3.6523647395370062e-06
) O 0 1.2285779860121693e-07
has O 0 1.2584040121055295e-07
been O 0 1.1810895017561052e-07
mapped O 0 5.2741459199978635e-08
to O 0 3.395574310616212e-08
six O 0 5.068353559067873e-08
specific O 0 1.6024053195451415e-08
sites O 0 1.5065087666243926e-07
throughout O 0 1.7143534591923526e-07
the O 0 1.076811940947664e-06
emerin O 0 4.933774562232429e-06
molecule O 0 3.586564787383395e-07
using O 0 1.1082237705295483e-07
phage O 0 6.647049985986087e-07
- O 0 4.704986338310846e-07
displayed O 0 5.139496010997391e-07
peptide O 0 6.849128340036259e-07
libraries O 0 3.8749402619941975e-07
and O 0 1.2891383960322855e-07
has O 0 9.4286690455192e-08
been O 0 6.502857274881535e-08
used O 0 4.807167997000761e-08
to O 0 5.466823438382562e-08
localize O 0 4.6296095206344035e-06
emerin O 0 1.6162715837708674e-05
in O 0 5.855337690263696e-07
human O 0 1.0469716471561696e-06
and O 0 8.099574984044011e-07
rabbit O 0 9.313699592894409e-06
heart O 0 0.006357342004776001
. O 0 4.725437520392006e-06

Several O 0 7.741642912151292e-05
mAbs O 0 0.00013423903146758676
against O 0 6.291702447924763e-06
different O 0 5.097773509987746e-07
emerin O 0 4.675333184422925e-05
epitopes O 0 9.124520147452131e-06
did O 0 5.175687647351879e-07
not O 0 1.2323341991304915e-07
recognize O 0 2.396803608917253e-07
intercalated O 0 2.4402861527050845e-05
discs O 0 1.624007745704148e-05
in O 0 4.514849933912046e-06
the O 0 2.9329825338209048e-05
heart O 0 0.0656837448477745
, O 0 2.737658633122919e-07
though O 0 3.941527637607578e-08
they O 0 1.7560720877440872e-08
recognized O 0 3.13269367779867e-07
cardiomyocyte O 0 9.223399501934182e-06
nuclei O 0 6.689813289995072e-06
strongly O 0 1.1457684649940347e-06
, O 0 1.8972069426581584e-07
both O 0 1.9737655065910076e-07
at O 0 1.8184675354859792e-05
the O 0 4.362101662991336e-06
rim O 0 5.686261829396244e-06
and O 0 1.474910931165141e-07
in O 0 1.084043105947785e-06
intranuclear O 0 2.451907676004339e-05
spots O 0 1.577050170453731e-06
or O 0 5.948345460637938e-07
channels O 0 2.1492032828973606e-06
. O 0 1.4773281691304874e-06

A O 0 0.0005348575068637729
polyclonal O 0 0.0012268282007426023
rabbit O 0 0.00018045023898594081
antiserum O 0 0.0002759318449534476
against O 0 3.528110755723901e-05
emerin O 0 0.0001789868256310001
did O 0 2.2212695967027685e-06
recognize O 0 7.653517286598799e-07
both O 0 6.986600169511803e-07
nuclear O 0 1.1570495189516805e-05
membrane O 0 8.222016731451731e-06
and O 0 1.3828512237523682e-06
intercalated O 0 6.199714698595926e-05
discs O 0 1.0597611435514409e-05
but O 0 1.196034418171621e-07
, O 0 1.8767241982686755e-08
after O 0 4.8258907980880394e-08
affinity O 0 1.453915245974713e-07
purification O 0 1.2607706594280899e-06
against O 0 1.0426672361063538e-06
a O 0 1.3537218137571472e-06
pure O 0 7.346371148742037e-06
- O 0 8.90423143573571e-06
emerin O 0 3.4644395782379434e-05
band O 0 3.909828592441045e-06
on O 0 1.7346389995509526e-06
a O 0 6.984921583352843e-07
western O 0 7.252938303281553e-07
blot O 0 4.375129265099531e-06
, O 0 2.2833279444967047e-07
it O 0 5.210423736912162e-08
stained O 0 1.3612197108159307e-05
only O 0 1.4657447877652885e-07
the O 0 1.168497192338691e-06
nuclear O 0 1.3547314665629528e-05
membrane O 0 2.4749513613642193e-05
. O 0 3.159286279696971e-06

These O 0 2.443257653794717e-05
results O 0 1.960256849997677e-05
would O 0 1.3716451121581485e-06
not O 0 1.951894290641576e-07
be O 0 2.630303299611114e-07
expected O 0 5.6695671446505e-07
if O 0 1.6202776009777153e-07
immunostaining O 0 1.7164215023512952e-05
at O 0 2.7855321604874916e-05
intercalated O 0 3.4899527236120775e-05
discs O 0 1.860145857790485e-05
were O 0 2.118735892508994e-06
due O 0 2.9170187190175056e-06
to O 0 2.4215688654294354e-07
a O 0 1.1057855999752064e-06
product O 0 8.702496074874944e-07
of O 0 1.3437480447464623e-05
the O 0 1.5514426195295528e-05
emerin O 0 9.578201570548117e-05
gene O 0 1.2414209322741954e-06
and O 0 7.559287951153237e-07
, O 0 1.4664732361779897e-07
therefore O 0 1.1544327804813292e-07
, O 0 2.3263687864982785e-08
cast O 0 6.889273151955422e-08
some O 0 7.630848841699844e-09
doubt O 0 3.961825356668669e-08
upon O 0 7.569590820821759e-08
the O 0 1.0494592572740657e-07
hypothesis O 0 2.055972458947508e-07
that O 0 3.456812294189149e-07
cardiac B-Disease 1 0.9999998807907104
defects I-Disease 1 0.9970583915710449
in O 0 0.0007641710690222681
EDMD B-Disease 1 1.0
are O 0 1.6256699382211082e-06
caused O 0 2.1416028175735846e-05
by O 0 3.756813384825364e-07
absence O 0 9.82953224593075e-06
of O 0 4.730961154564284e-05
emerin O 0 0.00038301877793855965
from O 0 2.3004269678494893e-05
intercalated O 0 0.000666897976770997
discs O 0 0.00015601955237798393
. O 0 5.261458682070952e-06

Although O 0 6.028001007507555e-05
emerin O 0 0.0004726739425677806
was O 0 4.971306407242082e-05
abundant O 0 1.5309437912947033e-06
in O 0 1.2179299346826156e-06
the O 0 2.8350366392260185e-06
membranes O 0 4.315983460401185e-06
of O 0 0.0001758793368935585
cardiomyocyte O 0 0.0010833735577762127
nuclei O 0 6.690874579362571e-05
, O 0 1.1853812793560792e-06
it O 0 1.636483943912026e-07
was O 0 2.131010842276737e-05
absent O 0 2.8608769753191154e-06
from O 0 2.9346935548346664e-07
many O 0 2.207541349719122e-08
non O 0 2.283089315824327e-06
- O 0 4.92638810101198e-06
myocyte O 0 4.3363885197322816e-05
cells O 0 3.880979591031064e-07
in O 0 7.723128305769933e-07
the O 0 5.032269655202981e-06
heart O 0 0.0002495835069566965
. O 0 1.5000346138549503e-06

This O 0 8.416801392741036e-06
distribution O 0 1.0093482160300482e-05
of O 0 2.6702633476816118e-05
emerin O 0 0.00015397263632621616
was O 0 2.9988539608893916e-05
similar O 0 1.3596550729744195e-07
to O 0 9.028046576986526e-08
that O 0 5.8860244678271556e-08
of O 0 8.880979294190183e-06
lamin O 0 7.434700091835111e-05
A O 0 1.4024264601175673e-05
, O 0 1.4234488787678856e-07
a O 0 2.582355307367834e-07
candidate O 0 4.180126325081801e-07
gene O 0 1.7524558870718465e-07
for O 0 8.16736900333126e-08
an O 0 2.2012979172814084e-07
autosomal O 0 2.0466811747610336e-06
form O 0 1.3866387007510639e-06
of O 1 0.9639662504196167
EDMD B-Disease 1 1.0
. O 0 4.0505015931557864e-05

In O 0 7.806732173776254e-05
contrast O 0 2.8713713618344627e-05
, O 0 1.4569632185157388e-05
lamin O 0 0.0003851075016427785
B1 O 0 0.10736840218305588
was O 0 0.0002776253968477249
absent O 0 1.775650707713794e-05
from O 0 1.7937999245987157e-06
cardiomyocyte O 0 2.413704351056367e-05
nuclei O 0 9.28893314267043e-06
, O 0 4.7420459736713383e-07
showing O 0 4.488746981223812e-06
that O 0 3.0601327125623357e-06
lamin O 0 0.0004494975146371871
B1 O 0 0.017270643264055252
is O 0 2.950594080175506e-07
not O 0 2.2903412499886144e-08
essential O 0 1.1677579436764063e-07
for O 0 1.4493481614863413e-07
localization O 0 4.916447323921602e-06
of O 0 3.17674016514502e-06
emerin O 0 2.260404289700091e-05
to O 0 4.0463359596287773e-07
the O 0 8.850794074533042e-06
nuclear O 0 0.00024533114628866315
lamina O 0 0.008493133820593357
. O 0 6.390927410393488e-06

Lamin O 1 0.9853257536888123
B1 O 1 0.999453604221344
is O 0 1.2848580809077248e-05
also O 0 1.337102389697975e-06
almost O 0 7.050225576676894e-07
completely O 0 2.7816186047857627e-06
absent O 0 8.74386023497209e-06
from O 0 4.321890173741849e-06
skeletal O 0 0.00640691677108407
muscle O 0 5.472949123941362e-05
nuclei O 0 8.22221118141897e-05
. O 0 3.715581442520488e-06

In O 0 0.0006821214337833226
EDMD B-Disease 1 0.9999986886978149
, O 0 3.4515194329287624e-06
the O 0 8.510134534844838e-07
additional O 0 3.1939140399117605e-07
absence O 0 3.12632109853439e-05
of O 0 0.0003981147601734847
lamin O 1 0.9047280550003052
B1 O 1 0.9999909400939941
from O 0 0.0019117547199130058
heart O 1 0.9999910593032837
and O 0 0.0006943041807971895
skeletal O 1 1.0
muscle O 1 0.820365309715271
nuclei O 0 0.0006489274092018604
which O 0 1.8201116063210065e-06
already O 0 8.515638114658941e-07
lack O 0 3.164267809552257e-06
emerin O 0 3.283401747466996e-05
may O 0 2.411063348972675e-07
offer O 0 1.87201933954384e-08
an O 0 2.68298645522691e-08
alternative O 0 4.484099136448094e-08
explanation O 0 1.9048358979034674e-07
of O 0 1.9054440372201498e-06
why O 0 5.922093464505451e-07
these O 0 1.5465957403648645e-07
tissues O 0 3.377045459274086e-06
are O 0 1.602587929028232e-07
particularly O 0 1.4570008488590247e-07
affected O 0 3.391037921574025e-07
. O 0 6.175974931466044e-08
. O 0 3.404004758067458e-07

Genetic O 0 2.2458663806901313e-05
mapping O 0 3.0319290090119466e-05
of O 0 9.49008681345731e-05
the O 0 8.27908661449328e-05
copper B-Disease 1 0.8729361295700073
toxicosis I-Disease 0 0.0027303225360810757
locus O 0 3.88182197639253e-05
in O 0 6.323487468762323e-06
Bedlington O 0 7.448565884260461e-05
terriers O 0 1.0724997082434129e-05
to O 0 4.4187919456817326e-07
dog O 0 1.5190196336334338e-06
chromosome O 0 3.128315938738524e-06
10 O 0 1.3899831401431584e-06
, O 0 8.789090344407668e-08
in O 0 1.9472238932394248e-07
a O 0 4.084400586634729e-07
region O 0 5.81435472213343e-07
syntenic O 0 1.1752857972169295e-05
to O 0 2.338675102464549e-07
human O 0 1.8244197690364672e-06
chromosome O 0 1.3194832717999816e-05
region O 0 1.0490552085684612e-05
2p13 O 0 0.00024394305364694446
- O 0 4.913073644274846e-05
p16 O 0 3.6778725188924e-05
. O 0 1.2172541801191983e-06

Abnormal O 1 1.0
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999998807907104
accumulation I-Disease 1 0.9498393535614014
is O 0 1.1526004755069152e-06
recognized O 0 3.1101117770049314e-07
as O 0 8.440863439318491e-07
an O 0 6.5726135289878584e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 1 0.6448763012886047
man O 0 0.0008642284665256739
, O 0 7.467501745850313e-07
mouse O 0 1.264361117137014e-06
, O 0 3.5055009561801853e-07
rat O 0 4.801212071470218e-06
and O 0 9.378534855386533e-07
dog O 0 1.0109009963343851e-05
. O 0 2.580284899522667e-06

The O 0 8.044061542022973e-05
major O 0 9.270976443076506e-05
cause O 0 0.0001289736683247611
of O 1 0.6540917754173279
hepatic B-Disease 1 1.0
copper I-Disease 1 1.0
accumulation I-Disease 1 0.9998623132705688
in O 0 5.1266400987515226e-05
man O 0 1.273479028895963e-05
is O 0 3.695392649660789e-07
a O 0 7.131148436201329e-07
dysfunctional O 0 7.410346825054148e-06
ATP7B O 0 0.00022517105389852077
gene O 0 2.1492298856173875e-06
, O 0 5.422614322014851e-07
causing O 0 1.3093037523503881e-05
Wilson B-Disease 0 2.2284955775830895e-05
disease I-Disease 0 3.514956551953219e-05
( O 0 3.288477898877318e-07
WD B-Disease 0 4.555877239909023e-05
) O 0 8.332951892953133e-07
. O 0 1.0234659839625238e-06

Mutations O 0 0.00010210736218141392
in O 0 3.8731512177037075e-05
the O 0 2.2848686057841405e-05
ATP7B O 0 0.0001503142120782286
genes O 0 5.925098776060622e-07
have O 0 2.4659834707563277e-07
also O 0 3.278141775808763e-07
been O 0 5.617168881144607e-07
demonstrated O 0 9.90706780612527e-07
in O 0 1.7222532733285334e-06
mouse O 0 5.72409271626384e-06
and O 0 3.669618990898016e-06
rat O 0 3.6072273360332474e-05
. O 0 1.9451281332294457e-06

The O 0 0.0005052812048234046
ATP7B O 0 0.0056676906533539295
gene O 0 1.0452025890117511e-05
has O 0 1.26775637454557e-06
been O 0 4.285577404061769e-07
excluded O 0 2.298652503895937e-07
in O 0 6.46322604325178e-08
the O 0 1.6153990145539865e-07
much O 0 1.2342476907178934e-07
rarer O 0 3.5154482702637324e-06
human O 0 0.0002377553901169449
copper B-Disease 1 1.0
overload I-Disease 1 0.9999997615814209
disease O 1 0.9996956586837769
non B-Disease 0 0.0019438028102740645
- I-Disease 0 2.5505241865175776e-05
Indian I-Disease 0 1.6663323094689986e-06
childhood I-Disease 0 0.0001043012089212425
cirrhosis I-Disease 1 0.9999997615814209
, O 0 1.0902247993271885e-07
indicating O 0 6.765860689483816e-07
genetic O 0 4.224808662911528e-07
heterogeneity O 0 9.976641194953118e-06
. O 0 2.129258973582182e-06

By O 0 5.71774171476136e-06
investigating O 0 8.877896107151173e-06
the O 0 2.7272451461612945e-06
common O 0 4.463246568775503e-06
autosomal O 0 0.016646388918161392
recessive O 1 0.9988383650779724
copper B-Disease 1 1.0
toxicosis I-Disease 1 0.9999371767044067
( O 0 1.98489215108566e-06
CT B-Disease 0 0.00024260772624984384
) O 0 3.176865845944121e-07
in O 0 2.087848315568408e-06
Bedlington O 0 0.00023471338499803096
terriers O 0 4.132443791604601e-05
, O 0 8.43270768768889e-08
we O 0 8.18389533918662e-09
have O 0 4.453148960692488e-09
identified O 0 3.3524174547494567e-09
a O 0 6.591867940386464e-09
new O 0 2.802893472875212e-09
locus O 0 1.055592306897779e-07
involved O 0 7.902509224777532e-08
in O 0 8.892708137864247e-06
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.2284613805823028e-05

We O 0 1.7640235455473885e-05
examined O 0 7.480184649466537e-06
whether O 0 5.794051389784727e-07
the O 0 5.478505954670254e-06
WD B-Disease 0 0.00020164434681646526
gene O 0 2.1680292775272392e-05
ATP7B O 0 0.0003711244207806885
was O 0 3.742670742212795e-05
also O 0 5.74464820601861e-07
causative O 0 2.7262622097623535e-06
for O 0 8.653229883748281e-07
CT B-Disease 0 0.0006230049184523523
by O 0 1.2044158665958093e-06
investigating O 0 1.0716537417465588e-06
the O 0 7.155610546760727e-06
chromosomal O 0 0.0008713080314919353
co O 0 0.003698341315612197
- O 0 0.00013889427646063268
localization O 0 0.0007371401297859848
of O 0 0.00011410073784645647
ATP7B O 0 0.0005984528688713908
and O 0 1.589603812135465e-06
C04107 O 0 6.770696927560493e-06
, O 0 6.450799361346071e-08
using O 0 2.1241504555291613e-08
fluorescence O 0 2.3478418142985902e-07
in O 0 3.4689719541347586e-07
situ O 0 4.7825765250308905e-06
hybridization O 0 2.0673031997375801e-07
( O 0 1.5614649839790218e-07
FISH O 0 7.35080391223164e-07
) O 0 1.3610510052330937e-07
. O 0 3.7640072036992933e-07

C04107 O 0 0.0026463631074875593
is O 0 1.2281764611543622e-05
an O 0 1.1144742302349187e-06
anonymous O 0 2.5246531549782958e-06
microsatellite O 0 1.6583595424890518e-05
marker O 0 4.549702498479746e-05
closely O 0 9.165476626549207e-07
linked O 0 1.1405330951674841e-05
to O 0 1.7070850617528777e-06
CT B-Disease 0 0.13450635969638824
. O 0 6.674646101600956e-06

However O 0 0.00012198565673315898
, O 0 1.4730184375366662e-05
BAC O 0 0.0002845589187927544
clones O 0 6.478631348727504e-06
containing O 0 6.1632940742128994e-06
ATP7B O 0 0.00012135138240410015
and O 0 2.494122099960805e-06
C04107 O 0 3.100022877333686e-05
mapped O 0 4.086074568476761e-06
to O 0 1.1031271469619242e-06
the O 0 4.548125616565812e-06
canine O 0 3.404834933462553e-05
chromosome O 0 2.6418389097671025e-05
regions O 0 6.449165994126815e-06
CFA22q11 O 0 0.00023402868828270584
and O 0 3.520003474477562e-06
CFA10q26 O 0 7.825528882676736e-05
, O 0 5.306829962137272e-07
respectively O 0 8.03999284926249e-07
, O 0 2.5272008485899278e-08
demonstrating O 0 2.2109804831416113e-07
that O 0 7.347846064931218e-08
WD B-Disease 0 6.955115622986341e-06
cannot O 0 2.3814899918761512e-07
be O 0 1.4786009217004903e-07
homologous O 0 2.527341393943061e-07
to O 0 3.993744712715852e-07
CT B-Disease 0 0.00027013561339117587
. O 0 2.3975012481969316e-06

The O 0 0.0006889001233503222
copper O 0 0.002806182252243161
transport O 0 9.743171540321782e-05
genes O 0 1.5000838175183162e-05
CTR1 O 0 0.0009481613524258137
and O 0 9.015301657200325e-06
CTR2 O 0 0.00045518160914070904
were O 0 6.465256319643231e-06
also O 0 4.7269921310544305e-07
excluded O 0 8.391558594667003e-07
as O 0 3.0669849593323306e-07
candidate O 0 3.040866261017072e-07
genes O 0 1.8173747662331152e-07
for O 0 5.07691197526583e-07
CT B-Disease 0 0.0002439328090986237
since O 0 9.22470292152866e-07
they O 0 2.0277214574093705e-08
both O 0 2.632327777973842e-08
mapped O 0 2.6113130502380955e-07
to O 0 1.7739419888584962e-07
canine O 0 1.734844408929348e-05
chromosome O 0 5.579540811595507e-05
region O 0 3.8791582483099774e-05
CFA11q22 O 0 0.0017588455229997635
. O 0 1.0472120266058482e-05

2 O 0 0.000164597702678293
- O 0 7.673244545003399e-05
22 O 0 3.6799072404392064e-05
. O 0 2.2122635527921375e-06

5 O 0 0.0008493815548717976
. O 0 7.797453872626647e-05

A O 0 0.00019850872922688723
transcribed O 0 4.77568173664622e-05
sequence O 0 4.862961304752389e-06
identified O 0 3.223380190320313e-06
from O 0 3.017446033481974e-06
the O 0 3.190363031535526e-06
C04107 O 0 1.4989082956162747e-05
- O 0 1.0613339327392168e-05
containing O 0 7.773205652483739e-06
BAC O 0 0.00025792428641580045
was O 0 3.119637767667882e-05
found O 0 1.108407658989563e-07
to O 0 2.1889462686885963e-08
be O 0 6.7763750166705e-08
homologous O 0 9.159590064200529e-08
to O 0 1.0618826706831896e-07
a O 0 8.293572477668931e-07
gene O 0 3.6841041151092213e-07
expressed O 0 4.911002520202601e-07
from O 0 2.489500047886395e-06
human O 0 1.8376596244706889e-06
chromosome O 0 1.760040868248325e-05
2p13 O 0 7.89957630331628e-05
- O 0 2.1906014808337204e-05
p16 O 0 7.261171958816703e-06
, O 0 1.1915533093542763e-07
a O 0 2.0781752141374454e-07
region O 0 1.774898095163735e-07
devoid O 0 8.056094884523191e-07
of O 0 4.6362183070414176e-07
any O 0 1.0086240109785649e-07
positional O 0 6.825863692938583e-06
candidate O 0 7.718232154729776e-06
genes O 0 2.0860532004007837e-06
. O 0 2.63112383436237e-06

Molecular O 0 0.0002550767094362527
analysis O 0 9.015894647745881e-06
of O 0 2.392122769379057e-05
the O 0 1.0296110303897876e-05
APC B-Disease 0 1.1938414900214411e-05
gene O 0 2.054653407412843e-07
in O 0 3.5471472870085563e-07
205 O 0 2.0853492515016114e-06
families O 0 6.668059171488494e-08
: O 0 3.1357838992107645e-08
extended O 0 1.0941803338937461e-06
genotype O 0 2.4275536816276144e-06
- O 0 5.67123925065971e-06
phenotype O 0 1.2102810842407052e-06
correlations O 0 2.510554850232438e-06
in O 0 6.0948678992645e-07
FAP B-Disease 0 2.0633810891013127e-06
and O 0 3.4748783406257644e-08
evidence O 0 5.2411330386803456e-08
for O 0 4.333439918013937e-08
the O 0 1.4814223447956465e-07
role O 0 4.6027898292777536e-07
of O 0 5.992734259052668e-06
APC B-Disease 0 1.883163713500835e-05
amino O 0 9.242367013939656e-07
acid O 0 1.7637009364079859e-07
changes O 0 2.857722734006529e-07
in O 0 9.477028652327135e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9986262321472168
. O 0 9.959938324755058e-06

BACKGROUND O 0 0.000603294640313834
/ O 0 0.00013736984692513943
AIMS O 0 9.036640221893322e-06
The O 0 1.6033798146963818e-06
development O 0 1.5229741620714776e-05
of O 1 0.9969624876976013
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.5410702189910808e-06
a O 0 2.6214408421765256e-07
variable O 0 1.7380190797666728e-07
range O 0 1.5915759377094219e-07
of O 0 1.330320401393692e-06
extracolonic O 0 5.251041511655785e-05
manifestations O 0 4.123405597056262e-05
in O 0 7.320355962292524e-06
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.9999958276748657
polyposis I-Disease 1 1.0
( O 0 1.3945950740890112e-05
FAP B-Disease 0 1.4363822629093193e-05
) O 0 3.667151915465183e-08
is O 0 8.115748073578288e-09
the O 0 2.010437860633374e-08
result O 0 7.168056725959104e-08
of O 0 7.278035241142788e-07
the O 0 9.223700203619956e-07
dominant O 0 1.2576364269989426e-06
inheritance O 0 4.315913884056499e-06
of O 0 3.808955443673767e-05
adenomatous B-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999884366989136
coli I-Disease 1 0.9999737739562988
( O 0 9.626625796954613e-06
APC B-Disease 0 3.521781400195323e-05
) O 0 2.6563665755929833e-07
gene O 0 6.311638571787626e-07
mutations O 0 8.254119734374399e-07
. O 0 1.476117063248239e-06

In O 0 2.1451778593473136e-05
this O 0 3.7622416471094766e-07
study O 0 2.506750433894922e-07
, O 0 2.8990973177656088e-08
direct O 0 7.765729748143713e-08
mutation O 0 1.1468731742070304e-07
analysis O 0 1.8174407045989938e-07
of O 0 6.198083156050416e-06
the O 0 1.1594906936807092e-05
APC B-Disease 0 2.4606217266409658e-05
gene O 0 8.756826446187915e-07
was O 0 8.282986527774483e-06
performed O 0 8.263311315204191e-07
to O 0 1.1667083299471415e-07
determine O 0 5.4981575203783e-07
genotype O 0 6.598364052479155e-06
- O 0 1.4526165614370257e-05
phenotype O 0 2.348590442124987e-06
correlations O 0 3.969930730818305e-06
for O 0 9.603413673175965e-07
nine O 0 6.7509863583836704e-06
extracolonic O 0 3.090114478254691e-05
manifestations O 0 1.0792981811391655e-05
and O 0 2.3075941157912894e-07
to O 0 4.422586030727871e-08
investigate O 0 6.771193028498601e-08
the O 0 3.2511798053747043e-07
incidence O 0 4.739260475616902e-05
of O 0 2.4905448299250565e-05
APC B-Disease 0 3.4622466046130285e-05
mutations O 0 1.4881213417083927e-07
in O 0 1.3947101251687855e-06
non O 0 0.206038236618042
- O 1 0.9999830722808838
FAP O 1 0.9999992847442627
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.902688710397342e-06

METHODS O 0 0.0002533939841669053
The O 0 4.6146004024194553e-05
APC B-Disease 0 7.316184928640723e-05
gene O 0 1.2327484455454396e-06
was O 0 5.359355327527737e-06
analysed O 0 3.2109284120451775e-07
in O 0 2.2507296648655029e-07
190 O 0 1.3421731637208723e-06
unrelated O 0 6.637535534537164e-07
FAP B-Disease 0 1.6278992234219913e-06
and O 0 8.07711444394954e-08
15 O 0 3.5921896142099285e-06
non O 0 0.0011942372657358646
- O 1 0.9999756813049316
FAP O 1 0.9999992847442627
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 9.990571015805472e-06
using O 0 8.70691224008624e-07
denaturing O 0 7.875221490394324e-05
gradient O 0 5.985252573736943e-05
gel O 0 1.069270456355298e-05
electrophoresis O 0 5.713102837034967e-06
, O 0 2.3097209123079665e-07
the O 0 4.951129426444822e-07
protein O 0 6.706810040668643e-07
truncation O 0 4.2298142943764105e-06
test O 0 2.6883378723141504e-07
, O 0 2.637735541100028e-08
and O 0 1.626835732793097e-08
direct O 0 3.072441927542968e-07
sequencing O 0 4.210118277114816e-06
. O 0 1.2768127817253117e-06

RESULTS O 0 0.0021811590995639563
Chain O 0 0.0002517574466764927
terminating O 0 5.6231754570035264e-05
signals O 0 1.1524088222358841e-05
were O 0 7.268518515957112e-07
only O 0 3.770117729118283e-08
identified O 0 6.410763830899668e-08
in O 0 1.665598290401249e-07
patients O 0 1.687555908347349e-07
belonging O 0 4.5569294115921366e-07
to O 0 1.2692235884514957e-07
the O 0 2.1730363641836448e-06
FAP B-Disease 0 1.0516897418710869e-05
group O 0 3.586243337849737e-07
( O 0 8.911591464766389e-08
105 O 0 3.904384811903583e-06
patients O 0 2.568517629697453e-07
) O 0 3.9525650663563283e-07
. O 0 6.290337069003726e-07

Amino O 0 0.0005055536748841405
acid O 0 2.3813974621589296e-05
changes O 0 1.5759030702611199e-06
were O 0 2.906843747041421e-06
identified O 0 3.520476354879065e-07
in O 0 9.9900466921099e-07
four O 0 1.018422381093842e-06
patients O 0 6.119154818406969e-07
, O 0 2.4386048380620196e-07
three O 0 3.510211286084086e-07
of O 0 1.0825082426890731e-05
whom O 0 2.6909360713034403e-06
belonged O 0 4.898821316601243e-06
to O 0 1.9655212213365303e-07
the O 0 2.0593488443410024e-06
non O 0 8.082437852863222e-05
- O 0 3.912274769390933e-05
FAP O 0 9.02869851415744e-06
group O 0 4.845795160690614e-07
of O 0 0.004210632760077715
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0008875020430423319
. O 0 3.988776370533742e-06

Genotype O 0 0.006059287115931511
- O 0 0.0008500167750753462
phenotype O 0 2.1830062905792147e-05
correlations O 0 1.9527373297023587e-05
identified O 0 8.743758144191816e-07
significant O 0 2.320510787967578e-07
differences O 0 1.9444144072622294e-07
in O 0 5.451901188280317e-07
the O 0 4.688847070610791e-07
nature O 0 2.633317706113303e-07
of O 0 7.849387770875182e-07
certain O 0 3.626399518452672e-07
extracolonic O 0 5.404189505497925e-05
manifestations O 0 4.955247277393937e-05
in O 0 2.9329326025617775e-06
FAP B-Disease 0 1.1240371350140776e-05
patients O 0 1.582476727435278e-07
belonging O 0 2.0637989450733585e-07
to O 0 2.8773046167884786e-08
three O 0 8.827294095681282e-08
mutation O 0 8.686525916346e-07
subgroups O 0 1.024017547024414e-05
. O 0 1.5214525319606764e-06

CONCLUSIONS O 0 0.0004986679996363819
Extended O 0 0.00043551012640818954
genotype O 0 0.00010736429976532236
- O 0 5.237579534878023e-05
phenotype O 0 6.88880618326948e-06
correlations O 0 5.478626007970888e-06
made O 0 7.286313348231488e-07
in O 0 4.0235633491647604e-07
this O 0 8.589274358428156e-08
study O 0 4.5083430677550496e-07
may O 0 7.025539616734022e-07
have O 0 1.0865007027405227e-07
the O 0 2.3166057872003876e-07
potential O 0 2.543980883729091e-07
to O 0 9.54335916958371e-08
determine O 0 1.5522286389568762e-07
the O 0 8.790445349404763e-07
most O 0 6.0222063780202e-08
appropriate O 0 8.806474482980775e-08
surveillance O 0 1.925071956065949e-06
and O 0 4.905245418740378e-07
prophylactic O 1 0.9986844658851624
treatment O 0 0.07806393504142761
regimens O 0 2.066326851490885e-05
for O 0 2.2532661603236193e-07
those O 0 3.8613052311120555e-08
patients O 0 5.439666139750443e-08
with O 0 1.1959621737389625e-08
mutations O 0 2.055223546904017e-07
associated O 0 3.204568486125936e-07
with O 0 8.556244779356348e-08
life O 0 1.8023670236289036e-06
threatening O 0 7.583906608488178e-06
conditions O 0 2.4064092940534465e-05
. O 0 3.79883567802608e-06

This O 0 8.568436896894127e-06
study O 0 1.8639975678524934e-06
also O 0 2.1410109241060127e-07
provided O 0 9.705708237106592e-08
evidence O 0 1.4934656178411387e-07
for O 0 1.914641529765504e-07
the O 0 2.8132535589975305e-06
pathological O 0 0.00022412215184886009
nature O 0 7.238355919980677e-06
of O 0 0.0002849531010724604
amino O 0 8.02254544396419e-06
acid O 0 8.627043257547484e-07
changes O 0 1.3928212183600408e-07
in O 0 1.0859771464311052e-06
APC O 0 3.743966090041795e-06
associated O 0 6.511805850095698e-08
with O 0 1.2883009326003503e-08
both O 0 6.34889971706798e-08
FAP B-Disease 0 3.856477178487694e-06
and O 0 2.9983564786562056e-07
non O 0 0.0031171340961009264
- O 1 0.9999876022338867
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 7.906314749561716e-06
. O 0 2.3973453266989964e-07
. O 0 4.935045581078157e-07

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 0.12568597495555878
cancer B-Disease 1 0.9999951124191284
risk O 0 3.305172504042275e-05
of O 0 8.677723963046446e-05
the O 0 7.772680692141876e-05
APC O 0 0.0001642775459913537
I1307K O 0 7.196306250989437e-05
polymorphism O 0 1.0466488674865104e-05
. O 0 2.0082243281649426e-06

Germ O 0 0.24704459309577942
- O 0 0.0005093259387649596
line O 0 4.432860077940859e-05
and O 0 8.157481374837516e-07
somatic O 0 3.861869117827155e-06
truncating O 0 1.2305788914090954e-05
mutations O 0 3.4155814887526503e-07
of O 0 7.161850589909591e-06
the O 0 8.14363647805294e-06
APC B-Disease 0 7.948241545818746e-06
gene O 0 6.573689859123988e-08
are O 0 3.5684390997658966e-09
thought O 0 1.3304819468373807e-08
to O 0 2.074738603141668e-08
initiate O 0 5.969337053102208e-06
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.999972939491272
formation O 0 8.142593287630007e-05
in O 0 0.00011197850835742429
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.5678513646125793
sporadic O 1 0.9999997615814209
colorectal O 1 1.0
carcinogenesis O 1 0.9999998807907104
, O 0 3.110099214609363e-06
respectively O 0 6.696559921692824e-06
. O 0 4.478133348584379e-07

Recently O 0 0.0005849653971381485
, O 0 1.3907249012845568e-05
an O 0 4.711223482445348e-06
isoleucine O 0 4.04570710088592e-05
- O 0 1.1030125278921332e-05
- O 0 1.839486685639713e-05
> O 0 6.480633601313457e-06
lysine O 0 2.747867483776645e-06
polymorphism O 0 4.262767276941304e-07
at O 0 8.488366802339442e-06
codon O 0 4.490262654144317e-06
1307 O 0 1.0576632121228613e-05
( O 0 1.0385215176711426e-07
I1307K O 0 1.8072552165904199e-06
) O 0 6.931529838993811e-08
of O 0 1.3902165392210009e-06
the O 0 4.8327433432859834e-06
APC B-Disease 0 1.2324051567702554e-05
gene O 0 5.44077579434088e-07
has O 0 2.681810826743458e-07
been O 0 2.3151481798322493e-07
identified O 0 5.148797654896953e-08
in O 0 5.1856080318657405e-08
6 O 0 6.441602522500034e-07
% O 0 1.257609767435497e-07
- O 0 3.7314435985535965e-07
7 O 0 6.796605589443061e-07
% O 0 6.954068254572121e-08
of O 0 4.525400925103895e-07
the O 0 9.926729944709223e-07
Ashkenazi O 0 1.587673750691465e-06
Jewish O 0 3.700139359352761e-07
population O 0 1.202098616204239e-07
. O 0 1.5038060041661083e-07

To O 0 6.351924639602657e-06
assess O 0 1.2292041901673656e-05
the O 0 6.106659839133499e-06
risk O 0 1.3995681911183055e-06
of O 0 6.950327815502533e-07
this O 0 9.596897143637761e-08
common O 0 3.13379644012457e-07
APC B-Disease 0 4.51034793513827e-06
allelic O 0 2.893700411732425e-06
variant O 0 6.259276688069804e-06
in O 0 3.14671742671635e-05
colorectal O 1 1.0
carcinogenesis O 1 0.9999724626541138
, O 0 1.035801005855319e-06
we O 0 5.934611380098431e-08
have O 0 2.637785989634267e-08
analyzed O 0 8.612389024165168e-08
a O 0 6.435413268945922e-08
large O 0 2.1484089529621997e-07
cohort O 0 4.845998319069622e-06
of O 0 2.3929262624733383e-06
unselected O 0 0.00020648054487537593
Ashkenazi O 0 7.12416613168898e-06
Jewish O 0 2.548092197685037e-06
subjects O 0 2.2051463020034134e-06
with O 0 1.2539084082163754e-06
adenomatous B-Disease 0 0.010958378203213215
polyps I-Disease 0 0.0011794307501986623
and O 0 1.868614504019206e-06
. O 0 1.3110015970596578e-06
or O 0 0.49029234051704407
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 9.267653808819887e-07
for O 0 4.1486333657303476e-07
the O 0 5.085739758214913e-06
APC O 0 2.9965327485115267e-05
I1307K O 0 2.9932996767456643e-05
polymorphism O 0 1.5662388250348158e-05
. O 0 2.6074533252540277e-06

The O 0 0.0004764331679325551
APC O 0 0.00018247564730700105
I1307K O 0 6.96117349434644e-05
allele O 0 3.984837803727714e-06
was O 0 7.252507202792913e-06
identified O 0 1.737301431603555e-07
in O 0 1.9418997965203744e-07
48 O 0 7.290011012628383e-07
( O 0 4.465799108288593e-08
10 O 0 7.77100410687126e-08
. O 0 5.897832888734911e-09
1 O 0 1.0473317502146529e-07
% O 0 3.666851000616589e-08
) O 0 1.7071412727887036e-08
of O 0 3.0451701604761183e-07
476 O 0 2.2088332116254605e-05
patients O 0 1.8660535943126888e-06
. O 0 2.4844293875503354e-06

Compared O 0 7.771865784889087e-05
with O 0 1.0812924529091106e-06
the O 0 1.2736654753098264e-06
frequency O 0 1.880065042314527e-06
in O 0 1.5481762716262892e-07
two O 0 2.5983576179555712e-08
separate O 0 2.189998582480257e-08
population O 0 3.905465106868178e-08
control O 0 4.2150415424657695e-07
groups O 0 3.55406122309887e-08
, O 0 1.1118293485878894e-07
the O 0 1.3531630429497454e-06
APC O 0 3.059130904148333e-05
I1307K O 0 2.0418974600033835e-05
allele O 0 1.1433320423748228e-06
is O 0 1.3018824063237844e-07
associated O 0 2.990930525470503e-08
with O 0 4.169994571867619e-09
an O 0 1.735434551619619e-08
estimated O 0 6.743688629740063e-08
relative O 0 4.6879884507688985e-07
risk O 0 2.5677604753582273e-07
of O 0 4.915162662655348e-06
1 O 0 9.744578164827544e-06
. O 0 1.5694866988269496e-06

5 O 0 9.255730401491746e-05
- O 0 7.691002974752337e-05
1 O 0 1.5075471310410649e-05
. O 0 3.3003741464199265e-06

7 O 0 0.00018593123240862042
for O 0 1.8509512301534414e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 0.031143397092819214
( O 0 2.1308089799276786e-06
both O 0 1.1598937135204324e-06
P O 0 0.0001681758149061352
= O 0 2.320396561117377e-06
. O 0 1.4335286380173784e-07
01 O 0 1.7382724763592705e-05
) O 0 1.6945065794971015e-07
. O 0 4.198520571208064e-07

Furthermore O 0 0.00010120441584149376
, O 0 3.09392294184363e-06
compared O 0 2.9439199806802208e-06
with O 0 7.990536232682643e-07
noncarriers O 0 0.00012458681885618716
, O 0 3.879546056850813e-06
APC O 0 3.7797763070557266e-05
I1307K O 0 1.008575509331422e-05
carriers O 0 1.9872832979217492e-07
had O 0 2.878227576275094e-07
increased O 0 4.3948702455054445e-07
numbers O 0 1.2596058240887942e-07
of O 0 2.909764134528814e-06
adenomas B-Disease 0 0.01722775585949421
and O 0 1.4481889593298547e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9060420989990234
per O 0 8.745995728531852e-06
patient O 0 1.379787249788933e-06
( O 0 2.5082999854930677e-07
P O 0 2.0317698727012612e-05
= O 0 6.773246923330589e-07
. O 0 7.93619250316624e-08
03 O 0 8.288707249448635e-06
) O 0 8.174475851774332e-08
, O 0 4.3779532887811e-08
as O 0 5.399785152349068e-08
well O 0 5.6644118728854664e-08
as O 0 1.0949887752076393e-07
a O 0 2.0722735882827692e-07
younger O 0 2.2227267493235559e-07
age O 0 7.772692356411426e-07
at O 0 6.857533207949018e-06
diagnosis O 0 1.2196514035167638e-05
. O 0 1.2650789358303882e-06

We O 0 2.2627680664299987e-05
conclude O 0 1.3188429875299335e-05
that O 0 1.0912355037362431e-06
the O 0 5.285271072352771e-06
APC O 0 3.920857125194743e-05
I1307K O 0 2.3915250494610518e-05
variant O 0 7.581057616334874e-06
leads O 0 4.651218660001177e-06
to O 0 1.2695422810793389e-06
increased O 0 0.0003565871447790414
adenoma B-Disease 1 1.0
formation O 0 0.00015708088176324964
and O 0 5.048939783591777e-06
directly O 0 5.78972105813591e-07
contributes O 0 2.166174084550221e-07
to O 0 6.178850497917665e-08
3 O 0 1.7518127037874365e-07
% O 0 1.9517001348390295e-08
- O 0 3.131599868311241e-08
4 O 0 2.8323828615839375e-08
% O 0 2.860536918447565e-09
of O 0 1.2301731189268139e-08
all O 0 1.7592469703231473e-08
Ashkenazi O 0 4.919233106193133e-06
Jewish O 0 0.01791704259812832
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.981882400694303e-06

The O 0 1.74061151483329e-05
estimated O 0 4.316811100579798e-06
relative O 0 1.5721272575319745e-05
risk O 0 2.508774059606367e-06
for O 0 3.6292502159085416e-07
carriers O 0 8.08034087640408e-07
may O 0 3.490189612875838e-07
justify O 0 1.0827562135773405e-07
specific O 0 1.9048389532372312e-08
clinical O 0 1.4043707778910175e-06
screening O 0 8.476018820147146e-07
for O 0 5.289459181767597e-07
the O 0 1.4671112467112835e-06
360 O 0 2.6885657007369446e-06
, O 0 1.4434347406222514e-07
000 O 0 1.3508356460079085e-06
Americans O 0 7.438559634920239e-08
expected O 0 3.3443916436226573e-07
to O 0 1.3723578717872442e-07
harbor O 0 8.432596587226726e-06
this O 0 8.087427261216362e-08
allele O 0 1.100986679603011e-07
, O 0 2.5506096790195443e-08
and O 0 1.4345059362597112e-08
genetic O 0 7.376830524208344e-08
testing O 0 1.9660816974464979e-07
in O 0 7.382079729723046e-07
the O 0 1.5715461358922767e-06
setting O 0 3.263759708715952e-06
of O 0 8.233833796111867e-06
long O 0 5.227682777331211e-06
- O 0 8.712903763807844e-06
term O 0 4.8189644985541236e-06
- O 0 9.35509490318509e-07
outcome O 0 1.774202615933973e-07
studies O 0 3.0556981300833286e-07
may O 0 1.2921775294216786e-07
impact O 0 3.424217709380173e-07
significantly O 0 1.135818138209288e-06
on O 0 0.2034827023744583
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 4.0428647480439395e-05
in O 0 9.228084252299595e-08
this O 0 2.482147287707903e-08
population O 0 9.65196917945832e-08
. O 0 1.7318771483587625e-07

Localization O 0 0.003632914973422885
of O 0 9.61718033067882e-05
human O 0 1.710410106170457e-05
BRCA1 O 0 1.0262279829476029e-05
and O 0 1.0129151633009315e-06
its O 0 7.254114962051972e-07
loss O 0 1.3763408787781373e-05
in O 0 2.606498810564517e-06
high O 0 0.029944544658064842
- O 0 3.45208500220906e-05
grade O 0 0.004043112974613905
, O 0 6.09185804023582e-07
non B-Disease 1 0.5188693404197693
- I-Disease 1 0.9999923706054688
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 7.206400914583355e-05

Although O 0 9.025771760207135e-06
the O 0 2.315144911335665e-06
link O 0 3.207092277079937e-06
between O 0 2.388844677625457e-06
the O 0 1.3267690519569442e-05
BRCA1 O 0 0.0002900944964494556
tumour B-Disease 1 1.0
- O 1 0.9349069595336914
suppressor O 1 0.9995546936988831
gene O 0 2.9875322979933117e-06
and O 0 3.8868270166858565e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 7.210371222754475e-06
established O 0 7.558070365121239e-07
, O 0 4.794869923330225e-08
the O 0 1.6421576276570704e-07
role O 0 4.001995250746404e-07
, O 0 1.0059975608101013e-07
if O 0 1.587417308712702e-08
any O 0 1.4247006241419058e-08
, O 0 2.857980696546747e-08
of O 0 3.5313240687173675e-07
BRCA1 O 0 3.0330284062074497e-06
in O 0 3.361811195645714e-06
non B-Disease 0 0.05031898617744446
- I-Disease 1 0.504547119140625
familial I-Disease 1 0.9172182083129883
cancers I-Disease 1 0.9999997615814209
is O 0 1.0407326954009477e-05
unclear O 0 4.1928092286980245e-06
. O 0 9.726702501211548e-07

BRCA1 O 0 0.0011249942472204566
mutations O 0 1.3256826605356764e-05
are O 0 4.4265527776587987e-07
rare O 0 2.253601394386351e-07
in O 0 8.470894954371033e-07
sporadic B-Disease 0 9.201977081829682e-05
cancers I-Disease 1 0.9994019269943237
, O 0 1.113316329792724e-06
but O 0 6.608727431967054e-08
loss O 0 2.4727687559789047e-06
of O 0 5.105113359604729e-06
BRCA1 O 0 4.929645001539029e-06
resulting O 0 1.8826164023266756e-06
from O 0 1.072963755177625e-06
reduced O 0 1.2007927807644592e-06
expression O 0 1.4702136468258686e-06
or O 0 6.478097702711239e-07
incorrect O 0 1.9068693291046657e-06
subcellular O 0 6.328595918603241e-05
localization O 0 1.5375795555883087e-05
is O 0 1.9251731941949402e-07
postulated O 0 3.9667182250013866e-07
to O 0 1.1580657321985655e-08
be O 0 1.1140875777471138e-08
important O 0 2.341303328989852e-08
in O 0 1.4340291443204478e-07
non B-Disease 0 3.999112959718332e-05
- I-Disease 0 0.026227444410324097
familial I-Disease 1 0.9994794726371765
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.00040546164382249117

Epigenetic O 0 0.03283129259943962
loss O 0 0.033447377383708954
, O 0 9.58114287641365e-06
however O 0 8.568474640924251e-07
, O 0 9.148467938757676e-08
has O 0 7.342845265156939e-08
not O 0 2.1921803039504084e-08
received O 0 2.7794951051873795e-07
general O 0 2.820189365593251e-06
acceptance O 0 4.755542249768041e-06
due O 0 1.607509511813987e-05
to O 0 2.5764467181943473e-07
controversy O 0 8.053160627241596e-07
regarding O 0 8.361880645679776e-07
the O 0 4.101421382074477e-06
subcellular O 0 6.028127245372161e-05
localization O 0 3.932503022952005e-05
of O 0 5.497688562172698e-06
BRCA1 O 0 5.022622644901276e-06
proteins O 0 6.227181188478426e-07
, O 0 1.8861410921999777e-07
reports O 0 1.8982873939421552e-07
of O 0 8.842575880407821e-07
which O 0 4.467597136681434e-07
have O 0 1.970011851426534e-07
ranged O 0 1.5120161151571665e-05
from O 0 7.897850764493342e-07
exclusively O 0 2.5936938641279994e-07
nuclear O 0 3.626839315984398e-06
, O 0 1.1162831015099073e-07
to O 0 7.401367696502348e-08
conditionally O 0 1.1916220046259696e-06
nuclear O 0 2.9431453185679857e-06
, O 0 9.275570533873179e-08
to O 0 6.648730277447612e-08
the O 0 3.1825652513362e-06
ER O 0 0.00021872953220736235
/ O 0 2.784469870675821e-05
golgi O 0 0.0001264539605472237
, O 0 5.794316848550807e-07
to O 0 2.4676137400092557e-07
cytoplasmic O 0 5.67725146538578e-06
invaginations O 0 4.04255224566441e-05
into O 0 1.4258376950238016e-06
the O 0 6.208198556123534e-06
nucleus O 0 7.941679541545454e-06
. O 0 9.963216598407598e-07

In O 0 0.0001030188868753612
an O 0 5.203568889555754e-06
attempt O 0 3.5522998587111942e-06
to O 0 7.309670877475583e-07
resolve O 0 1.6839592262840597e-06
this O 0 4.974634180143767e-07
issue O 0 1.1157291055496898e-06
, O 0 2.2209063388345385e-07
we O 0 7.502780619006444e-08
have O 0 7.64501209005175e-08
comprehensively O 0 1.4388019735633861e-06
characterized O 0 1.4657478004664881e-06
19 O 0 7.697892215219326e-06
anti O 0 9.714923180581536e-06
- O 0 6.919337010913296e-06
BRCA1 O 0 1.1655934031296056e-06
antibodies O 0 1.0378120123277768e-06
. O 0 1.913131654873723e-06

These O 0 1.3145097000233363e-05
reagents O 0 5.422614049166441e-05
detect O 0 1.442184020561399e-05
a O 0 6.0187780945852865e-06
220 O 0 5.1550750868045725e-06
- O 0 2.676914846233558e-06
kD O 0 7.667451427550986e-06
protein O 0 4.72816026331202e-07
localized O 0 7.592609563289443e-07
in O 0 3.265856776124565e-07
discrete O 0 1.2110315310565056e-06
nuclear O 0 1.0139936421182938e-05
foci O 0 1.1284889296803158e-05
in O 0 8.209560178329411e-07
all O 0 2.3541645077784779e-07
epithelial O 0 1.713913843559567e-05
cell O 0 1.178961156256264e-05
lines O 0 9.872059081317275e-07
, O 0 1.573256369624687e-08
including O 0 9.937441980412132e-09
those O 0 1.329198529020914e-08
derived O 0 4.6720549562451197e-07
from O 0 3.093542318310938e-06
breast B-Disease 0 6.059596489649266e-05
malignancies I-Disease 0 0.00023571919882670045
. O 0 4.3383547563280445e-06

Immunohistochemical O 0 0.004997634328901768
staining O 0 0.0006928331567905843
of O 0 0.00015652019646950066
human O 0 3.194934470229782e-05
breast O 0 0.00018378595996182412
specimens O 0 2.616378424136201e-06
also O 0 1.2417311836543377e-06
revealed O 0 6.371976724039996e-06
BRCA1 O 0 2.393263639532961e-05
nuclear O 0 0.00010286142787663266
foci O 0 0.000855793827213347
in O 0 1.6733562006265856e-05
benign O 1 0.9999819993972778
breast O 1 0.9948021173477173
, O 0 6.135005605756305e-06
invasive B-Disease 0 0.0016615954227745533
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999966621398926
and O 0 0.0015930586960166693
low B-Disease 1 0.9999996423721313
- I-Disease 1 0.9995569586753845
grade I-Disease 1 0.9999940395355225
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 1.8693932361202314e-05

Conversely O 0 0.00022050058760214597
, O 0 6.173153451527469e-06
BRCA1 O 0 7.696901775489096e-06
expression O 0 4.611111307895044e-06
was O 0 1.426064864062937e-05
reduced O 0 1.700387429082184e-06
or O 0 3.95584578427588e-07
undetectable O 0 6.043451776349684e-06
in O 0 1.4463338970926998e-07
the O 0 2.111356423029065e-07
majority O 0 2.5784123280914173e-08
of O 0 2.824544253599015e-06
high O 0 0.005698110908269882
- O 0 5.780027640867047e-05
grade O 0 0.14529991149902344
, O 0 3.839171313302359e-06
ductal B-Disease 1 0.9999854564666748
carcinomas I-Disease 1 1.0
, O 0 3.826458396360977e-06
suggesting O 0 1.7532059928271337e-06
that O 0 1.8440869098412804e-07
absence O 0 3.4837091789086116e-06
of O 0 1.0133101568499114e-05
BRCA1 O 0 6.28882298769895e-06
may O 0 1.2670021760641248e-06
contribute O 0 6.470960300930528e-08
to O 0 1.080528093666544e-07
the O 0 7.23848302186525e-07
pathogenesis O 0 8.818288733891677e-06
of O 0 2.043941407237071e-07
a O 0 7.377266797448101e-08
significant O 0 5.3527585919255216e-08
percentage O 0 7.704259132879088e-07
of O 0 1.852761101872602e-06
sporadic B-Disease 0 0.0319083109498024
breast I-Disease 1 0.9999979734420776
cancers I-Disease 1 0.9999759197235107
. O 0 2.7422963739809347e-06
. O 0 1.4555678262695437e-06

